{
  "export_metadata": {
    "created_at": "2026-01-31T18:16:02.551299",
    "source_folder": "/home/inna/github/selene_shell_to_brain/papers",
    "files_processed": 12,
    "files_failed": 0,
    "total_chunks": 837,
    "collection_name": "knowledge_base",
    "chunk_config": {
      "chunk_size": 1500,
      "overlap": 200,
      "min_chunk_size": 100
    }
  },
  "ids": [
    "72dac8e22d304c10_0000",
    "72dac8e22d304c10_0001",
    "72dac8e22d304c10_0002",
    "72dac8e22d304c10_0003",
    "72dac8e22d304c10_0004",
    "72dac8e22d304c10_0005",
    "72dac8e22d304c10_0006",
    "72dac8e22d304c10_0007",
    "72dac8e22d304c10_0008",
    "72dac8e22d304c10_0009",
    "72dac8e22d304c10_0010",
    "72dac8e22d304c10_0011",
    "72dac8e22d304c10_0012",
    "72dac8e22d304c10_0013",
    "72dac8e22d304c10_0014",
    "72dac8e22d304c10_0015",
    "72dac8e22d304c10_0016",
    "72dac8e22d304c10_0017",
    "72dac8e22d304c10_0018",
    "72dac8e22d304c10_0019",
    "72dac8e22d304c10_0020",
    "72dac8e22d304c10_0021",
    "72dac8e22d304c10_0022",
    "72dac8e22d304c10_0023",
    "72dac8e22d304c10_0024",
    "72dac8e22d304c10_0025",
    "72dac8e22d304c10_0026",
    "72dac8e22d304c10_0027",
    "72dac8e22d304c10_0028",
    "72dac8e22d304c10_0029",
    "72dac8e22d304c10_0030",
    "72dac8e22d304c10_0031",
    "72dac8e22d304c10_0032",
    "72dac8e22d304c10_0033",
    "72dac8e22d304c10_0034",
    "72dac8e22d304c10_0035",
    "72dac8e22d304c10_0036",
    "72dac8e22d304c10_0037",
    "72dac8e22d304c10_0038",
    "72dac8e22d304c10_0039",
    "72dac8e22d304c10_0040",
    "72dac8e22d304c10_0041",
    "72dac8e22d304c10_0042",
    "72dac8e22d304c10_0043",
    "72dac8e22d304c10_0044",
    "72dac8e22d304c10_0045",
    "72dac8e22d304c10_0046",
    "72dac8e22d304c10_0047",
    "72dac8e22d304c10_0048",
    "72dac8e22d304c10_0049",
    "72dac8e22d304c10_0050",
    "72dac8e22d304c10_0051",
    "72dac8e22d304c10_0052",
    "72dac8e22d304c10_0053",
    "72dac8e22d304c10_0054",
    "72dac8e22d304c10_0055",
    "72dac8e22d304c10_0056",
    "72dac8e22d304c10_0057",
    "72dac8e22d304c10_0058",
    "72dac8e22d304c10_0059",
    "72dac8e22d304c10_0060",
    "72dac8e22d304c10_0061",
    "72dac8e22d304c10_0062",
    "72dac8e22d304c10_0063",
    "72dac8e22d304c10_0064",
    "72dac8e22d304c10_0065",
    "72dac8e22d304c10_0066",
    "72dac8e22d304c10_0067",
    "72dac8e22d304c10_0068",
    "72dac8e22d304c10_0069",
    "72dac8e22d304c10_0070",
    "72dac8e22d304c10_0071",
    "72dac8e22d304c10_0072",
    "72dac8e22d304c10_0073",
    "72dac8e22d304c10_0074",
    "72dac8e22d304c10_0075",
    "72dac8e22d304c10_0076",
    "72dac8e22d304c10_0077",
    "72dac8e22d304c10_0078",
    "72dac8e22d304c10_0079",
    "72dac8e22d304c10_0080",
    "72dac8e22d304c10_0081",
    "72dac8e22d304c10_0082",
    "72dac8e22d304c10_0083",
    "72dac8e22d304c10_0084",
    "72dac8e22d304c10_0085",
    "72dac8e22d304c10_0086",
    "72dac8e22d304c10_0087",
    "72dac8e22d304c10_0088",
    "72dac8e22d304c10_0089",
    "72dac8e22d304c10_0090",
    "72dac8e22d304c10_0091",
    "72dac8e22d304c10_0092",
    "72dac8e22d304c10_0093",
    "72dac8e22d304c10_0094",
    "72dac8e22d304c10_0095",
    "72dac8e22d304c10_0096",
    "72dac8e22d304c10_0097",
    "72dac8e22d304c10_0098",
    "72dac8e22d304c10_0099",
    "72dac8e22d304c10_0100",
    "72dac8e22d304c10_0101",
    "72dac8e22d304c10_0102",
    "72dac8e22d304c10_0103",
    "72dac8e22d304c10_0104",
    "72dac8e22d304c10_0105",
    "72dac8e22d304c10_0106",
    "72dac8e22d304c10_0107",
    "72dac8e22d304c10_0108",
    "72dac8e22d304c10_0109",
    "72dac8e22d304c10_0110",
    "72dac8e22d304c10_0111",
    "72dac8e22d304c10_0112",
    "72dac8e22d304c10_0113",
    "72dac8e22d304c10_0114",
    "72dac8e22d304c10_0115",
    "72dac8e22d304c10_0116",
    "72dac8e22d304c10_0117",
    "72dac8e22d304c10_0118",
    "72dac8e22d304c10_0119",
    "94cf041592dc7c98_0000",
    "94cf041592dc7c98_0001",
    "94cf041592dc7c98_0002",
    "94cf041592dc7c98_0003",
    "94cf041592dc7c98_0004",
    "94cf041592dc7c98_0005",
    "94cf041592dc7c98_0006",
    "94cf041592dc7c98_0007",
    "94cf041592dc7c98_0008",
    "94cf041592dc7c98_0009",
    "94cf041592dc7c98_0010",
    "94cf041592dc7c98_0011",
    "94cf041592dc7c98_0012",
    "94cf041592dc7c98_0013",
    "94cf041592dc7c98_0014",
    "94cf041592dc7c98_0015",
    "94cf041592dc7c98_0016",
    "94cf041592dc7c98_0017",
    "94cf041592dc7c98_0018",
    "94cf041592dc7c98_0019",
    "94cf041592dc7c98_0020",
    "94cf041592dc7c98_0021",
    "94cf041592dc7c98_0022",
    "94cf041592dc7c98_0023",
    "94cf041592dc7c98_0024",
    "94cf041592dc7c98_0025",
    "94cf041592dc7c98_0026",
    "94cf041592dc7c98_0027",
    "94cf041592dc7c98_0028",
    "94cf041592dc7c98_0029",
    "94cf041592dc7c98_0030",
    "94cf041592dc7c98_0031",
    "94cf041592dc7c98_0032",
    "94cf041592dc7c98_0033",
    "94cf041592dc7c98_0034",
    "94cf041592dc7c98_0035",
    "94cf041592dc7c98_0036",
    "94cf041592dc7c98_0037",
    "94cf041592dc7c98_0038",
    "94cf041592dc7c98_0039",
    "94cf041592dc7c98_0040",
    "94cf041592dc7c98_0041",
    "94cf041592dc7c98_0042",
    "94cf041592dc7c98_0043",
    "94cf041592dc7c98_0044",
    "94cf041592dc7c98_0045",
    "94cf041592dc7c98_0046",
    "94cf041592dc7c98_0047",
    "94cf041592dc7c98_0048",
    "94cf041592dc7c98_0049",
    "94cf041592dc7c98_0050",
    "94cf041592dc7c98_0051",
    "94cf041592dc7c98_0052",
    "94cf041592dc7c98_0053",
    "94cf041592dc7c98_0054",
    "94cf041592dc7c98_0055",
    "94cf041592dc7c98_0056",
    "94cf041592dc7c98_0057",
    "94cf041592dc7c98_0058",
    "94cf041592dc7c98_0059",
    "94cf041592dc7c98_0060",
    "94cf041592dc7c98_0061",
    "94cf041592dc7c98_0062",
    "94cf041592dc7c98_0063",
    "94cf041592dc7c98_0064",
    "94cf041592dc7c98_0065",
    "94cf041592dc7c98_0066",
    "94cf041592dc7c98_0067",
    "94cf041592dc7c98_0068",
    "94cf041592dc7c98_0069",
    "94cf041592dc7c98_0070",
    "94cf041592dc7c98_0071",
    "94cf041592dc7c98_0072",
    "94cf041592dc7c98_0073",
    "94cf041592dc7c98_0074",
    "94cf041592dc7c98_0075",
    "94cf041592dc7c98_0076",
    "94cf041592dc7c98_0077",
    "94cf041592dc7c98_0078",
    "94cf041592dc7c98_0079",
    "94cf041592dc7c98_0080",
    "94cf041592dc7c98_0081",
    "94cf041592dc7c98_0082",
    "94cf041592dc7c98_0083",
    "94cf041592dc7c98_0084",
    "94cf041592dc7c98_0085",
    "94cf041592dc7c98_0086",
    "94cf041592dc7c98_0087",
    "94cf041592dc7c98_0088",
    "94cf041592dc7c98_0089",
    "94cf041592dc7c98_0090",
    "94cf041592dc7c98_0091",
    "94cf041592dc7c98_0092",
    "94cf041592dc7c98_0093",
    "94cf041592dc7c98_0094",
    "94cf041592dc7c98_0095",
    "cea37916f0dda945_0000",
    "cea37916f0dda945_0001",
    "cea37916f0dda945_0002",
    "cea37916f0dda945_0003",
    "cea37916f0dda945_0004",
    "cea37916f0dda945_0005",
    "cea37916f0dda945_0006",
    "cea37916f0dda945_0007",
    "cea37916f0dda945_0008",
    "cea37916f0dda945_0009",
    "cea37916f0dda945_0010",
    "cea37916f0dda945_0011",
    "cea37916f0dda945_0012",
    "cea37916f0dda945_0013",
    "cea37916f0dda945_0014",
    "cea37916f0dda945_0015",
    "cea37916f0dda945_0016",
    "cea37916f0dda945_0017",
    "cea37916f0dda945_0018",
    "cea37916f0dda945_0019",
    "cea37916f0dda945_0020",
    "cea37916f0dda945_0021",
    "cea37916f0dda945_0022",
    "cea37916f0dda945_0023",
    "cea37916f0dda945_0024",
    "cea37916f0dda945_0025",
    "cea37916f0dda945_0026",
    "cea37916f0dda945_0027",
    "cea37916f0dda945_0028",
    "cea37916f0dda945_0029",
    "cea37916f0dda945_0030",
    "cea37916f0dda945_0031",
    "cea37916f0dda945_0032",
    "cea37916f0dda945_0033",
    "cea37916f0dda945_0034",
    "cea37916f0dda945_0035",
    "cea37916f0dda945_0036",
    "cea37916f0dda945_0037",
    "cea37916f0dda945_0038",
    "cea37916f0dda945_0039",
    "cea37916f0dda945_0040",
    "cea37916f0dda945_0041",
    "cea37916f0dda945_0042",
    "cea37916f0dda945_0043",
    "cea37916f0dda945_0044",
    "cea37916f0dda945_0045",
    "cea37916f0dda945_0046",
    "cea37916f0dda945_0047",
    "cea37916f0dda945_0048",
    "cea37916f0dda945_0049",
    "cea37916f0dda945_0050",
    "cea37916f0dda945_0051",
    "cea37916f0dda945_0052",
    "cea37916f0dda945_0053",
    "cea37916f0dda945_0054",
    "cea37916f0dda945_0055",
    "cea37916f0dda945_0056",
    "cea37916f0dda945_0057",
    "cea37916f0dda945_0058",
    "cea37916f0dda945_0059",
    "cea37916f0dda945_0060",
    "cea37916f0dda945_0061",
    "cea37916f0dda945_0062",
    "cea37916f0dda945_0063",
    "cea37916f0dda945_0064",
    "cea37916f0dda945_0065",
    "cea37916f0dda945_0066",
    "cea37916f0dda945_0067",
    "cea37916f0dda945_0068",
    "cea37916f0dda945_0069",
    "cea37916f0dda945_0070",
    "cea37916f0dda945_0071",
    "cea37916f0dda945_0072",
    "cea37916f0dda945_0073",
    "cea37916f0dda945_0074",
    "cea37916f0dda945_0075",
    "cea37916f0dda945_0076",
    "cea37916f0dda945_0077",
    "cea37916f0dda945_0078",
    "cea37916f0dda945_0079",
    "cea37916f0dda945_0080",
    "cea37916f0dda945_0081",
    "cea37916f0dda945_0082",
    "cea37916f0dda945_0083",
    "cea37916f0dda945_0084",
    "cea37916f0dda945_0085",
    "cea37916f0dda945_0086",
    "cea37916f0dda945_0087",
    "cea37916f0dda945_0088",
    "cea37916f0dda945_0089",
    "cea37916f0dda945_0090",
    "cea37916f0dda945_0091",
    "cea37916f0dda945_0092",
    "cea37916f0dda945_0093",
    "cea37916f0dda945_0094",
    "cea37916f0dda945_0095",
    "cea37916f0dda945_0096",
    "cea37916f0dda945_0097",
    "cea37916f0dda945_0098",
    "cea37916f0dda945_0099",
    "cea37916f0dda945_0100",
    "cea37916f0dda945_0101",
    "cea37916f0dda945_0102",
    "cea37916f0dda945_0103",
    "cea37916f0dda945_0104",
    "cea37916f0dda945_0105",
    "cea37916f0dda945_0106",
    "cea37916f0dda945_0107",
    "cea37916f0dda945_0108",
    "cea37916f0dda945_0109",
    "cea37916f0dda945_0110",
    "cea37916f0dda945_0111",
    "cea37916f0dda945_0112",
    "cea37916f0dda945_0113",
    "cea37916f0dda945_0114",
    "cea37916f0dda945_0115",
    "cea37916f0dda945_0116",
    "cea37916f0dda945_0117",
    "cea37916f0dda945_0118",
    "cea37916f0dda945_0119",
    "cea37916f0dda945_0120",
    "cea37916f0dda945_0121",
    "cea37916f0dda945_0122",
    "cea37916f0dda945_0123",
    "cea37916f0dda945_0124",
    "cea37916f0dda945_0125",
    "cea37916f0dda945_0126",
    "cea37916f0dda945_0127",
    "cea37916f0dda945_0128",
    "cea37916f0dda945_0129",
    "cea37916f0dda945_0130",
    "cea37916f0dda945_0131",
    "979530a2a09b907f_0000",
    "979530a2a09b907f_0001",
    "979530a2a09b907f_0002",
    "979530a2a09b907f_0003",
    "979530a2a09b907f_0004",
    "979530a2a09b907f_0005",
    "979530a2a09b907f_0006",
    "979530a2a09b907f_0007",
    "979530a2a09b907f_0008",
    "979530a2a09b907f_0009",
    "979530a2a09b907f_0010",
    "979530a2a09b907f_0011",
    "979530a2a09b907f_0012",
    "979530a2a09b907f_0013",
    "979530a2a09b907f_0014",
    "979530a2a09b907f_0015",
    "979530a2a09b907f_0016",
    "979530a2a09b907f_0017",
    "979530a2a09b907f_0018",
    "979530a2a09b907f_0019",
    "979530a2a09b907f_0020",
    "979530a2a09b907f_0021",
    "979530a2a09b907f_0022",
    "979530a2a09b907f_0023",
    "979530a2a09b907f_0024",
    "979530a2a09b907f_0025",
    "979530a2a09b907f_0026",
    "979530a2a09b907f_0027",
    "979530a2a09b907f_0028",
    "979530a2a09b907f_0029",
    "979530a2a09b907f_0030",
    "979530a2a09b907f_0031",
    "979530a2a09b907f_0032",
    "979530a2a09b907f_0033",
    "979530a2a09b907f_0034",
    "979530a2a09b907f_0035",
    "979530a2a09b907f_0036",
    "979530a2a09b907f_0037",
    "979530a2a09b907f_0038",
    "979530a2a09b907f_0039",
    "979530a2a09b907f_0040",
    "979530a2a09b907f_0041",
    "979530a2a09b907f_0042",
    "979530a2a09b907f_0043",
    "979530a2a09b907f_0044",
    "979530a2a09b907f_0045",
    "979530a2a09b907f_0046",
    "979530a2a09b907f_0047",
    "979530a2a09b907f_0048",
    "979530a2a09b907f_0049",
    "979530a2a09b907f_0050",
    "979530a2a09b907f_0051",
    "6a35680300af17ac_0000",
    "6a35680300af17ac_0001",
    "6a35680300af17ac_0002",
    "6a35680300af17ac_0003",
    "6a35680300af17ac_0004",
    "6a35680300af17ac_0005",
    "6a35680300af17ac_0006",
    "6a35680300af17ac_0007",
    "6a35680300af17ac_0008",
    "6a35680300af17ac_0009",
    "6a35680300af17ac_0010",
    "6a35680300af17ac_0011",
    "6a35680300af17ac_0012",
    "6a35680300af17ac_0013",
    "6a35680300af17ac_0014",
    "6a35680300af17ac_0015",
    "6a35680300af17ac_0016",
    "6a35680300af17ac_0017",
    "6a35680300af17ac_0018",
    "6a35680300af17ac_0019",
    "6a35680300af17ac_0020",
    "6a35680300af17ac_0021",
    "6a35680300af17ac_0022",
    "6a35680300af17ac_0023",
    "6a35680300af17ac_0024",
    "6a35680300af17ac_0025",
    "6a35680300af17ac_0026",
    "6a35680300af17ac_0027",
    "6a35680300af17ac_0028",
    "6a35680300af17ac_0029",
    "6a35680300af17ac_0030",
    "6a35680300af17ac_0031",
    "6a35680300af17ac_0032",
    "6a35680300af17ac_0033",
    "6a35680300af17ac_0034",
    "6a35680300af17ac_0035",
    "6a35680300af17ac_0036",
    "6a35680300af17ac_0037",
    "6a35680300af17ac_0038",
    "6a35680300af17ac_0039",
    "6a35680300af17ac_0040",
    "6a35680300af17ac_0041",
    "6a35680300af17ac_0042",
    "6a35680300af17ac_0043",
    "6a35680300af17ac_0044",
    "6a35680300af17ac_0045",
    "6a35680300af17ac_0046",
    "6a35680300af17ac_0047",
    "6a35680300af17ac_0048",
    "6a35680300af17ac_0049",
    "6a35680300af17ac_0050",
    "6a35680300af17ac_0051",
    "6a35680300af17ac_0052",
    "9f4d1afee7ea46b7_0000",
    "9f4d1afee7ea46b7_0001",
    "9f4d1afee7ea46b7_0002",
    "9f4d1afee7ea46b7_0003",
    "9f4d1afee7ea46b7_0004",
    "9f4d1afee7ea46b7_0005",
    "9f4d1afee7ea46b7_0006",
    "9f4d1afee7ea46b7_0007",
    "9f4d1afee7ea46b7_0008",
    "9f4d1afee7ea46b7_0009",
    "9f4d1afee7ea46b7_0010",
    "9f4d1afee7ea46b7_0011",
    "9f4d1afee7ea46b7_0012",
    "9f4d1afee7ea46b7_0013",
    "9f4d1afee7ea46b7_0014",
    "9f4d1afee7ea46b7_0015",
    "9f4d1afee7ea46b7_0016",
    "9f4d1afee7ea46b7_0017",
    "9f4d1afee7ea46b7_0018",
    "9f4d1afee7ea46b7_0019",
    "9f4d1afee7ea46b7_0020",
    "9f4d1afee7ea46b7_0021",
    "9f4d1afee7ea46b7_0022",
    "9f4d1afee7ea46b7_0023",
    "9f4d1afee7ea46b7_0024",
    "9f4d1afee7ea46b7_0025",
    "9f4d1afee7ea46b7_0026",
    "9f4d1afee7ea46b7_0027",
    "9f4d1afee7ea46b7_0028",
    "9f4d1afee7ea46b7_0029",
    "9f4d1afee7ea46b7_0030",
    "9f4d1afee7ea46b7_0031",
    "9f4d1afee7ea46b7_0032",
    "9f4d1afee7ea46b7_0033",
    "9f4d1afee7ea46b7_0034",
    "9f4d1afee7ea46b7_0035",
    "9f4d1afee7ea46b7_0036",
    "9f4d1afee7ea46b7_0037",
    "9f4d1afee7ea46b7_0038",
    "9f4d1afee7ea46b7_0039",
    "9f4d1afee7ea46b7_0040",
    "9f4d1afee7ea46b7_0041",
    "9f4d1afee7ea46b7_0042",
    "9f4d1afee7ea46b7_0043",
    "9f4d1afee7ea46b7_0044",
    "9f4d1afee7ea46b7_0045",
    "9f4d1afee7ea46b7_0046",
    "9f4d1afee7ea46b7_0047",
    "9f4d1afee7ea46b7_0048",
    "9f4d1afee7ea46b7_0049",
    "9f4d1afee7ea46b7_0050",
    "9f4d1afee7ea46b7_0051",
    "9f4d1afee7ea46b7_0052",
    "9f4d1afee7ea46b7_0053",
    "9f4d1afee7ea46b7_0054",
    "9f4d1afee7ea46b7_0055",
    "9f4d1afee7ea46b7_0056",
    "9f4d1afee7ea46b7_0057",
    "9f4d1afee7ea46b7_0058",
    "9f4d1afee7ea46b7_0059",
    "9f4d1afee7ea46b7_0060",
    "9f4d1afee7ea46b7_0061",
    "9f4d1afee7ea46b7_0062",
    "9f4d1afee7ea46b7_0063",
    "9f4d1afee7ea46b7_0064",
    "9f4d1afee7ea46b7_0065",
    "cfdc9e0fe68aa1d9_0000",
    "cfdc9e0fe68aa1d9_0001",
    "cfdc9e0fe68aa1d9_0002",
    "cfdc9e0fe68aa1d9_0003",
    "cfdc9e0fe68aa1d9_0004",
    "cfdc9e0fe68aa1d9_0005",
    "cfdc9e0fe68aa1d9_0006",
    "cfdc9e0fe68aa1d9_0007",
    "cfdc9e0fe68aa1d9_0008",
    "cfdc9e0fe68aa1d9_0009",
    "cfdc9e0fe68aa1d9_0010",
    "cfdc9e0fe68aa1d9_0011",
    "cfdc9e0fe68aa1d9_0012",
    "cfdc9e0fe68aa1d9_0013",
    "cfdc9e0fe68aa1d9_0014",
    "cfdc9e0fe68aa1d9_0015",
    "cfdc9e0fe68aa1d9_0016",
    "cfdc9e0fe68aa1d9_0017",
    "cfdc9e0fe68aa1d9_0018",
    "cfdc9e0fe68aa1d9_0019",
    "cfdc9e0fe68aa1d9_0020",
    "cfdc9e0fe68aa1d9_0021",
    "cfdc9e0fe68aa1d9_0022",
    "cfdc9e0fe68aa1d9_0023",
    "cfdc9e0fe68aa1d9_0024",
    "cfdc9e0fe68aa1d9_0025",
    "cfdc9e0fe68aa1d9_0026",
    "cfdc9e0fe68aa1d9_0027",
    "cfdc9e0fe68aa1d9_0028",
    "cfdc9e0fe68aa1d9_0029",
    "cfdc9e0fe68aa1d9_0030",
    "cfdc9e0fe68aa1d9_0031",
    "cfdc9e0fe68aa1d9_0032",
    "cfdc9e0fe68aa1d9_0033",
    "cfdc9e0fe68aa1d9_0034",
    "cfdc9e0fe68aa1d9_0035",
    "cfdc9e0fe68aa1d9_0036",
    "cfdc9e0fe68aa1d9_0037",
    "cfdc9e0fe68aa1d9_0038",
    "cfdc9e0fe68aa1d9_0039",
    "cfdc9e0fe68aa1d9_0040",
    "cfdc9e0fe68aa1d9_0041",
    "cfdc9e0fe68aa1d9_0042",
    "cfdc9e0fe68aa1d9_0043",
    "cfdc9e0fe68aa1d9_0044",
    "cfdc9e0fe68aa1d9_0045",
    "cfdc9e0fe68aa1d9_0046",
    "cfdc9e0fe68aa1d9_0047",
    "cfdc9e0fe68aa1d9_0048",
    "cfdc9e0fe68aa1d9_0049",
    "cfdc9e0fe68aa1d9_0050",
    "cfdc9e0fe68aa1d9_0051",
    "cfdc9e0fe68aa1d9_0052",
    "cfdc9e0fe68aa1d9_0053",
    "cfdc9e0fe68aa1d9_0054",
    "cfdc9e0fe68aa1d9_0055",
    "cfdc9e0fe68aa1d9_0056",
    "cfdc9e0fe68aa1d9_0057",
    "cfdc9e0fe68aa1d9_0058",
    "cfdc9e0fe68aa1d9_0059",
    "cfdc9e0fe68aa1d9_0060",
    "cfdc9e0fe68aa1d9_0061",
    "cfdc9e0fe68aa1d9_0062",
    "cfdc9e0fe68aa1d9_0063",
    "cfdc9e0fe68aa1d9_0064",
    "39b2e57f352cae0c_0000",
    "39b2e57f352cae0c_0001",
    "39b2e57f352cae0c_0002",
    "39b2e57f352cae0c_0003",
    "39b2e57f352cae0c_0004",
    "dbf09fc79ecab9fc_0000",
    "dbf09fc79ecab9fc_0001",
    "dbf09fc79ecab9fc_0002",
    "dbf09fc79ecab9fc_0003",
    "dbf09fc79ecab9fc_0004",
    "6dbe4d1b07b7e25d_0000",
    "6dbe4d1b07b7e25d_0001",
    "6dbe4d1b07b7e25d_0002",
    "6dbe4d1b07b7e25d_0003",
    "6dbe4d1b07b7e25d_0004",
    "d41b9a1bf248aa4a_0000",
    "d41b9a1bf248aa4a_0001",
    "d41b9a1bf248aa4a_0002",
    "d41b9a1bf248aa4a_0003",
    "d41b9a1bf248aa4a_0004",
    "d41b9a1bf248aa4a_0005",
    "d41b9a1bf248aa4a_0006",
    "d41b9a1bf248aa4a_0007",
    "d41b9a1bf248aa4a_0008",
    "d41b9a1bf248aa4a_0009",
    "d41b9a1bf248aa4a_0010",
    "d41b9a1bf248aa4a_0011",
    "d41b9a1bf248aa4a_0012",
    "d41b9a1bf248aa4a_0013",
    "d41b9a1bf248aa4a_0014",
    "d41b9a1bf248aa4a_0015",
    "d41b9a1bf248aa4a_0016",
    "d41b9a1bf248aa4a_0017",
    "d41b9a1bf248aa4a_0018",
    "d41b9a1bf248aa4a_0019",
    "d41b9a1bf248aa4a_0020",
    "d41b9a1bf248aa4a_0021",
    "d41b9a1bf248aa4a_0022",
    "d41b9a1bf248aa4a_0023",
    "d41b9a1bf248aa4a_0024",
    "d41b9a1bf248aa4a_0025",
    "d41b9a1bf248aa4a_0026",
    "d41b9a1bf248aa4a_0027",
    "d41b9a1bf248aa4a_0028",
    "d41b9a1bf248aa4a_0029",
    "d41b9a1bf248aa4a_0030",
    "d41b9a1bf248aa4a_0031",
    "d41b9a1bf248aa4a_0032",
    "d41b9a1bf248aa4a_0033",
    "d41b9a1bf248aa4a_0034",
    "d41b9a1bf248aa4a_0035",
    "d41b9a1bf248aa4a_0036",
    "d41b9a1bf248aa4a_0037",
    "d41b9a1bf248aa4a_0038",
    "d41b9a1bf248aa4a_0039",
    "d41b9a1bf248aa4a_0040",
    "d41b9a1bf248aa4a_0041",
    "d41b9a1bf248aa4a_0042",
    "d41b9a1bf248aa4a_0043",
    "d41b9a1bf248aa4a_0044",
    "d41b9a1bf248aa4a_0045",
    "d41b9a1bf248aa4a_0046",
    "d41b9a1bf248aa4a_0047",
    "d41b9a1bf248aa4a_0048",
    "d41b9a1bf248aa4a_0049",
    "d41b9a1bf248aa4a_0050",
    "d41b9a1bf248aa4a_0051",
    "d41b9a1bf248aa4a_0052",
    "d41b9a1bf248aa4a_0053",
    "d41b9a1bf248aa4a_0054",
    "d41b9a1bf248aa4a_0055",
    "d41b9a1bf248aa4a_0056",
    "d41b9a1bf248aa4a_0057",
    "d41b9a1bf248aa4a_0058",
    "d41b9a1bf248aa4a_0059",
    "d41b9a1bf248aa4a_0060",
    "d41b9a1bf248aa4a_0061",
    "d41b9a1bf248aa4a_0062",
    "d41b9a1bf248aa4a_0063",
    "d41b9a1bf248aa4a_0064",
    "d41b9a1bf248aa4a_0065",
    "d41b9a1bf248aa4a_0066",
    "d41b9a1bf248aa4a_0067",
    "d41b9a1bf248aa4a_0068",
    "d41b9a1bf248aa4a_0069",
    "d41b9a1bf248aa4a_0070",
    "d41b9a1bf248aa4a_0071",
    "d41b9a1bf248aa4a_0072",
    "d41b9a1bf248aa4a_0073",
    "d41b9a1bf248aa4a_0074",
    "d41b9a1bf248aa4a_0075",
    "d41b9a1bf248aa4a_0076",
    "d41b9a1bf248aa4a_0077",
    "d41b9a1bf248aa4a_0078",
    "d41b9a1bf248aa4a_0079",
    "d41b9a1bf248aa4a_0080",
    "d41b9a1bf248aa4a_0081",
    "d41b9a1bf248aa4a_0082",
    "d41b9a1bf248aa4a_0083",
    "d41b9a1bf248aa4a_0084",
    "d41b9a1bf248aa4a_0085",
    "d41b9a1bf248aa4a_0086",
    "d41b9a1bf248aa4a_0087",
    "22a05f37b2f52af0_0000",
    "22a05f37b2f52af0_0001",
    "22a05f37b2f52af0_0002",
    "22a05f37b2f52af0_0003",
    "22a05f37b2f52af0_0004",
    "22a05f37b2f52af0_0005",
    "22a05f37b2f52af0_0006",
    "22a05f37b2f52af0_0007",
    "22a05f37b2f52af0_0008",
    "22a05f37b2f52af0_0009",
    "22a05f37b2f52af0_0010",
    "22a05f37b2f52af0_0011",
    "22a05f37b2f52af0_0012",
    "22a05f37b2f52af0_0013",
    "22a05f37b2f52af0_0014",
    "22a05f37b2f52af0_0015",
    "22a05f37b2f52af0_0016",
    "22a05f37b2f52af0_0017",
    "22a05f37b2f52af0_0018",
    "22a05f37b2f52af0_0019",
    "22a05f37b2f52af0_0020",
    "22a05f37b2f52af0_0021",
    "22a05f37b2f52af0_0022",
    "22a05f37b2f52af0_0023",
    "22a05f37b2f52af0_0024",
    "22a05f37b2f52af0_0025",
    "22a05f37b2f52af0_0026",
    "22a05f37b2f52af0_0027",
    "22a05f37b2f52af0_0028",
    "22a05f37b2f52af0_0029",
    "22a05f37b2f52af0_0030",
    "22a05f37b2f52af0_0031",
    "22a05f37b2f52af0_0032",
    "22a05f37b2f52af0_0033",
    "22a05f37b2f52af0_0034",
    "22a05f37b2f52af0_0035",
    "22a05f37b2f52af0_0036",
    "22a05f37b2f52af0_0037",
    "22a05f37b2f52af0_0038",
    "22a05f37b2f52af0_0039",
    "22a05f37b2f52af0_0040",
    "22a05f37b2f52af0_0041",
    "22a05f37b2f52af0_0042",
    "22a05f37b2f52af0_0043",
    "22a05f37b2f52af0_0044",
    "22a05f37b2f52af0_0045",
    "22a05f37b2f52af0_0046",
    "22a05f37b2f52af0_0047",
    "22a05f37b2f52af0_0048",
    "22a05f37b2f52af0_0049",
    "22a05f37b2f52af0_0050",
    "22a05f37b2f52af0_0051",
    "22a05f37b2f52af0_0052",
    "22a05f37b2f52af0_0053",
    "22a05f37b2f52af0_0054",
    "22a05f37b2f52af0_0055",
    "22a05f37b2f52af0_0056",
    "22a05f37b2f52af0_0057",
    "22a05f37b2f52af0_0058",
    "22a05f37b2f52af0_0059",
    "22a05f37b2f52af0_0060",
    "22a05f37b2f52af0_0061",
    "22a05f37b2f52af0_0062",
    "22a05f37b2f52af0_0063",
    "22a05f37b2f52af0_0064",
    "22a05f37b2f52af0_0065",
    "22a05f37b2f52af0_0066",
    "22a05f37b2f52af0_0067",
    "22a05f37b2f52af0_0068",
    "22a05f37b2f52af0_0069",
    "22a05f37b2f52af0_0070",
    "22a05f37b2f52af0_0071",
    "22a05f37b2f52af0_0072",
    "22a05f37b2f52af0_0073",
    "22a05f37b2f52af0_0074",
    "22a05f37b2f52af0_0075",
    "22a05f37b2f52af0_0076",
    "22a05f37b2f52af0_0077",
    "22a05f37b2f52af0_0078",
    "22a05f37b2f52af0_0079",
    "22a05f37b2f52af0_0080",
    "22a05f37b2f52af0_0081",
    "22a05f37b2f52af0_0082",
    "22a05f37b2f52af0_0083",
    "22a05f37b2f52af0_0084",
    "22a05f37b2f52af0_0085",
    "22a05f37b2f52af0_0086",
    "22a05f37b2f52af0_0087",
    "22a05f37b2f52af0_0088",
    "22a05f37b2f52af0_0089",
    "22a05f37b2f52af0_0090",
    "22a05f37b2f52af0_0091",
    "22a05f37b2f52af0_0092",
    "22a05f37b2f52af0_0093",
    "22a05f37b2f52af0_0094",
    "22a05f37b2f52af0_0095",
    "22a05f37b2f52af0_0096",
    "22a05f37b2f52af0_0097",
    "22a05f37b2f52af0_0098",
    "22a05f37b2f52af0_0099",
    "22a05f37b2f52af0_0100",
    "22a05f37b2f52af0_0101",
    "22a05f37b2f52af0_0102",
    "22a05f37b2f52af0_0103",
    "22a05f37b2f52af0_0104",
    "22a05f37b2f52af0_0105",
    "22a05f37b2f52af0_0106",
    "22a05f37b2f52af0_0107",
    "22a05f37b2f52af0_0108",
    "22a05f37b2f52af0_0109",
    "22a05f37b2f52af0_0110",
    "22a05f37b2f52af0_0111",
    "22a05f37b2f52af0_0112",
    "22a05f37b2f52af0_0113",
    "22a05f37b2f52af0_0114",
    "22a05f37b2f52af0_0115",
    "22a05f37b2f52af0_0116",
    "22a05f37b2f52af0_0117",
    "22a05f37b2f52af0_0118",
    "22a05f37b2f52af0_0119",
    "22a05f37b2f52af0_0120",
    "22a05f37b2f52af0_0121",
    "22a05f37b2f52af0_0122",
    "22a05f37b2f52af0_0123",
    "22a05f37b2f52af0_0124",
    "22a05f37b2f52af0_0125",
    "22a05f37b2f52af0_0126",
    "22a05f37b2f52af0_0127",
    "22a05f37b2f52af0_0128",
    "22a05f37b2f52af0_0129",
    "22a05f37b2f52af0_0130",
    "22a05f37b2f52af0_0131",
    "22a05f37b2f52af0_0132",
    "22a05f37b2f52af0_0133",
    "22a05f37b2f52af0_0134",
    "22a05f37b2f52af0_0135",
    "22a05f37b2f52af0_0136",
    "22a05f37b2f52af0_0137",
    "22a05f37b2f52af0_0138",
    "22a05f37b2f52af0_0139",
    "22a05f37b2f52af0_0140",
    "22a05f37b2f52af0_0141",
    "22a05f37b2f52af0_0142",
    "22a05f37b2f52af0_0143",
    "22a05f37b2f52af0_0144",
    "22a05f37b2f52af0_0145",
    "22a05f37b2f52af0_0146",
    "22a05f37b2f52af0_0147",
    "22a05f37b2f52af0_0148",
    "22a05f37b2f52af0_0149"
  ],
  "documents": [
    "NAMS P OSITION STATEMENT Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society Abstract Objective: To review evidence regarding osteoporosis screening, prevention, diagnosis, and management in the past decade and update the position statement published by The North American Menopause Society (NAMS) in 2010 regarding the management of osteoporosis in postmenopausal women as new therapies and paradigms have become available. Design: NAMS enlisted a panel of clinician experts in the field of metabolic bone diseases and/or women’s health to review and update the 2010 NAMS position statement and recommendations on the basis of new evidence and clinical judgement. The panel’s recommendations were reviewed and approved by the NAMS Board of Trustees. Results: Osteoporosis, especially prevalent in older postmenopausal women, increases the risk of fractures that can be associated with significant morbidity and mortality. Postmenopausal bone loss, related to estrogen deficiency, is the primary contributor to osteoporosis. Other important risk factors for postmenopausal osteoporosis include advanced age, genetics, smoking, thinness, and many diseases and drugs that impair bone health.",
    "Other important risk factors for postmenopausal osteoporosis include advanced age, genetics, smoking, thinness, and many diseases and drugs that impair bone health. An evaluation of these risk factors to identify candidates for osteoporosis screening and recommending nonpharmaco- logic measures such as good nutrition (especially adequate intake of protein, calcium, and vitamin D), regular physical activity, and avoiding smoking and excessive alcohol consumption are appropriate for all postmenopausal women. For women at high risk for osteoporosis, especially perimenopausal women with low bone density and other risk factors, estrogen or other therapies are available to prevent bone loss. For women with osteoporosis and/or other risk factors for fracture, including advanced age and previous fractures, the primary goal of therapy is to prevent new fractures. This is accomplished by combining nonpharmacologic measures, drugs to increase bone density and to improve bone strength, and strategies to reduce fall risk. If pharmacologic therapy is indicated, government- approved options include estrogen agonists/antagonists, bisphosphonates, RANK ligand inhibitors, parathyroid hormone-receptor agonists, and inhibitors of sclerostin. Conclusions: Osteoporosis is a common disorder in postmenopausal women.",
    "Conclusions: Osteoporosis is a common disorder in postmenopausal women. Management of skeletal health in postmenopausal women involves assessing risk factors for fracture, reducing modifiable risk factors through dietary and lifestyle changes, and the use of pharmacologic therapy for patients at significant risk of osteoporosis or fracture. For women with osteoporosis, lifelong management is necessary. Treatment decisions occur continuously over the lifespan of a postmenopausal woman. Decisions must be individualized and should include the patient in the process of shared decision-making. Key Words: Bisphosphonates – Bone mineral density – Calcium – Estrogen agonists/antagonists – Falls – Fractures – Osteoporosis – Parathyroid hormone-receptor agonists – Postmenopause – Prevention – RANK ligand inhibitors – Vitamin D. O steoporosis can be a serious health threat for post- menopausal women by predisposing them to frac- tures that may be associated with substantial morbidity and mortality, especially in older women. Clinical management cannot be defined or confined only by ‘‘evi- dence.’’ There is no single or optimal management strategy for a chronic disorder such as osteoporosis. When evidence is lacking, clinicians use clinical judgement, consisting of Received June 8, 2021; revised and accepted June 8, 2021.",
    "When evidence is lacking, clinicians use clinical judgement, consisting of Received June 8, 2021; revised and accepted June 8, 2021. This position statement was developed by The North American Meno- pause Society (NAMS), with representatives of the NAMS Board of Trustees and other experts in women’s health: Jennifer Blake, MD; Felicia A. Cosman, MD; E. Michael Lewiecki, MD, FACP, FACE; Michael R. McClung, MD, FACP, FACE; JoAnn V. Pinkerton, MD, FACOG, NCMP; and Marla Shapiro, MD, CM, CCFP, MHSc, FRCP(C), NCMP. The Board of Trustees conducted independent review and revision and approved the position statement on June 7, 2021. This position statement was made possible by donations to the NAMS Education & Research Fund. There was no commercial support. Address correspondence to: The North American Menopause Society, 30050 Chagrin Blvd, Suite 120W, Pepper Pike, OH 44124. E-mail: [EMAIL] Website: www.menopause.org Menopause, Vol. 28, No. 9, 2021 973 Menopause: The Journal of The North American Menopause Society Vol. 28, No. 9, pp. 973-997 DOI: 10.1097/GME.0000000000001831 /C2232021 by The North American Menopause Society individualized management decisions for each patient and for different stages in the course of the disease and based on a combination of known evidence, knowledge of the physiol- ogy of the problem being addressed, and their experience.",
    "1 The North American Menopause Society (NAMS) creates position statements on specific disorders to provide reliable and accurate information regarding management of meno- pause-associated health conditions. Here, NAMS provides guidance on the diagnosis, assessment, prevention, and treat- ment of osteoporosis in postmenopausal women in North America. The recommendations herein are based, where possible, on evidence provided by clinical trials and, where evidence does not exist, current best clinical practice in the opinions and clinical judgment of an editorial panel consisting of clinicians and researchers with expertise in metabolic bone diseases or women’s health. These statements do not represent guidelines or codified practice standards as defined by regulating bodies and insurance agencies. Rather, the editorial panel has attempted to provide sufficient information for clinicians to approach postmenopausal women with or at risk for osteopo- rosis with a confident understanding of management options. The recommendations are focused on the perceptions of the needs of healthcare professionals caring for the skeletal health of postmenopausal women in the primary care setting. The guidance provided herein is generally consistent with recom- mendations for the assessment and treatment of postmeno- pausal osteoporosis available from several other North American societies and organizations.",
    "2-8 This position statement is an update of the 2010 position statement, ‘‘Management of Osteoporosis in Postmenopausal Women.’’9 Since then, several new medications with sophis- ticated mechanisms of action have received government approval on the basis of randomized, controlled trial (RCT) data. In addition, new knowledge about the pathophysiology and epidemiology of postmenopausal osteoporosis has become available, as have new perspectives about the role of hormone therapy (HT) in the management of skeletal health, longer experience with the efficacy and safety of older osteoporosis drugs, the potential role of drug holidays for bisphosphonates, and new paradigms regarding sequential use of and anabolic and antiremodeling osteoporosis therapies. These advances have created the need to update the position statement. METHODS For this revision, NAMS enlisted a six-person editorial panel composed of clinicians and researchers with expertise in metabolic bone diseases or women’s health to review the 2010 position statement, identify key studies and evidence pub- lished subsequently, and reach consensus on recommenda- tions. The editorial panel reviewed clinical studies published in English related to osteoporosis management in postmen- opausal women. Priority was given to evidence from RCTs and meta-analyses of such trials, followed by evidence from systematic reviews and controlled observational studies, using criteria described elsewhere.",
    "Priority was given to evidence from RCTs and meta-analyses of such trials, followed by evidence from systematic reviews and controlled observational studies, using criteria described elsewhere. 10 Because standards of care and available treatment options differ throughout the world, the focus is limited to therapies for postmenopausal osteoporosis available in North America. The NAMS Board of Trustees was responsible for the final review and approval of this position statement. EVALUATING PATIENTS FOR AND WITH OSTEOPOROSIS Background Osteoporosis—the most common bone disorder affecting humans—is a generalized skeletal disorder characterized by compromised bone strength, predisposing a person to an increased risk of fracture, most importantly of the spine and hip. 11 These and other serious fractures occur most commonly in older postmenopausal women and are often life-altering events. However, the bone loss that results in osteoporosis is most marked during the menopause transition and early menopause. Less serious fractures, such as wrist fractures, occur in young postmenopausal women and are important warning signs of osteoporosis. Persons with osteoporosis and high risk of fracture can be readily identified. Both general and pharmacologic manage- ment strategies are available to slow or prevent bone loss and to reduce fracture risk.",
    "Both general and pharmacologic manage- ment strategies are available to slow or prevent bone loss and to reduce fracture risk. Because osteoporosis is such a com- mon disorder, skeletal health assessment should be a part of the routine evaluation of all postmenopausal women, and all professionals caring for postmenopausal women should be competent and confident about undertaking that evaluation. Pathophysiology In adults, bone tissue undergoes constant change by a process called bone remodeling . Old bone material (mineral and protein matrix) is resorbed (removed) by osteoclasts and replaced with new healthy bone by osteoblasts. Osteocytes interconnect in the solid matrix of bone via an extensive canalicular network that senses both mechanical loading and focal bone damage. Osteocytes secrete molecules that regu- late both the location of and the rate of bone remodeling. These include receptor activator of nuclear factor kappa- b (RANK) ligand, a growth-promoting factor whose interaction with its receptor RANK is required for the proliferation, differentiation, and activity of osteoclasts; and sclerostin, an inhibitor of bone formation. Osteocyte activity is, in turn, regulated by mechanical loading and circulating hormones including parathyroid hormone (PTH) and estrogen. Bone strength (and, hence, fracture risk) is dependent on many qualities of bone, of which bone mineral density (BMD) is the most commonly measured.",
    "Bone strength (and, hence, fracture risk) is dependent on many qualities of bone, of which bone mineral density (BMD) is the most commonly measured. 11 Bone density at any given age is a function of both peak bone mass (reached by age 30) and how much bone is subsequently lost. In healthy premen- opausal women, bone mass is quite stable. The amount of old bone resorbed is replaced with an almost equal amount of new bone. 12 During perimenopause, estrogen deficiency results in increased expression of RANK ligand, activating osteoclasts. Bone resorption becomes more rapid, exceeding the ability of NAMS POSITION STATEMENT 974 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society osteoblasts to form new bone, resulting in an accelerated phase of bone loss during the menopause transition. 12,13 The average annual rate of bone loss is about 2%, beginning 1 to 3 years before menopause and lasting for 5 to 10 years, resulting in an average loss of BMD of 10% to 12% in the spine and hip across the menopause transition. 12 Rates of loss are somewhat greater in thin versus heavy women. After this interval of relatively rapid bone loss, bone density decreases about 0.5% per year. This imbalance in remodeling continues into advanced age in which an additional deficit in osteoblast function limits bone formation.",
    "This imbalance in remodeling continues into advanced age in which an additional deficit in osteoblast function limits bone formation. By age 80 years, women have lost, on average, approximately 30% of their peak bone mass.4 Bone loss after menopause results in a gradual but progres- sive deterioration of the microarchitecture of both trabecular and cortical bone, weakening the skeleton and increasing the risk of fracture. The thick and numerous trabeculae seen in the spine and ends of long bones in premenopausal women become thinned and perforated and may be completely resorbed, result- ing in empty spaces where bone tissue once existed. The thick outer shell of cortical bone is thinned from the inside and becomes more porous because of the dominance of bone resorption over formation. This imbalance in bone remodeling can be accentuated by a very sedentary lifestyle, contributing to accelerated bone loss in older inactive women. Many diseases and medications can amplify these effects by either increasing bone resorption or inhibiting bone formation. Other factors, including bone mineralization, matrix com- position, microstructure, and microdamage, as well as age- related factors such as the accumulation of advanced glyca- tion end products, affect the quality and integrity of bone tissue. These factors cannot be directly measured in clinical practice.",
    "These factors cannot be directly measured in clinical practice. These combined changes in bone mass, structure, and quality result in impaired bone strength and the increased fracture risk of postmenopausal osteoporosis. Bone mineral density The measurement of areal bone density (the amount of bone mineral divided by the area of the bone scanned) by dual- energy X-ray absorptiometry (DXA), is the principal clinical tool used to assess skeletal health. Careful attention to the quality of both the acquisition and interpretation of DXA bone density tests is necessary. 14 To standardize bone density values from different skeletal sites, results are reported as T-scores or Z-scores: /C15 The T-score compares a woman’s bone density to the average value of healthy young women and is expressed in standard deviation (SD) units. A T-score of þ1 repre- sents a value 1 SD above the young normal mean, whereas a value 2.5 SDs below the young normal mean would equate to a T-score of /C0 2.5. By convention, the White (non-race adjusted), young, normal value serves as the reference for T-scores in women of all races. /C15 The Z-score is the number of SDs above or below the average bone density for the average person of the same age, sex, and ethnicity. The normal range for Z-score is /C0 2.0 to þ2.0. The Z-score has limited value in postmenopausal women. Studies to date provide inadequate data on racial inequities in health care.",
    "The normal range for Z-score is /C0 2.0 to þ2.0. The Z-score has limited value in postmenopausal women. Studies to date provide inadequate data on racial inequities in health care. Individual- and system-level issues that pro- mote inequality need to be addressed in further research studies. 15 Diagnosing osteoporosis Diagnostic categorization by bone density is based on recommendations of a World Health Organization Study Group (Table 1). 16 In North America, the standard criterion for the diagnosis of osteoporosis in postmenopausal women is a T-score of /C0 2.5 or less at the lumbar spine (LS; at least two vertebral levels measured in the posterior-anterior projection but not the lateral projection), femoral neck (FN), or total hip (TH) by DXA testing. If anatomic factors such as arthritis or hip replacement make measurements of the spine and hip invalid, bone density of the distal one-third site of the radius (forearm) may be considered a diagnostic site, but other methods of diagnosing osteoporosis and assessing fracture risk also should be considered. When a woman’s T-score increases with treatment from less than /C0 2.5 to values above /C0 2.5, the diagnosis of osteoporosis persists. 17 The diagnosis of low BMD, or osteopenia, does not nec- essarily indicate that bone loss has occurred.",
    "17 The diagnosis of low BMD, or osteopenia, does not nec- essarily indicate that bone loss has occurred. This term has limited clinical use because it includes young postmenopausal women without other risk factors who are at low risk of fracture as well as older women with other risk factors who are at very high risk of fracture. T-scores can be generated from other methods of BMD assessment, and some of those measurements have been shown to predict fracture risk. In general, however, T-scores from those other methods should not be used to diagnose osteoporosis. 18 In addition to BMD, the clinical diagnosis of osteoporosis can be made in postmenopausal women who present with fractures of their spine or hip or who have other risk factors resulting in high fracture risk (Table 2). 7 Osteoporosis is categorized as either primary or secondary. Primary osteoporosis refers to bone loss that occurs after menopause and with aging. Secondary osteoporosis is diag- nosed when medications such as glucocorticoids or diseases contribute to bone loss. Prevalence In the 2013-2014 National Health and Nutrition Examina- tion Survey, 16.5% of American women aged 50 years or older had osteoporosis, defined as a BMD T-score of /C0 2.5 or lower at either the FN or LS. 19 Similar prevalence has been observed in Canada and Mexico. 20,21 The prevalence of osteoporosis by low FN BMD increases with age, from TABLE 1.",
    "19 Similar prevalence has been observed in Canada and Mexico. 20,21 The prevalence of osteoporosis by low FN BMD increases with age, from TABLE 1. Diagnostic categories based on femoral neck T-scores Normal T-score /C21/C0 1.0 Low bone mass a T-score between 1.0 and /C0 2.5 Osteoporosis T-score /C20/C0 2.5 aThis category is often referred to as osteopenia. Kanis JA, et al. 16 NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 975 6.8% in women aged 50 to 59 years to 34.9% in women aged 80 years and older. 22 In the United States, the rates of osteo- porosis vary with ethnicity: Black Americans have the highest BMD, whereas Asian Americans have the lowest. 23 These differences, however, may be related more to body weight than to race. 24 More than 2 million fractures related to osteoporosis occur each year in the United States, including more than 700,000 clinical vertebral fractures and 300,000 hip fractures, result- ing in more than 500,000 hospital admissions. 25 Most of these fractures occur in older postmenopausal women, with two- thirds of the fractures occurring after age 75. 26 For a White American woman aged 50 years, the risk of suffering an osteoporotic fracture in her remaining lifetime has been estimated at 40%, and for hip, forearm, and symptomatic vertebral fracture is at 17.5%, 16.0%, and 15.6%, respec- tively.",
    "27 Lifetime risks for hip fracture are 17% for White Americans, 14% for Hispanic Americans, and 6% for Black Americans.28 Age-adjusted rates of hip fracture in women in the United States and Canada appeared to be decreasing after 1997. However, recent data suggest that those rates have plateaued and may even be increasing again, perhaps related to the declining use of osteoporosis medications since 2008. 29,30 The absolute number of patients who have fractures will continue to increase because of population growth. 22 Morbidity and mortality Hip fractures, occurring on average at age 82, elicit a particularly devastating toll, resulting in higher cost and disability than all other fracture types combined. 31 Hip frac- tures cause up to a 25% increase in mortality within 1 year of the incident. 32 Up to 25% of women require long-term care after a hip fracture, and 50% will have some long-term loss of mobility. The annual incidence of experiencing a second hip fracture is 2% to 10%, with the second fracture occurring, on average, about 2 years after the first. 33 Fractures at other sites, including the spine, humerus, and pelvis, also can result in serious morbidity.",
    "33 Fractures at other sites, including the spine, humerus, and pelvis, also can result in serious morbidity. 34 Multiple or severe vertebral fractures may cause substantial pain as well as loss of height and exaggerated curvature of the thoracic spine (kyphosis), restricted movement, and impaired lung function.35 Only about one-third of vertebral fractures that can be diagnosed radiographically come to clinical atten- tion. 35,36 Existing vertebral fractures increase the risk of subsequent vertebral fracture by five- to seven-fold. 37 The relative risk for mortality after vertebral fracture is as high as with hip fracture. 38 Postfracture pain, loss of mobility, changed body image, and loss of independence can have strong effects on self-esteem and mood. 39 Clinical assessment Evaluation of skeletal health, including the assessment of risk factors for low BMD and fracture, should be undertaken in all postmenopausal women. This information can identify women for BMD testing and shape recommendations for clinical management. Risk factors and risk assessment It is important to distinguish between risk factors for osteoporosis as defined by BMD and risk factors for fracture. Major risk factors for low BMD in postmenopausal women include menopause status, advanced age, genetics, thinness, and diseases or drugs with adverse skeletal effects.",
    "Major risk factors for low BMD in postmenopausal women include menopause status, advanced age, genetics, thinness, and diseases or drugs with adverse skeletal effects. Low BMD, as well as a history of previous fracture, older age, parental history of hip fracture, frailty, and other medical problems are important risk factors for fracture. Tools to assess the risk of low BMD and of osteoporotic fracture are available. Risk factors for low bone density. /C15 Advanced age . Bone loss decreases progressively with advancing age, and the prevalence of osteoporosis increases as women grow older. /C15 Thinness. Bone density in healthy women is strongly correlated with body weight. 40 Being thin —often cited as body weight less than 127 lb (57.7 kg), the lower quartile of weight for US women aged older than 65 years, or body mass index (BMI) less than 21 kg/m 2—is a risk factor for low BMD. /C15 Genetics. Family studies demonstrate that 50% to 85% of the variance in BMD is genetically determined. 41 Many genes have been weakly associated with low bone mass in humans. /C15 Smoking. Women who currently smoke have lower BMD than do nonsmokers. 42 Smokers are generally thinner and have earlier menopause and lower serum estradiol levels than nonsmokers. /C15 Diseases and drugs . Many diseases and drugs adversely affect the skeleton (Table 3).",
    "/C15 Diseases and drugs . Many diseases and drugs adversely affect the skeleton (Table 3). 4,7 These include eating dis- orders, chronic inflammatory illnesses (ie, rheumatoid arthritis), diseases causing malabsorption (ie, celiac dis- ease), and various endocrinopathies (hyperparathyroidism, Cushing syndrome). Drugs can cause bone loss by increas- ing bone resorption (aromatase inhibitors [AIs]), impairing vitamin D metabolism (phenytoin), or reducing bone for- mation (glucocorticoids), as can surgeries such as gastric bypass. Notable factors not predictive of low BMD include daily or lifetime intake of calcium or vitamin D, alcohol or caffeine TABLE 2. Diagnosing osteoporosis in postmenopausal women 1. BMD T-score by DXA of /C0 2.5 or lower in the LS or proximal femur (TH or FN) 2. History of vertebral (spine) or hip fracture, irrespective of BMD or other risk factors 3. Low bone mass (T-score between /C0 1.0 and /C0 2.5) and any of the following a. History of fracture of proximal humerus, pelvis, or distal forearm b. History of multiple fractures at other sites (excluding face, feet, and hands) c. Increased fracture risk using FRAX country-specific thresholds BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; FN, femoral neck; FRAX, Fracture Risk Assessment Tool; LS, lumbar spine; TH, total hip. Camacho PM, et al. 7 NAMS POSITION STATEMENT 976 Menopause, Vol. 28, No.",
    "Camacho PM, et al. 7 NAMS POSITION STATEMENT 976 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society intake, current or past physical activity, and reproductive history. Tools to predict low bone mineral density in postmenopausal women. Several simple tools are available to identify postmeno- pausal women likely to have low BMD. The Osteoporosis Self-Assessment Tool combines age and body weight in this formula: Osteoporosis Self-Assessment Tool T-score ¼ 0.2 /C2 (weight in kg minus age in years), truncated to yield integer. 43 Using a definition of less than 2 as high risk, the performance of the Osteoporosis Self-Assessment Tool in identifying postmenopausal White women with BMD T-score values of /C0 2.5 or lower at either the LS or FN demonstrated a sensitivity of 95.3% and a corresponding specificity of 39.6%. The Osteoporosis Risk Assessment Instrument demonstrated sensitivity of 93.3% and 94.4% for selecting Canadian women with low BMD and osteoporosis, respectively. 44 These tools are most useful for selecting young postmenopausal women for BMD testing. Risk factors for fracture. The most important risk factors for fracture in postmeno- pausal women are history of previous fracture or falls, older age, and low BMD. Combining these and other independent risk factors improves the ability to identify patients at high risk of fracture.",
    "Combining these and other independent risk factors improves the ability to identify patients at high risk of fracture. 45 Several fracture risk-assessment tools are available to estimate a person’s risk of fracture, including the Canadian Association of Radiologists and Osteoporosis Canada calculator. 46 This computer-based algorithm is available online (www.sheffield.ac.uk/FRAX/) and in com- mon DXA software. In addition to age, sex, and BMI, FRAX combines age, sex, BMI, and independent risk factors on the basis of meta-analyses of large observational cohorts (Table 4). 47 Separate databases are used to estimate fracture risk in White, Black, Asian, and Hispanic women in the United States. Details of the use of the FRAX tool, including its strengths and limitations, have been reviewed elsewhere. 48 /C15 Prior fracture . Having or having had a fracture since menopause is the most important and powerful risk factor for having another fracture. 49 The risk of refracture is especially high (up to 19% within 12 mo) in patients with recent fractures. 37,50 This has led some organizations to describe patients with a recent osteoporotic fracture as being at very high or imminent risk of fracture. 7,51 This increased risk gradually diminishes but persists for at least 10 years, with the average risk over that time being about two-fold higher than expected for their age and BMD.",
    "7,51 This increased risk gradually diminishes but persists for at least 10 years, with the average risk over that time being about two-fold higher than expected for their age and BMD. – In the past, terms such as fragility or nontraumatic fractures were used to define fractures related to osteo- porosis and that predicted future fractures. – Recent evidence suggests that all fractures, except those of the face, skull, hands, and feet, are associated with low BMD and future fracture risk, irrespective of association with trauma. 52 /C15 Low bone density . The strongest correlation of BMD and fracture risk is with hip bone density. 53 Hip fracture risk increases by 2.6-fold for each age-adjusted SD (one Z- score unit) decrease in FN BMD. The magnitude of risk associated with low BMD is modulated by age and other risk factors. TABLE 3.",
    "The magnitude of risk associated with low BMD is modulated by age and other risk factors. TABLE 3. Common or important medications and medical conditions that can adversely affect bone health Medications Medications causing bone loss Aromatase inhibitors Glucocorticoids for >3m o Thyroid hormone in excess Immunosuppressive agents (eg, cyclosporine) Gonadotropin-releasing hormone agonists or antagonists Some anticonvulsants (eg, phenytoin) Cytotoxic agents Intramuscular medroxyprogesterone Medications associated with increased fracture risk Proton pump inhibitors Thiazolidinediones SGLT2-inhibitors Insulin with hypoglycemia Selective serotonin-reuptake inhibitors Selective norepinephrine-reuptake inhibitors Medical conditions Genetic disorders Osteogenesis imperfecta Hypophosphatasia Thalassemia Hemochromatosis Endocrinopathies Gonadal insufficiency (primary and secondary) Type 1 and type 2 diabetes mellitus Hyperthyroidism Primary hyperparathyroidism Hypercortisolism, including Cushing syndrome Nutritional disorders Eating disorders Obesity Disorders of calcium balance Vitamin D deficiency Hypercalciuria Gastrointestinal diseases Malabsorption syndromes (eg, celiac disease) Inflammatory bowel disease Gastrectomy Chronic liver disease Other disorders and conditions Chronic renal disease Systemic mastocytosis Rheumatologic diseases (eg, rheumatoid arthritis) Hematologic malignancies (eg, leukemia, multiple myeloma) Frailty Neuromuscular or visual impairment SGLT2, sodium glucose cotransporter 2.",
    "Cosman F, et al 4; Camacho PM, et al. 7 NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 977 /C15 Age. For any BMD value, older women are at higher fracture risk than are younger postmenopausal women. 45 /C15 Parental history of hip fracture . The strongest compo- nent of a family history to predict fracture risk is a parental history of hip fracture. 54 /C15 Smoking. Fracture risk in postmenopausal women who smoke is increased about 30%, independent of BMD. 55 /C15 Excessive alcohol intake . Consuming more than three servings of alcohol daily is associated with a 38% and 68% increase risk of major osteoporotic and hip fracture, respectively. 56 Risk factors not incorporated into FRAX include those not available in the databases on which FRAX was based (eg, falls) or were not known when FRAX was developed (diabe- tes): /C15 Falls. Most fractures, including many vertebral fractures, occur after a fall from a standing height or less. 57,58 As a result, risk factors for falls, including a history of recent falls; weakness; impaired balance, coordination, vision, or hearing; obesity; and arthritis, are also risk factors for fracture. /C15 Diseases and drugs . Poor health is a risk factor for fracture; most diseases are associated with a general increase in fracture risk (Table 3). 4,7 Diseases and drugs such as type 2 diabetes, obesity, and proton pump inhibitors are associated with increased fracture risk without causing bone loss.",
    "4,7 Diseases and drugs such as type 2 diabetes, obesity, and proton pump inhibitors are associated with increased fracture risk without causing bone loss. Disorders and drugs that affect muscle strength and balance such as frailty, stroke, and antidepressant medications increase risks of falls and fracture. Other known risk factors for fracture include dementia, low physical activity, thoracic kyphosis, rates of bone loss, and both weight and height loss. 52,59 Other risk-assessment methods. Bone density can be assessed by techniques other than DXA, including ultrasound and quantitative computed tomography (CT). T-score values obtained with these tech- niques are not substitutes for T-scores of the hip or spine obtained with DXA because they may overestimate or under- estimate BMD and thus fracture risk. 60 For those few patients who cannot have DXA measurements at the hip or spine, assessing fracture risk with FRAX without BMD provides more useful information than does BMD measured by alternate techniques. Biomechanical CT analyzes quantitative CT scans of the LS and hip with an algorithm called finite element analysis that provides validated estimates of bone strength in individ- ual patients. 61 Biomechanical CT predicts fracture risk, although its advantage over DXA is small. Access to bio- mechanical CT is limited, and its role in routine clinical practice has not been defined.",
    "61 Biomechanical CT predicts fracture risk, although its advantage over DXA is small. Access to bio- mechanical CT is limited, and its role in routine clinical practice has not been defined. Trabecular bone score is a special software available for DXA machines that analyzes the heterogeneity of density distribution on routine LS DXA images. Trabecular bone score measurements correlate with trabecular microarchitec- ture and predict fracture risk independently from bone den- sity. 62 Trabecular bone score has recently been incorporated into FRAX. 63 Using trabecular bone score is most helpful in women whose fracture risk is near the treatment threshold. Assessing fall risk, with special emphasis on a history of a recent fall, is an important part of risk assessment in older women. 57 The Stopping Elderly Accidents Deaths and Injury initiative developed by the Centers for Disease Control and Prevention provides an algorithm for fall-risk screening (www.cdc.gov/steadi/pdf/STEADI-Algorithm-508.pdf). Limitations to fracture-risk assessment. There are limitations to the use of any of the individual fracture-risk assessment tools and of the FRAX assessment tool. FRAX underestimates fracture risk in patients with falls or diabetes and in those with low spine but not FN BMD.",
    "FRAX underestimates fracture risk in patients with falls or diabetes and in those with low spine but not FN BMD. 64 In addition, current FRAX scoring does not allow input for quantification of risk factors, including dose of glucocorti- coid, amount of alcohol intake, duration and amount of cigarette smoking, or the number, type, or recency of prior fractures. 47 Despite these limitations, FRAX has been vali- dated as an accurate predictor of fracture probability in large populations in the United States and Canada. 65,66 However, its performance in identifying individual patients who will or will not fracture is less robust. 67 FRAX does not accurately predict BMD, but that is not what it was designed to do. 68 Until there are practical and inexpensive methods to measure bone strength accurately, estimating fracture risk with FRAX will remain one of the most useful tools. Indications for bone density testing Bone density should be measured in postmenopausal women with risk factors for low bone density where knowing the result will influence clinical management: /C15 Those with a history of fracture since menopause /C15 Those with known medical causes of bone loss or fracture /C15 Those aged 65 years and older /C15 Those aged 50 years and older with one or more of these additional risk factors: – Body weight less than 127 lb (57.7 kg) or BMI less than 21 kg/m 2 – History of hip fracture in a parent – Current smoker TABLE 4.",
    "Risk factors used in FRAX /C15 Age (40-90 y) /C15 Sex /C15 Weighta /C15 Heighta /C15 Previous fracture /C15 Parental history of hip fracture /C15 Current tobacco smoking /C15 Use of glucocorticoids /C15 Rheumatoid arthritis /C15 Alcohol intake of more than two units daily /C15 Secondary osteoporosis b /C15 FN BMD if available BMD, bone mineral density; FN, femoral neck; FRAX, Fracture Risk Assessment Tool. aBody mass index is automatically computed from height and weight. bOnly included in calculation when BMD is not available. Kanis JA, et al. 47 NAMS POSITION STATEMENT 978 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society – Discontinuing estrogen with additional risk factors for fracture In healthy postmenopausal women without osteoporosis, repeat BMD testing after 3 years does not enhance fracture risk prediction. 69 For postmenopausal women aged 50 to 64 years with baseline T-scores greater than /C0 1.5, retesting could be deferred to age 65, the age at which routine BMD screening is recommended for all women. 70 Earlier retesting should be considered in women within 5 years of menopause whose initial BMD T-score was lower than /C0 1.5 or in those with other important risk factors such as prior fracture or with medical problems or medications predisposing to bone loss.",
    "Physical examination The goals of evaluating postmenopausal women with oste- oporosis or important risk factors are to identify modifiable risk factors and secondary causes of bone loss, to quantify fracture risk and the severity of osteoporosis, and to determine appropriate candidates for pharmacologic therapy. This eval- uation requires a detailed history of risk factors for fractures and falls, other diseases and medications, previous fractures, and family history. A thorough physical examination should include evaluation of kyphosis, muscle strength, and balance. Standing height should be measured annually with an accurate method, such as a wall-mounted ruler or a stadiometer. Height loss of 1.5 in (3.8 cm) or more increases the likelihood that a vertebral fracture is present. This calls for evaluation by a lateral thoracolumbar radiograph or vertebral fracture assess- ment by DXA to identify asymptomatic compression verte- bral fractures. 71,72 Weight should be recorded to identify those women with low BMI and to be aware of weight changes, which may interfere with the interpretation of changes in BMD over time. For women with osteoporosis, examination also should include specific skeletal assessments such as bone tenderness (best elicited over the anterior tibia or thoracic vertebrae), indicating osteomalacia or focal bone disease, and joint laxity or blue sclera, features of osteogene- sis imperfecta.",
    "Laboratory evaluation For women with osteoporosis considering pharmacologic therapy, laboratory testing is performed to evaluate for sec- ondary causes of bone loss and to identify contraindications to specific therapies (Table 5). 4,5,7 Routine tests include com- plete blood cell count and general serum chemistry, especially serum calcium, creatinine, alkaline phosphatase, albumin, and serum phosphate. Measurement of 24-hour urinary calcium excretion is useful to detect patients with poor calcium absorption ( <100 mg/d) and those with hypercalciuria (>250 mg/d). Special laboratory tests should be considered in the presence of abnormal routine laboratory tests, clinical clues of other diseases, or unusual cases of osteoporosis. Biochemical markers of bone turnover. Bone turnover markers are serum tests that reflect either bone resorption by osteoclasts (fasting serum C-telopeptide of type I collagen) or bone formation by osteoblasts (bone- specific alkaline phosphatase or serum procollagen type I N-terminal propeptide). 73 Bone turnover markers cannot diagnose osteoporosis and have varying ability to predict TABLE 5.",
    "73 Bone turnover markers cannot diagnose osteoporosis and have varying ability to predict TABLE 5. Suggested laboratory tests for osteoporosis evaluation Diagnostic result Possible secondary cause Routine tests Complete blood count Anemia Multiple myeloma; celiac disease Elevated Hyperparathyroidism Serum calcium Low a Vitamin D deficiency; GI malabsorption; hypoparathyroidism Serum albumin (used to interpret serum calcium) Low Nutritional deficiencies; renal protein loss Serum phosphate Elevated Renal failure Low Hyperparathyroidism; renal phosphate wasting Serum creatinine Elevated b Renal failure; osteodystrophy Serum alkaline phosphatase Elevated Vitamin D deficiency; GI malabsorption; liver/biliary tract disease; Paget disease Low Hypophosphatasia Special tests Serum 25-hydroxyvitamin D Low Vitamin D deficiency; GI malabsorption Serum PTH Elevated Hyperparathyroidism, primary or secondary 24-hour urinary calcium Low Vitamin D deficiency; GI malabsorption Elevated Renal calcium leak; cancer involving bone, including myeloma; hyperthyroidism, hyperparathyroidism 24-hour urinary cortisol Elevated Cushing syndrome Serum protein electrophoresis Monoclonal band Multiple myeloma; MGUS Tissue transglutaminase Elevated Celiac disease Serum tryptase Elevated Mast cell disease Serum TSH Low Hyperthyroidism Decisions about laboratory testing depend on the clinical picture.",
    "GI, gastrointestinal; MGUS, monoclonal gammopathy of undetermined significance; PTH, parathyroid hormone; TSH, thyroid-stimulating hormone. aContraindication for bisphosphonates, denosumab, and romosozumab. bCaution or contraindication for bisphosphonate therapy. Cosman F, et al 4; Eastell R, et al 5; Camacho PM, et al. 7 NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 979 fracture risk in clinical trials. 74 Bone turnover markers have been used primarily in clinical trials to demonstrate group responses to treatment. Although used by some osteoporosis specialists, the routine use of bone turnover markers in the evaluation of patients with osteoporosis is not recommended. Key points /C15 Osteoporosis is a common disorder with potentially serious consequences. /C15 Assessment of skeletal health should be a part of routine care for all postmenopausal women. /C15 The annual examination should include measurements of height and weight; assessment for chronic back pain and kyphosis; and clinical risk factors for osteoporosis, frac- tures, and falls. /C15 The most important risk factors for future fracture are a history of previous fracture, older age, and low BMD. – Fracture risk is especially high in the first 2 years after an incident fracture. /C15 Bone mineral density testing is indicated for all postmen- opausal women with risk factors for low BMD or fracture. – DXA is the preferred technique for BMD testing.",
    "/C15 Bone mineral density testing is indicated for all postmen- opausal women with risk factors for low BMD or fracture. – DXA is the preferred technique for BMD testing. – For untreated postmenopausal women at low fracture risk, repeat DXA testing is not useful until at least 5 years have passed, unless rapid bone loss is antici- pated. /C15 Vertebral imaging is appropriate for postmenopausal women aged 70 years and older or with historical height loss. /C15 Secondary causes of osteoporosis should be evaluated before osteoporosis treatment has begun. /C15 The routine use of biochemical markers of bone turnover in clinical practice is not recommended. NONPHARMACOLOGIC TREATMENTS AND LIFESTYLE MODIFICATIONS The objectives of managing skeletal health in postmeno- pausal women are to prevent or minimize bone loss and to reduce the likelihood of fractures. All postmenopausal women, regardless of their BMD, clinical risk factors, or fracture risk, should be encouraged to adopt nonpharmaco- logic measures and lifestyle modifications, such as eating a balanced diet with adequate intakes of calcium and vitamin D, being physically active, and avoiding harmful lifestyle habits such as smoking, to support both general and bone health. 4,5,7,75 These general approaches, however, will not prevent bone loss in early menopause, will not significantly increase BMD in postmenopausal women, and are certainly not adequate treatment for women with osteoporosis.",
    "For women at high risk of fracture, pharmacologic therapy to strengthen the skeleton is required to reduce fracture risk. With obvious exceptions, such as the Women’s Health Initiative (WHI), most studies evaluating the effects of non- pharmacologic treatments and lifestyle modification are small and of short duration. As a result, recommendations here will be based on systematic reviews, meta-analyses, and expert opinion. Nutrition Calcium and vitamin D Sufficient intakes of calcium and vitamin D are necessary for normal skeletal growth during childhood and adolescence. The importance of these nutrients in healthy postmenopausal women is less clear. An Institute of Medicine (IOM; now called the National Academy of Medicine) committee con- cluded that scientific evidence supports important roles for calcium and vitamin D in skeletal health. Their proposed daily intakes of calcium for postmenopausal women were 1,000 mg to 1,200 mg, with an upper limit of 2,000 mg (Table 6). 76 The IOM commented that the recommendation for women aged 51 to 70 years is based on uncertain and inconsistent data. The average dietary calcium intake in postmenopausal women in the United States and Canada is 700 mg to 800 mg, about one-third of which comes from dairy products, meaning that an average dairy-free diet contains up to 500 mg of calcium. Few healthy women need to take more than 50 mg to 600 mg of a calcium supplement to achieve the IOM- recommended daily intake.",
    "Few healthy women need to take more than 50 mg to 600 mg of a calcium supplement to achieve the IOM- recommended daily intake. Patients with malabsorption or disorders of calcium metabolism such as hypoparathyroidism may require higher daily intakes of calcium and vitamin D. A listing of calcium content of foods and supplements is avail- able from the National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center (www. bones.nih.gov/health-info/bone/bone-health/nutrition/calcium- and-vitamin-d-important-every-age). No serious adverse events (AEs) have been observed with daily calcium intakes of less than 600 mg. Larger daily intakes are associated with gastrointestinal symptoms including bloating and constipation. In the WHI Calcium and Vitamin D study, the average dietary calcium intake was about 1,100 mg daily. In the group that took an additional 1,000 mg of a calcium supplement daily, the risk of kidney stones was increased by 17%. 77 The possi- bility that a calcium supplement of 1,000 mg daily (with total daily intake approximately 2,000 mg) is associated with increased cardiovascular risk was raised in a clinical trial and a subsequent meta-analysis. 78,79 That association was not observed in the WHI.80 A subsequent meta-analysis found that a calcium intake level of 2,000 mg to 2,500 mg per day was not associated with cardiovascular risk in healthy adults.",
    "81 However, in the absence of proof of benefit, a total daily calcium intake of more than 1,200 mg is not recommended for healthy postmenopausal women or those with osteoporosis. TABLE 6. Institute of Medicine recommendations for daily intakes of calcium and vitamin D for women aged older than 50 years Calcium, mg Vitamin D, IU Age range, y EAR a RDAb EARa RDAb 51-70 1,000 1,200 400 600 Over 70 1,000 1,200 400 800 EAR, estimated average requirement; IU, international units, RDA, recommended dietary allowance. aExpected to satisfy the needs of 50% of persons in that age group. bDaily dietary intake level of a nutrient considered sufficient to meet the requirements of 97.5% of healthy persons in that group. Institute of Medicine. 76 NAMS POSITION STATEMENT 980 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society Skeletal benefits of vitamin D supplementation in healthy adults are uncertain. The IOM recommends 600 IU for women aged between 50 and 70 years and 800 IU daily for those aged older than 70 years, stating that these intakes were sufficient to achieve serum 25-OHD levels of at least 20 ng/mL in most postmenopausal women. Meta-analyses of the effects of calcium and/or vitamin D on fracture risk provide inconsistent conclusions, with most reporting no benefit on fracture risk.",
    "Meta-analyses of the effects of calcium and/or vitamin D on fracture risk provide inconsistent conclusions, with most reporting no benefit on fracture risk. 82,83 In the bone health substudy in the Vitamin D and Omega-3 Trial, the bone density effects of 2,000 IU of cholecalciferol (vitamin D 3) daily were evaluated over 24 months in healthy women (average age, 63 y) with baseline serum 25-OHD levels of 27.6 ng/mL. 84 No effect was observed in the entire study group or in the subgroup with baseline serum 25-OHD levels less than 30 ng/mL. The inability to demonstrate effectiveness may be related to calcium and vitamin D being threshold nutrients; severe deficiencies may be harmful, but intakes more than the threshold to avoid deficiency does not provide additional benefit. Salutary effects of vitamin D with calcium on fracture risk have been observed most often in institutionalized or vitamin D-deficient older adults. 85 Most studies evaluating the effects of calcium or vitamin D have not restricted the study population to deficient participants. The US Preventive Services Task Force (USPSTF) concluded that there was insufficient evidence to assess the balance of the benefits and harms of daily supplementation with vitamin D 400 IU or more and calcium 1,000 mg or more daily for the primary prevention of fractures in community-dwelling, postmeno- pausal women. 86 They also recommended against the use of vitamin D supplements to prevent falls.",
    "86 They also recommended against the use of vitamin D supplements to prevent falls. 87 Women with osteoporosis do not require more calcium than women with normal BMD, and there is no convincing evi- dence that taking calcium and vitamin D supplements improves the effectiveness of osteoporosis drugs. 88 Adequate intakes of calcium and vitamin D are recommended when taking osteoporosis drugs to reduce the risk of treatment- induced hypocalcemia. 5 Protein intake Studies of relationships between protein intake and BMD or fracture risk have been inconsistent. In fall-prone older adults who were losing weight, higher protein intake was associated with reduced fall frequency. 89 Probiotics The gut microbiota can influence several aspects of bone health, including the absorption of calcium and vitamin D and immune response. In animal models, probiotics may prevent bone loss associated with estrogen deficiency, and prelimi- nary studies in humans suggest that probiotics could have a role in preventing bone loss. 90 Other supplements Strontium is a heavier divalent cation than calcium and increases BMD by being deposited in the skeleton. Strontium ranelate, a proprietary strontium salt, reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. 91 This drug was never approved in the United States or Canada, and it is no longer available in the rest of the world because of concerns about increased cardiovascular risk.",
    "91 This drug was never approved in the United States or Canada, and it is no longer available in the rest of the world because of concerns about increased cardiovascular risk. Other strontium salts (citrate, chloride) are promoted to support bone health in the United States, but there is no evidence for their effectiveness or safety. Meta-analysis found no meaningful relationship between magnesium intake and skeletal health. 92 Routine magnesium supplementation is not recommended in healthy adults with normal diets. Various vitamin K supplements have been promoted to improve bone health. A recent meta-analysis found no evi- dence that vitamin K affects bone density or vertebral fracture risk in postmenopausal women and that the evidence was insufficient to confirm a reduction in clinical fractures. 93 Phytoestrogens, including isoflavones, are plant-derived compounds with weak estrogenic activity. In a systematic review, some isoflavones (aglycone form) had a moderately beneficial effect against estrogen-deficiency bone loss. 94 Isoflavones are not recommended as effective strategies to prevent or treat postmenopausal osteoporosis. 95 There is also no compelling evidence for a beneficial effect of boron, zinc, black cohosh, berberine, or dehydroepiandros- terone on BMD or fracture risk in postmenopausal women. Avoiding harmful lifestyle factors Cessation of smoking and limiting alcohol intake are important general health measures.",
    "Avoiding harmful lifestyle factors Cessation of smoking and limiting alcohol intake are important general health measures. The AEs of smoking on bone health appear to reverse when smoking is stopped. 96 Physical activity and exercise Skeletal mass is strongly influenced by mechanical loading. During growth in children, impact-loading exercise programs induce small gains in BMD, whereas diseases causing immo- bilization are associated with low bone mass. A Cochrane review and several meta-analyses found relatively small, statistically significant effects of exercise on BMD compared with control groups in postmenopausal women. 97-99 The perception that exercise can reverse osteoporosis in postmenopausal women by inducing new bone formation is unfounded. Programs of regular exercise for general health can be recommended, especially those that increase muscle strength and improve balance, leading to fewer falls. Women with osteoporosis, especially those with vertebral fractures, should avoid activities that involve lifting or pulling with forward spine flexion or rotation and may benefit from an exercise program to stretch and strengthen the extensor muscles of the spine. 100 Fall prevention At least one-third of women aged 65 years and older experience one or more falls each year, and the risk of falling and of fracture increases with advancing age.101 Because most fractures occur as a result of a fall, attempts to reduce the NAMS POSITION STATEMENT Menopause, Vol. 28, No.",
    "28, No. 9, 2021 981 incidence of falls should be important components of reduc- ing fracture risk in older postmenopausal women. 4,7 A recent USPSTF report and a Cochrane review found that multicom- ponent exercise programs such as tai chi that target balance, gait, and muscle strength were the most effective ways to prevent falls and perhaps fractures in older adults. 86,101 Tapering the use of benzodiazepines, neuroleptic agents, and antidepressants reduced the risk of falling by more than 60%. Hip protectors may be considered in patients at high risk for falling, especially for patients in supervised settings such as long-term care facilities. 102 The Centers for Disease Con- trol and Prevention’s Stopping Elderly Accidents, Deaths, and Injuries initiative, based on published guidelines, provides useful tools for fall risk assessment and management (www.cdc.gov/steadi/). Key points /C15 Recommending and promoting healthy habits, including attention to nutrition, adequate calcium and vitamin D intake, physical activity, and avoidance of harmful habits is appropriate for all postmenopausal women. /C15 None of these approaches can significantly improve BMD or correct the architectural abnormalities of osteoporosis. /C15 The modest skeletal benefits of nonpharmacologic mea- sures should not be construed as sufficient or effective therapies for postmenopausal women with osteoporosis at high risk of fracture.",
    "/C15 The modest skeletal benefits of nonpharmacologic mea- sures should not be construed as sufficient or effective therapies for postmenopausal women with osteoporosis at high risk of fracture. /C15 The likelihood of falls can be decreased, however, and fracture risk may be reduced in older women. Prevention of falls is especially important in older women or those with decreased mobility. PHARMACOLOGIC THERAPY TO PREVENT BONE LOSS Several drugs with differing mechanisms of action have demonstrated the ability to prevent bone loss in postmeno- pausal women and to reduce fracture risk in women with postmenopausal osteoporosis. The mechanisms of action of all osteoporosis drugs are to modulate (either to inhibit or to activate) bone metabolism. Antiremodeling agents, often called antiresorptive drugs, include estrogen, estrogen ago- nists/antagonists (EAAs), bisphosphonates, and denosumab. They inhibit bone resorption, and to a lesser extent, bone formation. These drugs maintain or improve BMD and reduce fracture risk, but they do not improve or repair disruption of trabecular structure. In contrast, osteoanabolic agents, by stimulating new bone formation, improve cortical and/or trabecular bone structure and induce large increases in BMD, reducing fractures more quickly than do antiremodel- ing drugs. Prevention versus treatment Drugs are approved by North American regulatory agencies for either preventing or treating osteoporosis or both.",
    "Prevention versus treatment Drugs are approved by North American regulatory agencies for either preventing or treating osteoporosis or both. Since 2008, North American guidelines have focused on using osteoporosis drugs to reduce fracture risk. The concept of preventing osteoporosis by halting postmenopausal bone loss and its attendant damage to skeletal architecture is not recog- nized in those guidelines. On the basis of studies demonstrating prevention of bone loss in postmenopausal women without osteoporosis, various oral and transdermal estrogen preparations, alone or in com- bination with progestogens or bazedoxifene (BZA), as well as raloxifene, tibolone (in Mexico only), and four bisphospho- nate drugs (alendronate, risedronate, ibandronate, and zoledr- onate) have government approval for prevention of osteoporosis (Table 7). Bone density responses to these agents over 2 years in prevention studies are varied. The bone density benefits of therapy persist as long as therapy is continued, but the effects of estrogen-like drugs abate when treatment is discontinued. Markers of bone turnover return to pretreatment values within a few months, and BMD falls to pretreatment levels within 1 to 2 years of stopping therapy, effects pre- vented by switching to a bisphosphonate.",
    "103,104 Although using drugs to prevent osteoporosis is not included in national osteoporosis guidelines, a strong clinical argument can be made for doing so, especially in women who come to menopause with low bone mass. 105,106 On average, women lose about one T-score unit (10-12%) of bone mass across a normal menopause transition.12,107,108 With this rapid bone loss, significant and irreversible deterioration in trabec- ular microarchitecture occurs. These effects are preventable with estrogen and bisphosphonates. 106,109,110 However, with the exception of the WHI, strong evidence that preventing bone loss in young postmenopausal women results in fewer fractures in later life is lacking. A modeling exercise sug- gested that infrequent infusions of zoledronate at menopause would substantially reduce fracture risk and the number of women aged older than 65 years who had osteoporosis. 111 Support for the concept of osteoporosis prevention by anti- remodeling agents also is found in the treatment of women with AIs for nonmetastatic breast cancer who experience bone loss and increased fracture risk. 112 In these patients, bisphosphonates and denosumab prevented bone loss, and denosumab reduced the incidence of vertebral fractures by 50% within the first year of treatment, including in women with normal BMD values at baseline.",
    "113-115 Hormone therapy Several oral and transdermal systemic estrogen products are government approved in the United States and Canada for prevention of postmenopausal osteoporosis. Although no clear differences in the BMD responses among different estrogen preparations or between oral and transdermal admin- istration have been observed, transdermal estrogen appears to have less risk of venous thrombotic events and possibly stroke. Bone mineral density The beneficial effects of systemic standard doses of oral or transdermal HT on BMD, including estrogen plus progesto- gen therapy (EPT) for women with a uterus or estrogen-alone therapy (ET) for women without a uterus, have been shown in NAMS POSITION STATEMENT 982 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society RCTs in both younger and older postmenopausal women. 116- 120 In the Postmenopausal Estrogen/Progestin Interventions trial (N ¼ 875), 0.625 mg conjugated estrogens (CE), with or without a progestogen (either medroxyprogesterone acetate [MPA] or micronized progesterone [MP]), for 3 years signifi- cantly increased LS BMD by 3.5% to 5.0%, with a 1.7% increase in hip bone density. 116 In the WHI, a 5-year RCT in postmenopausal women aged 50 to 79 years (N ¼ 16,608), standard daily EPT doses (0.625 mg CE plus 2.5 mg MPA) significantly increased LS and TH bone density by 4.5% and 3.7%, respectively, relative to placebo.",
    "121 Oral 17-b estradiol in daily doses of 0.25 mg, 0.5 mg, and 1.0 mg increased LS BMD after 2 years by 0.4%, 2.3%, and 2.7%, respectively. 122 Combining those doses of estradiol with norethindrone ace- tate 0.5 mg daily resulted in larger increases in BMD. In a meta-analysis of 57 RCTs in postmenopausal women, consis- tent BMD increases with ET or EPT were observed at all skeletal sites versus placebo. 123 In trials of 2 years’ duration, the mean difference in BMD after EPT was 6.8% at the LS and 4.1% at the FN. Similarly, daily doses of 0.05 mg and 0.1 mg of estradiol acetate delivered via a vaginal ring significantly increased hip BMD (1.7% and 1.8%, respectively) and LS BMD (2.7% and 3.3%, respectively) compared with base- line. 124 Lower-than-standard doses of ET and EPT are asso- ciated with significant, albeit smaller, improvements in BMD, although the number of women experiencing bone loss on lower doses is likely higher. 118,120,122,125-127 Fracture risk In the WHI, ET with CE alone and EPT reduced the combined risk of vertebral fractures, hip fractures, and total fractures by 34% compared with placebo in a low-risk fracture population.121,128 Hip fracture risk was reduced by 30% (hazard ratio [HR], 0.7; unadjusted 95% confidence interval [CI], 0.4-1.0), vertebral fractures by 30% (HR, 0.7; unadjusted 95% CI, 0.4-1.0), and other osteoporotic fractures by 20% (HR, 0.8; 95% CI, 0.7-0.9).",
    "Meta-analysis and a systematic review, dominated by WHI results, demonstrated that 5 to 7 years of HT significantly reduced risk of spine, hip, and nonvertebral fractures. 129,130 Because no study, including the WHI, has evaluated the effects of estrogen on fracture risk in women with osteoporosis, estrogen is not approved as a treatment for postmenopausal osteoporosis. Doses of ET or EPT lower than used in the WHI have not been studied with regard to fracture efficacy. Safety In the WHI, initial reports of systemic EPT showed sta- tistically significant increased risks of breast cancer, stroke, and thromboembolic events. 131-133 In women with prior hysterectomy, CE alone for 6.8 years resulted in a statistically significant increased risk of stroke and deep venous throm- bosis, whereas breast cancer, coronary heart disease, total venous thromboembolism (VTE), and pulmonary embolism were not statistically increased. 134 In the WHI Memory Study, a statistically significant increase in probable dementia was noted in women aged 65 to 79 years who received EPT for a mean of 4.0 years. 135 After a mean follow-up of 5.2 years, there was a nonsignificant trend for increased probable dementia in women allocated to ET.",
    "135 After a mean follow-up of 5.2 years, there was a nonsignificant trend for increased probable dementia in women allocated to ET. Subgroup analyses suggest that the timing of initiation of HT influences the benefit-risk balance, with more favorable effects observed in women aged 60 years and younger or within 10 years of menopause, including less risk of cardio- vascular disease and possibly cognition. 136-138 In women aged older than 60 years or more than 10 years past the menopause TABLE 7.",
    "136-138 In women aged older than 60 years or more than 10 years past the menopause TABLE 7. Drugs approved in North America for preventing osteoporosis Drug Trade name(s) Drug class Dose, route of administration, and dosing interval CE Premarin Estrogen Oral; various doses and intervals (0.3, 0.45, 0.9, 1.25, 2.5 mg) Estradiol Various a Estrogen Oral and transdermal, various doses and intervals Estradiol þ NETA Activella, Amabelz Estrogen-progestin combination Estradiol 1 mg þ NETA 0.5 mg; estradiol 0.5 mg þ NETA 0.1 mg; PO daily Ethinyl estradiol þ NETA FemHRT, Jinteli Estrogen-progestin combination Ethinyl estradiol 2.5 mg þ NETA 0.5 mg; ethinyl estradiol 5 mg þ NETA 1 mg; PO daily CE þ MPA PremPro Estrogen-progestin combination CE þ MPA doses: CE 0.625 mg þ MPA 2.5 mg or 0.45 mg þ 1.5 mg; 0.3 mg þ1.5 mg; 0.625 mg þ 5 mg; PO daily CE þ BZA Duavee Estrogen-EAA com- bination CE 0.45 mg þ BZA 20 mg PO daily Tibolone Livial; generics Synthetic estrogen agonist 2.5 mg PO daily Raloxifene Evista; generics EAA 60 mg PO daily Alendronate Fosamax; generics Bisphosphonate 35 mg PO q wk Risedronate Actonel; Atelvia; generics Bisphosphonate 35 mg PO q wk or 150 mg PO q mo Ibandronate Boniva; generics Bisphosphonate 150 mg PO q mo Zoledronate Reclast; Aclasta; generics Bisphosphonate IV q 2 y available only in Mexico. BZA, bazedoxifene; CE, conjugated estrogens; EAA, estrogen agonist/antagonist; IV, intravenous; MPA, medroxyprogesterone acetate; NETA, norethindrone acetate; PO, orally.",
    "BZA, bazedoxifene; CE, conjugated estrogens; EAA, estrogen agonist/antagonist; IV, intravenous; MPA, medroxyprogesterone acetate; NETA, norethindrone acetate; PO, orally. aTrade names of estrogens approved for prevention of osteoporosis include Climara, Estrace, Minivelle, Premarin, Vivelle dot. NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 983 transition, beginning HT was associated with increased risks of stroke (relative risk [RR], 1.21; 95% CI, 1.06-1.38) and VTE (RR, 1.96; 95% CI, 1.37-2.80). Discontinuing hormone therapy The beneficial effects of estrogen on the skeleton begin to abate within a few months of stopping therapy. Bone mineral density loss of 3% to 6% occurs during the first year after cessation of systemic ET or EPT, and markers of bone turnover return to pretreatment values within a few months. 103,139 Within 2 years, BMD falls to levels seen in women who never took estrogen. 140 In the WHI, discontinua- tion of HT was associated with a return of fracture risk to levels seen in women who had received placebo, with no excess fracture risk observed. 141 The primary indication for systemic HT is for relief of vasomotor (VMS) and other menopause symptoms in post- menopausal women aged younger than 60 years and within 10 years of menopause, with secondary benefit on bone protection.",
    "142,143 However, well-counseled women with per- sistent menopause symptoms and those at high risk of fracture who cannot tolerate the other therapies may be candidates for HT for prevention or treatment of osteoporosis if benefits outweigh risks. Extended use of HT is an option for well- counseled women who have low bone mass, regardless of menopause symptoms, for prevention of further bone loss and/or reduction of fracture risk when alternate therapies are not appropriate or when the benefits of extended use are expected to exceed the risks. 142,144,145 Despite positive effects on bone, initiating HT in women aged older than 60 years or more than 10 years beyond menopause is generally not recommended because of con- cerns about cardiovascular safety. 142,146 Although the optimal time to initiate ET or EPT and the optimal duration of therapy have not been established, ET or EPT should largely be used in the early years after meno- pause. Women with primary ovarian insufficiency, premature menopause, or early surgical menopause experience long- term AEs on bone, cognition, mood, cardiovascular health, sexual health, and mortality. 147 For these women, an estrogen preparation should be considered, unless there are contra- indications, to prevent bone loss as well treat menopause symptoms, at least until the average age of natural meno- pause.",
    "142 Higher doses of HT may be needed to provide protection against bone loss in younger women, particularly those aged younger than 40 years. 125 Estrogen-receptor agonists/antagonists Raloxifene Estrogen agonists/antagonists, previously known as selec- tive estrogen-receptor modulators, have weak estrogen-like antiresorptive properties in bone. Raloxifene is the only EAA approved for the prevention and treatment of postmenopausal osteoporosis. In a 2-year RCT of 601 postmenopausal women without osteoporosis (mean age, 55 y), raloxifene 60 mg per day improved BMD by 1.6% at the LS and 1.2% at the FN compared with placebo (decreases of 0.8% and 1.2%, respec- tively). 148 Bone loss resumes when raloxifene therapy is stopped.149 Raloxifene is associated with bone loss when given to premenopausal women. 150 Adverse events with raloxifene include increased hot flashes, leg cramps, and an increased risk of VTE. 151,152 In postmenopausal women with osteoporosis, raloxifene signif- icantly reduced the incidence of invasive breast cancer by 76% after 3 years and by 59% after 8 years of therapy. 153,154 Bazedoxifene with conjugated estrogens Bazedoxifene is an EAA that has effects similar to raloxi- fene on bone density and fracture risk in women with osteo- porosis.155 It is not approved as monotherapy in the United States or Canada.",
    "A daily fixed-dose combination of BZA 20 mg with CE 0.45 mg improved VMS, decreased bone turnover markers, and prevented bone loss over 2 years in young postmeno- pausal women. 156-158 In a pooled analysis from phase 3 trials in young postmenopausal women with normal or low BMD, bone density changes versus placebo with BZA plus CE were 2.3% and 1.4% at the LS and TH, respectively. 159 Because BZA is a uterus antagonist, and the rates of endometrial hyperplasia were less than 1% and comparable to placebo, progestogens do not need to be taken with this combination therapy, based on safety data up to 2 years. 158,160 In RCTs of up to 2 years with the combination of CE and BZA, mammographic breast density and rates of breast tenderness, breast cancer, vaginal bleeding, cardiovascular events, and VTE were similar to placebo.157 This combination has been approved in the United States, Canada, and Mexico for the management of moderate to severe VMS and in the United States and Mexico for prevention of postmenopausal osteoporosis. This product contains a warning similar to other estrogen-containing products. The best candidates for BZA with CE are postmenopausal women with a uterus who need relief from hot flashes and prevention of bone loss. Caution should be exercised in beginning any HT in women aged older than 60 years. Tibolone Tibolone, a synthetic hormone derived from the Mexican yam, has metabolites with estrogenic, androgenic, and pro- gestogenic effects.",
    "Tibolone Tibolone, a synthetic hormone derived from the Mexican yam, has metabolites with estrogenic, androgenic, and pro- gestogenic effects. 161 In young postmenopausal women, tibo- lone prevented hot flashes, bone loss, and vaginal atrophy. 162 In women with postmenopausal osteoporosis, tibolone 1.25 mg daily significantly reduced the risk of vertebral and nonvertebral fracture but increased stroke risk. 163 It has not been approved in the United States or Canada but is used in Mexico for osteoporosis prevention. Bisphosphonates These analogs of pyrophosphate bind to bone matrix and are absorbed into osteoclasts at sites of active bone remodel- ing. By interfering with important intracellular processes, NAMS POSITION STATEMENT 984 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society bisphosphonates impair osteoclast function. Bone remodeling decreases, and BMD increases. 164 There are bisphosphonates approved for both the prevention and treatment of postmenopausal osteoporosis. In young postmenopausal women, bisphosphonates increase BMD over 24 months by 3.1% to 6.0% in the LS and by 1.8% to 4.0% in the proximal femur. 165-168 Doses of zoledronate and alendronate approved for prevention are 50% smaller than the doses approved for osteoporosis treatment. Bone mineral density decreases slowly on stopping alendro- nate or zoledronate.",
    "Bone mineral density decreases slowly on stopping alendro- nate or zoledronate. 103,169 Bisphosphonates can be considered to prevent bone loss in early menopause if estrogen cannot be taken or when ET or raloxifene therapy is discontinued. Key points /C15 Intervening to prevent rapid bone loss and deterioration of skeletal structure is a unique opportunity to maintain bone health. /C15 Such intervention would be most appropriate in women with low BMD who are experiencing relatively rapid bone loss because of acute estrogen deficiency in the perimenopausal and early postmenopausal periods or on discontinuing ET. /C15 For younger, healthy postmenopausal women, particularly those with VMS, who are candidates for prevention of bone loss, estrogen alone (if no uterus) or combined with progestogen or BZA are the most appropriate therapies. – A bisphosphonate could be chosen if estrogen is contra- indicated or on stopping ET. – Raloxifene is a good option for prevention of bone loss in postmenopausal women with an elevated risk of breast cancer and infrequent VMS. /C15 Bisphosphonates to prevent bone loss can be considered in postmenopausal women with low BMD (T-score </C0 1) and other risk factors for fracture (eg, family history) who do not meet criteria for osteoporosis treatment. PHARMACOTHERAPY TO TREAT OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN The primary objective of treating women with osteoporosis is to reduce the risk of fracture.",
    "PHARMACOTHERAPY TO TREAT OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN The primary objective of treating women with osteoporosis is to reduce the risk of fracture. All drugs approved for osteoporosis treatment have been shown in RCTs to reduce fracture risk (Table 8). 151,170-189 These drugs vary considerably in their mechanisms of action and their effectiveness. Details and nuances of their use are found in cited reviews. Combining therapies is not generally recommended to treat osteoporosis, although sequential therapies may play a role in preventing loss after certain therapies. Antiremodeling drugs Antiremodeling agents inhibit bone resorption by osteo- clasts, and secondarily, bone formation. Treatment results in the filling in of remodeling spaces in bone that are present at the beginning of therapy and in opening of fewer new remodeling spaces, resulting in increased BMD and skeletal strength and decreased fracture risk. These drugs do not repair deficits in trabecular architecture. Denosumab, the most potent inhibitor of bone remodeling, does reduce porosity in cortical bone. Protection from fractures occurs within 1 year of beginning therapy, persists as long as treatment is given, and wanes when treatment is stopped. Hypocalcemia has been reported with some of these agents. Low serum calcium should be corrected before beginning therapy.",
    "Hypocalcemia has been reported with some of these agents. Low serum calcium should be corrected before beginning therapy. Raloxifene In a pivotal RCT of postmenopausal women with osteopo- rosis, raloxifene significantly reduced the incidence of verte- bral fractures after 3 years by 30% and 50% in women with and without prevalent vertebral fracture, respectively. 151 Hip and nonvertebral fracture risk was not reduced with raloxifene therapy for up to 8 years. 152 TABLE 8.",
    "151 Hip and nonvertebral fracture risk was not reduced with raloxifene therapy for up to 8 years. 152 TABLE 8. Drugs approved in North America for treating women with postmenopausal osteoporosis Fracture risk reduction (in primary analyses of registration trials) Drug Trade names Drug class Dose, route of administration, and dosing interval Vertebral fracture Nonvertebral fracture Hip fracture Raloxifene151 Evista; generics EAA 60 mg/d PO U Alendronate170-172,184 Fosamax; Binosto; generics Bisphosphonate 70 mg q wk PO UU Risedronate173-175,185-187 Actonel; Atelvia; generics Bisphosphonate 35 mg q wk PO; 150 mg q mo PO UU U Ibandronate176,188,189 Boniva; generics Bisphosphonate 150 mg PO q mo; 3 mg IV q 3 mo U Zoledronate177 Reclast; Aclasta; generics Bisphosphonate 5 mg IV q y UU U Denosumab178,179 Prolia RANK ligand inhibitor 60 mg SQ q 6 mo UU U Teriparatide178,179 Forteo; Teribone PTH-receptor agonist 20 mg SQ daily UU Abaloparatide179,180 Tymlos PTH-receptor agonist 80 mg SQ daily UU Romosozumab181,182 Evenity Sclerostin inhibitor 210 mg SQ q mo UU U Calcitonin-salmon183 Calcimar; Fortical; generics Calcitonin 200 USP units by nasal spray daily U Available only in the United States. EAA, estrogen agonist/antagonist; IV, intravenous; PTH, parathyroid hormone; SQ, subcutaneous.",
    "EAA, estrogen agonist/antagonist; IV, intravenous; PTH, parathyroid hormone; SQ, subcutaneous. Ettinger B, et al 151; Liberman UA, et al 170; Black DM, et al 171;Cummings SR, et al 172; Harris ST, et al 173; Reginster J, et al 174; McClung MR, et al 175; Chesnut CH 3rd, et al 176; Black DM, et al 177; Cummings SR, et al 178; Neer RM, et al 179; Miller PD, et al 180; Cosman F, et al 181; Saag KG, et al 182; Chesnut CH 3rd, et al 183; Schnitzer T, et al 184; Brown JP, et al 185; Delmas PD, et al 186; McClung MR, et al 187; Miller PD, et al 188; Delmas PD, et al. 189 NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 985 In the pivotal study, raloxifene use was associated with a significant threefold increase in the risk of VTE without a significant difference in coronary or cerebrovascular events between placebo and raloxifene. 151 In postmenopausal women with risk factors for coronary heart disease, no significant effects of raloxifene on the risk of primary coro- nary events or stroke were observed over a median of 5.6 years.190 However, the risk of fatal stroke was increased (HR, 1.49). Therapy considerations. Raloxifene is an option for the treatment of postmenopausal osteoporosis in women with a low risk of hip fracture, an elevated risk of breast cancer, and low risk of stroke and VTE.",
    "Raloxifene is an option for the treatment of postmenopausal osteoporosis in women with a low risk of hip fracture, an elevated risk of breast cancer, and low risk of stroke and VTE. Bisphosphonates In RCTs, daily oral therapy with alendronate, risedronate, and ibandronate and annual intravenous dosing with zoledr- onate reduced the risk of vertebral fractures by 41% to 70% over 3 years in postmenopausal women with osteoporosis. 191 Alendronate, risedronate, and zoledronate also reduced the risk of hip and nonvertebral fractures by 28% to 50% and 20% to 38%, respectively, in long-term extension studies. Bone mineral density in the TH and FN plateaus after about 5 years, with no further increases over the next 4 to 5 years. 192,193 Registration for government approval of the commonly used weekly and monthly dosing regimens of the oral agents was based on studies comparing BMD responses to daily therapy rather than on fracture endpoint studies (Table 8). 151,170-189 Adverse events include diffuse bone and muscle pain of unknown mechanism, worsening upper gastrointestinal symp- toms with oral bisphosphonates, and flu-like symptoms in about one-third of patients with the first infusion of zoledr- onate. Renal failure has occurred with zoledronate in patients with compromised renal function. Oral bisphosphonates are to be used with caution, and zoledronate is contraindicated in patients with markedly impaired renal function.",
    "Oral bisphosphonates are to be used with caution, and zoledronate is contraindicated in patients with markedly impaired renal function. Osteonecro- sis of the jaw (ONJ) occurs infrequently (1 in 10,000-100,000 patient-years) with osteoporosis doses of bisphosphonates. 194 Invasive dental procedures and poor oral hygiene are risk factors for ONJ. Discontinuing therapy before an invasive dental procedure does not reduce the risk of ONJ, 195 but improving oral hygiene preoperatively and using topical antimicrobial therapy with dental extraction does appear to reduce risk. 196,197 A duration-dependent risk of subtrochanteric or femoral shaft fractures with atypical radiologic features becomes evident after 2 to 3 years of therapy, with an incidence of about 1 in 1,000 patients after 8 to 10 years of therapy. 198 The risk of these fractures appears to be greater in Asian women, in younger postmenopausal women with low BMD rather than osteoporosis, and in patients with some genetic skeletal disorders such as hypophosphatasia. 199 Pain in the thigh or groin is usually present for weeks to months before the atypical fracture occurs. Patients on bisphosphonates for more than 3 years should be cautioned to report new thigh or groin pain so that radiographic evaluation can be undertaken. The risk of atypical fracture may decrease on discontinuation of oral bisphosphonates. 200 Duration of therapy and bisphosphonate drug holiday.",
    "The risk of atypical fracture may decrease on discontinuation of oral bisphosphonates. 200 Duration of therapy and bisphosphonate drug holiday. The effects of bisphosphonate therapy on bone remodeling and protection from fracture wane slowly (over 1-5 y) when treatment is stopped. 192,193,201 Because of this unique phar- macology, a temporary withdrawal of therapy ( ‘‘bisphospho- nate holiday’’) can be considered after 3 to 5 years of therapy in patients at low or moderate fracture risk and who no longer meet criteria for therapy. 5,7,130,202 Fracture risk increases again when patients have been off oral bisphosphonate ther- apy for 2 years. 203 Osteoporosis treatment should be restarted with a significant decline in BMD, an intervening fracture, or other factors altering clinical risk.5,191,202 For patients remain- ing at high risk after 3 to 5 years of bisphosphonate therapy (history of previous spine or hip fracture or multiple other fractures, hip BMD values remaining in the osteoporosis range, or who have other important risk factors), continuing on the bisphosphonate or switching to denosumab or an osteoanabolic agent is recommended. 5,7,202 Therapy considerations. Bisphosphonates are appropriate to reduce fracture risk in women with postmenopausal osteoporosis. Use with caution in patients with significantly impaired renal function. Con- sider a bisphosphonate holiday only in women at low or moderate fracture risk.",
    "Use with caution in patients with significantly impaired renal function. Con- sider a bisphosphonate holiday only in women at low or moderate fracture risk. Denosumab This fully human monoclonal antibody inhibits RANK ligand, the principal stimulator of bone resorption. Treatment with denosumab 60 mg by subcutaneous injection every 6 months results in marked inhibition of bone remodeling, with resorption inhibited more than formation. 204 In a pivotal RCT, denosumab therapy for 3 years reduced the risk of vertebral fractures by 68% and hip fractures by 40% in postmenopausal women with osteoporosis. 178 Over 10 years, BMD increased by 21.7% and 9.2% in the LS and TH, respectively, and protection from fracture persisted or improved. In that trial, skin rash and skin infection occurred more frequently with denosumab than placebo but did not increase in frequency with long-term therapy. Denosumab can be used in patients with impaired renal function, but hypocalcemia is more common. Rare cases of atypical femoral fractures and ONJ were observed with long-term therapy. The relationship between duration of denosumab therapy and these possible AEs is unclear. No other AEs were observed over 10 years of treatment. 192 Discontinuing denosumab. On stopping denosumab treatment, bone turnover markers quickly rise above baseline levels before returning to pre- treatment levels after 1 to 2 years. Bone mineral density NAMS POSITION STATEMENT 986 Menopause, Vol. 28, No.",
    "Bone mineral density NAMS POSITION STATEMENT 986 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society decreases rapidly, and vertebral fracture protection is lost. Vertebral fractures, often multiple, occurring 3 to 18 months after stopping denosumab treatment have been reported. 205 There is no justification for a ‘‘holiday’’ with denosumab therapy. Whenever denosumab is stopped, therapy with a bisphosphonate should be used to prevent bone loss. 206,207 Therapy considerations. Denosumab is appropriate for women with postmenopausal osteoporosis, including those at high risk of fractures. There is no limit to the duration of denosumab therapy. Administration of denosumab should not be delayed or stopped beyond 7 months without subsequent therapy to prevent bone loss and vertebral fractures. Calcitonin-salmon Nasal spray calcitonin-salmon is recommended for the treatment of osteoporosis only for women who cannot tolerate other therapies. 5 Calcitonin-salmon may reduce pain and shorten time to mobilization after an acute vertebral frac- ture. 208 Osteoanabolic therapies These bone-building drugs stimulate bone formation and restore the structure of trabecular bone by increasing the number and width of trabeculae and improving cortical thickness. 209 The bone-forming effects of these agents dimin- ish over several months (antisclerostin therapy) to a few years (PTH-receptor agonists).",
    "209 The bone-forming effects of these agents dimin- ish over several months (antisclerostin therapy) to a few years (PTH-receptor agonists). For these and other reasons, therapy with anabolic agents is limited to treatment intervals of 12 to 24 months. Bone mineral density is lost rapidly when osteoa- nabolic agents are discontinued. To maintain the treatment benefits, these therapies should always be followed by an antiremodeling drug. Osteoanabolic therapies are more effec- tive than antiremodeling agents at increasing BMD and reducing fractures and should be the initial therapy for osteoporosis in women at very high or imminent risk of fracture. 6,7,51 Parathyroid hormone receptor agonists Teriparatide and abaloparatide activate the PTH receptor, stimulating bone formation on trabecular and endocortical bone surfaces, leading to increased skeletal mass and volume, improved trabecular microarchitecture, increased cortical width, and increased bone strength. 210,211 Both drugs, admin- istered by daily subcutaneous injection, significantly reduce risks of vertebral and nonvertebral fracture. Hip fracture efficacy was not demonstrated in individual randomized trials (limited by sample size), but a meta-analysis showed hip fracture efficacy with teriparatide. 212 Orthostatic hypotension with first doses and hypercalcemia are possible AEs. High doses of both drugs induced bone tumors in rats, but this risk has not been observed in clinical studies.",
    "212 Orthostatic hypotension with first doses and hypercalcemia are possible AEs. High doses of both drugs induced bone tumors in rats, but this risk has not been observed in clinical studies. Neither drug should be used in patients with hypercalcemia, at risk for osteosar- coma, or with skeletal metastases. Previously, treatment with both agents was limited to 2 years in one’s lifetime. The teriparatide label changed (November 2020) to allow a repeat teriparatide course in appropriate patients. Abaloparatide is not yet available in Canada. Teriparatide. Teriparatide is a synthetic peptide comprised of the first 34 amino acids of PTH. 210 In a phase 3 pivotal trial, teriparatide therapy for 18 to 19 months resulted in increases of LS bone density by 9.5% and TH bone density by 2.6%. 179 The risks of vertebral and nonvertebral fracture were reduced by 65% and 35%, respectively. In women with postmenopausal osteopo- rosis at high fracture risk, teriparatide reduced risks of verte- bral fracture by 56% and clinical fractures by 52% compared with risedronate. 213 Abaloparatide. Abaloparatide is a synthetic analog of PTH-related peptide analog, modified to potentiate its anabolic effect. 211 In a pivotal fracture trial, women with postmenopausal osteopo- rosis were randomized to blinded abaloparatide 80 mg, pla- cebo, or open label teriparatide for 18 months. 214 Bone mineral density increased with abaloparatide by 11.2% in the LS and by 4.2% after 18 months in TH BMD.",
    "214 Bone mineral density increased with abaloparatide by 11.2% in the LS and by 4.2% after 18 months in TH BMD. Over 18 months, risks of vertebral fracture and nonvertebral frac- ture were reduced by 86% and 43%, respectively. These fracture-prevention benefits achieved with abaloparatide were maintained for 2 additional years when women were switched to alendronate. Increases in BMD, especially at the hip, were greater with abaloparatide than with teriparatide, but there were no significant differences in fracture risk between the two therapies. Romosozumab Romosozumab is a humanized antisclerostin monoclonal antibody that stimulates bone formation while inhibiting bone resorption. 215 It is administered monthly as two subcutaneous injections totaling 210 mg for 12 months. In women with postmenopausal osteoporosis, average BMD increases with romosozumab at 1 year were 13.3% in the LS and 6.8% in the TH. With 12 months of romosozumab followed by 24 months of alendronate or denosumab, total increases in LS BMD were 14.9% and 18.1%, respectively, whereas increases in TH BMD were 7.0% with alendronate and 9.4% with denosu- mab. 181,182 In a pivotal RCT in women with postmenopausal osteopo- rosis, romosozumab, compared with placebo, significantly reduced vertebral fracture risk by 73% and clinical fractures (>85% of which were nonvertebral) by 36% after 12 months of therapy.181 The 25% reduction in nonvertebral fracture risk was not statistically significant.",
    "In a second pivotal trial in women at high risk of fracture, romosozumab was compared with alendronate. 182 At 12 months, vertebral fracture risk was reduced by 37% with romosozumab compared with alendronate. After that 12 months, all women received alendronate. At the end of the study (average, 33 mo; 21 mo on alendronate), NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 987 nonvertebral fractures were significantly reduced by 19% and hip fractures by 38% in patients receiving romosozumab during the first year of the study compared with those who received only alendronate throughout. The reduction in ver- tebral fracture risk observed during the 12 months of romo- sozumab compared with placebo or alendronate was maintained for at least 2 years while women took denosumab or alendronate. Romosozumab can produce mild injection-site reactions and hypersensitivity reactions. Compared with alendronate, romosozumab was associated with a higher risk of major cardiovascular AEs (heart attack, stroke, and cardiovascular death), but there was no difference in rates of these events with romosozumab versus placebo. The explanation for the disparity in the results of the two studies is unclear. 216 Romosozumab is not recommended for women at high risk of cardiovascular disease, particularly those who have had recent heart attacks or strokes. Therapy considerations.",
    "216 Romosozumab is not recommended for women at high risk of cardiovascular disease, particularly those who have had recent heart attacks or strokes. Therapy considerations. Osteoanabolic therapy results in larger, faster gains in BMD and better protection from fractures than do bisphosph- onates. Anabolic therapy should be followed by a potent antiremodeling agent to maintain gains in BMD. Bone min- eral density gains, particularly in the hip, are greater when the anabolic drug is administered before the antiremodeling drug compared with the opposite sequence. The best candidates are women at very high risk of fracture, including those with prior and especially recent fractures, very low BMD (T-score below /C0 3.0), and those who sustain fractures or lose BMD while taking antiremodeling therapy. DEVELOPING AN OSTEOPOROSIS TREATMENT PLAN Osteoporosis is a chronic, progressive, and currently incur- able disease requiring life-long management. There is no single treatment paradigm. Rather, treatment must be indi- vidualized and then monitored and altered depending on the course of the patient. Different medications are chosen depending on the patient’s age, BMD, fracture risk, and other considerations. Moreover, different medications may be chosen for the same patient at different stages of life. Optimal management will entail the use of osteoporosis therapies in various sequences to maximize benefits and minimize risks across the lifespan of a postmenopausal woman.",
    "Optimal management will entail the use of osteoporosis therapies in various sequences to maximize benefits and minimize risks across the lifespan of a postmenopausal woman. Goal-directed therapy, or ‘‘treat-to-target,’’ is an emerging concept to aid in the selection of initial therapy or when and how to change therapy for postmenopausal osteoporosis. 217 The fundamental principle of this concept is that the goal of treatment is to reach an acceptable level of fracture risk or suitable surrogate. The initial treatment is selected according to the likelihood of that treatment achieving this goal. If the response to the initial treatment does not achieve this goal, a change in treatment is considered. The value of BMD as an appropriate target as a surrogate of fracture risk is supported by recent studies documenting that the level of BMD achieved on osteoporosis treatments corre- lates strongly with a person’s current risk of fracture; the higher the TH BMD is on treatment, the lower the fracture risk. 218,219 Those studies suggested that optimal treatment benefit is achieved at TH T-score values between /C0 2.0 and /C0 1.5. These data are bolstered by robust evidence from meta- regressions of published clinical trials of many medications demonstrating a strong correlation between the magnitude of BMD increase with treatment and reduction of vertebral, nonvertebral, and hip fracture risk.",
    "220,221 These results suggest that, for patients with very low BMD or very high risk of fracture, beginning therapy with an osteoanabolic agent followed by an antiremodeling drug is most likely to achieve osteoporosis treatment goals. 51,222 The studies documenting the superiority of osteoanabolic treat- ments over antiremodeling drugs for reducing fracture risk in patients at very high risk of fracture strongly support this recommendation. 182,213 This approach is even more attractive on recall that the increase in BMD and fracture protection achieved with 12 to 18 months of osteoanabolic treatment persists for at least 2 years after patients are transitioned to a bisphosphonate or denosumab. 223,224 Based on these concepts, the choice of the initial treatment is based on the patient’s current BMD and fracture risk (Table 9). 6,7,51 If the response to the initial treatment does not achieve this target, a change in treatment is considered. If TABLE 9. Choosing an initial treatment for postmenopausal osteoporosis Fracture risk Example Recommended starting therapy Moderate Patient aged 62 y T-score: LS -2.6, FN -1.8 No other risk factors Raloxifene or a bisphosphonate High Patient aged 68 y, mother with hip fracture T-score: FN -2.8 Wrist fracture at age 60 Bisphosphonate or denosumab Very high Patient aged 72 y T-score: FN -3.0 Humerus fracture age 68 Two recent vertebral fractures Osteoanabolic drug FN, femoral neck; LS, lumbar spine.",
    "Shoback D, et al 6; Camacho PM, et al 7; Kanis JA, et al. 51 NAMS POSITION STATEMENT 988 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society the treatment goal has not been achieved with bisphosphonate therapy, switching to denosumab or an osteoanabolic drug should be considered. If the treatment target is reached after 3 to 5 years of bisphosphonate therapy, discontinuation of treatment for an interval could be considered, with plans to restart therapy if bone loss or fractures occur. If raloxifene or denosumab therapy is stopped, switching to a bisphosphonate would be indicated to prevent the rapid decrease in BMD and loss of fracture protection. Osteoanabolic therapy should always be followed by a bisphosphonate or by denosumab. Monitoring osteoporosis therapy Bone mineral density testing should be repeated 1 to 2 years after beginning osteoporosis therapy (depending on the drug used), with careful attention to quality control of the repeat testing. 4,7 For patients on bisphosphonates, repeating BMD testing again at 5 years is used to determine whether a ‘‘bisphosphonate holiday ’’ would be considered. 202 Although changes in bone turnover markers are used by some specialists to assess adherence and effectiveness of therapy, routine use of bone markers is not recommended. Follow-up contact by an office nurse may be the most effective means to enhance adherence to therapy.",
    "Follow-up contact by an office nurse may be the most effective means to enhance adherence to therapy. 225 Key points /C15 The choice of the initial treatment for osteoporosis is based on the patient’s current BMD and fracture risk. /C15 Raloxifene is an option for the treatment of postmeno- pausal osteoporosis in women with a low risk of hip fracture, an elevated risk of breast cancer, and low risk of stroke and VTE. /C15 Bisphosphonates are appropriate to reduce fracture risk in women with postmenopausal osteoporosis. – Use with caution in patients with significantly impaired renal function. – Consider a bisphosphonate holiday only in women at low fracture risk who no longer meet criteria for ther- apy. /C15 Restart therapy if bone loss or fractures occur or when patient again meets criteria for treatment. – For patients remaining at high fracture risk after 3 to 5 years of bisphosphonate therapy, continue treatment or switch to another drug. /C15 Denosumab is appropriate for women with postmeno- pausal osteoporosis, including those at high risk of fracture. – There is no limit to the duration of denosumab therapy. – Administration of denosumab should not be delayed or stopped beyond 7 months without subsequent therapy to prevent bone loss and vertebral fractures.",
    "– Administration of denosumab should not be delayed or stopped beyond 7 months without subsequent therapy to prevent bone loss and vertebral fractures. /C15 Osteoanabolic therapies are most appropriately used in women at very high risk of fracture, including those with prior and especially recent fractures, very low BMD (T- score below /C0 3.0), and those who sustain fractures or lose BMD while taking antiremodeling therapy. – Osteoanabolic therapies increase bone mass more rap- idly and reduce fracture risk more effectively than do bisphosphonates. – Anabolic therapy should be followed by an antiremod- eling agent to maintain bone density gains. – Bone mineral density gains, particularly in the hip, are greater when an anabolic drug is administered before an antiremodeling drug, compared with the opposite sequence. /C15 Bone mineral density measured while on therapy correlates with current fracture risk. /C15 If the response to the initial treatment does not achieve preventing bone loss or reducing the risk of fracture, a change in treatment should be considered. /C15 If drug-related AEs occur, appropriate management strate- gies should be instituted. If AEs persist, switching to another agent may be required. /C15 Identify barriers to nonadherence to therapy and encourage adherence to the treatment plan. Providing clear informa- tion to women regarding their risk for fracture and the purpose of osteoporosis therapy may be an optimal way to improve adherence.",
    "Providing clear informa- tion to women regarding their risk for fracture and the purpose of osteoporosis therapy may be an optimal way to improve adherence. /C15 Depending on the treatment, an appropriate interval for repeat BMD testing is 1 to 2 years after beginning treatment or when a change in therapy is considered. – Initial DXA and follow-up scans should ideally be performed on the same instrument, using the same procedure. Interpretation of BMD changes requires careful attention to DXA quality control. /C15 If progressive loss of BMD or fractures occurs while on therapy, evaluate for reasons for suboptimal response to therapy, including poor adherence and underlying medical conditions or medications. /C15 Even when treatment increases T-score values above /C0 2.5, the patient still has the diagnosis and risks of osteoporosis. /C15 Referral to bone specialists is recommended for women with very low T-scores, inadequate treatment response, including progressive decline in BMD or fractures while on therapy, or additional factors (eg, renal failure, hyperpara- thyroidism) requiring special management. CONCLUSIONS /C15 Osteoporosis is a chronic, progressive health issue affect- ing a large proportion of postmenopausal women. /C15 Menopause practitioners should be familiar and comfort- able with approaches to the assessment and management of bone health in their patients. /C15 Once diagnosed, patients with osteoporosis require lifelong management.",
    "/C15 Once diagnosed, patients with osteoporosis require lifelong management. /C15 Management of bone health in postmenopausal women involves assessment of risk factors for low BMD and fracture, encouraging healthy lifestyle habits to reduce risk factors, and if indicated, pharmacologic therapy. /C15 Effective tools for diagnosing osteoporosis and assessing fracture risk are available, and well-studied strategies exist for managing bone health in women at both low and high risk of fracture. /C15 By individualizing treatment approaches and monitoring and adjusting those approaches if the clinical picture changes, the consequences of osteoporosis on a meno- pausal woman’s activity and well-being can be minimized. RECOMMENDATIONS /C15 Encourage all postmenopausal women to employ lifestyle practices that reduce the risk of bone loss and osteoporotic NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 989 fractures: maintaining a healthy weight, eating a balanced diet, obtaining adequate calcium and vitamin D, partici- pating in regular physical activity, avoiding excessive alcohol consumption, not smoking, and using measures to prevent falls. /C15 The annual examination should include measurements of height and weight, assessment for chronic back pain, kyphosis, and clinical risk factors for osteoporosis, frac- tures, and falls. /C15 Evaluate BMD in all women – Aged 65 years and older.",
    "/C15 Evaluate BMD in all women – Aged 65 years and older. – With history of fracture (other than skull, facial bone, ankle, finger, and toe) after menopause. – With medical causes of bone loss such as AE therapy and systemic glucocorticoid therapy of more than 3 months. /C15 Consider BMD testing for postmenopausal women aged younger than 65 years who have one or more of these risk factors: – Discontinued estrogen with additional risk factors for fracture. – Thinness (body weight < 127 lb [57.7 kg] or BMI < 21 kg/m 2) – History of hip fracture in a parent. – Current smoking. – Excessive alcohol intake. – Long-term use of medications associated with bone loss such as prednisone or an AI. /C15 Use DXA as the preferred technique for BMD testing and the lowest T-scores at the LS, TH, or FN for diagnostic categorization. /C15 Vertebral imaging is appropriate for women aged 70 years and older or with historical height loss of more than 1.5 in. /C15 The IOM recommends daily intake of calcium 1,000 mg to 1,200 mg and vitamin D 3 400 IU to 800 IU for women aged 50 years and older. /C15 Routine use of calcium and vitamin D supplements is not recommended. Supplements should only be used when daily targets of calcium and vitamin D are not achieved from dietary sources. /C15 Drug therapy is recommended to prevent bone loss in postmenopausal women with – Premature menopause, at least until the average age of natural menopause.",
    "/C15 Drug therapy is recommended to prevent bone loss in postmenopausal women with – Premature menopause, at least until the average age of natural menopause. – Low BMD (T-score < /C0 1.0) and experiencing relatively rapid bone loss because of acute estrogen deficiency in the menopause transition or on discontinuing ET. – Low BMD (T-score < /C0 1.0) and other risk factors for fracture (eg, family history) but who do not meet the criteria for osteoporosis treatment. /C15 Drug therapy is recommended to treat osteoporosis in these populations: – All postmenopausal women who have had a vertebral or hip fracture. – All postmenopausal women who have BMD values consistent with osteoporosis (ie, T-scores < /C0 2.5) at the LS, FN, or TH region. – All postmenopausal women who have T-scores from /C0 1.0 to /C0 2.5 and any one of /C15 History of fracture of proximal humerus, pelvis, or distal forearm. /C15 History of multiple fractures at other sites (excluding face, feet, and hands). /C15 Increased fracture risk according to country-specific thresholds using FRAX. In the United States, those thresholds are a 10-year risk of major osteoporotic fracture (spine, hip, shoulder, and wrist) of at least 20% or of hip fracture of at least 3%. /C15 Perform comprehensive evaluation, including thorough medical history, physical examination, laboratory evalua- tion and, in women with historical height loss and kyphosis, vertebral imaging before beginning osteoporosis therapy.",
    "/C15 Ensure adequate total daily intake of calcium (1,000- 1,200 mg) and vitamin D (400-800 IU) as adjunct therapy for all postmenopausal women receiving pharmacologic interventions for osteoporosis. /C15 Consider osteoanabolic therapies for patients at very high risk of fracture, including older women with recent fractures, T-scores /C0 3.0 and lower, or multiple other risk factors. /C15 During therapy, reevaluate the treatment goals and the choice of medication on an ongoing basis through periodic medical examination and follow-up BMD testing. /C15 Once diagnosed, patients with osteoporosis require lifelong management to prevent fractures. ACKNOWLEDGMENTS AND DISCLOSURES NAMS appreciates the contributions of the ‘‘Management of Osteoporosis in Postmenopausal Women: The 2021 Posi- tion Statement of The North American Menopause Society ’’ Editorial Panel and the review by the NAMS Board of Trustees on this position statement. The authors, planners, reviewers, and staff who were in a position to control and influence the content of this activity were required to disclo- sure any relevant financial relationship(s) of the individuals or their spouse/partner that had occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content.",
    "After reviewing disclosures from all involved in the content of this activity, NAMS has implemented mechanisms to identify and resolve any conflicts for all involved, including review of content by those who had no conflicts of interest. Acknowledgments: The ‘‘Management of Osteoporosis in Postmenopausal Women: The 2021 Position Statement of The North American Menopause Society ’’ Editorial Panel: Michael R. McClung, MD, FACP, FACE, Co-Lead, Founding Director, Oregon Osteoporosis Center, Portland, Oregon, Professorial Fellow, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia; JoAnn V. Pinkerton, MD, FACOG, NCMP,Co-Lead, Professor of Obstetrics and Gynecology, Division Director of Midlife Health, The University of Virginia Health System, Charlottes- ville, Virginia; Jennifer Blake, MD, Chief Executive Officer, The Society of Obstetricians and Gynaecologists of Canada Ottawa, Ontario, Canada; Felicia A. Cosman, MD, Professor of Clinical Medicine, Columbia University College of Physi- cians and Surgeons, New York, New York; E. Michael Lewiecki, MD, FACP, FACE, Clinical Assistant Professor of Medicine, University of New Mexico School of Medicine, NAMS POSITION STATEMENT 990 Menopause, Vol. 28, No.",
    "28, No. 9, 2021 /C2232021 The North American Menopause Society Director, New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico; Marla Shapiro, MD, CM, CCFP, MHSc, FRCP(C), NCMP, Professor, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. NAMS recognizes the contributions of Kathy Method, MA, NAMS Communications Manager.",
    "This position statement was reviewed and approved by the 2020-2021 NAMS Board of Trustees: Hadine Joffe, MD, MSc, President; Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health, Harvard Medical School, Vice Chair for Psychiatry Research, Department of Psychiatry, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Chrisandra L. Shufelt, MD, MS, FACP, NCMP, President-Elect; Associate Director, Barbra Streisand Women’s Heart Center and Preventive and Rehabilitative Cardiac Center, Director, Women’s Hor- mone and Menopause Program, Associate Professor of Medi- cine, Cedars-Sinai Medical Center, Los Angeles, California; Susan D. Reed, MD, MPH, MS, Secretary; Research Director, Women’s Reproductive Health Research Program, Professor and Vice Chair, Department of Obstetrics and Gynecology, Adjunct Professor of Epidemiology, University of Washing- ton School of Medicine, Seattle, Washington; Lisa C. Larkin, MD, FACP, NCMP, IF, Treasurer; Lisa Larkin and Asso- ciates, Internal Medicine and Women’s Health, Cincinnati, Ohio; Rebecca C. Thurston, PhD, Immediate Past-President; Pittsburgh Foundation Chair in Women’s Health and Demen- tia, Professor of Psychiatry, Psychology, Epidemiology and Clinical and Translational Science, Director, Women’s Bio- behavioral Health Research Program, Training Director, Car- diovascular",
    "Demen- tia, Professor of Psychiatry, Psychology, Epidemiology and Clinical and Translational Science, Director, Women’s Bio- behavioral Health Research Program, Training Director, Car- diovascular Behavioral Medicine Research Training Program, University of Pittsburgh, Pittsburgh, Pennsylvania; Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, Medical Director; Professor and Chair, Department of Medicine, Penny and Bill George Director, May Clinic Center for Women’s Health, Mayo Clinic, Jacksonville, Florida; Janet S. Carpenter, PhD, RN, FAAN, Distinguished Professor, Department of Science of Nursing Care, Associate Dean for Research, Indiana University School of Nursing, Indian- apolis, Indiana; Lisa Astalos Chism, DNP, APRN, NCMP, FAANP, Clinical Director, Center for Breast Health, Oakland Macomb Obstetrics and Gynecology Associates, Adjunct Assistant Professor, Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan; Samar R. El Khoudary, PhD, MPH, BPharm, FAHA, Associate Professor, Department of Epidemiology, Epidemiology Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania; Michael R. McClung, MD, FACP, FASBMR, FACE, Found- ing Director, Oregon Osteoporosis Center, Portland, Oregon, Professorial Fellow, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia; Isaac Schiff, CM, MD, Joe Vincent Meigs Distinguished Professor of Gynecology, Harvard Medical School, Chief, Department of Obstetrics",
    "Research, Australian Catholic University, Melbourne, Australia; Isaac Schiff, CM, MD, Joe Vincent Meigs Distinguished Professor of Gynecology, Harvard Medical School, Chief, Department of Obstetrics and Gynecology, Emeritus, The Women’s Care Division, Massachusetts Gen- eral Hospital, Boston, Massachusetts; Wen Shen, MD, MPH, Assistant Professor, Department of Obstetrics and Gynecol- ogy, Johns Hopkins University School of Medicine, Balti- more, Maryland; Claudio N. Soares, MD, PhD, FRCPC, MBA, Professor and Head, Department of Psychiatry, Queen’s University School of Medicine, Executive Director, Research and Innovation, Providence Care Hospital, Execu- tive Lead, Strategy and New Partnerships, Canadian Bio- marker Integration Network in Depression (CAN-BIND), St. Michael’s Hospital, Toronto, Ontario, Canada.",
    "Financial disclosures/Conflicts of interest : For the ‘‘Man- agement of Osteoporosis in Postmenopausal Women: The 2021 Position Statement of The North American Menopause Society’’ Editorial Panel: Dr. Blake and Dr. Pinkerton report no relevant financial relationships. Dr. Cosman reports Con- sultant/Advisory Board for Amgen, EnteraBio, and Obseva; Speakers’ Bureau for Amgen and Radius Health. Dr. Lew- iecki reports Consultant/Advisory Board for Amgen and Radius; Speakers’ Bureau for Radius. Dr. McClung reports Consultant/Advisory Board for Amgen; Speakers’ Bureau for Amgen and Alexion. Dr. Shapiro reports Consultant/Advisory Board for Amgen, Aspen, Astellas, Bayer, BioSyent, Duch- esnay, GSK, Merck, Mithra, Pfizer, Searchlight, Sprout, Sunovion, and TherapeuticsMD. For additional contributors, Ms. Method reports no relevant financial relationships. For the NAMS Board of Trustees members who were not members of the Editorial Panel: Dr. El Khoudary, Dr. Faubion, Dr. Schiff, and Dr. Shufelt report no relevant financial relationships. Dr. Carpenter reports Consultant/ Advisory Board for RoundGlass and University of Wisconsin, Licenses/Fees for Astellas, Sojournix, and Kappa Sante ´. Dr. Chism reports Consultant/Advisory Board for Hologic and Pharmavite, Speakers’ Bureau for Amag, Astellas, and JDS Therapeutics, Royalties/Patents for Jones and Bartlett Pub- lishing.",
    "Dr. Chism reports Consultant/Advisory Board for Hologic and Pharmavite, Speakers’ Bureau for Amag, Astellas, and JDS Therapeutics, Royalties/Patents for Jones and Bartlett Pub- lishing. Dr. Joffe reports Consultant/Advisory Board for Eisai, Jazz, NeRRe/KaNDy, and Sojournix, Grant/Research Support for Brigham & Women’s Hospital Funds, Merck, NIH, NIA, NIMH, NCI, NeRRe/KaNDy, Pfizer, QUE Oncology, and V Foundation. Dr. Joffe’s spouse reports Employee for Merck, Consulting and Equity for Arsenal Biosciences and Tango. Dr. Larkin reports Consultant/Advisory Board for Allergan, Pharmavite, Radius, and TherapeuticsMD, Speakers’ Bureau for Allergan, Palatin, and TherapeuticsMD. Dr. Reed reports Grant/Research Support for Bayer and NIH, Royalties/Patents for UpToDate. Dr. Shen reports Stock/Ownership for Astra Zeneca, Akzo Nobel, Bristol Myers Squibb, Hologic, Johnson & Johnson, and Merck. Dr. Soares reports Consultant/Advi- sory Board for Lundbeck, and Otsuka, Grant/Research Sup- port for Ontario Research Fund, Ontario Brain Institute, and AHSC AFP Innovation Fund. Dr. Thurston reports Consul- tant/Advisory Board for Astellas, Pfizer, and Virtue Health. NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 991 REFERENCES 1. Spence JD. The need for clinical judgement in the application of evidence-based medicine. BMJ Evid Based Med 2020;25:172-177. 2. Committee on Practice Bulletins-Gynecology; The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin N. 129.",
    "BMJ Evid Based Med 2020;25:172-177. 2. Committee on Practice Bulletins-Gynecology; The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin N. 129. Osteoporosis. Obstet Gynecol 2012;120:718-734. 3. Papaioannou A, Morin S, Cheung AM, et al; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-1873. 4. Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteopo- rosis. Osteoporos Int 2014;25:2359-2381. Erratum in: Osteoporos Int 2015;26:2045-2047. 5. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019;104:1595-1622. 6. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline Update. J Clin Endocrinol Metab 2020;105:dgaa048. 7. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract 2020;26:564-570. 8. Conley RB, Adib G, Adler RA, et al. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition.",
    "Endocr Pract 2020;26:564-570. 8. Conley RB, Adib G, Adler RA, et al. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Orthop Trauma 2020;34:e125-e141. 9. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25-54. 10. Jackson R, Feder G. Guidelines for clinical guidelines [editorial]. BMJ 1998;317:427-428. 11. NIH Consensus Development Panel on Osteoporosis Prevention, Diag- nosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795. 12. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93:861-868. 13. Farr JN, Khosla S. Skeletal changes through the lifespan —from growth to senescence. Nat Rev Endocrinol 2015;11:513-521. 14. Martineau P, Morgan SL, Leslie WD. Bone mineral densitometry reporting: pearls and pitfalls. Can Assoc Radiol J 2020; 20:846537120919627. 15. Wu Q, Xiao X, Xu Y. Evaluating the performance of the WHO international reference standard for osteoporosis diagnosis in post- menopausal women of varied polygenic score and race. JC l i nM e d 2020;9:499. 16. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141. 17. Lewiecki EM, Binkley N, Bilezikian JP. Treated osteoporosis is still osteoporosis.",
    "J Bone Miner Res 1994;9:1137-1141. 17. Lewiecki EM, Binkley N, Bilezikian JP. Treated osteoporosis is still osteoporosis. J Bone Miner Res 2019;34:605-606. 18. Shuhart CR, Yeap SS, Anderson PA, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treat- ment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medi- cine, and Pediatrics. J Clin Densitom 2019;22:453-471. 19. Looker AC, Sarafrazi Isfahani N, Fan B, Shepherd JA. Trends in osteoporosis and low bone mass in older US adults, 2005-2006 through 2013-2014. Osteoporos Int 2017;28:1979-1988. 20. Berger C, Goltzman D, Langsetmo L, et al; CaMos Research Group. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 2010;25:1948-1957. 21. Clark P, Cons-Molina F, Deleze M, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009;20:275- 282. 22. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014;29:2520-2526. 23. Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups.J Bone Miner Res 2005;20:185- 194. 24.",
    "J Bone Miner Res 2014;29:2520-2526. 23. Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups.J Bone Miner Res 2005;20:185- 194. 24. Cauley JA, Lui LY, Ensrud KE, et al. Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA 2005;293:2102-2108. 25. Hansen D, Pellizari PM, Pyenson BS. Medicare Cost of Osteoporotic Fractures: 2021 Updated Report: The Clinical and Cost Burden of Fractures Associated With Osteoporosis. Milliman Research Report . Commissioned by the National Osteoporosis Foundation; 2021. 26. Hernlund E, Svedbom A, Iverga˚ rd M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EEPIA). Arch Osteoporos 2013;8:136. 27. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767. 28. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997;12:1761-1768. 29. Leslie WD, O’Donnell S, Jean S, et al; Osteoporosis Surveillance Expert Working Group. Trends in hip fracture rates in Canada. JAMA 2009;26:883-889. 30. Lewiecki EM, Wright NC, Curtis JR, et al. Hip fracture trends in the United States, 2002 to 2015. Osteoporos Int 2018;29:717-722.",
    "Trends in hip fracture rates in Canada. JAMA 2009;26:883-889. 30. Lewiecki EM, Wright NC, Curtis JR, et al. Hip fracture trends in the United States, 2002 to 2015. Osteoporos Int 2018;29:717-722. Erratum in: Osteoporos Int 2018;29:2583. 31. Dyer SM, Crotty M, Fairhall N, et al; C Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group. A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 2016;16:158. 32. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA 2009;302:1573- 1579. 33. Ferrari S, Reginster JY, Brandi ML, et al. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Arch Osteoporos 2016;11:37. 34. Fink HA, Ensrud KE, Nelson DB, et al. Disability after clinical fracture in postmenopausal women with low bone density: the Fracture Inter- vention Trial (FIT). Osteoporos Int 2003;14:69-76. 35. Kendler DL, Bauer DC, Davison KS, et al. Vertebral fractures: clinical importance and management. Am J Med 2016;129:221. e1-221.e10. 36. Fink HA, Milavetz DL, Palermo L, et al; Fracture Intervention Trial Research Group. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 2005;20:1216-1222. 37. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323. 38.",
    "J Bone Miner Res 2005;20:1216-1222. 37. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323. 38. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556- 561. 39. Gold DT. The nonskeletal consequences of osteoporotic fractures. Physiologic and social outcomes. Rheum Dis Clin North Am 2001;27: 255-262. 40. Johansson H, Kanis JA, Ode´n A, et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 2014;29:223-233. 41. Liu YJ, Zhang L, Papasian CJ, Deng HW. Genome-wide association studies for osteoporosis: a 2013 update. J Bone Metab 2014;21:99-116. 42. Cusano NE. Skeletal effects of smoking. Curr Osteoporos Rep 2015;13:302-309. 43. Cadarette SM, McIsaac WJ, Hawker GA, et al. The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. Osteoporos Int 2004;15:361-366. 44. Cadarette SM, Jaglal SB, Kreiger N, McIsaac WJ, Darlington GA, Tu JV. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ 2000;162:1289-1294. 45. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-995. 46. Leslie WD, Berger C, Langsetmo L, et al.",
    "Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-995. 46. Leslie WD, Berger C, Langsetmo L, et al. Canadian Multicenter Osteoporosis Study Research Group. Construction and validation of a simplified fracture risk assessment tool for Canadian women and NAMS POSITION STATEMENT 992 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society men: results from the CaMos and Manitoba cohorts. Osteoporos Int 2011;22:1873-1883. 47. Kanis JA, Hans D, Cooper C, et al. Task Force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-2411. 48. Kanis JA, Harvey NC, Johansson H, Ode ´n A, Leslie WD, McCloskey EV. FRAX update. J Clin Densitom 2017;20:360-367. 49. Kanis JA, Johansson H, Ode ´n A, et al. Characteristics of recurrent fractures. Osteoporos Int 2018;29:1747-1757. 50. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 2009;68:99-102. 51. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the manage- ment of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 2020;31:1-12. Erratum in: Osteoporos Int 2020;31:797- 798. 52. Leslie WD, Schousboe JT, Morin SN, et al. Fracture risk following high- trauma versus low-trauma fracture: a registry-based cohort study. Osteoporos Int 2020;31:1059-1067. 53.",
    "52. Leslie WD, Schousboe JT, Morin SN, et al. Fracture risk following high- trauma versus low-trauma fracture: a registry-based cohort study. Osteoporos Int 2020;31:1059-1067. 53. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-75. 54. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone 2004;35:1029-1037. 55. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta- analysis. Osteoporos Int 2005;16:155-162. 56. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737-742. 57. Ambrose AF, Cruz L, Paul G. Falls and fractures: a systematic approach to screening and prevention. Maturitas 2015;82:85-93. 58. Afrin N, Sund R, Honkanen R, et al. A fall in the previous 12 months predicts fracture in the subsequent 5 years in postmenopausal women. Osteoporos Int 2020;31:839-847. 59. Ambrose AF, Paul G, Hausdorff JM. Risk factors for falls among older adults: a review of the literature. Maturitas 2013;75:51-61. 60. Faulkner KG, von Stetten E, Miller P. Discordance in patient classifi- cation using T-scores. J Clin Densitom 1999;2:343-350. 61. Keaveny TM, Clarke BL, Cosman F, et al. Biomechanical computed tomography analysis (BCT) for clinical assessment of osteoporosis. Osteoporos Int 2020;31:1025-1048. 62. Silva BC, Leslie WD.",
    "61. Keaveny TM, Clarke BL, Cosman F, et al. Biomechanical computed tomography analysis (BCT) for clinical assessment of osteoporosis. Osteoporos Int 2020;31:1025-1048. 62. Silva BC, Leslie WD. Trabecular bone score: a new DXA-derived measurement for fracture risk assessment. Endocrinol Metab Clin North Am 2017;46:153-180. 63. McCloskey EV, Ode ´n A, Harvey NC, et al. Adjusting fracture probability by trabecular bone score. Calcif Tissue Int 2015;96: 500-509. 64. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012;27:301- 308. 65. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Manitoba Bone Density Program. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 2010;25:2350-2358. 66. Crandall CJ, Schousboe JT, Morin SN, Lix LM, Leslie W. Performance of FRAX and FRAX-based treatment thresholds in women aged 40 years and older: The Manitoba BMD Registry. J Bone Miner Res 2019;34:1419-1427. 67. Jiang X, Gruner M, Tre´mollieres F, et al. Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: a systematic review and meta-analysis. Bone 2017;99:20-25. 68. Crandall CJ, Larson J, Gourlay ML, et al.",
    "Bone 2017;99:20-25. 68. Crandall CJ, Larson J, Gourlay ML, et al. Osteoporosis screening in postmenopausal women 50 to 64 years old: comparison of US Preven- tive Services Task Force strategy and two traditional strategies in the Women’s Health Initiative. J Bone Miner Res 2014;29:1661-1666. 69. Crandall CJ, Larson J, Wright NC, et al. Serial bone density measure- ment and incident fracture risk discrimination in postmenopausal women. JAMA Intern Med 2020;180:1232-1240. 70. Gourlay ML, Overman RA, Ensrud KE. Bone density screening and re- screening in postmenopausal women and older men. Curr Osteoporos Rep 2015;13:390-398. 71. Hillier TA, Lui LY, Kado DM, et al. Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures. J Bone Miner Res 2012;27:153-159. 72. Yang J, Mao Y, Nieves JW. Identification of prevalent vertebral fractures using Vertebral Fracture Assessment (VFA) in asymptomatic postmenopausal women: a systematic review and meta-analysis. Bone 2020;136: 115358. 73. Jain S, Camacho P. Use of bone turnover markers in the management of osteoporosis. Curr Opin Endocrinol Diabetes Obes 2018;25:366-372. 74. Crandall CJ, Vasan S, LaCroix A, et al. Bone turnover markers are not associated with hip fracture risk: a case-control study in the Women’s Health Initiative. J Bone Miner Res 2018;33:1199-1208. 75. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General .",
    "J Bone Miner Res 2018;33:1199-1208. 75. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General . Rockville, MD: Office of the Surgeon General; 2004. 76. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Washington, DC: National Academies Press (US); 2011. 77. Wallace RB, Wactawski-Wende J, O’Sullivan MJ, et al. Urinary tract stone occurrence in the Women’s Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr 2011;94:270-277. 78. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336:262-266. 79. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analy- sis. BMJ 2010;341:c3691. 80. Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initia- tive clinical trial and cohort study. Osteoporos Int 2013;24:567-580. 81. Chung M, Tang AM, Fu Z, Wang DD, Newberry SJ. Calcium intake and cardiovascular disease risk: an updated systematic review and meta- analysis. Ann Intern Med 2016;165:856-866. Erratum in: Ann Intern Med 2017;166:687. 82.",
    "Calcium intake and cardiovascular disease risk: an updated systematic review and meta- analysis. Ann Intern Med 2016;165:856-866. Erratum in: Ann Intern Med 2017;166:687. 82. Avenell A, Mak JCS, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 2014;CD000227. 83. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC. Issues of trial selection and subgroup considerations in the recent meta-analysis of Zhao and colleagues on fracture reduction by calcium and vitamin D supplementation in community-dwelling older adults. Osteoporos Int 2018;29:2151-2152. 84. LeBoff MS, Chou SH, Murata EM, et al. Effects of supplemental vitamin D on bone health outcomes in women and men in the VITamin D and OmegA-3 TriaL (VITAL). JB o n eM i n e rR e s 2020;35:883-893. 85. Bouillon R, Lips P, Bilezikian JP. Vitamin D supplementation and musculoskeletal health. Lancet Diabetes Endocrinol 2019;7:85-86. 86. Preventive Services Task Force US, Grossman DC, Curry SJ, Owens DK, et al. Interventions to prevent falls in community-dwelling older adults: US Preventive Services Task Force Recommendation Statement. JAMA 2018;319:1696-1704. 87. Preventive Services Task Force US, Grossman DC, Curry SJ, Owens DK, et al. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: US Preventive Services Task Force Recommendation Statement.JAMA 2018;319:1592- 1599. 88.",
    "88. Reid IR, Bolland MJ. Controversies in medicine: the role of calcium and vitamin D supplements in adults. Med J Aust 2019;211:468-473. 89. Zoltick ES, Sahni S, McLean RR, Quach L, Casey VA, Hannan MT. Dietary protein intake and subsequent falls in older men and women: the Framingham Study. J Nutr Health Aging 2011;15:147-152. 90. Rizzoli R, Biver E. Are probiotics the new calcium and vitamin D for bone health? Curr Osteoporos Rep 2020;18:273-284. 91. Reginster JY, Brandi ML, Cannata-Andı ´a J, et al. The position of strontium ranelate in today’s management of osteoporosis. Osteoporos Int 2015;26:1667-1671. 92. Farsinejad-Marj M, Saneei P, Esmaillzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. Osteoporos Int 2016;27:1389-1399. 93. Mott A, Bradley T, Wright K, et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta- analysis of randomised controlled trials. Osteoporos Int 2019;30:1543- 1559. NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 993 94. Lambert MNT, Hu LM, Jeppesen PB. A systematic review and meta- analysis of the effects of isoflavone formulations against estrogen- deficient bone resorption in peri- and postmenopausal women. Am J Clin Nutr 2017;106:801-811. 95.",
    "A systematic review and meta- analysis of the effects of isoflavone formulations against estrogen- deficient bone resorption in peri- and postmenopausal women. Am J Clin Nutr 2017;106:801-811. 95. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011;18:732- 753. 96. Thorin MH, Wihlborg A, A ˚ kesson K, Gerdhem P. Smoking, smoking cessation, and fracture risk in elderly women followed for 10 years. Osteoporos Int 2016;27:249-255. 97. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011;CD000333. 98. Kistler-Fischbacher M, Weeks BK, Beck BR. The effect of exercise intensity on bone in postmenopausal women (part 1): a systematic review. Bone 2021;143:115696. 99. Kistler-Fischbacher M, Weeks BK, Beck BR. The effect of exercise intensity on bone in postmenopausal women (part 2): a meta-analysis. Bone 2021;143:115697. 100. Pfeifer M, Sinaki M, Geusens P, Boonen S, Preisinger E, Minne HW; ASBMR Working Group on Musculoskeletal Rehabilitation. Musculo- skeletal rehabilitation in osteoporosis: a review. J Bone Miner Res 2004;19:1208-1214. 101. Sherrington C, Fairhall NJ, Wallbank GK, et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev 2019;1:CD012424.",
    "101. Sherrington C, Fairhall NJ, Wallbank GK, et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev 2019;1:CD012424. 102. de Bot RTAL, Veldman HD, W itlox AM, van Rhijn LW, Hiligsmann M. Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk. Osteoporos Int 2020;31:1217-1229. 103. Wasnich RD, Bagger YZ, Hosking DJ, et al. Early Postme nopausal Intervention Cohort Study Group. Changes in bone density and turn- over after alendronate or estrogen withdrawal. Menopause 2004;11: 622-630. 104. Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replace- ment therapy: a randomized controlled trial. Arch Intern Med 2003;163:789-794. 105. McClung MR. Revisiting the prevention of bone loss at menopause. Menopause 2012;19:1173-1175. 106. Zaidi M, Turner CH, Canalis E, et al. Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. Curr Osteoporos Rep 2009;7:118- 126. 107. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimen- opausal bone loss: a prospective study. J Bone Miner Res 2000;15:1965- 1973. 108. Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN).",
    "Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res 2012;27:111-118. 109. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003;73:423-432. 110. Karlamangla AS, Burnett-Bowie SM, Crandall CJ. Bone health during the menopause transition and beyond. Obstet Gynecol Clin North Am 2018;45:695-708. 111. Billington EO, Leslie WD, Brown JP. et al. Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study. Osteoporos Int 2021;32:1313-1320. 112. Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Res Treat 2020;179:275-285. 113. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al; Austrian Breast and Colorectal Cancer Study Group. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-849. 114.",
    "Lancet Oncol 2008;9:840-849. 114. Gnant M, Pfeiler G, Dubsky PC, et al; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG- 18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;386:433-443. 115. Bouvard B, Chatelais J, Soulie ´ P, et al. Osteoporosis treatment and 10 years’ oestrogen receptor þ breast cancer outcome in postmeno- pausal women treated with aromatase inhibitors. Eur J Cancer 2018; 101:87-94. 116. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996;276:1389-1396. 117. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-492. 118. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med 1999;130:897-904. 119. Adami S, Suppi R, Bertoldo F, et al. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 1989;7:79-86. 120. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss: Transdermal Estradiol Investigator Group. Obstet Gynecol 1999;94: 330-336. 121.",
    "Obstet Gynecol 1999;94: 330-336. 121. Cauley JA, Robbins J, Chen Z, et al; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729-1738. 122. Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmen- opausal women: dose-dependent effects. Menopause 2005;12: 741-748. 123. Wells G, Tugwell P, Shea B, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-539. 124. Al-Azzawi F, Lees B, Thompson J, Stevenson JC. Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. Menopause 2005;12:331-339. 125. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxypro- gesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676. 126. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042- 1048.",
    "JAMA 2003;290:1042- 1048. 127. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451. 128. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al; Women’s Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized trial. J Bone Miner Res 2006;21:817-828. 129. Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 2019;104:1623- 1630. 130. Fink HA, MacDonald R, Forte ML, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med 2019;171:37-50. 131. Chlebowski RT, Hendrix SL, Langer RD, et al; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. 132. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al; WHI Inves- tigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003;289:2673-2684. 133. Manson JE, Hsia J, Johnson KC, et al; Women’s Health Initiative Investigators.",
    "JAMA 2003;289:2673-2684. 133. Manson JE, Hsia J, Johnson KC, et al; Women’s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. NAMS POSITION STATEMENT 994 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society 134. Anderson GL, Limacher M, Assaf AR, et al; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmen- opausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712. 135. Shumaker SA, Legault C, Rapp SR, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cogni- tive impairment in postmenopausal women: the Women’s Health Ini- tiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662. 136. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015(3);CD002229. 137. Nudy M, Jiang X, Aragaki AK, et al. The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the Women’s Health Initiative Calcium and Vitamin D randomized clinical trial. Menopause 2020;27:1265-1273. 138. Oliver-Williams C, Glisic M, Shahzad S, et al.",
    "Menopause 2020;27:1265-1273. 138. Oliver-Williams C, Glisic M, Shahzad S, et al. The route of administra- tion, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update 2019;25:257-271. 139. Heiss G, Wallace R, Anderson GL, et al; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045. 140. Papadakis G, Hans D, Gonzalez-Rodriguez E, et al. The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal. J Clin Endocrinol Metab 2016;101:5004- 5011. 141. Watts NB, Cauley JA, Jackson RD, et al. Women’s Health Initiative Investigators. No increase in fractures after stopping hormone therapy: results from the Women’s Health Initiative. J Clin Endocrinol Metab 2017;102:302-308. 142. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728-753. 143. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:CD004143. 144. Kaunitz AM. Extended duration use of menopausal hormone therapy. Menopause 2014;21:679-681. 145. ACOG Practice Bulletin No. 141: management of menopausal symp- toms. Obstet Gynecol 2014;123:202-216.",
    "Kaunitz AM. Extended duration use of menopausal hormone therapy. Menopause 2014;21:679-681. 145. ACOG Practice Bulletin No. 141: management of menopausal symp- toms. Obstet Gynecol 2014;123:202-216. Erratum in Obstet Gynecol 2018;131:166; Obstet Gynecol 2018;131:604. 146. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368. 147. Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015;18:483-491. 148. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641- 1647. 149. Neele SJM, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmeno- pausal women. Bone 2002;30:599-603. 150. Eng-Wong J, Reynolds JC, Venzon D, et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006;91:3941-3946. 151. Ettinger B, Black DM, Mitlack BH, et al.",
    "Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006;91:3941-3946. 151. Ettinger B, Black DM, Mitlack BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645. 152. Cranney A, Tugwell P, Zytaruk N, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteopo- rosis. Endocr Rev 2002;23:524-528. 153. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197. 154. Martino S, Cauley JA, Barrett-Connor E, et al; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761. 155. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of baze- doxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, pla- cebo-, and active-controlled clinical trial.",
    "Efficacy of baze- doxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, pla- cebo-, and active-controlled clinical trial. JB o n eM i n e rR e s 2008;23:1923-1934. 156. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estro- gens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-1052. 157. Pinkerton JV, Harvey JA, Lindsay R, et al; SMART-5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99: E189-E198. 158. Pinkerton JV, Conner EA. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Cli- macteric 2019;22:140-147. 159. Gallagher JC, Palacios S, Ryan KA, et al. Effect of conjugated estrogens/ bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. Menopause 2016;23:1083-1091. 160. Mirkin S, Pinkerton JV, Kagan R, et al. Gynecologic safety of conju- gated estrogens plus bazedoxifene: pooled analysis of five phase 3 trials. J Women’s Health (Larchmt) 2016;25:431-442. 161. Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016;10:CD008536. 162. Biglia N, Maffei S, Lello S, Nappi RE.",
    "Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016;10:CD008536. 162. Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on recent randomized controlled clinical trials. Gynecol Endocrinol 2010;26:804-814. 163. Cummings SR, Ettinger B, Delmas PD, et al; LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708. 164. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106. 165. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double- blind, randomized, controlled trial. Alendronate Osteoporosis Preven- tion Study Group. Ann Intern Med 1998;128:253-261. 166. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-con- trolled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000;85:1895-1900. 167. McClung MR, Wasnich RD, Recker R, et al; Oral Ibandronate Study Group. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004;19:11-18. 168. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL.",
    "J Bone Miner Res 2004;19:11-18. 168. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009;114:999-1007. 169. Grey A, Bolland MJ, Horne A, et al. Five years of anti-resorptive activity after a single dose of zoledronate —results from a randomized double- blind placebo-controlled trial. Bone 2012;50:1389-1393. 170. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. New Engl J Med 1995;333:1437-1443. 171. Black DM, Cummings SR, Karpf DB, et al. Ramdomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541. 172. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082. 173. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Verte- bral efficacy with risedronate therapy (VERT) study group. JAMA 1999;282:1344-1352.",
    "Verte- bral efficacy with risedronate therapy (VERT) study group. JAMA 1999;282:1344-1352. NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 995 174. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91. 175. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New Engl J Med 2001;344:333-340. 176. Chesnut CH 3rd, Saag A, Christiansen C, et al. Effects of oral ibandr- onate administered daily or intermittently on fracture risk in postmen- opausal osteoporosis. J Bone Miner Res 2004;19:1241-1249. 177. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-1822. 178. Cummings SR, San Martin J, McClung MR, et al; for the FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765. 179. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmen- opausal women with osteoporosis. NE n g lJM e d 2001;344: 1434-1441. 180. Miller PD, Hattersley G, Juel Riis b. et al; ACTIVE Study Investigators.",
    "NE n g lJM e d 2001;344: 1434-1441. 180. Miller PD, Hattersley G, Juel Riis b. et al; ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in post- menopausal women with osteoporosis: a randomized clinical trial. JAMA 2016;316:722-733. 181. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375:1532-1543. 182. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377:1417-1427. 183. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with estab- lished osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000;109:267-276. 184. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milan, Italy) 2000;12:1-12. 185. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteo- porosis. Calcif Tissue Int 2002;71:103-111. 186. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36-42. 187. McClung MR, Miller PD, Brown JP, et al.",
    "Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36-42. 187. McClung MR, Miller PD, Brown JP, et al. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int 2012;23:267-276. 188. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-1322. 189. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-1846. 190. Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125-137. 191. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.Am J Med2013;126:13-20. 192. Bone HG, Hosking D, Devogelaer JP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199. 193. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second exten- sion to the HORIZON-Pivotal Fracture Trial (PFT).",
    "193. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second exten- sion to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015;30:934-944. 194. Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491. 195. Kang SH, Park SJ, Kim MK. The effect of bisphosphonate discontinua- tion on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction. J Korean Assoc Oral Maxillofac Surg 2020;46:78-83. 196. Khan AA, Sa´ndor GK, Dore E, et al; Canadian Taskforce on Osteonec- rosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-490. 197. Zebic L, Patel V. Preventing medication-related osteonecrosis of the jaw. BMJ 2019;365:l1733. 198. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23. 199. Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep 2018;16:519-529. 200.",
    "199. Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep 2018;16:519-529. 200. Schilcher J, Koeppen V, Aspenberg P, Michae ¨lsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014;371:974-976. 201. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial long-term Extension (FLEX): a random- ized trial. JAMA 2006;296:2927-2938. 202. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016;31:16-35. 203. Curtis JR, Saag KG, Arora T, et al. Duration of bisphosphonate drug holidays and associated fracture risk. Med Care 2020;58:419-426. 204. Matsumoto T, Endo I. RANKL as a target for the treatment of osteopo- rosis. J Bone Miner Metab 2021;39:91-105. 205. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017;32:1291-1296. 206.",
    "Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017;32:1291-1296. 206. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 2019;34:2220-2228. 207. Kendler D, Chines A, Clark P, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 2020;105:e225-e264. 208. Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16:1281-1290. 209. Sølling ASK, Harsløf T, Langdahl B. Current status of bone-forming thera- pies for the management of osteoporosis.Drugs Aging2019; 36:625-638. 210. Minisola S, Cipriani C, Grotta GD, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis 2019;11:1759720X19877994. 211. Miller PD, Bilezikian JP, Fitzpatrick LA, et al. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin 2020;36:1861-1872. 212.",
    "211. Miller PD, Bilezikian JP, Fitzpatrick LA, et al. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin 2020;36:1861-1872. 212. Dı ´ez-Pe´rez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado- Rodrı´guez M. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 2019;120:1-8. 213. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018;391:230-240. Erratum in: Lancet 2018;391:204; Lancet 2018;392:2352. 214. Reginster JY, Al-Daghri NM, Bruyere O. Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. Expert Opin Pharmacother 2017;18:1811-18134. 215. McClung MR. Romosozumab for the treatment of osteoporosis. Osteo- poros Sarcopenia 2018;4:11-15. 216. Cummings SR, McCulloch C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int 2020;31:1019-1021. 217. Cummings SR, Cosman F, Lewiecki EM, et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF Working Group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017;32:3-10.",
    "Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF Working Group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017;32:3-10. NAMS POSITION STATEMENT 996 Menopause, Vol. 28, No. 9, 2021 /C2232021 The North American Menopause Society 218. Ferrari S, Libanati C, Lin CJF, et al. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of deno- sumab treatment. J Bone Miner Res 2019;34:1033-1040. 219. Cosman F, Lewiecki EM, Ebeling PR, et al. T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial. J Bone Miner Res 2020;35:1333-1342. 220. Bouxsein ML, Eastell R, Lui LY, et al; FNIH Bone Quality Project. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 2019;34:632-642. 221. Black DM, Bauer DC, Vittinghoff E, et al; Foundation for the National Institutes of Health Bone Quality Project. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomized controlled trials. Lancet Diabetes Endocrinol 2020;8:672-682. 222. Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 2017;32:198-202. 223. Bone HG, Cosman F, M iller PD, et al.",
    "222. Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 2017;32:198-202. 223. Bone HG, Cosman F, M iller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 2018;103: 2949-2957. 224. Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 2019;34:419-428. 225. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-1123. ‘‘Management of Osteoporosis in Postmenopausal Women: the 2021 Position Statement of The North American Menopause Society’’ has been designated a CME activity for all NAMS members. NAMS members should log in to the NAMS website, www.menopause.org, and then select Online CME in the Member Center. CME credit will be available from September 1, 2021, to September 1, 2022. NAMS POSITION STATEMENT Menopause, Vol. 28, No. 9, 2021 997",
    "NAMS POSITION STA TEMENT The 2023 nonhormone therapy position statement of The North American Menopause Society Abstract Objective: To update the evidence-based Nonhormonal Management of Menopause-Associated V asomotor Symp- toms: 2015 Position Statement of The North American Menopause Society . Methods:An advisory panel of clinicians and research experts in women’s health were selected to review and evaluate the literature published since the Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Po- sition Statement of The North American Menopause Society . Topics were divided into five sections for ease of review: lifestyle; mind-body techniques; prescription therapies; dietary supplements; and acupuncture, other treatments, and technologies. The panel assessed the most current and available literature to determine whether to recommend or not recommend use based on these levels of evidence: Level I, good and consistent scientific evidence; Level II, limited or inconsistent scientific evidence, and Level III, consensus and expert opinion. Results: Evidence-based review of the literature resulted in several nonhormone options for the treatment of vasomo- tor symptoms. Recommended: Cognitive-behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors/ serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II-III).",
    "Not recommended: Paced respiration (Level I); supplements/herbal remedies (Levels I-II); cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equol, cannabinoids, acupuncture, calibration of neural oscilla- tions (Level II); chiropractic interventions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III). Conclusion: Hormone therapy remains the most effective treatment for vasomotor symptoms and should be consid- ered in menopausal women within 10 years of their final menstrual periods. For women who are not good candidates for hormone therapy because of contraindications (eg, estrogen-dependent cancers or cardiovascular disease) or personal preference, it is important for healthcare professionals to be well informed about nonhormone treatment options for re- ducing vasomotor symptoms that are supported by the evidence. Key W ords:Clinical hypnosis – Cognitive-behavioral therapy– Gabapentin – Hormone therapy – Menopause – Nonhormone therapy – Selective serotonin reuptake inhibitors – Serotonin-norepinephrine reuptake inhibitors – Stellate ganglion block – Vasomotor symptoms. H ot flashes and night sweats (vasomotor symptoms [VMS]) are the most common symptoms of menopause and oc- cur in up to 80% of menopausal women.",
    "H ot flashes and night sweats (vasomotor symptoms [VMS]) are the most common symptoms of menopause and oc- cur in up to 80% of menopausal women. 1 Va s o m o t o r symptoms can be bothersome, lasting a mean duration of 7 to 9 years, and in one-third of women, can last more than 10 years.2 Hormone therapy (HT) remains the most effective treatment and should be considered in menopausal women aged younger than 60 years, within 10 years of their final menstrual periods, and without contraindications. Despite this, the use of HT has de- clined substantially after the publication of the W omen’sH e a l t h Initiative (WHI). 3-5 Evidence suggests that contrary to guideline recommendations, younger women and those with more VMS were less likely to receive HT after the WHI than before. 6 Addi- tionally, rates of continuation of HT have declined in women with more frequent VMS after the WHI, largely because of me- dia reports and provider advice. Despite the underuse of HT in symptomatic women, some may choose not to use HT or have contraindications to its use, such as a history of an estrogen-sensitive cancer (including breast cancer), coronary heart disease, myocardial infarction, Received March 21, 2023; revised and accepted March 21, 2023.",
    "This Position Statement was developed by The North American Menopause Society (NAMS) 2023 Nonhormone Therapy Position Statement Advisory Panel consisting of representatives of the NAMS Board of Trustees and other experts in women ’s health: Lead, Chrisandra L. Shufelt, MD, MS, F ACP , NCMP; Vivien Brown, MDCM, CCFP , FCFP , NCMP; Janet S. Carpenter, PhD, RN, F AAN; Lisa Astalos Chism, DNP , APRN, NCMP , F AANP; Stephanie S. Faubion, MD, MBA, F ACP , NCMP , IF; Hadine Joffe, MD, MSc; Juliana M. Kling, MD, MPH, NCMP , F ACP , IF; Claudio N. Soares, MD, PhD, FRCPC, MBA; Rebecca C. Thurston, PhD, F ABMR. The NAMS Board of Trustees conducted an independent review and revision and approved the position statement. This Position Statement was made possible by donations to the NAMS Education & Research Fund. There was no commercial support. Address correspondence to: The North American Menopause Society; 30050 Chagrin Blvd, Suite 120W; Pepper Pike, OH 44124. E-mail: [EMAIL] W ebsite: www .menopause.org. Menopause, V ol. 30, No. 6, 2023 573 Menopause: The Journal of The North American Menopause Society V ol. 30, No. 6, pp. 573-590 DOI: 10.1097/GME.0000000000002200 © 2023 by The North American Menopause Society stroke, venous thromboembolism, or inherited high risk of thromboembolic disease.7 Nonhormone options are important considerations for women who are not good candidates for HT .",
    "This Position Statement updates and expands information on the nonhormone management of VMS from the 2015 NAMS Position Statement on nonhormone therapies and is intended to provide direction to guide evidence-based nonhormone man- agement of VMS. METHODS An advisory panel of clinicians and research experts in the field of women ’s health was selected to review and evaluate the literature published after the Nonhormonal Management of Menopause-Associated V asomotor Symptoms: 2015 Position Statement of The North American Menopause Society . Topics were divided into five sections for ease of review: life- style; mind-body techniques; prescription therapies; dietary supplements; and acupuncture, other treatments, and technolo- gies. Individual panel members reviewed and evaluated the evidence on the different therapies for which they had special expertise, with the knowledge that trials of nonhormone treat- ments of VMS have a placebo improvement rate of 20% to 66%, and women with more anxiety show higher response to placebo. 8 The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society was written after an exten- sive review of the pertinent literature and includes key points identified during the review process. The resulting manuscript was submitted to and approved by the NAMS Board of Trustees.",
    "The resulting manuscript was submitted to and approved by the NAMS Board of Trustees. The panel assessed the most current and available literature to recommend or not recommend use with the level of evidence assigned on the basis of these categories:  Level I: Good and consistent scientific evidence. Level II: Limited or inconsistent scientific evidence. Level III: Consensus and expert opinion. This Position Statement uses gender-specific language as reflected in the referenced publications. However, NAMS recog- nizes that some persons experiencing menopause may identify differently than with the gender and pronouns used in this statement. LIFESTYLE Cooling techniques Hot flashes can be triggered by small, core-body-temperature elevations 9-11; therefore, it is feasible that changing lifestyle practices that control core body temperature may decrease VMS frequency. These include clothing adjustments (ie, dress- ing in layers; wearing sleeveless blouses; using breathable cloth- ing materials; avoiding pullover sweaters, tops, and scarves) and environmental controls (hand or electric fans; cold packs under the pillow; turning the pillow when feeling warm; dual control electric blankets or a bed fan; lower room temperature). One small (N = 20), uncontrolled trial of postmenopausal women showed benefits with the use of a forehead cooling device and sleep hygiene instructions for reduction in self-reports of sleep problems and VMS over a 4-week period.",
    "12 Another small trial (N = 39) of a nighttime thermal comfort intervention was stud- ied in a 4-week randomized, crossover trial.13 Wo me n r ep or te d no objective changes in the number or duration of nighttime VMS with this device, despite some self-reported improvements in sleep compared with baseline (ie, no device). Overall, cooling interventions must be tested in larger randomized, placebo-/ sham-controlled clinical trials for the treatment of VMS. (Level II; not recommended) A voiding triggers W o m e na r eo f t e nt o l dt oa v o i d“triggers” such as alcohol, caf- feine, spicy foods, or hot foods or liquids. One cross-sectional study of 4,595 Chinese women found a positive association be- tween alcohol intake and VMS 14; however, this has not been re- ported in other studies (such as the Melbourne W omen’sM i d l i f e Health Project).15 There are no clinical trials assessing the ef- fects of avoiding triggers for the alleviation of VMS. (Level II; not recommended) Exercise and yoga Observational studies revealed that women who exercise reg- ularly report fewer VMS. 16-18 However, others have found no relationship between level of physical activity or exercise and VMS, 19 and exercise may trigger VMS in symptomatic women.10 Several Cochrane reviews concluded that there was insufficient or poor evidence to consider exercise as a treatment for VMS.20-22 Among the challenges, methods and exercise in- terventions varied widely across studies.",
    "They included, for ex- ample, supervised walking versus yoga versus no intervention 23 and supervised aerobic exercise versus yoga versus usual activ- ity plus omega-3 or placebo pills. 24 No difference was found be- tween yoga and exercise. When study results comparing exer- cise to no exercise were pooled, exercise had no effect on VMS frequency. 22 One study in the Cochranereview comparing exercise and HT found that HT was far more effective than exer- cise in reducing VMS. A pooled analysis of individual data from four MsFLASH tri- als (N = 1,005) assessed various interventions compared with placebo for the treatment of VMS, including estradiol, antide- pressants, omega-3, cognitive-behavioral therapy (CBT) for in- somnia, and yoga or aerobic exercise. 25 Wo me n wi th m or e b ot h- ersome VMS benefited the most from estradiol, whereas those with VMS and insomnia improved with CBT for insomnia. Those with VMS and psychosocial complaints reported im- provement with antidepressants or CBT for insomnia. Overall, exercise and yoga led to smaller improvements and were not rec- ommended as single interventions for VMS. A systematic review and meta-analysis of 12 randomized, controlled trials (RCTs; N = 1,306) assessed yoga against no treatment, health education, exercise, and auricular acupressure for the treatment of VMS.",
    "26 Given that all outcomes were self-reported and that there was insufficient blinding of partici- pants, there was a high risk for reporting and detection bias among the studies. Additionally , there was significant heteroge- neity in yoga styles, intensity , and frequency, limiting the inter- pretability of the findings. Y oga had limited benefits compared NAMS POSITION STATEMENT 574 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society with exercise for the treatment of VMS, and there were no ben- efits compared with no treatment. Although there are other health benefits associated with exer- cise or yoga, the evidence of those interventions for the treat- ment of VMS is sparse. (Level II; not recommended) Dietary modification Research evaluating the relationship of diet and VMS is lim- ited. A study in postmenopausal women with more than two VMS per day (N = 84) randomized to a low-fat, plant-based diet and a half-cup of cooked soybeans per day versus no dietary changes found an 88% reduction in moderate to severe VMS compared with a 34% reduction in those with no dietary changes after 12 weeks. 27 In surveys, more vegetable and fruit consumption was associated with fewer menopause symp- toms, 28 and women who followed a vegan diet reported fewer bothersome VMS than those who ate meat. For both, increased vegetable consumption was associated with fewer bothersome symptoms.",
    "For both, increased vegetable consumption was associated with fewer bothersome symptoms. 29 One longitudinal cohort study showed high-fat and -sugar diets were associated with an increased risk of VMS.30 One study found that women who had higher soy milk and vegetable consumption had fewer menopause symptoms, whereas those who ate poultry and skimmed dairy products had worse menopause symptoms overall, including more VMS. 31 There is limited evidence from clinical trials to support the use of dietary modification for improving VMS. (Level III; not recommended) W eight loss Studies have found that women who are obese are more likely to report more frequent and severe hot flashes than women of normal weight. 32 Randomized, controlled trials have found that weight loss from behavioral interventions are associated with a decrease in VMS. 33,34 Additionally, reducing hot flashes was a major motivator for losing weight.33 Evidence suggests that the role of adiposity and weight loss in VMS may vary depending on age or menopause stage and specifically that adiposity acts as a risk factor for VMS earlier in the transition (perimenopause and early postmenopause) 35 but not when women are older or later in the transition. 36 Weight loss may have greater effects in reducing VMS when women are earlier in the transition.",
    "36 Weight loss may have greater effects in reducing VMS when women are earlier in the transition. 33 In an open-label single-arm pilot study of a weight-loss medica- tion (selective serotonin 2C [5-HT2C] receptor agonist) tested in 20 women, after 12-weeks there were both a decrease in weight and significant improvement in VMS (decline, 5.4 hot flashes/d) from baseline to week 12. 37 The study also found that after the weight-loss medication was stopped, there was a rapid increase in VMS with a return to baseline weight, further supporting the notion that weight loss improved VMS. How- ever, these studies are either small pilot studies, nonran- domized trials, or post hoc analyses of studies designed for a different purpose. Larger, rigorously designed RCTs are needed. The limited available evidence suggests that weight loss may be used to improve VMS for some women. (Levels II-III; recommended) Key points  There is no strong evidence that lifestyle changes such as cooling techniques and avoiding triggers improve VMS. There is insufficient or poor evidence to consider exercise or yoga as a treatment for VMS. A healthy diet is important for health promotion and chronic disease prevention; however, there is limited evidence to sup- port dietary modifications as a tool for improving VMS. W eight loss may be considered for improving VMS.",
    "W eight loss may be considered for improving VMS. MIND-BODY TECHNIQUES Cognitive-behavioral therapy Cognitive-behavioral therapy (CBT) has been shown to re- duce the degree to which VMS are rated as a problem. Initial ev- idence came from two double-blind RCTs: MENOS 1, which showed that group CBT compared with usual care reduced VMS problem ratings in 96 survivors of breast cancer, 38 and MENOS 2, which showed self-guided and group CBT com- pared with usual care reduced VMS problem ratings in 140 peri- menopausal and postmenopausal women without a history of breast cancer. 39 A clinical psychologist administered the group CBT interven- tion, which involved psychoeducation (physiology of VMS; how thoughts and emotions affect the perception of physical sensations), training in relaxation and paced breathing, and cog- nitive and behavioral strategies to manage VMS (identifying and challenging negative beliefs about VMS; monitoring and modifying triggers of VMS; relaxation exercises). The content of the self-guided CBT was identical to that of the group CBT and included a self-help book completed during a 4-week pe- riod, two contacts with a clinical psychologist, weekly home- work, and a compact disc for daily practice of relaxation and paced breathing. The usual-care group received information about VMS, ad- vice on treatment options and symptom management, and in- structions for paced breathing and relaxation.",
    "The usual-care group received information about VMS, ad- vice on treatment options and symptom management, and in- structions for paced breathing and relaxation. In both studies, improvements in VMS problem ratings were maintained at 26 weeks, and more women in the CBT group (65%-78% across studies) reached a clinically significant threshold for improve- ment in VMS that are rated as a problem than in the usual-care group. Beliefs about coping and control over VMS and beliefs about sleep and night sweats mediated the effect of CBT on VMS problem ratings. 40 Since these initial trials, several studies have extended this in- tervention to other modes of delivery and in other populations. T wo studies in survivors of breast cancer showed that CBT re- duced 1) VMS rated as a problem, hot flash interference, and self-reported VMS frequency when delivered by trained nurses in MENOS 4 (N = 130), 41 or 2) VMS rated as a problem and self-reported VMS frequency when delivered via the internet (with or without therapist support; N = 254). 42 A workplace study of 124 menopausal women with problem- atic VMS found that women who received CBT for VMS using a self-help book had significant reductions in their VMS problem ratings compared with a waitlist control. 43 Another study examined CBT in combination with physical exercise in NAMS POSITION STATEMENT Menopause, V ol. 30, No.",
    "43 Another study examined CBT in combination with physical exercise in NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 575 422 survivors of breast cancer, showing that CBT (with or with- out exercise), but not physical exercise alone, reduced VMS problem ratings but not VMS frequency compared with a waitlist control. 44 Finally , a study of 72 perimenopausal and postmenopausal women with VMS and depressed mood found that women ran- domized to a 12-week group-based CBT intervention had greater reductions in VMS bother and interference 45 as well as improve- ments in depressive symptoms than women randomized to a waitlist control. A caveat to this body of work is that the studies largely employ waitlist or usual-care controls, which are less rigorous controls than active controls matched on time and at- tention. However, the body of literature as a whole supports that CBT alleviates bothersome VMS for both survivors of breast cancer and menopausal women. (Level I; recommended) Mindfulness-based interventions Evidence is limited for mindfulness-based interventions (MBI) for the management of VMS. Common features of MBI in- clude instruction in meditation practices and how to approach thoughts, feelings, and bodily sensations in an accepting, nonjudg- mental manner. A widely disseminated MBI is mindfulness-based stress reduction (MBSR), a multicomponent intervention that includes mindfulness meditation, body awareness, and yoga.",
    "A widely disseminated MBI is mindfulness-based stress reduction (MBSR), a multicomponent intervention that includes mindfulness meditation, body awareness, and yoga. 46 An RCT of MBSR versus waitlist control was conducted in 110 women who had five or more moderate to severe hot flashes per day. The MBSR intervention was a standardized, widely used, 8-week program involving weekly 2.5-hour group classes, at-home practice (45 min, 6 d/wk), and an 8-hour in-person group retreat. V asomotor symptoms were assessed via a diary. After 20 weeks, the MBSR group showed greater reductions in hot flash bother (21.62% vs 10.50%; P = .07) and intensity (44.56% vs 26.97%; P = .057) than waitlist controls; these differences were marginally significant, reflecting the pilot nature of the study, variability in the outcome, and pronounced placebo effect. Several additional studies have examined MBSR or other MBI for a constellation of menopause symptoms (eg, VMS, anxiety, depressive symptoms, sleep disturbance) in women transitioning through menopause 47,48 who were survivors of breast cancer49 or who had undergone early bilateral oophorec- tomy.50 A meta-analysis similarly examined MBI for quality of life or general menopause symptoms.51 These studies have gen- erally shown positive effects in reducing menopause symptoms broadly, with mixed effects for VMS specifically.",
    "Given that these studies were limited by their small sizes or limited control groups and that they were not designed to consider VMS (eg, women with VMS were not specifically enrolled), there are not enough data to recommend MBSR for the management of VMS. Future rigorously designed trials are needed to test the efficacy of MBI for VMS. (Level II; not recommended) Clinical hypnosis Clinical hypnosis is a mind-body therapy that involves a deeply relaxed state and individualized mental imagery and sug- gestion. It has been widely used to manage other chronic symp- toms such as pain and anxiety. Hypnosis has been studied for the treatment of hot flashes in two trials —one randomized trial in survivors of breast cancer 52 and one RCT in women with at least seven hot flashes per day .53 In both trials, clinical hypnosis involved 5 weekly in-person sessions of hypnotherapy with at-home self-hypnosis practice. In a study of 60 women with a history of breast cancer, clinical hypnosis was significantly bet- ter at reducing hot flashes and improving mood and sleep than no treatment. 52 A 2013 single-blind RCT of 187 postmenopausal women reporting at least 50 hot flashes a week at baseline evaluated clin- ical hypnosis over 12 weeks against an active structured-attention control.",
    "52 A 2013 single-blind RCT of 187 postmenopausal women reporting at least 50 hot flashes a week at baseline evaluated clin- ical hypnosis over 12 weeks against an active structured-attention control. 53 Both clinical hypnosis and structured-attention con- trol included 5 weekly sessions that included discussion of symptoms, attentive listening, interpersonal exchange, avoid- ance of negative suggestions, monitoring, measurement, and en- couragement provided in a therapeutic environment with a trained clinician. The hypnosis group additionally received hyp- notic inductions and cooling suggestions. Participants in the clinical-hypnosis arm reported significantly lower hot flash fre- quency (74% vs 17%; P < .001) and hot flash scores (frequency times severity, 80% vs 15%;P < .001) than controls. In addition, physiologically monitored hot flashes were reduced signifi- cantly more in the hypnosis group than in the attention-control group (57% vs 10%; P < .001), indicating a clinically signifi- cant improvement. A follow-up analysis showed that effects were not related to women’s expectations about whether hypno- sis would work. 54 The program can be delivered via a trained provider or accessed via a smartphone application. (Level I; recommended) Paced respiration Paced respiration is unlikely to provide any benefit for hot flashes. Paced respiration involves taking six to eight slow, deep breaths per minute while inhaling through the nose and exhaling through the mouth.",
    "Paced respiration involves taking six to eight slow, deep breaths per minute while inhaling through the nose and exhaling through the mouth. Paced respiration was shown to reduce hot flashes in several small studies that were done in a behavioral laboratory . 55-57 T wo larger studies did not show any benefits over other forms of breathing. In a randomized trial of 208 women, paced respiration was no better than shallow breathing or usual care for reducing hot flash frequency, severity, bother, or inter- ference. 58 Similarly, in a randomized trial of 92 women, paced respiration practiced once or twice per day was no better than usual breathing for reducing hot flash scores (frequency times severity). 59 A third study showed that women who used a chest device to guide their slow, deep breathing practice at home for at least 15 minutes per day had significantly less benefit than a control group assigned to music listening. 60 (Level I; not recommended) Relaxation Evidence is limited and incons istent on relaxation for hot flashes. A 2014 Cochrane review61 a n da2 0 0 8s y s t e m a t i cr e - view62 both concluded that evidence from RCTs of relaxation was insufficient. There are two studies that were not included in either review. The first was a nonblinded, randomized trial show- ing a reduction in hot flash frequency with applied relaxation (n = 33) compared with a waitlist control group (n = 27). 63,64 NAMS POSITION STATEMENT 576 Menopause, V ol. 30, No.",
    "63,64 NAMS POSITION STATEMENT 576 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society The second was a randomized trial comparing a nine-module, internet-delivered, applied relaxation program to an untreated control group. Of 46 women randomized in a 1:1 fashion, 66% dropped out early (no reasons provided), and the study had to be terminated. Limitations across studies included small sample sizes or lack of an appropriate attention-control group. 55,56,63,65-68 (Level II; not recommended) Key points  CBT has been shown to reduce the bother and interference associated with VMS. Clinical hypnosis has been shown to reduce VMS frequency and severity . MBSR interventions for the management of VMS are limited by sample size and lack of control groups and are not de- signed to consider VMS; therefore, there are not enough data to recommend treatment. Paced breathing and relaxation techniques do not alleviate VMS and are not recommended. PRESCRIPTION THERAPIES Many nonhormone prescription therapies have been evaluated and found to significantly reduce VMS in symptomatic meno- pausal women. However, there are only two FDA approved for this indication: paroxetine mesylate 7.5 mg daily and fezolinetant 45 mg daily. Other medications that reduce VMS include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and oxybutynin. T ypically, the onset of action is within 2 weeks.",
    "T ypically, the onset of action is within 2 weeks. There are limited trials comparing nonhormone prescription therapies head-to-head with hormone therapy. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors Evidence exists that SSRIs and SNRIs are associated with mild to moderate improvements in VMS, regardless of whether meno- pause is natural or surgical, as supported by meta-analyses, 69-71 a pooled analysis,72 a Cochranereview,73 and a review focused on evidence in survivors of cancer.74 Limitations to these reviews in- clude heterogeneity of the populations and variations in inclusion criteria, as well as variability in the population that was tested, dosing, length of treatment, and outcomes evaluated. Paroxetine, 75 escitalopram,76 citalopram,77 venlafaxine,78,79 and desvenlafaxine80 have been shown to significantly reduce VMS in large, double-blind RCTs of symptomatic women. Duloxetine has been found to reduce VMS in smaller studies. 81,82Hot flash reduc- tions vary from 25% to 69% with these treatments, with im- provements in composite hot flash severity and frequency from 27% to 61%. Trends toward improvement have been seen with sertraline and fluoxetine, but these were statistically insignifi- cant; therefore, they are not recommended.",
    "Trends toward improvement have been seen with sertraline and fluoxetine, but these were statistically insignifi- cant; therefore, they are not recommended. 69,79,83-86 A pooled analysis from three RCTs showed that 10 mg to 20 mg of escitalopram, 0.5 mg of oral 17 β-estradiol, and 75 mg of venlafaxine daily resulted in comparable reductions in VMS frequency. A trial reported that 75 mg per day of venlafaxine was similar to low-dose oral estradiol 0.5 mg per day. 79,87 Oral estradiol reduced the frequency of hot flashes by 2.3 more per day than placebo ( P < .001), whereas venlafaxine reduced the frequency of hot flashes by 1.8 more per day than placebo ( P = .005). However, neither of these tri- als allowed dose escalation, in which case estradiol would be expected to provide 77% improvement in hot flashes on average. 88 A low-dose paroxetine salt (7.5 mg/d) was the first nonhormone pharmaceutical FDA approved for the treatment of moderate to severe VMS, with improvements found in VMS severity and frequency for up to 24 months, along with improvements in sleep disruption, without weight gain or nega- tive effects on libido. 89,90 Prior neuroleptic syndrome, serotonin syndrome, and concur- rent use of monoamine oxidase inhibitors are contraindications to SSRIs and SNRIs.",
    "89,90 Prior neuroleptic syndrome, serotonin syndrome, and concur- rent use of monoamine oxidase inhibitors are contraindications to SSRIs and SNRIs. Caution should be taken in prescribing in patients with uncontrolled seizures, bipolar disorder, kidney or liver insufficiency, uncontrolled hyponatremia, and poorly controlled hypertension, as well as concurrent use of other SSRIs or SNRIs and pertinent polymorphisms in cytochrome P450 enzyme pathways. Black box warnings include uncom- mon suicidal thoughts in adolescents and children within the first few months. Coadministration of SSRIs may lead to inhibition of CYP2D6 (the enzyme that converts tamoxifen to its most active metabolite, endoxifen) in women using tamoxifen, particularly with paroxetine and fluoxetine. Safer choices for those on ta- moxifen include venlafaxine, desvenlafaxine, escitalopram, or citalopram because they have less of an effect on the CYP2D6 enzyme. There is a possible reported risk of bone fracture with SSRIs because serotonin alters signaling on bone metabo- lism, 91,92 although this has not been seen with short-term use.93 They may produce nausea or dizziness, which typically improves after 1 to 2 weeks. (Level I; recommended) Gabapentinoids Gabapentin is FDA approved as an antiepileptic drug that is commonly used to treat diabetic neuropathy and postherpetic neuralgia.",
    "(Level I; recommended) Gabapentinoids Gabapentin is FDA approved as an antiepileptic drug that is commonly used to treat diabetic neuropathy and postherpetic neuralgia. However, several trials studying the dose of 900 mg (300 mg three times/d) show that this has improved the fre- quency and severity of VMS. 94-96 Possible adverse events (AEs) include dizziness, unstead iness, and drowsiness, typi- cally seen during the first week, with improvement during the second week and resolution by week 4. In a placebo-controlled trial, higher doses of gabapentin (titrated to 2,400 mg/d) were as beneficial as estrogen (conjugated equine estrogens 0.625 mg/d) in reducing hot flash severity scores. 97 Adverse events of gabapentin at this dose included dizziness, headache, and dis- orientation, which limited its potential benefits. Because drows- iness is an AE, and the half-life is short, bedtime dosing of gabapentin may be a good choice for women with disruptive s l e e pf r o mV M S .B l a c kb o xw a r n i n gs for all antiepileptic agents, including gabapentin, include uncommon suicidal thoughts or behaviors. Adverse events include drowsiness, dizziness, and impaired balance or coordination. The suggested dosing (Table 1) for gabapentin is 900 mg to 2,400 mg per day in divided doses. (Level I; recommended) NAMS POSITION STATEMENT Menopause, V ol. 30, No.",
    "The suggested dosing (Table 1) for gabapentin is 900 mg to 2,400 mg per day in divided doses. (Level I; recommended) NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 577 Pregabalin Pregabalin is a gamma-aminobutyric acid analog structurally related to gabapentin FDA approved for the management of neuropathic pain and seizures. There has been one phase 3 RCT in 163 women (40% with a history of cancer) evaluating pregabalin for VMS. 98 After 6 weeks of treatment, pregabalin at a dose of 75 mg twice a day or 150 mg twice a day decreased VMS frequency by 59% and 61%, respectively , whereas pla- cebo decreased symptoms by 35%. There were more dizziness and cognitive difficulties reported in those taking pregabalin. Because of limited studies, AEs, including weight gain, and be- cause pregabalin is listed as a Schedule V controlled substance (because of the potential for abuse), pregabalin is not recom- mended. (Level III; not recommended) Clonidine Clonidine is a centrally activeα-2 adrenergic agonist that has been shown to be modestly more beneficial than placebo 69 but less beneficial than SSRIs, SNRIs, and gabapentin in reducing VMS. 69,73 It is used infrequently because of AEs, including hy- potension, lightheadedness, headache, dry mouth, dizziness, se- dation, and constipation. Sudden cessation can lead to significant elevations in blood pressure. Because there are other more effec- tive therapies with fewer AEs, clonidine is not recommended.",
    "Sudden cessation can lead to significant elevations in blood pressure. Because there are other more effec- tive therapies with fewer AEs, clonidine is not recommended. (Levels I-III, not recommended) Oxybutynin Oxybutynin is an antimuscarinic, anticholinergic therapy that is used for the treatment of overactive bladder and urinary urge incontinence. One prospective study 99 and two randomized, double-blind studies100,101 in postmenopausal women demon- strated that oxybutynin at doses ranging from 2.5 mg or 5 mg twice daily up to 15 mg extended-release daily significantly im- proved moderate to severe VMS. Adverse events of oxybutynin are usually dose-dependent and most commonly include a dry mouth and urinary difficulties. Long-term use of anticholiner- gics may be associated with cognitive decline, particularly in older persons. 102-104 (Levels I-II; recommended) Suvorexant Suvorexant is a dual orexin-receptor antagonist that blocks the effects of the hypothalamic neuropeptide orexin-A, which promotes wakefulness and may be involved in the occurrences of hot flashes. Postmenopausal women have plasma levels that are three times higher than premenopausal women, which may contribute to sleep disruption and impaired thermoregulation. 105 Suvorexant has been shown to reduce insomnia severity,106-108 and findings in a small study of menopausal women showed that it led to reductions in nighttime VMS frequency compared with placebo and was well tolerated.",
    "109 Suvorexant did not improve daytime VMS. Given limited data to support its use, suvorexant is not recommended. (Level II; not recommended) Neurokinin B antagonists New nonhormone therapies, only one of which (fezolinetant) is FDA approved, are important because their development was founded on the burgeoning understanding of VMS physiology . It is recognized that pulsatile gonadotrophin-releasing hormone (GnRH) secretion is itself driven by an ensemble of pacemaker cells that produce kisspeptin, neurokinin B, and dynorphin, leading to the coined acronymKNDy (pronounced candy)t od e - scribe this unique subset of hypothalamic neurons. These KNDy neurons are surrounded by a dense plexus of intercon- nected fibers to ensure that all KNDy neurons fire in concert and together constitute the GnRH pulse generator. 110 Neurokinin B stimulates and dynorphin inhibits sustained pul- satile kisspeptin secretion. In turn, kisspeptin acts directly on GnRH neurons to stimulate GnRH secretion, thereby driving lu- teinizing hormone (LH) and follicle-stimulating hormone (FSH) release. In parallel with the effect of KNDy neurons on GnRH in the hypothalamus, the KNDy neuronal plexus has direct effects on the adjacent hypothalamic thermoregulatory center. 111 After declines in circulating levels of estradiol across the menopause transition, VMS are triggered by hyperactivity of the KNDy neu- ron plexus, resulting in hypersecretion of neurokinin B.",
    "111 After declines in circulating levels of estradiol across the menopause transition, VMS are triggered by hyperactivity of the KNDy neu- ron plexus, resulting in hypersecretion of neurokinin B. 112 Hyper- secretion of neurokinin B fromthe KNDy neurons onto the adja- cent thermoregulatory center in the hypothalamus111 causes dis- ruption of temperature control and the occurrence of VMS.112,113 Therapeutic development of neurokinin B antagonists was initi- ated as a novel strategy to target VMS. This nonhormone approach directly targets the neural mechanism underlying VMS. Published results of RCTs are available for three distinct agents, with fezolinetant, which is FDA approved, and elinzanetant 114-116 in development. A third agent, antagonist (MLE4901),117,118,121 is no longer being pursued as a VMS treatment. TABLE 1.",
    "A third agent, antagonist (MLE4901),117,118,121 is no longer being pursued as a VMS treatment. TABLE 1. Suggested dosing ranges for nonhormone prescription therapies SSRIs Paroxetine salt 7.5 mg Single dose, no titration needed Paroxetine 10-25 mg/d Start with 10 mg/d Citalopram 10-20 mg/d Start with 10 mg/d Escitalopram 10-20 mg/d Start with 10 mg/d (for sensitive or older women, start with 5 mg/d for titration, but this dose has not been evaluated for effic acy) SNRIs Desvenlafaxine 100-150 mg/d Start with 25-50 mg/d and titrate up by that amount each day V enlafaxine 37.5-150 mg/d Start with 37.5 mg/d Gabapentinoids Gabapentin 900-2,400 mg/d Start with 100-300 mg at night, then add 300 mg at night, then a separate dose of 300 mg in the morning (start 100 mg if concerned about sensitivity) Neurokinin B antagonists Fezolinetant 45 mg/d Single dose, no titration needed SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors. NAMS POSITION STATEMENT 578 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society Published trial results include demonstration of efficacy of fezolinetant116,119,120 and elinzanetant116,121 relative to placebo. Fezolinetant is a selective neurokinin B receptor-3 antagonist found to be more beneficial than placebo within and up to 12 weeks of use. Elinzanetant is a dual neurokinin B receptor-3 and receptor-1 antagonist found to be more beneficial than pla- cebo within 2 weeks of use.",
    "Elinzanetant is a dual neurokinin B receptor-3 and receptor-1 antagonist found to be more beneficial than pla- cebo within 2 weeks of use. Phase 3 trials have demonstrated safety, with headache as the most common AE. 120 Elevation of hepatic enzymes was rare and resolved either during continued treatment or with treatment discontinuation. The effect of neurokinin B antagonists on other symptoms that commonly co-occur with VMS or are frequently experienced dur- ing the menopause transition has received less attention. Early ev- idence suggests benefit for quality of life- and VMS-related dis- tress, nocturnal awakenings, and sleep quality. 114-116,119,121-123Fur- ther effect on VMS-related mood and genitourinary, sexual, cardiovascular, metabolic, and bone health are lacking. Higher doses appear to suppress LH but not estradiol in postmenopausal women with VMS. 114 However, potentially advantageous and detrimental effects on other physiologic processes have yet to be fully investigated in larger populations. Key points  SSRIs and SNRIs are associated with mild to moderate im- provements in VMS. Gabapentin is associated with improvements in the frequency and severity of VMS. Pregabalin is not recommended for VMS because of AEs and controlled-substance prescribing restrictions. Because of significant AEs and no recent studies showing greater benefit than placebo, clonidine is not recommended.",
    "Because of significant AEs and no recent studies showing greater benefit than placebo, clonidine is not recommended. Oxybutynin has been shown to reduce moderate to severe VMS, although in older adults, long-term use may be associ- ated with cognitive decline. Given limited data, suvorexant is not recommended. Fezolinetant is a first-in-class neurokinin B antagonist that is FDA approved for management of vasomotor symptoms. DIET ARY SUPPLEMENTS Managing VMS with dietary supplements is complex and challenging because there are limited rigorous randomized, clin- ical trial data from which to evaluate supplements and a lack of government regulation to ensure their purity and safety . These over-the-counter products remain widely marketed through direct-to-consumer marketing. They are permitted to market to- ward specific claims of alleviating symptoms despite limited ev- idence as long as there is no claim to provide disease benefit. Dietary supplements with limited or inconsistent evidence of benefit Soy foods and soy extracts Soy is the most widely used isoflavone-containing food. Isoflavones are a class of phytochemicals, a broad group of nonsteroidal compounds of diverse structure that bind to estro- gen receptors (ERs) in animals and human beings. Isoflavones have a greater affinity for ER- β than for ER- α and possess both estrogen-agonist and estrogen-antagonist properties.",
    "Isoflavones have a greater affinity for ER- β than for ER- α and possess both estrogen-agonist and estrogen-antagonist properties. 124 Soy is among the eight most common food allergens, 125 and reactions can range from mild (eg, bloating, flatulence, loose stools) to severe (eg, anaphylaxis). “The Nonhormonal Management of Menopause-Associated V asomotor Symptoms: 2015 Position Statement of The North American Menopause Society ” noted mixed evidence for use of soy for VMS. 126 Soy trials published since 2015 are difficult to summarize because of the wide variation in interventions tested (eg, soy-based drinks, 127,128 soy isoflavone derivatives in tablets only129 or combined with exercise,130 or mixed with other supplements [herbals, vitamins, or minerals]), with widely varying dosages tested. 131-135 These studies also have signifi- cant limitations, including small sample sizes, 129-131,133,134 use of symptom checklists 126-131,133,135 rather than VMS di- aries,134 and relatively short-term assessment of outcomes.",
    "For example, most participants reported VMS after 12 weeks of treatment, 127-129,131,133-135yet meta-analyses suggest more than 13 weeks are needed to demonstrate half of the expected maximal effects, 136 and more than 16 weeks are needed for optimal ef- fects.137 As a result of these study differences and limitations, the findings are mixed, with some studies showing soy to be beneficial for reducing VMS or severity, 131,132,135 and others showing no benefit of soy over placebo127,128,130,133or finding soy to be less beneficial than other treatments.129 (Level II; not recommended) Soy metabolite equol Equol is a nonsteroidal estrogen that binds to ER-α and ER-β, but because of its high affinity for ER-β, it is often designated as an ER- β agonist. Few studies have considered whether study participants can metabolize soy, which is critical for soy’s poten- tial estrogenic effects. Only 35% of North American women can metabolize the soy isoflavone daidzein to equol. 138 Women who are able to metabolize soy into equol would be expected to expe- rience relief from VMS with soy products or equol. W omen who cannot produce equol after ingesting soy do not benefit from soy but would be expected to benefit from equol. T ests to ascertain whether women are equol producers are not commercially avail- able to the public or healthcare professionals.",
    "T ests to ascertain whether women are equol producers are not commercially avail- able to the public or healthcare professionals. A 2019 systematic review and meta-analysis found positive effects of equol supplementation over placebo for reducing VMS frequency in three of five trials. 139 Null findings in the re- maining two trials were hypothesized to have been because of large differences in VMS at baseline in one trial and inclusion of only equol-producing women in the largest trial. A limitation in most studies (4 of the 6) was inclusion of fewer than 50 par- ticipants per group. There is currently mixed evidence for soy foods, soy extracts, and the soy metabolite equol from widely diverse studies, with some significant limitations. (Level II; not recommended) Pollen extract A proprietary extract made from flower pollen has been avail- able under the brand names Relizen, Serelys, Femal, and Femalen. One RCT (N = 53) found that women randomized to receive pollen extract showed significant reductions in VMS on the Menopause NAMS POSITION STATEMENT Menopause, V ol. 30, No.",
    "One RCT (N = 53) found that women randomized to receive pollen extract showed significant reductions in VMS on the Menopause NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 579 Rating Scale (MRS; 65% VMS reduction with pollen extract vs 38% with placebo, P < .006) and daily diaries (27% greater re- duction with treatment than placebo,P < .026) after 3 months of use.140 A single-arm multicenter study (N = 104) found a signif- icant decrease in menopause symptoms after 12 weeks ’ use of pollen extract.141 An additional observational, single-arm study (N = 108) that included perimenopausal and menopausal women found reduction in hot flashes after 3 months ’ use of pollen extract.142 However, based on expert opinion and limited scientific research for the management of VMS, pollen extract is not recommended. (Level III; not recommended) Ammonium succinate An ammonium succinate-based supplement (Amberen) was studied for the management of menopause symptoms in a manufacturer-sponsored clinical trial, with an initial study pub- lished in 2016, 143 and later a pooled analysis including this study and a second additional study was published in 2019. 144 The studies were identical multicenter, double-blind, 90-day RCTs including women aged 42 to 60 years with mild to mod- erate menopause symptoms (n = 227).",
    "144 The studies were identical multicenter, double-blind, 90-day RCTs including women aged 42 to 60 years with mild to mod- erate menopause symptoms (n = 227). Both studies showed im- provement in menopause symptoms such as sleep, fatigue, loss of interest in sex, joint and muscle pain, VMS, and a decrease in anxiety compared with the placebo group. W omen in the ammo- nium succinate-supplement group also showed an increase in serum estradiol levels and a decrease in leptin. The authors con- cluded that the pooled analysis of the two studies found that the ammonium succinate-based supplement improved meno- pause symptoms, including VMS, compared with placebo. Because of limited studies and the results being based on manufacturer-sponsored clin ical trials, ammonium succinate is not recommended. (Level II; not recommended) Lactobacillus acidophilus Lactobacillus acidophilus YT1 was studied for managing menopause symptoms. 145 One 12-week, multicenter, double blind, RCTl (N = 67) involved women with menopause symp- toms including VMS. After 12 weeks, total Kupperman Index (KI) scores decreased, and quality of life was improved (Menopause-Specific Quality of Life [MSQOL] questionnaire) in all four symptom domains (physical, psychological, vasomotor, and sexual). There were no reported changes in hormone levels or endometrial lining.",
    "There were no reported changes in hormone levels or endometrial lining. Given that this data is limited to one small study, based on global menopause symptom ratings, and has not been replicated, it is not recommended at this time. (Level II; not recommended) Rhubarb Siberian rhubarb (Rheum rhaponticum)i su s e da saf o o da n d as a medicinal plant for constipation, diarrhea, and other gastroin- testinal complaints. A single commercial preparation of rhubarb extract, which has been used in Germany for more than 20 years, was introduced in the United States (Estrovera). The product con- tains a proprietary extract called rhaponticinor extract ERr 731 and contains estrogenic properties but is not estrogen. One study randomized 109 symptomatic perimenopausal women to ERr 731 (n = 54) or placebo (n = 55) daily for 12 weeks. 146 Only 7 of 55 women randomized to placebo completed the trial (12.7% retention rate), and 39 of 54 women randomized to active treatment completed the trial. The researchers reported that at 12 weeks, the MRS total score and each symptom within the scale (including VMS) significantly improved in the active-treatment group versus placebo. Human safety data were drawn from a group of 23 women followed for 48 weeks, 20 of whom com- pleted a 96-week observation period. Few AEs were reported. 147 Another open-label, single-arm study in Indian perimenopausal women over 12 weeks reported improved menopause symp- toms.",
    "Few AEs were reported. 147 Another open-label, single-arm study in Indian perimenopausal women over 12 weeks reported improved menopause symp- toms. 148 Given the extremely low retention rate in clinical trials and the open-label study design in one study, the conclusions are limited. (Level II; not recommended) Dietary supplements without demonstrated evidence of benefit Black cohosh Black cohosh, scientific name Actaea racemosa L. (previ- ously Cimicifugae racemosae), is the most purchased botanical for menopause symptoms. The active ingredients in black co- hosh extract are unknown, and its mechanism of action is un- clear. At one time it was thought to be estrogenic, with in vitro and in vivo assays indicating estrogen-like activity . 149 Other studies indicate activity similar to selective estrogen-receptor modulators 150 or modulation of serotonergic pathways, as well as antioxidant and anti-inflammatory effects. Reports of possible hepatotoxicity started to appear after 2000. After examining all reported cases, the US Pharmacope- ial Convention Dietary Supplements-Botanicals Expert Com- mittee found 30 reports possibly related to black cohosh.",
    "After examining all reported cases, the US Pharmacope- ial Convention Dietary Supplements-Botanicals Expert Com- mittee found 30 reports possibly related to black cohosh. The committee issued a directive that black cohosh products carry a warning statement: “Discontinue use and consult a health- care practitioner if you have a liver disorder or develop symp- toms of liver trouble, such as abdominal pain, dark urine, or jaundice.” 151 A2 0 1 2Cochranereview152 analyzed 16 RCTs of 2,027 peri- menopausal or postmenopausal women treated with black co- hosh using a median daily dose of 40 mg for a mean duration of 23 weeks. There was no significant difference between black cohosh and placebo in the frequency of VMS. Data on safety were inconclusive. Other literature compared black cohosh to HT in a randomized trial of three groups: group A, 1 mg estra- diol plus cyclic 4 mg medroxyprogesterone acetate; group B, 1 mg estradiol daily plus cyclic 100 mg micronized progester- one; and group C, 100 mg Cimicifuga foetida extract daily. 153 The study was limited by sample size because only 81 women (84%) completed the study , and although the KI scores were re- duced in each group, there were no significant differences be- tween groups. Despite this, the authors concluded that C foetida extract could alleviate VMS after 12 weeks.",
    "Despite this, the authors concluded that C foetida extract could alleviate VMS after 12 weeks. Another large sys- tematic review (35 studies and one meta-analysis) noted that the effects of C foetida was possibly dose-dependent as well as augmented when combined with other products such as St. John ’sw o r t . 154 At this time, there is in sufficient evidence to support the use of black cohosh for VMS. (Level I; not recommended) NAMS POSITION STATEMENT 580 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society Other supplements Wild yam. Dioscorea barbasco, Dm e x i c a n a,a n d Dv i l l o s a are the varieties of wild yam most commonly used. Dv i l l o s a , also known as Mexican yam or wild yam root, contains diosgenin, a steroid precursor used in the manufacture of syn- thetic steroids. Diosgenin is converted in vitro to progesterone, but there is no biochemical pathway for this conversion in vivo. Evidence for Dioscorea for VMS is limited. One clinical trial employing a yam cream to treat VMS reported no significant benefit. 155 T ested yam creams often do not contain any yam ex- tract, and many have been adulterated with undisclosed steroids, including estrogens, progesterone, and medroxyprogesterone acetate. Because of the potential harm that may result from adul- terants and lack of efficacy data, yam creams are not recom- mended for VMS.",
    "Because of the potential harm that may result from adul- terants and lack of efficacy data, yam creams are not recom- mended for VMS. (Level II; not recommended) Dong quai, also known as Angelica sinensis,d a n gg u i ,a n d tang kuei, is the root of the Angelica polymorpha Maxim var sinensis (Oliv). Researchers enrolled 71 women in an RCT of 4.5 g dong quai per day or placebo. 156 After 24 weeks, there were no differences in VMS frequency; KI scores; levels of FSH, LH, or estradiol; vaginal maturation index; or endometrial thickness. Dong quai does not appear to alleviate VMS, and there are a number of safety concerns, including possible photo- sensitization, anticoagulation, and carcinogenicity . (Level II; not recommended) Evening primrose, Oenothera biennisL, is a flowering plant rich in linolenic acid and γ-linolenic acid. There is a single trial of evening primrose oil for m enopause symptoms in which 56 women were randomized to evening primrose oil 500 mg per day or placebo for 6 months. 157 Evening primrose oil did not show benefit over placebo, with VMS declining by 1.0 per day with evening primrose oil and by 2.6 per day with placebo. (Level II; not recommended) Maca (Lepidium Meyennii Walp, Lepidium peruvianum Chacon), a traditional foodstuff from South America, contains a weak phytosterol (β-sitosterol) also found in several other bo- tanicals such as saw palmetto.",
    "Both methanolic and aqueous ex- tracts of maca exhibit estrogenic activity in vitro, but studies have found no in vivo estrogenic effects. In a systematic review, four studies showed improvements in Greene Climacteric Scale or KI scores. However, because of quality, design, sample sizes, or limited reporting of study data, 158 existing evidence is not strong enough to support the use of maca for VMS. (Level II; not recommended) Ginseng.There are two distinct true ginsengs in common use; Panax ginseng and Panax quinquefolius, as well as a third substance, Siberian ginseng ( Acanthopanax senticosus or Eleutherococcus senticosus ), a member of a closely related family of plants (Araliacea). In a study of a specific proprietary product, G115 (Ginsana in the United States), 384 postmeno- pausal women were randomized to G115 or placebo. 159 After 16 weeks, women taking G115 did not show greater VMS reduc- tions than with placebo. Similarly, researchers found no significant effect of Korean red ginseng on VMS frequency versus pla- cebo. 160 A second study similarly found that ginseng failed to affect VMS when measured by the KI and the MRS. 161 Thus, ginseng does not appear to be beneficial for VMS. (Level I; not recommended) Labisia pumila /Eurycoma longifolia was studied in a double-blind, 24-week RCT of women aged 41 to 55 years (N = 119) experiencing menopause symptoms (MRS and MSQOL questionnaire used for assessment of symptoms).",
    "162 At week 12, the group randomized to active treatment experi- enced improvement in symptoms (65%) compared with placebo (60%; P < .01). However, at weeks 12 to 24, significant im- provement in the MRS and MSQOL questionnaire scores were noted in both treatment and placebo groups (P <. 0 0 1 ) .O v e r a l l , the authors concluded that there were no significant differences in menopause symptoms between treatment and placebo groups. (Level I; not recommended) Chasteberry. Vitex species have estrogenic properties, and compounds such as apigenin and penduletin are their ER-β-selective compounds, whereas rotundifuran and agnuside activate ER- α-dependent responses. 163 Four double-blind RCTs have tested supplements containing varying amounts of Vitex agnus-castus (an amount equivalent to 1,000 mg dried vitex fruit, 164,165 50 mg of vitex fruit extract, 166 or 125 mg vitex fruit167) in combination with various other supplements 165-167 or combined with Nigella satvia and citalopram 20 mg per day.164 All trials included perimenopausal or postmenopausal women with VMS and included methods to assess compliance. The largest and most rigorous trial (n = 100) compared a mixed supplement to placebo and found no group differences in daily diary VMS frequency or questionnaire VMS intensity after 16 weeks of treatment.",
    "165 The remaining three smaller (<50 women/group) trials used less rigorous questionnaire-only measures of VMS (rather than di aries) and found significant reductions in VMS frequency , bother, or intensity ratings after 8 to 12 weeks of treatment. 164,166,167 Few AEs were reported in any of the trials. Because of differences in the compounds that were tested, it is not possible to conclude that Vitex alone im- proves VMS. (Level II; not recommended) Milk thistle is a member of the Asteracease family , a thera- peutic herb used for fever and kidney and spleen disease. One previous study evaluated its effect in polyherbal formulations that included black cohosh, dong quai, and other herbs. It has been evaluated in a small RCT of 40 women receiving Silybum marianum extract and 40 women receiving placebo over a 12-week period and reported improvement in hot flashes and night sweats severity over placebo. 168 Because of the limitations of one study , there is not enough evidence to make a recommen- dation. (Level II; not recommended) Omega-3 fatty acid supplements contain polyunsaturated fatty acids, including eicosapentaenoic acid, docosahexaenoic acid, and α-linolenic acid. Phospholipids, a major component of neuronal cells, contain a high prevalence of fatty acids.",
    "Phospholipids, a major component of neuronal cells, contain a high prevalence of fatty acids. T wo trials have evaluated omega-3s for VMS: In an 8-week trial of 91 women randomized to placebo or omega-3 supplement (total daily dose, 1,100 mg eicosapentaenoic acid plus 50 mg docosahexaenoic acid), VMS frequency and intensity were signif- icantly improved with omega-3 compared with placebo. 169 In a 12-week trial, women were randomized in a 1:1 ratio to NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 581 omega-3s (n = 177) or placebo (n = 178) and simultaneously in a 3:3:4 ratio to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). There were no significant differences in VMS frequency or bother with omega-3s or pla- cebo. 170 Therefore, there is mixed and inconclusive evidence for the use of omega-3s for the management of VMS. (Levels I- II; not recommended) Vitamin E. Previous studies investigating the effects of vita- min E for VMS treatment incl uded two crossover trials (N = 120; N = 50) that showed limited reduction in VMS fre- quency with vitamin E compared with placebo. 171,172 There is very little evidence for vitamin E having significant benefit in re- ducing VMS. A study from Iran with a total of 93 participants evaluated the use of curcumin alone and vitamin E alone in reduc- ing VMS as well as other symptoms of menopause versus pla- cebo (30 women/group).",
    "A study from Iran with a total of 93 participants evaluated the use of curcumin alone and vitamin E alone in reduc- ing VMS as well as other symptoms of menopause versus pla- cebo (30 women/group). 173 There was some improvement seen at 4 weeks for curcumin and at 8 weeks for vitamin E compared with placebo. Results were significant at 4 weeks for curcumin and at 8 weeks for vitamin E, but sample sizes were small, limit- ing conclusions. Therefore, vitamin E is not recommended for the management of VMS. (Level I; not recommended) Cannabinoids The data evaluating the relationship between cannabinoids and menopause symptoms is very limited. This lack of evidence is particularly notable because more than one-quarter of women have used or are using marijuana to treat their menopause symp- toms. 174 A systematic review found only three small studies that evaluated cannabis use and its associations with menopause symptoms, including VMS, insomnia, mood, and depression/ anxiety. 175 Based on the lack of available evidence, cannabi- noids cannot be recommended for the treatment of VMS. (Level II; not recommended) Key points  Given mixed evidence of benefit for VMS, soy foods, soy ex- tracts, and the soy metabolite equol are not recommended. Given the lack of rigorous, evidence-based scientific re- search supporting the use of any over-the-counter supple- ments and herbal therapies for the management of VMS, these remedies are not recommended.",
    "Cannabinoids are not recommended for the treatment of VMS. ACUPUNCTURE, OTHER TREA TMENTS, AND TECHNOLOGIES Acupuncture Acupuncture is a component of the ancient practice of tradi- tional Chinese medicine in which thin needles are inserted into the skin at key points in the body and activated through specific movements (manual acupuncture) or with electrical stimulation (electroacupuncture) to create an energy flow, or Qi, which is believed to improve overall health. Sham acupuncture is a placebo-equivalent treatment involving needles inserted at unre- lated points or needles that do not pierce the skin. Over the last decade, several systematic reviews and meta-analyses examined acupuncture versus no treatment or sham intervention for the treatment of VMS. In most systematic reviews, 176-178 as well as in RCTs, 179 acupuncture was deemed to alleviate some menopause-related symptoms (eg, mood, sleep, pain) as reflected in the reduction in menopause-related total scores (eg, KI, Greene Climacteric Scale) or the improvement in quality-of-life measurements (eg, MSQOL questionnaire); it had, however, little to no clinical benefit for the improvement of VMS compared with sham interventions, either for symp- tomatic midlife women or for survivors of breast cancer.",
    "Consistent with this conclusion, a 2018 study (umbrella meta-analysis) that included three systematic reviews and four RCTs found modest benefits of acupuncture for the alleviation of menopause-related symptoms, quality of life, and VMS sever- ity or frequency when treatments were compared with no treat- ment. 180 Results, however, were no longer clinically significant when acupuncture was compared with sham intervention. There has been a considerable debate regarding the use of ap- propriate comparisons or control groups in acupuncture studies; some have argued, for example, that sham interventions may not be physiologically inert and therefore would not be the most ap- propriate comparison for studies or trials that aim to inform clin- ical practice. It is important to note that although most studies that compared traditional acupuncture with sham interventions found no significant difference in VMS frequency or severity, trials with electroacupuncture showed some benefits with this intervention and even stronger results for electroacupuncture when compared with manual acupuncture. 181 In a 2021 model-based meta-analysis, Li and colleagues assessed 17 studies (1,123 participants), including manual acu- puncture, electroacupuncture, and sham acupuncture.",
    "181 In a 2021 model-based meta-analysis, Li and colleagues assessed 17 studies (1,123 participants), including manual acu- puncture, electroacupuncture, and sham acupuncture. 178 The au- thors found that after 8 weeks of treatment, both electroacupuncture and a combination of both acupuncture modalities (traditional acupuncture and electroacupuncture) led to significant reduc- tion of VMS per day compared with sham intervention. More- over, the benefits of electroacupuncture for VMS were compa- rable to those reported in previous studies using nonhormone, pharmacologic treatments such as SSRIs, SNRIs, gabapentin, and escitalopram. Existing evidence does not support the use of traditional acu- puncture for the treatment of VMS, neither for midlife women nor for VMS in survivors of breast cancer. (Level I; not recom- mended). The use of electroacupuncture, although more promising, still warrants further investigation. (Level II; not recommended) Stellate ganglion block Stellate ganglion blockade is a widely used treatment for pain management, including for migraine and complex regional pain syndrome. The treatment is accomplished through the injection of an anesthetic agent at the lower cervical or upper thoracic region because the stellate ganglion is located bilaterally in the C6-T2 re- gion of the anterior cervical spine. Adverse events, such as tran- sient seizures or a bleeding complication, are extremely rare and minimized using imaging guidance during the procedure.",
    "Adverse events, such as tran- sient seizures or a bleeding complication, are extremely rare and minimized using imaging guidance during the procedure. 182 Stellate ganglion blockade has emerged as a potential treat- ment option for VMS in both midlife women and those with breast cancer, although the exact mechanism of action of stellate ganglion blockade on VMS remains unclear. NAMS POSITION STATEMENT 582 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society One randomized, sham-controlled trial assessed active stel- late ganglion blockade with bupivacaine versus a sham proce- dure (subcutaneous saline injection) for VMS in women with natural or surgical menopause (N = 40). 183 Over a 6-month follow-up, there was a reduction in subjectively reported VMS intensity and frequency (moderate to very severe) in the stellate ganglion blockade group compared with the sham-control group. Moreover, there was a reduction (21%, P < .05) of physiologic VMS measured with ambulatory skin conductance monitors from baseline to 3 months in the stellate ganglion blockade group, whereas the sham-control group showed no reduction. Four uncon- trolled, open-label studies showed that stellate ganglion blockade reduced VMS, with effects ranging from a 45% to a 90% reduc- tion 6 weeks to several months after blockade.",
    "Four uncon- trolled, open-label studies showed that stellate ganglion blockade reduced VMS, with effects ranging from a 45% to a 90% reduc- tion 6 weeks to several months after blockade. 184-187 In a study of patients with breast cancer (N = 40), stellate gan- glion blockade (10 mL 0.5% bupivacaine injected bilaterally) was compared with paroxetine 7.5 mg per day over a 6-week pe- riod. 188 Both treatments had a positive effect on an index com- prising both VMS frequency and severity , with no significant differences between treatments. Overall, stellate ganglion blockade might help alleviate mod- erate to very severe VMS in select women. Results from ongo- ing larger RCTs are needed to provide more definitive evidence. Given that stellate ganglion blockade is a procedure that in- volves potential risks and AEs, its potential use for VMS should be carefully evaluated. (Levels II-III; recommended) Calibration of neural oscillations High-resolution, relational, resonance-based electroencephalic mirroring is a closed-loop acoustic stimulation neurotechnology based on the principle of allostasis. Essentially, scalp sensors and software algorithms translatespecific brain frequencies into audible tones of varying pitch in real time, and these tones are immediately mirrored back via ear buds, allowing the brain to “listen to itself ” in an acoustic mirror.",
    "High-resolution, rela- tional, resonance-based electroencephalic mirroring has shown some preliminary benefits for the management of insomnia 189 and for military-related stress.190 In an uncontrolled study, 14 women showed a significant re- duction in VMS frequency and severity after administration with high-resolution, relational, resonance-based electroencephalic mirroring aimed at autocalibration of neural oscillations. 191 Given the lack of controlled trials, high-resolution, relational, resonance-based electroencephalic mirroring is not recom- mended for treatment of VMS. (Level II; not recommended) Chiropractic intervention There have been no clinical trials of chiropractic interventions for VMS, and epidemiologic survey data show no association be- tween use of such interventions and VMS. 192 Chiropractic inter- ventions are not recommended for treatment of VMS. (Level II; not recommended) Key points  Existing evidence does not support the use of traditional acu- puncture for the treatment of VMS; electroacupuncture re- quires more rigorous study before it can be recommended. Stellate ganglion blockade might alleviate moderate to very severe VMS in select women but is associated with potential risk. Calibration of neural oscillations and chiropractic interven- tions are not recommended for treatment of VMS. RECOMMENDATIONS V asomotor symptoms are common in midlife women and re- main undertreated.",
    "RECOMMENDATIONS V asomotor symptoms are common in midlife women and re- main undertreated. These symptoms can disrupt a women ’s overall quality of life and last a mean duration of 7 to 9 years, longer in some women. Hormone therapy remains the first-line recommended treatment to ameliorate VMS in healthy women at or around the time of menopause. However, it is important to recognize that not all women are candidates for HT because of contraindications or personal preference. This Position Statement supports the use of and recommends CBT , clinical hypnosis, SSRIs, SNRIs, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II- III). There is negative or insufficient evidence for these, so they are not recommended: paced respiration (Level I); supplements/ herbal remedies (Levels I-II); cooling techniques, avoiding trig- gers, exercise, yoga, MBI, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equ ol, cannabinoids, acupuncture, calibration of neural oscillations (Level II), chiropractic interven- tions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III). Clinici ans should be knowledgeable of the nonhormone options supported by evidence that are available to offer to women (Table 2). ACKNOWLEDGMENTS AND DISCLOSURES NAMS appreciates the contributions of the Advisory Panel and the work of the NAMS Board of Trustees on this Position Statement.",
    "ACKNOWLEDGMENTS AND DISCLOSURES NAMS appreciates the contributions of the Advisory Panel and the work of the NAMS Board of Trustees on this Position Statement. The authors, planners, reviewers, and staff who were in a position to control and influence the content of this activity were required to disclose all financial relationships with any in- eligible company within the last 24 months. Any financial rela- tionships that were determined by NAMS to be relevant to the activity have been mitigated. Acknowledgments The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel: Lead, Chrisandra L. Shufelt, MD, MS, F ACP , NCMP , Professor and Chair, Division of General Internal Medicine, Associate Direc- tor, W omen’s Health Research, Mayo Clinic, Jacksonville, Flor- ida. Vivien Brown, MDCM, CCFP , FCFP , NCMP , Assistant Professor, Faculty of Medicine, Department of Family and Community Medicine, University of Toronto, Ontario, Canada. Janet S. Carpenter, PhD, RN, F AAN, Distinguished Professor, Audrey Geisel Endowed Chair in Innovation, Indiana University School of Nursing, Indianapolis, Indiana. Lisa Astalos Chism, DNP , APRN, BC, CSC, NCMP , F AAN, F AANP , Clinical Director, Oakland Macomb Ob Gyn Center for Breast Health, Rochester Hills, Michigan.",
    "Lisa Astalos Chism, DNP , APRN, BC, CSC, NCMP , F AAN, F AANP , Clinical Director, Oakland Macomb Ob Gyn Center for Breast Health, Rochester Hills, Michigan. Stephanie S. Faubion, MD, MBA, F ACP , NCMP , IF , Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for W omen ’s Health. Hadine Joffe, MD, MSc, NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 583 Executive Director, Mary Horrigan Connors Center for Wo me n’s Health and Gender Biology; Paula A. Johnson Profes- sor of Psychiatry in the Field of W omen ’s Health; Executive Vice Chair for Academic and Faculty Affairs, Department of Psychiatry , Brigham and W omen’s Hospital, Harvard Medical School, Boston, Massachusetts. Juliana M. Kling, MD, MPH, NCMP , F ACP , IF , Professor of Medicine; Chair, Women’s Health Internal Medicine; Associate Chair of Equity, Inclusion, and Di- versity , Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona. Claudio N. Soares, MD, PhD, FRCPC, MBA, Professor and Head, Department of Psychiatry; Chair, Psychedelic Science Advisory Committee, Queen’sU n i v e r s i t y School of Medicine; Executive Lead, Canadian Biomarker Inte- gration Network in Depressio n (CAN-BIND); President and Chief Executive Officer, CAN-BIND Solutions, Ontario, Canada.",
    "Rebecca C. Thurston, PhD, F ABMR, Pittsburgh Foundation Chair in Women’s Health and Dementia; Professor of Psychi- atry, Psychology, Epidemiology and Clinical and Translational Science; Director, Women ’s Biobehavioral Health Research Program; Director, Cardiovascular Behavioral Medicine Re- search Training Program, University of Pittsburgh, Pittsburgh, Pennsylvania. NAMS recognizes the contributions of Carolyn Develen, NAMS Chief Operating Officer, and Kathy Method, MA, NAMS Editor.",
    "NAMS recognizes the contributions of Carolyn Develen, NAMS Chief Operating Officer, and Kathy Method, MA, NAMS Editor. This position statement was reviewed and approved by the 2022-2023 NAMS Board of Trustees: President, Susan D. Reed, MD, MPH, MS, NCMP , Professor Emeritus, Department of Obstetrics and Gynecology; Adjunct Professor of Epidemiol- ogy, University of Washington School of Medicine, Seattle, Washington.President-Elect,L i s aC .L a r k i n ,M D ,F A C P ,N C M P , IF , Founder and Chief Executive Officer, Ms.Medicine, Cincinnati, Ohio.Secretary,M o n i c aM .C h r i s t m a s ,M D ,F A C O G ,N C M P ,A s - sociate Professor and Director of the Menopause Program and Center for W omen's Integrated Health, Section of Minimally Inva- sive Gynecologic Surgery, UChicago Medicine and Biological Sci- ences, Chicago, Illinois.Treasurer, Claudio N. Soares, MD, PhD, FRCPC, MBA, Professor and Head, Department of Psychiatry; Chair, Psychedelic Science Advisory Committee, Queen’sU n i v e r - sity School of Medicine; Executive Lead, Canadian Biomarker In- tegration Network in Depression (CAN-BIND); President and Chief Executive Officer, CAN-BIND Solutions, Ontario, Canada.",
    "Medical Director, Stephanie S. Faubion, MD, MBA, F ACP , NCMP , IF , Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for Women’s Health.Immediate Past-President, Chrisandra L. Shufelt, MD, MS, F ACP , NCMP , Professor and Chair, Division of General Internal Medicine, Associate Director, Wo m e n’s Health Research Center, Mayo Clinic, Jacksonville, Florida. Janet S. Carpenter, PhD, RN, F AAN, Distinguished Pro- fessor, Audrey Geisel Endowed Chair in Innovation, Indiana Uni- versity School of Nursing, Indi anapolis, Indiana. Samar R. El Khoudary, PhD, MPH, BPharm, FAHA, Associate Professor, De- partment of Epidemiology, Epidemiology Data Center, Univer- sity of Pittsburgh, Pittsburgh, Pennsylvania. Laurie S. Jeffers, DNP , FNP-BC, NCMP , Codirector, Center for Midlife Health and Menopause, NYU Grossman School of Medicine, Department of Obstetrics and Gynecology, NYU Langone Health, New Y ork, New Y ork. Hadine Joffe, MD, MSc, Executive Director, Mary Horrigan Connors Center for W omen’s Health and Gender Biol- ogy; Paula A. Johnson Professor of Psychiatry in the Field of Wo me n’s Health; Executive Vice Chair for Academic and Fac- ulty Affairs, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. Cheryl Cox Kinney, MD, F ACOG, NCMP , Director, Center for Fe- male Health and Hormone Disorders, Medical City Dallas, Dallas, T exas.",
    "Cheryl Cox Kinney, MD, F ACOG, NCMP , Director, Center for Fe- male Health and Hormone Disorders, Medical City Dallas, Dallas, T exas. Isaac Schiff, CM, MD, Editor-in-Chief, Menopause, Joe Vincent Meigs Distinguished Professor of Gynecology, Harvard Medical School; Chief, Department of Obstetrics and Gy- necology, Emeritus, The Women’s Care Division, Massachusetts General Hospital, Boston, Massachusetts. W en Shen, MD, MPH, Associate Professor of Gynecologic Specialties; Associate TABLE 2.",
    "W en Shen, MD, MPH, Associate Professor of Gynecologic Specialties; Associate TABLE 2. Treatment recommendations for nonhormone therapies for vasomotor symptoms with levels of evidence Category Treatment Recommended Not recommended Lifestyle Cooling techniques Level II A voiding triggers Level II Exercise Level II Y oga Level II Dietary modifications Level III Weight loss Levels II-III Mind-body techniques Cognitive-behavioral therapy Level I Mindfulness-based interventions Level II Clinical hypnosis Level I Paced respiration Level I Relaxation Level II Prescription therapies SSRIs/SNRIs Level I Gabapentin Level I Pregabalin Level III Clonidine Levels I-III Oxybutynin Levels I-II Suvorexant Level II Fezolinetant Level I Dietary supplements Soy foods and soy extracts Level II Soy metabolites equol Level II Supplements/Herbal remediesa Levels I-III Cannabinoids Level II Acupuncture, other treatments, and technologies Acupuncture Level II Stellate ganglion block Levels II-III Calibration of neural oscillations Level II Chiropractic intervention Level II Level I, good and consistent scientific evidence; Level II, limited or inconsistent scientific evidence; Level III, consensus and expert opinion. SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.",
    "SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors. aPollen extract, ammonium succinate,Lactobacillus acidophilus,r h u b a r b ,b l a c k cohosh, wild yam, dong quai, evening primrose oil, maca, ginseng, labisia pumila/eurycoma longifolia , chasteberry, milk thistle, omega-3 fatty acids, vitamin E. NAMS POSITION STATEMENT 584 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society Professor of Oncology Center; Associate Professor, Johns Hop- kins School of Nursing Joint Appointment; Codirector of Johns Hopkins Women's Wellness and Healthy Aging Program, Johns Hopkins University School of Medicine, Baltimore, Maryland. Holly N. Thomas, MD, MS, NCMP , Assistant Professor of Medi- cine and Clinical and Translational Research, Director of the Com- parative Effectiveness Research Track, Director of the Leadership and Discovery Program, University of Pittsburgh, Pittsburgh, Pennsylvania. Financial disclosures All financial relationships with ineligible companies have been mitigated. For the Advisory Panel: Dr. Faubion reports no financial relationships with ineligible companies. Dr. Brown re- ports Consultant/Advisory Board and Speakers’ Bureau for GSK, Merck, Pfizer, Sanofi, Eisai, Sequeris, and Moderna; Speakers’ Bureau for Abbvie.",
    "Dr. Brown re- ports Consultant/Advisory Board and Speakers’ Bureau for GSK, Merck, Pfizer, Sanofi, Eisai, Sequeris, and Moderna; Speakers’ Bureau for Abbvie. Dr. Carpenter reports Consultant/Advisory Board for the University of Wisconsin Milwaukee, Simumetirx, SMX Health; Grant/Research Support from the NIH; Royalties/ Patents from Mapi Trust; Owner of JSCarpenter LLC. Dr. Chism reports Consultant/Advisory Board for Astellas and Pharmavite; Royalties from Jones and Bartlett Learning. Dr. Joffe reports Consultant/Advisory Board for Bayer, Hello Therapeutics, and Merck; Grant/Research Support from Merck, the NIH, and Pfizer. Dr. Kling reports Consultant f o rK i n d r a / P r o c t e r&G a m b l e and Triangle Insights Group; Speaker for Pri Med and SNSMA. Dr. Soares reports Consultant/Advisory Board for Bayer, Dia- mond Therapeutics, Eisai, Otsuka, and Pfizer; Executive Com- mittee Member for the Canadian Biomarker Integration Network in Depression. Dr. Shufelt reports Grant/Research Support from the NIH. Dr. Thurston reports Consultant for Astellas Pharma, Happify Health, Pfizer, Vira Health, and Virtue Health. For additional contributors: Ms. Develen and Ms. Method re- port no financial relationships with ineligible companies. For the NAMS Board of Trustees members who were not members of the Advisory Panel: Dr. Jeffers, Dr. Kinney, and Dr. Schiff report no financial relationships with ineligible com- panies.",
    "For the NAMS Board of Trustees members who were not members of the Advisory Panel: Dr. Jeffers, Dr. Kinney, and Dr. Schiff report no financial relationships with ineligible com- panies. Dr. Christmas reports Consultant/Advisory Board for the FDA Obstetrics, Reproductive, and Urologic Drugs Advisory Committee. Dr. El Khoudary reports Grant/Research Support from the NIH. Dr. Larkin reports Consultant/Advisory Board for Astellas, Myovant/Pfizer, Pharmavite, Procter & Gamble, Solv W ellness, and TherapeuticsMD; Speakers’ Bureau for Abbvie; and Board Member for HealthyW omen. Dr. Reed reports Consultant/ Advisory Board for the NIH; Grant/Research Support for Bayer and the NIH; and Royalties/Patents for UpToDate. Dr. Shen re- ports Consultant/Advisory Board for Merck; Stock/Ownership for Astra Zeneca, Akzo Nobel, Bristol Myers Squibb, Hologic, Johnson & Johnson, and Merck. Dr. Thomas reports Consultant/Ad- visory Board for Astellas; Grant/Research Support from the NIH. References 1. Gold EB, Colvin A, A vis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of W omen ’s Health Across the Nation. Am J Public Health 2006;96:1226-1235. doi: 10.2105/AJPH.2005.066936 2. A vis NE, Crawford SL, Greendale G, et al. Study of W omen's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA. Intern Med 2015;175:531-539. doi: 10. 1001/jamainternmed.2014.8063 3.",
    "Study of W omen's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA. Intern Med 2015;175:531-539. doi: 10. 1001/jamainternmed.2014.8063 3. Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause 2012;19:610-615. doi: 10.1097/gme.0b013e31823a3e5d 4. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W , Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the W omen ’s Health Initiative. Menopause 2012;19:616-621. doi: 10.1097/gme.0b013e31824bb039 5. W eissfeld JL, Liu W , W oods C, et al. Trends in oral and vaginally administered estrogen use among US women 50 years of age and older with commercial health insurance. Menopause 2018;25:611-614. doi: 10. 1097/GME.0000000000001054 6. Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the W omen ’s Health Initiative study results. Menopause 2018;26:588-597. doi: 10.1097/GME. 0000000000001282 7. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;:767-794. doi: 10.1097/GME.0000000000002028 8. van Die MD, Teede HJ, Bone KM, Reece JE, Burger HG. Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause.",
    "Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause. Menopause2009;16:792-796. doi: 10.1097/GME.0b013e318199d5e6 9. Freedman RR, Norton D, W oodward S, Cornélissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab1995;80:2354-2358. doi: 10.1210/jcem.80.8.7629229 10. Freedman RR, Krell W . Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999; 181:66-70. doi: 10.1016/s0002-9378(99)70437-0 11. Freedman RR, W oodward S. Core body temperature during menopausal hot flushes. Fertil Steril 1996;65:1141-1144. 12. Baker FC, de Zambotti M, Chiappetta L, Nofzinger EA. Effects of forehead cooling and supportive care on menopause-related sleep difficulties, hot flashes and menopausal symptoms: a pilot study. Behav Sleep Med 2021; 19:615-628. doi: 10.1080/15402002.2020.1826484 13. Composto J, Leichman ES, Luedtke K, Mindell JA. Thermal comfort intervention for hot-flash related insomnia symptoms in perimenopausal and postmenopausal-aged women: an exploratory study. Behav Sleep Med 2021;19:38-47. doi: 10.1080/15402002.2019.1699100 14. Zhang L, Ruan X, Cui Y , Gu M, Mueck AO. Menopausal symptoms and associated social and environmental factors in midlife Chinese women. Clin Interv Aging 2020;15:2195-2208. doi: 10.2147/CIA.S278976 15. Guthrie JR, Dennerstein L, Hopper JL, Burger HG.",
    "Clin Interv Aging 2020;15:2195-2208. doi: 10.2147/CIA.S278976 15. Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol 1996;88:437-442. doi: 10.1016/0029-7844(96)00196-2 16. Ivarrson T , Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas 1998;29:139-146. doi: 10.1016/s0378-5122(98)00004-8 17. Hammar M, Berg G, Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes? Acta Obstet Gynecol Scand 1990;69:409-412. doi: 10.3109/00016349009013303 18. Haimov-Kochman R, Constatini N, Brzezinski A, Hochner-Celnikier D. Regular exercise is the most significant lifestyle parameter associated with the severity of climacteric symptoms: a cross sectional study. Eur J Obstet Gynecol Reprod Biol 2013;170:229-234. doi: 10.1016/j.ejogrb. 2013.06.018 19. Kim MJ, Cho J, Ahn Y , Yim G, Park HY . Association between physical activity and menopausal symptoms in perimenopausal women. BMC W omens Health2014;14:122. doi: 10.1186/1472-6874-14-122 20. Daley A, MacArthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007: CD006108. doi: 10.1002/14651858.CD006108.pub2 21. Daley A, Stokes-Lampard H, Macarthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2011:CD006108. doi: 10.1002/14651858.CD006108.pub3 22.",
    "Daley A, Stokes-Lampard H, Macarthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2011:CD006108. doi: 10.1002/14651858.CD006108.pub3 22. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014: CD006108. doi: 10.1002/14651858.CD006108.pub4 23. Elavsky S, McAuley E. Physical activity and mental health outcomes during menopause: a randomized controlled trial. Ann Behav Med 2007; 33:132-142. doi: 10.1007/BF02879894 NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 585 24. Sternfeld B, Guthrie KA, Ensrud KE, et al. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause 2014; 21:330-338. doi: 10.1097/GME.0b013e31829e4089 25. Diem SJ, LaCroix AZ, Reed SD, et al. Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials. Menopause 2020;27:1126-1136. doi: 10.1097/GME.0000000000001597 26. Cramer H, Peng W , Lauche R. Y oga for menopausal symptoms —a systematic review and meta-analysis. Maturitas 2018;109:13-25. doi: 10. 1016/j.maturitas.2017.12.005 27. Barnard N, Kahleova H, Holtz DN, et al. A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial. Menopause 2023;30:80-87. doi: 10.1097/GME.0000000000002080 28. Soleymani M, Siassi F , Qorbani M, et al.",
    "A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial. Menopause 2023;30:80-87. doi: 10.1097/GME.0000000000002080 28. Soleymani M, Siassi F , Qorbani M, et al. Dietary patterns and their association with menopausal symptoms: a cross-sectional study.Menopause 2019;26:365-372. doi: 10.1097/GME.0000000000001245 29. Beezhold B, Radnitz C, McGrath RE, Feldman A. V egans report less bothersome vasomotor and physical menopausal symptoms than omnivores. Maturitas 2018;112:12-17. doi: 10.1016/j.maturitas.2018.03.009 30. Herber-Gast GC, Mishra GD. Fruit, Mediterranean-style, and high-fat and - sugar diets are associated with the risk of night sweats and hot flushes in midlife: results from a prospective cohort study. Am J Clin Nutr 2013;97: 1092-1099. doi: 10.3945/ajcn.112.049965 31. Flor-Alemany M, Marín-Jiménez N, Coll-Risco I, Aranda P , Aparicio V A. Influence of dietary habits and Mediterranean diet adherence on menopausal symptoms. The FLAMENCO project. Menopause 2020;27: 1015-1021. doi: 10.1097/GME.0000000000001574 32. Thurston RC, Sowers MR, Sternfeld B, et al. Gains in body fat and vasomotor symptom reporting over the menopausal transition: the Study of W omen’s Health Across the Nation. Am J Epidemiol 2009;170:766- 774. doi: 10.1093/aje/kwp203 33. Thurston RC, Ewing LJ, Low CA, Christie AJ, Levine MD. Behavioral weight loss for the management of menopausal hot flashes: a pilot study.",
    "Thurston RC, Ewing LJ, Low CA, Christie AJ, Levine MD. Behavioral weight loss for the management of menopausal hot flashes: a pilot study. Menopause 2015;22:59-65. doi: 10.1097/GME.0000000000000274 34. Huang AJ, Subak LL, Wing R, et al; Program to Reduce Incontinence by Diet and Exercise Investigators. An intensive behavioral weight loss intervention and hot flushes in women. Arch Intern Med 2010;170:1161-1167. doi: 10. 1001/archinternmed.2010.162. Erratum inArch Intern Med2010;170:1601. 35. Anderson DJ, Chung HF , Seib CA, et al. Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies. Am J Obstet Gynecol2020;222:478.e1-478.e17. doi: 10.1016/j.ajog.2019.10.103 36. Thurston RC, Santoro N, Matthews KA. Adiposity and hot flashes in midlife women: a modifying role of age. J Clin Endocrinol Metab 2011; 96:E1588-E1595. doi: 10.1210/jc.2011-1082 37. Kapoor E, Faubion S, Hurt RT , et al. A selective serotonin receptor agonist for weight loss and management of menopausal vasomotor symptoms in overweight midlife women: a pilot study . Menopause 2020;27:1228- 1235. doi: 10.1097/GME.0000000000001599 38. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012;13:309- 318. doi: 10.1016/S1470-2045(11)70364-3 39. A yers B, Smith M, Hellier J, Mann E, Hunter MS.",
    "Lancet Oncol 2012;13:309- 318. doi: 10.1016/S1470-2045(11)70364-3 39. A yers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 2012;19:749-759. doi: 10.1097/gme.0b013e31823fe835 40. Norton S, Chilcot J, Hunter MS. Cognitive-behavior therapy for menopausal symptoms (hot flashes and night sweats): moderators and mediators of treatment effects. Menopause 2014;21:574-578. doi: 10. 1097/GME.0000000000000095 41. Fenlon D, Maishman T , Day L, et al. Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: results of the MENOS4 randomised controlled trial. Psychooncology 2020;29:1514- 1523. doi: 10.1002/pon.5432 42. Atema V , van Leeuwen M, Kieffer JM, et al. Efficacy of internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. JC l i n Oncol 2019;37:809-822. doi: 10.1200/JCO.18.00655 43. Hardy C, Griffiths A, Norton S, Hunter MS. Self-help cognitive behavior therapy for working women with problematic hot flushes and night sweats (MENOS@W ork): a multicenter randomized controlled trial. Menopause 2018:508-519. doi: 10.1097/GME.0000000000001048 44. Duijts SF A, van Beurden M, Oldenburg HAS, et al.",
    "Menopause 2018:508-519. doi: 10.1097/GME.0000000000001048 44. Duijts SF A, van Beurden M, Oldenburg HAS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. JC l i nO n c o l2012;30:4124- 4133. doi: 10.1200/JCO.2012.41.8525 45. Green SM, Donegan E, Frey BN, et al. Cognitive behavior therapy for menopausal symptoms (CBT -Meno): a randomized controlled trial. Menopause 2019;26:972-980. doi: 10.1097/GME.0000000000001363 46. Carmody JF , Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause 2011;18:611-620. doi: 10.1097/gme. 0b013e318204a05c 47. W ong C, Yip BHK, Gao T , et al. Mindfulness-based stress reduction (MBSR) or psychoeducation for the reduction of menopausal symptoms: a randomized, controlled clinical trial. Sci Rep 2018;8:6609. doi: 10. 1038/s41598-018-24945-4 48. Y azdani Aliabadi M, Javadnoori M, Saki Malehi A, Aslani K. A study of mindfulness-based stress-reduction training effects on menopause-specific quality of life in postmenopausal women: a randomized controlled trial. Complement Ther Clin Pract 2021;44:101398. doi: 10.1016/j.ctcp.2021. 101398 49. Bower JE, Crosswell AD, Stanton AL, et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial.",
    "101398 49. Bower JE, Crosswell AD, Stanton AL, et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 2015;121:1240-1240. Erratum in: Cancer 2015;121:1910. doi: 10.1002/ cncr.29194 50. van Driel C, de Bock GH, Schroevers MJ, Mourits MJ. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.BJOG. 2019;126:402-411. doi: 10.1111/1471-0528.15471 51. Chen TL, Chang SC, Huang CY , Wang HH. Effectiveness of mindfulness-based interventions on quality of life and menopausal symptoms in menopausal women: a meta-analysis. J Psychosom Res 2021;147:110515. doi: 10.1016/j.jpsychores.2021.11051 52. Elkins G, Marcus J, Stearns V , et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022-5026. doi: 10.1200/JCO.2008.16.6389 53. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291-298. doi: 10.1097/gme.0b013e3 1826ce3ed 54. Sliwinski JR, Elkins GR. Hypnotherapy to reduce hot flashes: examination of response expectancies as a mediator of outcomes. J Evid Based Complementary Altern Med 2017;22:652-659. doi: 10. 1177/2156587217708523 55. Germaine LM, Freedman RR. Behavioral treatment of menopausal hot flashes: evaluation by objective methods.",
    "J Evid Based Complementary Altern Med 2017;22:652-659. doi: 10. 1177/2156587217708523 55. Germaine LM, Freedman RR. Behavioral treatment of menopausal hot flashes: evaluation by objective methods. J Consult Clin Psychol 1984; 52:1072-1079. doi: 10.1037//0022-006x.52.6.1072 56. Freedman RR, W oodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring.Am J Obstet Gynecol 1992; 167:436-439. doi: 10.1016/s0002-9378(11)91425-2 57. Freedman RR, Woodward S, Brown B, Javaid JI, Pandey GN. Biochemical and thermoregulatory effects of behavioral treatment for menopausal hot flashes. Menopause 1995;2:211-218. 58. Carpenter JS, Burns DS, Wu J, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial.J Gen Intern Med 2013;28:193-200. doi: 10.1007/s11606-012-2202-6 59. Sood R, Sood A, W olf SL, et al. Paced breathing compared with usual breathing for hot flashes. Menopause 2013;20:179-184. doi: 10.1097/ gme.0b013e31826934b6 60. Huang AJ, Phillips S, Schembri M, Vittinghoff E, Grady D. Device-guided slow-paced respiration for menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2015;125:1130-1138. doi: 10.1097/AOG. 0000000000000821 61. Saensak S, Vutyavanich T , Somboonporn W , Srisurapanont M. Relaxation for perimenopausal and postmenopausal symptoms. Cochrane Database Syst Rev 2014;7:CD008582. doi: 10.1002/14651858.CD008582.pub2 62. Tremblay A, Sheeran L, Aranda SK.",
    "Cochrane Database Syst Rev 2014;7:CD008582. doi: 10.1002/14651858.CD008582.pub2 62. Tremblay A, Sheeran L, Aranda SK. Psychoeducational interventions to alleviate hot flashes: a systematic review. Menopause 2008;15:193-202. doi: 10.1097/gme.0b013e31805c08dc 63. Lindh-Åstrand L, Nedstrand E. Effects of applied relaxation on VMS in postmenopausal women: a randomized controlled trial.Menopause 2013; 20:401-408. doi: 10.1097/gme.0b013e318272ce80 64. Lindh-Åstrand L, Holm ACS, Sydsjö G, Andersson G, Carlbring P , Nedstrand E. Internet-delivered applied relaxation for vasomotor symptoms in postmenopausal women: lessons from a failed trial. Maturitas 2015;80: 432-434. doi: 10.1016/j.maturitas.2015.01.010 NAMS POSITION STATEMENT 586 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society 65. Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol 1996;17:202-207. doi: 10.3109/01674829609025684 66. Nedstrand E, Wijma K, Wyon Y , Hammar M. V asomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study.Climacteric 2005;8:243-250. doi: 10.1080/13697130500118050 67. Nedstrand E, Wijma K, Wyon Y , Hammar M. Applied relaxation and oral estradiol treatment of VMS in postmenopausal women.Maturitas2005;51: 154-162. doi: 10.1016/j.maturitas.2004.05.017 68.",
    "Nedstrand E, Wijma K, Wyon Y , Hammar M. Applied relaxation and oral estradiol treatment of VMS in postmenopausal women.Maturitas2005;51: 154-162. doi: 10.1016/j.maturitas.2004.05.017 68. Fenlon DR, Corner JL, Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer.J Pain Symptom Manage2008;35:397-405. doi: 10.1016/j.jpainsymman. 2007.05.014 69. Nelson HD, V esco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071. doi: 10.1001/jama.295.17.2057 70. Shams T , Firwana B, Habib F , et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014; 29:204-213. doi: 10.1007/s11606-013-2535-9 71. Sun Z, Hao Y , Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest 2013;75:255-262. doi: 10.1159/ 000348564 72. Loprinzi CL, Sloan J, Stearns V , et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. JC l i n Oncol 2009;27:2831-2837. doi: 10.1200/JCO.2008.19.6253 73. Rada G, Capurro D, Pantoja T , et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010:CD004923. doi: 10.1002/14651858.CD004923.pub2 74. Fisher WI, Johnson AK, Elkins GR, et al.",
    "Cochrane Database Syst Rev 2010:CD004923. doi: 10.1002/14651858.CD004923.pub2 74. Fisher WI, Johnson AK, Elkins GR, et al. Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J Clin 2013;63:167- 192. doi: 10.3322/caac.21171 75. W ei D, Chen Y , Wu C, et al. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis. BJOG 2016;123:1735- 1743. doi: 10.1111/1471-0528.13951 76. Freeman EW , Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-274. doi: 10.1001/jama.2010.2016 77. Davari-Tanha F , Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H. Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double- blind, placebo-controlled trial. Arch Gynecol Obstet 2016;293:1007- 1013. doi: 10.1007/s00404-015-3900-1 78. Ramaswarmi R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. V enlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015;152:231-237. doi: 10.1007/s10549-015-3465-5 79. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058- 1066. doi: 10.1001/jamainternmed.2014.1891 80.",
    "JAMA Intern Med 2014;174:1058- 1066. doi: 10.1001/jamainternmed.2014.1891 80. Sun Z, Hao Y , Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest 2013;75:255-262. doi: 10.1159/ 000348564 81. Biglia N, Bounous VE, Susini T , et al. Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.Eur J Cancer Care 2018:27. doi: 10.1111/ecc.12484 82. Freeman MP , Hirschberg AM, Wang B, et al. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. Maturitas 2013;75:170-174. doi: 10. 1016/j.maturitas.2013.03.007 83. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF . Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obset Gynecol 2007;109:823-830. doi: 10.1097/01.AOG. 0000258278.73505.fa 84. Kerwin JP , Gordon PR, Senf JH. The variable response of women with menopausal hot flashes when treated with sertraline. Menopause 2007; 14:841-845. doi: 10.1097/GME.0b013e31802e7f22 85. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583. doi: 10. 1200/JCO.2002.20.6.1578 86. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms.",
    "J Clin Oncol 2002;20:1578-1583. doi: 10. 1200/JCO.2002.20.6.1578 86. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. Menopause 2007;14:223-229. doi: 10.1097/01.gme.0000243571.55699.4a 87. Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms. Obstet Gynecol2015;126:413-422. doi: 10.1097/AOG.0000000000000927 88. Maclennan AH, Broadbent JL, Lester S, Moore V . Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;2004:CD002978. doi: 10.1002/ 14651858.CD002978.pub2 89. Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027-1035. doi: 10.1097/GME.0b013e3182a66aa7 90. Riemma G, Schiattarella A, La V erde M, et al. Efficacy of low-dose paroxetine for the treatment of hot flushes in surgical and physiological postmenopausal women: systematic review and meta-analysis of randomized trials.Medicina (Kaunas)2019;55:554. doi: 10.3390/medicina55090554 91. Hanay EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 2010;46:13-17. doi: 10.1016/j.bone.2009.07.083 92.",
    "Bone 2010;46:13-17. doi: 10.1016/j.bone.2009.07.083 92. Sheu YH, Lanteigne A, Stürmer T , Pate V , Azrael D, Miller M. SSRI use and risk of fractures among perimenopausal women without mental disorders.Inj Prev2015;21:397-403. doi: 10.1136/injuryprev-2014-041483 93. Diem SJ, Joffe H, Larson JC, et al. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. JC l i nE n d o c r i n o lM e t a b 2014;99:E1732-E1737. doi: 10.1210/jc.2014-2288 94. Brown JN, Wright BR. Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy2009;29:74-81. doi: 10.1592/phco.29.1.74 95. Hayes LP , Carroll DG, Kelley KW . Use of gabapentin for the management of natural or surgical menopausal hot flashes.Ann Pharmacother2011;45: 388-394. doi: 10.1345/aph.1P366 96. Y oon SH, Lee JY , Lee C, Lee H, Kim SN. Gabapentin for the treatment of hot flushes in menopause: a meta-analysis. Menopause 2020;27:485-493. doi: 10.1097/GME.0000000000001491 97. Reddy SY , Warner H, Guttuso T Jr., et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-48. doi: 10.1097/01.AOG.0000222383.43913.ed 98. Loprinzi CL, Qin R, Balcueva EP , et al. Phase III, randomized, double- blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. JC l i nO n c o l 2010;28:641-647. Erratum in: JC l i n Oncol 2010;28:1808. doi: 10.1200/JCO.2009.24.5647 99. Kim WO, Kil HK, Y oon KB, Y oo JH.",
    "JC l i nO n c o l 2010;28:641-647. Erratum in: JC l i n Oncol 2010;28:1808. doi: 10.1200/JCO.2009.24.5647 99. Kim WO, Kil HK, Y oon KB, Y oo JH. Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients. Acta Derm V enereol2010;90:291-293. doi: 10.2340/00015555-0828 100. Simon JA, Gaines T , LaGuardia KD; Extended-Release Oxybutynin Therapy for VMS Study Group. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause 2016;23:1214-1221. doi: 10.1097/GME.0000000000000773 101. Leon-Ferre RA, Novotny PJ, W olfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603).JNCI Cancer Spectr 2019; 21:pkz088. doi: 10.1093/jncics/pkz088 102. Duong V , Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. I n tU r o g y n e c o lJ2021;32:2693-2702. doi: 10.1007/s00192-021-04909-5 103. Risacher SL, McDonald BC, Tallman EF , et al; Alzheimer ’sD i s e a s e Neuroimaging Initiative. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 2016;73:721-732. doi: 10.1001/ jamaneurol.2016.0580 104. Gray SL, Anderson ML, Dublin S, et al.",
    "JAMA Neurol 2016;73:721-732. doi: 10.1001/ jamaneurol.2016.0580 104. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study .JAMA Intern Med 2015;175:401-407. doi: 10.1001/jamainternmed.2014.7663 105. El-Sedeek MS, Korish AA, Deef MM. Plasma orexin-A levels in postmenopausal women: possible interaction with estrogen and correlation with cardiovascular risk status. BJOG 2010;117:488-492. doi: 10.1111/j. 1471-0528.2009.02474.x 106. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry 2016;79:136-148. doi: 10.1016/j.biopsych.2014.10.003 107. Herring WJ, Connor KM, Snyder E, et al. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.Sleep Med2019;56:219-223. doi: 10.1016/j.sleep.2018.09.010 NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 587 108. Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials.J Clin Sleep Med2016;12:1215-1225. doi: 10.5664/jcsm.6116 109. Rahman SA, Nathan MD, Wiley A, et al. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.Sleep 2022;45: zsac007. doi: 10.1093/sleep/zsac00 110.",
    "doi: 10.1093/sleep/zsac00 110. Goodman RL, Herbison AE, Lehman MN, Navarro VM. Neuroendocrine control of gonadotropin-releasing hormone: pulsatile and surge modes of secretion. J Neuroendocrinol2022;18:e13094. doi: 10.1111/jne.13094 111. Rance NE, Y oung WS 3rd. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology 1991;128:2239-2247. doi: 10.1210/endo-128-5-2239 112. Padilla SL, Johnson CW , Barker FD, Patterson MA, Palmiter RD. A neural circuit underlying the generation of hot flushes.Cell Rep 2018;24:271-277. doi: 10.1016/j.celrep.2018.06.037 113. McCarthy EA, Dischino D, Maguire C, et al. Inhibiting kiss1 neurons with kappa opioid receptor agonists to treat polycystic ovary syndrome and vasomotor symptoms. J Clin Endocrinol Metab 2022;107:e328-e347. doi: 10.1210/clinem/dgab602 114. Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab 2019;104:5893-5905. doi: 10. 1210/jc.2019-00677 115. Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.Menopause 2020;27:382-392. doi: 10.1097/GME.000000000 0001510 116. Simon JA, Anderson RA, Ballantyne E, et al.",
    "Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause 2023; 30:239-246. doi: 10.1097/GME.0000000000002138 117. Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2017;389: 1809-1820. doi: 10.1016/S0140-6736(17)30823-1 118. Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause 2018;25:862-869. doi: 10.1097/GME.0000000000001090 119. Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT . J Clin Endocrinol Metab 2023;3:dgad058. doi: 10.1210/ clinem/dgad058 120. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.Lancet 2023;401: 1091-1102. doi: 10.1016/S0140-6736(23)00085-5 121. Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT -814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause2020;27:498-505. doi: 10.1097/GME.0000000000001500 122.",
    "Menopause2020;27:498-505. doi: 10.1097/GME.0000000000001500 122. Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo- controlled, double-blind, dose-ranging study (VEST A).Menopause 2020; 27:1350-1356. doi: 10.1097/GME.0000000000001621 123. Fraser GL, Hoveyda HR, Clarke IJ, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle. Endocrinology 2015;156: 4214-4225. doi: 10.1210/en.2015-1409 124. McCarty MF . Isoflavones made simple—genistein’s agonist activity for the beta-type estrogen receptor mediates their health benefits.Med Hypotheses 2006;66:1093-1114. doi: 10.1016/j.mehy.2004.11.046 125. Seth D, Poowutikul P , Pansare M, Kamat D. Food allergy: a review .Pediatr Ann 2020;49:e50-e58. doi: 10.3928/19382359-20191206-01 126. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause2015;22:1155-1172. doi: 10.1097/gme.0000000000000546 127. Furlong ON, Parr HJ, Hodge SJ, et al. Consumption of a soy drink has no effect on cognitive function but may alleviate vasomotor symptoms in post-menopausal women; a randomised trial. Eur J Nutr 2020;59:755- 766. doi: 10.1007/s00394-019-01942-5 128. Simpson EEA, Furlong ON, Parr HJ, et al.",
    "Eur J Nutr 2020;59:755- 766. doi: 10.1007/s00394-019-01942-5 128. Simpson EEA, Furlong ON, Parr HJ, et al. The effect of a randomized 12-week soy drink intervention on everyday mood in postmenopausal women. Menopause 2019;26:867-873. doi: 10.1097/gme.0000000000001322 129. Palma F , Fontanesi F , Facchinetti F , Cagnacci A. Acupuncture or phy(F) itoestrogens vs. (E)strogen plus progestin on menopausal symptoms. A randomized study. Gynecol Endocrinol 2019;35:995-998. doi: 10.1080/ 09513590.2019.1621835 130. Fontvieille A, Dionne IJ, Riesco E. Long-term exercise training and soy isoflavones to improve quality of life and climacteric symptoms. Climacteric 2017;20:233-239. doi: 10.1080/13697137.2017.1294153 131. Davinelli S, Scapagnini G, Marzatico F , Nobile V , Ferrara N, Corbi G. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: a randomized, placebo-controlled study. Maturitas 2017;96:77-83. doi: 10.1016/j.maturitas.2016.11.016 132. Imhof M, Gocan A, Imhof M, Schmidt M. Soy germ extract alleviates menopausal hot flushes: placebo-controlled double-blind trial.Eur J Clin Nutr 2018;72:961-970. doi: 10.1038/s41430-018-0173-3 1 3 3 .",
    "Imhof M, Gocan A, Imhof M, Schmidt M. Soy germ extract alleviates menopausal hot flushes: placebo-controlled double-blind trial.Eur J Clin Nutr 2018;72:961-970. doi: 10.1038/s41430-018-0173-3 1 3 3 . K i mH I ,K i mM K ,L e eI ,Y u nJ ,K i mE H ,S e oS K .E f f i c a c ya n ds a f e t yo fa standardized soy and hop extract on menopausal symptoms: a 12-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.J Altern Complement Med 2021;27:959-967. doi: 10.1089/acm.2021.0027 134. Mainini G, Passaro M, Sgambato R, et al. Phytoestrogens for menopausal vasomotor symptoms: efficacy of soybean isoflavones supplements for alleviating menopausal symptoms is positively related to hot flushes frequency. Clin Exp Obstet Gynecol 2017;44:521-523. doi: 10.12891/ceog4095.2017 135. Rattanatantikul T , Maiprasert M, Sugkraroek P , Bumrungpert A. Efficacy and safety of nutraceutical on menopausal symptoms in post-menopausal women: a randomized, double-blind, placebo-controlled clinical trial. J Diet Suppl 2022;19:168-183. doi: 10.1080/19390211.2020.1853648 136. Li L, Lv Y , Xu L, Zheng Q. Quantitative efficacy of soy isoflavones on menopausal hot flashes. Br J Clin Pharmacol 2015;79:593-604. doi: 10. 1111/bcp.12533 137. Li L, Xu L, Wu J, Dong L, Zhao S, Zheng Q. Comparative efficacy of nonhormonal drugs on menopausal hot flashes. Eur J Clin Pharmacol 2016;72:1051-1058. doi: 10.1007/s00228-016-2090-5 138. Newton KM, Reed SD, Uchiyama S, et al.",
    "Comparative efficacy of nonhormonal drugs on menopausal hot flashes. Eur J Clin Pharmacol 2016;72:1051-1058. doi: 10.1007/s00228-016-2090-5 138. Newton KM, Reed SD, Uchiyama S, et al. A cross-sectional study of equol producer status and self-reported vasomotor symptoms.Menopause 2015; 22:489-495. doi: 10.1097/GME.0000000000000363 139. Daily JW , Ko BS, Ryuk J, Liu M, Zhang W , Park S. Equol decreases hot flashes in postmenopausal women: a systematic review and meta-analysis of randomized clinical trials. J Med F ood 2019;22:127-139. doi: 10. 1089/jmf.2018.4265 140. Winther K, Rein E, Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric 2005;8:162-170. doi: 10.1080/13697130500117987 141. Fait T , Sailer M, Rigador P A. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélys® in the management of women with menopausal symptoms. Gynecol Endocrinol 2019;35: 360-363. doi: 10.1080/09513590.2018.1538347 142. Lello S, Capozzi A, Xholli A, Cagnacci A; Italian Society of Menopause (SIM) and Italian Society of Gynecology of the Third Age of W omen (SIGiTE), and of Writing Group of the Pollen Extract in Menopause Italian Study Group.",
    "The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicentre prospective observational study [published online ahead of print November 26, 2021].Minerva Obstet Gynecol. doi: 10.23736/S2724-606X.21.04964-2 143. Radzinskii VE, Kuznetsova IV , Uspenskaya YB, et al. Treatment of climacteric symptoms with an ammoniumsuccinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial.Gynecol Endocrinol 2016;32:64-68. doi: 10.1080/09513590.2016.1232686 144. Radzinsky VE, Uspenskaya Y , Shulman LP , Kuznetsova IV . Succinate- based dietary supplement for menopausal symptoms: a pooled analysis of two identical randomized, double-blind, placebo-controlled clinical trials. Obstet Gynecol Int2019;2019:1572196. doi: 10.1155/2019/1572196 145. Lim YE, Lee SY , Shin HS, et al. The effect of Lactobacillus Acidophilus YT1 (MENOLACTO) on improving menopausal symptoms: a randomized, double-blinded, placebo-controlled trial. JC l i nM e d 2020;9:2173. doi: 10.3390/jcm9072173 146. Heger M, V entskovskiy BM, Borzenko I, et al. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause 2006;13:744-759. doi: 10.1097/01. gme.0000240632.08182.e4 NAMS POSITION STATEMENT 588 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society 147.",
    "Menopause 2006;13:744-759. doi: 10.1097/01. gme.0000240632.08182.e4 NAMS POSITION STATEMENT 588 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society 147. Hasper I, V entskovskiy BM, Rettenberger R, Heger PW , Riley DS, Kaszkin- Bettag M. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms. Menopause2009;16:117-131. doi: 10.1097/GME.0b013e3181806446 148. Shah J, Chandanani S, Reddy J, et al. Evaluation of the efficacy and safety of Rheum rhaponticumroot extract (ERr 731) for menopausal symptoms in perimenopausal Indian women: an interim analysis.JM i d l i f eH e a l t h2021; 12:108-115. doi: 10.4103/jmh.jmh_86_21 149. Kruse SO, Löhning A, Pauli GF , Winterhoff H, Nahrstedt A. Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid. Planta Med 1999;65:763-764. doi: 10.1055/s-2006-960862 150. Wuttke W , Jarry H, Becker T , et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? Maturitas 2003;44(suppl 1):S9-S20. doi: 10.1016/s0378-5122(02)00344-4 151. Mahady GB, Low Dog T , Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity . Menopause 2008;15(4 Pt 1):628-638. doi: 10.1097/gme.0b013e31816054bf 152. Leach MJ, Moore V . Black cohosh (Cimicifuga spp.) for menopausal symptoms.",
    "Menopause 2008;15(4 Pt 1):628-638. doi: 10.1097/gme.0b013e31816054bf 152. Leach MJ, Moore V . Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012;2012:CD007244. doi: 10. 1002/14651858.CD007244.pub2 153. Gao L, Zheng T , Xue W , et al. Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women.Climacteric2018;21:69-74. doi: 10. 1080/13697137.2017.1406913 154. Castelo-Branco C, Gambacciani M, Cano A, et al. Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms—an update on the evidence. Climacteric 2021;24:109-119. doi: 10.1080/13697137. 2020.1820477 155. Komesaroff P A, Black CV , Cable V , Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 2001;4:144-150. 156. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997;68:981-986. doi: 10.1016/s0015-0282(97)00397-x 157. Chenoy R, Hussain S, Tayob Y , et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 1994;308:501-503. doi: 10.1136/bmj.308.6927.501 158. Lee MS, Shin BC, Y ang EJ, Lim HJ, Ernst E. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review .Maturitas 2011; 70:227-233. doi: 10.1016/j.maturitas.2011.07.017 159.",
    "Lee MS, Shin BC, Y ang EJ, Lim HJ, Ernst E. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review .Maturitas 2011; 70:227-233. doi: 10.1016/j.maturitas.2011.07.017 159. Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group.I n tJC l i nP h a r m a c o lR e s1999;19:89-99. 160. Kim HS, Y oon YJ, Lee JM, et al. A clinical study on the effect of red ginseng for postmenopausal hot flushes. J Orient Obstet Gynecol 2009; 22:132-139. 161. Kim SY , Seo SK, Choi YM, et al. Effects of red ginseng supplementation on menopausal symptoms and cardiovascular risk factors in postmenopausal women: a double-blind randomized controlled trial. Menopause 2012;19: 461-466. doi: 10.1097/gme.0b013e3182325e4b 162. Chinnappan SM, George A, Evans M, Anthony J. Efficacy of Labisia pumila and Eurycoma longifolia standardised extracts on hot flushes, quality of life, hormone and lipid profile of peri-menopausal and menopausal women: a randomised, placebo-controlled study . F ood Nutr Res 2020;3:64. doi: doi.org/10.29219/fnr.v64.3665 163. Hajirahimkhan A, Dietz BM, Bolton JL. Botanical modulation of menopausal symptoms: mechanisms of action?Planta Med 2013;79:538- 553. doi: 10.1055/s-0032-1328187 164.",
    "Hajirahimkhan A, Dietz BM, Bolton JL. Botanical modulation of menopausal symptoms: mechanisms of action?Planta Med 2013;79:538- 553. doi: 10.1055/s-0032-1328187 164. Molaie M, Darvishi B, Jafari Azar Z, Shirazi M, Amin G, Afshar S. Effects of a combination of Nigella sativa and Vitex agnus-castus with citalopram on healthy menopausal women with hot flashes: results from a subpopulation analysis. Gynecol Endocrinol2019;35:58-61. doi: 10.1080/09513590.2018.1499086 165. van Die MD, Burger HG, Bone KM, Cohen MM, T eede HJ. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause 2009;16:156-163. doi: 10.1097/ gme.0b013e31817fa9e0 166. Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol2007;23:117-122. doi: 10.1080/09513590701200900 167. Hafizi S, Abbassian A, Tabarrai M. The effect of Jazar supplement on quality of life and sexual function in postmenopausal women: a double- blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med 2021:8854182. doi: 10.1155/2021/8854182 168. Saberi Z, Gorji N, Memariani Z, Moeini R, Shirafkan H, Amiri M. Evaluation of the effect of Silybum marianum extract on menopausal symptoms: a randomized, double-blind placebo-controlled trial.Phytother Res 2020;34:3359-3366. doi: 10.1002/ptr.6789 169.",
    "Lucas M, Asselin G, Mérette C, Poulin MJ, Dodin S. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause 2009;16:357- 366. doi: 10.1097/gme.0b013e3181865386 170. Cohen LS, Joffe H, Guthrie KA, et al. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause 2014;21: 347-354. doi: 10.1097/GME.0b013e31829e40b8 171. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16:495-500. doi: 10.1200/JCO.1998.16.2.495 172. Ziaei S, Kazemnejad A, Zareai M. The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest 2007;64:204-207. doi: 10. 1159/000106491 173. Ataei-Almanghadim K, Farshbaf-Khalili A, Ostadrahimi AR, Shaseb E, Mirghafourvand M. The effect of oral capsule of curcumin and vitamin E on the hot flashes and anxiety in postmenopausal women: a triple blind randomised controlled trial.Complement Ther Med 2020;48:102267. doi: doi.org/10.1016/j.ctim.2019.102267 174. Dahlgren MK, El-Abboud C, Lambros AM, Sagar KA, Smith RT , Gruber SA. A survey of medical cannabis use during perimenopause and postmenopause. Menopause 2022;29:1028-1036. doi: 10.1097/GME.0000000000002018 175. Mejia-Gomez J, Phung N, Philippopoulos E, Murphy KE, W olfman W .",
    "Menopause 2022;29:1028-1036. doi: 10.1097/GME.0000000000002018 175. Mejia-Gomez J, Phung N, Philippopoulos E, Murphy KE, W olfman W . The impact of cannabis use on vasomotor symptoms, mood, insomnia and sexuality in perimenopausal and postmenopausal women: a systematic review. Climacteric2021;24:572-576. doi: 10.1080/13697137.2021.1898581 176. Chien TJ, Hsu CH, Liu CY , Fang CJ. Effect of acupuncture on hot flush and menopause symptoms in breast cancer —a systematic review and meta- analysis.PLoS One 2017;12:e0180918. doi: 10.1371/journal.pone.0180918 177. Chien TJ, Liu CY , Fang CJ, Kuo CY . The maintenance effect of acupuncture on breast cancer-related menopause symptoms: a systematic review. Climacteric2020;23:130-139. doi: 10.1080/13697137.2019.1664460 178. Li T , Zhang Y , Cheng Q, et al. Quantitative study on the efficacy of acupuncture in the treatment of menopausal hot flashes and its comparison with nonhormonal drugs. Menopause 2021;28:564-572. doi: 10.1097/GME.0000000000001767 179. Liu Z, Ai Y , Wang W , et al. Acupuncture for symptoms in menopause transition: a randomized controlled trial. Am J Obstet Gynecol 2018;219: 373.e1-373.e10. doi: 10.1016/j.ajog.2018.08.019 180. Befus D, Coeytaux RR, Goldstein KM, et al. Management of menopause symptoms with acupuncture: an umbrella systematic review and meta- analysis. JA l t e r nC o m p l e m e n tM e d2018;24:314-323. doi: 10.1089/acm. 2016.0408 181.",
    "Management of menopause symptoms with acupuncture: an umbrella systematic review and meta- analysis. JA l t e r nC o m p l e m e n tM e d2018;24:314-323. doi: 10.1089/acm. 2016.0408 181. Zhong Z, Dong H, Wang H, Huang Y , Huang D, Huang G. Electroacupuncture for the treatment of perimenopausal syndrome: a systematic review and meta-analysis of randomized controlled trials. Acupunct Med 2022;40:111-122. doi: 10.1177/09645284211055742 182. Higa K, Hirata K, Hirota K, Nitahara K, Shono S. Retropharyngeal hematoma after stellate ganglion block: Analysis of 27 patients reported in the literature. Anesthesiology 2006;105:1238-1245. doi: 10.1097/ 00000542-200612000-00024 183. Walega DR, Rubin LH, Banuvar S, Shulman LP , Maki PM. Effects of stellate ganglion block on VMS: findings from a randomized controlled clinical trial in postmenopausal women. Menopause 2014;21:807-814. doi: 10.1097/GME.0000000000000194 184. Lipov EG, Joshi JR, Xie H, Slavin KV . Updated findings on the effects of stellate-ganglion block on hot flushes and night awakenings.Lancet Oncol 2008;9:819-820. doi: 10.1016/S1470-2045(08)70218-3 185. Pachman DR, Barton D, Carns PE, et al. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer 2011;19:941-947. doi: 10.1007/s00520-010-0907-9 186. Haest K, Kumar A, V an Calster B, et al.",
    "Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer 2011;19:941-947. doi: 10.1007/s00520-010-0907-9 186. Haest K, Kumar A, V an Calster B, et al. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow- up. Ann Oncol 2012;23:1449-1454. doi: 10.1093/annonc/mdr478 187. van Gastel P , Kallewaard JW , van der Zanden M, de Boer H. Stellate- ganglion block as a treatment for severe postmenopausal flushing. Climacteric 2013;16:41-47. doi: 10.3109/13697137.2012.709889 188. Rahimzadeh P , Imani F , Nafissi N, Ebrahimi B, Faiz SHR. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and NAMS POSITION STATEMENT Menopause, V ol. 30, No. 6, 2023 589 sleep disturbance in breast cancer survivors. Cancer Manag Res 2018;10: 4831-4837. doi: 10.2147/CMAR.S173511 189. T egeler CL, Shaltout HA, Lee SW , Simpson SL, Gerdes L, T egeler CH. High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) improves symptoms and a utonomic function for insomnia: a randomized, placebo-controlled clinical trial.Brain Behav. 2020;10:e01826. doi: 10.1002/brb3.1826 190. Lee SW , Laurienti PJ, Burdette JH, et al. Functional brain network changes following use of an allostatic, closed-loop, acoustic stimulation neurotechnology for military-related traumatic stress.",
    "Lee SW , Laurienti PJ, Burdette JH, et al. Functional brain network changes following use of an allostatic, closed-loop, acoustic stimulation neurotechnology for military-related traumatic stress. J Neuroimaging 2019;29:70-78. doi: 10.1111/jon.12571 191. T egeler CH, T egeler CL, Cook JF , Lee SW , Pajewski NM. Reduction in menopause-related symptoms associated with use of a noninvasive neurotechnology for autocalibration of neural oscillations. Menopause 2015;22:650-655. doi: 10.1097/GME.0000000000000422 192. Goto V , Frange C, Andersen ML, Júnior JM, Tufik S, Hachul H. Chiropractic intervention in the treatment of postmenopausal climacteric symptoms and insomnia: a review.Maturitas2014;78:3-7. doi: 10.1016/j.maturitas.2014.02.004 The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society has been designated a CME ac- tivity for all NAMS members. NAMS members should log in to the NAMS website, www.menopause.org, and then select Online CME in the Member Center. CME credit will be available from June 1, 2023, to June 1, 2024. NAMS POSITION STATEMENT 590 Menopause, V ol. 30, No. 6, 2023 © 2023 by The North American Menopause Society",
    "Menopause: identification and management NICE guideline Published: 12 November 2015 Last updated: 7 November 2024 www.nice.org.uk/guidance/ng23 © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it.",
    "Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Contents Overview ... 5 Who is it for?",
    "Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Contents Overview ... 5 Who is it for? ... 5 Recommendations ... 6 1.1 Individualised care ... 7 1.2 Information and support ... 7 1.3 Identifying perimenopause and menopause ... 9 1.4 Discussing management options with people aged 40 or over ... 10 1.5 Managing symptoms associated with menopause in people aged 40 or over ... 13 1.6 Effects of hormone replacement therapy on specific health outcomes in people aged 40 or over ... 23 1.7 Diagnosing and managing premature ovarian insufficiency in people under 40 ... 44 1.8 Starting and stopping hormone replacement therapy for anyone ... 45 1.9 Reviewing treatment for anyone ... 47 Terms used in this guideline ... 47 Recommendations for research ... 50 Key recommendations for research ... 50 Other recommendations for research ... 56 Rationale and impact ... 57 Psychological support for early menopause ... 57 Identifying perimenopause and menopause ... 57 Discussing management options with people aged 40 or over ... 58 Cognitive behavioural therapy for vasomotor symptoms ... 60 Genitourinary symptoms associated with menopause in people with no personal history of breast cancer ... 61 Genitourinary symptoms associated with menopause in people with a personal history of breast cancer ... 64 Vaginal laser treatment ... 68 Management options for depressive symptoms or depression in people with menopause- associated symptoms ... 68 Menopause: identification and management (NG23) © NICE 2025.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Cognitive behavioural therapy for sleep problems associated with menopause ... 70 Taking medical history of coronary heart disease or stroke into account before offering treatment ... 72 Managing menopause-associated symptoms in people who have taken gender-affirming hormone therapy in the past ... 72 Effect of HRT on life expectancy in people aged 45 and over ... 74 Effect of combined HRT on specific health outcomes in people aged 45 or over ... 75 Effect of oestrogen-only HRT on specific health outcomes in people aged 45 or over ... 86 Cardiovascular disease prevention ... 96 Dementia prevention ... 97 Effects of HRT use in early menopause on specific health outcomes ... 97 Starting and stopping HRT for anyone ... 99 Implementation ... 102 Context ... 103 Finding more information and committee details ... 104 Update information ... 105 Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). This guideline is the basis of QS143. This guideline should be read in conjunction with NG112. Overview This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause. For information on related topics see our women's and reproductive health summary page.",
    "It aims to improve the consistency of support and information provided to people experiencing menopause. For information on related topics see our women's and reproductive health summary page. Who is it for? • Healthcare professionals who care for women, trans men and non-binary people registered female at birth with menopause-associated symptoms • Women, trans men, and non-binary people registered female at birth with menopause- associated symptoms, their families or carers, and the public. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Recommendations People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. NICE guidelines set out the care and services suitable for people with a specific condition or need, and people in particular circumstances or settings. We aim to improve quality by ensuring that people receive the best care and advice. Using inclusive language in healthcare is important for safety, and to promote equity, respect and effective communication with everyone.",
    "Using inclusive language in healthcare is important for safety, and to promote equity, respect and effective communication with everyone. Some recommendations in this guideline do not use inclusive language because: • the evidence has not been reviewed, and expert opinion is that groups covered by these recommendations cannot be extended or • the evidence has been reviewed, but the information available for some groups was too limited to make specific recommendations. Healthcare professionals should use their clinical judgement when implementing the recommendations, taking into account each person's circumstances, needs and preferences, and ensuring all people are treated with dignity and respect throughout their care. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding. This guideline covers women, trans men and non-binary people registered female at birth, who currently have menopause-associated symptoms or who will experience menopause in the future. The guideline does not cover people who are currently having gender- affirming hormone therapy.",
    "The guideline does not cover people who are currently having gender- affirming hormone therapy. For trans men and non-binary people who have taken such therapy in the past and are no longer taking it, only recommendations 1.5.34 and 1.5.35 in the section on gender affirming therapy and the recommendation for research on the Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). impact of hormone replacement therapy (HRT) on health outcomes for these groups of people apply. All other recommendations apply to women, trans men and non-binary people registered female at birth who have never taken gender-affirming hormone therapy. 1.1 Individualised care 1.1.1 Tailor your approach to the person at all times when identifying, discussing, investigating and managing menopause, and adapt the approach if symptoms change over time. Follow the recommendations in NICE's guideline on patient experience in adult NHS services. [2015] 1.1.2 For general principles on how to discuss symptom management plans with people, including how to communicate risks, benefits and consequences, see NICE's guideline on shared decision making. [2024] 1.2 Information and support 1.2.1 Share information about menopause with people who have associated symptoms or are approaching menopause, and their family members or carers (as appropriate).",
    "[2024] 1.2 Information and support 1.2.1 Share information about menopause with people who have associated symptoms or are approaching menopause, and their family members or carers (as appropriate). This information should include all of the following: • what menopause is, including that it is a life transition which: － usually takes place in mid-life and － can also happen earlier because of surgery or medical treatment, an inherited condition, or an unknown cause • commonly associated symptoms (see recommendation 1.2.2) • interventions, or changes the person can make to support their health and wellbeing. [2015, amended 2024] 1.2.2 Explain that symptoms associated with menopause may vary from minor to severe and be experienced over short or long time periods. As well as changes in menstrual cycle, symptoms may include: Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • vasomotor symptoms (hot flushes and sweats) • genitourinary symptoms (for example, vaginal dryness) • effects on mood (for example, depressive symptoms) • musculoskeletal symptoms (for example, joint and muscle pain) • sexual difficulties (for example, low sexual desire). [2015] 1.2.3 Share information about contraception with people who have menopause- associated symptoms. See, for example, the Faculty of Sexual and Reproductive Healthcare guidance on contraception for women aged over 40 years.",
    "See, for example, the Faculty of Sexual and Reproductive Healthcare guidance on contraception for women aged over 40 years. [2015] 1.2.4 Give advice on bone health to people experiencing menopause and discuss bone health with them at review appointments (see NICE's guideline on assessing the risk of fragility fracture in people with osteoporosis). [2015] 1.2.5 Explain to people experiencing menopause the importance of maintaining muscle mass and strength through physical activity. [2015, amended 2024] 1.2.6 Offer support and provide information about menopause and fertility to people who are likely to experience menopause as a result of medical or surgical treatment. Do this before and after they have their treatment. [2015, amended 2024] Psychological support for early menopause 1.2.7 Offer psychological support to people who are experiencing early menopause (that is, menopause between the ages of 40 and 44) and are distressed by their diagnosis or its consequences. If needed, refer them to psychology services. [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see rationale and impact section on psychological support for early menopause. Full details of the evidence and the committee's discussion are in evidence review I: early menopause.",
    "Full details of the evidence and the committee's discussion are in evidence review I: early menopause. 1.3 Identifying perimenopause and menopause 1.3.1 Identify the following, without laboratory tests, in otherwise healthy women, trans men and non-binary people registered female at birth who are aged 45 or over and have menopause-associated symptoms: • perimenopause, if they have vasomotor symptoms that have recently started and any changes in their menstrual cycle • menopause, if they have not had a period for at least 12 months and are not using hormonal contraception • menopause, in those who have had a hysterectomy, based on the type and combination of symptoms they have (for example, vasomotor symptoms). [2015] 1.3.2 Take into account that it can be difficult to identify menopause in people who are taking hormonal treatments, for example, for the treatment of heavy menstrual bleeding. [2015] 1.3.3 Be aware that people from some ethnic minority backgrounds and people with some lifelong conditions may experience menopause at a younger age. [2024] 1.3.4 Do not use the following laboratory and imaging tests to identify perimenopause or menopause in people aged 45 or over: • anti-Müllerian hormone • inhibin A Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • inhibin B • oestradiol • antral follicle count • ovarian volume.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • inhibin B • oestradiol • antral follicle count • ovarian volume. [2015] 1.3.5 Do not use a follicle-stimulating hormone (FSH) blood test to identify menopause in people using combined oestrogen and progestogen contraception or high- dose progestogen. [2015] 1.3.6 Consider using the person's serum FSH level to confirm menopause only: • in people aged 40 to 45 with menopause-associated symptoms, including a change in their menstrual cycle • in people under 40 in whom menopause is suspected (see also diagnosing and managing premature ovarian insufficiency). [2015] See also the recommendations on offering psychological support to: • people experiencing early menopause (aged 40 to 44)and • people with premature ovarian insufficiency. For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on identifying perimenopause and menopause. Full details of the evidence and the committee's discussion are in evidence review I: early menopause. 1.4 Discussing management options with people aged 40 or over This section only covers people aged 40 or over. For younger (under 40) women, trans men and non-binary people registered female at birth, see the recommendations on Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). diagnosing and managing premature ovarian insufficiency, including what to discuss with the person. 1.4.1 Discuss with the person the benefits and risks associated with each potential management option for menopause-associated symptoms. [2024] Hormone replacement therapy 1.4.2 When discussing hormone replacement therapy (HRT) as a possible treatment for menopause-associated symptoms (in line with the recommendations on managing symptoms associated with menopause in people aged 40 and over), talk about the benefits and risks associated with: • combined versus oestrogen-only HRT (see the recommendation and its rationale on indications for combined and oestrogen-only HRT, in the section on starting HRT about which of the 2 types of HRT the person would be offered, and why) • transdermal versus oral HRT • types of oestrogen and progestogen • sequential versus continuous combined HRT • dose and duration. [2024] Tailor the information about benefits and risks to the person's age, individual circumstances and potential risk factors. Use the information in managing symptoms associated with menopause in people aged 40 or over, and in the effect of HRT on specific health outcomes in people aged 40 or over to support this discussion.",
    "1.4.3 If a person chooses to take HRT: • discuss the possible duration of treatment at the outset • at every review, rediscuss the benefits and risks of continuing treatment (see the section on reviewing treatment for anyone) Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • explain that symptoms may return when HRT is stopped and discuss the option of restarting treatment if necessary. [2024] Cognitive behavioural therapy 1.4.4 When discussing cognitive behavioural therapy (CBT) as a possible management option for symptoms associated with menopause, explain what CBT is (including menopause-specific CBT) and talk about the available options, taking into account the person's preferences and needs, for example: • face-to-face or remote sessions • individual or group sessions • self-help options. [2024] For a short explanation of why the committee made the 2024 recommendations and how they might affect practice, see the rationale and impact section on discussing management options with people aged 40 or over. Full details of the evidence and the committee's discussion are in: • evidence review A: cognitive behavioural therapy • evidence review B1: managing genitourinary symptoms (network meta-analyses) • evidence review D: breast cancer • evidence review I: early menopause.",
    "Complementary therapies and unregulated preparations 1.4.5 Explain to people with menopause-associated symptoms that the efficacy and safety of unregulated hormone preparations are unknown. [2015] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). 1.4.6 Explain to people who wish to try complementary therapies for menopause- associated symptoms, that the safety, quality and purity of constituents in unregulated preparations may be unknown. [2015] 1.4.7 Explain to people that there is some evidence that isoflavones or black cohosh may relieve vasomotor symptoms associated with menopause. However, explain that: • multiple preparations are available, and their safety is uncertain • different preparations may vary • interactions with other medicines have been reported. [2015] 1.4.8 Advise people with a personal history of, or at high risk of, breast cancer that, although there is some evidence that St John's wort may help relieve vasomotor symptoms associated with menopause, there is uncertainty about: • appropriate dosage • persistence of effect • variation in the nature and potency of preparations • potential serious interactions with other medicines (including tamoxifen, anticoagulants and anticonvulsants). [2015] 1.5 Managing symptoms associated with menopause in people aged 40 or over This section only covers people aged 40 or over.",
    "[2015] 1.5 Managing symptoms associated with menopause in people aged 40 or over This section only covers people aged 40 or over. For younger (aged under 40) women, trans men, and non-binary people registered female at birth, see the recommendations on diagnosing and managing premature ovarian insufficiency. For information about how comorbidities, contraindications and medical history might affect management choices, see taking medical history into account before offering treatment. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). The benefits and risks of hormone replacement therapy (HRT) described in this guideline only cover the use of HRT within the licensed dosages. Making decisions using NICE guidelines has information about prescribing medicines. Vasomotor symptoms 1.5.1 Offer HRT to people with vasomotor symptoms associated with menopause. [2015] 1.5.2 Consider menopause-specific cognitive behavioural therapy (CBT) as an option for vasomotor symptoms associated with menopause: • in addition to HRT or • for people for whom HRT is contraindicated or • for those who prefer not to take HRT. [2024] 1.5.3 Do not routinely offer selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) or clonidine as first-line treatment for vasomotor symptoms alone.",
    "[2015] For a short explanation of why the committee made the 2024 recommendation on CBT and how it might affect practice, see the rationale and impact section on CBT for vasomotor symptoms. Full details of the evidence and the committee's discussion are in evidence review A: cognitive behavioural therapy. Genitourinary symptoms associated with menopause People with no history of breast cancer 1.5.4 Offer vaginal oestrogen to people with genitourinary symptoms associated with Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). menopause (including those using systemic HRT) and review regularly as per the recommendations on reviews in this guideline. [2024] 1.5.5 When discussing the option of vaginal oestrogen, explain that: • serious adverse effects are very rare • their treatment should be reviewed in line with recommendations 1.9.2 and 1.9.3 in the section on reviewing treatment • symptoms often return when vaginal oestrogen is stopped but treatment can be restarted if necessary • vaginal oestrogen is absorbed locally – a minimal amount is absorbed into the bloodstream (when compared with systemic HRT), but this is unlikely to have a significant effect throughout the body. [2024] 1.5.6 When someone chooses vaginal oestrogen, make a shared decision with the person about whether to use an oestrogen cream, gel, tablet, pessary or ring.",
    "[2024] 1.5.6 When someone chooses vaginal oestrogen, make a shared decision with the person about whether to use an oestrogen cream, gel, tablet, pessary or ring. [2024] 1.5.7 Advise people with genitourinary symptoms associated with menopause that vaginal oestrogen can be used on its own or in combination with non-hormonal moisturisers or lubricants. [2024] 1.5.8 For people with genitourinary symptoms in whom vaginal oestrogen preparations are contraindicated, or for people who would prefer not to use vaginal oestrogen, consider non-hormonal vaginal moisturisers or lubricants. [2024] 1.5.9 Consider vaginal prasterone for genitourinary symptoms if vaginal oestrogen, or non-hormonal moisturisers or lubricants have been ineffective or are not tolerated. [2024] 1.5.10 Consider ospemifene as an oral treatment for genitourinary symptoms, if the use of locally applied treatments is impractical, for example, because of disability. [2024] 1.5.11 For the use of vaginal oestrogen in people with genitourinary symptoms and an overactive bladder, see the section on choosing medicines for an overactive Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). bladder, in NICE's guideline on managing urinary incontinence and pelvic organ prolapse in women.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). bladder, in NICE's guideline on managing urinary incontinence and pelvic organ prolapse in women. [2024] 1.5.12 For the use of vaginal oestrogen in people with genitourinary symptoms and recurrent urinary tract infections, see the recommendations on oestrogen in NICE's guideline on recurrent urinary tract infection (UTI) and the patient decision aid on reducing the chance of recurrent UTI in postmenopausal women. [2024] For anyone who has been given any treatment for genitourinary symptoms associated with menopause, see the recommendations on reviewing treatment. For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on genitourinary symptoms associated with menopause in people with no personal history of breast cancer. Full details of the evidence and the committee's discussion are in evidence review B1: managing genitourinary symptoms (network meta-analyses). People with a personal history of breast cancer 1.5.13 Offer non-hormonal moisturisers or lubricants to people with a personal history of breast cancer and genitourinary symptoms associated with menopause.",
    "[2024] 1.5.14 Consider vaginal oestrogen for people with a personal history of breast cancer and genitourinary symptoms that have continued despite trying non-hormonal treatments (see also recommendation 1.5.15 for people receiving adjuvant aromatase inhibitor treatment for breast cancer). Vaginal oestrogen may be used in combination with a non-hormonal moisturiser or a lubricant. In November 2024, this was an off-label use of vaginal oestrogen. See NICE's information on prescribing medicines. [2024] 1.5.15 For people currently having aromatase inhibitors as adjuvant treatment for breast cancer, work with a breast cancer specialist to identify treatment options for genitourinary symptoms that have continued despite trying non-hormonal Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). treatments.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). treatments. 1.5.16 When assessing the safety of vaginal oestrogens for someone in relation to breast cancer recurrence, take into account all of the following: • the person's general risk factors for breast cancer recurrence (see recommendations 1.7.7 and 1.7.8 in NICE's guideline on early and locally advanced breast cancer for the definitions of medium or high risk and of low risk of recurrence) • it is unknown whether vaginal oestrogen affects the risks of breast cancer recurrence • vaginal oestrogen is absorbed locally, and some of it is absorbed into the bloodstream but compared with oestrogen from systemic HRT, the amount is minimal. [2024] 1.5.17 For people with a personal history of oestrogen receptor negative breast cancer, recognise that any oestrogen systemically absorbed from taking vaginal oestrogen is unlikely to increase the risk of breast cancer recurrence, and so it is likely to be safe. [2024] 1.5.18 For people with a personal history of oestrogen receptor positive breast cancer, recognise that: • it is unknown whether any oestrogen systemically absorbed from taking vaginal oestrogen could increase the risk of breast cancer recurrence and • adjuvants that block oestrogen receptors in cancer cells (for example, tamoxifen) would reduce any such potential impact.",
    "[2024] For anyone who has been given any treatment for genitourinary symptoms associated with menopause, see the recommendations on reviewing treatment. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made the 2024 recommendations and how they might affect practice, see the rationale and impact section on genitourinary symptoms associated with menopause in people with a personal history of breast cancer. Full details of the evidence and the committee's decision are in evidence review B2: managing genitourinary symptoms (breast cancer recurrence). Vaginal laser treatment 1.5.19 Do not offer vaginal laser treatment for genitourinary symptoms associated with menopause unless as part of a randomised controlled trial (see also NICE's interventional procedures guidance on transvaginal laser therapy for urogenital atrophy). [2024] For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on vaginal laser treatment. Full details of the evidence and the committee's discussion are in evidence review B2: managing genitourinary symptoms (breast cancer recurrence).",
    "Full details of the evidence and the committee's discussion are in evidence review B2: managing genitourinary symptoms (breast cancer recurrence). Depressive symptoms 1.5.20 Consider HRT to alleviate depressive symptoms (not meeting the criteria for a diagnosis of depression) with onset around the same time as other symptoms associated with menopause. [2015, amended 2024] 1.5.21 Consider CBT as an option for people who have depressive symptoms (not meeting the criteria for a diagnosis of depression) in association with vasomotor symptoms: • in addition to other management options or • for people for whom other options are contraindicated or Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • for those who prefer not to try other options. [2024] 1.5.22 For people experiencing menopause who are suspected to have or have been diagnosed with depression, follow the recommendations in this guideline alongside the recommendations in NICE's guideline on treating and managing depression in adults to achieve an optimal management plan. [2024] For a short explanation of why the committee made the 2024 recommendations and how they might affect practice, see the rationale and impact section on management options for depressive symptoms or depression in people with menopause-associated symptoms.",
    "Full details of the evidence and the committee's discussion are in evidence review A: cognitive behavioural therapy. Sleep 1.5.23 Consider menopause-specific CBT as an option for people who have sleep problems (such as night-time awakening) in association with vasomotor symptoms: • in addition to other management options (including HRT) or • for people for whom other options are contraindicated or • for people who prefer not to try other options. [2024] For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on CBT for sleep problems associated with menopause. Full details of the evidence and the committee's discussion are in evidence review A: cognitive behavioural therapy. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Altered sexual function 1.5.24 Consider testosterone supplementation for people with low sexual desire associated with menopause if HRT alone is not effective. [2015] Taking medical history into account before offering treatment for menopause associated symptoms In this guideline, medical history covers both personal history and family history (for example, of breast cancer).",
    "1.5.25 Consider referring people to a healthcare professional with expertise in menopause if: • they have symptoms associated with menopause and contraindications to HRT or • there is uncertainty about the most suitable management options for their symptoms. [2015] Type 2 diabetes 1.5.26 Consider HRT for menopause-associated symptoms in people with type 2 diabetes after taking comorbidities into account and seeking specialist advice if needed. [2015] Increased risk of venous thromboembolism 1.5.27 Consider transdermal rather than oral HRT for people with menopause- associated symptoms who are at increased risk of venous thromboembolism (VTE), including those with a body mass index (BMI) over 30 kg/m2 . [2015] 1.5.28 Consider referring people with menopause-associated symptoms who are at high risk of VTE (for example, those with a strong family history of VTE or a hereditary thrombophilia) to a haematologist for assessment before considering HRT. [2015] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Personal history of coronary heart disease or stroke 1.5.29 For people with a personal history of coronary heart disease or stroke, ensure that combined or oestrogen-only HRT is discussed with and offered, if appropriate, by a healthcare professional with expertise in menopause.",
    "[2024] In November 2024, use of combined or oestrogen-only HRT in people with active or recent arterial thromboembolic disease was off-label. See NICE's information on prescribing medicines. For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on taking coronary heart disease or stroke into account before offering treatment. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. Personal history of breast cancer or high risk of breast cancer 1.5.30 Offer people with menopause-associated symptoms and who have a personal history, or are at high risk, of breast cancer: • information on all management options available to them • referral to a healthcare professional with expertise in menopause. [2015, amended 2024] 1.5.31 For advice on the treatment of menopause-associated symptoms in people with a personal history of breast cancer or at high risk of breast cancer, see the section on menopause symptoms in NICE's guideline on early and locally advanced breast cancer and the section on risk reduction and treatment strategies in NICE's guideline on familial breast cancer. [2015] Also see the section on complementary therapy and unregulated preparations in this guideline. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). High familial risk of ovarian cancer See the section on HRT after risk-reducing surgery in NICE's guideline on identifying and managing familial and genetic risk of ovarian cancer. Planned medical or surgical treatment that is likely to result in menopause 1.5.32 Offer people who are likely to experience menopause as a result of medical or surgical treatment the opportunity to discuss fertility, both before and after they have their treatment, with a healthcare professional with expertise in fertility. [2015, amended 2024] 1.5.33 Offer people who are likely to experience menopause as a result of medical or surgical treatment the opportunity to discuss menopause, both before and after they have their treatment, with a healthcare professional with expertise in menopause. [2015, amended 2024] Gender-affirming hormone therapy: past use 1.5.34 Ensure that trans men or non-binary people registered female at birth who have taken gender-affirming hormone therapy in the past and have symptoms associated with menopause can discuss these with a healthcare professional with expertise in menopause.",
    "[2024] 1.5.35 Consider menopause-specific CBT for vasomotor symptoms, difficulties with sleep or depressive symptoms associated with menopause for trans men and non-binary people registered female at birth who have taken gender-affirming hormone therapy in the past. CBT could be used: • in addition to other management options or • for people for whom other options are contraindicated or • for those who prefer not to try other options. [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made the 2024 recommendations and how they might affect practice, see the rationale and impact section on managing menopause in people who have taken gender-affirming hormone therapy in the past. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. 1.6 Effects of hormone replacement therapy on specific health outcomes in people aged 40 or over The benefits and risks of hormone replacement therapy (HRT) described in this guideline only cover the use of HRT within the licensed dosages. Making decisions using NICE guidelines has information about prescribing medicines. See the recommendation for people in early menopause (ages 40 to 44), for information on the effect of either taking or not taking HRT in early menopause on specific health outcomes.",
    "See the recommendation for people in early menopause (ages 40 to 44), for information on the effect of either taking or not taking HRT in early menopause on specific health outcomes. People aged 45 or over 1.6.1 When discussing HRT as a treatment option for menopause-associated symptoms, explain that, overall, taking either combined HRT or oestrogen-only HRT is unlikely to affect life expectancy. [2024] For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on effect of HRT on life expectancy in people aged 45 or over. Full details of the evidence and the committee's discussion are in evidence review H: all-cause mortality. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Combined HRT This recommendation is for people with a uterus (see recommendation 1.8.1 on what type of HRT to offer). 1.6.2 When talking about combined HRT as a treatment option: • discuss different combined HRT options to identify the one that best balances benefits and risks for the person • share information from table 1: effect of combined HRT versus no HRT on specific health outcomes • refer to the discussion aid on HRT and the likelihood of some medical conditions to provide information on the extent of benefits and risks associated with HRT.",
    "[2024] See also the: • recommendations on discussing benefits and risks of HRT, including the need to tailor the treatment to the person's age, personal circumstances and potential risk factors and • section on communicating risks, benefits and consequences (including how to discuss numerical information) in NICE's guideline on shared decision making. Table 1 Combined HRT versus no HRT: effect on specific health outcomes – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? All-cause mortality (life expectancy) – Overall, life expectancy is unlikely to change with the use of combined HRT. [2024] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? Cancer: breast (Information in this table applies to people with no personal history of breast cancer) Breast cancer risk varies depending on a person's modifiable and non-modifiable risk factors.",
    "Cancer: breast (Information in this table applies to people with no personal history of breast cancer) Breast cancer risk varies depending on a person's modifiable and non-modifiable risk factors. [2024] Breast cancer risk increases with combined HRT and the increase: • rises with duration of use • is higher in people currently taking HRT than in those who have taken it in the past • declines after stopping HRT but persists at least 10 years after stopping use. There is a very small increase in risk of death from breast cancer with combined HRT. Use the discussion aid on HRT for the number of breast cancer cases per Breast cancer risk with sequential combined HRT is: • lower than with continuous combined HRT but • higher than without HRT. [2024] There is insufficient evidence to establish whether the increase in risk of breast cancer is different with preparations containing micronised progesterone or dydrogesterone from what it is with preparations containing other progestogens. [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? 1,000 people taking combined HRT over a 5- or 10- year period. [2024] Menopause: identification and management (NG23) © NICE 2025.",
    "Does the type of hormone affect these risks? 1,000 people taking combined HRT over a 5- or 10- year period. [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? Cancer: endometrial (Information in this table applies to people with no personal history of endometrial cancer) – – Endometrial cancer risk decreases with continuous combined HRT (use the discussion aid on HRT for the number of endometrial cancer cases per 1,000 people taking combined HRT over a 5-year period). [2024] Endometrial cancer risk may slightly increase with sequential combined HRT, and the increase may be greater with: • longer duration of use • fewer days of progestogen per cycle • increased dosage of – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? oestrogen.",
    "Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? oestrogen. [2024] Cancer: ovarian (Information in this table applies to people with no personal history of ovarian cancer) The baseline population risk of ovarian cancer in women aged under 60 is very low (use the discussion aid on HRT for the number of ovarian cancer cases per 1,000 people over a 5-year period). [2024] In people with ovaries, there is a very slight increase in ovarian cancer risk with combined HRT (use the discussion aid on HRT for the number of ovarian cancer cases per 1,000 people over a 5-year and a 10-year period). [2024] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? Coronary heart disease (Information in this table applies to people with no personal history of coronary heart disease) – Coronary heart disease risk does not increase with combined HRT (use the discussion aid on HRT for the number of coronary heart disease cases per 1,000 people over a 5-year period.) [2024] Mortality from cardiovascular disease does not increase with combined HRT.",
    "[2024] Mortality from cardiovascular disease does not increase with combined HRT. [2024] – – Dementia – Dementia risk might increase with combined HRT if it is started at 65 or over (use the discussion aid on HRT for the number of dementia cases per 1,000 people over a 4-year period). [2024] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? Muscle mass and strength – There is limited evidence suggesting that HRT may improve muscle mass and strength. [2015] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? Osteoporosis The baseline population risk of fragility fracture: • is low in the UK for women, trans men and non- binary people registered female at birth who are around the age of menopause, and • varies from one person to another. [2015] (Use the discussion aid on HRT for the incidence of fragility fractures in women not taking HRT.)",
    "[2015] (Use the discussion aid on HRT for the incidence of fragility fractures in women not taking HRT.) [2015] Fragility fracture risk is decreased while taking HRT and this benefit: • is maintained during treatment but decreases once treatment stops • may continue for longer in people who take HRT for longer. [2015] (Use the discussion aid on HRT for the incidence of fragility fractures in women taking HRT.) [2015] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? Stroke (Information in this table applies to people with no personal history of stroke) The baseline population risk of stroke in women aged under 60 is very low. [2024] – Stroke risk is unlikely to increase with the use of combined HRT that includes transdermal oestrogen (see the discussion aid on HRT, for the number of stroke cases per 1,000 people over a 5-year period). [2024] Stroke risk increases with combined HRT containing oral oestrogen and the increase: • rises with higher oestrogen dosage and longer duration of treatment, for example, if used for more than 5 years • is greater – Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? with increasing age at first starting HRT • differs between ethnic groups and may be greater in Black people. (See the discussion aid on HRT, for the number of stroke cases per 1,000 people over a 5-year period.) [2024] Type 2 diabetes – The risk of developing type 2 diabetes does not increase with HRT. [2015] Generally, no adverse effect on blood glucose control is reported when taking HRT. [2015] The risk is not affected whether HRT is taken orally or transdermally. [2015] – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking combined hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way combined HRT is taken affect these risks? Does the type of hormone affect these risks? Venous thromboembolism (VTE) – VTE risk is not increased with transdermal HRT. [2015] VTE risk is increased with oral HRT. [2015] VTE risk is greater with oral than transdermal HRT. [2015] – Table 1 lists the differences in specific health outcomes between people who are taking or have taken combined HRT, and those who have never had HRT.",
    "[2015] – Table 1 lists the differences in specific health outcomes between people who are taking or have taken combined HRT, and those who have never had HRT. The statements from 2015 in tables 1 and 2 do not distinguish between combined and oestrogen-only HRT. These statements have been included in both tables to better support discussions. A downloadable version of this table is also available. For a short explanation of why the committee made the 2024 recommendations and how they might affect practice, see the rationale and impact section on effect of combined HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in: • evidence review C: cardiovascular disease and stroke • evidence review D: breast cancer • evidence review E: endometrial cancer • evidence review F: ovarian cancer • evidence review G: dementia. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). Oestrogen-only HRT This recommendation is for people who have had a total hysterectomy (see recommendation 1.8.1 on what type of HRT to offer).",
    "Oestrogen-only HRT This recommendation is for people who have had a total hysterectomy (see recommendation 1.8.1 on what type of HRT to offer). 1.6.3 When talking about oestrogen-only HRT as a treatment option: • discuss different oestrogen-only HRT options to identify the one that best balances benefits and risks for the person • share information from table 2: effect of oestrogen-only HRT versus no HRT on specific health outcomes • refer to the discussion aid on HRT and the likelihood of some medical conditions to provide information on the extent of benefits and risks associated with HRT. [2024] See also the: • recommendation on discussing benefits and risks of HRT, including the need to tailor the treatment to the person's age, personal circumstances and potential risk factors and • section on communicating risks, benefits and consequences (including how to discuss numerical information) in NICE's guideline on shared decision making. Table 2 Oestrogen-only HRT versus no HRT: effect on specific health outcomes – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks? All-cause mortality (life expectancy) – Overall, life expectancy is unlikely to change with the use of oestrogen-only HRT. [2024] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "[2024] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks? Cancer: breast (Information in this table applies to people with no personal history of breast cancer) Breast cancer risk varies depending on a person's modifiable and non-modifiable risk factors. [2024] There is very little or no increase in breast cancer risk with oestrogen-only HRT. There is little or no increase in the risk of breast cancer mortality with oestrogen-only HRT. Use the discussion aid on HRT for the number of breast cancer cases per 1,000 people taking oestrogen-only HRT over a 5- or 10-year period. [2024] – Breast cancer risk is similar with oestradiol and with conjugated equine oestrogen. [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks?",
    "Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks? Cancer: endometrial (Information in this table applies to people with no personal history of endometrial cancer) – In people with a uterus, endometrial cancer risk increases with oestrogen-only HRT (use the discussion aid on HRT for the number of endometrial cancer cases per 1,000 people taking oestrogen-only HRT over a 5-year period). [2024] See also recommendation 1.8.1 on which type of HRT to offer depending on whether people have a uterus or not in the section on starting HRT. [2024] In people with a uterus, endometrial cancer risk increases with both oral and transdermal oestrogen-only HRT. [2024] – Cancer: ovarian (Information in this table applies to people with no personal history of ovarian cancer) The baseline population risk of ovarian cancer in women aged under 60 is very low. (Use the discussion aid on HRT for the number of ovarian cancer cases per 1,000 people over a 5-year period). [2024] In people with ovaries, ovarian cancer risk increases very slightly after 5 years of using oestrogen-only HRT and this risk increases with duration of use (use the discussion aid on HRT for the number of ovarian cancer cases per 1,000 people over a 5-year and a 10-year period). [2024] Ovarian cancer risk increases with both transdermal and oral oestrogen-only HRT. [2024] – Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "[2024] Ovarian cancer risk increases with both transdermal and oral oestrogen-only HRT. [2024] – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks? Coronary heart disease (Information in this table applies to people with no personal history of coronary heart disease) – Coronary heart disease risk does not increase with oestrogen-only HRT (use the discussion aid on HRT for the number of coronary heart disease cases per 1,000 people over a 5-year period). [2024] Mortality from cardiovascular disease does not increase with oestrogen-only HRT. [2024] – – Dementia – Dementia risk is unlikely to increase with oestrogen-only HRT (see the discussion aid on HRT for the number of dementia cases per 1,000 people over a 5-year period). [2024] – – Muscle mass and strength – There is limited evidence suggesting that HRT may improve muscle mass and strength. [2015] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome?",
    "Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks? Osteoporosis The baseline population risk of fragility fracture: • is low in the UK for women, trans men and non- binary people registered female at birth who are around the age of menopause and • varies from one person to another. (Use the discussion aid on HRT for the incidence of fragility fractures in women.) [2015] Fragility fracture risk is decreased while taking HRT and this benefit: • is maintained during treatment but decreases once treatment stops • may continue for longer in people who take HRT for longer. (Use the discussion aid on HRT for the incidence of fragility fractures in women.) [2015] – – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks? Stroke (Information in this table applies to people with no personal history of stroke) The baseline population risk of stroke in women aged under 60 is very low.",
    "Stroke (Information in this table applies to people with no personal history of stroke) The baseline population risk of stroke in women aged under 60 is very low. [2024] – Stroke risk increases with oral oestrogen- only HRT and the increase: • rises with the dosage of oestrogen • is greater if HRT is started after the age of 60. (See the discussion aid on HRT, for the number of stroke cases per 1,000 people over a 5-year period.) [2024] Stroke risk is unlikely to increase with transdermal oestrogen-only HRT (see the discussion aid on HRT, for the number of stroke cases per 1,000 – Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). – Baseline risk How does taking oestrogen-only hormone replacement therapy (HRT) impact the risks related to this outcome? Does the way oestrogen-only HRT is taken affect these risks? Does the type of hormone taken affect these risks? people over a 5-year period). [2024] Type 2 diabetes – The risk of developing type 2 diabetes does not increase with HRT. [2015] Generally, no adverse effect on blood glucose control is reported when taking HRT. [2015] The risk is not affected whether HRT is taken orally or transdermally. [2015] – Venous thromboembolism (VTE) – VTE risk is not increased with transdermal HRT. [2015] VTE risk is increased with oral HRT. [2015] VTE risk is greater with oral than transdermal HRT.",
    "[2015] – Venous thromboembolism (VTE) – VTE risk is not increased with transdermal HRT. [2015] VTE risk is increased with oral HRT. [2015] VTE risk is greater with oral than transdermal HRT. [2015] – Table 2 lists the differences in specific health outcomes between people who are taking or have taken oestrogen-only HRT, and those who have never had HRT. The statements from 2015 in tables 1 and 2 do not distinguish between combined and oestrogen-only HRT. These statements have been included in both tables to better support discussions. A downloadable version of this table is also available. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on effect of oestrogen-only HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in: • evidence review C: cardiovascular disease and stroke • evidence review D: breast cancer • evidence review E: endometrial cancer • evidence review F: ovarian cancer • evidence review G: dementia. Cardiovascular disease prevention 1.6.4 Do not offer combined or oestrogen-only HRT for primary or secondary prevention of cardiovascular disease.",
    "Cardiovascular disease prevention 1.6.4 Do not offer combined or oestrogen-only HRT for primary or secondary prevention of cardiovascular disease. For guidance on ways to reduce the risk of cardiovascular disease (for example, lifestyle changes), refer to NICE's guideline on cardiovascular disease: risk assessment and reduction, including lipid modification. [2024] For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on cardiovascular disease prevention. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. Dementia prevention 1.6.5 Do not offer combined or oestrogen-only HRT for the purpose of dementia prevention. For dementia prevention, see NICE's guideline on dementia, disability Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). and frailty in later life – mid-life approaches to delay or prevent onset. [2024] For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on dementia prevention. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke.",
    "Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. People in early menopause (ages 40 to 44) 1.6.6 When discussing HRT as a treatment option, explain to people experiencing early menopause that, for them, the benefits and risks of either taking or not taking HRT are likely to lie between those for people with premature ovarian insufficiency and those for people aged 45 or over. [2024] See also the recommendations on discussing benefits and risks in the section on HRT and managing symptoms associated with menopause for people aged 40 and over, including the need to tailor the treatment to the person's age, personal circumstances and potential risk factors. For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on effects of HRT in early menopause on specific health outcomes. Full details of the evidence and the committee's discussion are in evidence review I: early menopause. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). 1.7 Diagnosing and managing premature ovarian insufficiency in people under 40 Diagnosing premature ovarian insufficiency 1.7.1 Take into account the person's clinical history (for example, previous medical or surgical treatment) and family history when diagnosing premature ovarian insufficiency.",
    "[2015] 1.7.2 Diagnose premature ovarian insufficiency in women, trans men and non-binary people registered female at birth who are under 40 based on: • menopause-associated symptoms, including no or infrequent periods (taking into account whether the person has had a hysterectomy) and • elevated follicle stimulating hormone (FSH) levels on 2 blood samples taken 4 to 6 weeks apart. [2015] 1.7.3 Do not diagnose premature ovarian insufficiency on the basis of a single blood test. [2015] 1.7.4 Do not routinely use anti-Müllerian hormone testing to diagnose premature ovarian insufficiency. [2015] 1.7.5 If there is doubt about the diagnosis of premature ovarian insufficiency, refer the person to a specialist with expertise in menopause or reproductive medicine. [2015] Managing premature ovarian insufficiency 1.7.6 Offer sex steroid replacement with a choice of hormone replacement therapy (HRT) or a combined hormonal contraceptive to people with premature ovarian insufficiency, unless contraindicated (for example, in people with hormone- sensitive cancer). [2015] 1.7.7 Explain to people with premature ovarian insufficiency: Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights).",
    "All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). • the importance of starting hormonal treatment either with HRT or a combined hormonal contraceptive and continuing treatment until at least the age of natural menopause (unless contraindicated) • that the baseline population risk of diseases such as breast cancer and cardiovascular disease increases with age and is very low in people under the age of 40 • that HRT may have a beneficial effect on blood pressure when compared with a combined oral contraceptive • that both HRT and combined oral contraceptives offer bone protection • that HRT is not a contraceptive. [2015] 1.7.8 Give people with premature ovarian insufficiency and contraindications to hormonal treatments advice, including on bone and cardiovascular health, and on symptom management. [2015] 1.7.9 Consider referring people with premature ovarian insufficiency to healthcare professionals with the relevant experience to help them manage all aspects of physical and psychosocial health related to their condition. [2015] 1.8 Starting and stopping hormone replacement therapy for anyone Starting HRT 1.8.1 For people who wish to take hormone replacement therapy (HRT) for symptoms associated with menopause: • offer combined HRT to people with a uterus • offer oestrogen-only HRT to people who have had a total hysterectomy. Also see recommendation 1.8.2. [2024] Menopause: identification and management (NG23) © NICE 2025.",
    "Also see recommendation 1.8.2. [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). 1.8.2 For people with a condition that may be affected by HRT, consider seeking advice on the choice of HRT from a healthcare professional with specialist knowledge of that condition. [2024] 1.8.3 If a person chooses to take HRT, use the lowest effective dosage. [2024] 1.8.4 Explain to people with a uterus that vaginal bleeding is a common side effect of systemic HRT within the first 3 months of treatment, and they will be asked about this during their 3-month review. Advise them to seek medical help promptly if they experience vaginal bleeding after 3 months. [2015] Stopping HRT 1.8.5 Offer people who are stopping HRT a choice of gradually reducing or immediately stopping treatment. [2015] 1.8.6 Explain to people that: • gradually reducing HRT may limit recurrence of symptoms in the short term • gradually reducing or immediately stopping HRT makes no difference to their symptoms in the longer term. [2015] 1.8.7 Stop systemic HRT in people who are diagnosed with breast cancer in line with the recommendations on menopause symptoms in NICE's guideline on early and locally advanced breast cancer. [2024] For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on starting and stopping HRT for anyone.",
    "[2024] For a short explanation of why the committee made the 2024 recommendation and how it might affect practice, see the rationale and impact section on starting and stopping HRT for anyone. Full details of the evidence and the committee's discussion are in: • evidence review D: breast cancer risk • evidence review E: endometrial cancer risk. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). 1.9 Reviewing treatment for anyone 1.9.1 Discuss with people the importance of keeping up to date with nationally recommended health screening. [2015] 1.9.2 Review each treatment for symptoms associated with menopause: • at 3 months to assess efficacy and tolerability • annually thereafter, unless there are clinical indications for an earlier review (such as treatment ineffectiveness, side effects or adverse events). [2015] 1.9.3 Refer people to a healthcare professional with expertise in menopause if treatments do not improve their menopause-associated symptoms or they have ongoing side effects. [2015] Terms used in this guideline This section defines terms that have been used in a particular way for this guideline. For other definitions, see the NICE glossary and the Think Local, Act Personal Care and Support Jargon Buster. Combined HRT Hormone replacement therapy (HRT) with oestrogen and progestogen.",
    "For other definitions, see the NICE glossary and the Think Local, Act Personal Care and Support Jargon Buster. Combined HRT Hormone replacement therapy (HRT) with oestrogen and progestogen. Continuous combined HRT HRT in which oestrogen and progestogen are taken together, daily. Depressive symptoms For the purposes of this guideline, depressive symptoms are any symptoms included in the ICD-11 and DSM-5 criteria for the diagnosis of depression, as reproduced in NICE's guideline on managing and treating depression in adults, but the extent, duration and number of which does not lead to a diagnosis of: Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • depression, as defined by ICD-11 or DSM-5 or • chronic depressive symptoms, as defined in NICE's guideline on managing and treating depression in adults. Genitourinary symptoms associated with menopause Genitourinary symptoms associated with menopause include vulvovaginal dryness, pain with sex, vulvovaginal discomfort or irritation, and discomfort or pain when urinating.",
    "Healthcare professional with expertise in menopause Healthcare professionals with specialist knowledge, skills and training who can (in collaboration with the relevant specialists) manage, or advise colleagues in managing, complex menopause-related needs and risk factors affecting decision making, including: • complex medical problems that potentially affect use of treatments for menopause associated symptoms • menopause associated symptoms for those at elevated risk of breast or ovarian cancer, or with a personal history of hormone dependent cancer. Their training should be recognised by a professional body such as the British Menopause Society, the Faculty of Sexual and Reproductive Healthcare or the Royal College of Obstetricians and Gynaecologists. Sequential combined HRT Sometimes also referred to as combined cyclical HRT. A form of HRT in which oestrogen is taken every day, and the progestogen is taken for usually half of the month. Systemic HRT HRT in which the hormones are absorbed into the bloodstream and have an effect throughout the body. As part of systemic HRT: • oestrogen can be taken orally, or transdermally, as a patch, gel or spray that delivers the hormone through the skin Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • progestogen can be taken orally, transdermally as a patch, or be delivered through an intrauterine system.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • progestogen can be taken orally, transdermally as a patch, or be delivered through an intrauterine system. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Recommendations for research The guideline committee has made the following recommendations for research. Key recommendations for research 1 Impact of HRT on health outcomes in early menopause What is the effect of either taking or not taking hormone replacement therapy (HRT) on health outcomes for people experiencing early menopause (aged 40 to 44)? [2024] For a short explanation of why the committee made this recommendation for research, see the rationale section on effects of HRT use in early menopause on specific health outcomes. Full details of the evidence and the committee's discussion are in evidence review I: early menopause. 2 Type of progestogen in HRT and breast cancer or cardiovascular disease Do different types of progestogen (for example, micronised progesterone) alter the risks of breast cancer or cardiovascular disease? [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "[2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made this recommendation for research, see the rationale section on effect of combined HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in: • evidence review C: cardiovascular disease and stroke • evidence review D: breast cancer • evidence review E: endometrial cancer. 3 Mode of administration of HRT Combined HRT Do different modes of administration of combined HRT alter the risks of breast cancer, coronary heart disease or dementia? [2024] For a short explanation of why the committee made this recommendation for research, see the rationale section on effect of combined HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in: • evidence review C: cardiovascular disease and stroke • evidence review D: breast cancer • evidence review E: endometrial cancer. Oestrogen-only HRT Do different modes of administration of oestrogen-only HRT alter the risks of breast cancer, coronary heart disease or dementia? [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "[2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made this recommendation for research, see the rationale section on effect of oestrogen-only HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in: • evidence review C: cardiovascular disease and stroke • evidence review D: breast cancer • evidence review E: endometrial cancer. 4 Safety of vaginal oestrogen use for longer than 12 months What is the safety of vaginal oestrogen use for longer than 12 months? [2024] For a short explanation of why the committee made this recommendation for research, see the rationale section on genitourinary symptoms associated with menopause in people with no personal history of breast cancer. Full details of the evidence and the committee's discussion are in evidence review B1: managing genitourinary symptoms (network meta-analyses). 5 Safety of vaginal oestrogen in terms of breast cancer recurrence For people with a personal history of breast cancer, or at high familial or genetic risk of breast cancer, does vaginal oestrogen for genitourinary symptoms associated with menopause increase the risk of recurrence or incidence of breast cancer? [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "[2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made this recommendation for research, see the rationale section on genitourinary symptoms associated with menopause in people with a personal history of breast cancer. Full details of the evidence and the committee's discussion are in in evidence review B2: managing genitourinary symptoms (breast cancer recurrence). 6 Impact of timing of HRT for menopause-associated symptoms on risk of coronary heart disease Combined HRT Does the person's age at menopause or the time between the person's menopause and their first use of HRT affect the long-term risk of coronary heart disease in people who take or have taken combined HRT? [2024] For a short explanation of why the committee made this recommendation for research, see the rationale section on effect of combined HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. Oestrogen-only HRT Does the person's age at menopause or the time between the person's menopause and their first use of HRT affect the long-term risk of coronary heart disease in people who take or have taken oestrogen-only HRT? [2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "[2024] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). For a short explanation of why the committee made this recommendation for research, see the rationale section on effect of oestrogen-only HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. 7 Vaginal laser treatment for genitourinary symptoms associated with menopause What is the safety and efficacy of vaginal laser treatment for genitourinary symptoms associated with menopause? [2024] For a short explanation of why the committee made this recommendation for research, see the rationale section on vaginal laser treatment. Full details of the evidence and the committee's discussion are in evidence review B1: managing genitourinary symptoms (network meta-analyses).",
    "Full details of the evidence and the committee's discussion are in evidence review B1: managing genitourinary symptoms (network meta-analyses). 8 Impact of HRT on health outcomes for trans men and non- binary people registered female at birth (who are not taking gender-affirming hormone therapy at the time of taking HRT or in the follow-up period) What is the impact of HRT on health outcomes for trans men and non-binary people registered female at birth (who are not taking gender-affirming hormone therapy at the time of taking HRT or in the follow-up period) in relation to: • cardiovascular disease • stroke • breast, endometrial and ovarian cancer • dementia Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • all-cause mortality? [2024] For a short explanation of why the committee made this recommendation for research, see the rationale section on managing menopause in people who have taken gender-affirming hormone therapy in the past. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. 9 Impact of HRT on health outcomes for people from ethnic minority backgrounds What is the impact of HRT on health outcomes for people from ethnic minority backgrounds in relation to: • cardiovascular disease • stroke • breast, endometrial and ovarian cancer • dementia • all-cause mortality?",
    "[2024] For a short explanation of why the committee made this recommendation for research, see the rationale section on effects of combined HRT on specific health outcomes in people aged 45 or over. Full details of the evidence and the committee's discussion are in evidence review C: cardiovascular disease and stroke. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Other recommendations for research 10 People with a personal history of breast cancer What is the safety and effectiveness of alternatives to systemic HRT as treatments for menopause-associated symptoms in people who have had breast cancer? [2015] 11 Effects of HRT on dementia risk What are the effects of HRT use on the risk of dementia? [2015, amended 2024] 12 Premature ovarian insufficiency What are the main clinical manifestations of premature ovarian insufficiency and the short- and long-term impact of the most common therapeutic interventions? [2015] 13 Breast cancer and venous thromboembolism What is the impact of oestradiol in combination with the levonorgestrel-releasing intra- uterine system (LNG-IUS) on the risk of breast cancer and venous thromboembolism (VTE)? [2015] 14 Breast cancer recurrence What is the impact of systemic HRT use in people with a previous diagnosis of breast cancer on the risk of breast cancer recurrence, mortality or the aggressiveness of the tumour?",
    "[2015] Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Rationale and impact These sections briefly explain why the committee made the recommendations and how they might affect practice. Psychological support for early menopause Recommendation 1.2.7 Why the committee made the recommendation In the committee's experience, some people can be distressed by going through menopause at an earlier age than expected and earlier than their peers. If someone is experiencing emotional distress to a level that raises concerns, the committee agreed that they may need to be referred to psychology services. How the recommendation might affect practice It is common practice to provide psychological support to this group of people. While a potential referral will have a resource impact, support from psychology services will lead to improvements in quality of life and reduce future contacts with health services. Return to recommendation Identifying perimenopause and menopause Recommendation 1.3.3 Why the committee made the recommendation Evidence is lacking on the average age of menopause in people from ethnic minority backgrounds. However, the committee was aware, from experience, that people from some ethnic minority groups, and people with some lifelong conditions (for example, Down's syndrome), experience menopause at a younger age.",
    "The committee agreed it was important to raise awareness of this so that healthcare professionals can more easily Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). identify symptoms of menopause in ethnic minority populations or in people with lifelong conditions. How the recommendation might affect practice The recommendation will raise awareness that people from some ethnic minority groups, and those with some lifelong conditions, experience menopause at a younger age. It is unclear whether this will change clinical practice, but it might lead to earlier identification of menopause and earlier management of menopause symptoms. Return to recommendation Discussing management options with people aged 40 or over Recommendations 1.4.1 to 1.4.4 Why the committee made the recommendations Based on experience, the committee agreed that these basic principles of care would allow people to make an informed choice about management options: • using an individualised approach with discussions about benefits and risks of any management option and • tailoring information to individual circumstances and potential risk factors. Hormone replacement therapy The committee noted there are different ways of prescribing hormone replacement therapy (HRT) in terms of mode of administration, types of hormones, schedule, and individualised dose and duration.",
    "All these options influence benefits and risks so the best combination of them differs from one person to another and should be carefully chosen with, and for, each person. The committee agreed that clinicians should provide and discuss information about all this so that the person can take an active part in shared decision making. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Baseline risks of specific health outcomes and the benefits and risks of HRT also depend on a person's age at the start of perimenopause, as well as their individual circumstances and risk factors. It is particularly important to take age into account, for example, when thinking about the: • risks of dementia or stroke with HRT and • use of HRT in people experiencing early menopause. The committee agreed it was essential to discuss duration of use when a person chooses to take HRT. It was decided that this was important because, even if the exact duration is unknown at the start, people would get an idea (from the clinician's knowledge about typical use) how long they may be taking HRT for and be made aware that this would be discussed again at reviews. The committee also agreed that it is impossible to recommend 1 specific duration of use because this would depend on several factors, including the reason for starting HRT and a person's medical history, age and symptoms.",
    "It was agreed that it was important to discuss continuation of HRT at every review because circumstances and preferences could change. The committee acknowledged that, in many people, menopause symptoms may return when HRT is stopped. They agreed this should also be discussed with the person in the context of duration of use. The person should also be aware that, if this happens, they could restart HRT, if this would still provide the best balance benefits and risks for them. Cognitive behavioural therapy Evidence showed that cognitive behavioural therapy (CBT) could be an option for some people with vasomotor symptoms, depressive symptoms or sleep problems. CBT could be used either alongside HRT or, for people for whom HRT is contraindicated or who prefer not to take it, instead of HRT. Several types of CBT (for example, online or group sessions) were found to be effective, but the evidence did not show that 1 option was better than another. The committee therefore recommended that the available options should be discussed with the person. They were also aware that some people needed information on what CBT involves. It was recognised that people have different preferences and needs and that these should be taken into account during these discussions (for example, reasonable adjustments may be needed for people with learning disabilities). How the recommendations might affect practice The recommendations reflect best practice principles for shared decision-making.",
    "How the recommendations might affect practice The recommendations reflect best practice principles for shared decision-making. The Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). recommendations will make healthcare professionals aware of what to discuss as part of this process. Return to recommendations Cognitive behavioural therapy for vasomotor symptoms Recommendation 1.5.2 Why the committee made the recommendation The committee based the recommendation on both the evidence and their expert knowledge. They looked at evidence on CBT compared with no intervention or to treatment as usual. There was no evidence available for trans men and non-binary people registered female at birth. However, the committee agreed that the use of CBT for menopause-associated symptoms would be suitable for anyone, regardless of whether they have taken gender- affirming hormone therapy in the past. (This is also covered in the rationale on managing symptoms associated with menopause in people who have taken gender-affirming hormone therapy in the past.) Overall, the evidence showed CBT was beneficial for women with vasomotor symptoms associated with menopause. The benefits related to 3 outcomes: the frequency of symptoms, severity of symptoms and how much the symptoms bothered the person (using a questionnaire that measured 'distress or bother').",
    "The benefits related to 3 outcomes: the frequency of symptoms, severity of symptoms and how much the symptoms bothered the person (using a questionnaire that measured 'distress or bother'). The greatest effect was seen in how much symptoms bothered the person – many women felt their symptoms affected them less after taking part in CBT. The committee also discussed the following limitations that affected the quality of the evidence: • some concerns related to study design and to potential bias in the way studies were carried out • uncertainties around outcomes, with different results being obtained for different Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). outcome measurement scales and subgroups • uncertainties around how large the effect of CBT was, even when it was found to be effective. For this reason, the committee decided to recommend CBT in addition to HRT, or as an option for people who prefer not to take HRT or for whom HRT is contraindicated. They also agreed the chosen CBT approach should be specifically designed for menopause symptoms. How the recommendation might affect practice These recommendations are a change to clinical practice.",
    "They also agreed the chosen CBT approach should be specifically designed for menopause symptoms. How the recommendation might affect practice These recommendations are a change to clinical practice. While wider use of CBT as an additional option could increase costs and add pressure to already limited services, especially in the short-term, it also gives people more choices for managing symptoms, including the option to have both CBT and HRT. This may lead to better outcomes. The committee noted that there are long waiting times for CBT. They also noted that people currently trained in providing this kind of therapy may not be familiar with menopause-specific CBT, so training on this may incur costs and increase waiting times in the short term. However, online and group CBT may be easier and less costly to adapt to be menopause specific. There are also resources available to train people in providing menopause-specific CBT (that could also inform the adaptation of online CBT), which could facilitate implementation. Currently, the treatment recommended for vasomotor symptoms associated with menopause is HRT. Access to CBT may address some health inequalities, providing other effective options for those who cannot or do not wish to use pharmacological treatments for menopause symptoms.",
    "Access to CBT may address some health inequalities, providing other effective options for those who cannot or do not wish to use pharmacological treatments for menopause symptoms. Return to recommendation Genitourinary symptoms associated with menopause in people with no personal history of breast cancer Recommendations 1.5.4 to 1.5.12 Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Why the committee made the recommendations The committee discussed evidence from network meta-analyses (NMA) which looked at a number of management options for specific subtypes of genitourinary symptoms associated with menopause such as vaginal dryness, pain with sex, and vulvovaginal discomfort or irritation. They also took into account evidence from the health economic model developed for the 2024 update of this guideline. There was no evidence available for trans men and non-binary people registered female at birth. The committee agreed that their conclusion from the available evidence could be extended to those who have never taken gender-affirming hormone therapy. But they did not think they could be extended to those who have taken this type of therapy in the past, because it is not known whether such therapy would alter the benefits and risks of any management option (especially hormonal treatments), or which management option might be best for the person.",
    "Evidence showed that vaginal oestrogen (particularly estriol but also oestradiol) was effective in reducing vaginal dryness and pain with sex. Estriol also showed effectiveness in reducing vulvovaginal discomfort or irritation. The economic model conducted for this review showed that vaginal oestrogen was cost-effective. There was limited evidence on long-term use of vaginal oestrogen preparations. However, the committee acknowledged that efficacy and tolerability would be assessed regularly, as per the recommendations on reviewing treatment. To gain a better understanding of it, the committee made a recommendation for research on the safety of vaginal oestrogen when used for more than 12 months. Based on their expertise, the committee agreed that what is known about the safety of long-term use should be taken into account and discussed with the person before offering vaginal oestrogen. They agreed that the following points should also be brought up: • Serious adverse effects from vaginal oestrogen are rare. For example, the committee was aware of the 2019 Medicines and Healthcare products Regulatory Agency drug safety update on HRT safety advice, which states that there is no evidence of an effect of vaginal oestrogen on breast cancer risk. This was consistent with the findings from the NMA, which showed that discontinuation due to adverse events was relatively low. Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • In the committee's experience, people are not always aware that symptoms often return when vaginal oestrogen is stopped. • Because absorption into the bloodstream is minimal, there is no need to combine vaginal oestrogens with systemic progestogen treatment to protect the person against endometrial hyperplasia and cancer (whereas, with systemic HRT, people with a uterus need progestogen treatment for protection – see the rationale section on starting and stopping HRT). Preparations were not all shown to be equally effective. However, there were also uncertainties around the differences observed. So, the committee agreed that, overall, it was unlikely that 1 type of vaginal oestrogen preparation would be more effective than another. They concluded that people with genitourinary symptoms associated with menopause should be given different options for vaginal oestrogen preparations so they could choose the 1 they prefer. The committee thought that people did not always realise that moisturisers or lubricants can be used alone or in addition to vaginal oestrogen and, therefore, thought that this information should be included in discussions about management options.",
    "The NMA suggested that non-hormonal vaginal moisturisers and lubricants were less effective than vaginal oestrogen, but a smaller proportion of people stopped using their treatment when using non-hormonal vaginal moisturisers or lubricants than when using other types of treatments. This may suggest that, when non-hormonal vaginal moisturisers and lubricants worked for a person, the person felt comfortable to keep using them (for example, because these are readily available over the counter options). While the evidence highlighted uncertainty around the effectiveness of non-hormonal moisturisers and lubricants, based on their experience, the committee decided that moisturisers and lubricants could be tried when vaginal oestrogen is contraindicated or not preferred. The committee discussed the role of vaginal prasterone and oral ospemifene in the management of genitourinary symptoms associated with menopause. They noted that both these medicines are more expensive than vaginal oestrogen, moisturisers or lubricants. However, the NMA showed them to be effective in reducing vaginal dryness and pain with sex but not vulvovaginal discomfort or irritation. They were also seldom discontinued because of adverse events. The economic model showed vaginal prasterone was not cost-effective as a first-line option. However, given its clinical effectiveness, the committee agreed that it could be Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "However, given its clinical effectiveness, the committee agreed that it could be Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). offered as a second-line management option when other options (vaginal oestrogen, or non-hormonal moisturisers or lubricants) are ineffective for persisting genitourinary symptoms or are not tolerated. Evidence showed that ospemifene was not cost-effective and could therefore not be recommended as a first-line treatment option for all people with genitourinary symptoms associated with menopause. However, the committee noted that, for some people, local application of vaginal oestrogen may be impractical. For example, people with physical or intellectual disabilities may find it difficult to use local vaginal oestrogen. Ospemifene is an oral tablet and should therefore be considered as an option in such specific circumstances. The committee was aware that the symptoms of overactive bladder can occur alongside genitourinary symptoms associated with menopause and that vaginal oestrogen can be given in these circumstances. They decided not to include people with a personal history of breast cancer in the recommendation on this because vaginal oestrogen is not the first- line treatment for genitourinary symptoms associated with menopause in this population.",
    "How the recommendations might affect practice The evidence showed that the most cost-effective option for the treatment of genitourinary symptoms associated with menopause is vaginal oestrogen, which is routinely offered in current practice. The recommendations will standardise practice rather than change it. Return to recommendations Genitourinary symptoms associated with menopause in people with a personal history of breast cancer Recommendations 1.5.13 to 1.5.18 Why the committee made the recommendations The committee acknowledged that evidence was sparse, with only 4 studies providing information on breast cancer recurrence in people with a personal history of breast cancer Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). taking vaginal hormone treatment for genitourinary symptoms associated with menopause. The committee also had methodological concerns about some of the studies, particularly about: • how they accounted for confounding factors (including how many factors, which factors and how they accounted for these factors in their analysis of data) and • duration of follow-up, which was not long enough to capture breast cancer recurrence. There was no evidence available for trans men and non-binary people registered female at birth.",
    "There was no evidence available for trans men and non-binary people registered female at birth. The committee agreed that their conclusion from the available evidence could be extended to those who have never taken gender-affirming hormone therapy. But they did not think they could be extended to those who have taken this type of therapy in the past, because it is not known whether such therapy would alter the benefits and risks of any management option (especially hormonal treatments), or which management option might be best for the person. The committee discussed the evidence comparing vaginal oestrogen to no treatment in women with a personal history of breast cancer. Most of the evidence included all women together and so did not distinguish between those who used adjuvant treatment for breast cancer and those who did not. Based on this evidence, it is not possible to say with certainty whether vaginal oestrogen, when used for genitourinary symptoms associated with menopause, leads to any change in breast cancer recurrence or not. The uncertainties around the evidence also led the committee to agree that: • The first choice for people with a personal history of breast cancer and genitourinary symptoms associated with menopause should be non-hormonal moisturisers and lubricants.",
    "• Vaginal oestrogen should only be considered as a second-line option, when non- hormonal treatment has not been effective, and symptoms continue to impact negatively on the person's quality of life. The committee noted that people may not realise that non-hormonal moisturisers and lubricants could also be used in combination with vaginal oestrogen, so they agreed to highlight this. The committee made these recommendations because: • non-hormonal treatment may be less effective than local hormonal treatment but Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • although it is important to treat menopause-associated symptoms, the risk of breast cancer recurrence is a greater concern. The committee advised that the mechanism of action of aromatase inhibitors makes genitourinary symptoms likely. However, the mechanism of action of tamoxifen is less likely to cause genitourinary symptoms and may even alleviate some of them. Vaginal oestrogen may also lessen the efficacy of aromatase inhibitors. The committee agreed it could not be confident about the evidence on the safety of local vaginal oestrogens in those taking either tamoxifen or aromatase inhibitors.",
    "The committee agreed it could not be confident about the evidence on the safety of local vaginal oestrogens in those taking either tamoxifen or aromatase inhibitors. This was because of: • concerns about the quality of the evidence and • lack of data comparing the risk of breast cancer recurrence in people taking aromatase inhibitors alone with the same risk in people taking vaginal oestrogen (the comparison was aromatase inhibitor versus aromatase inhibitor plus vaginal oestrogen). For this reason, the committee agreed that, if vaginal oestrogen is considered for people on aromatase inhibitors as an adjuvant treatment, treatment options should be discussed with a breast cancer specialist (for example, this may include switching to tamoxifen). The committee noted that treatment decisions would need to be tailored to each person because: • Some people have a lower risk of breast cancer recurrence than others (as covered by NICE's guideline on early and locally advanced breast cancer). The committee decided that this was an important factor because it is worse to potentially add to the risk of those who already have a high risk than those who have a low risk of recurrence. • Vaginal oestrogen is absorbed locally. Some of it is absorbed systemically, that is, further into the body, but, compared with systemic HRT, the amount is minimal, and so it may or may not be a sufficient amount to affect breast cancer recurrence.",
    "This makes it difficult to assess the safety of vaginal oestrogen with respect to breast cancer recurrence. In someone with an oestrogen receptor negative breast cancer, oestrogen does not affect the growth of cancer cells, but in someone with an oestrogen receptor positive breast cancer, it increases the risk of recurrence. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). In someone with an oestrogen receptor positive breast cancer taking adjuvant treatment: • if this treatment inhibits the production of oestrogen (in the ovaries or in fat or muscle tissues), it will have no effect on any oestrogen coming from a source outside the body, and this oestrogen would then be able to bind to cancer cells and stimulate their growth but • if this treatment stops oestrogen from binding to oestrogen receptors (regardless of whether the oestrogen is produced by the body or absorbed from some treatment), it will stop oestrogen, regardless of source, from binding to receptors on cancer cells and so their growth will not be stimulated. There was relatively little evidence for the use of vaginal oestrogen to manage genitourinary symptoms associated with menopause after breast cancer, particularly related to long-term use and use in conjunction with adjuvant therapy.",
    "Therefore, the committee made a recommendation for research on the safety of vaginal oestrogen in terms of breast cancer recurrence. People who carry genetic variants that increase the risk of breast cancer No evidence on the use of vaginal oestrogen was identified for people who carry genetic variants that increase the risk of breast cancer. The committee therefore decided that it could not make a recommendation but made a recommendation for research on the safety of vaginal oestrogens for people who have a high genetic risk of breast cancer. How the recommendations might affect practice The recommendation about the use of non-hormonal treatment options as first-line treatment for people with a personal history of breast cancer and genitourinary symptoms associated with menopause is in line with current practice. There is variation in: • the clinical factors taken into account when considering local vaginal oestrogens after an ineffective first-line treatment • when to seek specialist oncology advice • what is discussed with people, particularly around the uncertainty of the evidence. The recommendations will standardise practice. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "The recommendations will standardise practice. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Return to recommendations Vaginal laser treatment Recommendation 1.5.19 Why the committee made the recommendation The committee made a recommendation on vaginal laser treatment that applies to people with genitourinary symptoms associated with menopause, regardless of whether they have a personal history of breast cancer. The evidence showed that laser treatment was effective for all outcomes. However, the committee agreed that, despite some promising results, the evidence base was too small. In addition, laser treatment has a potential for harm (for example, scarring) and evidence showed it was not cost-effective. As a result, it should only be offered in the context of research. The committee also made a recommendation for research on vaginal laser treatment to address this. There was no evidence available for trans men and non-binary people registered female at birth. The committee agreed that their conclusion from the available evidence could be extended to those who have never taken gender-affirming hormone therapy.",
    "The committee agreed that their conclusion from the available evidence could be extended to those who have never taken gender-affirming hormone therapy. But they did not think they could be extended to those who have taken this type of therapy in the past, because it is not known whether such therapy would alter the benefits and risks of any treatment (especially hormonal treatments), or which treatment option might be best for the person. How the recommendation might affect practice Laser treatment was not included in the previous version of this guideline, but the recommendation to only consider it in the context of research will not affect practice. Return to recommendation Management options for depressive symptoms or depression in people with menopause-associated Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). symptoms Recommendations 1.5.21 and 1.5.22 Why the committee made the recommendations The committee made recommendations based on the evidence which looked at CBT compared with no treatment or to treatment as usual, in the context of menopause. The common criteria used in all studies to show that women had experienced or were approaching menopause was the presence of vasomotor symptoms. There was no evidence available for trans men and non-binary people registered female at birth.",
    "There was no evidence available for trans men and non-binary people registered female at birth. However, the committee agreed that the use of CBT for menopause symptoms would be suitable for anyone, regardless of whether they have taken gender-affirming hormone therapy in the past. (For more details, see the rationale on managing symptoms associated with menopause in people who have taken gender-affirming hormone therapy in the past.) There were many different scales and measurements for mental health-related symptoms, and, in the context of menopause: • most of the evidence on depressive symptoms showed no difference between CBT and the comparison groups (no treatment or treatment as usual) • some evidence showed that CBT improved mood in women with depressive symptoms • no evidence showed that CBT might make depressive symptoms any more severe. There were some concerns about the evidence. These related to study design and to biases in the way studies were carried out. There were also uncertainties around: • the outcomes, with different results being obtained for different outcome measurement scales and subgroups and • how large the effect of CBT was, even when it was found to be effective. However, the committee acknowledged that the overall effectiveness of CBT for depressive symptoms is established (see NICE's guideline on depression in adults). For this reason, they agreed that CBT should be a management option for depressive symptoms associated with vasomotor symptoms.",
    "For this reason, they agreed that CBT should be a management option for depressive symptoms associated with vasomotor symptoms. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). If depression is suspected or diagnosed, the committee noted that the optimal treatment plan can only be achieved by following both this menopause guideline and NICE's guideline on depression in adults. How the recommendations might affect practice These recommendations could lead to a change to clinical practice. Wider use of CBT could increase costs and add pressure onto already limited services, especially in the short term. However, it also gives people more management choices, including the option to have both CBT and HRT. Having more options may result in better outcomes. There are currently long waiting times for CBT. However, the use of online and group CBT may make it easier and less costly to introduce CBT for depressive symptoms associated with menopause, where this option is not already in place. Return to recommendations Cognitive behavioural therapy for sleep problems associated with menopause Recommendation 1.5.23 Why the committee made the recommendation The committee based the recommendation on the evidence on CBT compared with no treatment or compared with treatment as usual. There was no evidence available for trans men and non-binary people registered female at birth.",
    "There was no evidence available for trans men and non-binary people registered female at birth. However, the committee agreed that the use of CBT for menopause symptoms would be suitable for anyone, regardless of whether they have taken gender-affirming hormone therapy in the past. (For more details, see the rationale on managing symptoms associated with menopause in people who have taken gender-affirming hormone therapy in the past.) Evidence showed CBT improved sleep quality, but this varied depending on the scale used to measure sleep disturbances. The committee agreed it was difficult to define difficulties with sleep, but the evidence showed that CBT was beneficial for various aspects of sleep, Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). as defined by each scale (for example, the measures contributing to scales included the number of hours of sleep per night, how long it takes to fall asleep and the number and duration of night-time awakenings; there were also some specific scales for insomnia). The committee acknowledged there may be other options to manage difficulties with sleep associated with menopause. NICE will monitor evidence on these for a future update.",
    "The committee acknowledged there may be other options to manage difficulties with sleep associated with menopause. NICE will monitor evidence on these for a future update. While not all the CBT approaches used in the evidence were specifically developed for menopause-associated symptoms, the committee agreed that this kind of CBT would be more effective given that the evidence showed that: • the women with sleep problems also had vasomotor symptoms which can negatively impact sleep and • menopause-specific CBT was also beneficial for the management of vasomotor symptoms. The committee agreed that the evidence had some limitations, including uncertainties around: • outcomes, with different results being obtained for different outcome measurement scales and subgroups • how large the effect of CBT was, even when it was shown to be effective. The committee also had concerns around study design and biases around how studies were carried out. As a result, they recommended CBT as an option rather than as routine management for sleep problems associated with menopause. How the recommendation might affect practice These recommendations could lead to a change to clinical practice. Although increased use of CBT could have a resource impact and add pressure to already limited services, especially in the short term, it also provides more management choices, including the option to have both CBT and other treatments (including HRT). This may lead to better outcomes.",
    "This may lead to better outcomes. There are currently long waiting lists for CBT and people who are already trained in this type of therapy may need further training before they can provide menopause-specific Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). CBT. However, the use of online or group CBT may make it easier and less costly to adapt as menopause-specific CBT. The committee was aware of existing resources that can be used to train people in providing menopause-specific CBT (including adapting online CBT). They agreed that this would facilitate implementation. Return to recommendation Taking medical history of coronary heart disease or stroke into account before offering treatment Recommendation 1.5.29 Why the committee made the recommendation For people with a history of coronary heart disease or stroke, the committee agreed that different risk factors mean that people have different baseline levels of risk. They concluded that decisions on HRT use for menopause-associated symptoms would need to be tailored to the person and their particular risk factors and risk levels and that, therefore, these decisions should be made with a healthcare professional with expertise in menopause. How the recommendation might affect practice It is current practice that people with pre-existing conditions get expert advice on HRT as a treatment option for menopause-associated symptoms.",
    "How the recommendation might affect practice It is current practice that people with pre-existing conditions get expert advice on HRT as a treatment option for menopause-associated symptoms. However, there is variation in which expert would be consulted on this. This recommendation will standardise practice. Return to recommendation Managing menopause-associated symptoms in people who have taken gender-affirming hormone therapy in the past Recommendations 1.5.34 and 1.5.35 Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Why the committee made the recommendations The committee noted a lack of evidence on HRT use in trans men and non-binary people registered female at birth who have taken gender-affirming hormone therapy in the past. This uncertainty means that, for example, it is not known whether past hormone treatment could influence the choice of HRT, or whether giving HRT to someone who previously had hormone therapy would alter their health risks. For this reason, the committee agreed that trans men and non-binary people registered female at birth who have taken gender- affirming hormone therapy in the past should be able to discuss their menopause- associated symptoms with a healthcare professional with expertise in menopause. They can then make a shared decision about any potential treatment the person may wish to have.",
    "They can then make a shared decision about any potential treatment the person may wish to have. Because of the lack of evidence, the committee also made a recommendation for research on the impact of HRT on health outcomes for trans men and non-binary people registered female at birth, which covers people who have never taken gender-affirming hormone therapy, or who have taken it in the past but are not currently taking it. The committee discussed the evidence related to CBT. This did not include evidence related to trans men or non-binary people registered female at birth. However, the committee agreed that the use of CBT for menopause symptoms would be suitable for any person, regardless of whether they have taken gender-affirming hormone therapy in the past. The committee decided to make a specific recommendation for trans men and non-binary people registered female at birth who have taken gender-affirming hormone therapy in the past to promote equality in access to CBT services for managing menopause-associated symptoms within these groups, acknowledging their unique experiences and needs. Because, without further evidence, other recommendations in this guideline cannot be extended to these groups, the committee agreed that a separate recommendation would highlight CBT as a management option for these groups.",
    "How the recommendations might affect practice In the committee's experience, there is no clear current practice related to the treatment of menopause-associated symptoms in people who have taken gender-affirming hormone therapy in the past. The committee agreed that access to both advice from a healthcare professional with expertise in menopause and to CBT were a matter of equality and inclusivity. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). The recommendations may increase the number of referrals both to healthcare professionals with expertise in menopause, and for CBT. The committee noted that there is pressure on services providing CBT. However, the recommendations should also lead to more appropriate care and improved outcomes for people who have had gender-affirming hormone therapy in the past. Return to recommendations Effect of HRT on life expectancy in people aged 45 and over Recommendation 1.6.1 Why the committee made the recommendation The committee discussed the evidence on the impact of HRT on all-cause mortality (life expectancy). The multitude of confounding factors that may affect life expectancy meant that evidence had to be restricted to randomised controlled trials (RCTs). This is because, in RCTs, participants are randomly assigned to different treatment groups, which helps control known and unknown confounders.",
    "This is because, in RCTs, participants are randomly assigned to different treatment groups, which helps control known and unknown confounders. The committee noted that high-quality evidence showed no difference in mortality with either oestrogen-only or combined HRT compared with not taking HRT. They agreed that this was an important finding and therefore emphasised the need to tell people thinking about either treatment option that taking combined or oestrogen-only HRT is unlikely to affect life expectancy. The committee looked at the analysis for groups of women starting HRT at different ages. They noted that, for most age groups, there was no difference in mortality between those who are taking or have taken HRT compared with placebo. There was also no significant variation in this difference depending on the age of starting HRT. A decrease in all-cause mortality was reported for 1 isolated subgroup (women starting oestrogen-only HRT aged between 50 and 59). In isolation, this was a statistically significant figure. But in a wider context, it cannot be interpreted as good evidence of a different effect in this group. This is because: Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "This is because: Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • there was no identifiable pattern of change in risk as people aged and • the statistical analysis showed that any differences observed between age groups could be down to random chance and therefore did not represent a real difference between age groups. As a result, the committee did not refer to this decrease in all-cause mortality in the recommendation. How the recommendation might affect practice It is current practice to discuss benefits and risks with people when treatment options are being considered. The effect of treatment on life expectancy is an important part of these discussions and was not covered in the previous version of this guideline. The recommendations will standardise the information that will be given. But it is unclear how this will change the treatment choices made and how this will impact on practice. Return to recommendation Effect of combined HRT on specific health outcomes in people aged 45 or over Recommendation 1.6.2 and table 1 What this rationale covers The committee highlighted the importance of presenting people with a complete picture of benefits and risks associated with HRT to enable shared and informed decision making.",
    "This rationale briefly describes the available evidence on combined HRT and how it affects risks related to: • cancer: breast • cancer: endometrial • cancer: ovarian • coronary heart disease Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • stroke • dementia. It also covers other considerations related to cardiovascular disease, and the need for further research in this area. There was no evidence available for trans men and non-binary people registered female at birth. The committee agreed that their conclusion from the available evidence could be extended to those who have never taken gender-affirming hormone therapy. But they did not think it could be extended to those who have taken this type of therapy in the past, because it is not known whether such therapy would alter the benefits and risks of any treatment (especially hormonal treatments), or which treatment option might be best for the person. So, they made a recommendation for research on the impact of HRT on health outcomes for these groups. Combined and oestrogen-only HRT are prescribed to different groups of people, and so the committee looked separately at the benefits and risks associated with the 2 types of HRT.",
    "Combined and oestrogen-only HRT are prescribed to different groups of people, and so the committee looked separately at the benefits and risks associated with the 2 types of HRT. Why the committee made this recommendation Cancer: breast In line with other NICE guidance, the committee agreed that advice needs to be tailored to the person according to their individual risk factors, such as having a family history of breast cancer, living with overweight, or drinking alcohol. The committee acknowledged that people also need to be made aware that these factors will affect absolute risks of breast cancer both when not taking and when taking HRT. The committee discussed evidence on the effect of taking HRT on breast cancer incidence and breast cancer-related mortality. For: • breast cancer incidence, the evidence came from randomised controlled trials (RCTs) and a meta-analysis of individual patient data from observational studies • breast cancer-related mortality, the evidence came from one RCT and an observational study. Overall, it showed the risk of breast cancer incidence was consistently greater with combined HRT than with oestrogen-only HRT. The committee therefore looked in more Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). detail at how combined HRT or oestrogen-only HRT each might affect the risk of breast cancer.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). detail at how combined HRT or oestrogen-only HRT each might affect the risk of breast cancer. RCT evidence Evidence from RCTs showed an increased risk of breast cancer incidence for women who are taking or have taken combined HRT compared with women taking placebo. The group included in the trial took combined HRT for approximately 6 years and was followed up for breast cancer for about 7 years after the trial ended. The evidence showed that, with combined HRT, breast cancer risk was increased regardless of ethnicity or whether there was a family history of breast cancer. Observational study evidence Evidence from observational studies was consistent with evidence from the RCTs but provided further information on the duration and recency of use. It showed that, for women who were taking combined HRT, the risk of breast cancer incidence: • was higher than in those who did not take HRT • started increasing in the first year of use • increased with duration of use. For women who had taken combined HRT in the past, it showed that the risk of breast cancer incidence: • remained higher than for women who did not take HRT • was greater the longer women had used combined HRT • reduced after stopping HRT but was still increased for as long as at least 10 years after stopping use.",
    "The evidence showed that breast cancer risk with sequential combined HRT is lower than with continuous combined HRT but is higher than without HRT. The committee therefore decided that this should be discussed as part of shared decision making so that people can make an informed choice. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). All types of progestogen were associated with an increased risk of breast cancer incidence, although there was limited evidence on the risk of breast cancer incidence with micronised progesterone or dydrogesterone. Overall, there was insufficient evidence to say whether micronised progesterone or dydrogesterone may lead to a different risk of breast cancer incidence and therefore the committee made a recommendation for research on whether different types of progestogen in HRT alter breast cancer risk. It was unclear from the evidence whether, for people who take HRT, the risk of breast cancer changes with the mode of administration. The committee therefore made a recommendation for research on modes of administration for systemic HRT. Mortality related to breast cancer Both RCT and observational evidence showed that mortality from breast cancer was slightly higher in women who have taken combined HRT than in those who have not taken HRT.",
    "The committee agreed that a difference in breast cancer mortality would be consistent with an increase in breast cancer incidence and agreed that this should be explained to people. However, they also emphasised that the difference in risk: • is very small between those who have taken HRT and those who have not and • should be thought about within the wider context, in that there is no overall change in life expectancy with HRT. Return to recommendation Cancer: endometrial The committee discussed evidence from RCTs and observational studies. Some of the RCT evidence showed that using continuous combined HRT decreased the risk of endometrial cancer for women taking combined HRT, compared with women not taking HRT. For women currently taking continuous combined HRT, with any duration of use, some observational studies showed a reduced risk of endometrial cancer while others showed that there was no difference in risk of endometrial cancer compared with women not taking HRT. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). The committee discussed the well-established association between oestrogen-only HRT and the risk of endometrial cancer.",
    "Subject to Notice of rights ([URL] conditions#notice-of-rights). The committee discussed the well-established association between oestrogen-only HRT and the risk of endometrial cancer. They agreed it was important to explain to people with a uterus that: • this is why they would be offered combined HRT as per recommendation 1.8.1 in the section on starting HRT but • although oestrogen has an adverse effect on the endometrium when used on its own, progestogens counteract this in a dose-dependent manner. They concluded that continuous combined HRT, where progestogen is taken every day with oestrogen, decreases the risk of endometrial cancer. Evidence from another observational study showed that sequential combined HRT, when used for 10 years or more, increases the risk of endometrial cancer, but not when it is used for less than 10 years. Based on their own knowledge and experience, the committee agreed that the risk is likely to increase slowly over time. They agreed that, with sequential combined HRT, the protective effect of progestogen increases with the number of days on which progestogen is taken every month. Because the way sequential HRT is taken may vary in duration of use, days of progestogen per cycle, and oestrogen dose, the committee decided to highlight how different sequential HRT regimens and duration of use affect the risk of endometrial cancer.",
    "However, they recognised that, overall, this corresponded to a very slight increase in the absolute risk of endometrial cancer. Return to recommendation Cancer: ovarian The committee discussed the evidence from RCTs as well as from observational studies. Overall, evidence from an RCT suggests that the risk of ovarian cancer may increase in people taking combined HRT compared with people not taking HRT. The committee noted that the number of people diagnosed with ovarian cancer was very small in both groups and this made the evidence less robust. The observational evidence showed that the risk of ovarian cancer increased with HRT use. The committee noted that both the number of participants and the number of Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). diagnosed cases of ovarian cancer were far larger in the observational evidence than in the RCT, which made the findings more robust. However, the committee agreed that, although the risk was increased overall, the risk was small in absolute terms, especially with the low baseline risk of ovarian cancer. Overall, there was an increase in ovarian cancer incidence by 1 in 1,000. The committee agreed that all of this should be explained when HRT is being considered. Return to recommendation Coronary heart disease The committee based their recommendations on evidence from RCTs and observational studies.",
    "Return to recommendation Coronary heart disease The committee based their recommendations on evidence from RCTs and observational studies. The majority of the RCT and observational evidence both showed that the risk of coronary heart disease did not increase when taking HRT. The committee agreed this information should be shared with people to allow them to make an informed decision. The committee also discussed the evidence on the possible impact of 2 factors: • the length of time between menopause and first use of HRT • duration of HRT use. They looked at coronary heart disease risk for different subgroups, and at the statistical significance of any differences observed between these subgroups. As a result, they agreed they could not make any recommendations about the impact of either of these factors on coronary heart disease risk in people taking HRT. This is because there were: • no statistically significant subgroup differences in the RCT evidence and • inconsistent results between different observational studies. Findings from the RCT evidence did not all lead to the same conclusions. For coronary heart disease and cardiac event composite scores, most RCT evidence showed no difference between combined HRT and placebo. This was shown for both continuous and sequential HRT. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). However, some isolated results were not in line with this overall trend, but for most of them: • the isolated results were not statistically significant or • the difference between the group in which these results were obtained and other subgroups was not statistically significant. See evidence review C: cardiovascular disease and stroke for further discussion of this. Mortality related to coronary heart disease The committee looked at RCT and observational study evidence which showed that, for women with no history of coronary heart disease, there was no increase in mortality from cardiovascular disease from taking HRT. They agreed that it was important for people to know this so they could make an informed choice. Return to recommendation Stroke The committee based their recommendations on RCTs and observational studies. Evidence showed a significant difference in risk depending on the mode of administration. The use of combined HRT does not increase the risk of stroke when the oestrogen component is taken transdermally, but it does increase the risk if it is taken orally. These findings were supported by observational evidence. The committee decided that it was important to share this information so that it could be taken into consideration.",
    "These findings were supported by observational evidence. The committee decided that it was important to share this information so that it could be taken into consideration. However, national statistics show that the baseline risk for stroke in women aged under 60 is very low. The committee agreed that this should be explained to anyone thinking about HRT because the risk may remain small despite any change in risk reported in the RCT and observational study findings. RCT evidence The RCTs showed that, overall, there is an increased risk of stroke in women currently taking combined HRT with oral oestrogen. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Evidence on duration of use showed that risk of stroke: • did not increase when combined HRT was used for up to 4 years but • increased when combined HRT was taken for 5 to 9 years. Evidence related to age at starting combined HRT containing oral oestrogen also showed a greater risk of stroke in women currently taking HRT. This risk increased with age at starting HRT (that is, the older people were when they started taking HRT). This was when HRT was taken for 5 to 9 years. Evidence also showed significant differences in the risk of stroke depending on ethnicity.",
    "This was when HRT was taken for 5 to 9 years. Evidence also showed significant differences in the risk of stroke depending on ethnicity. Among those taking combined HRT, the risk of stroke was greater in women of Black ethnicity compared with people from other backgrounds, though numbers of people affected by stroke in all ethnic minority groups were small. Because of the small size of the population taking part in the trials, the evidence was not very robust, so the committee reflected this uncertainty by explaining that the risk 'may' be greater for Black people. The committee agreed that all of this should be explained to people from ethnic minority backgrounds to help them reach a decision. Observational evidence Observational evidence on oral oestrogen doses as part of combined HRT, when compared with not taking HRT, showed: • an increased risk of stroke in women taking continuous combined HRT when the oestrogen dose was high and • no difference in risk when the oestrogen dose was lower. Return to recommendation Impact of timing of HRT for menopause symptoms on risk of coronary heart disease There was not a lot of data to check whether the following factors impact on risk of coronary heart disease: • the age of the person when they start HRT and Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • the time between a person's menopause and when they start HRT.",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • the time between a person's menopause and when they start HRT. This resulted in what is called 'lack of statistical power'. In other words, the lack of data means that statistical test could show a difference where there is none. In what little data was available, the risk did not have a clear tendency to decrease or increase with either of the above 2 factors (that is, with the age of the person when they start HRT or the time between a person's menopause and when they start HRT). As a result, the committee decided to make a recommendation for research on the impact of timing of HRT on risk of coronary heart disease. Impact of the type of progestogen in combined HRT on cardiovascular disease risk There was insufficient evidence to conclude whether, as part of HRT, different progestogens had different impact on risk of cardiovascular disease. The committee made a key recommendation for research on different types of progestogen. Impact of mode of administration of combined HRT on coronary heart disease There was insufficient evidence on whether 1 mode of administration of combined HRT differed to another in its impact on risk of coronary heart disease. The committee therefore made a key recommendation for research on different modes of administration.",
    "The committee therefore made a key recommendation for research on different modes of administration. Risk of cardiovascular disease with HRT in people from ethnic minority backgrounds The committee noted that there was little evidence on how HRT affects people from ethnic minority backgrounds in terms of cardiovascular health and stroke (as well as all other health outcomes), so they made a recommendation for research on the impact of HRT on health outcomes for these groups of people. Other considerations relating to cardiovascular disease The committee were aware of systematic reviews by Boardman et al. (2015), Kim et al. (2020) and Salpeter et al. (2006) – see the list of excluded studies in evidence review C: cardiovascular disease and stroke. These 3 systematic reviews did not meet the inclusion Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). criteria of NICE's 2024 evidence review because: • they combined data for participants who received combined HRT and oestrogen-only HRT (Boardman et al. 2015) or • some individual studies included within a review did not match NICE's 2024 criteria and therefore the entire systematic review could not be included (Kim et al. 2020 and Salpeter et al. 2006). The studies included in these systematic reviews were checked and any that matched the relevant criteria were included in NICE's 2024 evidence review.",
    "2020 and Salpeter et al. 2006). The studies included in these systematic reviews were checked and any that matched the relevant criteria were included in NICE's 2024 evidence review. However, the committee did comment on whether the conclusions made in NICE's 2024 evidence review aligned with the findings of these 3 systematic reviews. Although there were differences observed in certain areas, none of them challenged the overall conclusion that HRT does not increase coronary heart disease risk. Dementia The committee noted that there was relatively little evidence on dementia compared with other health outcomes, with only 7 studies identified. They acknowledged that most of the evidence was from observational studies and so they very carefully looked at how various confounders had been adjusted for. The committee agreed that some of the evidence did not make the necessary adjustments for confounding factors, such as socioeconomic status, or did not reliably ascertain incidence of dementia. To guide their discussions and support the recommendations, the committee agreed to focus on 2 observational studies, 1 from the UK and the other from Denmark (which both made the most appropriate adjustments for confounders). They also focused on the Women's Health Initiative Memory Study (WHIMS) of women starting HRT over the age of 65, which is based on data from an RCT from the Women's Health Initiative (WHI).",
    "They also focused on the Women's Health Initiative Memory Study (WHIMS) of women starting HRT over the age of 65, which is based on data from an RCT from the Women's Health Initiative (WHI). The committee agreed that the evidence from the 2 observational studies was inconsistent: • One study showed no difference in risk of dementia between combined HRT use and no HRT, with different durations of use. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • The other study showed an increase in incidence of dementia with combined HRT use when compared with no HRT, and the risk increased with duration of use. The committee agreed that, although both studies adjusted for many relevant confounders, neither adjusted for all. They concluded that the evidence might be at risk of bias from confounding. They noted that the evidence was for all types of dementia. The risk for some types of dementia may be different to others, and the proportion of each type identified at follow- up may differ for each study. The committee thought this may explain some of the differences in risk. Evidence from the WHIMS study on combined HRT compared with placebo was inconsistent with the observational evidence from the UK, but in line with that from Denmark (showing an increased risk in dementia in the HRT group).",
    "They also noted that the population was different from a typical group of people taking HRT, in that they first started taking HRT at age 65 or over. The committee were not unanimous in their interpretation of the evidence and how to formulate a recommendation best reflecting the evidence base. Some members of the committee had concerns about highlighting a risk of dementia when evidence from a UK setting showed no difference in risk. However, the committee reached a majority decision. Taking all evidence into account, they decided the evidence pointed towards a possible increased risk in dementia incidence if HRT is started at a later age. They agreed it was important that people thinking about HRT for menopause-associated symptoms should be made aware of this, so that they could make an informed decision. As part of this, the committee: • chose to use the word 'might' to express uncertainty, given the differences between study results • agreed that it was important to highlight, based on the WHIMS evidence, the increase in risk that was noted when HRT was started over 65 years of age. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Recommendations for research The committee recognised that there are still uncertainties around the current evidence base and that further research is needed.",
    "Recommendations for research The committee recognised that there are still uncertainties around the current evidence base and that further research is needed. They noted that the previous version of the guideline included a recommendation for research related to dementia and decided to keep this. The evidence was unclear about the impact of mode of administration on risk of dementia. The committee therefore prioritised a recommendation for research on mode of administration for systemic HRT. Return to recommendation How the recommendation might affect practice It is current practice to discuss benefits and risks with people when thinking about treatment options. The recommendation will standardise and update the information that will be shared. While the 2024 version of this guideline includes some new or updated information to share, it is unclear how this will affect treatment choices and impact on practice. It is possible that the recommendation may increase the use of transdermal HRT, given that it was not associated with an increased risk of stroke (and, according to 2015 recommendations that were not reviewed in 2024, it is also associated with a lower risk of venous thromboembolism than oral preparations).",
    "Return to recommendation Effect of oestrogen-only HRT on specific health outcomes in people aged 45 or over Recommendation 1.6.3 and table 2 What this rationale covers The committee agreed that people should be presented with a complete picture of benefits and risks associated with HRT to enable shared, and informed, decision making. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). This rationale briefly describes the available evidence on oestrogen-only HRT and how it affects risks related to: • cancer: breast • cancer: endometrial • cancer: ovarian • coronary heart disease • stroke • dementia. It also covers other considerations related to cardiovascular disease, and the need for further research in this area. There was no evidence available for trans men and non-binary people registered female at birth. The committee agreed that their conclusion from the available evidence could be extended to those who have never taken gender-affirming hormone therapy. But they did not think it could be extended to those who have taken this type of therapy in the past, because it is not known whether such therapy would alter the benefits and risks of any management option (especially hormonal treatments), or which management option might be best for the person. So, they made a recommendation for research on the impact of HRT on health outcomes for these groups.",
    "So, they made a recommendation for research on the impact of HRT on health outcomes for these groups. Combined and oestrogen-only HRT are prescribed to different groups of people, as per recommendation 1.8.1, and so the committee looked separately at the benefits and risks associated with the 2 types of HRT. Why the committee made this recommendation Cancer: breast In line with other NICE guidance, the committee agreed that advice needs to be tailored to the person according to their individual risk factors, such as having a family history of breast cancer, living with overweight, or drinking alcohol. The committee acknowledged that people also need to be made aware that these factors will affect absolute risks of breast cancer both when not taking and when taking HRT. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). The committee discussed evidence on the effect of taking HRT on breast cancer incidence and breast cancer-related mortality. For: • breast cancer incidence, the evidence came from randomised controlled trials (RCTs) and a meta-analysis of individual patient data from observational studies • breast cancer-related mortality, the evidence came from one RCT and an observational study. Overall, it showed the risk of breast cancer incidence was consistently greater with combined HRT than with oestrogen-only HRT.",
    "Overall, it showed the risk of breast cancer incidence was consistently greater with combined HRT than with oestrogen-only HRT. Only women, trans men and non-binary people who have had a hysterectomy are eligible to take oestrogen-only HRT, so most people taking HRT will take combined HRT. The committee discussed the evidence from the analysis of different durations of use of oestrogen-only HRT versus no HRT or versus placebo. RCT evidence RCT evidence showed a reduced risk in the incidence of breast cancer for women who are taking, or have taken, oestrogen-only HRT compared with women taking placebo. Women taking oestrogen-only HRT as part of the trial took it for approximately 6 years and were followed up for breast cancer for 7 years after the trial ended. The evidence showed the risk was reduced regardless of ethnicity. There was insufficient data to detect whether having or not having a family history of breast cancer lead to a different level of breast cancer risk with oestrogen-only HRT. Observational study evidence Evidence from observational studies was not consistent with the RCT evidence but provided further information on the duration and recency of use. It showed that for women currently taking oestrogen-only HRT, the risk of breast cancer incidence: • was higher in those who had been taking HRT for at least 1 year and • increased with duration of use.",
    "For women who had taken oestrogen-only HRT in the past, it showed the risk of breast Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). cancer incidence: • was not quite as high as in those currently taking it • was greater the longer they had taken HRT • remained higher than for women who had never taken HRT for up to at least 10 years after stopping use. Interpretation of the evidence on breast cancer incidence with oestrogen-only HRT The committee decided that the difference between RCT results and evidence from observational studies meant that it was not possible to be certain of the conclusions. They also agreed this should be highlighted in the wording of the recommendation, by explaining that there was little or no increase in the risk of breast cancer incidence. The committee also looked at evidence that compared different types of oestrogens and different modes of administration. The evidence did not show any differences in risk of incidence of breast cancer for different types of oestrogen. There was some uncertainty in relation to mode of administration. The committee therefore made a recommendation for research on mode of administration for systemic HRT. Mortality from breast cancer Evidence from an RCT showed that there was a reduction in the risk of mortality from breast cancer in those using oestrogen-only HRT compared with placebo.",
    "Mortality from breast cancer Evidence from an RCT showed that there was a reduction in the risk of mortality from breast cancer in those using oestrogen-only HRT compared with placebo. The observational data was not in line with the RCT data, as it showed there was an increased risk of mortality from breast cancer in oestrogen-only HRT users. The committee agreed that, although the RCT evidence showed a reduced risk, there was also evidence showing an increased risk. Therefore, it was important to highlight in the recommendations that there is a possibility of a small increase in the risk of breast cancer mortality. Return to recommendation Cancer: endometrial The committee discussed the evidence from RCTs and observational studies. The evidence from RCTs was unclear because there were only 2 studies with no, or few, cases of endometrial cancer. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). The committee also discussed the evidence from observational studies on oestrogen-only HRT versus no HRT in women with a uterus. It showed that the risk of endometrial cancer is increased in those: • currently taking oestrogen-only HRT and • who have been taking HRT for over 10 years (and are still taking it) or have taken oestrogen-only HRT in the past for over 10 years. This increase in risk was present regardless of whether the treatment was oral or transdermal.",
    "This increase in risk was present regardless of whether the treatment was oral or transdermal. The committee discussed the well-established association between oestrogen-only HRT and the risk of endometrial cancer. They agreed it was important to explain to people with a uterus that this is why they would be offered combined HRT as per recommendation 1.8.1 in the section on starting HRT. Return to recommendation Cancer: ovarian The committee discussed the evidence from observational studies. No evidence from RCTs was identified. Overall, with oestrogen-only HRT, the evidence showed that the risk of ovarian cancer: • was higher in those who had been taking HRT for at least 5 years • increased with duration of HRT use. However, the committee agreed that risk remained small in absolute terms, because the baseline risk of ovarian cancer is low. The risk increased by 1 in 1,000 women for oestrogen-only HRT, when currently taking it, having started at the age of 50. The committee agreed that all of this should be explained when HRT is being considered. Return to recommendation Coronary heart disease The committee based their recommendations on RCTs and observational studies. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). The majority of the RCT and observational evidence both showed the risk of coronary heart disease did not increase when taking HRT.",
    "Subject to Notice of rights ([URL] conditions#notice-of-rights). The majority of the RCT and observational evidence both showed the risk of coronary heart disease did not increase when taking HRT. The committee agreed this information should be shared with people to allow them to make an informed decision. The committee also discussed the evidence on the possible impact of 2 factors: • the length of time between menopause and the first use of HRT • the person's age at first HRT use. They looked at coronary heart disease risk for different subgroups, and at the statistical significance of any differences observed between these subgroups. As a result, they agreed they could not make any recommendations about the impact of either of these factors on coronary heart disease risk in people taking HRT. This is because there were: • no statistically significant subgroup differences in the RCT evidence • inconsistent results between different observational studies and • inconsistency between the conclusions of the RCT evidence and observational studies. RCT evidence When looking at women of all ages at first HRT use together as 1 group, the evidence showed no difference in risk of coronary heart disease between women who had been taking oestrogen-only HRT for 5 to 9 years and were still taking it, and women who were not taking HRT and had never taken it.",
    "Subgroup analysis that looked at whether coronary heart disease risk was affected differently (if at all) for people of different ages at first HRT use, showed: • an isolated reduced risk in 1 subgroup (when people were 50 to 59 at first HRT use) but • no difference in risk for any of the other subgroups. In addition, statistical testing showed that the difference between people aged 50 to 59 at first HRT use and other subgroups was not significant and so should not be included in information shared with people considering HRT. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Observational study evidence The committee looked at observational evidence on whether the length of time between a person's menopause and the moment they start HRT affects their risk of coronary heart disease. For women currently taking oestrogen-only HRT, who had been taking it for an unknown duration, the 2 observational studies reported different conclusions on this: • One study showed a reduced risk of coronary heart disease when HRT was started within 4 years of menopause, while the other study showed no difference in risk when HRT was started between the ages of 45 to 54 (which is likely to be within 4 years of menopause).",
    "• One study showed no difference when HRT was started more than 10 years after menopause, while the other study showed a reduction in risk when HRT was started between the ages of 65 and 74 (which is likely to be 10 years or more after menopause). The committee recognised that some observational studies may have been influenced by residual confounding factors such as socioeconomic status, smoking, medical history or other factors which may be related to HRT use and cardiovascular risk. Differences in direction of effect across study types When looking at the effect of age at first use of HRT on the risk of coronary heart disease, there was also some variation in results across different study types, for example: • the RCT evidence showed no difference in risk when HRT was started between the ages of 60 and 69 • an observational study showed a reduction in risk when HRT was started between the ages of 65 and 74. The age groups overlap between the RCT and observational study, but the results for these overlapping age groups are contradictory, making it difficult to reach a conclusion with regards to age trends. Mortality related to coronary heart disease The RCT and observational study evidence both showed that, for women with no history of coronary heart disease, there was no increase in mortality from cardiovascular disease Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). from taking HRT. The committee agreed that it was important for people to know this so they could make an informed choice. Return to recommendation Stroke The committee based their recommendations on RCTs and observational studies. The RCTs showed that, overall, there is an increased risk of stroke in women currently taking oral oestrogen-only HRT. These findings were supported by observational evidence. National statistics also show that the baseline risk for stroke in women aged under 60 is very low. The committee agreed that this should be explained to anyone thinking about HRT because the risk may remain small despite any change in risk reported in the RCT and observational study findings. Observational evidence showed that transdermal oestradiol did not increase the risk of stroke whereas oral oestradiol did. The committee noted that this was consistent with the pattern in combined HRT. They agreed that this should be explained so that people can factor this into their decision making. The observational evidence showed an increased risk of stroke when oestrogen-only HRT was given at a high dose while, at low and medium doses, there was no increase in risk for oestrogen-only HRT compared with no HRT. Risk was also increased in women currently taking oestrogen-only HRT who had been taking it for 5 to 9 years when they had been aged 60 years or over at first HRT use.",
    "Risk was also increased in women currently taking oestrogen-only HRT who had been taking it for 5 to 9 years when they had been aged 60 years or over at first HRT use. The committee decided that both these points should be covered when making shared decisions on treatment. Return to recommendation Impact of timing of HRT for menopause symptoms on risk of coronary heart disease There was not a lot of data to check whether the following factors impact on risk of coronary heart disease: • the age of the person when they start HRT and Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). • the time between a person's menopause and when they start HRT. This resulted in what is called 'lack of statistical power'. In other words, the small amount of data means that statistical test could show a difference where there is none. In what little data was available, the risk did not have a clear tendency to decrease or increase with either of the above 2 factors (that is, with the age of the person when they start HRT or the time between a person's menopause and when they start HRT). As a result, the committee decided to make a recommendation for research on the impact of timing of HRT on risk of coronary heart disease.",
    "As a result, the committee decided to make a recommendation for research on the impact of timing of HRT on risk of coronary heart disease. Impact of mode of administration of oestrogen-only HRT on coronary heart disease There was no evidence on whether 1 mode of administration of oestrogen-only HRT differed to another in its impact on risk of coronary heart disease. The committee therefore prioritised a recommendation for research on the mode of administration for systemic HRT. Risk of cardiovascular disease with HRT in people from ethnic minority backgrounds The committee noted that there was little evidence for people from ethnic minority backgrounds for cardiovascular health and stroke (as well as all other health outcomes), so they made a recommendation for research on the impact of HRT on health outcomes for these groups of people. Other considerations relating to cardiovascular disease The committee were aware of systematic reviews by Boardman et al. (2015), Kim et al. (2020) and Salpeter et al. (2006) – see the list of excluded studies in evidence review C: cardiovascular disease and stroke. These 3 systematic reviews did not meet the inclusion criteria of NICE's 2024 evidence review because: • they combined data for participants who received combined HRT and oestrogen-only HRT (Boardman et al. 2015) or • some individual studies included within a review did not match NICE's 2024 criteria Menopause: identification and management (NG23) © NICE 2025. All rights reserved.",
    "2015) or • some individual studies included within a review did not match NICE's 2024 criteria Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). and therefore the entire systematic review could not be included (Kim et al. 2020 and Salpeter et al. 2006). The studies included in these systematic reviews were checked and any relevant ones were then included in NICE's 2024 evidence review if they matched its criteria. However, the committee did comment on whether the conclusions made in NICE's 2024 evidence review aligned with the findings of these 3 systematic reviews. Although there were differences observed in certain areas, none of them challenged the overall conclusion that HRT does not increase coronary heart disease risk. Dementia The committee noted that there was relatively little evidence on dementia compared with other health outcomes, with only 7 studies identified. They acknowledged that most of the evidence was from observational studies and so they very carefully looked at how various confounders had been adjusted for. The committee agreed that some of the evidence did not make the necessary adjustments for confounding factors, such as socioeconomic status, or did not reliably ascertain incidence of dementia.",
    "The committee agreed that some of the evidence did not make the necessary adjustments for confounding factors, such as socioeconomic status, or did not reliably ascertain incidence of dementia. To guide their discussions and support the recommendations, the committee agreed to focus on 2 observational studies, 1 from the UK and 1 from Denmark (which both made the most appropriate adjustments for confounders). They also focused on the Women's Health Initiative Memory Study (WHIMS) of women starting HRT over the age of 65, which is based on data from a randomised controlled trial (RCT) from the Women's Health Initiative (WHI). The observational evidence showed no significant differences in dementia risk when comparing oestrogen-only HRT with no HRT use. The evidence from the WHIMS study also showed no significant differences in incidence of dementia, between those who are taking or have taken oestrogen-only HRT and those taking placebo. The committee discussed some of the limitations in the WHIMS study, such as the low incidence of dementia in the placebo arm, which was lower than the incidence of dementia in the UK. They also noted that the population was different from a typical group of people taking HRT, in that they first started taking HRT at the age of 65 or over. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights).",
    "Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Recommendations for research The committee recognised that there are still uncertainties around the current evidence base and that further research is needed. They noted that the previous version of the guideline included a recommendation for research related to dementia and decided to keep this. The evidence was unclear about the impact of mode of administration on risk of dementia. The committee therefore prioritised a recommendation for research on mode of administration for systemic HRT. Return to recommendation How the recommendation might affect practice It is current practice to discuss benefits and risks with people when considering treatment options. The recommendation will standardise the information that will be shared. While the 2024 version of this guideline includes some new or updated information to share, it is unclear how this will change the treatment choices made and how this will impact on practice. It is possible that the recommendation may increase the use of transdermal HRT since it was not associated with an increased risk of stroke (and, according to 2015 recommendations that were not reviewed in 2024, it is also associated with a lower risk of venous thromboembolism than oral preparations).",
    "Return to recommendation Cardiovascular disease prevention Recommendation 1.6.4 Why the committee made the recommendation Given the findings about the effect of HRT on coronary heart disease and stroke (as covered in the rationales on the effect of combined and of oestrogen-only HRT) the committee agreed that the evidence did not support the use of combined or oestrogen- only HRT for primary or secondary prevention of cardiovascular disease. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). How the recommendation might affect practice It is unclear whether it is current practice to use HRT for the specific purpose of primary or secondary coronary heart disease prevention. So, the recommendation is likely to standardise practice. Return to recommendation Dementia prevention Recommendation 1.6.5 Why the committee made the recommendation The committee noted the scope of this guideline and agreed that the indication for HRT prescriptions in the UK was menopause symptoms. Therefore, the aim of the included studies was not dementia prevention. They agreed it was important to highlight that the evidence did not support this indication. How the recommendation might affect practice It is unclear whether it is current practice to use HRT for the specific purpose of dementia prevention. So, the recommendation is likely to standardise practice.",
    "So, the recommendation is likely to standardise practice. Return to recommendation Effects of HRT use in early menopause on specific health outcomes Recommendation 1.6.6 Why the committee made the recommendation No evidence was identified on the benefits and risks of either taking or not taking HRT relating to osteoporosis, risk of fractures or cardiovascular outcomes, or endometrial or ovarian cancer in people experiencing early menopause (people aged 40 to 44). Some Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). evidence was identified on the effect of taking or not taking HRT on breast cancer risk in this age group. The committee did not look at evidence on whether early menopause itself may have an impact on health outcomes, and how to manage any impact it might have. Therefore, they could not make any recommendations on the benefits and risks of HRT to manage any differences in risk that may result from early menopause. The committee agreed it was important to take a person's age at the onset of menopause- associated symptoms into account during discussions about HRT (in line with the section on discussing management options). They agreed that the age cut-offs defining premature ovarian insufficiency (POI), early menopause and typical menopause were a little arbitrary.",
    "They agreed that the age cut-offs defining premature ovarian insufficiency (POI), early menopause and typical menopause were a little arbitrary. They also agreed it is clinically plausible that the benefits and risks evolve gradually from what they are for people with premature ovarian insufficiency to what they are for people aged 45 or over. As a result, it is likely that, for people with early menopause, the benefits and risks of either taking or not taking HRT lie somewhere between those for people with premature ovarian insufficiency and those for people aged 45 or over, for whom there is more evidence about these benefits and risks. The committee discussed the similarities between early menopause and POI. Although there is little evidence of the impact of HRT on health outcomes in people with POI, it is current practice for this group to take HRT routinely. HRT is offered to them to lower the risk of some health outcomes, for example, osteoporosis. The situation may be similar for early menopause, for which routine HRT is also current practice. Evidence showed that, as for people aged 45 or over, the risk of breast cancer in early menopause is increased when taking HRT compared with not taking HRT. However, the committee agreed that taking HRT in early menopause may affect the risk of different health outcome in different ways (that is, it may decrease some risks and increase others), as it does for people with POI and for people experiencing menopause at 45 or over.",
    "As a result, the lack of evidence on outcomes other than breast cancer meant that it was not possible to make recommendations about the overall balance of benefits and risks of taking or not taking HRT in early menopause. The committee agreed that it was important to highlight this lack of evidence and made a key recommendation for research on the impact of HRT in early menopause on specific health outcomes to address it. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). How the recommendation might affect practice While the recommendation may help people make decisions about treatment, it is unclear how it will change these decisions and how that will impact overall resource use. It would however be unethical to prevent such information being discussed with people experiencing early menopause even if it did lead to an increase in resource use. Return to recommendation Starting and stopping HRT for anyone Recommendations 1.8.1 to 1.8.3 and 1.8.7 Why the committee made the recommendations Starting HRT When a person decides they want to take HRT for menopause-associated symptoms, the committee recommended, that, if the person has a uterus, they should be offered combined oestrogen and progestogen. Whereas, if the person has had a total hysterectomy, they should be offered oestrogen alone.",
    "Whereas, if the person has had a total hysterectomy, they should be offered oestrogen alone. The main reason for this is the established knowledge that oestrogen alone, if given to people with an intact uterus, can stimulate the growth of the uterine lining (endometrium). In turn, this oestrogen stimulation can lead to an increased risk of endometrial hyperplasia (overgrowth of the endometrium) and potentially, endometrial cancer. This is consistent with the evidence showing that oestrogen-only HRT increases the incidence of endometrial cancer in people with a uterus (see the section related to the effect of oestrogen-only HRT on endometrial cancer for people aged 45 and over). However, because it is now considered unsafe to give oestrogen-only HRT to people with a uterus, no further research is being carried out, and the recommendation is based on established knowledge more than on the evidence identified for this guideline. Adding progestogen to the HRT regimen helps protect the endometrium by counteracting the stimulating effects of oestrogen, and so reduces the risk of endometrial hyperplasia and cancer. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] conditions#notice-of-rights). Progestogen is given to protect the uterine lining, so it is not needed for people who have had a total hysterectomy. The committee discussed that this may be different for people with a subtotal hysterectomy.",
    "The committee discussed that this may be different for people with a subtotal hysterectomy. They decided that they could not be prescriptive about the type of HRT to be used for people who have had a subtotal hysterectomy because their condition is clinically complex, and they had not reviewed evidence about the effect of HRT on risk of endometrial cancer for this group. They acknowledged that people who were going to have, or had had, a subtotal hysterectomy would likely be under the care of a specialist (or a relevant member of the associated multidisciplinary team) who could discuss HRT options tailored to their needs. Some people have a hysterectomy for a condition that may be affected by HRT, such as endometriosis. The committee did not review evidence related to such conditions. However, they recognised that the decision about the type of HRT that best balances benefits and risks for a person who has had a hysterectomy may be affected by the condition that led to the hysterectomy. For this reason, advice from a healthcare professional with specialist knowledge of that condition may be needed. The committee noted that it is common practice to prescribe the smallest effective dosage of a treatment to help balance its benefits and risks, so they recommended this for HRT too.",
    "The committee noted that it is common practice to prescribe the smallest effective dosage of a treatment to help balance its benefits and risks, so they recommended this for HRT too. Effectiveness of HRT can vary between people, so starting with the lowest effective dosage helps find the right balance between effectively treating symptoms and managing risks from the treatment, taking into account each person's specific needs. Stopping HRT A personal history of cancer is a contraindication to systemic HRT because it has been shown that systemic HRT can lead to cancer progression or recurrence. Therefore, the committee agreed that systemic HRT should be stopped in people who are diagnosed with breast cancer because this would be off-label use and therefore there would be safety concerns. However, they agreed that this is already covered in NICE's guideline on early and locally advanced breast cancer. How the recommendations might affect practice The recommendations reflect current practice in choice of HRT prescribing for people with a uterus or for people who have had a total hysterectomy. It is common practice to seek advice from a healthcare professional with expertise in a Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). condition when the clinical situation is complex, such as identifying the most suitable type of HRT for someone whose condition may be affected by it.",
    "condition when the clinical situation is complex, such as identifying the most suitable type of HRT for someone whose condition may be affected by it. This would usually be an informal process, so it is unlikely to have a significant impact on practice. Stopping HRT if a person is diagnosed with breast cancer is also current practice. Return to recommendations Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). Implementation Through engagement with stakeholders and with the help of the guideline committee, NICE has identified areas of its guideline on menopause that (at the time of the 2024 update) may be a significant change to practice or challenging to implement. These are: • access to healthcare professionals with expertise in menopause • communicating the benefits and risks of hormone replacement therapy (HRT) • access to menopause specific cognitive behavioural therapy (CBT) • equity of services. For further information and support, see tools and resources. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). Context Since the previous version of this guideline was published, new evidence that could affect recommendations was identified through NICE's surveillance process. Full details are set out in the surveillance review decisions from 2019 and 2021.",
    "Full details are set out in the surveillance review decisions from 2019 and 2021. Menopause is the point at which menstrual cycles stop. Menopause usually happens in women, and in some non-binary and trans people, when they are aged 45 to 55, but can happen earlier, for example, because of surgery or medical treatment. The time period when symptoms first start and there are changes to the menstrual cycle is called perimenopause. Its duration varies, but it typically lasts a few years, and leads to menopause. Based on evidence, 3% to 8% of people experiencing menopause are estimated to have early menopause (perimenopause starting between 40 and 44 years), and 1% are estimated to have premature ovarian insufficiency (perimenopause starting before 40 years). Menopause can affect people in a variety of ways. Most experience some symptoms, although not everyone seeks treatment. Some people have symptoms that may significantly impact their daily life, and they need treatment, for example, hormone replacement therapy (sometimes called HRT or menopause hormone therapy). Menopause symptoms may last for a long time, with a median duration of 7 years. Common symptoms associated with menopause are vasomotor symptoms (hot flushes and night sweats) and vaginal dryness.",
    "Menopause symptoms may last for a long time, with a median duration of 7 years. Common symptoms associated with menopause are vasomotor symptoms (hot flushes and night sweats) and vaginal dryness. In 2019, the Medicines and Healthcare products Regulatory Agency (MHRA) published a drug safety update on hormone replacement therapy based on the Collaborative Group on Hormonal Factors in Breast Cancer's 2019 meta-analysis of type and timing of menopausal hormone therapy and breast cancer risk, and this guideline takes this update into account. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). Finding more information and committee details To find NICE guidance on related topics, including guidance in development, see the NICE topic page on menopause. For full details of the evidence and the guideline committee's discussions, see the evidence reviews. You can also find information about how the guideline was developed, including details of the committee. NICE has produced tools and resources to help you put this guideline into practice. For general help and advice on putting our guidelines into practice, see resources to help you put NICE guidance into practice. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights).",
    "Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). Update information November 2024: We have reviewed the evidence and made new or updated recommendations on: • cognitive behavioural therapy to manage symptoms associated with the menopause • managing genitourinary symptoms associated with the menopause • the effects of hormone replacement therapy (HRT) on specific health outcomes. These recommendations are marked [2024]. We have also made some changes without an evidence review. These changes include clarifying: • the information about menopause and fertility that should be shared and discussed with people who have associated symptoms or are approaching menopause, including those who are likely to experience menopause as a result of medical or surgical treatment • when to refer people to a healthcare professional with expertise in menopause, or fertility, or both • how to address the possible effects of menopause on mental health. These are marked [2015, amended 2024]. We have also made some presentational changes without changing the meaning of the recommendations. • Changes have been made to the wording to bring the language and style up to date. • Information on the risk of the effects of hormone replacement therapy (HRT) on some health outcomes (muscle mass and strength, osteoporosis, type 2 diabetes and venous thromboembolism) has been clarified.",
    "These recommendations are marked [2015]. Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights). Minor changes since publication May 2025: We amended the rationale and impact sections on the effects of combined HRT and oestrogen-only HRT on specific health outcomes in people aged 45 and over to clarify details about the evidence for: • combined HRT and risk related to breast cancer and ovarian cancer • oestrogen-only HRT and risk related to breast cancer. ISBN: 978-1-4731-6550-2 Menopause: identification and management (NG23) © NICE 2025. All rights reserved. Subject to Notice of rights ([URL] and-conditions#notice-of-rights).",
    "Series www.thelancet.com Vol 403 March 9, 2024 947 Menopause 1 An empowerment model for managing menopause Martha Hickey, Andrea Z LaCroix, Jennifer Doust, Gita D Mishra, Muthusamy Sivakami, Deborah Garlick, Myra S Hunter Menopause eventually happens to all people with typically functioning ovaries, and almost one billion women worldwide are postmenopausal. Although the biology of typical menopause is ubiquitous, the experience varies substantially. Factors contributing to the experience include not only individual factors, such as the nature and severity of symptoms, but also psychological, social, and contextual considerations, many of which are modifiable. In this first paper in the Lancet Series on menopause, we argue for a new approach that goes beyond the treatment of specific symptoms, to encompass a broad model to support women transitioning this life stage, using the model of empowerment. WHO defines empowerment as an active process of gaining knowledge, confidence, and self- determination to self-manage health and make informed decisions about care. Rather than focusing on menopause as an endocrine deficiency, we propose an empowerment model that recognises factors modifying the experience, in which the patient is an expert in their own condition and the health-care worker supports the patient to become an equal and active partner in managing their own care.",
    "Background Although menopause is biologically inevitable, experiences vary considerably and are shaped by factors including symptoms, race and ethnicity, social meanings, expectations, self-esteem, life adversity, and general health. In many high-income countries (HICs), meno - pause is commonly described as a medical problem and sometimes as a hormone deficiency disorder with typical symptoms and long-term health risks that are best managed by hormone replacement. 1 However, this disease-based model is challenging in practice given the wide variation in experiences between women and their changing experiences over time. Also, the inevitability of menopause makes finding out whether long-term health outcomes are due to menopause or ageing difficult, particularly given the scarcity of adequate prospective data for long-term health consequences of premature or early menopause. Although management of symptoms is impor tant, a medicalised view of menopause can be dis empowering for women, leading to over-treatment and overlooking potential positive effects, such as better mental health with age and freedom from menstruation, menstrual disorders, and contraception. 2 In this first paper in our Lancet Series, we consider a new approach to menopause that goes beyond the treatment of specific symptoms, based on the model of health empowerment.",
    "2 In this first paper in our Lancet Series, we consider a new approach to menopause that goes beyond the treatment of specific symptoms, based on the model of health empowerment. WHO defines empower ment as an active process of gaining knowledge, confidence, and self-determination to self-manage health and make informed decisions about care. 3 Although the principles of health empowerment have not previously been applied to menopause, in 2005 the US National Institutes of Health (NIH) identified the need to develop and disseminate information emphasising menopause as an ordinary, healthy phase of women’s lives and promoting its demedicalisation. 4 Across several health domains there is growing evidence that empowerment is an effective tool to optimise self-management of health, which can also reduce health-care costs. 5 To be empowered, women must be informed and listened to. Women have clearly stated that they want their voices heard and their experiences of menopause acknowledged and validated. Unfortunately, some women report that their concerns are dismissed, particularly those from minority groups. 6 We propose a more inclusive approach (figure 1).",
    "Unfortunately, some women report that their concerns are dismissed, particularly those from minority groups. 6 We propose a more inclusive approach (figure 1). Key components of menopause empowerment include access to evidence-based and balanced information, preferably before the onset of menopause (panel), tools to support decision making around treatments for symptoms (eg, decision aids), and access to a supportive clinician who listens with empathy and offers treatment if needed by using a shared decision- making model (figure 1). More broadly, challenging widespread stigma about menopause as a period of decline and decay and creating a more menopause-friendly work environment might help to empower women. 8 In this paper, we focus on empowerment in the context of typical menopause. In other papers in the Series, we consider other types of menopause which might affect the experience and we believe warrant more attention: early menopause, menopause after cancer, and mental health during the menopause transition. Lancet 2024; 403: 947–57 Published Online March 5, 2024 [URL] S0140-6736(23)02799-X See Perspectives pages 893 and 894 This is the first in a Series of four papers about menopause.",
    "Lancet 2024; 403: 947–57 Published Online March 5, 2024 [URL] S0140-6736(23)02799-X See Perspectives pages 893 and 894 This is the first in a Series of four papers about menopause. All papers in the Series are available at www.thelancet.com/ series/menopause-2024 Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne and the Royal Women’s Hospital, Melbourne, VIC, Australia (Prof M Hickey MBChB MD); Department of Epidemiology, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, CA, USA (Prof A Z LaCroix PhD); Centre for Longitudinal and Life Course Research, School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia (J Doust BMBS PhD); NHMRC Centre for Research Excellence in Women and NCDs, School of Public Health, University of Queensland, Brisbane, QLD, Australia (Prof G D Mishra PhD); School of Health Systems Studies, Tata Institute of Social Sciences, Mumbai, India (Prof M Sivakami MA PhD); Henpicked, London, UK (D Garlick MBA); Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK (M S Hunter PhD) Correspondence to: Professor Martha Hickey, Department of Obstetrics, Gynaecology and Newborn Health, The Royal Women’s Hospital, Melbourne, VIC 3052, Australia [EMAIL] Key messages • Most women navigate menopause without the need for medical treatments • Over-medicalisation of menopause can lead to disempowerment and over-treatment • New tools are available to support the empowerment of women to navigate the menopause transition • Empowerment is likely to confer benefits for women across socioeconomic and geographical locations, health services, and economies Series 948 www.thelancet.com Vol 403 March 9, 2024 Menopause as a hormone deficiency disease Menopause became medicalised in the early 20th century, with the belief that women’s identity (so-called femininity) and physical and mental health was predicated on the balance between oestrogen excess or deficiency.",
    "1 A wide range of mental and physical disorders in women were (and still are) attributed to hormonal imbalance. Loss of oestrogen after menopause was thought to be individually and socially harmful, and to have consequences such as “untold misery of alcoholism, drug addiction, divorce and broken homes”. 10 Oestrogen treatment emerged during the rejuvenation and anti- ageing movements of the early 1900s. Hormones extracted from animals were injected into humans to counter the perceived deficiencies of age. 1 In women, oestrogens were widely prescribed for menstrual and reproductive disorders, pregnancy compli cations (eg, diethylstilbestrol), psychoses, and depression.10 From the 1940s, purpose-designed hormone replacement therapy (HRT), extracted from pregnant mares’ urine, was widely promoted for the “unstable, estrogen-starved postmeno - pausal woman”.11 Access to HRT has directly benefited many women, bringing the first effective treatment for menopausal symptoms and potential long-term benefits for younger menopausal women. However, as predicted by The Lancet in 1975, “The prospect of universal treatment of a large section of the female population is clearly a glittering commercial prize for the pharmaceutical industry” and uptake was rapid. By the mid-1960s around a third of UK women aged 50–64 were taking HRT, making it the most commonly prescribed medication in this population.",
    "By the mid-1960s around a third of UK women aged 50–64 were taking HRT, making it the most commonly prescribed medication in this population. 12 Uptake was low in low-income and middle-income countries (LMICs), where menopause is generally considered a part of the natural ageing process, bringing benefits, such as the cessation of menstruation. 13 The use of HRT (now called menopausal hormone therapy [MHT]) plummeted in 2002, when a large randomised placebo-controlled trial (RCT) was terminated early due to its findings of an increased risk of breast cancer with combined MHT, 14 inadequate benefit in the primary outcome (coronary heart disease), and increased risk of stroke with oestrogen-only MHT. 15 This drop in MHT use was followed by a decreased incidence of breast cancer in some countries 16 and an increased risk of fracture in others. 17 Although long- term follow-up from this RCT has shown no increase in all-cause mortality after 5–7 years of MHT, uptake has never returned to previous levels in most countries. In the UK, use of MHT increased by around 60% between 2020 and 2022, particularly in women from the most affluent areas of the country. 18 The reasons for this increased use are uncertain but might reflect the subtantial increase in media attention towards menopause. We argue that additional strategies beyond medication are needed to effectively support women as they transition menopause.",
    "Panel: How clinicians can support empowerment in the management of menopause Before menopause • Provide evidence-based information about what to expect • Challenge overly negative assumptions about menopause and ageing and encourage discussion with friends and family • Encourage routines that might reduce stress and improve mood—eg, mindfulness and exercise During the menopause transition • Provide reassurance and offer effective treatments for symptoms as requested • Provide realistic information about the likely effects of treatment, the potential for residual symptoms, and the possibility that symptoms could recur when treatment stops • Offer reassurance that vasomotor symptoms are usually time limited and might be most frequent in the year around the final menstrual period 7 • Offer behavioural strategies that might reduce the anxiety that can accompany hot flushes, and provide advice on sleep hygiene • Offer advice about lifestyle factors, addressing sleep, alcohol, and smoking, which can exacerbate vasomotor symptoms • Challenge self-critical beliefs, which can increase arousal and make flushes worse • Offer advice about management of symptoms in the workplace 8 • Encourage connections with other women for discussion and support After menopause • Offer effective treatments for persistent vasomotor or genitourinary symptoms • Encourage good general health9 • Offer screening as indicated for primary and secondary prevention of chronic disease Figure 1: Empowering women to",
    "persistent vasomotor or genitourinary symptoms • Encourage good general health9 • Offer screening as indicated for primary and secondary prevention of chronic disease Figure 1: Empowering women to manage menopause Shared decision making Creating a menopause-friendly work environment Access to a supportive and informed clinician willing to listen and oﬀer treatment as needed Challenging stigma and gender- based ageism Access to realistic and balanced information Access to tools supporting decision making about treatments Menopause empowerment For general health information see [URL] well/ Series www.thelancet.com Vol 403 March 9, 2024 949 Search strategy and selection criteria We searched databases on MEDLINE, Embase, BioMed Central, Cochrane, and Google from December, 2020, to July, 2023, with key words tailored to each section of the manuscript combining “menopaus*”, “psychotherapy*”, “premature ovarian insufficiency”, and “postmenopaus*” with “menopausal symptom*”, “vasomotor symptom*”, “genitourinary symptom*”, “genitourinary syndrome of menopause”, “hormone therap*”, “hormone replacement therap*”, “non-hormonal therapy*”, “psychotherapy*”, “empower*”, “disempower*”, “self confiden*”, “self-deter- mination”, “self manag*”, “care model”, “model of care”, “model of self care”, “shared decision making”, “meno- pause at work”, “working”, “employment”, “ageism”, “ageist”, “age discrimination”, and “age prejudice”.",
    "We cross-referenced these terms with “systematic review*”, “meta-analysis”, “metaanalysis”, “randomised/randomized con trolled trial*”, “clinical guideline*”, “clinical practice guideline*”, and “core outcomes” and websites and guide- lines of menopause societies, including British Meno - pause Society, International Menopause Society, North American Menopause Society, Australasian Meno pause Society, the United States Preventive Task Force (USPTF) recommendations on Meno pause, and the National Institute of Clinical Excellence (NICE) guidelines. The Turning Research Into Practice and PubMed databases were searched for evidence-based guidelines and systematic reviews. We prioritised the most recent evidence from RCTs and recommendations from international guidelines based on systematic reviews of the evidence (eg, NICE and USPTF). Only publications in English were included. What is menopause? The menopause occurs with the final menstrual period; thus, the occurrence of menopause can only be determined in retrospect, and women are considered postmenopausal after 12 months with no periods. 19 The timing of menopause is thought to be predicated on the size of the primordial follicle pool (ie, ovarian reserve), which is fixed by the time of birth. When the follicle count drops below a critical threshold, ovulation becomes intermittent and eventually stops.",
    "When the follicle count drops below a critical threshold, ovulation becomes intermittent and eventually stops. The process of going through the menopause starts with menstrual cycle changes and ends 1 year after the final menstrual period (figure 2). 19 Women with irregular menstrual cycles, following endometrial ablation or hysterectomy, and users of hormonal contraception might be uncertain about the timing of menopause. Menopause happens to all people with typically functioning ovaries who reach the relevant age. We recognise that this population includes some transgender men and other gender-diverse people; therefore, in some instances, we have referred to “people” rather than “women” to be as accurate and inclusive as possible. However, since much published work refers to people experiencing menopause collectively as women and does not clarify how findings might apply to the specific needs of gender-diverse people, we have also used “women” in some instances, to avoid inappropriate generalisation. Evidence on menopause in gender-diverse individuals is scarce and needs more attention. 20 Predicting the onset of menopause Changes in the menstrual cycle are the most reliable indicator of the menopause transition. 19 Blood tests, such as measurement of anti-mullerian hormone, are uninformative for women older than 45 years. 21 The transition usually starts at around age 47 years in HICs and lasts for 4 years on average, with the average age at menopause being 51 years.",
    "21 The transition usually starts at around age 47 years in HICs and lasts for 4 years on average, with the average age at menopause being 51 years. 21 Timing might be earlier in LMICs; for example, data from India indicate that the mean age at menopause is approximately 46 years. 22 Globally, around 10% of women experience premature menopause (before age 40 years) or early menopause (at age 40–44 years), 23 which can be iatrogenic (eg, following chemotherapy or radiation for cancer or bilateral oophorectomy) or spontaneous. What symptoms are caused by menopause? In a large US longitudinal study, during the menopausal transition, prolonged menstrual bleeding affected more than 90% of women at least once and nearly 80% of women at least three times, and about a third of women had 3 or more days of heavy bleeding on at least three occasions. 24 Heavy and irregular bleeding could affect many aspects of life, including work. Access to toilet facilities and breaks might help. The menopause transition is also when vasomotor symptoms are most likely to start. 25 More information is needed about how best to manage bleeding problems and menopausal symptoms over this period. Apart from menstrual cycle changes, there is uncertainty about what other symptoms menopause causes, with no universal menopause syndrome.",
    "Apart from menstrual cycle changes, there is uncertainty about what other symptoms menopause causes, with no universal menopause syndrome. 26 In 2005, an NIH interdisciplinary expert consensus concluded that many women have few or no symptoms and that only vasomotor symptoms, vaginal dryness, and possibly sleep disturbance were clearly attributable to menopause. 4 Subsequently, prospective studies reported that depressive symptoms and disturbances in sleep and Figure 2: Reproductive stages over time spanning the menopausal transition 21 FSH=follicle-stimulating hormone. Stage –3 (ie, late reproductive) Cycles regular or slightly irregular Normal to variable FSH Ovarian reserve low Stage –2 (ie, early menopausal transition) ≥7-day diﬀerence in cycle length Variable FSH Ovarian reserve low Stage –1 (ie, late menopausal transition) Cycles ≥60 days apart FSH high Ovarian reserve low Stage +1 (ie, early postmenopause) Menses have ended FSH high Ovarian reserve very low to undetectable Series 950 www.thelancet.com Vol 403 March 9, 2024 cognition can temporarily worsen for some women. 27,28 Whether the menopause transition is associated with clinically significant increased anxiety is uncertain and prospective studies show inconsistent findings. 29 One US prospective study of 255 women reported an increase in aches, joint pain, and stiffness.",
    "29 One US prospective study of 255 women reported an increase in aches, joint pain, and stiffness. 30 The 1946 British Birth Cohort reported that psychological symptoms and discomfort with sex increase in around 10–20% of women over the menopause transition. 31 Less is known about menopausal symptoms in LMICs, but cross-cultural studies suggest that sleep disturbance and muscle and joint pain are more common than vasomotor symptoms, 32,33 although findings are conflicting.34 Vasomotor symptoms In HICs, about 40% of women report vasomotor symptoms in the early menopause transition, peaking at 60–80% in the 2 years after the final menstrual period. 19,31 These can continue for 4–7 years on average but usually decrease over time. 7 Predicting individual symptoms is difficult but prospective studies show that vasomotor symptoms starting in the early menopause transition are more likely to be persistent. 35 Symptom severity can contribute to women seeking treatment for vasomotor symptoms. A pooled analysis of eight cohort studies of more than 21 000 women reported that 38% had moderate or severe vasomotor symptoms.36 A prospective US study (n=255) found that a third of women recruited before menopause had persistent moderate or severe symptoms for 10 years. 37 Vasomotor symptoms seem to differ between ethnic and racial groups.",
    "37 Vasomotor symptoms seem to differ between ethnic and racial groups. For example, Black and Hispanic women report more severe vasomotor symptoms and Asian American women less severe vasomotor symptoms compared with White women, 26 but less is known about minoritised racial and ethnic groups in other multicultural countries, such as the UK. Within the USA there might be sub-variations in the menopausal symptom experience of Asian women. 38 As well as frequency and severity, other factors influence the experience of vasomotor symptoms, such as attitudes towards menopause and ageing, religion, socioeconomic status, lifestyle (eg, diet and exercise), and methodological limitations of individual studies. 34 However, it is important not to make assumptions about women’s experience of menopause based on ethnicity or race. The degree of interference from vasomotor symptoms, which is strongly influenced by psychological, social, and biological factors, is a priority for menopausal women. 39 There is a bi-directional association between vasomotor symptoms and stress, making stress a potentially modifiable factor. There is also a two-way association between vasomotor symptoms and depressed mood. Women with more severe vasomotor symptoms tend to report more depressive symptoms, and women who are depressed can find vasomotor symptoms hard to manage. 40,41 Other potentially modifiable factors include smoking, high BMI, depressed mood, anxiety, and negative beliefs about menopause.",
    "40,41 Other potentially modifiable factors include smoking, high BMI, depressed mood, anxiety, and negative beliefs about menopause. Lifestyle and behavioural changes have shown some success in reducing troublesome symptoms, although findings are mixed (panel). 36,42,43 Muscle and joint pains Most studies of menopausal symptoms were conducted in White women from HICs or in racial subgroups within these countries. Women in LMICs report substantial differences in the experience of menopause. Southeast Asian women in LMICs might be less troubled by vasomotor symptoms and more likely to report muscle and joint pains than women in HICs. 44 MHT can modestly improve joint pain but the effect on muscle aches is unknown. 45 Sleep disturbance Sleep disturbances are more common in women than in men across the life course and can increase over the menopause transition. 46 Night-time awakenings due to vasomotor symptoms are common, but sleep can be disturbed for other reasons over this period, and conditions such as obstructive sleep apnoea or depression can contribute. 46 Menopausal symptoms that disturb sleep can affect daytime function, including mood and concentration. An international, consumer-driven process to find out what outcomes should be measured in menopause clinical trials concluded that the effect of treatments on sleep was a priority area.",
    "An international, consumer-driven process to find out what outcomes should be measured in menopause clinical trials concluded that the effect of treatments on sleep was a priority area. 47 Genitourinary symptoms Between 10% and 40% of postmenopausal women report symptoms such as vaginal dryness, vulvovaginal irritation or itching, and dyspareunia. 48 Unlike vasomotor symptoms, these genitourinary symptoms tend to start after menopause and can persist into older age. Genitourinary changes, such as vaginal dryness, can also be secondary to ageing. Other symptoms The effects of hormone changes can be difficult to differentiate from concurrent life events such as caring for children at home, managing paid and unpaid employment, taking responsibility for ageing parents, and balancing conflicting life roles. 49 In particular, changes in mood and cognition and sexual difficulties commonly ascribed to menopause can be caused or exacerbated by these life stressors. 50 Similarly, although subjective changes in concentration and memory are common over the menopause transition, these have not been clearly linked to long-term cognitive decline. Prospective studies of objective measures of cognition over the menopause transition show only small and mostly temporary memory changes in a minority of women, an observation that many find reassuring.",
    "51,52 Series www.thelancet.com Vol 403 March 9, 2024 951 Subjective changes in memory and concentration can be more common, but whether these changes are secondary to factors such as sleep disturbance is uncertain. 53 Menopause and long-term health Natural menopause at the average age is associated with an increased incidence of some health problems and a reduced incidence of others. Although bone density is known to decline after menopause, whether menopause at the average age increases other chronic conditions such as diabetes, dementia, or cardiovascular disease is uncertain. Prospective studies of body composition and weight have shown mixed findings, but the Study of Women’s Health Across the Nation showed a small increase in weight gain of 0·25 kg per year over the menopause transition, which stabilised postmenopause. The average absolute weight gain associated with menopause was 1·6 kg. 54 Managing menopausal symptoms Although there is uncertainty about the symptoms menopause causes, vasomotor symptoms are consistently reported and are the leading patient priority for treatment, followed by sleep, concentration, and fatigue. 55 Psychological therapies The most troublesome aspects of vasomotor symptoms are frequency, severity, bother, and impact on sleep. 55 Effective non-pharmacological treatments for vasomotor symptoms include purpose-designed cognitive behaviour therapy (CBT) and hypnosis.",
    "55 Effective non-pharmacological treatments for vasomotor symptoms include purpose-designed cognitive behaviour therapy (CBT) and hypnosis. 56 In 2022, a systematic review and meta-analysis including 14 RCTs reported that CBT was superior to control groups in reducing hot flushes, night sweats, sleep disturbance, depression, anxiety, and fatigue and significantly improved quality of life, although effects were generally small to moderate. 57 CBT also reduces problematic vasomotor symptoms at work and after breast cancer. 58 CBT can be delivered in groups by health professionals , with the use of self-help books, online, or by telephone.58 Clinicians should advise patients that RCTs of acupuncture, plant-based therapies, and exercise have largely not shown benefit over placebo or sham procedure for vasomotor symptoms. 59 Clinicans should offer advice about lifestyle factors, addressing sleep, alcohol, and smoking, which can exacerbate vasomotor symptoms (panel). The North American Menopause Society recommends clinical hypnosis for vasomotor symptoms. This recommendation is based on two RCTs showing a statistically significant improvement in the frequency and severity of vasomotor symptoms. 60,61 At 12 weeks the reduction in subjective hot flushes with hypnosis was 74·2% versus 17·1% in controls. Clinical hypnosis also reduced interference due to vasomotor symptoms and improved sleep quality. Hypnosis can be delivered by a trained provider or accessed on a smartphone app.",
    "Clinical hypnosis also reduced interference due to vasomotor symptoms and improved sleep quality. Hypnosis can be delivered by a trained provider or accessed on a smartphone app. Medical therapies The North American Menopause Society recommends specific MHT, gabapentin, and oxybutynin, which have mild to moderate efficacy and reduce hot flushes by 1–2 per day with no clinically significant improvement in menopause-related quality of life. 60 Targeted therapy with the neurokinin B receptor antagonist fezolinetant is available in the USA and some European countries. Two large RCTs have compared the efficacy of fezolinetant versus placebo for vasomotor symptoms over 12 weeks, with a 40-week open label extension. 62,63 With 45 mg per day (the dose now marketed), there was a statistically significant reduction in hot flush frequency and severity up to 1 year and serious adverse events were infrequent. Fezolinetant also improved menopause-related quality of life. 64 Although clinical trials of neurokinin B receptor antagonists in patients with cancer have not yet been published, breast cancer is not a contraindication to fezolinetant use in the USA. However, improvements in vasomotor symptoms with fezolinetant are modest and do not meet the minimally important clinical difference 65 for hot flush frequency or menopause-related quality of life.",
    "However, improvements in vasomotor symptoms with fezolinetant are modest and do not meet the minimally important clinical difference 65 for hot flush frequency or menopause-related quality of life. A meta-analysis published in 2024, 66 which included 2168 patients from five RCTs, reported a 22·5% mean improvement in frequency of vasomotor symptoms, with small improvements in menopause-related quality of life. In 2023, the independent US Institute for Clinical and Economic Review concluded that fezolinetant was less effective than MHT for vasomotor symptoms, and that MHT might provide additional benefits for sleep, vaginal dryness, and fracture prevention. 67 Help-seeking for menopausal symptoms is highly contextual, but 13% of women in HICs are given MHT.36 In the UK, NICE recommends MHT after discussion of the short-term and long-term risks and benefits, which are likely to differ according to patient’s age and type of MHT. 68 For those with problematic symptoms, MHT generally leads to statistically and clinically significant reductions in vasomotor symptom frequency and severity, along with improvements in menopause-related quality of life. 67 For standard (1 mg) and low (0·5 mg) dose estradiol, this improvement equates to around 2–4 fewer hot flushes per day versus placebo, which might not be clinically meaningful for those with very frequent symptoms.",
    "67 Vasomotor symptoms can co-occur with sleep and mood disturbance 69,70 and a 2022 systematic review reported that MHT led to small improvements in sleep.71 However, the primary indication for MHT is the treatment of problematic vasomotor symptoms. 72 MHT might improve sleep, memory, and concentration in women taking it for vasomotor symptoms but it is unlikely to have any effect in women without vasomotor symptoms. 73 For symptom clusters such as hot flushes, disturbed sleep, and depressed mood, RCTs show that CBT is effective. 57 Systemic MHT improves vaginal dryness, but a 2023 systematic review of ten RCTs reported that MHT can worsen or cause urinary incontinence. 74 Hence, vaginal For more on CBT delivered in groups by health professions see [URL] Series 952 www.thelancet.com Vol 403 March 9, 2024 dryness is best managaed with vaginal oestrogen. Patients’ priorities for symptom control should inform shared decision making around treatment. Although combined and oestrogen-only MHT preparations have similar efficacy, their risk profile differs. For example, a 2004 RCT of more than 27 000 women showed that combined MHT increased breast cancer risk, but oestrogen-only MHT did not. 15 More recently, large observational studies including individual participant meta-analyses from over 108 000 patients with breast cancer found that all types of systemic MHT increased risk of breast cancer; risk was substantially greater with combined MHT compared with oestrogen alone.",
    "The authors estimated that about one in 50 users of combined MHT will develop breast cancer after 5 years of continued use. 75 Combined MHT is the most frequently prescribed form of MHT. In the UK, an estimated 80% of MHT users take a combined preparation because adequate dose and duration of progestogen is needed to prevent endometrial hyperplasia. 68 The mode of delivery of MHT also affects the risk to benefit ratio. Transdermal MHT is as effective as oral MHT for vasomotor symptoms 76 but a systematic review in 2018 found that transdermal MHT did not increase venous thromboembolic disease, although evidence quality was low to moderate. 15,77,78 Decisions about how to take MHT should be shared, although patients should be made aware that transdermal preparations appear safer regarding venous thromboembolic risk. The Monthly Index of Medical Specialities lists contraindications to MHT including oestrogen-sensitive cancer, history of venous thromboembolism or pulmonary embolism, active or recent arterial thromboembolic disease (eg, angina and myocardial infarction), acute liver disease, unexplained genital bleeding, pregnancy, elevated triglycerides, untreated hypertension, porphyria, and previous stroke or transient ischaemic attack. Recom - mendations on the duration of MHT use vary, but in their 2022 guidelines, the North American Menopause Society cautions against starting MHT after age 60 years or beyond 10 years since menopause.",
    "56 However, the relative risks versus benefits of continuing MHT beyond age 60 years are uncertain and require a shared decision- making approach. Stopping MHT commonly leads to resurgent vasomotor symptoms in up to 50% of patients, and whether this resurgence reflects ongoing menopausal symptoms or a withdrawal effect from MHT is uncertain. 79 Neither stopping MHT slowly nor stopping gradually have been shown to prevent resurgent symptoms. 80 Shared decision making about treatment should consider the degree of symptom bother, personal preferences, cardiovascular disease and breast cancer risk, and uterine status (ie, having had a hysterectomy or not). 72 Fracture risk increases after menopause and NICE indicates that 5 years of MHT reduces risk by 25 fractures per 1000 women on average (range nine to 37 fewer fractures per 1000 women). 68 However, benefits dissipate by 5 years after MHT is discontinued. 68,81 Therefore, 10 years of MHT from age 50 years to 60 years will not appreciably reduce fracture risk because fractures are uncommon at this age. Although MHT is approved in some countries for the prevention of osteoporosis, the US Preventive Services Task Force recommended in 2022 that MHT should not be used for the primary prevention of any chronic conditions solely because of the unfavourable risk versus benefit balance.",
    "82 In 2023, the Endocrine Society recommended that MHT only be used to prevent osteoporosis in those at substantial risk for whom other therapies are not tolerated or appropriate. 72 For women with predominantly genitourinary symptoms, a 2021 meta-analysis reported that vaginal (topical) oestrogens can reduce dryness and prevent recurrent urinary tract infection. 83 An RCT of daily intravaginal dehydroepiandrosterone showed signifi - cantly reduced dyspareunia and vaginal dryness at 12 weeks. 84 Placebo-controlled RCTs have shown that ospemifene, a selective oestrogen receptor modulator, improves vaginal dryness and dyspareunia. 85 However, there are no clinical trials directly comparing ospemifene with vaginal oestrogen, and published trials have focused on objective outcomes such as vaginal pH and the appearance of vaginal cells on microscopy, which are not priorities for symptomatic women or clinicians. 71 Information about vaginal laser is still emerging, but RCTs in participants with and without breast cancer have shown no benefit over sham procedure for genitourinary symptom severity, 86,87 stress incontinence,88 or sexual function. 89 Shared decision making for genitourinary symptoms should include discussion of over-the-counter moisturisers and lubricants, vaginal oestrogen or dehydroepiandrosterone, and oral ospemifene.",
    "89 Shared decision making for genitourinary symptoms should include discussion of over-the-counter moisturisers and lubricants, vaginal oestrogen or dehydroepiandrosterone, and oral ospemifene. 72 Interventions to support empowerment Many women navigate menopause without the need for medical intervention, but some experience symptoms that affect function and quality of life. Those seeking medical care are often looking for information rather than drug treatment unless their symptoms are severe. 90 Women need easy access to unbiased, accurate information in a form they can understand, created without industry influence and without any hidden agendas to sell a drug or service. 91 Accessing credible information can be challenging, particularly for women in LMICs where home remedies, ayurvedic, and homoeopathic therapies are often preferred to medical treatments for menopausal symptoms. 33 Clinicians caring for patients with menopausal symptoms can empower and support them by listening with empathy, validating their experiences, and being aware of the social and cultural differences that can underlie those experiences (figure 1). Normalising menopause and providing realistic and balanced information about the likely nature, severity, and duration of symptoms can be Series www.thelancet.com Vol 403 March 9, 2024 953 empowering for women and help them to make decisions about management (panel).",
    "For those seeking treatment, clinicians should offer evidence-based information about the range of effective interventions for problematic symptoms, including non- pharmacological and non-hormonal methods, with a model of shared decision making (figure 1). 92 However, MHT is the only treatment that benefits both vasomotor and genitourinary symptoms and reduces fracture risk. Menopausal symptoms commonly cluster, and patients experiencing clusters of hot flushes, disturbed sleep, and depressed mood might benefit from interventions that improve multiple symptoms, such as CBT, or non- hormonal treatments that benefit both vasomotor symptoms and depressed mood. 58,93 A qualitative study of CBT for vasomotor symptoms reported that women felt empowered by learning to self-manage their symptoms, including greater knowledge about menopause, acceptance of their symptoms, and new coping strategies leading to greater confidence and a sense of control. 94 Empowerment can directly improve the experience of menopause. A UK qualitative study reported the complex narrative of menopause as a normal event, a struggle, a loss of identity, and as a time of liberation and transformation. 95 Unfortunately, many women seeking treatment for menopausal symptoms report feeling dismissed and receiving inaccurate information and ineffective treatments. 96 Provision of realistic and impartial information is essential.",
    "96 Provision of realistic and impartial information is essential. For example, My Meno Plan was funded by the US NIH and developed without commercial input. It provides evidence-based information about typical changes over the menopause transition and postmeno - pause and options for self-management and treatment. No treatments are 100% effective, and counselling should be realistic about what improvements to expect and what side-effects can occur (for example, improvement of sleep, memory, and concentration with MHT only for those with problematic vasomotor symptoms 73). Also, postmenopausal women considering combined MHT should be aware that up to 50% develop bleeding in the initial months, which might require investigation to rule out endometrial hyperplasia or cancer with ultrasound and potentially lead to hysteroscopy and biopsy. 97 The effect of MHT on bleeding patterns in the perimenopause are not well understood, but intrauterine progestogen might offer better control of heavy bleeding compared with combined MHT. 98 Women aged 45–55 years represent a highly productive group making an essential contribution to society and social structures. Women older than 40 years are the fastest growing sector of the paid workforce in HICs, and most essential and voluntary workers are women. 99 Many are working during the menopause transition, and symptoms at work can be particularly problematic due to embarrassment and concerns about the reactions of other people.",
    "99 Many are working during the menopause transition, and symptoms at work can be particularly problematic due to embarrassment and concerns about the reactions of other people. This situation can be particularly challenging for those working in informal economies and in LMICs. According to the UK Health and Safety Executive, women aged 45–54 years report more work- related stress than men or women of any other age group, associated with high job demands and inadequate control and support at work. 100 These women have clearly indicated how things could improve. A qualitative study with 137 participants reported that women want their managers to be informed and empathetic about menopause and how symptoms might be exacerbated by the work environment. 101 They also wanted their workplace to offer open and supportive communication and helpful work policies including flexible work hours. Many health and social care workers are women. Uniforms that are heavy or made of non-breathable fabric are an avoidable source of discomfort for menopausal women. 102 Practical adjustments to support and empower menopausal women at work include informed and empathetic managers, fans, control of ambient air temperature, and uniforms made from breathable fabrics. 8,100 Evidence from the UN (in 2023) and WHO (in 2021) reports that around 90% of people hold gender biases 103 and more than 50% hold ageist attitudes.",
    "8,100 Evidence from the UN (in 2023) and WHO (in 2021) reports that around 90% of people hold gender biases 103 and more than 50% hold ageist attitudes. 104 For older women experiencing menopause, these biases can intersect to reinforce negative attitudes and experiences. Clinicians can help by recognising these biases in themselves and avoiding framing menopause as a period of decay and decline (panel). Negative attitudes towards menopause can directly affect personal experiences. In 2010, a systematic review reported that women with neutral or positive attitudes towards menopause tended to have a greater sense of control than women with more negative attitudes. 105 On the basis of a systematic review of qualitative studies, clinicians can offer reassurance that many women experience growing confidence and assertiveness, freedom from some responsibilities, shifts in family relationships, and accepting and embracing age. 95,105 Future developments There is considerable variation between women in their experience of menopause and few ways to predict who might have symptoms and for how long. Predictive models using genetic and environmental data can inform tools for individual use. Similarly, future studies might be able to identify personalised treatments for those with specific clusters of symptoms or those identified by digital health measures.",
    "Similarly, future studies might be able to identify personalised treatments for those with specific clusters of symptoms or those identified by digital health measures. There is clearly a need for more evidence-based strategies to relieve menopausal symptoms, which requires a skilled workforce to provide clinical care. Ageism is a powerful social determinant of health, and in countries where menopause is equated with physical and mental decline, it is not surprising that many find this transition daunting. Actively challenging ageism and encouraging a more positive discourse can help reduce For more on My Meno Plan see [URL] Series 954 www.thelancet.com Vol 403 March 9, 2024 anxiety for women approaching menopause.92 The social value of older women can affect this experience. In contexts in which women’s value is predicated on reproduction, menopause tends to reduce social status. By contrast, in societies in which ageing confers respect, such as in Indigenous communities in Australia, menopause is considered less problematic. 106 Growing public discourse about menopause in some settings (eg, the UK) is raising awareness and could help change the culture by reducing stigma and shame and encouraging open discussion. Women have indicated that they want this topic to come out of the shadows and be more openly discussed, particularly in the workplace. They want their experiences heard by each other and their health-care providers.",
    "They want their experiences heard by each other and their health-care providers. 91 Public initiatives aiming to empower women by dispelling myths, sharing realistic experiences, and promoting positive images include Menopause Café, and arts initiatives such as Flesh after Fifty directly challenge negative beliefs and create new positive role models. Digital health, including use of mobile health apps, telemedicine, and data analytics to improve health systems, surged during the COVID-19 pandemic. New tools are emerging that are designed to empower women to recognise, understand, and manage their own menopausal symptoms through digital technology. For example, Henpicked menopause hub and Women Living Better provide evidence-based, realistic, and clear information about the menopause transition and its symptoms, including stories from women with lived experience and information about treatment options. Women can use the My Meno Plan tool to compare treatments and develop their own management approach in consultation with their health-care provider. Much information about menopause available online is driven by commercial interests. The National Library of Medicine tool can be used for evaluating the quality of online health information. People in LMICs can benefit from proactive information from health-care providers about what to expect at menopause.",
    "People in LMICs can benefit from proactive information from health-care providers about what to expect at menopause. In 2021, a European consensus recommended that workplaces should create an open, inclusive, and supportive culture around menopause, with occupational health professionals and human resource managers working together. 8 To enable employers to make these changes, online resources such as Menopause at Work provide evidence-based and practical information for employers to support their employees, including education, communication, and flexible work policies. However, more information is needed about what workplace interventions are effective. Despite substantial gaps in knowledge about menopause, research has largely focused on developing new drugs for vasomotor symptoms, although most women do not choose to take medication. Interpretation of these clinical trials has been hindered by inadequate agreed patient-reported outcome measures and inconsistent measures for the same symptom, 107 which For more on the National Library of Medicine tool see [URL] webeval/webeval.html For Menopause at Work see [URL] org/ limits comparisons between treatments and precludes data pooling. To standardise these measures, the Core Outcomes in Menopause initiative reached global consensus among clinicians, researchers, and women with lived experience of menopause across 28 countries to find out which outcomes should be measured in future clinical trials for menopausal symptoms.",
    "47,108 Most research in menopause is from HICs. Little is known about the diversity of experience across LMICs, and what is known suggests that the differences are greater than the similarities. 109 In addition, women have not been widely consulted about their priorities for menopause research. A Menopause Priority Setting Partnership is underway with the James Lind Alliance 110 to find out the research priorities of affected women and their health-care providers for menopause research. In her 2023 book Period, Kate Clancy described how menstruation is routinely stigmatised as an unruly pathology requiring medical management and as a lamentable curse of womanhood. 111 Perceptions of meno- pause are similar and contribute to disempower ment and negative experiences. Women are shamed for menstruating, and then shamed for not menstruating. 2020 was the start of the WHO and UN decade of healthy ageing. Priority areas of the Global Coalition on Aging include women’s lifelong health needs and risks and how best to deliver integrated, person-centred care across the life course. Health literacy, access to quality health care, and economic participation are inextricably linked. By connecting healthy ageing with women’s rights, global and national policy leaders can help to empower women to live long, healthy lives. Contributors MH conceived and designed the paper, wrote the initial draft, and was responsible for revising this draft on the basis of comments from the other authors.",
    "Contributors MH conceived and designed the paper, wrote the initial draft, and was responsible for revising this draft on the basis of comments from the other authors. AZL, JD, GDM, MS, DG, and MSH made substantial contributions to the conception or design of the work, or to the acquisition, analysis, or interpretation of data for the work. AZL, JD, GDM, MS, DG, and MSH contributed towards drafting the work or revising it critically for important intellectual content, approved the final version to be published, and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MH is responsible for the final approval of this manuscript and agrees to be accountable.",
    "MH is responsible for the final approval of this manuscript and agrees to be accountable. Declaration of interests MH declares salary funding from the Australian National Health and Medical Research Council, support for meeting attendance from the UK National Institute for Health and Care Excellence, and the following roles: principal investigator for a clinical trial of salpingectomy vs salpingo-oophorectomy for prevention of ovarian cancer (TUBA-WISP II); board member for Breastscreen Victoria; editor for the Cochrane Collaboration; recipient of a fellowship from the Lundbeck Foundation (2022-23); site investigator for a clinical trial of a non-hormonal agent (Q-122) for vasomotor symptoms in patients with breast cancer (QUE Oncology, 2020-22); and site investigator for a clinical trial of a medical device for treating vaginal dryness (Madorra). AZL has grant funding for research on menopause from the National Institute on Aging of the National Institutes of Health in the USA. MSH has worked in collaboration with Rightsteps UK to develop CBT solutions for menopausal symptoms 2020–25 and is author of two books on CBT for menopausal symptoms with Melanie Smith. All other authors declare no conflicts of interest.",
    "All other authors declare no conflicts of interest. For Menopause Cafe see https:// www.menopausecafe.net/ For Flesh after Fifty see https:// www.fleshafterfifty.com/ For Henpicked see https:// henpicked.net/ For Women Living Better see [URL] For the Global Coalition on Aging see https:// globalcoalitiononaging.com/ Series www.thelancet.com Vol 403 March 9, 2024 955 References 1 Banks E. From dogs’ testicles to mares ’ urine: the origins and contemporary use of hormonal therapy for the menopause. Feminst Review 2002; 72: 2–25. 2 Steptoe A, Deaton A, Stone AA. Subjective wellbeing, health, and ageing. Lancet 2015; 385: 640–48. 3 WHO. Health promotion glossary. G eneva: World Health Organisation, 1998. 4 National Institutes of Health. National Institutes of Health State- of-the-Science Conference statement: management of menopause- related symptoms. Ann Intern Med 2005; 142: 1003–13. 5 Scambler S, Newton P, Asimakopoulou K. The context of empowerment and self-care within the field of diabetes. Health (London) 2014; 18: 545–60. 6 Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas 2007; 58: 348–58. 7 Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531–39. 8 Rees M, Bitzer J, Cano A, et al.",
    "7 Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531–39. 8 Rees M, Bitzer J, Cano A, et al. Global consensus recommendations on menopause in the workplace: a European Menopause and Andropause Society (EMAS) position statement. Maturitas 2021; 151: 55–62. 9 NHS, Age UK. A practical guide to healthy ageing. [URL] nhs.uk/Livewell/men60-plus/Documents/Age%20UK%20and%20 NHS%20A%20Guide%20To%20Healthy%20Ageing.pdf (accessed Feb 9, 2024). 10 Winston RA. Feminine forever. London: W H Allen and Virgin Books, 1966. 11 Wilson RA, Wilson TA. The fate of the nontreated postmenopausal woman: a plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc 1963; 11: 347–62. 12 Townsend J. Hormone replacement therapy: assessment of present use, costs, and trends. Br J Gen Pract 1998; 48: 955–58. 13 Aaron R, Muliyil J, Abraham S. M edico-social dimensions of menopause: a cross-sectional study from rural south India. Natl Med J India 2002; 15: 14–17 . 14 Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33. 15 Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.",
    "15 Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12. 16 Banks E, Canfell K. Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. Breast Cancer Res 2010; 12: 103. 17 Karim R, Dell RM, Greene DF, Mack WJ, G allagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011; 18: 1172–77 . 18 NHS Business Services A uthority. NHS publishes new HRT official statistics. Oct 6, 2022. [URL] publishes-new-hrt-official-statistics (accessed Feb 9, 2024). 19 Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause 2012; 19: 387–95. 20 Glyde T. LGBTQIA+ menopause: room for improvement. Lancet 2022; 400: 1578–79. 21 Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab 2021; 106: 1–15. 22 Prasad JB, Tyagi NK, Verma P. Age at menopause in India: a systematic review. Diabetes Metab Syndr 2021; 15: 373–77 . 23 Zhu D, Chung HF, Dobson AJ, et al.",
    "J Clin Endocrinol Metab 2021; 106: 1–15. 22 Prasad JB, Tyagi NK, Verma P. Age at menopause in India: a systematic review. Diabetes Metab Syndr 2021; 15: 373–77 . 23 Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 2020; 35: 1933–43. 24 Paramsothy P, Harlow SD, Greendale GA, et al. Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women’s Health Across the Nation (SWAN): a prospective cohort study. BJOG 2014; 121: 1564–73. 25 Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab 2021; 106: 1–15. 26 Avis NE, Crawford SL, Green R. Vasomotor symptoms across the menopause transition: differences among women. Obstet Gynecol Clin North Am 2018; 45: 629–40. 27 Woods NF, Mitchell ES. The Seattle Midlife Women’s Health Study: a longitudinal prospective study of women during the menopausal transition and early postmenopause. Womens Midlife Health 2016; 2: 6. 28 El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause 2019; 26: 1213–27 . 29 Bryant C, Judd FK, Hickey M. Anxiety during the menopausal transition: a systematic review. J Affect Disord 2012; 139: 141–48.",
    "Menopause 2019; 26: 1213–27 . 29 Bryant C, Judd FK, Hickey M. Anxiety during the menopausal transition: a systematic review. J Affect Disord 2012; 139: 141–48. 30 Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007; 110: 230–40. 31 Mishra GD, Kuh D. Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. BMJ 2012; 344: e402. 32 Obermeyer CM. Menopause across cultures: a review of the evidence. Menopause 2000; 7: 184–92. 33 Singh V, Sivakami M. Normality, freedom, and distress: listening to the menopausal experiences of Indian women of Haryana. In: Bobel C, Winkler IT, Fahs B, Hasson KA, Kissling EA, Roberts T-A, eds. The Palgrave handbook of critical menstruation studies. Singapore: Springer Singapore, 2020: 985–99. 34 Islam RM, Bell RJ, Rizvi F, Davis SR. Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review. Menopause 2017; 24: 1313–22. 35 Paramsothy P, Harlow SD, Nan B, et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause 2017; 24: 142–49. 36 Anderson DJ, Chung HF, Seib CA, et al. Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies. Am J Obstet Gynecol 2020; 222: 478.e1–17 . 37 Freeman EW, Sammel MD, Sanders RJ.",
    "Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies. Am J Obstet Gynecol 2020; 222: 478.e1–17 . 37 Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014; 21: 924–32. 38 Im EO, Lee SH, Chee W. Subethnic differences in the menopausal symptom experience of Asian American midlife women. J Transcult Nurs 2010; 21: 123–33. 39 Hunter MS, Chilcot J. Testing a cognitive model of menopausal hot flushes and night sweats. J Psychosom Res 2013; 74: 307–12. 40 Woods NF, Mitchell ES, Percival DB, Smith-DiJulio K. Is the menopausal transition stressful? Observations of perceived stress from the Seattle Midlife Women’s Health Study. Menopause 2009; 16: 90–97 . 41 Arnot M, Emmott EH, Mace R. The relationship between social support, stressful events, and menopause symptoms. PLoS One 2021; 16: e0245444. 42 Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007; 10: 197–214. 43 Freeman EW, Sammel MD, Gross SA, Pien GW. Poor sleep in relation to natural menopause: a population-based 14-year follow-up of midlife women. Menopause 2015; 22: 719–26. 44 Islam MR, Gartoulla P, Bell RJ, Fradkin P, Davis SR. Prevalence of menopausal symptoms in Asian midlife women: a systematic review. Climacteric 2015; 18: 157–76. 45 Chlebowski RT, Cirillo DJ, Eaton CB, et al.",
    "Prevalence of menopausal symptoms in Asian midlife women: a systematic review. Climacteric 2015; 18: 157–76. 45 Chlebowski RT, Cirillo DJ, Eaton CB, et al. Estrogen alone and joint symptoms in the Women’s Health Initiative randomized trial. Menopause 2013; 20: 600–08. 46 Baker FC, Lampio L, Saaresranta T, P olo-Kantola P. Sleep and sleep disorders in the menopausal transition. Sleep Med Clin 2018; 13: 443–56. 47 Lensen S, Bell RJ, Carpenter JS, et al. A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. Menopause 2021; 28: 859–66. 48 Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016; 2016: CD001500. Series 956 www.thelancet.com Vol 403 March 9, 2024 49 Tooth L, Mishra G. Socioeconomic factors associated with trajectories of caring by young and mid-aged women: a cohort study. BMC Public Health 2014; 14: 74. 50 Nelson HD. Menopause. Lancet 2008; 371: 760–70. 51 Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology 2009; 72: 1850–57 . 52 Maki PM. Verbal memory and menopause. Maturitas 2015; 82: 288–90. 53 Woods NF, Coslov N, Richardson MK. Effects of bothersome symptoms during the late reproductive stage and menopausal transition: observations from the Women Living Better Survey. Menopause 2023; 30: 45–55.",
    "Effects of bothersome symptoms during the late reproductive stage and menopausal transition: observations from the Women Living Better Survey. Menopause 2023; 30: 45–55. 54 Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight 2019; 4: e124865. 55 Carpenter JS, Woods NF, Otte JL, et al. MsFLASH participants’ priorities for alleviating menopausal symptoms. Climacteric 2015; 18: 859–66. 56 The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022; 29: 767–94. 57 Ye M, Shou M, Zhang J, et al. Efficacy of cognitive therapy and behavior therapy for menopausal symptoms: a systematic review and meta-analysis. Psychol Med 2022; 52: 433–45. 58 Hunter MS. Cognitive behavioral therapy for menopausal symptoms. Climacteric 2021; 24: 51–56. 59 Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016; 315: 2554–63. 60 The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause 2023; 30: 573–90. 61 Elkins GR, Fisher WI, Johnson AK, C arpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial.",
    "Menopause 2023; 30: 573–90. 61 Elkins GR, Fisher WI, Johnson AK, C arpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013; 20: 291–98. 62 Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 2023; 401: 1091–102. 63 Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab 2023; 108: 1981–97 . 64 Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, doseranging study (VESTA). Menopause 2020; 27: 1350–56. 65 Constantine GD, Simon JA, Kaunitz AM, et al. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial. Menopause 2020; 27: 1236–41. 66 Bonga KN, Mishra A, Maiti R, P adhy BM, Meher BR, Srinivasan A. Efficacy and safety of fezolinetant for the treatment of menopause associated vasomotor symptoms: a meta-analysis. Obstet Gynecol 2024, published online Jan 16. doi:10.1097/AOG.0000000000005508. 67 Beaudoin FL, McQueen RB, Wright A, et al.",
    "Obstet Gynecol 2024, published online Jan 16. doi:10.1097/AOG.0000000000005508. 67 Beaudoin FL, McQueen RB, Wright A, et al. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value; final evidence report. Jan 23, 2023. [URL] Menopause_FinalReport_01232023.pdf (accessed Feb 9, 2024). 68 Lumsden MA, Davies M, Sarri G. Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) guideline. JAMA Intern Med 2016; 176: 1205–06. 69 Cray LA, Woods NF, Herting JR, Mitchell ES. Symptom clusters during the late reproductive stage through the early postmenopause: observations from the Seattle Midlife Women’s Health Study. Menopause 2012; 19: 864–69. 70 Woods NF, Hohensee C, Carpenter JS, et al. Symptom clusters among MsFLASH clinical trial participants. Menopause 2016; 23: 158–65. 71 Pan Z, Wen S, Qiao X, Yang M, Shen X, Xu L. Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Menopause 2022; 29: 627–35. 72 Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. Hormones and aging: an Endocrine Society Scientific statement. J Clin Endocrinol Metab 2023; 108: 1835–74. 73 Savolainen-Peltonen H, Hautamäki H, Tuomikoski P, Ylikorkala O, Mikkola TS. Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. Menopause 2014; 21: 732–39.",
    "Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. Menopause 2014; 21: 732–39. 74 Christmas MM, Iyer S, Daisy C, Maristany S, Letko J, Hickey M. Menopause hormone therapy and urinary symptoms: a systematic review. Menopause 2023; 30: 672–85. 75 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159–68. 76 Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low- dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause 2017; 24: 238–46. 77 Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY . Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227–31. 78 Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res 2018; 168: 83–95. 79 Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women’s Health Initiative randomized, placebo-controlled trial.",
    "79 Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women’s Health Initiative randomized, placebo-controlled trial. Menopause 2010; 17: 946–54. 80 Lindh-Astrand L, Bixo M, Hirschberg AL, S undström-Poromaa I, Hammar M. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause 2010; 17: 72–79. 81 Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 3975–4011. 82 Mangione CM, Barry MJ, Nicholson WK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US Preventive Services Task Force recommendation statement. JAMA 2022; 328: 1740–46. 83 Chen YY , Su TH, Lau HH. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J 2021; 32: 17–25. 84 Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2018; 25: 1339–53. 85 Archer DF, Goldstein SR, Simon JA, et al.",
    "Menopause 2018; 25: 1339–53. 85 Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo- controlled, multicenter trial. Menopause 2019; 26: 611–21. 86 Li FG, Maheux-Lacroix S, Deans R, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA 2021; 326: 1381–89. 87 Page AS, Verbakel JY , Verhaeghe J, Latul YP, Housmans S, Deprest J. Laser versus sham for genitourinary syndrome of menopause: a randomised controlled trial. BJOG 2023; 130: 312–19. 88 Alexander JW, Karjalainen P, Ow LL, et al. CO(2) surgical laser for treatment of stress urinary incontinence in women: a randomized controlled trial. Am J Obstet Gynecol 2022; 227: 473. 89 Mension E, Alonso I, Anglès-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open 2023; 6: e2255697 . Series www.thelancet.com Vol 403 March 9, 2024 957 90 Constantine GD, Graham S, Clerinx C, et al. Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries. Post Reprod Health 2016; 22: 112–22. 91 LaCroix A, Ensrud K. The flash dance of midlife: the Skylight 1 trial.",
    "Post Reprod Health 2016; 22: 112–22. 91 LaCroix A, Ensrud K. The flash dance of midlife: the Skylight 1 trial. Nat Med 2023; 29: 1324–25. 92 Hickey M, Hunter MS, Santoro N, Ussher J. Normalising menopause. BMJ 2022; 377: e069369. 93 Hickey M, Szabo RA, Hunter MS. Non-hormonal treatments for menopausal symptoms. BMJ 2017; 359: j5101. 94 Balabanovic J, Ayers B, Hunter MS. C ognitive behaviour therapy for menopausal hot flushes and night sweats: a qualitative analysis of women’s experiences of group and self-help CBT. Behav Cogn Psychother 2013; 41: 441–57 . 95 de Salis I, Owen-Smith A, Donovan JL, Lawlor DA. Experiencing menopause in the UK: the interrelated narratives of normality, distress, and transformation. J Women Aging 2018; 30: 520–40. 96 Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause- specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas 2009; 62: 153–59. 97 Abdullahi Idle S, Panay N, Hamoda H. A cross-sectional national questionnaire survey assessing the views of members of the British Menopause Society on the management of patients with unscheduled bleeding on hormone replacement therapy. Post Reprod Health 2021; 27: 159–65. 98 Somboonporn W, Panna S, Temtanakitpaisan T, Kaewrudee S, Soontrapa S. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis.",
    "Menopause 2011; 18: 1060–66. 99 Hammarberg K, Holton S, Michelmore J, Fisher J, Hickey M. Thriving in older age: a national survey of women in Australia. Maturitas 2019; 122: 60–65. 100 Hardy C, Thorne E, Griffiths A, Hunter MS. Work outcomes in midlife women: the impact of menopause, work stress and working environment. Womens Midlife Health 2018; 4: 3. 101 Hardy C, Griffiths A, Hunter MS. What do working menopausal women want? A qualitative investigation into women’s perspectives on employer and line manager support. Maturitas 2017; 101: 37–41. 102 Jack G, Riach K, Bariola E, Pitts M, Schapper J, Sarrel P. Menopause in the workplace: what employers should be doing. Maturitas 2016; 85: 88–95. 103 Zarocostas J. UNDP reports that 90% of people hold gender-based biases. Lancet 2023; 401: 2026. 104 Mikton C, de la Fuente-Núñez V, Officer A, Krug E. Ageism: a social determinant of health that has come of age. Lancet 2021; 397: 1333–34. 105 Ayers B, Forshaw M, Hunter MS. The impact of attitudes towards the menopause on women’s symptom experience: a systematic review. Maturitas 2010; 65: 28–36. 106 Jurgenson JR, Jones EK, Haynes E, Green C, Thompson SC. Exploring Australian Aboriginal women’s experiences of menopause: a descriptive study. BMC Womens Health 2014; 14: 4 7. 107 Iliodromiti S, Wang W, L umsden MA, et al. Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review. BJOG 2020; 127: 320–33. 108 Lensen S, Archer D, Bell RJ, et al.",
    "Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review. BJOG 2020; 127: 320–33. 108 Lensen S, Archer D, Bell RJ, et al. A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. Menopause 2021; 28: 852–58. 109 Avis NE, Brockwell S, Colvin A. A universal menopausal syndrome? Am J Med 2005; 118 (suppl 12B): 37–46. 110 The University of Chicago Obstetrics & Gynecology. M enopause priority setting partnership. [URL] menopause-priority-setting-partnership (accessed Feb 15, 2024). 111 Clancy K. Period: the real story of menstruation. Princeton, NJ: Princeton University Press, 2023. Copyright © 2024 Elsevier Ltd. All rights reserved.",
    "Series 958 www.thelancet.com Vol 403 March 9, 2024 Menopause 2 Optimising health after early menopause Gita D Mishra, Melanie C Davies, Sarah Hillman, Hsin-Fang Chung, Subho Roy, Kate Maclaran, Martha Hickey The typical age at menopause is 50–51 years in high-income countries. However, early menopause is common, with around 8% of women in high-income countries and 12% of women globally experiencing menopause between the ages of 40 years and 44 years. Menopause before age 40 years (premature ovarian insufficiency) affects an additional 2–4% of women. Both early menopause and premature ovarian insufficiency can herald an increased risk of chronic disease, including osteoporosis and cardiovascular disease. People who enter menopause at younger ages might also experience distress and feel less supported than those who reach menopause at the average age. Clinical practice guidelines are available for the diagnosis and management of premature ovarian insufficiency, but there is a gap in clinical guidance for early menopause. We argue that instead of distinct age thresholds being applied, early menopause should be seen on a spectrum between premature ovarian insufficiency and menopause at the average age. This Series paper presents evidence for the short-term and long-term consequences of early menopause.",
    "This Series paper presents evidence for the short-term and long-term consequences of early menopause. We offer a practical framework for clinicians to guide diagnosis and management of early menopause, which considers the nature and severity of symptoms, age and medical history, and the individual’s wishes and priorities to optimise their quality of life and short-term and long-term health. We conclude with recommendations for future research to address key gaps in the current evidence. Introduction Menopause marks the permanent cessation of menstrual cycles, usually confirmed after 12 consecutive months of amenorrhoea. Natural menopause typically occurs at around age 50–51 years in high-income countries (HICs). 1,2 In clinical practice, the onset of menstrual changes and menopausal symptoms generally indicates the start of perimenopause or menopausal transition. While the menopause is marked by the final menstrual period, symptoms can persist for years into the postmenopause. 3 Early menopause is usually defined as occurring between the ages of 40 years and 44 years, whereas premature ovarian insufficiency indicates menopause before age 40 years. Both can be either spontaneous or iatrogenic, with iatrogenic causes including bilateral oophorectomy and chemotherapy or pelvic radiation treatment for cancer.",
    "Both can be either spontaneous or iatrogenic, with iatrogenic causes including bilateral oophorectomy and chemotherapy or pelvic radiation treatment for cancer. In this Series paper, we outline the evidence suggesting that both premature ovarian insufficiency and early menopause are linked with increased risk of chronic conditions in later life, such as cardiovascular disease and osteoporosis, although data are generally scarce around early menopause. Similarly, although consensus guidance exists for diagnosing and managing premature ovarian insufficiency, no guidance is available for early menopause. Given the scarcity of specific evidence regarding the long- term health implications of early menopause, we argue that early menopause should be considered as being on a spectrum between premature ovarian insufficiency and the typical age of menopause. To prevent patients from falling through this gap in care, we offer a practical framework to guide diagnosis and management of early menopause and identify evidence-based approaches for individuals either with or at risk of early menopause to optimise their health and quality of life in the short and long term. This process has identified key evidence gaps for further research and areas where people with early menopause require greater support. Menopause happens to all people with typically functioning ovaries who reach the relevant age.",
    "Menopause happens to all people with typically functioning ovaries who reach the relevant age. We recognise that this population includes some transgender men and other gender-diverse people; therefore, in some instances, we have referred to “people” rather than “women” in order to be as accurate and inclusive as possible. However, since much published work refers to people experiencing menopause collectively as women and does not clarify how findings might apply to the specific needs of gender-diverse people, we have also used “women” in some instances, to avoid inappropriate generalisation. More information is needed about the experience of menopause in transgender men and gender-diverse people. 4 Search strategy and selection criteria We conducted a review of published articles up to July, 2023, on the PubMed, Embase, Scopus, and Cochrane Lancet 2024; 403: 958–68 Published Online March 5, 2024 [URL] S0140-6736(23)02800-3 See Perspectives pages 893 and 894 This is the second in a Series of four papers about menopause.",
    "All papers in the Series are available at www.thelancet.com/ series/menopause-2024 Australian Women and Girls’ Health Research Centre, School of Public Health, University of Queensland, Brisbane, QLD, Australia (Prof G D Mishra PhD, H-F Chung PhD MPH); Institute for Women’s Health, University College London, London, UK (Prof M C Davies MBBS MA); Unit of Academic Primary Care, Warwick Medical School, University of Warwick, Coventry, UK (S Hillman MBChB PhD); Department of Anthropology, University of Calcutta, Kolkata, India (Prof S Roy PhD); Department of Gynaecology, Chelsea and Westminster Hospital, London, UK (K Maclaran MBChB MD); Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne and the Royal Women’s Hospital, Melbourne, VIC, Australia (Prof M Hickey MBChB MD) Correspondence to: Prof Gita D Mishra, Australian Women and Girls’ Health Research Centre, School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia [EMAIL] Key messages • Early menopause, defined as menopause between ages 40 years and 44 years, affects approximately 12% of women globally. • Diagnosis of early menopause is often delayed and can cause emotional distress, particularly in individuals hoping to become pregnant. • We propose that early menopause should be considered as being on a spectrum between premature ovarian insufficiency and menopause at the average age.",
    "• We propose that early menopause should be considered as being on a spectrum between premature ovarian insufficiency and menopause at the average age. • We present a framework for the diagnosis and evaluation of early menopause for use in clinical practice. Series www.thelancet.com Vol 403 March 9, 2024 959 databases. The search was restricted to studies published in English with the following keywords and medical subject heading terms in PubMed (MeSH) and Embase (Emtree): “menopause”; “premature menopause”; “pre- mature ovarian insufficiency”; “early menopause”; “meno- pausal symptoms”; “vasomotor symptoms”; “menopausal hormone therapy”; “hormone therapy”; “hormone replace- ment therapy”; and “non-hormonal therapy”. For long- term health outcomes, we combined these terms with “chronic disease”, “non-communicable disease”, “osteoporosis”, “fracture”, “cardiovascular disease”, “heart disease”, “stroke”, “depression”, “dementia”, “cancer”, and “mortality”. We prioritised the most robust evidence from clinical trials, systematic reviews, meta-analyses, and pooled studies. We also reviewed guidelines and position statements from the period 2010–23 on menopause management. Background Biology The pool of primordial follicles is established in utero, with a peak of 6–7 million oocytes at 16–20 weeks’ gestation.",
    "Background Biology The pool of primordial follicles is established in utero, with a peak of 6–7 million oocytes at 16–20 weeks’ gestation. 5 Most follicles undergo atresia and decline to approximately 700 000 normal oocytes at birth, approximately 300 000 oocytes by menarche, and fewer than 1000 oocytes at menopause. 5–7 Both the size of the pool of primordial follicles and the rate of follicular atresia probably determine the timing of menopause, but the underlying mechanisms regulating these factors are poorly understood. 8–10 Prevalence of early menopause and premature ovarian insufficiency Estimates for the prevalence of spontaneous early meno- pause and premature ovarian insufficiency vary substantially according to the population studied. The International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease Events (InterLACE) pooled individual data from over 50 000 women with spontaneous menopause from nine studies in HICs to show that 7 ·6% of women had early menopause and 2% had premature ovarian insufficiency.11 Global estimates, from a meta-analysis of 31 studies including over 150 000 women with spontaneous menopause, show a higher prevalence of 12·2% (95% CI 10·5–14) for early menopause, and 3·7% (3·1–4·3) for premature ovarian insufficiency, potentially reflecting a lower mean age at menopause in low-income and middle-income countries (LMICs).",
    "12 A national study from China found a prevalence of 10·9% for spontaneous early menopause and a prevalence of 3·2% for premature ovarian insufficiency. 13 The prevalence in India is even higher at 20·2% for early menopause, with two prevalence estimates for premature ovarian insufficiency of 1·5% and 2 ·1%, 14,15 and an average age at menopause of 46 years.16 Another reason for differences in prevalence might be the age limits used for observational studies on menopause (eg, arbitrarily setting a minimum age of 35 years for inclusion in a study will exclude some individuals who had premature ovarian insufficiency at an earlier age). 17 Although secular trends in many countries show an increase in the age at menopause is evident in many countries, 18–20 global evidence is scarce regarding trends in the prevalence of premature ovarian insufficiency and early menopause. 12 A substantial proportion of cases of premature ovarian insufficiency and early menopause have iatrogenic causes, with wide variations according to gynaecological surgical practices in different countries. A national study in India reported that the prevalence of iatrogenic premature ovarian insufficiency was 1·7%, solely due to bilateral oophorectomy. 14 By contrast, a registry-based study (n=1 036 918) from Sweden reported an overall prevalence of 1·9% for spontaneous and iatrogenic premature ovarian insufficiency and, of these women, 10·7% had iatrogenic premature ovarian insufficiency.",
    "21 As survival rates for young patients with cancer increase, iatrogenic premature ovarian insufficiency and early menopause will probably increase secondary to chemotherapy and radiotherapy. 22 Risk factors for spontaneous early menopause and premature ovarian insufficiency Bilateral oophorectomy in premenopausal individuals will induce surgical menopause. Unilateral oophorectomy is also associated with a younger age at menopause, on average 1·8 years younger compared with people with intact ovaries. 23 Hysterectomy alone with ovarian preservation is associated with menopause 1 ·9 years earlier than in women who do not have this procedure.24 The mechanisms underlying spontaneous early menopause and premature ovarian insufficiency are poorly understood. Studies in HICs indicate that genetic factors account for roughly half of the variation in age at natural menopause, estimated at 42% of variation in the UK, 44% in the Netherlands, and 52% in the USA. 25–27 These data are supported by retrospective studies reporting a six-fold to eight-fold increase in the risk of menopause before age 45 years for women with a maternal history of early menopause or premature ovarian insufficiency. 28,29 Recent genome-wide association studies have also identified specific genetic factors linked with the timing of menopause that provide insights on potential causal pathways for ovarian ageing.",
    "28,29 Recent genome-wide association studies have also identified specific genetic factors linked with the timing of menopause that provide insights on potential causal pathways for ovarian ageing. 30 Nulliparity is associated with early menopause and premature ovarian insufficiency, although the direction of this relationship is uncertain since there could be shared factors that affect both nulliparity and age at menopause. The InterLACE consortium found (in a pooled analysis of 51 450 women in nine studies) that nulliparous women were twice as likely to have premature ovarian insufficiency and 30% more likely to have early menopause than women with two or more children. 11 Nulliparous women who also had early Series 960 www.thelancet.com Vol 403 March 9, 2024 menarche (before age 12 years) had a five-fold increased risk of premature ovarian insufficiency and double the risk of early menopause, compared with women who had menarche at 12 years or older with two or more children. 11 In studies from LMICs, women in India 31 and China 13 with premature ovarian insufficiency were more likely to have had an earlier age when first giving birth and a shorter duration of breastfeeding, although again the causal pathways at work remain unclear. Globally, cigarette smoking is a well established risk factor for early menopause.",
    "Globally, cigarette smoking is a well established risk factor for early menopause. 13,14,32,33 InterLACE reported that participants who currently smoked were twice as likely to have premature ovarian insufficiency as those who had never smoked, and 80% more likely to have early menopause. 34 There was a consistent dose–response relationship for participants who currently smoked and those who formerly smoked (duration and cumulative dose), but those who stopped smoking at least 10 years before menopause had a similar risk of early menopause to individuals who had never smoked. The prevalence of smoking has declined markedly in many HICs over recent decades, but the effect of this decline on rates of early menopause and premature ovarian insufficiency has yet to be documented. Implications of early menopause and premature ovarian insufficiency Menopausal symptoms The effect of menopause and its symptoms on individuals will be highly contextual. 35 Common symptoms directly attributable to menopause include vasomotor symptoms (including hot flushes and night sweats), sleep disturbance, and vaginal dryness. 36–38 In addition, some studies have identified depressed mood and aches and joint pain,39 with south Asian and Chinese women (living in HICs) more likely to report joint pain.",
    "36–38 In addition, some studies have identified depressed mood and aches and joint pain,39 with south Asian and Chinese women (living in HICs) more likely to report joint pain. 40,41 The prevalence of moderate- to-severe vasomotor symptoms in natural menopause also varies considerably across populations, with prevalence findings from an international survey ranging from 40% in Europe and 34% in the USA to 16% in Japan. 42 Whether menopausal symptoms following early menopause and premature ovarian insufficiency differ in nature, severity, or duration compared with symptoms following menopause at the average age is unknown. For iatrogenic early menopause and premature ovarian insufficiency, the abrupt cessation of oestrogen is thought to lead to more severe symptoms. 43 However, in the only prospective controlled study of surgical menopause, vasomotor symptoms at 12 months affected 82% of individuals who did not take menopausal hormone therapy (MHT), including 68% who reported mild symptoms, suggesting that severe vasomotor symptoms are not inevitable after surgical menopause. 44 The diagnosis of menopause from 5 years to a decade or more earlier than expected can carry stigma and might affect self-esteem. 45 Symptoms in the years leading up to menopause can affect intimate relationships and, for some people, the loss of fertility can be especially distressing.",
    "45 Symptoms in the years leading up to menopause can affect intimate relationships and, for some people, the loss of fertility can be especially distressing. The experience of menopausal symptoms can affect not only an individual’s quality of life but also their effectiveness in the workplace, with economic consequences due to lower workforce participation rates. 46–48 For example, a 2022 study from the UK found that women with early menopause had lower labour market participation at age 50 years than other women. 47 For individuals with iatrogenic early menopause or premature ovarian insufficiency, the change in circulating sex steroid concentrations occurs suddenly, and often in the context of treatment burden (eg, from chemotherapy) for a recent disease diagnosis, such as breast cancer. Some studies of women with iatrogenic premature ovarian insufficiency report low social support, 49 moderate-to-severe emotional distress,50 and high rates of depression.51 Although studies are scarce, some of these adverse outcomes could plausibly apply to people with menopause in their early 40s. Longer-term health implications Bone health Oestrogens contribute to the regulation of bone resorption and formation. 10 Women with premature ovarian insufficiency and early menopause are at increased risk of fragility fractures.",
    "10 Women with premature ovarian insufficiency and early menopause are at increased risk of fragility fractures. A cross-sectional study of 4725 women from the Netherlands found that those with spontaneous early menopause or premature ovarian insufficiency had a 50% higher overall fracture rate up to age 80 years compared with those with menopause at the average age. 52 Similar findings are reported in prospective studies from Sweden (osteoporosis and fragility fracture by age 77 years) 53 and the Netherlands (vertebral fractures at age 62 years).54 Cardiovascular disease Since the late 1980s, cardiovascular risk has been thought to be influenced by oestrogen exposure, contributing to gender differences in the incidence of cardiovascular disease. People with early menopause or premature ovarian insufficiency are at increased risk of coronary heart disease, stroke, and cardiovascular disease-related mortality. 55–57 Pooled data from 15 studies (from Australia, Japan, Scandinavia, the UK, and the USA) show that women with spontaneous early menopause had a 30% increased risk (and women with premature ovarian insufficiency had a 55% increased risk) of a cardiovascular disease event compared with individuals with menopause at age 50–54 years, although these risks attenuated over time, with no difference found by age 70 years.",
    "58 Women with surgical early menopause or premature ovarian insufficiency were at an even higher relative risk (60% and 90%, respectively) for cardiovascular disease events. 59 Findings from the UK Biobank study show both spontaneous and iatrogenic premature ovarian insufficiency are associated with increased risk of Series www.thelancet.com Vol 403 March 9, 2024 961 hyperlipidaemia, hypertension, and type 2 diabetes, compared with menopause at the average age.60 Mental health and neurological conditions Unfortunately, little is known about early menopause and mental health. Premature ovarian insufficiency might negatively affect mental health in the short and long term. A meta-analysis of four studies with 3033 women with spontaneous premature ovarian insufficiency found that they were twice as likely to develop depression compared with women with menopause at age 40 years or older. 61 In a retrospective UK study of 136 women with premature ovarian insufficiency, 78% reported a negative effect on their self-image and confidence and lower general health, mental wellbeing, and sexual satisfaction compared with before their diagnosis. 62 No evidence for the mental health effects of early menopause was identified in our review of the literature.",
    "62 No evidence for the mental health effects of early menopause was identified in our review of the literature. Surgical menopause at or before age 45 years has been associated with higher risk of dementia and faster overall cognitive decline, 63 but the specific relationship between early menopause and premature ovarian insufficiency and neurological conditions is less clear. A cohort study based on the Korean National Health Insurance System database (with prospective data on 4·7 million post- menopausal women) reported that early menopause or premature ovarian insufficiency was associated with all- cause dementia, with the risk declining as age at menopause increased. 64 In a French population cohort study (n=4868), however, no association was found between early menopause and a decline in cognitive function in later life (tested across multiple domains), whereas both surgical and spontaneous premature ovarian insufficiency were linked with a decline in verbal fluency and visual memory. 65 Oestrogen-sensitive cancers Breast cancer is the most common cancer in HICs, and most breast cancers are oestrogen-sensitive. Women with menopause before age 45 years are at lower relative risk of breast cancer (by 27% for early menopause and 33% for premature ovarian insufficiency), 66,67 and at lower risk for endometrial and ovarian cancers compared with women with menopause at age 50–54 years.",
    "10,66 Life expectancy Overall the evidence indicates that earlier natural meno - pause is associated with higher all-cause mortality, 68 and this risk is greater with premature ovarian insufficiency than with early menopause. A meta-analysis of seven studies found that premature ovarian insufficiency was linked with a 40% increased relative risk (RR; 95% CI 1·10–1·77) of all-cause mortality, whereas for women with early menopause the association was limited to a small increased risk of ischaemic heart disease (RR 1·09, 1·00–1·18). 69 A large US study of women with natural menopause who did not smoke and had not had MHT 70 found that early menopause was linked with a 9% increased relative risk of death due to coronary heart disease and a 19% increased risk for respiratory disease, which were the two main contributors to a small but identifiable increased risk of all-cause mortality (RR 1·04, 95% CI 1 ·00–1·08). Similarly, a large Canadian study of prophylactic bilateral oophorectomy 71 found that women with iatrogenic early menopause had a higher likelihood of all-cause mortality (hazard ratio 1 ·16, 95% CI 1·04–1·30) and this association increased further for those with iatrogenic premature ovarian insufficiency (1·31, 1·18–1·45) compared with women who had this surgery at age 50–55 years.",
    "This study included women both with and without hormone therapy, and for both the early menopause and premature ovarian insufficiency groups the association with all-cause mortality was largely driven by deaths from causes other than cancer. 71 Diagnosis and management of early menopause The initial challenge for health professionals is to make the diagnosis of early menopause and to explain the condition and potential consequences. Most international guidelines advise offering MHT to individuals without contraindications following early menopause. 72–74 MHT is highly effective for short-term symptoms, but it has not been shown to improve long-term health outcomes. Early menopause has implications for fertility, contraception, and potentially for sexual function. Addressing the psychological needs of people with early menopause and offering long-term follow-up and support is crucial. 45,50,75 Diagnosis The diagnosis of early menopause might not be straightforward unless a clear iatrogenic cause is identified. In individuals with spontaneous early menopause presenting with secondary amenorrhoea, vasomotor symptoms, or both, investigations are indicated to establish the diagnosis. 76 Some people will be amenorrhoeic after hysterectomy with ovarian conservation, or while taking long-acting progestogen contraception, so the diagnosis is made on the basis of symptoms and biochemistry.",
    "There are no consensus criteria for diagnosing early menopause after cancer treatment, which can cause transient or fluctuating symptoms. Although evidence on early menopause diagnoses is scarce, some studies report that people with premature ovarian insufficiency might experience delayed diagnosis. In a US study, 77 more than half of women with spontaneous premature ovarian insufficiency reported seeing three different clinicians, and for 25% of the women, establishing a diagnosis took over 5 years. Similarly, for 25% of Australian women with premature ovarian insufficiency, diagnosis was delayed for more than 2 years and most saw at least two clinicians. 51 As a result, some individuals might be categorised as having early menopause rather than premature ovarian insufficiency. Most women receiving a diagnosis of spontaneous premature ovarian insufficiency Series 962 www.thelancet.com Vol 403 March 9, 2024 are dissatisfied with the clinical interaction,50 but we do not know the views of people diagnosed with early menopause. For both groups, navigating treatment entails further complexity as patients grapple with the risks and efficacy of hormonal and non-hormonal therapies. 78 Treatment options Lifestyle interventions Advice on healthy lifestyles should be a routine part of clinical interactions with health professionals and is particularly relevant for people experiencing early menopause or premature ovarian insufficiency.",
    "In these patients, the aims should be reducing cardiovascular risk (eg, through smoking cessation) and promoting bone health (eg, through weight-bearing exercise and a calcium- rich diet). 2 Non-hormonal treatments Complementary and alternative remedies are widely marketed and used for vasomotor symptoms. 79 There is a lack of evidence for the efficacy of herbal treatments and dietary supplements to relieve vasomotor symptoms, with the possible exception of isoflavones and black cohosh, and findings of studies might not translate into clinical practice, as preparations vary considerably. 76,80 Psychological interventions, particularly cognitive behavioural therapy, reduce the effects of vasomotor symptoms and improve sleep and mood disturbance generally associated with menopause. 76,81 A randomised control trial (RCT) has shown the efficacy of mindfulness for reducing hot flashes and improving quality of life for women with premature ovarian insufficiency. 82 Non-hormonal pharmacological treatments 83 are offered to people who have contraindications to oestrogen treatment (eg, individuals with oestrogen-sensitive breast cancer). 84 For vasomotor symptoms, the most widely used treatments are selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors.",
    "84 For vasomotor symptoms, the most widely used treatments are selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors. 83 Gabapentinoids and oxybutynin are less widely used, but neurokinin-3 receptor antagonists, such as fezolinetant, show promise in reducing moderate-to-severe vasomotor symptoms associated with menopause. 85,86 Pharmacological treatments for women with low bone mineral density include vitamin D and calcium supplements, 87,88 but the value of these interventions has not been explored in young women and is likely to vary in different populations according to ethnicity and dietary habits. Bisphosphonates are not generally used in spontaneous early menopause but can be given in oncology practice, particularly when oestrogen is contraindicated. 89 Hormonal treatments In the general population, MHT is highly effective in relieving some symptoms of menopause with a dose- dependent response, and it is generally prescribed as physiological oestradiol-based preparations. 80 Oestrogen is given in combination with progestogen to avoid unscheduled bleeding and the risk of endometrial hyperplasia, unless individuals have undergone hyster - ectomy. A combined oral contraceptive might be a convenient and acceptable preparation for young people with premature ovarian insufficiency, although the relative efficacy of this treatment compared with MHT, for both short-term and long-term outcomes, is unclear.",
    "Serious adverse effects from a combined oral contraceptive are rare but increase with age, 75,90 so MHT is preferred for early menopause. Systemic treatment can be given orally or transdermally, the latter having metabolic advantages. Topical (intravaginal) treatment is effective in relieving urogenital symptoms and might be required in addition to MHT; 75 endometrial protection is not required with topical oestrogen. Oestrogen replacement is recommended following both premature ovarian insufficiency and early menopause until the typical age of menopause, 74,91 but the optimum duration of use is uncertain. Although oestrogen treatment is often initiated for symptom control, longer-term use is advised in the expectation of improved health outcomes. The adverse health effects of early menopause are less severe than those of premature ovarian insufficiency, as would be expected given the relative duration and degree of oestrogen loss. 58,68,92 There might, therefore, be fewer potential health benefits from MHT for early menopause than for premature ovarian insufficiency. Moreover, these treatment benefits need to be set against the risks of adverse effects, which are related to age. Prevention of osteoporosis and the maintenance of bone health is a major rationale for the use of MHT following premature ovarian insufficiency.",
    "Prevention of osteoporosis and the maintenance of bone health is a major rationale for the use of MHT following premature ovarian insufficiency. 2 Clinical guidance is extrapolated from the Women’s Health Initiative (WHI) data, which showed that MHT in older postmenopausal women improves bone mineral density and reduces vertebral and hip fracture risk. 93,94 However, fractures are uncommon in women younger than 45 years (the association between low bone mineral density and fracture is age-dependent, mediated by falls). 95 There are a few small prospective studies showing the benefit of MHT on bone health in premature ovarian insufficiency. 2 However, bone health in early menopause specifically has not been sufficiently studied. Early cohort studies suggested that MHT might have a role in the prevention of cardiovascular disease in postmenopausal women but this role was not confirmed by large randomised trials. 96,97 The largest trial (the WHI) showed an increase in the risk of ischaemic heart disease and stroke in people taking oestrogen. 97,98 However, a subgroup analysis of women aged 50–59 years showed some risk reduction in coronary heart disease and mortality with MHT.",
    "97,98 However, a subgroup analysis of women aged 50–59 years showed some risk reduction in coronary heart disease and mortality with MHT. 99,100 Although a Cochrane review found reduced risk for coronary heart disease for women who started MHT less than 10 years after the menopause (RR 0·52, 95% CI 0·29–0·96), it confirmed an increased risk of venous thromboembolism (1· 74, 1·11–2·73), and Series www.thelancet.com Vol 403 March 9, 2024 963 was unable to support the use of MHT for primary or secondary prevention of coronary heart disease.99 Findings from the analysis of pooled data from InterLACE 59 only detected a reduction in risk in cardiovascular disease for women with MHT after surgical early menopause or premature ovarian insufficiency, but not for those with spontaneous early menopause and premature ovarian insufficiency. A study of women in the USA with bilateral oophorectomy before age 45 years 101 found that those receiving MHT had no evidence of increased mortality from cardiovascular disease compared with women from the same age group who did not have bilateral oophorectomy, whereas those who had not taken MHT were at increased risk (hazard ratio [HR] 1 ·84, 95% CI 1·27–2·68), compared with women from the same age group who did not have bilateral oophorectomy. 101 There are no RCTs of MHT, however, in women with early menopause or premature ovarian insufficiency.",
    "101 There are no RCTs of MHT, however, in women with early menopause or premature ovarian insufficiency. Concern was raised by the Women’s Health Initiative study’s findings of an increased risk of dementia in older users of MHT, which might reflect the thrombotic risk of MHT. 102 There is very little information, however, on the effect of oestrogen treatment on cognitive function in younger people with early menopause or premature ovarian insufficiency. A population-based cohort study of women aged at least 65 years found that both spontaneous and surgical premature ovarian insufficiency were associated with poorer cognitive function in later life, 65 but found no evidence of a cognitive benefit from MHT. Risk of breast cancer is slightly increased in healthy premenopausal women with long-term use of a combined oral contraceptive 103,104 and is increased in older postmenopausal women taking combined MHT. 105,106 However, the type of MHT is important: long-term follow-up from participants in the Women’s Health Initiative study showed a reduction in breast cancer risk with previous use of oestrogen alone, but an increased risk with previous use of combined MHT. 107 Whether the type of progestogen affects breast cancer risk is uncertain. 108 Breast cancer risk increases with both age and the duration of MHT use.",
    "107 Whether the type of progestogen affects breast cancer risk is uncertain. 108 Breast cancer risk increases with both age and the duration of MHT use. For women with early menopause starting MHT aged 40–44 years, observational data suggest that the increase in breast cancer risk is similar to that in women with menopause at the average age. 106 Few women in long-term observational studies started MHT before the age of 40 years, although these women are at increased risk after more than 15 years of MHT use. 106 There are no randomised data relating to breast cancer risk in early menopause or premature ovarian insufficiency. Optimising health outcomes for women with early menopause Clinical guidelines Existing clinical practice guidelines for menopause management rarely address early menopause. A systematic review of 22 current guidelines 109 found that some include premature ovarian insufficiency but have little advice in relation to early menopause. For example, the UK National Institute for Health and Care Excellence guidelines on the diagnosis and management of menopause include some recommendations on premature ovarian insufficiency and address the diagnosis of early menopause but not its management. 76 The European Society of Human Reproduction and Embryology published specific pre - mature ovarian insufficiency guidelines in 2015, but has no clinical guidelines for early menopause.",
    "76 The European Society of Human Reproduction and Embryology published specific pre - mature ovarian insufficiency guidelines in 2015, but has no clinical guidelines for early menopause. 2 In 2014, Jane and Davis 110 produced a practitioner toolkit for managing menopause in women aged 40 years and older on the basis of recommendations in position statements and practice guidelines. Building on this model, we have, in turn, developed a practical clinical framework to assist with diagnosis and management of early menopause (figure). Management recommendations are limited by the scarcity of evidence relating specifically to early menopause. However, the boundaries between typical menopause, early menopause, and premature ovarian insufficiency are arbitrary, and age cutoffs are often crossed in clinical practice during the lengthy process of menopause transi- tion. Early menopause occupies a zone between premature ovarian insufficiency and menopause at the typical age, so extrapolating from existing studies in these groups while awaiting further targeted studies seems reasonable. People with early menopause should be aware of the potential long-term risks, including osteoporosis, fractures, and cardiovascular disease. Ensuring this awareness provides an opportunity for a broader discussion on the key role of health behaviours (eg, smoking cessation, healthy diet, healthy bodyweight, and exercise) for cardiometabolic health and maintenance of bone density.",
    "Clinicians might also see opportunities to address specific risk factors. Individualised care Considerable scope exists to provide a more holistic and individualised approach to the management of early menopause. This approach could be part of a broader attitude to reproductive health that ideally engages with individuals, especially those at risk of early menopause, well before the menopausal transition. 111 For example, discussion of early menopause should be part of consultations with individuals with BRCA1/2 mutations, which place them at high risk of breast and ovarian cancer, who might be planning the timing of risk- reducing bilateral salpingo-oophorectomy. Improving community information on early menopause and premature ovarian insufficiency and natural menopause could aid prompt diagnoses. Social media is often a primary source of health information for women 112 and there is a need for objective and evidence- based online resources. For example, a co-designed digital health resource for women with early menopause or premature ovarian insufficiency and health practitioners targets these unmet needs for information Series 964 www.thelancet.com Vol 403 March 9, 2024 and support management. 113 Clinical guidelines should now routinely be translated into lay terms, allowing patients direct access to high-quality information.",
    "113 Clinical guidelines should now routinely be translated into lay terms, allowing patients direct access to high-quality information. Future recommendations Reducing the risk of early menopause The incidence of iatrogenic early menopause can be reduced by changes in the management of benign gynaecological conditions (eg, hysterectomy rates have reduced since the introduction of intrauterine progestogen devices), and by modifications in oncology practice (eg, the use of less gonadotoxic chemotherapy regimens). Research priorities There are substantial gaps in our knowledge of the cause, natural history, and optimal management of early Figure: Practical framework for diagnosis, evaluation, and management of early menopause FSH=follicle-stimulating hormone. MHT=menopausal hormone therapy. TSH=thyroid-stimulating hormone. *Might not be apparent if the individual is taking hormonal contraception or has had a previous hysterectomy. †Symptoms of menopause can vary between individuals and in the same individual over time. Some people have no symptoms apart from cessation of menstruation. Symptoms such as mood disturbances, anxiety, brain fog, palpitations, and low libido are common but might not be attributable to menopause. ‡Intermenstrual or post-coital bleeding needs further investigation; also consider further investigation for heavier bleeding. §A raised FSH concentration is confirmation of a diagnosis, but a typical FSH concentration does not rule out perimenopause.",
    "§A raised FSH concentration is confirmation of a diagnosis, but a typical FSH concentration does not rule out perimenopause. If uncertain, repeat testing might be needed. This test can guide contraceptive needs. FSH is of no value while the individual is taking combined oral contraception, and of limited value if they are taking any hormonal treatment.",
    "¶For example, Healthtalk Australia’s digital resource on early menopause and the Daisy Network Individual aged 40–45 years presenting with: Menstrual irregularity* or secondary amenorrhoea* and any of the following symptoms†: • Va somotor symptoms, • Poor sleep, • Dyspareunia, • Va ginal d ryness, • Urinary symptoms, or • Joint pain and stiﬀness Examination and screening • Measure height and weight and BMI • Measure blood pressure • Breast and pelvic examinations are not routinely required • Check patient’s knowledge of breast self-examination and cancer screening (breast and cervix) Initial investigations • FSH§ • TSH if clinically indicated • Cardiovascular risk proﬁle if clinically indicated • Bone densitometry if clinically indicated Consider (or rule out) other causes of menstrual disturbance • Pregnancy • Polycystic ovarian syndrome • Low bodyweight or excessive exercise • Medication Clinical evaluation Change in bleeding pattern‡ • >12 months of amenorrhoea (probably menopause) • <12 months of amenorrhoea (probably perimenopause) Menopausal symptoms (as above) Past medical history • Risk factors for early menopause Previous gynaecological surgery (eg, hysterectomy, oophorectomy, or surgery for endometriosis) Previous cancer treatment (eg, chemotherapy, pelvic irradiation, or pelvic surgery) Thyroid disease or other autoimmune diseases • Potential contraindications to MHT → Seek specialist advice Previous venous thromboembolism or thrombophilia Cardiovascular disease or",
    "pelvic surgery) Thyroid disease or other autoimmune diseases • Potential contraindications to MHT → Seek specialist advice Previous venous thromboembolism or thrombophilia Cardiovascular disease or uncontrolled hypertension Active liver disease Oestrogen-dependent cancer Family history • Early menopause or premature ovarian insuﬃciency • Cardiovascular disease • Diabetes • Osteoporosis • Breast cancer • Venous thromboembolism Lifestyle (including factors for cardiovascular disease) • Smoking (current and past) • Alcohol consumption • Diet and supplements • Exercise Current medication • Hormonal contraception • MHT • Other hormonal treatment (eg, aromatase inhibitors) Reproductive history • Need for contraception • Family completion Ongoing care • Explain the diagnosis • Oﬀer information and support¶ • Consider the individual’s priorities Management of vasomotor symptoms Vulvovaginal symptoms Sexual dysfunction Contraceptive or fertility needs Long-term health concerns • Provide general health and lifestyle advice (eg, advice on managing weight, stopping smoking, and reducing alcohol intake) • Provide advice on bone and heart health (eg, advice on weight-bearing exercise and dietary calcium intake) • Treat the symptoms Oﬀer MHT for menopause symptoms → Discuss route and dose Oﬀer vaginal oestrogen for urogenital symptoms Consider non-hormonal treatment for vasomotor symptoms if MHT is contraindicated • Manage the individual’s long-term health Individually assess the beneﬁts",
    "vaginal oestrogen for urogenital symptoms Consider non-hormonal treatment for vasomotor symptoms if MHT is contraindicated • Manage the individual’s long-term health Individually assess the beneﬁts and risks of MHT taken for 5 years or more → Consider cardiovascular risk proﬁle → Consider bone densitometry if clinically indicated For more on Healthtalk Australia’s digital resource on early menopause see https:// www.healthtalkaustralia.org/ early-menopause-experiences- and-perspectives-of-women- and-health-professionals/ For more on the Daisy Network see [URL] org/ Series www.thelancet.com Vol 403 March 9, 2024 965 menopause (panel).",
    "There are also important evidence gaps for both premature ovarian insufficiency and early menopause in LMICs, particular around under- reporting. 114,115 Governments should be encouraged to look beyond reproductive and child health programmes and consider the health consequences of ageing and management of associated conditions, such as menopause. With the shift to routine digital health management, there might be new opportunities to collect detailed data on the diagnosis and management of early menopause. Similarly, the rise of digital health hubs on early menopause and premature ovarian insufficiency provides considerable research opportunities to engage with people on their menopausal experiences and evaluate the effect of information strategies on subsequent treatment choices. In summary, approximately 8–10% of women globally experience early menopause, but the causes, natural history, and potential long-term health outcomes are poorly understood. In particular, whether MHT confers long-term health benefits for people with early menopause is unclear. Information on early menopause is largely extrapolated from existing evidence on premature ovarian insufficiency or from studies of menopause at the average age. Interpretation of this evidence assumes a spectrum of age at menopause, with consequences reflecting the timing and duration of oestrogen withdrawal.",
    "Interpretation of this evidence assumes a spectrum of age at menopause, with consequences reflecting the timing and duration of oestrogen withdrawal. Unfortunately, there is insufficient evidence for current guidance advising MHT until the average age at menopause (ie, 50 years) and so treatment should be considered on an individualised basis. Clinicians and researchers should work with people experiencing early menopause to establish their personal priorities for research and wishes for treatment. Contributors MH and GDM conceived and designed this Series paper. GDM wrote the initial draft and was responsible for revising this draft on the basis of comments from all other authors. MCD, SH, H-FC, SR, KM, and MH made substantial contributions to the conception or design of this Series paper; or to the acquisition, analysis, or interpretation of data. MCD, SH, H-FC, SR, KM, and MH made substantial contributions to drafting this Series paper or revising it critically for important intellectual content; and gave their final approval of the submitted version. MCD, SH, H-FC, SR, KM, and MH agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MH is responsible for the final approval of this manuscript.",
    "MH is responsible for the final approval of this manuscript. Declaration of interests MH declares salary funding from the Australian National Health and Medical Research Council, support for meeting attendance from the UK National Institute for Health and Care Excellence, and the following roles: principal investigator for a clinical trial of salpingectomy vs salpingo-oophorectomy for prevention of ovarian cancer (TUBA-WISP II); board member for Breastscreen Victoria; editor for the Cochrane Collaboration; recipient of a fellowship from the Lundbeck Foundation (2022-23); site investigator for a clinical trial of a non-hormonal agent (Q-122) for vasomotor symptoms in patients with breast cancer (QUE Oncology, 2020-22); and site investigator for a clinical trial of a medical device for treating vaginal dryness (Madorra). All other authors declare no competing interests. References 1 Schoenaker DA, Jackson CA, Rowlands JV , Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol 2014; 43: 1542–62. 2 European Society of Human R eproduction and Embryology Guideline Group on premature ovarian insufficiency. Guideline of the European Society of Human Reproduction and Embryology: management of women with premature ovarian insufficiency. European Society of Human Reproduction and Embryology, December, 2015.",
    "European Society of Human Reproduction and Embryology, December, 2015. [URL] eshre.eu/Guidelines-and-Legal/Guidelines/Management-of- premature-ovarian-insufficiency.aspx (accessed Feb 8, 2024). 3 Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531–39. 4 Glyde T. LGBTQIA+ menopause: room for improvement. Lancet 2022; 400: 1578–79. 5 Baker TG. A quantitative and cytological study of germ cells in human ovaries. Proc R Soc Lond, B 1963; 158: 417–33. 6 Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod 2008; 23: 699–708. 7 Forabosco A, Sforza C. Establishment of ovarian reserve: a quantitative morphometric study of the developing human ovary. Fertil Steril 2007; 88: 675–83.",
    "Hum Reprod 2008; 23: 699–708. 7 Forabosco A, Sforza C. Establishment of ovarian reserve: a quantitative morphometric study of the developing human ovary. Fertil Steril 2007; 88: 675–83. Panel: Research priorities to improve our knowledge of early menopause More information is needed on: • People’s experiences of early menopause diagnoses, particularly how to reduce diagnostic delay to inform effective interventions • The priorities of people who experience the menopause transition for research gaps in early menopause to guide the future research agenda; in collaboration with the James Lind Alliance, a Menopause Priority Setting Partnership is underway, including people with premature ovarian insufficiency and early menopause • The views of patients on the optimal management of early menopause, including unmet needs around diagnosis and treatment • The causes and natural history of early menopause to establish who is at risk • Long-term health outcomes following early menopause, which need to be assessed in prospective studies to inform prevention and early diagnosis of adverse outcomes • Early menopause across diverse populations, including in low-income and middle-income countries • The safety and effectiveness of treatment options (including but not limited to menopausal hormone therapy) following early menopause, in particular in managing menopausal symptoms, improving quality of life, and reducing chronic disease risks in both the short and long term • The effectiveness of interventions for people with early menopause in improving health behaviours that reduce the potential risk of cardiovascular disease and poor bone health For more on the James Lind Alliance see [URL] nihr.ac.uk/ Series 966 www.thelancet.com Vol 403 March 9, 2024 8 Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF.",
    "Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992; 7: 1342–46. 9 Ginsberg J. What determines the age at the menopause? BMJ 1991; 302: 1288–89. 10 Davis SR, Lambrinoudaki I, Lumsden M, et al. Menopause. Nat Rev Dis Primers 2015; 1: 15004. 11 Mishra GD, Pandeya N, Dobson AJ, et al. Early menarche, nulliparity and the risk for premature and early natural menopause. Hum Reprod 2017; 32: 679–86. 12 Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric 2019; 22: 403–11. 13 Wang M, Kartsonaki C, Guo Y , et al. Factors related to age at natural menopause in China: results from the China Kadoorie Biobank. Menopause 2021; 28: 1130–42. 14 Meher T, Sahoo H. Premature menopause among women in India: evidence from National Family Health Survey-IV. J Obstet Gynaecol Res 2021; 47: 4426–39. 15 Pallikadavath S, Ogollah R, Singh A, Dean T, Dewey A, Stones W. Natural menopause among women below 50 years in India: a population-based study. Indian J Med Res 2016; 144: 366–77. 16 Ahuja M. Age of menopause and determinants of menopause age: a PAN India survey by IMS. J Midlife Health 2016; 7: 126–31. 17 Sievert LL. Menopause: a biocultural perspective. New Brunswick, NJ: Rutgers University Press, 2006. 18 Gottschalk MS, Eskild A, Hofvind S, Gran JM, Bjelland EK.",
    "J Midlife Health 2016; 7: 126–31. 17 Sievert LL. Menopause: a biocultural perspective. New Brunswick, NJ: Rutgers University Press, 2006. 18 Gottschalk MS, Eskild A, Hofvind S, Gran JM, Bjelland EK. Temporal trends in age at menarche and age at menopause: a population study of 312 656 women in Norway. Hum Reprod 2020; 35: 464–71. 19 Appiah D, Nwabuo CC, Ebong IA, Wellons MF, Winters SJ. Trends in age at natural menopause and reproductive life span among US women, 1959–2018. JAMA 2021; 325: 1328–30. 20 Lewington S, Li L, Murugasen S, et al. Temporal trends of main reproductive characteristics in ten urban and rural regions of China: the China Kadoorie Biobank study of 300 000 women. Int J Epidemiol 2014; 43: 1252–62. 21 Lagergren K, Hammar M, Nedstrand E, B ladh M, Sydsjö G. The prevalence of primary ovarian insufficiency in Sweden; a national register study. BMC Womens Health 2018; 18: 175. 22 Gargus E, Deans R, Anazodo A, Woodruff TK. Management of primary ovarian insufficiency symptoms in survivors of childhood and adolescent cancer. J Natl Compr Canc Netw 2018; 16: 1137–49. 23 Rosendahl M, Simonsen MK, Kjer JJ. The influence of unilateral oophorectomy on the age of menopause. Climacteric 2017; 20: 540–44. 24 Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F, Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol 2011; 118: 1271–79. 25 Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ.",
    "Obstet Gynecol 2011; 118: 1271–79. 25 Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause 2011; 18: 956–61. 26 van Asselt KM, Kok HS, Pearson PL, et al. H eritability of menopausal age in mothers and daughters. Fertil Steril 2004; 82: 1348–51. 27 Murabito JM, Yang Q, Fox C, Wilson PW, Cupples LA. Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 3427–30. 28 Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril 1995; 64: 740–45. 29 Torgerson DJ, Thomas RE, Reid DM. Mothers and daughters menopausal ages: is there a link? Eur J Obstet Gynecol Reprod Biol 1997; 74: 63–66. 30 Ruth KS, Day FR, Hussain J, et al. Genetic insights into biological mechanisms governing human ovarian ageing. Nature 2021; 596: 393–97. 31 Dasgupta D, Pal B, Ray S. F actors that discriminate age at menopause: a study of Bengali Hindu women of West Bengal. Am J Hum Biol 2015; 27: 710–15. 32 Giri R, Vincent AJ. Prevalence and risk factors of premature ovarian insufficiency/early menopause. Semin Reprod Med 2020; 38: 237–46. 33 Mishra GD, Chung HF, Cano A, et al. EMAS position statement: predictors of premature and early natural menopause. Maturitas 2019; 123: 82–88. 34 Zhu D, Chung HF, Pandeya N, et al.",
    "33 Mishra GD, Chung HF, Cano A, et al. EMAS position statement: predictors of premature and early natural menopause. Maturitas 2019; 123: 82–88. 34 Zhu D, Chung HF, Pandeya N, et al. Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: a pooled analysis of individual data from 17 observational studies. PLoS Med 2018; 15: e1002704. 35 Hunter MS, Mann E. A cognitive model of menopausal hot flushes and night sweats. J Psychosom Res 2010; 69: 491–501. 36 National Institutes of Health. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consens State Sci Statements 2005; 22: 1–38. 37 Zervas IM, Lambrinoudaki I, Spyropoulou AC, et al. Additive effect of depressed mood and vasomotor symptoms on postmenopausal insomnia. Menopause 2009; 16: 837–42. 38 Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril 2014; 101: 905–15. 39 Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007; 110: 230–40. 40 Zou P, Luo Y , Wyslobicky M, et al. Menopausal experiences of South Asian immigrant women: a scoping review. Menopause 2022; 29: 360–71. 41 Zou P, Shao J, Luo Y , Huang Y , Zhang H, Sidani S. Menopausal transition experiences and management strategies of Chinese immigrant women: a scoping review. Menopause 2020; 27: 1434–43. 42 Nappi RE, Kroll R, Siddiqui E, et al.",
    "Menopause 2020; 27: 1434–43. 42 Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause 2021; 28: 875–82. 43 Benshushan A, Rojansky N, Chaviv M, et al. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo- oophorectomy. Climacteric 2009; 12: 404–09. 44 Hickey M, Moss KM, Krejany EO, et al. What happens after menopause? (WHAM): a prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol Oncol 2021; 163: 148–54. 45 Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. J Psychosom Obstet Gynaecol 2000; 21: 167–74. 46 Avis NE, Colvin A, Bromberger JT, et al. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women’s Health Across the Nation. Menopause 2009; 16: 860–69. 47 Bryson A, Conti G, Hardy R, P eycheva D, Sullivan A. The consequences of early menopause and menopause symptoms for labour market participation. Soc Sci Med 2022; 293: 114676. 48 Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health 2013; 22: 983–90. 49 Orshan SA, Ventura JL, Covington SN, V anderhoof VH, Troendle JF, Nelson LM.",
    "J Womens Health 2013; 22: 983–90. 49 Orshan SA, Ventura JL, Covington SN, V anderhoof VH, Troendle JF, Nelson LM. Women with spontaneous 46,XX primary ovarian insufficiency (hypergonadotropic hypogonadism) have lower perceived social support than control women. Fertil Steril 2009; 92: 688–93. 50 Groff AA, Covington SN, Halverson LR, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril 2005; 83: 1734–41. 51 Deeks AA, Gibson-Helm M, T eede H, Vincent A. Premature menopause: a comprehensive understanding of psychosocial aspects. Climacteric 2011; 14: 565–72. 52 van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003; 14: 525–30. 53 Svejme O, Ahlborg HG, Nilsson JA, Karlsson MK. Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. BJOG 2012; 119: 810–16. 54 van der Klift M, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 2004; 19: 1172–80. 55 De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376: 911–21. 56 Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 2012; 19: 1081–87.",
    "Menopause 2012; 19: 1081–87. Series www.thelancet.com Vol 403 March 9, 2024 967 57 Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016; 1: 767–76. 58 Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019; 4: e553–64. 59 Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 2020; 35: 1933–43. 60 Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA 2019; 322: 2411–21. 61 Georgakis MK, Thomopoulos TP, Diamantaras AA, et al. Association of age at menopause and duration of reproductive period with depression after menopause: a systematic review and meta-analysis. JAMA Psychiatry 2016; 73: 139–49. 62 Singer D, Mann E, Hunter MS, Pitkin J, Panay N. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric 2011; 14: 428–37 . 63 Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petri- dou ET.",
    "Climacteric 2011; 14: 428–37 . 63 Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petri- dou ET. Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta- analysis. Psychoneuroendocrinology 2019; 106: 9–19. 64 Yoo JE, Shin DW, Han K, et al. Female reproductive factors and the risk of dementia: a nationwide cohort study. Eur J Neurol 2020; 27: 1448–58. 65 Ryan J, Scali J, Carrière I, et al. Impact of a premature menopause on cognitive function in later life. BJOG 2014; 121: 1729–39. 66 Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012; 13: 1141–51. 67 Nichols HB, Visvanathan K, Newcomb PA, et al. Bilateral oophorectomy in relation to risk of postmenopausal breast cancer: confounding by nonmalignant indications for surgery? Am J Epidemiol 2011; 173: 1111–20. 68 Jacobsen BK, Heuch I, Kvåle G. Age at natural menopause and all- cause mortality: a 37-year follow-up of 19 731 Norwegian women. Am J Epidemiol 2003; 157: 923–29. 69 Tao XY , Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric 2016; 19: 27–36. 70 Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162: 1089–97.",
    "Climacteric 2016; 19: 27–36. 70 Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162: 1089–97. 71 Cusimano MC, Chiu M, Ferguson SE, et al. Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: population based cohort study. BMJ 2021; 375: e067528. 72 The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022; 29: 767–94. 73 Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19: 109–50. 74 British Menopause Society . BMS & WHC’s 2020 recommendations on hormone replacement therapy in menopausal women. British Menopause Society, March, 2021. [URL] publications/consensus-statements/bms-whcs-2020- recommendations-on-hormone-replacement-therapy-in- menopausal-women/(accessed Feb 8, 2024). 75 Touboul C, Uzan C, Ichanté JL, et al. Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer. Oncologist 2011; 16: 1250–57. 76 National Institute for Health and Care Excellence. NICE guideline (NG23). Menopause: diagnosis and management. National Institute for Health and Care Excellence, Nov 12, 2015. [URL] uk/guidance/ng23 (accessed Feb 8, 2024).",
    "NICE guideline (NG23). Menopause: diagnosis and management. National Institute for Health and Care Excellence, Nov 12, 2015. [URL] uk/guidance/ng23 (accessed Feb 8, 2024). 77 Alzubaidi NH, Chapin HL, Vanderhoof VH, Calis KA, N elson LM. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002; 99: 720–25. 78 Johnston-Ataata K, Flore J, Kokanovic R. Women’s experiences of diagnosis and treatment of early menopause and premature ovarian insufficiency: a qualitative study. Semin Reprod Med 2020; 38: 247–55. 79 Posadzki P, Lee MS, Moon TW, Choi TY , Park TY , Ernst E. Prevalence of complementary and alternative medicine (CAM) use by menopausal women: a systematic review of surveys. Maturitas 2013; 75: 34–43. 80 Sarri G, Pedder H, Dias S, Guo Y , Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG 2017; 124: 1514–23. 81 van Driel CM, Stuursma A, Schroevers MJ, Mourits MJ, de Bock GH. Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. BJOG 2019; 126: 330–39. 82 Pyri F, Abedi P, Maraghi E, J efreh M. Erratum: the effect of mindfulness on quality of life among women with premature ovarian insufficiency: a randomized clinical trial.",
    "BJOG 2019; 126: 330–39. 82 Pyri F, Abedi P, Maraghi E, J efreh M. Erratum: the effect of mindfulness on quality of life among women with premature ovarian insufficiency: a randomized clinical trial. J Midlife Health 2021; 12: 250. 83 Hickey M, Szabo RA, Hunter MS. Non-hormonal treatments for menopausal symptoms. BMJ 2017; 359: j5101. 84 Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; 9: CD004923. 85 Menown SJ, Tello JA. Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review. Adv Ther 2021; 38: 5025–45. 86 Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 2023; 401: 1091–102. 87 Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–83. 88 Prentice RL, Pettinger MB, Jackson RD, et al. H ealth risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int 2013; 24: 567–80. 89 Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.",
    "89 Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (suppl 1): S3–18. 90 Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects: a review. JAMA 2021; 326: 2507–18. 91 Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society white paper. Climacteric 2020; 23: 426–46. 92 Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005; 16: 556–62. 93 Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1729–38. 94 Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12. 95 McClung MR. The relationship between bone mineral density and fracture risk. Curr Osteoporos Rep 2005; 3: 57–63. 96 Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998; 280: 605–13. 97 Manson JE, Hsia J, Johnson KC, et al.",
    "Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998; 280: 605–13. 97 Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–34. Series 968 www.thelancet.com Vol 403 March 9, 2024 98 Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003; 289: 2673–84. 99 Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 3: CD002229. 100 Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–77. 101 Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16: 15–23. 102 Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651–62. 103 Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017; 377: 2228–39.",
    "103 Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017; 377: 2228–39. 104 Barańska A, Błaszczuk A, Kanadys W, M alm M, Drop K, Polz-Dacewicz M. Oral contraceptive use and breast cancer risk assessment: a systematic review and meta-analysis of case-control studies, 2009–2020. Cancers 2021; 13: 5654. 105 Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA 2017; 318: 927–38. 106 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159–68. 107 Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA 2020; 324: 369–80. 108 Vinogradova Y , Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020; 371: m3873. 109 Yeganeh L, Boyle JA, Wood A, Teede H, Vincent AJ. Menopause guideline appraisal and algorithm development for premature ovarian insufficiency. Maturitas 2019; 130: 21–31.",
    "BMJ 2020; 371: m3873. 109 Yeganeh L, Boyle JA, Wood A, Teede H, Vincent AJ. Menopause guideline appraisal and algorithm development for premature ovarian insufficiency. Maturitas 2019; 130: 21–31. 110 Jane FM, Davis SR. A practitioner’s toolkit for managing the menopause. Climacteric 2014; 17: 564–79. 111 Department of Health and Social C are. Our vision for the Women’s Health Strategy for England. Dec 23, 2021. [URL] government/publications/our-vision-for-the-womens-health- strategy-for-england (accessed Feb 8, 2024). 112 Department for Health and Social C are. Results of the ‘Women’s Health – Let’s talk about it’ survey. April 13, 2022. [URL] uk/government/calls-for-evidence/womens-health-strategy-call-for- evidence/outcome/results-of-the-womens-health-lets-talk-about-it- survey (accessed Feb 8, 2024). 113 Yeganeh L, Johnston-Ataata K, Vincent AJ, et al. Co-designing an early menopause digital resource: model for interdisciplinary knowledge translation. Semin Reprod Med 2020; 38: 315–22. 114 Ray S. Is menopause a health risk for Bengali women? Open Anthropol J 2010; 3: 161–67. 115 Syamala T, Sivakami M. M enopause: an emerging issue in India. Econ Polit Wkly 2005; 40: 4923–30. Copyright © 2024 Elsevier Ltd. All rights reserved.",
    "Series www.thelancet.com Vol 403 March 9, 2024 969 Menopause 3 Promoting good mental health over the menopause transition Lydia Brown, Myra S Hunter, Rong Chen, Carolyn J Crandall, Jennifer L Gordon, Gita D Mishra, Viktoria Rother, Hadine Joffe*, Martha Hickey* The potential risk for mental health conditions over the menopause transition shapes women’s expectations and informs putative physiological mechanisms regulating women’s mental health. We review evidence from prospective studies reporting on associations between mental health conditions and the menopause transition. Major depressive disorder and the more prevalent subthreshold depressive symptoms are the most common conditions studied. We reviewed 12 prospective studies reporting depressive symptoms, major depressive disorder, or both over the menopause transition and found no compelling evidence for a universal increased risk for either condition. However, specific subgroups of participants, primarily defined by menopause-related risk factors (ie, vasomotor symptoms that are severe or disturb sleep, a long duration of the transition, or reproductive hormone dynamics) and psychosocial risk factors (eg, stressful life events), were vulnerable to depressive symptoms. The increased risk of major depressive disorder over the menopause transition appears predominantly in individuals with previous major depressive disorder. Greater focus on recognising risk factors in primary care is warranted.",
    "Greater focus on recognising risk factors in primary care is warranted. On the basis of scarce data, we found no compelling evidence that risk of anxiety, bipolar disorder, or psychosis is universally elevated over the menopause transition. Potential misattribution of psychological distress and psychiatric disorders to menopause could harm women by delaying accurate diagnosis and the initiation of effective psychotropic treatments, and by creating negative expectations for people approaching menopause. A paradigm shift is needed. We conclude with recommendations for the detection and treatment of depressive symptoms or major depressive disorder and strategies to promote good mental health over the menopause transition, while responsibly preparing and supporting those at risk. Introduction The menopause transition usually starts around age 47 years with the onset of menstrual changes and ends at the final menstrual period. 1 Perimenopause is a related term. Perimenopause includes the menopause transition and the 12 months following the final menstrual period (early postmenopausal stage). The attribution of psychological distress to the menopause in high-income countries is long-standing. In 1816, Charles-Pierre-Louis de Gardanne included “hysteria, or nervous affection of the uterus” as a typical symptom of the menopause.",
    "In 1816, Charles-Pierre-Louis de Gardanne included “hysteria, or nervous affection of the uterus” as a typical symptom of the menopause. 2 In 1959, Kupperman, Wetchler, and Blatt described the menopause as a “rather unpleasant and possibly dangerous” 3 period of life, and developed the first widely used menopause symptom checklist. 4 Notably, this scale, the 11-item Blatt– Kupperman Index, includes psychological symptoms such as melancholia and nervousness, informing the inclusion of psychological symptoms in contemporary menopause rating scales. 5,6 Although this approach has raised the profile of mental health conditions requiring care, it might also have contributed to the widespread belief that the menopause transition is universally associated with poor mental health. Anxiety, 7,8 paranoid thinking,9 schizophrenic psychosis,10 and even suicidality11,12 have been attributed to the menopause, yet the empirical evidence to support these claims has not been subject to rigorous scientific review. This Series paper has three objectives. First, we review findings from prospective studies investigating the association between the menopause transition and risk of mental health symptoms and disorders, including depression, anxiety, bipolar disorder, psychosis, and suicide risk.",
    "Second, since most research has focused on the relationship between the menopause transition and the risk of depressive symptoms and major depressive disorder, we contextualise these findings and explore vulnerability factors that help explain why some subgroups of people are at risk of depressive symptoms Lancet 2024; 403: 969–83 Published Online March 5, 2024 [URL] S0140-6736(23)02801-5 See Perspectives pages 893 and 894 This is the third in a Series of four papers about menopause. All papers in the Series are available at www.thelancet.com/ series/menopause-2024.",
    "All papers in the Series are available at www.thelancet.com/ series/menopause-2024. *Joint senior authors Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, VIC, Australia (L Brown PhD MPsych); Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne and the Royal Women’s Hospital, Melbourne, VIC, Australia (Prof M Hickey MBChB MD); Academic Research Collaborative in Health, La Trobe University, Bundoora, VIC, Australia (L Brown); Healthscope Hospitals, Melbourne, VIC, Australia (L Brown); Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK (M S Hunter PhD); Department of Obstetrics and Gynaecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China (R Chen MD); Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA (C J Crandall MD MS); Department of Psychology, University of Regina, Regina, SK, Canada (J L Gordon PhD); NHMRC Centre for Research Excellence in Women and NCDs, School of Public Health, University of Queensland, Brisbane, QLD, Australia (Prof G D Mishra PhD); Inner West Area Mental Health Service, Royal Melbourne Hospital, Melbourne, VIC, Key messages • Concerns about increased risks of anxiety and depression may shape expectations and experiences of menopause.",
    "• However, women are not universally or uniformly at risk of psychological symptoms over the menopause transition. • Risk factors for depressive symptoms at this time include severe and prolonged vasomotor symptoms, chronic sleep disturbance, and stressful life events, and women with previous depressive disorder might be at increased risk of recurrence of a new depressive episode during the menopause transition. • The menopause transition often coincides with important life stressors, health conditions, and role transitions that increase vulnerability to depression. • Clinicians should not assume that psychological symptoms during the menopause transition are always attributable to hormonal changes and should offer evidence-based treatments; menopausal hormone therapy can improve concurrent depressive symptoms for patients with troublesome vasomotor symptoms. Series 970 www.thelancet.com Vol 403 March 9, 2024 Australia (V Rother MSc); Connors Center for Women’s Health and Gender Biology and Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA (H Joffe MD MSc) Correspondence to: Dr Lydia Brown, Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, VIC 3052, Australia [EMAIL] or major depressive disorder over the menopause transition.",
    "Third, we conclude with recommendations for the detection and treatment of depressive symptoms or major depressive disorder and strategies to promote mental health over the menopause transition. Menopause happens to all people with typically functioning ovaries who reach the relevant age. We recognise that this population includes some transgender men and other gender-diverse people; therefore, in this Series, we sometimes refer to “people” rather than “women” in order to be as accurate and inclusive as possible. However, since much published work refers to people experiencing menopause collectively as women and does not clarify how findings might apply to the specific needs of gender-diverse people, we have also used “women” in some instances, to avoid inappropriate generalisation. More information is needed about the experience of menopause in transgender men and gender-diverse people. 13 Search strategy and selection criteria We searched the databases MEDLINE, Embase, and PsycInfo from Jan 1, 1990, to July 1, 2023. Key terms were customised for individual sections and included “menopaus*”, “perimenopause*”, and “postmenopaus*” combined with “depression”, “depressive disorder*”, “anxiety”, “bipolar”, “bi-polar”, “psychosis”, “psychotic”, “schizophren*”, and “suicid*”.",
    "For sections reporting on the absolute and relative risk of mental health symptoms or disorders over the menopause transition, we limited our review a priori to cohort studies with more than 100 participants for whom prospective data on the risk of mental health symptoms or disorders in the menopause transition compared with before the menopause transition (ie, premenopause) were available. When a prospective study reported data in more than one paper, we have reported findings from the most comprehensive study with the largest sample size or longest follow-up period. Findings were cross-checked against relevant meta-analyses, systematic reviews, and clinical guidelines. In sections reporting on risk factors and recommendations, we prioritised findings from prospective studies, clinical guidelines, and recent randomised controlled trials (RCTs). Findings from prospective studies Depression An association between the menopause and depression is widely promoted. Highly cited papers state a doubled to quadrupled risk of depressive symptoms or depressive disorders over the menopause transition. 7,14,15 However, most papers report the relative risk rather than the absolute risk. Furthermore, studies have often not adequately distinguished between depressive symptoms and depressive disorder.",
    "7,14,15 However, most papers report the relative risk rather than the absolute risk. Furthermore, studies have often not adequately distinguished between depressive symptoms and depressive disorder. Generally, depressive symptoms are more prevalent, less debilitating, and do not constitute a clinical depressive disorder, the most common and burdensome of which is major depressive disorder (table 1). 18 The presence of depressive symptoms does not necessarily imply that a person is experiencing a depressive episode. 19 Self-report scales typically include generic symptoms, such as sleep problems, appetite disturbance, and fatigue, that have a range of physical, psychological, and social causes that are not limited to depression. For example, during the menopause transition, vasomotor symptoms (hot flushes and night sweats) might cause sleep disturbance, which could elevate scores on a depressive symptom scale even without core depressive symptoms (ie, low mood and anhedonia).",
    "Definitive diagnosis of major Major depressive disorder Depressive symptoms Method of assessment Typically assessed by a trained health professional through a clinical interview Assessed through a self-administered questionnaire Prevalence Global 12-month prevalence of approximately 6%16 Prevalence is established with a cutoff score to represent the presence or absence of clinically significant symptoms; on the 20-item CES-D, a cutoff score of ≥16 is commonly used to indicate the presence of clinically significant depressive symptoms Symptoms Nine symptoms including two core symptoms of depressed mood and anhedonia; symptoms can be remembered with the SIGECAPS mnemonic: depressed mood and sleep changes (insomnia or hypersomnia), interest (markedly diminished pleasure in all or almost all activities), guilt (excessive guilt or feelings of worthlessness), energy loss or fatigue, concentration disturbance, appetite or weight changes, psychomotor retardation or agitation, and suicidal ideation or thoughts of death that are recurrent The CES-D measures symptoms of depression on a frequency scale ranging from 0 (rarely or none of the time) to 3 (most or all the time) Diagnosis Requires co-occurrence of at least five of the nine symptoms, including at least one core symptom; symptoms must be sustained and clearly present nearly every day and must represent a change from previous functioning; symptoms must cause clinically significant distress or impairment in daily life functioning The CES-D is not diagnostic of major depressive disorder; meta-analysis 17 indicates that a cutoff of ≥16 on the CES-D has a specificity of only 0·70 for major depressive disorder in the general population or primary care settings Timeframe Symptoms must persist over at least 2 weeks Symptoms can ebb and flow and might not be sustained; the CES-D measures symptoms over the past week CES-D=Center for Epidemiologic Studies Depression Scale.",
    "Table 1: Differences between major depressive disorder and depressive symptoms Series www.thelancet.com Vol 403 March 9, 2024 971 Country Participants (n) Ethnicity Inclusion criteria Duration of follow-up Outcome measure Effect of the menopause transition on risk of depressive symptoms Major depressive disorder* Study of Women’s Health Across the Nation (SWAN)† 20–22 USA 443 47% White; 28% African American; 25% Chinese, Hispanic, or Japanese Premenopausal or perimenopausal women aged 42–52 years at baseline with an intact uterus and no use of MHT 13 years and 13 assessments SCID The most recent publication (13 years of follow-up) with the largest sample size 20 found that the menopause transition was associated with an increased risk of recurrence of major depressive disorder (HR 2·67, 95% CI 1·04–6·86, p=0·04 in perimenopause; 4·03, 1·15–14·15, p=0·03 in early postmenopause) but not new onset major depressive disorder Zurich Study‡ 23 Switzerland 168 Not reported Women aged 21 years at baseline 29 years and seven assessments (menopause data measured at two timepoints) SPIKE Women who transitioned to perimenopause (OR 0·71, 95% CI 0·34–1·51) or postmenopause (0·57, 0·24–1·37) were not at increased risk of major depressive disorder Depressive symptoms Penn Ovarian Aging Study (POAS)§ 15,24,25 USA 436 Stratified sample: 50% African American and 50% White Premenopausal women aged 35– 47 years at baseline 8 years and ten assessments CES-D (cutoff of 16) At 8-year follow-up, the",
    "15,24,25 USA 436 Stratified sample: 50% African American and 50% White Premenopausal women aged 35– 47 years at baseline 8 years and ten assessments CES-D (cutoff of 16) At 8-year follow-up, the menopause transition was associated with a quadrupled risk of new onset depressive symptoms in a subsample without a personal history (n=231) relative to the premenopausal baseline (OR 4·29, 95% CI 2·39–7·72), and the effect was stronger (5·44, 2·56–11·59) when adjusting for covariates; however, data at 14 years of follow-up 24 show evidence of declining depressive symptom prevalence from 10 years before to 7 years after the menopause Study of Women’s Health Across the Nation (SWAN) §26,27 USA 3302 47% White; 28% African American; and 25% Chinese, Hispanic,or Japanese Premenopausal or perimenopausal women aged 42–52 years at baseline with an intact uterus and no use of MHT 13 years and 13 assessments CES-D (cutoff of 16) The early and late menopause transitions were associated with elevated risk of depressive symptoms, with the highest risk in the late menopause transition (adjusted OR 1·68, 95% CI 1·28–2·20) and early postmenopause (1·83, 1·40–2·42) Australian Longitudinal Study of Women’s Health (ALSWH)† 28 Australia 5895 73% Australian- born; 17% from another English- speaking background; 6% European; and 3·5% Asian or other Women aged 45–50 years at baseline; women reporting use of an oral contraceptive pill were excluded from analysis 15 years and seven assessments CES-D",
    "background; 6% European; and 3·5% Asian or other Women aged 45–50 years at baseline; women reporting use of an oral contraceptive pill were excluded from analysis 15 years and seven assessments CES-D (continuous) In longitudinal analyses, entering the menopause transition did not increase the risk of depressive symptoms (adjusted B 0·03, 95% CI –0·29 to 0·35); remaining in the menopause transition at consecutive study timepoints was associated with increased depressive symptoms: women in the menopause transition scored 0·29 points higher on the CES-D 10 compared with women remaining in postmenopause (95% CI 0·02 to 0·61); overall, women in the menopause transition scored 0·19 points higher on the CES-D compared with those in postmenopause (–0·02 to 0·31) Eindhoven Perimenopausal Osteoporosis Study† 29 Netherlands 2103 100% Dutch Women aged between approximately 47 years and 54 years; women who used hormone therapy or who had undergone hysterectomy or oophorectomy were excluded from analyses 3·5 years and two assessments EDS (cutoff of 12) Entering the menopause transition was potentially a risk factor for depressive symptoms in multivariate modelling, but the effect was sensitive to the statistical methodology used; with the step-wise method of logistic regression, transition from premenopause to perimenopause (OR 1·80, 95% CI 1·12–3·33) and perimenopause to postmenopause (1·81, 1·25–2·26) were associated with a significantly increased risk of depressive symptoms; with the",
    "premenopause to perimenopause (OR 1·80, 95% CI 1·12–3·33) and perimenopause to postmenopause (1·81, 1·25–2·26) were associated with a significantly increased risk of depressive symptoms; with the enter method of logistic regression, the transition from premenopause to perimenopause did not increase the risk of depressive symptoms (1·14, 0·64–2·02) (Table 2 continues on next page) Series 972 www.thelancet.com Vol 403 March 9, 2024 Country Participants (n) Ethnicity Inclusion criteria Duration of follow-up Outcome measure Effect of the menopause transition on risk of depressive symptoms (Continued from previous page) Harvard Study of Mood and Cycles †14 USA 460 Not reported Premenopausal women aged 36–45 years at baseline with no lifetime diagnosis of major depressive disorder 6 years and seven assessments (six assessments in the first 3 years, and the seventh at 6 years) CES-D (cutoff of 16), SCID, or at least one positive response to three questions about mood symptoms Overall, the menopause transition was associated with increased risk of depressive symptoms at borderline statistical significance (OR 1·8, 95% CI 1·0–3·2); women with both vasomotor symptoms and stressful life events were at increased risk of depressive symptoms during the menopause transition (adjusted OR 2·5, 95% CI 1·2–5·2); for women with one or neither of these risk factors, risk of depressive symptoms was not increased over the menopause transition Massachusetts Women’s Health Study† 30 USA 2565 Not",
    "95% CI 1·2–5·2); for women with one or neither of these risk factors, risk of depressive symptoms was not increased over the menopause transition Massachusetts Women’s Health Study† 30 USA 2565 Not reported Premenopausal and perimenopausal women aged 45–55 years at baseline with a uterus and at least one ovary intact 5 years and six assessments CES-D (cutoff of 16) Risk of depressive symptoms was independent of reproductive stage, but women experiencing a long menopause transition (>27 months) were twice as likely to report depressive symptoms; this effect was accounted for by including vasomotor symptoms and the presence of menstrual problems in multivariate modelling Personality and Total Health Through Life (PATH)† 31 Australia 711 Not reported Premenopausal women aged 40–44 years at baseline; women using MHT and women who had had an oophorectomy or hysterectomy were excluded from analyses 8 years and two assessments GDS (symptom count) Women in the menopause transition at follow-up were at greater risk of experiencing depressive symptoms relative to women who remained premenopausal (IRR 1·29, 95% CI 1·10–1·52); in subgroup analyses, the effect was only seen in women without a probable history of major depressive disorder (1·35, 1·08–1·68); depressive symptoms were independent of reproductive stage among women with a personal history of probable major depressive disorder Seattle Midlife Women’s Health Study† 32 USA 302 77% White; 11% African American; and 8·3% Asian",
    "of reproductive stage among women with a personal history of probable major depressive disorder Seattle Midlife Women’s Health Study† 32 USA 302 77% White; 11% African American; and 8·3% Asian American, or Pacific Islander Women aged 35–55 years at baseline; women taking hormones were excluded from analyses 9 years and annual assessments CES-D Risk of depressive symptoms was independent of reproductive stage; reproductive stages were not significant predictors of depressive symptoms when entered simultaneously in a multivariable model but were included in the final model because they were the major research focus of the paper; in the final model, the late menopause transition was associated with elevated depressive symptoms (β 1·37, p=0·03) The Manitoba Project† 33 Canada 477 Not reported Women aged 45–55 years who had either menstruated in the past 3 months or had previously had a hysterectomy 3 years and six assessments (depressive symptoms measured at five timepoints) CES-D (cutoff of 16) The menopause transition was not associated with an increased risk of depressive symptoms compared with remaining premenopausal; however, among women without depressive symptoms at baseline, women who had a hysterectomy were more likely to develop depressive symptoms than premenopausal women (OR 1·7, 95% CI 1·15–2·6) Midlife Women’s Health Study‡ 34 USA 264 51% White; 26% African American; and 23% Latina Regularly menstruating individuals aged 40–50 years; women taking hormone therapy or",
    "(OR 1·7, 95% CI 1·15–2·6) Midlife Women’s Health Study‡ 34 USA 264 51% White; 26% African American; and 23% Latina Regularly menstruating individuals aged 40–50 years; women taking hormone therapy or antidepressants, or who had a history of major chronic illness were excluded from enrolment 3 years and six assessments CES-D At 36 months, only 64 women (24%) had transitioned to being in the menopause transition; menopausal stage was not a significant predictor of CES-D scores or risk of depression (score ≥16); women who were in the menopause transition had a non-significantly higher mean score on the CESD (mean 12·6) compared with women who remained premenopausal (10·9) (Table 2 continues on next page) Series www.thelancet.com Vol 403 March 9, 2024 973 depressive disorder requires clinician-rated interviews.",
    "Of the 12 prospective studies investigating the association between the menopause transition and depression (table 2), only two 20,23 have uniformly diagnosed major depressive disorder with clinician- rated interviews, probably due to the expense of implementing this assessment. Hence, our understanding of the risk of major depressive disorder over the menopause transition assessed uniformly by clinical interviews is limited to data from 600 women globally. Major depressive disorder Major depressive disorder affects approximately 6% of the global population each year and is diagnosed twice as often in women as in men. 16 The mechanisms underlying this sex difference are poorly understood, but changes in endogenous sex steroid hormones have been identified as a contributory factor. 1 The menopause transition is marked by changes in circulating sex steroids compared with before the menopause transition (premenopause). 37 Specifically, oestradiol variability is more marked during the early menopause transition, and then progesterone production reduces then stops as ovulation ceases in the late menopause transition. 1 The menopause transition often coincides with substantial midlife stresses, health conditions, and role transitions, which increase individuals’ vulnerability to depression. 20 One prospective study suggests that women with a previous history of major depressive disorder are at increased risk of recurrence over the menopause transition.",
    "20 One prospective study suggests that women with a previous history of major depressive disorder are at increased risk of recurrence over the menopause transition. The Study of Women’s Health Across the Nation (SWAN) Mental Health substudy (n=425) 20 reported a 2·67-fold increased risk of major depressive disorder recurrence over the menopause transition (95% CI 1·04–6·86; p=0·04). 20 However, there was no increased risk of first lifetime episodes of major depressive disorder. First-onset major depressive disorder was predicted by risk factors unrelated to the menopause transition, such as trait anxiety, low physical functioning, and physical illness. Over 30 years, the longitudinal Zurich Study (n=168) 23 measured the prevalence of major depressive disorder at age 41 years and again at age 50 years. They found no increase in major depressive disorder in people who became perimenopausal or postmenopausal over this period, although only 27% of the sample group had reached postmenopause at follow- up and, unlike SWAN, this study did not include annual assessments of reproductive stage and mood. In summary, the few available prospective data suggest that the menopause transition might be a vulnerable period for the recurrence of major depressive disorder but not for first lifetime onset of this condition. Future research is needed to clarify menopause-related factors that might increase the risk of first lifetime onset major depressive disorder during the menopause transition.",
    "Future research is needed to clarify menopause-related factors that might increase the risk of first lifetime onset major depressive disorder during the menopause transition. Country Participants (n) Ethnicity Inclusion criteria Duration of follow-up Outcome measure Effect of the menopause transition on risk of depressive symptoms (Continued from previous page) PALM Study‡ 35 China 430 Not reported Women aged 35–64 years with an intact uterus and at least one ovary; women who had had a hysterectomy or were taking hormone therapies were excluded from analyses 9 years and annual assessments HADS-D (cutoff of ≥8) There was no evidence of increased risk of depressive symptoms during the menopause transition; the prevalence of depressive symptoms was 14·5% in women with premenopause, 18·2% during the menopause transition, and 19·6% in postmenopause; these differences were not statistically significant Zurich Study‡ 23 Switzerland 168 Not reported Women aged 21 years at baseline 29 years and seven assessments (menopause data measured at two timepoints when women were aged 41 years and 50 years) SCL-90-R The transition to perimenopause or postmenopause was not associated with increased risk of depressive symptoms (transition to perimenopause: b 0·090, 95% CI –0·13 to 0·31; transition to postmenopause: 0·00, –0·22 to 0·22) The self-report tools were either not valid measures of major depressive disorder14 or used the Patient Health Questionnaire, which has been found to greatly overestimate the prevalence of major depressive disorder.36 CES-D=Centre for Epidemiologic Studies Depression Scale.",
    "DSM=Diagnostic and Statistical Manual of Mental Disorders. EDS=Edinburgh Depression Scale. GDS=Goldberg Depression Scale. HADS-D=Hospital Anxiety and Depression Scale–depression subscale. HR=hazard ratio. IRR=incidence rate ratio. MHT=menopausal hormone therapy. OR=odds ratio. SCID=Structured Clinical Interview for DSM-IV. SCL-90-R=Symptom Checklist-90-Revised. SPIKE=Structured Psychopathological Interview and Rating of the Social Consequences of Psychological Disturbances for Epidemiology. *Major depressive disorder is uniformly diagnosed with a structured clinical interview. The Harvard Study of Mood and Cycles and the Penn Ovarian Aging Study were excluded from this section because they used a combination of clinical interviews and self-report screening tools to assess for major depressive disorder. †The study reported mixed findings or evidence of an effect limited to some women with risk factors. ‡The study did not find evidence of increased risk of depressive symptoms or disorders over the menopause transition compared with the premenopausal baseline. §The study found uniform increased risk of depressive symptoms or disorders over the menopause transition compared with the premenopausal baseline.",
    "§The study found uniform increased risk of depressive symptoms or disorders over the menopause transition compared with the premenopausal baseline. Table 2: Findings from prospective studies investigating the relationship between reproductive stage and depressive symptoms and disorders Series 974 www.thelancet.com Vol 403 March 9, 2024 Depressive symptoms Four prospective studies have measured the prevalence of depressive symptoms over the menopause transition for groups with and without previous major depressive disorder. 28,29,35,38 These studies report prevalences of between 16·5%29 and 27·8%,38 which are slightly higher than those seen in the late premenopause (between 14·3% 29 and 20·9%).38 However, a 13-year prospective study over the menopause transition reported that depressive symptoms were much higher (50–65%) in people with previous major depressive disorder. 24 These data suggest that for people without previous major depressive disorder, the absolute risk of depressive symptoms is not markedly elevated over the menopause transition. Less is known about the prevalence of depressive symptoms during the menopause transition in low- income and middle-income countries. Of the 12 prospective studies tracking changes in depressive symptoms across the menopause transition, only one, the PALM study from China, 35 was not conducted in a high-income country. The remaining studies were conducted in the USA (n=6), Europe (n=2), Australia (n=2), and Canada (n=1).",
    "The remaining studies were conducted in the USA (n=6), Europe (n=2), Australia (n=2), and Canada (n=1). The PALM study found a prevalence of depressive symptoms of 14·5% in the premenopause (baseline), which rose slightly to 18·2% during the menopause transition and to 19·6% in the postmenopause. These differences were not statistically significant. Of the 12 prospective studies that have considered the relative risk of depressive symptoms during the menopause transition compared with the premenopause, two 15,26 reported increased depressive symptoms, and three23,34,35 found no association. The remaining seven studies reported mixed results. Four identified specific subgroups as being at risk of depressive symptoms, including people with a combination of vasomotor symptoms and adverse life events in the 6 months before assessment, 14 people with a hysterectomy, 33 people without a history of probable major depressive disorder,31 and people with a longer duration of the menopause transition. 30 One study found an association contingent on time spent in the menopause transition. 28 Women who remained perimenopausal across recurrent surveys had a higher risk of depressive symptoms. Two studies found evidence of a possible association between depressive symptoms and the menopause, but this association was sensitive to the statistical approach used (table 2).",
    "Two studies found evidence of a possible association between depressive symptoms and the menopause, but this association was sensitive to the statistical approach used (table 2). 29,32 SWAN26,27 and the Penn Ovarian Aging Study (POAS)15,25 reported an increased risk of depressive symptoms over the menopause transition compared with the premenopause. SWAN 26,27 followed over 3000 women in the USA for more than 13 years and found an increase in depressive symptoms during the menopause transition (adjusted odds ratio [OR] 1·68, 95% CI 1·28–2·20). 26 At the 8-year follow-up in women who were aged 35–47 years and premenopausal at baseline, 15 POAS15,25 found that the menopause transition more than quadrupled the risk of depressive symptoms (OR 4·29, 95% CI 2·39–7·72). Taken in isolation, this result suggests a substantial risk of depressive symptoms that could be alarming for women and their clinicians. However, in women with no previous depressive disorder, a minority (10–30%) reported clinically significant depressive symptoms across both the late premenopause and menopause transition, with no obvious increase in depressive symptoms in the years preceding the final menstrual period (figure 1). 24 By contrast, 45–65% of women with previous major depressive disorder reported depressive symptoms over late premenopause and the menopause transition.",
    "24 By contrast, 45–65% of women with previous major depressive disorder reported depressive symptoms over late premenopause and the menopause transition. POAS found the risk of depressive symptoms reduced after menopause, 24 whereas SWAN found evidence of ongoing risk, especially in women with a history of depressive symptoms. 39 Five prospective studies did not find a universally increased risk of depressive symptoms over the menopause transition, but their findings offer clarification about at-risk subgroups. 14,28,30 The Harvard Study of Mood and Cycles 14 in the USA found a marginally significant association overall (OR 1·8, 95% CI 1·00–3·20), but subgroup analyses showed that only women with both vasomotor symptoms and stressful life events in the 6 months before assessment were at risk of depressive symptoms (adjusted OR 2·5, 95% CI 1·20–5·20). The duration of the menopause transition varies substantially between individuals. Both the Massachusetts Women’s Health Study (n=2565, USA) 30 and the Australian Longitudinal Study of Women’s Health (ALSWH; n =5,895)28 reported that Figure 1: Proportion of participants with a score of 16 or higher on the CES-D in each study year, grouped by history of depression at study enrolment Reproduced from Freeman and colleagues, 24 by permission of the American Medical Association. Error bars indicate SE. CES-D=Center for Epidemiologic Studies Depression Scale.",
    "Error bars indicate SE. CES-D=Center for Epidemiologic Studies Depression Scale. ≤–10 –9 –8 –7 –6 –5 –4 –3 –2 –1 0 1 2 3 4 5 6 7 ≥8 0 0·100 0·200 0·300 0·400 0·500 0·600 0·700 0·800 0·900 1·000 Proportion of participants with a CES-D score ≥16 Time before or after menopause (years) No history of depression History o f depression Series www.thelancet.com Vol 403 March 9, 2024 975 longer time spent in the menopause transition was associated with significantly increased risk of depressive symptoms. In the Massachusetts Study, increasing depressive symptoms associated with a long menopause transition were explained by vasomotor symptoms and menstrual symptoms in multivariable modelling. 30 In agreement, ALSWH found that women who remained perimenopausal across recurrent surveys had a higher risk of depressive symptoms (a Center for Epidemiologic Studies Depression Scale [CES-D] score of 0·29 points higher, 95% CI 0·02–0·61) than those who remained postmenopausal. PATH 31 found an association overall, but in subgroup analyses only individuals without a history of probable major depressive disorder were at increased risk of more symptoms of depression during the menopause transition (incidence rate ratio 1·35, 95% CI 1·08–1·68).",
    "The Manitoba Project 33 found no association between reproductive stage and risk of depressive symptoms overall, but participants with a hysterectomy who did not have depressive symptoms at baseline were more likely to develop depressive symptoms than those who were premenopausal (OR 1·7, 95% CI 1·15–2·6). The Eindhoven Perimenopausal Osteoporosis Study (EPOS) 29 and Seattle Midlife Women’s Health Study 32 found a possible increased risk of depressive symptoms over the menopause transition, but the association was sensitive to the statistical analysis used (table 2). For example, EPOS found evidence of increased symptoms of depression during the menopause transition with the stepwise method but not with the enter method of logistic regression. 29 The Zurich study,23 PALM study,35 and Midlife Women’s Health study 34 found no increased risk of depressive symptoms over the menopause transition. In the Midlife Women’s Health study, just 64 participants (24%) had entered the menopause transition at the endpoint of the study, which limited the study’s statistical power to detect an association. In summary, on the basis of mixed findings from prospective studies, we found no compelling evidence for a universal or uniform increased risk of depressive symptoms over the menopause transition. Greater awareness of risk factors might inform an understanding of the mechanisms underlying depressive symptoms in subgroups of women and provide new opportunities for prevention and treatment.",
    "Greater awareness of risk factors might inform an understanding of the mechanisms underlying depressive symptoms in subgroups of women and provide new opportunities for prevention and treatment. Anxiety Associations between the menopause transition and anxiety are poorly understood. 40 One prospective study measuring anxiety disorders found no increase over the menopause transition. 23 Four prospective studies have measured changes in anxiety symptoms over the menopause transition, with mixed results (appendix p 1). Two studies found no increase in anxiety symptoms over the menopause transition. 23,35 In contrast, the SWAN 41 and PATH31 studies found that people with low anxiety in the premenopause were at risk of increased anxiety symptoms during the menopause transition. The SWAN study controlled for vasomotor symptoms, which is important since symptoms of menopause can overlap with symptoms of anxiety, such as sweating, a racing heart, and rapid breathing. Findings from POAS suggest that anxiety exacerbates vasomotor symptoms. Women with physical symptoms of anxiety were at increased risk of developing moderate or severe vasomotor symptoms over the menopause transition. 42 In China, the PALM study 43 found a bidirectional longitudinal relationship between symptoms of anxiety and bother due to vasomotor symptoms, suggesting that anxiety could be both a cause and consequence of vasomotor symptoms.",
    "In summary, there is no consistent evidence that anxiety increases over the menopause transition. However, somatic anxiety might predict moderate or severe vasomotor symptoms, suggesting that reducing anxiety might reduce bother from vasomotor symptoms and is a potential target for intervention. Other mental health disorders Bipolar disorder No prospective studies have investigated psychiatric symptoms over the menopause transition in people with bipolar disorder. One small study (n=47) found that depressive episodes (but not mood elevation) measured prospectively over the menopause transition were increased compared with retrospective self-reports of premenopausal depressive episode frequency. 44 A systematic review of nine cross-sectional or retrospective studies reported an increase in symptoms of bipolar disorder over the menopause transition, largely on the basis of retrospective self-reports. 45 The largest of these studies found that 25·9% (57 of 220) of participants with bipolar 1 disorder retrospectively self-reported having “perimenopausal mood symptoms”, compared with 12·5% (7 of 56) of their relatives without a diagnosed mood disorder. 46 Schizophrenia spectrum and other psychotic disorders It has been widely suggested that the menopause transition is a vulnerable period for new onset or recurrent episodes of schizophrenic psychosis, 10 however empirical evidence supporting this claim is scarce.",
    "We found no prospective studies investigating rates of psychotic symptoms or disorders over the menopause transition. A meta-analysis of 83 studies found that women but not men experience a small increase in first lifetime onset psychosis after age 45 years. 47 These data informed the oestrogen hypothesis, which suggests that a decline in oestrogens across the menopause transition might trigger psychosis in women. 10 A large (n=61 889) Finnish study48 found that women with schizophrenia-spectrum See Online for appendix Series 976 www.thelancet.com Vol 403 March 9, 2024 disorders were more often hospitalised for psychosis after age 45 years than men were. 48 However, oestrogen withdrawal does not occur uniformly at this age and circulating oestradiol concentrations in the early menopause transition can be markedly elevated in a woman’s late 40s. 49 The mean age of onset of schizophrenic psychosis is 20–40 years when oestradiol concentrations are generally high (appendix p 4). Suicidality and the menopause transition The risk of suicide is higher in men than in women across the lifespan, and midlife is a time of elevated suicide risk for both sexes. 50,51 Recent media reports have suggested that women are at elevated risk of suicide over the menopause transition. 11,12 However, there is no substantive evidence of an association between attempted or completed suicide and the menopause transition.",
    "11,12 However, there is no substantive evidence of an association between attempted or completed suicide and the menopause transition. One cross-sectional study from Korea (n=45 177)52 showed increased suicidal ideation (thoughts about wanting to die in the past year) during the menopause transition (prevalence of 7·2% compared with a premenopause prevalence of 5·73%). Although the study measured self- reported rates of suicide attempts, no relationship between these rates and reproductive stage was reported. 52 A US study of 298 women in treatment for mood disorders found no association between reproductive stage and suicidal ideation or attempts. 53 One longitudinal study (n=291 709) in US veterans 54 found that use of menopausal hormone therapy (MHT) was associated with significantly increased risk of attempted and completed suicide over the next 4·5 years. These associations with death by suicide remained significant after accounting for psychiatric comorbidity and psychoactive medications. 54 In summary, despite claims that the menopause transition is associated with increased risk of suicide, empirical data to support these claims are scarce. However, some evidence suggests that use of MHT is associated with suicide attempts and completion. The reasons for this association are uncertain. Who is at risk of experiencing depressive symptoms or disorders over the menopause transition?",
    "The reasons for this association are uncertain. Who is at risk of experiencing depressive symptoms or disorders over the menopause transition? Large prospective studies report that a small subgroup of about 5–9% 28,55 of women experience increasing depressive symptoms over midlife, whereas a similar proportion (8·5–11%) 28,55 report decreasing depressive symptoms. Menopause-specific and general risk and resilience factors might help explain why a subgroup of women could be at risk of depressive symptoms or disorders over the menopause transition. Established psychosocial risk factors for depressive symptoms Prospective studies confirm that established psychosocial stressors such as financial problems, 29 unemployment,29 poor social support, 26 and stressful life events 29,32 are important predictors of depressive symptoms during the menopause transition. 23,29,26 Similarly, adverse childhood experiences,56 being from a minority ethnic group, 25 higher BMI, 15,29 neuroticism, 23 and lifestyle behaviours (eg, smoking and lack of physical activity) 26 are also associated with increased risk of depressive symptoms. Emerging evidence suggests that psychosocial factors can interact with sex steroid hormones to modify mood.",
    "Emerging evidence suggests that psychosocial factors can interact with sex steroid hormones to modify mood. A prospective study (n=52) 57 found that greater variability in serially measured oestradiol over 14 months predicted greater depressive symptoms, but only in individuals with very stressful life events in the 6 months before baseline assessment, suggesting an interaction between established risk factors for depression and endocrine changes over the menopause transition. Menopause-related factors Type and timing of menopause The type (natural or surgical) and timing of menopause might influence the risk of depressive symptoms. Prospective studies show that surgical menopause (ie, from bilateral oophorectomy before natural menopause) confers greater risk 58–60 than hysterectomy alone. 58,59 However, the effects might be transitory. A prospective controlled study of depressive symptoms and anxiety following surgical menopause showed a doubling in new-onset depressive symptoms at 12 months, which had resolved by 24 months. 61 Abrupt changes in sex steroid hormones following oophorectomy might contribute to this effect. However, women undergoing surgical menopause commonly have other risk factors for depression, such as adverse childhood experiences, abuse, and chronic pelvic pain.",
    "However, women undergoing surgical menopause commonly have other risk factors for depression, such as adverse childhood experiences, abuse, and chronic pelvic pain. 62 Similarly, women with spontaneous premature 63 or early 64 menopause are at increased risk of depressive symptoms, but are more likely to have experienced cancer treatment, infertility, and gynaecological pathology than women who have menopause at the average age. Hence, factors other than endocrine changes might influence mood for these subgroups. Longer duration of the menopause transition has also been associated with increased risk of depressive symptoms, 28,30,60 potentially explained by extended time with vasomotor symptoms.30 Vasomotor symptoms and sleep disturbance A systematic review of 33 publications65 reported that the presence and frequency of vasomotor symptoms were bidirectionally associated with depressive symptoms. 65 Some women are more bothered by vasomotor symptoms than others and this variability might relate to mood, stress, and the degree of sleep disturbance. The extent to which vasomotor symptoms are problematic or interfere with daily life predicts mood disturbance and quality of life more than vasomotor symptom frequency does. 66 A pooled analysis of longitudinal data from over 20 000 women found that sleep disturbance largely Series www.thelancet.com Vol 403 March 9, 2024 977 accounted for the association between vasomotor symptoms and depressed mood.",
    "67 In an experimental ovarian suppression model of menopause, vasomotor symptoms at night but not during the day contributed to depressed mood independent of their effect on sleep. 68 Effective management of nocturnal vasomotor symptoms and sleep disturbance might play an important part in the prevention and management of mood disturbances over the menopause transition. Sex steroids Oestradiol variability, 15,57,69,70 low progesterone con cen- tration,70 and change in the ratio of testosterone concentration to oestradiol concentration 71 have been associated with an increased risk of depressive symptoms, but findings vary and these associations have not been consistently replicated. 26,32,72,73 Prospective studies with annual measures of oestradiol concentration and mood found no associations with depressive symptoms, 26,32,73 and cross-sectional studies report no differences in oestradiol concentrations in perimenopausal women with a depressive disorder compared with those without. 74 However, epidemiological 15,57 and repeated-measures 69,70 studies with more frequent assessments report that greater oestradiol variability is associated with worse mood. Circulating progesterone is reduced over the menopause transition. One study found that low progesterone concentrations were associated with worse mood.",
    "Circulating progesterone is reduced over the menopause transition. One study found that low progesterone concentrations were associated with worse mood. 70 Some women might be more mood-sensitive to changes in oestradiol concentrations than others, 75,76 as was shown for women with previous major depressive disorder during the menopause transition who experienced a relapse of symptoms when MHT was withdrawn. 75 Together, these data suggest that greater oestradiol variability and possibly a decline in progesterone might increase the risk of depressive symptoms, especially in vulnerable women. However, there are no established ways of predicting vulnerability to depressed mood following fluctuations in ovarian sex steroids. Psychosocial and cultural aspects of menopause Psychosocial and cultural factors shape mental health over the menopause transition. Negative expectations and attitudes towards menopause (eg, “[d]uring the menopause or the change of life, I became, or expect to become, irritable or depressed”) 27 and ageing60 (eg, worry about physical decline) predict subsequent depressive symptoms. Most women experience vasomotor symptoms.",
    "Most women experience vasomotor symptoms. Together with predisposing factors such as anxiety, people with more negative attitudes towards menopause might have unhelpful cognitive appraisals of vasomotor symptoms (eg, thinking that people will notice their hot flashes or that their symptoms will never end), which might increase their distress and amplify the effects of these symptoms on their mood and functioning. 77 By contrast, positive coping strategies might minimise the effect of vasomotor symptoms on mood. There are marked global differences in attitudes towards menopause, which might help to explain the variation in attributed symptoms across different cultures. 78 For example, White Australians report higher rates of depressive symptoms together with fears of ageing than Laotian women, who position menopause as a positive event. 79 Optimising mental health at menopause Identifying modifiable factors is essential to inform preventive interventions. Managing troublesome vasomotor symptoms and sleep disturbance might reduce the risk of depressive symptoms and possibly major depressive disorder. Effective pharmacological and non-pharmacological interventions for vasomotor symptoms are widely available. 80 Evidence-based information promoting more positive or neutral attitudes towards ageing and menopause might be helpful (panel). Increasing social support and physical activity are other potentially modifiable targets.",
    "Increasing social support and physical activity are other potentially modifiable targets. 55 Furthermore, a systematic review has identified psychological resources including optimism, healthy self-image, and perceived control as being protective of mental health across the menopause transition. 81 Cognitive behaviour therapy (CBT) is a proven intervention for depression and anxiety across life stages and is effective for sleep disturbance and for vasomotor symptoms. CBT is specifically recommended by UK National Institute for Health and Care Excellence (NICE) guidelines for depressed mood during menopause. 82 The North American Menopause Society 2023 guidelines also recommend CBT for bothersome vasomotor symptoms. 83 In summary, women with previous major depressive disorder might be at elevated risk of recurrence over the menopause transition. Vulnerability to depressive symptoms includes both established psychosocial risk factors and menopause-specific factors, which might interact (figure 2). Detection and treatment of depressive symptoms and major depressive disorder over the menopause transition A US survey of trainee physicians84 found that only 6·8% felt adequately prepared to address menopause, despite recognising the importance of this life stage. 84 Understanding the associations between menopause and mental health and evaluating and managing mental health disorders and symptoms are essential aspects of midlife care.",
    "84 Understanding the associations between menopause and mental health and evaluating and managing mental health disorders and symptoms are essential aspects of midlife care. Detection The approach to diagnosis and management of depressive symptoms and major depressive disorder over the menopause transition should mirror that at other life stages. 85 Because the menopause transition is a risk period for recurrence of major depressive disorder, women with previous experience of this condition require Series 978 www.thelancet.com Vol 403 March 9, 2024 vigilant monitoring during this life stage. Although the menopause transition is not a risk period for first lifetime onset major depressive disorder, UK guidelines 86 recommend being alert to depression across adulthood and considering screening. During the menopause transition, clinicians should consider risk factors for mental illness, including previous history, and both established psychosocial and menopause-related risk factors (figure 2). Prevention RCTs have considered psychosocial 87,88 and hormonal interventions76 for the primary prevention of depressive symptoms or disorders over the menopause transition. Mindfulness based stress reduction (MBSR) is an 8-week group intervention designed to ameliorate stress through mindfulness meditation and yoga techniques.",
    "Mindfulness based stress reduction (MBSR) is an 8-week group intervention designed to ameliorate stress through mindfulness meditation and yoga techniques. Two RCTs investigated the efficacy of MBSR to prevent depressive symptoms 88 and cope with severe vasomotor symptoms.89 In 104 euthymic women in menopause, MBSR effectively prevented the development of depressive symptoms while also promoting higher levels of resilience and lower levels of stress and anxiety relative to participants who were on the waiting list for treatment. 88 These benefits were particularly evident in participants with previous major depressive disorder, stressful life events in the 6 months before assessment, and increased mood sensitivity to oestradiol fluctuations. In an RCT of 172 euthymic women in perimenopause and early postmenopause, 76 high-dose MHT (100 μg transdermal oestradiol with progesterone every 3 months) halved the risk of emergent depressive symptoms compared with placebo over 12 months (incidence 17·3% vs 32·3%), particularly in those with stressful life events in the 6 months before assessment.",
    "However, MHT was not specifically effective in preventing major depressive disorder in women who had already experienced this condition, who are a group more Panel: Promoting mental health over the menopause transition Key findings from prospective data Depressive symptoms or depressive disorder • Risk of first lifetime major depressive disorder is not increased over the menopause transition, but individuals with previous major depressive disorder might be at increased risk of recurrence • Women are not universally or uniformly at risk of depressive symptoms over the menopause transition; only a minority experience depressive symptoms, and these symptoms are more common in people with previous major depressive disorder • Vulnerability to depressive symptoms over the menopause transition is due to established and menopause-related risk factors (figure 2) • The type and timing of menopause might contribute to risk; surgical menopause might be more likely than natural menopause to increase depressive symptoms • Frequent, severe, or nocturnal vasomotor symptoms can be associated with increased risk of depressive symptoms • Fluctuations in oestradiol concentrations might contribute to vulnerability to depressive symptoms in some individuals, especially those who are mood-sensitive to oestradiol; however, findings are mixed and there are no established biomarkers Other symptoms or disorders • Scarce evidence suggests that the risk of anxiety disorders does not increase over the",
    "to oestradiol; however, findings are mixed and there are no established biomarkers Other symptoms or disorders • Scarce evidence suggests that the risk of anxiety disorders does not increase over the menopause transition; 17 women are not universally or uniformly at risk of experiencing symptoms of anxiety over the menopause • The onset or trajectory of psychosis has not been shown to be affected by the menopause transition • No studies have found that the menopause transition increases risk of suicide attempt or completion Recommendations for clinicians • Provide individuals with evidence-based information about menopause, including clear statements that most individuals are not at risk of mental health problems • Be aware of who is at risk of depressive symptoms and major depressive disorder; consider treating modifiable risk factors such as severe vasomotor symptoms and sleep problems when these are present • Do not automatically assume that psychological symptoms over the menopause transition are attributable to menopause; investigate and manage these symptoms as at any other life stage • Be cautious about discontinuing active treatments for major depressive disorder (eg, antidepressants or psychotherapy) over the menopause transition due to the possible increased risk of recurrence Social change to improve mental health over the menopause transition • Challenge assumptions that the menopause transition confers universal risk for depression, anxiety, and other mental",
    "recurrence Social change to improve mental health over the menopause transition • Challenge assumptions that the menopause transition confers universal risk for depression, anxiety, and other mental health symptoms or disorders, since these assumptions are inaccurate and potentially harmful • Learn from societies in which ageing in women confers status and in which views of menopause are more affirming • Model empowered views of the menopause and women’s ageing to cultivate more positive attitudes at the societal level • Promote gender equity and safety across the lifespan since early adversity increases the risk of poor mental health at midlife Series www.thelancet.com Vol 403 March 9, 2024 979 at risk of depression over the menopause transition.",
    "Also, this regimen did not contain adequate dose and duration of progesterone to prevent endometrial hyperplasia. 90 In summary, emerging evidence suggests that, among women at elevated risk, psychosocial interventions might prevent depressive symptoms over the menopause transition. Overall, the evidence does not support MHT to prevent depressive symptoms or major depressive disorder over the menopause transition. Treatment Depressive disorders over the menopause transition should be treated as at any other life stage, within a personalised framework that considers previous history, hormone sensitivity, and psychosocial and menopause- related factors in the cause, recurrence, and maintenance of symptoms. 91 Effective options for major depressive disorder include psychotherapy, antidepressants, and interventional psychiatric approaches. Psychotherapy might be particularly helpful when symptoms are caused or exacerbated by exogenous stressors, including life events and role transitions common in midlife women. Selected antidepressants including selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors might confer additional benefits by treating both depression and vasomotor symptoms. 92 The duration of antidepressant treatment for major depressive disorder during the menopause transition has not been studied and standard treatment duration guidelines are therefore advised.",
    "92 The duration of antidepressant treatment for major depressive disorder during the menopause transition has not been studied and standard treatment duration guidelines are therefore advised. For people experiencing major depressive disorder as they approach the menopause transition, consideration should be given to continuing antidepressants due to the increased risk of recurrence. 93 MHT is not an approved treatment for depressive symptoms or major depressive disorder by regulatory agencies in Europe or the USA due to insufficient evidence for efficacy. Trials of MHT as a treatment for major depressive disorder have had small sample sizes (combined n=222 on MHT and a placebo) and shown mixed results. 94–97 Two RCTs (combined n=84) found that transdermal oestradiol was superior to a placebo in women with perimenopause and early postmenopause over 3 weeks 94 and 12 weeks 95 of administration. Two other RCTs (combined n=138) of transdermal oestradiol for major depressive disorder and other unipolar depressive disorders in women in perimenopause 96 or a mixed cohort of women in perimenopause and postmenopause 97 reported no benefits over a placebo. MHT improves concurrent depressive symptoms for patients with bothersome vasomotor symptoms, 98 but it is not a primary approach for depressive symptoms in the absense of vasomotor symptoms.",
    "MHT improves concurrent depressive symptoms for patients with bothersome vasomotor symptoms, 98 but it is not a primary approach for depressive symptoms in the absense of vasomotor symptoms. A meta-analysis of Figure 2: Interactions between menopause-specific and established psychosocial risk factors for depression and potentially modifiable protective factors that predict increased risk or resilience to depressive symptoms during the menopause transition The intertwined arrows indicate that risk and resilience factors can interact with each other to elevate or reduce the overall risk of depressive symptoms.",
    "Menopause-related risk factors Type and timing of menopause • Early menopause • Surgical menopause • Long menopause transition Menopausal symptoms • Sleep disturbance • Frequent or severe or nocturnal vasomotor symptoms Hormonal factors • Sex steroid variability • Mood sensitivity to oestradiol Attitudes • Negative attitudes to menopause or ageing Potentially modiﬁable protective factors Menopause-related factors • Treatment of vasomotor symptoms • Treatment of sleep disturbance • Positive attitudes towards menopause and ageing Psychosocial factors • Social support • Healthy lifestyle (eg, physical activity, healthy diet, and quitting smoking) • Psychological resources (eg, stress management, coping strategies, and positive self-image) Established psychosocial risk factors • Lifetime history of depression • Adverse childhood experiences • Psychosocial stressors • Stressful life events • Financial diﬃculties • Minority status • Unemployment • Lack of social support • Lifestyle factors: sedentary lifestyle; high BMI; and smoking • Personality traits (eg, neuroticism) Increased risk of depressive symptoms Decreased risk of depressive symptoms Series 980 www.thelancet.com Vol 403 March 9, 2024 12 RCTs found that bioidentical oestrogen was ineffective in reducing depressive symptoms in women in perimenopause and postmenopause. 99 Despite this result, some organisations suggest considering MHT to treat depressive symptoms during the menopause transition.",
    "99 Despite this result, some organisations suggest considering MHT to treat depressive symptoms during the menopause transition. 100 Promoting good mental health over the menopause transition WHO defines health promotion as a “process of enabling people to increase control over, and to improve, their health”. 101 Information resources for people transitioning the menopause might contain mixed messages about what to expect and fail to identify at-risk groups. For example, the UK National Health Service and Mayo Clinic websites list mood changes as symptoms of menopause, whereas Johns Hopkins University emphasises that the association between menopause and mental health is inconclusive. Our findings support enhanced awareness of groups and individuals at risk for poor mental health over the menopause transition and caution against automatically attributing depressed mood or other mental health symptoms or disorders to menopause. This assumption is potentially harmful, as it creates negative expectations that reinforce stereotypes about the menopause and ageing. A survey of more than 7000 European and Australian midlife women 102 found that about half (48% of European respondents and 56% of Australian respondents) were concerned about managing menopause and that most did not feel “very well supported” in terms of their symptoms during the menopause transition.",
    "102 Women and their clinicians need access to accurate and consistent information about what to expect, who is at risk for poor mental health, and when to seek help (panel). For people at risk of depressive symptoms over the menopause transition (figure 2), addressing modifiable risk factors, such as sleep disturbance, troublesome vasomotor symptoms, and stress exposures, while promoting more positive attitudes towards menopause and ageing, might be beneficial. According to UN data, 90% of people hold gender biases against women. 103 Outdated views about menopause might be both a cause and a consequence of gender bias. Promoting gender equity and safety across the lifespan is relevant, since early life adversity is a powerful predictor of midlife mental health. 56 Midlife is often a period of low wellbeing for both men and women,104 and, therefore, a potential window of opportunity to prioritise mental health optimisation. Psychological interventions such as MBSR show promise for prevention, 88 and CBT can reduce anxiety and depressed mood, together with vasomotor symptoms.82 Primary care providers and community health educators can contribute to improving care with helpful health messaging and evidence-based practices that empower women and promote mental health over the menopause transition.",
    "For more on the UK National Health Service overview of menopause see [URL] nhs.uk/conditions/menopause/ For more on the Mayo Clinic overview of menopause see [URL] diseases-conditions/menopause/ symptoms-causes/syc-20353397 For more on the Johns Hopkins Introduction to Menopause see [URL] org/health/conditions-and- diseases/introduction-to- menopause Contributors MH and LB conceived and designed this Series paper. LB wrote the initial draft and was responsible for revising this draft on the basis of comments from all other authors. MSH, RC, CJC, JLG, GDM, VR, HJ, and MH made substantial contributions to the conception or design of this Series paper; or to the acquisition, analysis, or interpretation of data. MSH, RC, CJC, JLG, GDM, VR, HJ, and MH made substantial contributions to drafting this Series paper or revising it critically for important intellectual content; and gave their final approval of the submitted version. MSH, RC, CJC, JLG, GDM, VR, HJ, and MH agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Declaration of interests MSH declares consultation for Rightsteps UK. HJ declares grant funding from the National Institutes of Health (grant numbers U54AG062322 and R01MH128617), Pfizer, and Merck; and consulting for Bayer, Merck, and Hello Therapeutics.",
    "HJ declares grant funding from the National Institutes of Health (grant numbers U54AG062322 and R01MH128617), Pfizer, and Merck; and consulting for Bayer, Merck, and Hello Therapeutics. MH declares salary funding from the Australian National Health and Medical Research Council, support for meeting attendance from the UK National Institute for Health and Care Excellence, and the following roles: principal investigator for a clinical trial of salpingectomy vs salpingo-oophorectomy for prevention of ovarian cancer (TUBA-WISP II); board member for Breastscreen Victoria; editor for the Cochrane Collaboration; recipient of a fellowship from the Lundbeck Foundation (2022-23); site investigator for a clinical trial of a non-hormonal agent (Q-122) for vasomotor symptoms in patients with breast cancer (QUE Oncology, 2020-22); and site investigator for a clinical trial of a medical device for treating vaginal dryness (Madorra). All other authors declare no competing interests. Acknowledgments We would like to acknowledge Hannah Shribman-Brown for assistance with proofreading and Patrick Condron for assistance with literature searches. HJ would like to acknowledge support from the National Institutes of Health (grant numbers U54AG062322 and R01MH128617). References 1 Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab 2021; 106: 1–15. 2 Mattern S. The slow moon climbs.",
    "J Clin Endocrinol Metab 2021; 106: 1–15. 2 Mattern S. The slow moon climbs. Princeton, NJ: Princeton University Press, 2019. 3 Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. J Am Med Assoc 1959; 171: 1627–37 . 4 Blatt MH, Wiesbader H, Kupperman HS. Vitamin E and climacteric syndrome: failure of effective control as measured by menopausal index. AMA Arch Intern Med 1953; 91: 792–99. 5 Hauser G, Huber I, Keller P, Lauritzen C, Schneider H. Evaluation of climacteric symptoms (menopause rating scale). Zentralbl Gynäkol 1994; 116: 16–23 (in German). 6 Greene JG. Constructing a standard climacteric scale. Maturitas 2008; 61: 78–84. 7 Brinton RD, Yao J, Yin F, Mack WJ, C adenas E. Perimenopause as a neurological transition state. Nat Rev Endocrinol 2015; 11: 393–405. 8 Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause—global prevalence, physiology and implications. Nat Rev Endocrinol 2018; 14: 199–215. 9 Kulkarni J, Gavrilidis E, Hudaib A-R, Bleeker C, Worsley R, Gurvich C. Development and validation of a new rating scale for perimenopausal depression—the Meno-D. Transl Psychiatry 2018; 8: 123. 10 Riecher-Rössler A. Oestrogens, prolactin, hypothalamic-pituitary- gonadal axis, and schizophrenic psychoses. Lancet Psychiatry 2017; 4: 63–72. 11 Hinsliff G. Not just hot flushes: how menopause can destroy mental health. The Guardian, Jan 12, 2023.",
    "Lancet Psychiatry 2017; 4: 63–72. 11 Hinsliff G. Not just hot flushes: how menopause can destroy mental health. The Guardian, Jan 12, 2023. [URL] theguardian.com/society/2023/jan/12/not-just-hot-flushes-how- menopause-can-destroy-mental-health (accessed April 4, 2023). 12 Thomas R. Watchdog calls for review of menopause link to poor mental health after woman’s suicide. Independent, March 23, 2023. [URL] mental-health-suicide-b2305933.html (accessed March 25, 2023). 13 Glyde T. LGBTQIA+ menopause: room for improvement. Lancet 2022; 400: 1578–79. Series www.thelancet.com Vol 403 March 9, 2024 981 14 Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2006; 63: 385–90. 15 Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006; 63: 375–82. 16 Otte C, Gold SM, Penninx BW , et al. Major depressive disorder. Nat Rev Dis Primers 2016; 2: 16065. 17 Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis. PLoS One 2016; 11: e0155431. 18 Rodríguez MR, Nuevo R, Chatterji S, Ayuso-Mateos JL. Definitions and factors associated with subthreshold depressive conditions: a systematic review.",
    "PLoS One 2016; 11: e0155431. 18 Rodríguez MR, Nuevo R, Chatterji S, Ayuso-Mateos JL. Definitions and factors associated with subthreshold depressive conditions: a systematic review. BMC Psychiatry 2012; 12: 181. 19 Mulder RT. An epidemic of depression or the medicalization of distress? Perspect Biol Med 2008; 51: 238–50. 20 Bromberger JT, Schott L, Kravitz HM, Joffe H. Risk factors for major depression during midlife among a community sample of women with and without prior major depression: are they the same or different? Psychol Med 2015; 45: 1653–64. 21 Bromberger JT, Kravitz HM, Matthews K, Y ouk A, Brown C, Feng W. Predictors of first lifetime episodes of major depression in midlife women. Psychol Med 2009; 39: 55–64. 22 Bromberger JT, Kravitz HM, Chang Y-F, C yranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med 2011; 41: 1879–88. 23 Rössler W, Ajdacic-Gross V, Riecher-Rössler A, Angst J, Hengartner MP. Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study. World Psychiatry 2016; 15: 146–54. 24 Freeman EW, Sammel MD, Boorman DW, Zhang R. Longitudinal pattern of depressive symptoms around natural menopause. JAMA Psychiatry 2014; 71: 36–43. 25 Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause.",
    "JAMA Psychiatry 2014; 71: 36–43. 25 Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004; 61: 62–70. 26 Bromberger JT, Schott LL, Kravitz HM, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN). Arch Gen Psychiatry 2010; 67: 598–607 . 27 Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women’s Health Across the Nation (SWAN). J Affect Disord 2007; 103: 267–72. 28 Hickey M, Schoenaker DA, Joffe H, Mishra GD. Depressive symptoms across the menopause transition: findings from a large population-based cohort study. Menopause 2016; 23: 1287–93. 29 Maartens LW, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas 2002; 42: 195–200. 30 Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women’s Health Study. Ann Epidemiol 1994; 4: 214–20. 31 Mulhall S, Andel R, Anstey KJ. Variation in symptoms of depression and anxiety in midlife women by menopausal status. Maturitas 2018; 108: 7–12.",
    "Ann Epidemiol 1994; 4: 214–20. 31 Mulhall S, Andel R, Anstey KJ. Variation in symptoms of depression and anxiety in midlife women by menopausal status. Maturitas 2018; 108: 7–12. 32 Woods NF, Smith-DiJulio K, Percival DB, Tao EY , Mariella A, Mitchell S. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women’s Health Study. Menopause 2008; 15: 223–32. 33 Kaufert PA, Gilbert P, Tate R. The M anitoba Project: a re-examination of the link between menopause and depression. Maturitas 1992; 14: 143–55. 34 Jones HJ, Minarik PA, Gilliss CL, Lee KA. Depressive symptoms associated with physical health problems in midlife women: a longitudinal study. J Affect Disord 2020; 263: 301–09. 35 Tang R, Luo M, Li J, et al. Symptoms of anxiety and depression among Chinese women transitioning through menopause: findings from a prospective community-based cohort study. Fertil Steril 2019; 112: 1160–71. 36 Levis B, Benedetti A, Ioannidis JP, et al. Patient H ealth Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. J Clin Epidemiol 2020; 122: 115–28. 37 Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159–68.",
    "Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159–68. 38 Bromberger JT, Harlow S, A vis N, Kravitz HM, Cordal A. Racial/ ethnic differences in the prevalence of depressive symptoms among middle-aged women: the Study of Women’s Health Across the Nation (SWAN). Am J Public Health 2004; 94: 1378–85. 39 Kravitz HM, Colvin AB, Avis NE, J offe H, Chen Y , Bromberger JT. Risk of high depressive symptoms after the final menstrual period: the Study of Women’s Health Across the Nation (SWAN). Menopause 2022; 29: 805–15. 40 Bryant C, Judd FK, Hickey M. Anxiety during the menopausal transition: a systematic review. J Affect Disord 2012; 139: 141–48. 41 Bromberger JT, Kravitz HM, Chang Y , et al. Does risk for anxiety increase during the menopausal transition? Study of women’s health across the nation. Menopause 2013; 20: 488–95. 42 Freeman EW, Sammel MD. Anxiety as a risk factor for menopausal hot flashes: evidence from the Penn Ovarian Aging cohort. Menopause 2016; 23: 942–49. 43 Tang R, Luo M, Li J, et al. Relationships between vasomotor symptoms and mood in midlife urban Chinese women: observations in a prospective study. J Clin Endocrinol Metab 2020; 105: 3437–48. 44 Marsh WK, Templeton A, Ketter TA, Rasgon NL. Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: preliminary report.",
    "44 Marsh WK, Templeton A, Ketter TA, Rasgon NL. Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: preliminary report. J Psychiatr Res 2008; 42: 247–51. 45 Perich T, Ussher J, Meade T. Menopause and illness course in bipolar disorder: a systematic review. Bipolar Disord 2017; 19: 434–43. 46 Payne JL, Roy PS, Murphy-Eberenz K, et al. Reproductive cycle- associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 2007; 99: 221–29. 47 Kirkbride JB, Errazuriz A, Croudace TJ, et al. Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses. PLoS One 2012; 7: e31660. 48 Sommer IE, Brand BA, Gangadin S, Tanskanen A, Tiihonen J, Taipale H. Women with schizophrenia-spectrum disorders after menopause: a vulnerable group for relapse. Schizophr Bull 2023; 49: 136–43. 49 Tepper PG, Randolph JF Jr, McConnell DS, et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women’s Health across the Nation (SWAN). J Clin Endocrinol Metab 2012; 97: 2872–80. 50 Australia Bureau of Statistics. Causes of Death Australia, 2020. Canberra, ACT: Australia Bureau of Statistics, 2021. 51 Nasir R, John E, Windsor-Shellard B. Suicides in England and Wales: 2020 registrations. London: Office for National Statistics, 2021. 52 An SY , Kim Y , Kwon R, et al.",
    "51 Nasir R, John E, Windsor-Shellard B. Suicides in England and Wales: 2020 registrations. London: Office for National Statistics, 2021. 52 An SY , Kim Y , Kwon R, et al. Depressive symptoms and suicidality by menopausal stages among middle-aged Korean women. Epidemiol Psychiatr Sci 2022; 31: e60. 53 Weiss SJ, Simeonova DI, Kimmel MC, Battle CL, Maki PM, Flynn HA. Anxiety and physical health problems increase the odds of women having more severe symptoms of depression. Arch Womens Ment Health 2016; 19: 491–99. 54 Gibson CJ, Li Y , Jasuja GK, Self KJ, Seal KH, Byers AL. Menopausal hormone therapy and suicide in a national sample of midlife and older women veterans. Med Care 2021; 59: S70–76. 55 Bromberger JT, Schott LL, Avis NE, et al. Psychosocial and health- related risk factors for depressive symptom trajectories among midlife women over 15 years: Study of Women’s Health Across the Nation (SWAN). Psychol Med 2019; 49: 250–59. 56 Liveri K, Dagla M, Sarantaki A, Orovou E, Antoniou E. Abuse of girls during childhood and its impacts on the health of their adult lives: a systematic review. Cureus 2023; 15: e34981. 57 Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Leserman J, Girdler SS. Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause 2016; 23: 257–66.",
    "Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause 2016; 23: 257–66. Series 982 www.thelancet.com Vol 403 March 9, 2024 58 Wilson L, Pandeya N, Byles J, Mishra G. Hysterectomy and incidence of depressive symptoms in midlife women: the Australian Longitudinal Study on Women’s Health. Epidemiol Psychiatr Sci 2018; 27: 381–92. 59 Chen X, Guo T, Li B. Influence of prophylactic oophorectomy on mood and sexual function in women of menopausal transition or postmenopausal period. Arch Gynecol Obstet 2013; 288: 1101–06. 60 Dennerstein L, Guthrie JR, Clark M, Lehert P, Henderson VW . A population-based study of depressed mood in middle-aged, Australian-born women. Menopause 2004; 11: 563–68. 61 Hickey M, Moss KM, Brand A, et al. What happens after menopause? (WHAM): a prospective controlled study of depression and anxiety up to 12 months after premenopausal risk- reducing bilateral salpingo-oophorectomy. Gynecol Oncol 2021; 161: 527–34. 62 Rocca WA, Mielke MM, Gazzuola Rocca L, Stewart EA. Premature or early bilateral oophorectomy: a 2021 update. Climacteric 2021; 24: 466–73. 63 Shea AK, Sohel N, Gilsing A, M ayhew AJ, Griffith LE, Raina P. Depression, hormone therapy, and the menopausal transition among women aged 45 to 64 years using Canadian Longitudinal Study on aging baseline data. Menopause 2020; 27: 763–70. 64 Marsh WK, Bromberger JT, Crawford SL, et al.",
    "Menopause 2020; 27: 763–70. 64 Marsh WK, Bromberger JT, Crawford SL, et al. Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause. Menopause 2017; 24: 1351–59. 65 Worsley R, Bell R, Kulkarni J, Davis SR. The association between vasomotor symptoms and depression during perimenopause: a systematic review. Maturitas 2014; 77: 111–17 . 66 Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013; 16: 235–39. 67 Chung H-F, Pandeya N, Dobson AJ, et al. The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium. Psychol Med 2018; 48: 2550–61. 68 Joffe H, Crawford SL, Freeman MP, et al. Independent contributions of nocturnal hot flashes and sleep disturbance to depression in estrogen-deprived women. J Clin Endocrinol Metab 2016; 101: 3847–55. 69 Gordon JL, Eisenlohr-Moul TA, Rubinow DR, Schrubbe L, Girdler SS. Naturally occurring changes in estradiol concentrations in the menopause transition predict morning cortisol and negative mood in perimenopausal depression. Clin Psychol Sci 2016; 4: 919–35. 70 Joffe H, de Wit A, Coborn J, et al. Impact of estradiol variability and progesterone on mood in perimenopausal women with depressive symptoms. J Clin Endocrinol Metab 2020; 105: e642–50.",
    "70 Joffe H, de Wit A, Coborn J, et al. Impact of estradiol variability and progesterone on mood in perimenopausal women with depressive symptoms. J Clin Endocrinol Metab 2020; 105: e642–50. 71 Sander B, Muftah A, Sykes Tottenham L, Grummisch JA, Gordon JL. Testosterone and depressive symptoms during the late menopause transition. Biol Sex Differ 2021; 12: 44. 72 Hengartner MP. Subtle scientific fallacies undermine the validity of neuroendocrinological research: do not draw premature conclusions on the role of female sex hormones. Front Behav Neurosci 2017; 11: 3. 73 Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001; 4: 243–49. 74 Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St Clair L. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology 2002; 27: 907–20. 75 Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry 2015; 72: 714–26. 76 Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry 2018; 75: 149–57 . 77 Hunter MS, Mann E. A cognitive model of menopausal hot flushes and night sweats. J Psychosom Res 2010; 69: 491–501.",
    "JAMA Psychiatry 2018; 75: 149–57 . 77 Hunter MS, Mann E. A cognitive model of menopausal hot flushes and night sweats. J Psychosom Res 2010; 69: 491–501. 78 Avis NE, Crawford S. Cultural differences in symptoms and attitudes toward menopause. Menopause Manag 2008; 17: 8. 79 Sayakhot P, Vincent A, Teede H. Cross-cultural study: experience, understanding of menopause, and related therapies in Australian and Laotian women. Menopause 2012; 19: 1300–08. 80 Hickey M, LaCroix AZ, Doust J, et al. An empowerment model for managing menopause. Lancet 2024; published online March 5. [URL] 81 Süss H, Ehlert U. Psychological resilience during the perimenopause. Maturitas 2020; 131: 48–56. 82 Hunter MS, Chilcot J. Is cognitive behaviour therapy an effective option for women who have troublesome menopausal symptoms? Br J Health Psychol 2021; 26: 697–708. 83 Faubion SS, Crandall CJ, Davis L, et al. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause 2022; 29: 767–94. 84 Kling JM, MacLaughlin KL, Schnatz PF, et al. Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents: a cross-sectional survey. Mayo Clin Proc 2019; 94: 242–53. 85 National Institute for Health and Care Excellence. Depression in adults: recognition and management. 2021. [URL] co.uk/mental-health/nice-depression-guideline/454977 .article (accessed May 1, 2022). 86 National Institute for Health and Care Excellence.",
    "2021. [URL] co.uk/mental-health/nice-depression-guideline/454977 .article (accessed May 1, 2022). 86 National Institute for Health and Care Excellence. Depression in adults: treatment and management. June 29, 2022. [URL] nice.org.uk/guidance/ng222/chapter/Recommendations# recognition-and-assessment (accessed May 31, 2023). 87 Almeida OP, Marsh K, Murray K, et al. R educing depression during the menopausal transition with health coaching: results from the healthy menopausal transition randomised controlled trial. Maturitas 2016; 92: 41–48. 88 Gordon JL, Halleran M, Beshai S, Eisenlohr-Moul TA, Frederick J, Campbell TS. Endocrine and psychosocial moderators of mindfulness-based stress reduction for the prevention of perimenopausal depressive symptoms: a randomized controlled trial. Psychoneuroendocrinology 2021; 130: 105277 . 89 Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause 2011; 18: 611–20. 90 Joffe H, Hickey M. Should hormone therapy be used to prevent depressive symptoms during the menopause transition? JAMA Psychiatry 2018; 75: 125–26. 91 Stute P, Spyropoulou A, Karageorgiou V, et al. Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas 2020; 131: 91–101. 92 Hickey M, Szabo RA, Hunter MS. Non-hormonal treatments for menopausal symptoms. BMJ 2017; 359: j5101. 93 Lewis G, Marston L, Duffy L, et al.",
    "Maturitas 2020; 131: 91–101. 92 Hickey M, Szabo RA, Hunter MS. Non-hormonal treatments for menopausal symptoms. BMJ 2017; 359: j5101. 93 Lewis G, Marston L, Duffy L, et al. Maintenance or discontinuation of antidepressants in primary care. N Engl J Med 2021; 385: 1257–67 . 94 Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000; 183: 414–20. 95 Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58: 529–34. 96 Schmidt PJ, Wei S-M, Martinez PE, et al. The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression. Menopause 2021; 28: 369–83. 97 Joffe H, Petrillo LF, Koukopoulos A, et al. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab 2011; 96: E1044–54. 98 Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS– cognitive and affective study. PLoS Med 2015; 12: e1001833, discussion e1001833. 99 Whedon JM, KizhakkeVeettil A, Rugo NA, Kieffer KA. B ioidentical estrogen for menopausal depressive symptoms: a systematic review and meta-analysis.",
    "99 Whedon JM, KizhakkeVeettil A, Rugo NA, Kieffer KA. B ioidentical estrogen for menopausal depressive symptoms: a systematic review and meta-analysis. J Womens Health (Larchmt) 2017; 26: 18–28. 100 National Institute for Health and Care Excellence. Menopause: diagnosis and management. 2015. [URL] guidance/ng23 (accessed April 14, 2022). 101 WHO. Ottawa charter for health promotion, 1986. Geneva: World Health Organization Regional Office for Europe, 1986. Series www.thelancet.com Vol 403 March 9, 2024 983 102 Panay N, Palacios S, Davison S, Baber R. Women’s perception of the menopause transition: a multinational, prospective, community-based survey. GREM 2021; 2: 178–83. 103 Zarocostas J. UNDP reports that 90% of people hold gender-based biases. Lancet 2023; 401: 2026. 104 Steptoe A, Deaton A, Stone AA. Subjective wellbeing, health, and ageing. Lancet 2015; 385: 640–48. Copyright © 2024 Elsevier Ltd. All rights reserved.",
    "Series 984 www.thelancet.com Vol 403 March 9, 2024 Menopause 4 Managing menopause after cancer Martha Hickey, Partha Basu, Jenifer Sassarini, Mariken E Stegmann, Elisabete Weiderpass, Karen Nakawala Chilowa, Cheng-Har Yip, Ann H Partridge, Donal J Brennan Globally, 9 million women are diagnosed with cancer each year. Breast cancer is the most commonly diagnosed cancer worldwide, followed by colorectal cancer in high-income countries and cervical cancer in low-income countries. Survival from cancer is improving and more women are experiencing long-term effects of cancer treatment, such as premature ovarian insufficiency or early menopause. Managing menopausal symptoms after cancer can be challenging, and more severe than at natural menopause. Menopausal symptoms can extend beyond hot flushes and night sweats (vasomotor symptoms). Treatment-induced symptoms might include sexual dysfunction and impairment of sleep, mood, and quality of life. In the long term, premature ovarian insufficiency might increase the risk of chronic conditions such as osteoporosis and cardiovascular disease. Diagnosing menopause after cancer can be challenging as menopausal symptoms can overlap with other common symptoms in patients with cancer, such as fatigue and sexual dysfunction. Menopausal hormone therapy is an effective treatment for vasomotor symptoms and seems to be safe for many patients with cancer.",
    "Menopausal hormone therapy is an effective treatment for vasomotor symptoms and seems to be safe for many patients with cancer. When hormone therapy is contraindicated or avoided, emerging evidence supports the efficacy of non-pharmacological and non-hormonal treatments, although most evidence is based on women older than 50 years with breast cancer. Vaginal oestrogen seems safe for most patients with genitourinary symptoms, but there are few non-hormonal options. Many patients have inadequate centralised care for managing menopausal symptoms after cancer treatment, and more information is needed about cost-effective and patient-focused models of care for this growing population. Introduction The average age at natural menopause is 51 years in high-income countries (HICs). 1 A systematic review and meta-analysis in 2014 showed an earlier age at menopause in low-income and middle-income countries (LMICs) across Asia, India, Latin America, and the Middle East. 2 Menopause is more likely to be premature (ie, occurring before age 40 years) or early (ie, at age 41–44 years) after cancer and burgeoning evidence indicates that young age at menopause can be a risk factor for chronic disease. 3 A 2017 meta-analysis of 45 studies in female patients who had survived cancer found a median age at menopause of 44 years.",
    "3 A 2017 meta-analysis of 45 studies in female patients who had survived cancer found a median age at menopause of 44 years. 4 Guidelines from the UK National Institute for Health and Care Excellence (NICE) recommend menopausal hormone therapy (MHT) for younger postmenopausal women without contraindications, 5 but often the safety and efficacy of MHT after cancer is uncertain. Crucially, most patients who have troublesome menopausal symptoms after cancer do not have access to effective treatments, even in HICs. 6 This Series paper will address the prevention and management of menopausal symptoms after cancer, including evidence about health disparities if available. 7 Menopause happens to all people with typically functioning ovaries who reach the relevant age. We recognise that this population includes some transgender men and other gender-diverse people; therefore, in some instances, we have referred to “people” rather than “women” to be as accurate and inclusive as possible. However, since much published work refers to people experiencing menopause collectively as women and does not clarify how findings might apply to the specific needs of gender-diverse people, we have also used “women” in some instances, to avoid inappropriate generalisation. More information is needed about the experience of menopause in transgender men and gender-diverse people. Evidence on menopause in gender-diverse people is scarce and this area needs more attention.",
    "More information is needed about the experience of menopause in transgender men and gender-diverse people. Evidence on menopause in gender-diverse people is scarce and this area needs more attention. 8 Search strategy and selection criteria The recommendations in this Series paper are based on a review of the published literature and appraisal of professional guidelines. We searched databases on MEDLINE, Embase, BioMed Central, Cochrane, and Google from Dec 7, 2020, to Jan 8, 2024, with keywords tailored to each section of the manuscript including “cancer”, “neoplasm*”, “cancer survivor*”, “menopause”, “post meno pause”, “perimeno pause”, “menopausal symptom*”, “vasomotor symp tom*”, “hot flush*”, “hot flash*”, “night sweat*”, “sleep disturbance*”, “sleep disorder*”, “vaginal dryness”, “geni tourinary syndrome of menopause”, “dyspareunia”, “sexual dysfunction”, “quality of life”, “menopausal hor mone therapy”, “hormone therapy”, “hormone replace ment therapy”, “cognitive behaviour therapy”, “cognitive behavioral therapy”, “non- hormonal treatment*” , “non hor monal treatment*”, “low and middle income countr*”, “high income countr*”, “cancer”, “BRCA1”, “BRCA2”, “risk reducing salpingo- oophorectomy”, “RRSO”, “osteo porosis”, “premature ovarian failure”, “premature ovarian insufficiency”, “chemotherapy”, “radiation”, “venous thrombo -embolic disease”, “multidisciplinary care”.",
    "We cross-referenced these terms with “systematic review*”, “meta-analysis”, “metaanalysis”, “randomised/ran domized controlled Lancet 2024; 403: 984–96 Published Online March 5, 2024 [URL] S0140-6736(23)02802-7 See Perspectives pages 893 and 894 This is the fourth in a Series of four papers about menopause.",
    "All papers in the Series are available at www.thelancet.com/ series/menopause-2024 Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne and the Royal Women’s Hospital, Melbourne, VIC, Australia (Prof M Hickey MBChB MD); Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, WHO, Lyon, France (P Basu MD PhD); Department of Obstetrics and Gynaecology, School of Gynaecology, University of Glasgow, Glasgow, UK (J Sassarini MBChB PhD); Department of Primary and Long-term Care, University Medical Center Groningen, University of Groningen, Groningen, Netherlands (M E Stegmann MD PhD); International Agency for Research on Cancer, WHO, Lyon, France (E Weiderpass MD PhD); Teal Sisters, Lusaka, Zambia (K Nakawala Chilowa); Department of Surgery, University of Malaya, Kuala Lumpur, Malaysia (Prof C-H Yip MD); Department of Medical Oncology, Dana- Farber Cancer Institute, Boston, MA, USA (Prof A H Partridge MD MPH); Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland (Prof D J Brennan MB PhD); Systems Biology Ireland, UCD School of Medicine, Dublin, Ireland (Prof D J Brennan) Series www.thelancet.com Vol 403 March 9, 2024 985 Correspondence to: Professor Martha Hickey, Department of Obstetrics, Gynaecology, and Newborn Health, The Women’s Hospital, Melbourne, VIC 3052, Australia [EMAIL] trial*”, “clinical guideline*”, “clinical practice guideline*”.",
    "We also searched websites and guidelines of menopause societies including the British Menopause Society, International Menopause Society, North American Menopause Society, Australasian Meno pause Society, and the NICE guidelines. The Turning Research into Practice and PubMed databases were searched for evidence-based guidelines and systematic reviews. We prioritised the most recent evidence from randomised controlled trials and recommendations from international guidelines based on systematic reviews of the evidence (eg, WHO, International Agency for Research on Cancer, NICE, US Preventive Task Force, National Comprehensive Cancer Network, and American Society of Clinical Oncology). Only publications in English were included. The growing burden of menopausal symptoms after cancer treatment In premenopausal women, treatment for common cancers such as breast, gynaecological, haematological, and some low colorectal cancers will often cause ovarian damage, potentially inducing permanent menopause. 9 Perimenopausal or postmenopausal women diagnosed with oestrogen-receptor-positive cancers while taking MHT will be advised to stop, which can cause resurgent vasomotor symptoms that are further exacerbated by anti-oestrogen therapy. 10 The standard of care for premenopausal high-risk oestrogen-receptor-positive breast cancer includes gonadotoxic chemotherapy followed by ovarian suppression plus oral endocrine therapy.",
    "10 The standard of care for premenopausal high-risk oestrogen-receptor-positive breast cancer includes gonadotoxic chemotherapy followed by ovarian suppression plus oral endocrine therapy. This treatment can lead to more severe vasomotor symptoms (ie, hot flushes and night sweats) compared with natural menopause, particularly in younger women. 11,12 Patients with oestrogen-receptor-positive postmenopausal breast cancer are advised to take third-generation aromatase inhibitors (eg, anastrozole, letrozole, and exemestane), which can induce or aggravate menopausal symptoms including hot flushes, night sweats, and vaginal dryness. 13 Menopausal symptoms are a common reason for not starting or prematurely stopping endocrine therapy, which directly increases morbidity and mortality from breast cancer. 11 Newer protocols extending endocrine therapy from 5 years to 10 years in oestrogen-receptor- positive or pro gesterone-receptor-positive cancer are likely to increase the burden of symptoms. In a 2021 community-based survey (n=385), the prevalence of menopausal symptoms in survivors of breast cancer 6 years after diagnosis was high: 346 (90%) had vasomotor symptoms or sleep disturbance, 289 (75%) had vaginal dryness, 240 (62%) had mood swings, and 229 (59%) had sexual difficulties. 6 Severity of hot flushes and sleep disturbance predicted their inability to resume everyday activities. Less than a third were offered treatment and less than half found this to be effective.",
    "6 Severity of hot flushes and sleep disturbance predicted their inability to resume everyday activities. Less than a third were offered treatment and less than half found this to be effective. These symptoms can cause distress and impair quality of life, and managing these symptoms is a leading priority for patients with cancer. 14 Around a third of patients with breast cancer are dissatisfied with the information provided about the effects of cancer treatment on reproductive outcomes such as menopause. 15 Around one in 400 women are at elevated risk of ovarian cancer due to pathogenic gene variants such as BRCA1 or BRCA2. 16,17 International guidelines advise risk-reducing bilateral salpingo-oophorectomy by age 35–40 years, which will induce surgical menopause. 18 Patients’ concerns about managing menopausal symptoms after bilateral salpingo-oophorectomy are a leading barrier to this potentially life-saving surgery 19 and many clinicians are uncertain how best to manage surgical menopause in this population. 20 The clinical case in panel 1 emphasises the importance of pre- operative counselling about the probable consequences of surgical menopause in these patients and of postoperative symptom management. In 2023, new international consensus guidelines provided recommendations for symptom management and prevention of chronic disease following risk-reducing salpingo-oophorectomy in premenopausal women with the BRCA1 or BRCA2 pathogenic variant.",
    "21 Key messages • More than 9 million women are diagnosed with cancer each year and treatments commonly induce early menopause and menopausal symptoms • Many patients do not have access to effective treatments, even in high-income countries, with an even greater impairment of quality of life and psychological distress in low-income settings • Diagnosing menopause after cancer can be challenging and many women resume menstruation within 2 years of chemotherapy completion; undetectable anti-Müllerian hormone at 30 months predicts menopause after chemotherapy for breast cancer and menopause is almost universal after ovarian radiation • Women younger than 45 years without contraindications should be offered an individualised treatment plan including menopausal hormone therapy after cancer treatment • If menopausal hormone therapy is contraindicated, non-pharmacological and non-hormonal treatments are available for vasomotor symptoms; vaginal oestrogen seems to be safe for most patients with cancer and growing evidence supports safety after breast cancer • Multidisciplinary management of menopause after cancer is essential and should include primary care and, if appropriate, allied health practitioners • Reaching the population who need treatment is a global problem and online platforms are being developed to better support and empower patients with cancer to make shared, evidenced-based decisions with their local health-care provider Series 986 www.thelancet.com Vol 403 March 9, 2024 Around 1· 8 million women are diagnosed with gynaecological cancers every year and treatments such as bilateral oophorectomy, pelvic radiation, and gonadotoxic chemotherapy commonly induce premature ovarian insufficiency (POI) or early menopause.",
    "22 In 2020, around 10% of cancers diagnosed in women were colorectal. 23 Colorectal cancer rates are increasing in younger women, particularly rectal and anal cancer, which are commonly treated with pelvic irradiation that will induce menopause. 24 Leukaemia and lymphomas comprise about 4% of all cancers in women younger than 50 years and are commonly treated with a stem-cell transplant. 24 Gonadotoxic chemotherapy before stem-cell trans plantation will induce menopause in around 80% of premenopausal women, depending on their age and nature of the conditioning regimen. 25,26 Unmet needs of women with cancer in LMICs Survivors of cancer who are socioeconomically disadvantaged have poor health-related quality of life, in both low-income and high-income settings, due to underdiagnosis of menopausal symptoms and barriers to timely and appropriate care. 27 Multiple studies have shown that general physical health declines during midlife (age 35–65 years) in women from LMICs. 28 Impaired quality of Panel 1: Fictional clinical case study • A 37-year-old woman with a male partner and two children aged 5 years and 3 years visited her primary care provider because of sleeping difficulties. The primary care provider knows her well. The patient previously had imaging to investigate right-sided pain, which revealed a complex ovarian mass. This mass was subsequently found to be stage 1C1 high-grade serous ovarian cancer.",
    "The patient previously had imaging to investigate right-sided pain, which revealed a complex ovarian mass. This mass was subsequently found to be stage 1C1 high-grade serous ovarian cancer. She had a total abdominal hysterectomy and removal of both ovaries, staging laparotomy, and adjuvant systemic chemotherapy. Genetic testing showed that she carried the BRCA1 pathogenic variant, so both ovaries were removed. She also decided to undergo risk-reducing bilateral mastectomy with informed consent. • When the primary care provider asked more about her sleeping problems, the patient started to cry. She was frustrated by this show of emotion and said that she was not herself anymore. She found that minor problems were harder to deal with and she easily became emotional, which had caused arguments with her partner and her parents. Her family members were concerned about her health during her cancer treatment, but now that she was cured, they did not understand why she was always angry or sad. When she tried to make up with her partner, he often wanted to initiate sex. However, sexual intercourse was painful. Also, she was self-conscious about her appearance after mastectomy. • She was concerned about these changes and the effect they had on her life, especially at night. When she eventually fell asleep, she sometimes suddenly woke up feeling very hot, sweaty, and anxious. Sometimes these sensations also occurred during the day.",
    "When she eventually fell asleep, she sometimes suddenly woke up feeling very hot, sweaty, and anxious. Sometimes these sensations also occurred during the day. After telling her story, she felt relieved to have told someone about her problems and was hopeful that the primary care provider could help to solve them. • The primary care provider discussed with the patient that her symptoms (mood changes, vaginal dryness, hot flushes, and sleep disturbance) are all common after surgical menopause. This information gave great relief to the patient, who did not realise that removing her ovaries might have this effect. Previously she was blaming herself for feeling angry or sad, felt guilty about being unwilling to have penetrative intercourse, and was concerned about her relationship. She was also fearful that night sweats were a sign of brain metastases from her ovarian cancer. The primary care provider gave her information about symptoms after surgical menopause and possible treatments and made another appointment. • When she returned a week later, the patient felt somewhat better. However, she continued to experience troublesome hot flushes, sleep disturbance, and vaginal dryness. The primary care provider had contacted the gynaecological oncologist to discuss treatment options.",
    "The primary care provider had contacted the gynaecological oncologist to discuss treatment options. They advised that there were no contraindications to menopausal hormone therapy (MHT) in women with a history of high-grade serous ovarian cancer; however, the relevant studies had small sample sizes and short follow-up. Although the patient had a BRCA1 pathogenic variant, there were no substantial concerns about breast cancer because she had undergone bilateral mastectomy and would be receiving oestrogen-only MHT. • Together, the patient and the primary care provider discussed the treatment options. Initially, the patient was reluctant to consider pharmacological therapies because she had taken so much medication in the previous year. During an individualised discussion of the risks and benefits, the primary care provider explained that MHT was the most effective treatment for hot flushes and night sweats and would also prevent bone loss. The patient and the primary care provider made a joint decision that she should try MHT. • A month later, the patient reported that her vasomotor symptoms were greatly improved and her sleep was much better. Her relationship with her family had improved and she had returned to work. She had recommenced sexual activity but continued to experience vaginal dryness, so the primary care provider offered vaginal topical oestrogen. However, the patient continued to experience anxiety, particularly a fear of cancer recurrence.",
    "However, the patient continued to experience anxiety, particularly a fear of cancer recurrence. Together, they agreed that help from a psychologist was needed, and the patient was referred for cognitive behavioural therapy. Series www.thelancet.com Vol 403 March 9, 2024 987 life and psychological distress after cancer treatment is more severe in survivors from LMICs compared with survivors in HICs. Longitudinal studies reported young age and late cancer stage at diagnosis, low education and health literacy, financial hardships, and inadequate availability of supportive care as the primary reasons for continued distress of the people who survived cancer in LMICs. 29 Menopause-related symptoms and their consequences often receive little attention, as follow-up care is focused predominantly on surveillance for cancer recurrence. Minimising the health consequences of menopausal symptoms induced or exacerbated by cancer treatment and offering resource-appropriate solutions will substan- tially improve the quality of life of thousands of women every year. Preservation of ovarian function before cancer treatment Cancer treatments, including oophorectomy, gonadotoxic chemotherapy, and pelvic radiation, can induce meno pause. Recognising the potential short- term and long-term value of preserving ovarian function, the European Society of Medical Oncology has produced guidelines recommending strategies to preserve fertility and ovarian function after cancer (panel 2).",
    "30 Gonadotoxic chemo therapy, particularly regimens containing alkylating agents, commonly damage ovarian function and can induce permanent menopause. 31 The effect of new targeted therapies and immunotherapy on ovarian function is uncertain, but in mice, immunotherapy is gonadotoxic and reduces ovarian reserve. 32 In 2018, a systematic review found that ovarian suppression with gonadotropin-hormone-releasing hormone analogues before chemo therapy for breast cancer reduced chemotherapy-induced ovarian failure by around 50%. 33 A randomised trial is underway to determine if gonadotropin-releasing hormone agonists provide ovarian protection in young women and adolescents undergoing chemotherapy for cancer (eg, breast, lymphoma, leukaemia, and sarcoma), 34 but evidence to date shows little benefit for patients with haematological cancer. 35 The effect of pre-chemotherapy gonadotropin- hormone-releasing hormone analogues on age at menopause and long-term ovarian function is unknown. Pelvic radiation for locally advanced colorectal and cervical cancers will induce menopause in around 94·1% of premenopausal women. 36 There are few effective options for preventing ovarian damage due to chemotherapy. Preclinical data suggest that modification of pathways to primordial follicle apoptosis can protect the ovaries during chemoradiation. 37 However, this approach has not yet been trialled in women.",
    "Preclinical data suggest that modification of pathways to primordial follicle apoptosis can protect the ovaries during chemoradiation. 37 However, this approach has not yet been trialled in women. Moving the ovaries outside the field of radiation (transposition) can be protective and should be discussed as part of shared decision making. A 2019 systematic review of ovarian transposition before external beam pelvic radiation (n=765) concluded that ovarian function could be preserved in 20–100% of cases, 38 with efficacy primarily dependent on age. In a small series of 22 women with low rectal (n=20) or anal (n=2) cancer, transposition preserved ovarian function in 90% of participants younger than 40 years but only in 38% of those older than 40 years 39 (panel 2). Diagnosing and managing menopause after cancer There are no consensus criteria for diagnosing menopause after cancer. General diagnostic criteria, such as more than 12 months of amenorrhoea and elevated follicle stimulating hormone, cannot reliably be used, as ovarian function can resume many years after treatment. Although circulating anti-Müllerian hormone can indicate reduced ovarian reserve after chemotherapy, it does not reliably predict fertility, duration of reproductive life-span, or ovarian function.",
    "Although circulating anti-Müllerian hormone can indicate reduced ovarian reserve after chemotherapy, it does not reliably predict fertility, duration of reproductive life-span, or ovarian function. 40 A cross-sectional study of 1043 women aged 20–35 years found that 31·6% had amenorrhoea after cancer treatment, with risk factors including chemotherapy, older age at diagnosis, and never having been pregnant. Overall, 70% resumed menstruation, with almost all (90%) resuming menstruation within 2 years of treatment.",
    "Overall, 70% resumed menstruation, with almost all (90%) resuming menstruation within 2 years of treatment. 41 Women younger than 45 years with prolonged amenorrhoea after gonadotoxic cancer treatment should be offered MHT, provided they do not have Panel 2: Circumstances in which ovarian function can be preserved in gynaecological cancer Consider ovarian preservation in premenopausal women with: • Cervical cancer—stage 1 or 2A human papillomavirus- associated adenocarcinoma and squamous carcinoma of the cervix undergoing radical hysterectomy • Endometrial cancer—stage 1 low grade (not associated with Lynch syndrome or TP53 mutated); future molecular subtyping of endometrial cancer might improve stratification of care • Ovarian cancer—stage 1 (A) low grade, contralateral ovary could be preserved after explaining the 6–13% risk of recurrence in the preserved ovary; germ cell tumours with early unilateral disease Consider elective transposition in women younger than 40 years with: • Cervical cancer—locally advanced, if primary chemoradiation is planned • Rectal cancer—requiring neo-adjuvant chemoradiation • Cancer requiring pelvic radiation (eg, anal, vulval, sarcoma) Consider intra-operative transposition in women with: • Cervical cancer—if radical hysterectomy is abandoned due to positive node or if adjuvant radiation is likely • Rectal cancer—if adjuvant radiation is likely to be needed due to close margins or intra-operative complications Series 988 www.thelancet.com Vol 403 March 9, 2024 contraindications.",
    "Management should be tailored to the individual, taking into account the patient’s age, cancer type, time since diagnosis (competing risks change over time), quality of life (menopausal symptoms), comorbidities (eg, venous thromboembolism, polypharmacy, and the potential for drug interactions), risk factors for chronic disease (eg, osteoporosis and ischaemic heart disease), and views and preferences. Evidence of moderate-to-low quality from the general population suggests that transdermal MHT does not increase venous thromboembolism rates. 42 Since patients with cancer are at elevated risk of venous thromboembolism, we recommend offering transdermal rather than oral MHT. Testing of ovarian function after 12 months can be considered, depending on the cancer treatment. For example, ovarian function is unlikely to resume after pelvic radiation without ovarian transposition but might resume after chemotherapy for breast cancer, particularly in young women. In patients aged 40–45 years with breast cancer and secondary amenorrhoea after chemotherapy, an undetectable anti-mullerian hormone at 30 months is a reliable predictor of permanent menopause. 43 In addition to MHT, there is growing evidence supporting the efficacy of non-hormonal and non- pharmacological therapies for menopausal symptoms, which has substantially increased treatment options for the management of vasomotor symptoms and (to a lesser extent) genitourinary symptoms associated with menopause.",
    "44 MHT In the general population, MHT reduces vasomotor symptoms by around 85% and treating vasomotor symptoms can also improve sleep and quality of life. 45 Less is known about the efficacy and safety of MHT after cancer, but a systematic review reported an increased risk of recurrence following oestrogen-receptor-positive (but not negative) breast cancer. 46 Much of the evidence informing this systematic review came from a large randomised controlled trial (RCT) of tibolone (LIBERATE), which reported a significantly increased risk of new breast cancers and breast cancer recurrence with tibolone compared with placebo. 47 When the findings from LIBERATE were removed from the systematic review, there was no longer a statistically significant harm for patients with breast cancer. However, given concerns for an increased risk of breast cancer recurrence, especially in patients who might benefit from low circulating oestrogen concentrations, we generally recommend against MHT in survivors of breast cancer, particularly those with oestrogen-receptor-positive disease. However, exceptions can be made if quality of life is substantially affected or disease risks are low after careful discussion and shared decision making (figure 1).",
    "However, exceptions can be made if quality of life is substantially affected or disease risks are low after careful discussion and shared decision making (figure 1). For patients with cancer and POI or early menopause who are eligible to take MHT, the optimal duration of use is uncertain but should be considered until the average age of menopause (≥45 years) depending on symptoms and other health indices such as bone density. Figure 1 summarises available evidence regarding the safety of MHT after cancer. Figure 2 summarises advice about MHT use in female-specific cancer, and figure 3 Figure 1: Use of systemic MHT (or tibolone) by cancer type Red indicates that MHT should be avoided; yellow indicates that MHT should be considered. Grading uses the Grading of Recommendations, Assessment, Development, and Evaluation approach. 64 MHT=menopausal hormone therapy. HR=hazard ratio. RCT=randomised controlled trial. *After oestrogen-receptor-negative breast cancer, consider MHT if menopausal symptoms do not respond to non-hormonal treatments, particularly following bilateral mastectomy. Discuss with the patient that evidence to inform the safety of MHT in these circumstances is limited.",
    "65–69 Eﬀect of MHT on cancer outcomes Level of evidence MHT use Systematic review and meta-analysis (n=4050) found increased risk of recurrence with tibolone or MHT (HR 1·46) 46 Breast cancer: overall Moderate Avoid MHT Subgroup analysis found no increased risk of recurrence with tibolone or MHT (HR 1·19) 46 Breast cancer: oestrogen- receptor-negative Moderate Consider MHT in speciﬁc patients* Mixed evidence: prospective cohort study (n=727) 60 and SEER data (n=485)61 showed improved cancer outcomes; retrospective study (n=498) 62 and RCT63 showed increased mortality Lung cancer Moderate Consider MHT Meta-analysis suggests better cancer outcomes with MHT 59 Kidney cancer Low Consider MHT Do not express oestrogen receptors, MHT thought to be safe 58 Vaginal, vulval, and anal squamous cell carcinoma Very low Consider MHT Systematic review found uncertain evidence for eﬃcacy or safety of MHT 57 Epithelial ovarian cancer Moderate Consider MHT European guidelines suggest oﬀering on an individualised basis 48 Ovarian germ cell tumours Very low Consider MHT One case–control study (n=244) reported improved cancer outcomes 56 Hepatocellular cancer Very low Consider MHT One large prospective study (n=834)54 and one national cohort study55 reported improved cancer outcomes Colorectal cancer Low Consider MHT One small study (n=206) showed no eﬀect on cancer outcomes 53 Early cutaneous malignant melanoma Very low Consider MHT One small study (n=130) showed no eﬀect on cancer outcomes 52",
    "Low Consider MHT One small study (n=206) showed no eﬀect on cancer outcomes 53 Early cutaneous malignant melanoma Very low Consider MHT One small study (n=130) showed no eﬀect on cancer outcomes 52 Haematological cancer Very low Consider MHT One small retrospective study (n=120) found no eﬀect on cancer outcomes; 50 European guidelines suggest oﬀering MHT 51 Cervical cancer Very low Consider MHT Systematic review found no eﬀect on cancer outcomes 49 Low-grade, early-stage endometrial cancer Moderate Consider MHT European guidelines suggest avoiding MHT, might be oestrogen sensistive 48 Ovarian cancer: low-grade serous and granulosa cell Very low Avoid MHT European guidelines suggest avoiding MHT, might be oestrogen sensitive 48 Uterine sarcomas Very low Avoid MHT Subgroup analysis found increased risk of recurrence (HR 1·80) with tibolone or MHT 46 Breast cancer: oestrogen- receptor-positive Moderate Avoid MHT Series www.thelancet.com Vol 403 March 9, 2024 989 provides specific advice for MHT after cancers that affect both men and women.",
    "Decisions about MHT after cancer should use a shared decision-making approach, including the patient and the treating oncologist. Non-pharmacological therapies for vasomotor symptoms Non-pharmacological approaches can also reduce the effects of vasomotor symptoms after cancer. Cognitive behaviour therapy (CBT) has the strongest evidence base. After breast cancer, CBT is effective delivered to groups, individually, online, or by specialist nurses, with a sustained effect at 26 weeks versus usual care, and it improves sleep and depressive symptoms. 70 CBT reduces interference and bother due to vasomotor symptoms, which is a priority area for patients. 71 Two small RCTs of hypnosis in patients with breast cancer showed improvements in vasomotor symptoms, mood, and sleep. 44 Stellate ganglion block involves injection of local anaesthetic into the neck for the management of conditions such as complex regional pain and peripheral vascular disease. One small, randomised sham-controlled trial (n=40) showed a reduction in moderate-to-severe vasomotor symptoms with stellate ganglion block. 72,73 However, this procedure is invasive and costly, with small but serious health risks. Acupuncture is of uncertain benefit for vasomotor symptoms but can help with fatigue and joint pain after breast cancer.",
    "Acupuncture is of uncertain benefit for vasomotor symptoms but can help with fatigue and joint pain after breast cancer. 44 Small RCTs indicate that yoga, relaxation training, and mindfulness-based stress reduction reduce vasomotor symptoms, with benefits for sleep, depressive symptoms, and self-reported stress. 44 Physical exercise, supplements, and homoeopathy are ineffective.44 Lifestyle changes, such as dressing in layers, can help and a cool pad pillow topper reduces vasomotor symptoms after breast cancer. 74 Non-hormonal treatments for vasomotor symptoms In patients in whom MHT is contraindicated or should be avoided after cancer (table), a burgeoning number of non- hormonal therapies are available. However, unlike MHT these therapies will not improve genitourinary symptoms or prevent fracture. Some antidepressants reduce vasomotor symptoms by 40–60%. 75 The anticonvulsants pregabalin and gabapentin have similar efficacy. 75 The antihypertensive clonidine is less effective than venlafaxine. 44 One small RCT showed that oxybutynin was effective for vasomotor symptoms after breast cancer. 76 There are few head-to-head trials of non-hormonal treatments for vasomotor symptoms, which makes knowing what works best difficult. Selecting non- hormonal treatments should follow a shared decision making approach. For example, gabapentin reduces vasomotor symptoms but can cause drowsiness and hence is often more suitable for night-time symptoms.",
    "For example, gabapentin reduces vasomotor symptoms but can cause drowsiness and hence is often more suitable for night-time symptoms. The dose of escitalopram for vasomotor symptoms is equivalent to the antidepressant dose so can be considered for patients who also have depression. Existing medications will also guide choice. Selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors should not be used together. A suggested approach to starting non-hormonal treatments for vasomotor symptoms is oxybutynin 2·5–5 mg twice a day, escitalopram 10–20 mg, or venlafaxine 37 ·5 mg increasing to 75 mg controlled release. Gabapentin (300–900 mg) reduces night sweats and causes drowsiness, which might improve sleep. 44 A systematic review of the side-effects of these non-hormonal therapies in patients with breast cancer reported that 81% of patients experienced adverse effects, which were graded as mild in 67%. 77 Higher doses of gabapentin and venlafaxine were most likely to induce side-effects. 77 Antidepressants should be stopped gradually. Targeted therapy with the neurokinin B receptor antagonist fezolinetant is available in the USA and some European countries. Two large RCTs have compared the efficacy of fezolinetant versus placebo for vasomotor symptoms over 12 weeks, with a 40-week open label extension.",
    "Two large RCTs have compared the efficacy of fezolinetant versus placebo for vasomotor symptoms over 12 weeks, with a 40-week open label extension. 78,79 With 45 mg per day (the dose now marketed), there was a statistically significant reduction in hot flush frequency and severity up to 1 year and serious adverse events were infrequent. Fezolinetant also improved menopause-related quality of life. 80 Although clinical trials of neurokinin B receptor antagonists in patients with cancer have not yet been Figure 2: Use of MHT after female-specific cancers MHT=menopausal hormone therapy. HPV=human papillomavirus. *Consider transdermal due to increased venous thromboembolism risk. †Fully resected, no invasive implants.",
    "HPV=human papillomavirus. *Consider transdermal due to increased venous thromboembolism risk. †Fully resected, no invasive implants. Ovarian cancer Depends on histological subtype Can have MHT • High-grade serous • Endometrioid • Mucinous • Clear cell* • Borderline† • Germ cell Avoid MHT • Low-grade serous • Granulosa cell tumours • Sex cord stromal tumours Uterine cancer Carcinoma Can have MHT • Endometrioid • Serous • Carcinosarcoma Sarcoma Can be oestrogen sensitive No data on MHT post diagnosis • Leiomyosarcoma • High-grade endometrial stromal sarcoma Avoid MHT • Low-grade endometrial sarcoma • Adenosarcoma Breast cancer • Avoid MHT in oestrogen-receptor-positive tumours • Consider MHT in triple-negative breast cancer if other options exhausted or prophylactic mastectomy Cervical cancer • HPV-related cancers should have MHT (including adenocarcinoma) • Non-HPV related cancers require caution, particularly gastric subtype Vulval or vaginal cancer • Patients with HIV-related cancers should have MHT • Avoid MHT in certain non-HPV-related cancers including DES-related adenocarcinoma and Paget’s-related adenocarcinoma Series 990 www.thelancet.com Vol 403 March 9, 2024 published, breast cancer is not a contraindication to fezolinetant use in the USA. However, improvements in vasomotor symptoms with fezolinetant are modest and do not meet the minimally important clinical difference 81 for hot flush frequency or menopause-related quality of life.",
    "However, improvements in vasomotor symptoms with fezolinetant are modest and do not meet the minimally important clinical difference 81 for hot flush frequency or menopause-related quality of life. A meta-analysis published in 2024, 82 which included 2168 patients from five RCTs, reported a 22 ·5% mean improvement in frequency of vasomotor symptoms, with small improvements in menopause-related quality of life. In 2023, the independent US Institute for Clinical and Economic Review concluded that fezolinetant was less effective than MHT for vasomotor symptoms, and that MHT might provide additional benefits for sleep, vaginal dryness, and fracture prevention. 83 Managing sexual difficulties and dysfunction In 2016, a systematic review reported that sexual dysfunction affected 78% of patients with gynaecological cancer and 65% of patients with breast or colorectal cancer, particularly premenopausal women. 84 Sexual dysfunction can arise from factors that are biological (eg, menopause or surgery), psychological (eg, depression, anxiety, or body image), interpersonal (eg, relationship and communication issues), and sociocultural (eg, religion or cultural). A holistic approach including partners might be best suited to address these issues.",
    "A holistic approach including partners might be best suited to address these issues. The American Society of Clinical Oncology advises that health-care professionals should initiate a discussion about sexual problems with all patients with cancer and offer psychosocial or psychosexual counselling to improve sexual response, body image, intimacy and relationship issues, and overall sexual functioning and satisfaction. 85 However, less than 25% of patients with cancer seek professional help. 86 Less is known about the psychosexual effects of cancer in LMICs, where there might be substantial cultural differences in beliefs and understanding about sex and approaches to managing sexual dysfunction compared with HICs. 87 Management of genitourinary symptoms and sexual dysfunction after breast cancer A 2018 consensus guideline from the American College of Obstetrics and Gynecology advised non-hormonal agents as first-line therapy, with vaginal oestrogens reserved for persistent symptoms after discussion with the treating oncologist. 88,89 In the general population, vaginal oestrogens improve dryness with no differences between products. 90 Although often recommended for long-term use, a 2020 systematic review reported that safety data are limited to 1 year. 91 Less is known about the efficacy and safety of vaginal oestrogen after breast cancer.",
    "91 Less is known about the efficacy and safety of vaginal oestrogen after breast cancer. In 2022, a Danish data linkage study reported a small increase in breast cancer recurrence in patients taking adjuvant aromatase inhibitors and using vaginal oestrogen, although their survival was no worse. 92 In 2024, a UK registry-based study of 49 237 patients aged 40–79 years with breast cancer showed no evidence of increased breast cancer mortality in those who used versus those who did not use vaginal oestrogen, although only 5% used vaginal oestrogen. 93 Vaginal oestrogens are systemically absorbed in small but measurable amounts, which are dose dependent, with low and ultra-low doses leading to low or no measurable absorption. 94 In the general population, an RCT of daily vaginal prasterone for 12 weeks showed a reduction in pain during sexual activity and an improvement in vaginal dryness. 95 However, one RCT (n=464) of vaginal prasterone after Figure 3: Use of MHT after non-female specific cancers MHT=menopausal hormone therapy.",
    "95 However, one RCT (n=464) of vaginal prasterone after Figure 3: Use of MHT after non-female specific cancers MHT=menopausal hormone therapy. Glioma or meningioma Might be oestrogen-responsive No data on MHT post diagnosis Head and neck cancer Can have MHT Lymphoma Can have MHT Thyroid cancer Can have MHT Kidney cancer Can have MHT Colorectal cancer Should have MHT Gastric or oesophageal cancer Oestrogen receptor and androgen receptor expression associated with worse prognosis, avoid MHT Bladder cancer Might be oestrogen-sensitive No data on MHT post diagnosis Malignant melanoma Can have MHT Pancreatic cancer Can have MHT Hepatocellular cancer Can have MHT Lung cancer Might be oestrogen- responsive, conﬂicting evidence on MHT post diagnosis Vasomotor symptoms Sexual dysfunction Vaginal dryness Selected SSRIs and SNRIs Likely Unlikely* Unlikely Specific anticonvulsants Likely Unlikely Unlikely Oxybutynin Likely Unlikely Unlikely Clonidine Likely Unlikely Unlikely Vaginal lubricants or moisturisers Unlikely Possible Possible Vaginal carbon dioxide laser Unlikely Unlikely Unlikely Stellate ganglion block Possible Unlikely Unlikely Cognitive behavioural therapy Likely Likely Unlikely Physical exercise Unlikely Unlikely Unlikely Acupuncture Possible Unlikely Unlikely Hypnosis Likely Unlikely Unlikely Yoga and mindfulness-based stress reduction Possible Unlikely Unlikely Effectiveness is defined as likely (evidence from randomised controlled trials), possible (evidence from single-arm studies), or unlikely (no evidence of effectiveness).",
    "SNRIs=serotonin norepinephrine reuptake inhibitors. SSRIs=selective serotonin reuptake inhibitors. All trials are in patients with breast cancer. Adapted from Franzoi and colleagues with permission. 44 *Does not worsen sexual function when used for vasomotor symptoms. Table: Effectiveness of non-hormonal treatments for vasomotor symptoms, sexual difficulties, and vaginal dryness Series www.thelancet.com Vol 403 March 9, 2024 991 breast cancer showed no benefit compared with vaginal moisturiser at 8 weeks.96 Ospemifene is an oral treatment for vaginal dryness that is approved for use after breast cancer in the UK and the USA. In the general population, ospemifene is superior to placebo for vaginal dryness and improves sexual function at 12 weeks. 97 However, there are no direct comparator trials with vaginal oestrogen, and efficacy and safety of ospemifene after cancer are unknown. 96 There is little evidence to support the efficacy of lubricants and moisturisers. One small RCT comparing silicone with water-based lubricants in patients with breast cancer taking aromatase inhibitors found that silicone lubricants were more effective for sexual pain but more than 80% of patients still had sexual pain despite lubricant use. 98 One RCT of vulval anaesthetic (lignocaine) after breast cancer showed reduced pain with intercourse. 99 Cancer and its treatment might also reduce libido and sexual satisfaction.",
    "98 One RCT of vulval anaesthetic (lignocaine) after breast cancer showed reduced pain with intercourse. 99 Cancer and its treatment might also reduce libido and sexual satisfaction. One RCT showed that intravaginal testosterone reduced pain and dryness and increased satisfaction in patients with breast cancer taking aromatase inhibitors. 100 However, the safety of testosterone after breast cancer is uncertain. Psychosexual inter ventions including CB T, education, and counselling might be helpful.101 An RCT showed that CBT improved overall sexual function and desire, arousal and vaginal lubrication, and sexual pleasure and reduced discomfort and distress after breast cancer. 102 Brief sexual counselling by telephone or in person might also be effective.103 Management of genitourinary symptoms and sexual dysfunction after pelvic radiotherapy The vaginal effects of external beam radiotherapy or brachytherapy, particularly vaginal dryness, fibrosis, and shortening, which can present as pain with sexual activity and impaired sexual function, can be more severe than those of chemotherapy. 101 Vaginal dilators are reco - mmended to maintain vaginal capacity after pelvic radiation, but uptake is low at less than 25% of patients and the evidence base is scant. 101 In 2014, a systematic review found no reliable evidence that routine regular vaginal dilation during radiotherapy prevents stenosis or improves quality of life.",
    "101 In 2014, a systematic review found no reliable evidence that routine regular vaginal dilation during radiotherapy prevents stenosis or improves quality of life. 104 Vaginal oestrogen is commonly offered with little evidence to support efficacy. Pelvic floor dysfunction, including urinary and faecal incontinence, dyspareunia, and vaginismus, are common after gynaecological cancer treatment. A small RCT (n=34) showed that pelvic floor physiotherapy improved sexual function after gynaecological cancer. 105 Integrative oncology Integrative oncology describes the use of complementary treatments alongside conventional cancer therapies. This approach takes a patient-centred, evidence-informed perspective and uses mind–body practices, natural products, and lifestyle modifications alongside conventional treatments. Integrative oncology might include therapies such as CBT, mindfulness, and hypnosis for vasomotor symptoms, mood, and sleep. 106 Patients with cancer in many settings rely on traditional, complementary, and integrative treatments that are culturally appropriate and more accessible than conventional therapies. 107 Although there is very little evidence to support the use of traditional and complementary therapies in cancer treatment, several randomised controlled trials have shown benefits for reducing symptoms such as fatigue, depression, anxiety, and insomnia, which could improve quality of life.",
    "108 Multidisciplinary care Managing menopause after cancer requires a multidisciplinary clinical team and the use of an evidence base to inform practice, optimal models for service delivery, and investment in sectors such as primary care and allied health. Tertiary-based care cannot meet the needs of the growing number of people who survive cancer. Since menopausal symptoms affect a wide range of these patients, siloed care within tumour streams could lead to duplication of precious services. In Australia, the multidisciplinary Menopausal Service after Cancer (MSAC) provided by gynaecologists, endocrinologists, and primary care and allied health providers manages vasomotor and genitourinary symptoms, sleep and mood disturbance, and sexual difficulties across cancer types and in one place. 109 A 2021 study showed statistically significant improvements in the four most troublesome symptoms (ie, hot flushes, fatigue, sleep difficulties, and loss of interest in sex) in patients whose care was managed through MSAC. 110 To minimise cost and reduce waste, clear guidelines are needed to support the management of menopausal symptoms after cancer. This approach should include high-quality information for patients about hormonal, non-hormonal, and psychological treatment options that stratify risk according to cancer type. Involving patients in decisions about their care and enabling them to make informed choices is key and is likely to lead to better outcomes.",
    "Involving patients in decisions about their care and enabling them to make informed choices is key and is likely to lead to better outcomes. COVID-19 changed how medical care is delivered. Telemedicine can extend the reach of care and increase convenience for patients. In 2021, a systematic review reported that digital health interventions were helpful and effective for supportive care in patients with cancer. Most studies reported positive outcomes for symptoms such as fatigue and pain, health-related quality of life, functional capacity, and mood compared with usual care, although most studies were in breast cancer. 111 Telehealth is also accessible and effective for managing menopausal symptoms after cancer and could reduce the burden of hospital appointments. Patients with cancer often prefer video telehealth when physical examination is not needed. 112 Telehealth can also be delivered directly to the primary care provider who has reviewed and examined the patient, which can reduce the need for tertiary referral. 113 Tertiary care should be multidisciplinary, inclusive of all symptomatic patients, and should aim to manage all Series 992 www.thelancet.com Vol 403 March 9, 2024 common symptoms. 114 In-person visits are needed for vulval and vaginal examination to manage chronic genital graft versus host disease, which affects around 30% of allograft patients in whom effective management can prevent severe complications such as vaginal stenosis.",
    "115 In breast cancer, RCT evidence supports the role of nurse practitioners in patient counselling and education and to assess symptoms. 116 Allied health professionals such as primary care providers are well placed to provide ongoing psychological support, monitor for short-term and long-term complications of cancer treatment, modify risk factors, and make timely onward referral as needed. Care delivered by allied health-care professionals and their peers in discussion with cancer specialists might be more sustainable than ongoing tertiary care. Health disparities in LMICs Rates of treatment-induced menopause are elevated in LMICs, where the average age at cancer diagnosis is 40–50 years compared with 66 years in HICs. 24 In these settings, more women are diagnosed with cancer when they are still premenopausal and are exposed to treatments that are likely to induce POI or early menopause. Prevention and management of treatment-induced menopause is an unmet need in LMICs. Supportive care should be integrated into the comprehensive cancer care model through the training of primary and tertiary health- care providers and the provision of essential and affordable medication to manage symptoms. Education for patients and their carers should include identification of symptoms, self-management approaches, and pathways for seeking care.",
    "Education for patients and their carers should include identification of symptoms, self-management approaches, and pathways for seeking care. Scarcity of evidence from high-quality research is commonly cited as the key reason for not integrating traditional and complementary medicine into cancer survivorship care. 117 Evidence gaps Almost all published studies of menopause and cancer are in early breast cancer, and less is known about advanced breast cancer or other cancers in women. There are no reliable ways of predicting who will experience severe or prolonged menopausal symptoms following cancer treatment. In breast cancer, vaginal dryness is more common with aromatase inhibitors than tamoxifen, and some evidence suggests that switching between tamoxifen and aromatase inhibitors can improve vasomotor symptoms in postmenopausal women. 13,118 Among premenopausal women, switching to tamoxifen plus ovarian function suppression or tamoxifen alone might improve vaginal dryness, and this treatment can be considered by the treating oncologist when weighing the advantages and disadvantages of disease risks and tolerance of therapy. 119 Decisions regarding the necessity and type of hormonal therapy used for breast cancer treatment depend on menopausal status, evolving literature, disease risk, and patients’ comorbidities, tolerance over time, and preferences.",
    "Although aromatase inhibitors have become the standard of care for many patients with oestrogen- positive breast cancer (with ovarian suppression in premenopausal women), there are commonly issues with access and cost for women in LMICs. Tamoxifen is widely used for premenopausal and postmenopausal women in these settings, and it is included in WHO’s list of essential cancer medicines. More information is needed about the effect of long-term tamoxifen use on menopausal symptoms and quality of life for patients from LMICs, especially when they transition from premenopausal to postmenopausal. Most clinical trials of treatments for menopausal symptoms were done in older women but younger patients with cancer can experience severe symptoms and worse quality of life. 120 Little is known about the effects of cancer treatment in lesbian, gay, bisexual, transgender, queer or questioning, and intersex (LGBTQI+) individuals, but some people report hostility and prejudice from health-care providers and anxiety about disclosing their sexual orientation and gender identity. 121 In Australia, these data have informed a new information resource for LGBTQI+ people with cancer. Although new non-hormonal and non-pharmacological treatments are needed for patients with contraindications to MHT, young patients with cancer who are eligible to take MHT might not be offered it.",
    "Although new non-hormonal and non-pharmacological treatments are needed for patients with contraindications to MHT, young patients with cancer who are eligible to take MHT might not be offered it. New MHT preparations are emerging, including selective oestrogen receptor modulators and non-hormonal therapies targeting the neurokinin B receptor. One targeted therapy (Q-122) has shown moderate efficacy for vasomotor symptoms in patients with breast cancer taking endocrine therapy. 122 Fezolinetant is available in some countries for vasomotor symptoms, with efficacy, safety, and tolerability shown up to 1 year in the general population. 78,123 However, efficacy and safety of this agent after cancer are not clear. Safe and effective non-hormonal treatments for managing genitourinary symptoms after cancer are needed. The efficacy of vaginal laser is uncertain. A 2021 randomised sham-controlled trial of vaginal laser for genitourinary symptoms in postmenopausal women, of whom around half had previous breast cancer, found no difference between the sham and laser groups. 124 In 2023, a randomised trial of carbon dioxide laser on sexual function in survivors of breast cancer showed no benefit over sham laser. 125 Reaching the population who need treatment is a global problem. Novel online information and treatment resources based on stepped care aim to increase knowledge and improve access to treatment.",
    "125 Reaching the population who need treatment is a global problem. Novel online information and treatment resources based on stepped care aim to increase knowledge and improve access to treatment. In gynaecological cancer, new personalised online resources co-developed with patients provide much-needed information and symptomatic support. Contributors MH conceived and designed the paper, wrote the initial draft, and was responsible for revising this draft based on comments from the other authors. PB, JS, MES, EW, KNC, C-HY , AHP, and DJB made substantial For more on the resource for LGBTQI+ people with cancer see [URL] au/cancer-information/lgbtqi/ For more on the personalised online resources see https:// thisisgo.ie/ Series www.thelancet.com Vol 403 March 9, 2024 993 contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content; provided final approval of the version to be published; and agreed to be accountable for all aspects of the work by ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MH is responsible for the final approval of this manuscript and agrees to be accountable. PB and EW are personnel of the International Agency for Research on Cancer or WHO.",
    "MH is responsible for the final approval of this manuscript and agrees to be accountable. PB and EW are personnel of the International Agency for Research on Cancer or WHO. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer or WHO. Declaration of interests MH declares salary funding from the Australian National Health and Medical Research Council, support for meeting attendance from the UK National Institute for Health and Care Excellence, and the following roles: principal investigator for a clinical trial of salpingectomy vs salpingo-oophorectomy for prevention of ovarian cancer (TUBA-WISP II); board member for Breastscreen Victoria; editor for the Cochrane Collaboration; recipient of a fellowship from the Lundbeck Foundation (2022-23); site investigator for a clinical trial of a non-hormonal agent (Q-122) for vasomotor symptoms in patients with breast cancer (QUE Oncology, 2020-22); and site investigator for a clinical trial of a medical device for treating vaginal dryness (Madorra). JS is a site investigator for neurokinin B antagonist for vasomotor symptoms and has received travel grants for conference attendance from Mylan and Besins. AHP has received royalties for coauthorship of the breast cancer survivorship section of UpToDate.",
    "AHP has received royalties for coauthorship of the breast cancer survivorship section of UpToDate. DJB acknowledges financial support from Precision Oncology Ireland, which is part- funded by the Science Foundation Ireland Strategic Partnership Programme (grant number 18/SPP/3522), and has received co-funding from AstraZeneca. DJB is the principal investigator of an investigator- initiated clinical trial of digital cognitive behavioural therapy and gabapentin for treatment of menopause symptoms after cancer, supported by the Irish Cancer Society (WHIBREN2020). DJB has received speaker fees or honoraria from Bayer, GSK, MSD, Olympus, and AstraZeneca and has participated on a data safety monitoring board or advisory board for Astellas, Bayer, and GSK. All other authors declare no competing interests. References 1 Zhu D, Chung H-F, Pandeya N, et al. Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies. Eur J Epidemiol 2018; 33: 699–710. 2 Schoenaker DA, Jackson CA, Rowlands JV , Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol 2014; 43: 1542–62. 3 Xu X, Jones M, Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum Reprod 2020; 35: 203–11.",
    "3 Xu X, Jones M, Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum Reprod 2020; 35: 203–11. 4 Overbeek A, van den Berg MH, van Leeuwen FE, Kaspers GJ, Lambalk CB, van Dulmen-den Broeder E. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: a systematic review. Cancer Treat Rev 2017; 53: 10–24. 5 Lumsden MA, Davies M, Sarri G. Diagnosis and management of menopause: the National Institute for Health and Care Excellence (NICE) guideline. JAMA Intern Med 2016; 176: 1205–06. 6 Peate M, Saunders C, Cohen P, Hickey M. Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors. Breast Cancer Res Treat 2021; 187: 427–35. 7 Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet 2017; 389: 847–60. 8 Glyde T. LGBTQIA+ menopause: room for improvement. Lancet 2022; 400: 1578–79. 9 Szabo RA, Marino JL, Hickey M. M anaging menopausal symptoms after cancer. Climacteric 2019; 22: 572–78. 10 Perrone G, Capri O, Galoppi P, et al. Menopausal symptoms after the discontinuation of long-term hormone replacement therapy in women under 60: a 3-year follow-up. Gynecol Obstet Invest 2013; 76: 38–43. 11 Bernhard J, Luo W, Ribi K, et al.",
    "Gynecol Obstet Invest 2013; 76: 38–43. 11 Bernhard J, Luo W, Ribi K, et al. P atient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16: 848–58. 12 Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014; 21: 267–74. 13 Ganz PA, Cecchini RS, Julian TB, et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 2016; 387: 857–65. 14 Boundouki G, Wilson R, Duxbury P, et al. Patient and public priorities for breast cancer research: a qualitative study in the UK. BMJ Open 2021; 11: e036072. 15 Scanlon M, Blaes A, Geller M, M ajhail NS, Lindgren B, Haddad T. Patient satisfaction with physician discussions of treatment impact on fertility, menopause and sexual health among pre-menopausal women with cancer. J Cancer 2012; 3: 217–25. 16 National Cancer Institute. BRCA gene mutations: cancer risk and genetic testing. Nov 19, 2020. [URL] cancer/causes-prevention/genetics/brca-fact-sheet (accessed Feb 8, 2024).",
    "16 National Cancer Institute. BRCA gene mutations: cancer risk and genetic testing. Nov 19, 2020. [URL] cancer/causes-prevention/genetics/brca-fact-sheet (accessed Feb 8, 2024). 17 Liu YL, Breen K, Catchings A, et al. Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol Pract 2022; 18: 201–09. 18 Daly MB, Pal T, Berry MP, et al. G enetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19: 77–102. 19 Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M. Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women. Menopause 2020; 27: 26–32. 20 Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo- oophorectomy? Menopause 2020; 27: 20–25. 21 Nebgen DR, Domchek SM, Kotsopoulos J, et al. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: scoping review and international consensus recommendations. BJOG 2023; 130: 1437–50. 22 Brennan A, Brennan D, Rees M, Hickey M. M anagement of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int J Gynecol Cancer 2021; 31: 352–59. 23 International Agency for Research on Cancer . Colorectal cancer.",
    "Int J Gynecol Cancer 2021; 31: 352–59. 23 International Agency for Research on Cancer . Colorectal cancer. [URL] (accessed Feb 15, 2024). 24 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49. 25 Oktay K, Harvey BE, Partridge AH, et al. F ertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018; 36: 1994–2001. 26 Lee YJ, Kim JS, Jo JC, et al. Risk factors of menopause after allogeneic hematopoietic cell transplantation in premenopausal adult women. Eur J Haematol 2023; 111: 449–57 . 27 Niksic M, Rachet B, Warburton FG, Wardle J, Ramirez AJ, Forbes LJ. Cancer symptom awareness and barriers to symptomatic presentation in England--are we clear on cancer? Br J Cancer 2015; 113: 533–42. 28 Leone T. Women ’s mid-life health in low and middle income countries: a comparative analysis of the timing and speed of health deterioration in six countries. SSM Popul Health 2018; 7: 100341. Series 994 www.thelancet.com Vol 403 March 9, 2024 29 Kimman ML, Jan S, Peters SAE, et al. H ealth-related quality of life and psychological distress among cancer survivors in Southeast Asia: results from a longitudinal study in eight low- and middle- income countries. BMC Med 2017; 15: 10. 30 Lambertini M, Peccatori FA, Demeestere I, et al.",
    "BMC Med 2017; 15: 10. 30 Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol 2020; 31: 1664–78. 31 Poorvu PD, Frazier AL, Feraco AM, et al. Cancer treatment-related infertility: a critical review of the evidence. JNCI Cancer Spectr 2019; 3: pkz008. 32 Winship AL, Alesi LR, Sant S, et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer 2022; 3: 1–13. 33 Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin- releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol 2018; 36: 1981–90. 34 Rodriguez-Wallberg KA, Nilsson HP, Bergh J, et al. ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study. BMJ Open 2023; 13: e078023. 35 Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 2016; 34: 2568–74.",
    "J Clin Oncol 2016; 34: 2568–74. 36 Wan J, Gai Y , Li G, Tao Z, Zhang Z. Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage 2/3 colorectal cancer. Clin Colorectal Cancer 2015; 14: 31–34. 37 Kim S, Kim SW, Han SJ, et al. M olecular mechanism and prevention strategy of chemotherapy- and radiotherapy-induced ovarian damage. Int J Mol Sci 2021; 22: 7484. 38 Hoekman EJ, Broeders EABJ, Louwe LA, Nout RA, Jansen FW, de Kroon CD. Ovarian function after ovarian transposition and additional pelvic radiotherapy: a systematic review. Eur J Surg Oncol 2019; 45: 1328–40. 39 Sioulas VD, Jorge S, Chern JY , et al. Robotically assisted laparoscopic ovarian transposition in women with lower gastrointestinal cancer undergoing pelvic radiotherapy. Ann Surg Oncol 2017; 24: 251–56. 40 Anderson RA, Cameron D, Clatot F, et al. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update 2022; 28: 417–34. 41 Jacobson MH, Mertens AC, Spencer JB, Manatunga AK, Howards PP. Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. Fertil Steril 2016; 105: 765–72. 42 Goldštajn MŠ, Mikuš M, Ferrari FA, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Arch Gynecol Obstet 2023; 307: 1727–45. 43 Anderson RA, Kelsey TW, P erdrix A, et al.",
    "Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Arch Gynecol Obstet 2023; 307: 1727–45. 43 Anderson RA, Kelsey TW, P erdrix A, et al. Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer. Breast Cancer Res Treat 2022; 192: 273–82. 44 Franzoi MA, Agostinetto E, Perachino M, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol 2021; 22: e303–13. 45 Sarri G, Pedder H, Dias S, Guo Y , Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG 2017; 124: 1514–23. 46 Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat 2021; 191: 269–75. 47 Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135–46. 48 Rees M, Angioli R, Coleman RL, et al.",
    "Lancet Oncol 2009; 10: 135–46. 48 Rees M, Angioli R, Coleman RL, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas 2020; 134: 56–61. 49 Edey KA, Rundle S, Hickey M. H ormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev 2018; 5: CD008830. 50 Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987; 26: 169–77 . 51 Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer 2018; 28: 641–55. 52 Yang X, Wang C, He X, et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric 2017; 20: 268–73. 53 MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 2004; 90: 770–72. 54 Chan JA, Meyerhardt JA, Chan AT , Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol 2006; 24: 5680–86.",
    "54 Chan JA, Meyerhardt JA, Chan AT , Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol 2006; 24: 5680–86. 55 Ji J, Sundquist J, Sundquist K. Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: a population-based study in Sweden. Int J Cancer 2018; 142: 2003–10. 56 Hassan MM, Botrus G, Abdel-Wahab R, et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2017; 15: 1791–99. 57 Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev 2020; 1: CD012559. 58 Brennan A, Rees M. Menopausal hormone therapy in women with benign gynaecological conditions and cancer. Best Pract Res Clin Endocrinol Metab 2021; 35: 101575. 59 Zhang X, Du Y , Tan X, et al. The relationship between hormone replacement therapy and risk of kidney cancer in women: a meta-analysis. Cancer Control 2020; 27: 1073274820930194. 60 Clague J, Reynolds P, Henderson KD, et al. M enopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study. PLoS One 2014; 9: e103735. 61 Katcoff H, Wenzlaff AS, Schwartz AG. Survival in women with NSCLC: the role of reproductive history and hormone use. J Thorac Oncol 2014; 9: 355–61.",
    "PLoS One 2014; 9: e103735. 61 Katcoff H, Wenzlaff AS, Schwartz AG. Survival in women with NSCLC: the role of reproductive history and hormone use. J Thorac Oncol 2014; 9: 355–61. 62 Ganti AK, Sahmoun AE, Panwalkar A W, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006; 24: 59–63. 63 Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374: 1243–51. 64 Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook. October, 2013. [URL] html (accessed Feb 15, 2024). 65 Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol 2019; 153: 192–200. 66 Steenbeek MP, Harmsen MG, Hoogerbrugge N, et al. Association of salpingectomy with delayed oophorectomy versus salpingo- oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: a nonrandomized controlled trial. JAMA Oncol 2021; 7: 1203–12. 67 Hickey M, Moss KM, Krejany EO, et al. What happens after menopause? (WHAM): a prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.",
    "What happens after menopause? (WHAM): a prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol Oncol 2021; 163: 148–54. 68 Hickey M, Moss KM, Krejany EO, et al. What happens after menopause? (WHAM): a prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol Oncol 2021; 162: 447–53. Series www.thelancet.com Vol 403 March 9, 2024 995 69 Hickey M, Moss KM, Brand A, et al. What happens after menopause? (WHAM): a prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol 2021; 161: 527–34. 70 Hunter MS. Cognitive behavioral therapy for menopausal symptoms. Climacteric 2021; 24: 51–56. 71 Lensen S, Archer D, Bell RJ, et al. A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. Menopause 2021; 28: 852–58. 72 Walega DR, Rubin LH, Banuvar S, Shulman LP, Maki PM. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women. Menopause 2014; 21: 807–14. 73 Rahimzadeh P, Imani F, Nafissi N, Ebrahimi B, Faiz SHR. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors.",
    "73 Rahimzadeh P, Imani F, Nafissi N, Ebrahimi B, Faiz SHR. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors. Cancer Manag Res 2018; 10: 4831–37 . 74 Marshall-McKenna R, Morrison A, Stirling L, et al. A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Support Care Cancer 2016; 24: 1821–29. 75 Hickey M, Szabo RA, Hunter MS. Non-hormonal treatments for menopausal symptoms. BMJ 2017; 359: j5101. 76 Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr 2019; 4: pkz088. 77 Hervik JB, Stub T. Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: a systematic review and meta-analysis. Breast Cancer Res Treat 2016; 160: 223–36. 78 Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 2023; 401: 1091–102. 79 Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab 2023; 108: 1981–97 . 80 Santoro N, Waldbaum A, Lederman S, et al.",
    "J Clin Endocrinol Metab 2023; 108: 1981–97 . 80 Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose- ranging study (VESTA). Menopause 2020; 27: 1350–56. 81 Constantine GD, Graham S, Clerinx C, et al. Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries. Post Reprod Health 2016; 22: 112–22. 82 Bonga KN, Mishra A, Maiti R, P adhy BM, Meher BR, Srinivasan A. Efficacy and safety of fezolinetant for the treatment of menopause- associated vasomotor symptoms: a meta-analysis. Obstet Gynecol 2024, published online Jan 16. [URL] aog.0000000000005508. 83 Beaudoin FL, McQueen RB, Wright A, et al. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value; final evidence report. Jan 23, 2023. [URL] Menopause_FinalReport_01232023.pdf (accessed Feb 9, 2024). 84 Maiorino MI, Chiodini P, Bellastella G, Giugliano D, Esposito K. Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine 2016; 54: 329–41. 85 Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline adaptation of Cancer Care Ontario Guideline.",
    "Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline adaptation of Cancer Care Ontario Guideline. J Clin Oncol 2018; 36: 492–511. 86 Schover LR. Sexual quality of life in men and women after cancer . Climacteric 2019; 22: 553–57 . 87 Sopfe J, Pettigrew J, Afghahi A, Appiah LC, Coons HL. Interventions to improve sexual health in women living with and surviving cancer: review and recommendations. Cancers (Basel) 2021; 13: 3153. 88 Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women’s Sexual Health. Menopause 2018; 25: 596–608. 89 Farrell R. ACOG committee opinion no 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016; 127: e93–96. 90 Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016; 2016: CD001500. 91 Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause 2020; 27: 339–60. 92 Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst 2022; 114: 1347–54.",
    "Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst 2022; 114: 1347–54. 93 McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol 2024; 10: 103–08. 94 Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause 2020; 27: 361–70. 95 Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2018; 25: 1339–53. 96 Barton DL, Sloan JA, Shuster LT, et al. E valuating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 2018; 26: 643–50. 97 Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo- controlled, multicenter trial. Menopause 2019; 26: 611–21. 98 Hickey M, Marino JL, Braat S, Wong S. A randomized, double- blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 2016; 158: 79–90. 99 Goetsch MF, Lim JY , Caughey AB.",
    "Breast Cancer Res Treat 2016; 158: 79–90. 99 Goetsch MF, Lim JY , Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015; 33: 3394–400. 100 Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 2018; 103: 4146–54. 101 Suvaal I, Hummel SB, Mens JM, et al. A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study): design of a multicentre randomized controlled trial. BMC Cancer 2021; 21: 1295. 102 Hummel SB, van Lankveld JJDM, Oldenburg HSA, et al. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 2017; 35: 1328–40. 103 Marcus AC, Garrett KM, Cella D, et al. Can telephone counseling post-treatment improve psychosocial outcomes among early stage breast cancer survivors? Psychooncology 2010; 19: 923–32. 104 Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2014; 2014: CD007291. 105 Yang EJ, Lim JY , Rah UW, Kim YB. Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecol Oncol 2012; 125: 705–11.",
    "Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecol Oncol 2012; 125: 705–11. 106 Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington JE, Thomas PW. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to 3 breast cancer: a randomized, controlled trial. J Clin Oncol 2012; 30: 1335–42. 107 Mao JJ, Pillai GG, Andrade CJ, et al. Integrative oncology: addressing the global challenges of cancer prevention and treatment. CA Cancer J Clin 2022; 72: 144–64. 108 Calcagni N, Gana K, Quintard B. A systematic review of complementary and alternative medicine in oncology: psychological and physical effects of manipulative and body-based practices. PLoS One 2019; 14: e0223564. 109 Hickey M, Emery LI, Gregson J, Doherty DA, Saunders CM. The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. Menopause 2010; 17: 727–33. Series 996 www.thelancet.com Vol 403 March 9, 2024 110 Hollingworth J, Walsh L, Tran S, et al. Does a multidisciplinary menopausal symptoms after cancer clinic reduce symptoms? Support Care Cancer 2022; 30: 2245–52. 111 Marthick M, McGregor D, Alison J, Cheema B, Dhillon H, Shaw T. Supportive care interventions for people with cancer assisted by digital technology: systematic review. J Med Internet Res 2021; 23: e24722.",
    "J Med Internet Res 2021; 23: e24722. 112 Rachagan N, Szabo RA, Rio I, Rees F, Hiscock HM, Hickey M. Video telehealth to manage menopausal symptoms after cancer: a prospective study of clinicians and patient satisfaction. Menopause 2023; 30: 143–48. 113 Kwok J, Olayiwola JN, Knox M, Murphy EJ, Tuot DS. Electronic consultation system demonstrates educational benefit for primary care providers. J Telemed Telecare 2018; 24: 465–72. 114 Cohen PA, Brennan A, Marino JL, Saunders CM, Hickey M. Managing menopausal symptoms after breast cancer— a multidisciplinary approach. Maturitas 2017; 105: 4–7 . 115 Lev-Sagie A, Adar-Walling E, Gumer A, Grisariu S, Avni B. Management and long-term consequences of genital graft versus host disease following hematopoietic stem cell transplantation. Bone Marrow Transplant 2020; 55: 2234–43. 116 Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000; 92: 1054–64. 117 WHO. WHO Traditional Medicine Strategy 2014–23. G eneva: World Health Organization, 2013. 118 Kadakia KC, Kidwell KM, Seewald NJ, et al. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 2017; 164: 411–19. 119 Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer.",
    "Breast Cancer Res Treat 2017; 164: 411–19. 119 Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379: 122–37 . 120 Di Meglio A, Havas J, Gbenou AS, et al. Dynamics of long-term patient-reported quality of life and health behaviors after adjuvant breast cancer chemotherapy. J Clin Oncol 2022; 40: 3190–204. 121 Ussher JM, Perz J, Allison K, et al. Attitudes, knowledge and practice behaviours of oncology health care professionals towards lesbian, gay, bisexual, transgender, queer and intersex (LGBTQI) patients and their carers: a mixed-methods study. Patient Educ Couns 2022; 105: 2512–23. 122 Vrselja A, Latifi A, Baber RJ, et al. Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2022; 400: 1704–11. 123 Neal-Perry G, Cano A, Lederman S, et al. Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial. Obstet Gynecol 2023; 141: 737–47 . 124 Li F, Picard-Fortin V, Maheux-Lacroix S, et al. The efficacy of vaginal laser and other energy-based treatments on genital symptoms in postmenopausal women: a systematic review and meta-analysis. J Minim Invasive Gynecol 2021; 28: 668–83. 125 Mension E, Alonso I, Anglès-Acedo S, et al.",
    "J Minim Invasive Gynecol 2021; 28: 668–83. 125 Mension E, Alonso I, Anglès-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open 2023; 6: e2255697 . Copyright © 2024 Elsevier Ltd. All rights reserved.",
    "Perspectives www.thelancet.com Vol 403 March 9, 2024 893 Profile Martha Hickey: responding to the complexity of menopause Menopause is the focus of Martha Hickey’s clinical work and research. “Not just as a hormonal event, but the meaning for individuals and society and how this affects the experience”, says Hickey, Professor of Obstetrics and Gynaeco logy at the University of Melbourne and Consultant in Gynaecology and Head of Menopause Services at the Royal Women’s Hospital in Melbourne, VIC, Australia. She takes a feminist perspective on meno pause, which includes normalising this life transition and chal lenging the prevalent idea that it marks a period of physical and mental decline. “Menopause challenges us to consider the role and social value of older women and the narra tive that women’s behaviour and physical and mental health is powerfully regulated by their hormones”, says Hickey, a Topic Expert for the UK updated NICE guidelines on menopause and lead author of the Lancet menopause Series. The approach of this Series is to “move beyond describing and treating symptoms to a broader model of empowering women to manage this life transition”, Hickey says. The Series aims to provide the best available evidence, including symptom management and optimisation of health into later life.",
    "The Series aims to provide the best available evidence, including symptom management and optimisation of health into later life. Speaking about the Series paper on mental health, Hickey comments: “Although it’s widely believed that mental health conditions such as depression or anxiety increase over the menopause transition, we did not confirm this. Most women do not develop mental health problems at menopause, but a particular group are at risk. Knowing this can inform new approaches to prevention and support. This information may alleviate concerns of others to know that they are unlikely to develop mental health problems.” Hickey grew up in Bristol, UK, and completed a degree in psychology and a master’s in clinical psychology at the University of Manchester. After working as a clinical psycho­ logist she later qualified in medicine at the University of Bristol and specialised in obstetrics and gynaecology. Hickey trained at St Mary’s Hospital and Imperial College London in the UK and at a research appointment at the University of Sydney in Australia. Completing her UK specialist training in 2001, she relocated to Australia with her young family the next year, becoming Assistant Professor at the University of Western Australia (UWA) and Consultant in Obstetrics and Gynaecology at King Edward Memorial Hospital in Perth. She was appointed Professor of Obstetrics and Gynaecology at UWA in 2006.",
    "She was appointed Professor of Obstetrics and Gynaecology at UWA in 2006. Hickey took up her current roles at the Univer­ sity of Melbourne and Royal Women’s Hospital in 2010. Among Hickey’s proudest achievements is establishing, in 2003, the first multidisciplinary service for managing meno­ pause after cancer, which has been replicated elsewhere. For the research underpinning the service, she says “we consulted with cancer patients, GPs, surgeons, and oncologists to work out what was needed. We found that people wanted common symptoms such as hot flushes or night sweats, sexual difficulties, and sleep and mood problems managed in one place, clear communication between health ­care providers about what treatments were safe and effective, and the option of drug­free treatments.” Her clinical practice includes patients with BRCA1/2 pathogenic variants who are considering risk ­reducing salpingo ­oophorectomy (RRSO) causing surgical menopause. Recognising a gap in clinical care, Hickey led a large prospective controlled study that generated patient resources and knowledge to inform practice. In 2023, she led international clinical guidelines on care after RRSO. She is now leading the Australian sites for a surgical trial of salpingectomy versus RRSO in high ­risk women.",
    "In 2023, she led international clinical guidelines on care after RRSO. She is now leading the Australian sites for a surgical trial of salpingectomy versus RRSO in high ­risk women. Her team also leads a Menopause Priority Setting Partnership with the non ­profit James Lind Alliance to determine priority research areas for those with lived experience of menopause and their health ­care providers. Jane Ussher, Professor of Women’s Health Psychology at Western Sydney University’s Translational Health Research Institute, describes Hickey as “tireless in her appetite for bettering the health of women” and credits Hickey’s “acknowledgement of the complexity of women’s experiences of menopause, which cannot be understood within an entirely medical lens”. Hickey recognises the benefits of menopausal hormone therapy (MHT), but sees a need for “greater transparency around how these products are marketed, such as the wide­ spread use of terms such as ‘bioidentical’ or ‘body identical’, which imply that MHT is completely natural and safe”. She hopes the Lancet Series will encourage “more discussion about the diversity of menopause experiences, less shame, and greater clarity about the risks and benefits of MHT. Like other life transitions menopause often has positive and negative aspects. Whilst it is important to hear about difficulties, persistent messaging around loss of youth, cognitive function, and sexuality does not reflect the reality for many.",
    "Whilst it is important to hear about difficulties, persistent messaging around loss of youth, cognitive function, and sexuality does not reflect the reality for many. Older women are not just oestrogen­starved young women.” To counter negative images of menopause and ageing in women, Hickey led the Flesh after Fifty art exhibition. She believes a “greater appreciation of the incredible contribution that older women make to our economy and communities” is needed. “Women over 50 are the fastest growing demo­ graphic group in many countries, making an essential contri­ bution to society, families, communities, the paid and unpaid workforce. We need to support and empower women as they age and should not portray menopause as a period of decline and decay. Many women have healthy, rich, and fulfilling lives after menopause. They don’t necessarily need medical care, but they do need to be listened to, respected, and supported.” Udani Samarasekera Published Online March 5, 2024 [URL] S0140­6736(24)00368­4 See Perspectives  See Series , 958, 969 and 984 For the Menopause Priority Setting Partnership see https:// obgyn.uchicago.edu/research/ menopause­priority­setting­ partnership For Flesh after Fifty see https:// www.fleshafterfifty.com/ Ponch Hawkes",
    "Perspectives 894 www.thelancet.com Vol 403 March 9, 2024 Published Online March 5, 2024 [URL] S0140­6736(24)00369­6 See Perspectives  See Series , 958, 969 and 984 For 500 Strong see [URL] fleshafterfifty.com/strong.html For Flesh after Fifty see https:// www.fleshafterfifty.com/ For the Flesh after Fifty video essay see [URL] fleshafterfifty.com/event­ videos.html For the Flesh after Fifty podcast see [URL] com/podcasts.html Photographer Ponch Hawkes stands in front of 33 linear metres of joyful, playful images of older women at the 500 Strong exhibition 500 Strong: celebrating older women’s bodies in menopause and beyond The images shown here are a selection from the 500 Strong exhibition by Ponch Hawkes, first exhibited in Victoria, Australia, in 2021. Photographer Ponch Hawkes’ career spans over 50 years and her works, which explore feminism, gender, identity, ageing, and human rights, among other themes, are collected internationally. 500 Strong was part of a larger art exhibition called Flesh after Fifty: Changing Images of Older Women in Art, an artistic examination of older women in art through the media of photography, video, sculpture, painting, and prints. Flesh after Fifty, which was initiated by gynaecologist Martha Hickey and curated by Jane Scott, explored and challenged negative images of ageing in women and created emotive, affirming, and realistic portrayals of older women.",
    "A parallel health programme addressed menopause, body image, particularly for trans gender and gender diverse people, women’s safety, and mental health; the event was captured in a video essay and podcast. Powerful and joyful images of naked older women are rarely seen. For 500 Strong, cis and trans women older than 50 years from across Victoria were invited to participate through networks, health and women’s groups, social and traditional media, and community organisations. Asking them to pose naked without photoshopping or adornment was a challenge for all involved. All were invited to cover their faces for anonymity, but many wanted to be identifiable. The models are from diverse background ethnicities, sizes, ages (50–93 years), and included people with disabilities. 500 Strong aimed to celebrate the diversity and reality of older women’s bodies and display their strength. What emerged was so much more. Those who took part shared their pride and shame about their bodies and life stories made visible on their flesh. All challenged themselves to let the world see their reality. The success of 500 Strong exceeded expectations. More than 50 000 people have view ed this work, which will culminate in an exhibition at the Museum of Australian Photography, VIC, Australia, from Nov 22, 2024, to Feb 16, 2025.",
    "More than 50 000 people have view ed this work, which will culminate in an exhibition at the Museum of Australian Photography, VIC, Australia, from Nov 22, 2024, to Feb 16, 2025. An independent evaluation of 500 Strong by Kim Goodwin showed that the exhibition changed attitudes towards older women by showing powerful and positive images that those who attended had not previously seen. Representation is empowering and 500 Strong complements The Lancet’s menopause Series by showing that menopause does not lead to decay and decline and that many older women love who they are. Such empowerment needs to be part of the health response to menopause. While almost all the participants in 500 Strong had experi­ enced menopause, this did not define them. It was a part of the journey that brought them to the studio because older women should be celebrated. *Ponch Hawkes, Jane Scott, Martha Hickey Melbourne, VIC, Australia (PH); Art & Stuff, Melbourne, VIC, Australia (JS); Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne and Women’s Hospital, Melbourne, VIC, Australia (MH) [URL] © Jodie Hutchinson 2021 PH is the artist of 500 Strong. MH is a lead author of The Lancet’s Series on the menopause and the principal investigator for the Flesh after Fifty project, which included 500 Strong. JS is the Lead Curator of Flesh after Fifty that was funded by Creative Victoria, philanthropy, and private donors.",
    "JS is the Lead Curator of Flesh after Fifty that was funded by Creative Victoria, philanthropy, and private donors. Perspectives www.thelancet.com Vol 403 March 9, 2024 895 “I’m continuing my challenge of growing old disgracefully—not conforming to society’s ideal of older women.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives 896 www.thelancet.com Vol 403 March 9, 2024 ”I feel it’s important for the general public to know that many women of all ages have had mastectomies, and not all women have reconstructions, we are all beautiful.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives www.thelancet.com Vol 403 March 9, 2024 897 ”I hate the invisibility of older women that society demands, I’m grateful for my body.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives 898 www.thelancet.com Vol 403 March 9, 2024 ”Listen to women. Embracing the changes in my body is about embracing who I am.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives www.thelancet.com Vol 403 March 9, 2024 899 “I’m celebrating this age! It is filled with strength and vitality and I wanted to celebrate with others.” Comments from 500 Strong participant. Photograph by Ponch Hawkes.",
    "It is filled with strength and vitality and I wanted to celebrate with others.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives 900 www.thelancet.com Vol 403 March 9, 2024 “Believe in embracing the body you have, whatever shape and size.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives www.thelancet.com Vol 403 March 9, 2024 901 “Getting naked is a present to myself and a sign of new beginnings as I embrace menopause and becoming older.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives 902 www.thelancet.com Vol 403 March 9, 2024 ”Let’s celebrate bodies that have survived and thrived. We must challenge the ‘value’ society places on our looks.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021 Perspectives www.thelancet.com Vol 403 March 9, 2024 903 “I want to thank my body for caring for me in this lifetime, even though it is old now.” Comments from 500 Strong participant. Photograph by Ponch Hawkes. © Ponch Hawkes 2021",
    "Editorial For most women, menopause is a natural phase of life that they transition as part of biological ageing. However, as highlighted in a Series of four papers in today’s Lancet—published ahead of International Women’s Day on March 8—commercial companies and individuals with vested interests have over-medicalised menopause. The framing of this natural period of transition as a disease of oestrogen deficiency that can be eased only by replacing the missing hormones fuels negative attitudes to menopause and exacerbates stigma. Furthermore, appropriation of feminist narratives by commercial organisations , which position use of menopausal hormonal therapy (MHT) as a way to empower women to regain control of their bodies, while downplaying risks, further endorses the framing of menopause as a disease. As described in the Series, women’s experience of menopause varies hugely and there is no one-size-fits- all approach to management. Many women transition this stage of life uneventfully, whereas some experience prolonged or severe symptoms and need information, support, or medical treatment. The most common symptoms associated with menopause include vasomotor symptoms such as hot flushes and night sweats, sleep disturbances, vaginal dryness, and muscle and joint pain. Menopause is commonly perceived to be associated with poor mental health.",
    "Menopause is commonly perceived to be associated with poor mental health. However, there is no strong evidence that the risk of first-onset clinical depression is increased over the menopause, although this can be a vulnerable period for recurrence in those with previous clinical depression. MHT is the most effective treatment for vasomotor symptoms, but it is not without risk: robust epidemiological evidence suggests that one additional case of breast cancer will occur for every 50 women taking systemic, combined MHT from age 50 years, and one in 70 for oestrogen-only MHT. There is no excess risk from vaginal oestrogen. All women who request MHT, after weighing up the short- term and long-term benefits and risks with their clinician, should be offered treatment unless contraindicated. Acute shortages of MHT, as seen in many parts of the world, could have a detrimental effect on women’s quality of life. Not all women wish to, or can, take MHT however, and treatments such as cognitive behavioural therapy can also help to counter vasomotor symptoms and potentially improve mood and sleep. Easy access to impartial information—not from those who are marketing a product or service—both before and during the menopause transition, as well as an informed, engaged clinician who will listen with empathy, are crucial to facilitate shared decision making. Historically, women have been poorly served by both the research community and by society.",
    "Historically, women have been poorly served by both the research community and by society. At The Lancet, we are redoubling our efforts in this regard by designating Women and Health as one of our areas of focus in 2024, with the aim of showcasing important work and promoting sex and gender equity in research. Increased awareness and advocacy of women’s health are crucial to reverse the long-standing gender biases in medicine. But over- medicalisation of menopause and promotion of MHT as a panacea is unhelpful and only serves to divide opinions further. It is time for a sensible conversation about menopause to enable informed, individualised decision making on optimal management of this transition. Greater diversity in research that addresses priority areas for women is needed. A paucity of information and education on menopause has led to symptoms being dismissed by uninformed health-care professionals and a lack of understanding in the workplace. After failed attempts in the UK to make menopause, like pregnancy, a protected characteristic under the 2010 Equality Act, the Equality and Human Rights Commission released guidance recently suggesting that menopause symptoms could be considered a disability if disruptive enough to interfere with everyday activities, and that employers are legally obliged to make reasonable adjustments. However, interpreting menopause more broadly as a disability risks further fuelling the ageism and stigma that older women already face.",
    "However, interpreting menopause more broadly as a disability risks further fuelling the ageism and stigma that older women already face. Menopausal women can be strong, healthy, and happy— as highlighted by the selection of inspirational images of older women that accompany the Series. Menopause can also be a time for women to reassess their identities, to embrace this next phase in their lives and the freedom from menstruation and menstrual pain, and to challenge negative perceptions of older women, which are prevalent in some societies. We need to send a realistic, balanced message to women and to society: menopause does not herald the start of a period of decay and decline but is a developmental life stage that can be negotiated successfully with access to evidence- based information as well as appropriate social and medical support. Women deserve nothing less.",
    "Women deserve nothing less. Time for a balanced conversation about menopause www.thelancet.com Vol 403 March 9, 2024 877 Published Online March 5, 2024 [URL] S0140-6736(24)00462-8 See Perspectives pages 893 and 894 See Series pages 947 , 958, 969, and 984 For more on the use of feminist narratives by commercial organisations see BMJ 2024; 384: e076710 For more on the risks of MHT see Articles Lancet 2019; 394: 1159–68 For the Equality and Human Rights Commission guidance see [URL] equalityhumanrights.com/ guidance/menopause- workplace-guidance-employers For the art project, from which the images of older women are taken, see [URL] fleshafterfifty.com AlonzoDesign/Getty Images n The Lancet",
    "Downloadedfrom[URL] Downloadedfrom[URL] NAMS P OSITION STATEMENT The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society Abstract Objective: To update and expand the 2013 position statement of The North American Menopause Society (NAMS) on the management of the genitourinary syndrome of menopause (GSM), of which symptomatic vulvovaginal atrophy (VVA) is a component. Methods: A Panel of acknowledged experts in the field of ge nitourinary health revi ewed the literature to evaluate new evidence on vaginal hormone therapies as well as on other management options available or in development for GSM. A search of PubMed was conducted identifying medical literature on VVA and GSM published since the 2013 position statement on the role of pharmacologic and nonpharmacologic treatments for VVA in postmenopausal women. The Panel revised and added recommendations on the basis of current evidence. The Panel’s conclusions and recommendations were reviewed and approved by the NAMS Board of Trustees. Results: Genitourinary syndrome of menopause affects approximately 27% to 84% of postmenopausal women and can significantly impair health, sexual function, and quality of life. Genitourinary syndrome of menopause is likely underdiagnosed and undertreated. In most cases, symptoms can be effectively managed.",
    "Genitourinary syndrome of menopause is likely underdiagnosed and undertreated. In most cases, symptoms can be effectively managed. A number of over- the-counter and government-approved prescription therapies available in the United States and Canada demonstrate effectiveness, depending on the severity of symptoms. These include vaginal lubricants and moisturizers, vaginal estrogens and dehydroepiandrosterone (DHEA), systemic hormone therapy, and the estrogen agonist/antagonist ospemifene. Long-term studies on the endometrial safety of vaginal estrogen, vaginal DHEA, and ospemifene are lacking. There are insufficient placebo-controlled trials of energy-based therapies, including laser, to draw conclusions on efficacy and safety or to make treatment recommendations. Conclusions: Clinicians can resolve many distressing genitourinary symptoms and improve sexual health and the quality of life of postmenopausal women by educating women about, diagnosing, and appropriately managing GSM. Choice of therapy depends on the severity of symptoms, the effectiveness and safety of treatments for the individual patient, and patient preference. Nonhormone therapies available without a prescription provide sufficient relief for most women with mild symptoms. Low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy, and ospemifene are effective treatments for moderate to severe GSM.",
    "Low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy, and ospemifene are effective treatments for moderate to severe GSM. When low-dose vaginal estrogen or DHEA or ospemifene is administered, a progestogen is not indicated; however, endometrial safety has not been studied in clinical trials beyond 1 year. There are insufficient data at present to confirm the safety of vaginal estrogen or DHEA or ospemifene in women with breast cancer; management of GSM should consider the woman’s needs and the recommendations of her oncologist. Key Words: Dyspareunia – Genitourinary syndrom e of menopause – Ospemifene – Vaginal dehydroepiandrosterone – Vaginal dryness – Vaginal estrogen – Vulvovaginal atrophy. G enitourinary syndrome of menopause (GSM) describes the symptoms and signs resulting from the effect of estrogen deficiency on the female genitourinary tract. Symptoms associated with GSM are highly prevalent, affecting approximately 27% to 84% of postmenopausal women. 1-4 In one report of more than Received May 14, 2020; revised and accepted May 14, 2020.",
    "Symptoms associated with GSM are highly prevalent, affecting approximately 27% to 84% of postmenopausal women. 1-4 In one report of more than Received May 14, 2020; revised and accepted May 14, 2020. This position statement was developed by The North American Meno- pause Society (NAMS) consisting of representatives of the NAMS Board of Trustees and other experts in women’s health: Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF; Sheryl A. Kingsberg, PhD; Jan L. Shifren, MD, NCMP, FACOG; Caroline Mitchell, MD, MPH; Andrew M. Kau- nitz, MD, FACOG, NCMP; Lisa Larkin, MD, FACP, NCMP, IF; Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC; Amanda Clark, MD, MCR, NCMP, FACOG; James A. Simon, MD, CCD, NCMP, IF, FACOG. The Board of Trustees conducted independent review and revision and approved the position statement on May 5, 2020. This position statement was made possible by donations to the NAMS Education & Research Fund. There was no commercial support. Address correspondence to: The North American Menopause Society, 30100 Chagrin Blvd, Suite 201, Pepper Pike, OH 44124. E-mail: [EMAIL] Website: www.menopause.org. 976 Menopause, Vol. 27, No. 9, 2020 Menopause: The Journal of The North American Menopause Society Vol. 27, No. 9, pp. 976-992 DOI: 10.1097/GME.0000000000001609 /C2232020 by The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.",
    "Unauthorized reproduction of this article is prohibited. 900 women undergoing routine examinations, GSM was identified in 84% of women 6 years after menopause. 4 Principal symptoms included vaginal dryness, painful sex, burning, and dysuria. In contrast to vasomotor symptoms (VMS) that usually improve over time, GSM is generally progressive without effective therapy. Despite the high prev- alence of GSM and lack of improvement without treatment, only a minority of affected women seek help or are offered treatment by their healthcare providers. 5,6 In a survey of 1,858 US postmenopausal women with genitourinary symptoms, 50% had never used any therapy for this problem.6 The reluctance of women as well as health- care providers to initiate discussion of genitourinary symp- toms and safety concerns about hormone therapies contribute to limited assessment and treatment of GSM. 7,8 The genitourinary syndrome of menopause often has significant adverse effects on a woman’s sexual health and quality of life (QOL). 9 Women who are not sexually active also experience bot hersome symptoms of GSM, affecting activities of daily living. 10 In the Vaginal Health: Insights, Views & Attitudes (VIVA) online survey of 3,520 postmenopausal women in s ix countries, 45% reported experiencing vaginal symptoms, and 75% felt that their symptoms negatively affected their lives.",
    "11 In 500 US women in the VIVA survey, of the 48% with vaginal discomfort, the most common symptoms were vaginal dryness and pain during intercourse. 5 Women in VIVA in the United States reported t hese adverse events (AEs) of vaginal discomfort: /C15 Negative effect on their lives (80%) /C15 Adverse effects on sexual intimacy (75%) /C15 Feeling less sexual (68%) /C15 Feeling old (36%) /C15 Negative consequences on marriage/relationship (33%) /C15 Negative effect on self-esteem (26%) /C15 Lower QOL (25%) In a survey of 3,046 US women, Real Women’s Views of Treatment Options for Menopausal Vaginal Changes (REVIVE),7 women reported that their vulvovaginal atrophy (VVA) symptoms: /C15 Led to some loss of intimacy (85%) /C15 Detracted from enjoyment of sex (59%) /C15 Interfered with their relationship (47%) /C15 Negatively affected sleep (29%) /C15 Adversely affected general enjoyment of life (27%) This updated position statement reviews the science of genitourinary aging and assesses the safety and effectiveness of available treatment options for postmenopausal women with GSM. METHODS A nine-member Panel composed of expert clinicians and researchers in the field of genitourinary health reviewed the literature to evaluate new evidence on management strategies, including vaginal estrogens, vaginal dehydroepiandrosterone (DHEA), ospemifene, and other management options avail- able or in development for symptomatic GSM.",
    "A literature search was conducted using the terms ‘‘genitourinary syn- drome of menopause/GSM,’’ ‘‘vulvovaginal atrophy/VVA,’’ ‘‘atrophic vaginitis, ’’ ‘‘ dyspareunia,’’ ‘‘ vaginal dryness, ’’ and ‘‘vaginal lubrication. ’’ If evidence was contradictory or inadequate to form a conclusion, a consensus-based opin- ion was established. The Panel’s completed draft of the updated Position State- ment was submitted to the NAMS Board of Trustees for additional review, comments, and edits. The Board is com- posed of both clinicians and researchers from multiple spe- cialties and disciplines. The Board approved the Position Statement with edits after final Panel review. TERMINOLOGY Genitourinary syndrome of menopause describes the symp- toms and signs resulting from the effect of estrogen deficiency on the female genitourinary tract, including the vagina, labia, urethra, and bladder.12 This syndrome includes genital symp- toms of dryness, burning, and irritation; urinary symptoms and conditions of dysuria, urgency, and recurrent urinary tract infections (UTIs); and sexual symptoms of pain and dryness. Physical changes and signs are varied. Women may experi- ence some or all of the symptoms and signs, which must be bothersome for a diagnosis of the syndrome. Other causes of similar signs and symptoms must be ruled out, including vulvovaginal dermatoses, infection, or cancer.",
    "Other causes of similar signs and symptoms must be ruled out, including vulvovaginal dermatoses, infection, or cancer. Vulvovaginal atrophy is a component of GSM.13 Although VVA was the commonly used term in the past to describe the genitourinary changes of menopause, it has limitations. Vul- vovaginal atrophy describes the appearance of the genital tissues but not the associated symptoms. It does not include urinary tract changes related to estrogen deficiency, and the term atrophy has negative associations for women. The term genitourinary syndrome of menopause was developed during a consensus conference of experts 12 and subsequently was accepted as the preferred term by many medical societies, including The North American Menopause Society and the American College of Obstetricians and Gynecologists. ANATOMY AND PHYSIOLOGY The genital and lower urinary tract share a common embryologic origin in women, with the urethra, bladder trigone, vulvar vestibule, and the upper vagina all derived from the same estrogen receptor (ER)-rich primitive urogeni- tal sinus tissue.14 The vulva is also derived from the urogenital sinus, but the epithelium of the labia majora is of ectodermal origin. The vagina is composed of an inner stratified squa- mous epithelium, a middle muscular layer, and an outer fibrous layer.",
    "The vagina is composed of an inner stratified squa- mous epithelium, a middle muscular layer, and an outer fibrous layer. In the presence of endogenous estrogen after puberty and before menopause, the lining of the vagina is characterized by a thickened, rugated surface that is well vascularized and lubricated in most women. Estrogen is a dominant regulator of vaginal and lower urinary tract physiology. Estrogen receptor- a is present in NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 977 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. the vaginal tissues of both premenopausal and postmeno- pausal women, whereas ER- b appears to have no or low expression in postmenopause vaginal tissue. Estrogen therapy (ET) does not appear to affect the presence of ER- b.15,16 Estrogen receptor density is highest in the vagina, with decreasing density across the external genitalia to the skin. The density of the androgen receptor is the reverse. There are low levels in the vagina and higher levels in the external genitalia. Progesterone receptors are found in the vagina and the transitional epithelium of the vulvovaginal junction. 17 Estrogen receptors have also been found on autonomic and sensory neurons in the vagin a and vulva. Estrogen therapy has been reported to decrease the density of sensory nocicep- tor neurons in the vagina. This function may serve to decrease the discomfort associated with GSM.",
    "Estrogen therapy has been reported to decrease the density of sensory nocicep- tor neurons in the vagina. This function may serve to decrease the discomfort associated with GSM. 18 With respect to the lower urinary tract, estrogen and progesterone receptors have been identified in the urethr a, bladder, and pelvic floor muscles.14 The changing physiology of the vaginal epithelium after menopause is not completely understood. On the basis of a cell-culture model that used vaginal-cervical epithelial cells, diminished estrogen levels and aging were found to be independent factors in decreasing vaginal-cervical paracellu- lar permeability, a change potentially related to vaginal dryness.19 With atrophy, wet-mount microscopy shows more than one white blood cell per epithelial cell and immature vaginal epithelial cells with relatively large nuclei (parabasal cells). Cytology shows an increase in parabasal and interme- diate cells, and superficial cells decrease or are absent. 20 Immune cell populations seem to be similar or slightly decreased in number, with similar cytolytic capacity as before menopause.21-23 However, some studies show differences in inflammatory markers in the vaginal fluid of postmenopausal women compared with premenopausal women. 24 Hormone changes throughout the life cycle influence the vaginal microbiome from birth through postmenopause.",
    "24 Hormone changes throughout the life cycle influence the vaginal microbiome from birth through postmenopause. 25,26 During the reproductive years, the presence of a microbial community dominated by Lactobacillus species is associated with a lower pH and lower risk for bacterial vaginosis (BV), sexually transmitted infections, UTIs, and HIV infection.27-35 After menopause, women are less likely to have a Lacto- bacillus-dominant vaginal bacterial community and less likely to have a low vaginal pH. 26.36,37 Although cultiva- tion-based studies show a significantly lower quantity of vaginal Lactobacillus in postmenopausal women, 37 several newer sequencing studies observe that close to half have a high proportion of lactobacilli. 38,39 In one study, a higher proportion of Lactobacillus correlated inversely with exam- iner-reported dryness in postmenopausal women, 38 but in another study, there was no association betweenLactobacillus dominance and the severity of patient-reported symptoms. 40 The vaginal bacteria community of postmenopausal women has many similarities with that of reproductive-aged women with BV: high pH, 36 higher diversity, 41 and an abnormal Nugent score.42 In many women with GSM, however, these abnormalities reflect a decline in lactobacilli rather than an increase in the prevalence of pathogens. 42,43 Treatment with systemic or topical estrogen is associated with an increase in detection of vaginal lactobacilli.",
    "42,43 Treatment with systemic or topical estrogen is associated with an increase in detection of vaginal lactobacilli. 44,45 This suggests that for many postmenopausal women, the best approach to promoting a healthy vaginal microbial community is not antibiotic therapy (as though treating BV) but rather vaginal estrogen therapy. PRESENTATION The diagnosis of GSM requires the presence of both characteristic examination findings and bothersome symp- toms. The most commonly reported symptoms include irrita- tion of the vulva, inadequate vaginal lubrication, burning, dysuria, dyspareunia, and vaginal discharge. Symptoms adversely affecting sexual function are often the most dis- tressing.12,46,47 Signs of GSM include labial atrophy, vaginal dryness, introital stenosis, clitoral atrophy, and phimosis of the pre- puce. Severe GSM can result in a vaginal surface that is friable and hypopigmented, with petechiae, ulcerations, and tears, as well as urethral findings such as caruncles, prolapse, or polyps. Bleeding may occur from minimal trauma, such as speculum insertion. Genitourinary atrophic changes increase the likelihood of trauma, pain, recurrent UTIs, bleeding with or after sex, and absence of sexual activity. 20,47 The genitourinary syndrome of menopause most commonly develops in the setting of hypoestrogenism associated with natural menopause.",
    "20,47 The genitourinary syndrome of menopause most commonly develops in the setting of hypoestrogenism associated with natural menopause. Hypoestrogenic states also may occur in the setting of primary ovarian insufficiency (POI), surgical menopause (bilateral oophorectomy with or without hysterec- tomy), hypothalamic amenorrhea, the postpartum state and breastfeeding, use of gonadotropin-releasing hormone agonists or aromatase inhibitors (AIs), and cancer treatments such as surgery, pelvic radiation therapy, or chemotherapy that render ovaries inactive, either temporarily or permanently. Several studies suggest that early estrogen deficiency caused by premature menopause or POI is associated with more severe sexual dysfunction compared with age-matched controls.48,49 Younger women with vaginal atrophy and dys- pareunia may be especially distressed by changes in sexual function. Women with surgical menopause often present with a more severe GSM symptom profile than do women with natural menopause, likely because of the concomitant, abrupt, and persistent 50% decline in circulating androgen levels that occurs in addition to the loss of estradiol.",
    "50,51 Genitourinary syndrome of menopause that develops in the setting of chemotherapy-induced menopause has been associated in some studies with greater sexual dysfunction and distress 52- 54 and with poorer QOL outcomes.55-58 Younger women with GSM related to induced menopause from cancer treatment may be especially distressed by changes in sexual func- tion.52,55 The stress, fatigue, and mood changes that accom- pany a cancer diagnosis and its treatment also contribute to sexual problems. Aromatase inhibitors reduce breast cancer recurrence by blocking conversion of androgens to estrogens and NAMS POSITION STATEMENT 978 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. inducing a profound estrogen-deficiency state. The mag- nitude and duration of estroge n deficiency induced by AIs result in the development of severe GSM in most survi- vors, particularly given that extended duration therapy is now typical. 59-61 Compared with tamoxifen, AIs result in a greater incidence of vaginal dryness and dyspareunia, causing a large percentage of AI users to express dissat- isfaction with their sex lives. 60,62-64 EVALUATION AND DIAGNOSIS The evaluation of GSM includes a history and pelvic examination. A medical history may identify contributing factors, alternative etiologies, and effective therapeutic inter- ventions.",
    "A medical history may identify contributing factors, alternative etiologies, and effective therapeutic inter- ventions. The pelvic examination should identify signs con- sistent with GSM and eliminate other pathologic conditions that may cause similar symptoms. History Because women may not spontaneously report symp- toms of GSM and related sexual concerns, providers should inquire about sympto ms in all perimenopausal and postmenopausal women as part of a routine review of systems. The EMPOWER survey queried 1,858 meno- pausal US women with symptoms suggestive of GSM and found that in women who had never used any treatment, almost three-quarters had never discussed their symptoms with a healthcare provider. 6 The main reason for this reticence was the assumption that GSM was simply a natural part of aging with which women needed to live. Results of the Women’s Voices in the Menopause survey revealed that in more than 1,000 US respondents, one- third of those with vaginal d iscomfort had not spoken with anyone regarding their cond ition and one-third preferred that discussion regarding vag inal discomfort be initiated by their healthcare providers. 65 These survey results underscore the importance of clini- cians being proactive in asking menopausal women whether symptoms suggestive of GSM are present. The goal of the history is to determine whether symptoms of GSM are present, whether they are bothersome, and how they affect the woman’s sexual health and QOL.",
    "The goal of the history is to determine whether symptoms of GSM are present, whether they are bothersome, and how they affect the woman’s sexual health and QOL. In the absence of symptoms, atrophic changes noted on examination do not necessarily require treatment, although women should be informed that these changes may worsen over time without proactive management. Symptoms similar to GSM result from many other con- ditions. The differential diagnosis includes allergic or inflammatory conditions (eg , lichen sclerosus, erosive lichen planus, desquamative inflammatory vaginitis, con- tact dermatitis, and cicatrici al pemphigoid), vulvovaginal candidiasis and other infections, trauma, foreign bodies, malignancy, vulvodynia, vestibulodynia, chronic pelvic pain, provoked pelvic floor hypertonia (previously known as vaginismus), and other medical conditions (eg, diabetes, lupus erythematosus) or psychological disorders. An alter- nate etiology is more likely in women with chronic or recurrent vulvovaginal sympt oms that were present before menopause. Documentation of GSM should include a description of symptoms, including time of onset, duration, level of associ- ated distress, and effect on QOL. A sexual history that includes partner relationship(s), current level and types of sexual activity, and the effect of GSM symptoms on sex life and partner relationships is useful in determining manage- ment strategies.",
    "Previous interventions should be discussed, including their efficacy and adverse effects. For a woman with a history of cancer, additional informa- tion is relevant, including cancer site, age at diagnosis, hormone receptor status, treatments (past, current), and type of menopause (spontaneous or induced). Cancer treatments, especially surgery and radiation therapy, can damage the vaginal epithelium, the vascular supply, and the anatomy of the vaginal canal. Some treated women experience a narrowed or foreshortened vagina. Genitourinary changes associated with cancer treatments can produce pain with pelvic examinations, dyspareunia, recurrent UTIs, and an increased risk of vaginal infections. 52,66 Physical examination The pelvic examination helps to exclude other vulvova- ginal conditions that can cause similar symptoms. As GSM progresses, examination of the external genitalia often reveals reduced mons pubis a nd labia majora bulk, reduced labia minora tissue and pigmentation, and prominence (telescoping) and erythema of the urethral meatus. Urethral caruncle, a benign outgrowth of inflammatory tissue arising from the posterior urethral me atus, is common in postmen- opausal women and likely rel ated to hypoestrogenism. The clitoris may recede and in so me cases become completely flush with the surrounding tissue. The vestibular tissue may become pale. If the introitus is noted to be narrow, use of a narrow pediatric vaginal speculum with lubricant is appropriate.",
    "The vestibular tissue may become pale. If the introitus is noted to be narrow, use of a narrow pediatric vaginal speculum with lubricant is appropriate. The vaginal mucosa may appear smooth (loss of rugation), shiny, and dry. Minimal blunt trauma from the speculum may result in petechiae (reflecting mucosal thinning) or bleeding (fria- bility). With progression of GSM, attenuation of the vaginal fornices may be apparent, and the cervix may appear flush with the vaginal apex. With atrophic vaginitis, brown or yellow (sometimes mal- odorous) discharge may be present. With severe GSM, there may be such shortening of the vaginal vault and narrowing of the introitus that speculum insertion and visual inspection of the vaginal vault as well as cervix may not be possible. Although the vaginal maturation index (VMI) and vaginal pH are routinely assessed in clinical trials, they are not essential to make a diagnosis of GSM in clinical practice. With GSM, vaginal pH is typically greater than 5.0. Wet- mount microscopy shows more than one white blood cell per epithelial cell, immature vaginal epithelial cells with rela- tively large nuclei (parabasal cells), and reduced or absent lactobacilli. Repopulation with diverse flora can occur, NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 979 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.",
    "27, No. 9, 2020 979 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. including enteric organisms commonly associated with UTIs.67 The appearance of the wet mount in severe GSM may be difficult to distinguish from that of desquamative inflammatory vaginitis or vaginal erosive lichen planus. 68 A culture or vulvovaginal biopsy should be considered if there are atypical findings or if the vulvovaginal symptoms fail to resolve after a trial of vaginal estrogens or DHEA. A woman’s symptoms do not always correlate with physi- cal findings. For example, a woman who is not sexually active may have few symptoms, despite signs of advanced genito- urinary atrophy on examination. In contrast, a woman with an active sex life may complain of dryness and discomfort with sex, whereas the pelvic examination suggests only mild atrophy. Of note, women who are not sexually active also may be bothered by symptoms related to GSM, including discomfort with exercise or dysuria and benefit from treat- ment. Thus, both history and examination are essential to making a correct diagnosis. TREATMENT The primary goal of treating GSM is to alleviate symptoms. For the woman with GSM, after excluding other causes of her symptoms, treatment can be approached in a stepwise fashion based on symptom severity.",
    "For the woman with GSM, after excluding other causes of her symptoms, treatment can be approached in a stepwise fashion based on symptom severity. First-line therapies for less- severe symptoms include nonhormone vulvar and vaginal lubricants with sexual activity and long-acting vaginal mois- turizers used regularly (several times/wk). Although not supported by clinical trials, regular, gentle vaginal stretching exercises (eg, pain-free insertion of a finger or dilator) or sexual activity may reduce GSM symptoms. Prescription therapies include low-dose vaginal estrogens, vaginal DHEA inserts, and oral ospemifene. For women with moderate to severe dyspareunia associated with GSM with concurrent VMS, transdermal and oral HT are effective options. Symp- tom reduction may take 1 to 3 months, and continued therapy is generally required because symptoms are likely to recur on cessation of treatment. Outcomes data on the symptom recur- rence rate are lacking. Some women may already have vaginal narrowing or provoked pelvic floor hypertonia limiting vaginal penetration. Gentle stretching of the vagina with the use of lubricated vaginal dilators of graduated sizes (or an expandable dilator) can play an important role in restoring and maintaining vaginal function for penetration. Reinitiating regular sexual activity once vaginal penetration is again comfortable, if desired, may help to maintain vaginal pliability.",
    "Reinitiating regular sexual activity once vaginal penetration is again comfortable, if desired, may help to maintain vaginal pliability. Many women with this condition benefit from referral for pelvic floor physical therapy (PFPT). 69,70 Starting pharmacologic treat- ment to restore tissue integrity before initiating vaginal dilatation and/or PFPT may facilitate progress. Nonprescription therapies Lubricants and moisturizers First-line therapies to alleviate symptoms of GSM include over-the-counter (OTC) nonhormone vaginal lubricants and moisturizers, a number of which are available (Table 1), but few clinical studies have been conducted on the efficacy of these products. A vaginal moisturizer is a bioadhesive product used regu- larly, most often two to three times a week, irrespective of the timing of sexual activity. The goal of use is to reduce daily symptoms of GSM as well as to facilitate comfortable sexual activity. Data suggesting improvement in genitourinary symptoms with nonhormone treatments are sparse, and to date, there are no adequately powered, randomized, double- blind, placebo controlled studies directly comparing low-dose vaginal estrogen therapies or vaginal DHEA with commonly used nonhormone treatments. One randomized, controlled, but short-term study demonstrated effectiveness of a pH- balanced gel compared with placebo in women treated for breast cancer. Mild irritation with administration was noted.",
    "Mild irritation with administration was noted. 71 In a randomized, controlled trial (RCT; N ¼ 302), a signifi- cant improvement in most bothersome symptom severity was seen in all three arms: the vaginal estradiol tablet (plus placebo gel), vaginal moisturizer (plus placebo tablet), and dual placebo arms. 72 In that trial, the placebo gel likely had lubricating properties. Vaginal lubricants are used by both (or all) partners to decrease discomfort caused by friction during sex. Regular use has also been associated with increase in pleasure and ease of orgasm. 73 In a review and meta-analysis, the effect of lubricant use on symptom severity could not be compared in studies because of heterogeneity. However, the meta-analysis of sexual function outcomes showed a small advantage to hormone-based therapies over lubricants in restoring sexual function. 74 One small crossover study in survivors of breast cancer demonstrated greater benefit with silicone-based lubri- cants compared with water based. 75 TABLE 1.",
    "74 One small crossover study in survivors of breast cancer demonstrated greater benefit with silicone-based lubri- cants compared with water based. 75 TABLE 1. Examples of nonhormone therapeutic options for dyspareunia secondary to GSM Lubricants Moisturizers Water based Astroglide Liquid Replens Astroglide Gel Liquid Me Again Astroglide Feminease Good Clean Love K-Y SILK-E Just Like Me Luvena K-Y Jelly Revaree Pre-Seed Silken Secret Slippery Stuff Hyalo-gyn Liquid Silk YES WB SYLK Sliquid Silicone based Astroglide X ID Millennium K-Y Intrigue Pink Pjur Eros Uberlube Sliquid Oil based Ele´gance Women’s Lubricants Olive oil YES OB NAMS POSITION STATEMENT 980 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society In studies examining the safety of personal moisturizers and lubricants, investigators found that a number of water- based products are hyperosmolar. 76,77 This characteristic is associated with epithelial cellular toxicity and damage in cultures of epithelial cells and ectocervical explants. Near iso-osmolar and silicone-based lubricants did not have this effect. The World Health Organization recommends an osmo- larity of less than 1,200 mOsm/kg. 78 One jelly and one moisturizer also were found to be toxic to lactobacilli. There are very few data on the health and safety effects of lubricants that contain flavors (sugar), warming properties, or solvents and preservatives such as propylene glycol and parabens.",
    "There are very few data on the health and safety effects of lubricants that contain flavors (sugar), warming properties, or solvents and preservatives such as propylene glycol and parabens. One study on the use of vaginal products in women aged 18 to 65 years reported a 2.2-fold risk of BV in women using petroleum jelly compared with controls and increased colo- nization with candida species with users of oils compared with nonusers.79 Because there are no published reports on the irritation potential of OTC vaginal lubricants and moisturizers, women can test these on a small patch of skin for 24 hours before using them intravaginally. If the product they test successfully on the skin still causes irritation in the vagina, a woman can switch to an iso-osmolar, propylene glycol-free, or silicone- based product (Table 1). It is noteworthy that oil-based lubricants can erode condoms; however, most brands of water-based and silicone-based lubricants are latex safe and condom compatible. Hyaluronic acid Hyaluronic acid is a polymer found in cartilage and other soft tissues in the body that is added to many commercial skin- care and wound-healing products because of its purported effect of drawing moisture to any area to which it is applied. In four small RCTs comparing hyaluronic acid to placebo or vaginal ET, the former was associated with a similar decrease in severity of dryness and dyspareunia.",
    "In four small RCTs comparing hyaluronic acid to placebo or vaginal ET, the former was associated with a similar decrease in severity of dryness and dyspareunia. 80-83 To date, there is no evidence that products with hyaluronic acid have a greater benefit than nonhyaluronic acid lubricants or moisturizers. Herbal products Herbal products appear ineffective for GSM. The Herbal Alternatives for Menopause study, a double-blind RCT in 351 women, identified no change in vaginal dryness, vaginal cytology, follicle-stimulating hormone or estradiol levels following treatment for 1 year with black cohosh, a multi- botanical supplement, or soy. 84 Prescription therapies For women with persistent GSM symptoms after nonhor- mone interventions, prescription therapies may provide greater benefit. Vaginal estrogen Estrogen delivered vaginally provides sufficient estrogen to relieve genitourinary symptoms with minimal absorption and is preferred over systemic therapy when only genitourinary symptoms are present. 85,86 When systemic HT is needed to treat other menopause symptoms, a woman also will generally derive satisfactory resolution of her genitourinary symptoms, although additional low-dose vaginal estrogen may be added if needed. Efficacy studies of low-dose vaginal ET use both subjective and objective outcome measures.",
    "Efficacy studies of low-dose vaginal ET use both subjective and objective outcome measures. Subjective effects are often assessed using patient-reported outcome measures that include improvements in symptoms such as dyspareunia, vaginal dryness, and lower urinary tract symptoms and clini- cian-reported outcomes such as the appearance of the vulvo- vaginal tissues. Objective outcomes include decreases in vaginal pH, increases in the number of vaginal lactobacilli, and favorable shifts in the vaginal and/or urethral cytology (greater numbers and percentages of superficial cells and fewer numbers and percentages of parabasal cells). 87,88 Efficacy Low-dose vaginal ET is available in several forms, includ- ing cream (estradiol, estrone, and conjugated estrogens), a slow-release estradiol intravaginal ring, and an estradiol vaginal tablet and insert. Products vary in dosage and formu- lation (Table 2). 89-97 All approved products have proven efficacy in placebo-controlled RCTs. 86,98-111 In the United States, FDA requires efficacy data for treatment of a specific, most bothersome symptom, which includes dyspareunia, vaginal dryness, vaginal/vulvar irritation, vaginal soreness, dysuria, or bleeding associated with sexual activity. Dyspar- eunia and vaginal dryness are the most common indications for low-dose vaginal ET. The comparative efficacy of the various forms of vaginal ET was evaluated in a 2016 Cochrane review comparing 19 trials.",
    "The comparative efficacy of the various forms of vaginal ET was evaluated in a 2016 Cochrane review comparing 19 trials. 112 This review concluded that all tested products alleviated symptoms of vaginal dryness and dyspareunia with similar efficacy. Comparative analyses of these trials are limited by variations in methods and outcome measures, small sample sizes, lack of blinding, and substantial hetero- geneity of results. Some trials of the same estrogen prepara- tion used different doses or dosing schedules. Some trials included preparations not approved for use in the United States or in Canada. Vaginal estrogen and urinary symptoms In a 2014 systematic review that included 44 RCTs, assessment of urinary symptoms was variable, leading to a lower quality of evidence for the effectiveness of vaginal estrogen for urinary symptoms compared with vulvovaginal symptoms.113 This review reported moderate-quality evi- dence supporting vaginal ET in the treatment of urge inconti- nence and recurrent UTIs and low or very-low quality evidence supporting the use of vaginal ET for improvement of dysuria, urinary frequency and urgency, nocturia, and stress incontinence. A Cochrane review of vaginal ET for urinary incontinence determined that vaginal ET improves incontinence (relative risk [RR], 0.74; 95% confidence interval [CI], 0.64-0.86) but NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 981 Copyright @ 2020 The North American Menopause Society.",
    "27, No. 9, 2020 981 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. that systemic estrogen alone and in combination with a progestogen worsens incontinence (RR, 1.32; 95% CI, 1.17-1.48 and RR, 1.11; 95% CI, 1.04-1.18, respectively). 114 Most of these studies were conducted for reasons other than urinary symptoms, failed to use validated tools to assess symptom severity and QOL, and showed statistically signifi- cant but not clinically relevant changes. For example, in the Heart and Estrogen/Progestin Replacement Study, women randomized to systemic oral estrogen plus progestogen ther- apy experienced 0.7 more leak episodes per week compared with 0.1 fewer episodes in the placebo group, but both changes met the a priori definition of ‘‘no change in inconti- nence severity. ’’115 Few trials have been conducted comparing vaginal ET to other treatments for postmenopausal urinary tract symptoms. Two small trials comparing vaginal ET (conjugated equine estrogens) to pelvic floor muscle therapy (PFMT) for urinary incontinence favored PFMT over vaginal estrogen, 114 but a trial that compared estriol alone to estriol combined with pelvic floor rehabilitation favored combined therapy.",
    "69 A comparison of the estradiol ring to oral oxybutynin showed similar efficacy for treatment of overactive bladder but with different AEs; oxybutynin resulted in more dry mouth, con- stipation, and blurry vision, whereas the estradiol ring resulted in more vaginal discharge.116 When women present with both vulvovaginal and urinary symptoms, an initial trial of vaginal ET is prudent. If urinary symptoms are not sufficiently improved or resolved after 3 months of vaginal ET, the use of other evidence-based therapies for urinary tract symptoms is warranted.117 Recurrent UTI, defined as the occurrence of two culture- proven UTIs in 6 months or three culture-proven UTIs in 1 year, commonly affects postmenopausal women and is a component of GSM. 118 Treatment of GSM with vaginal ET (conjugated equine estrogen cream or low-dose estradiol vaginal ring) in a small RCT reduced the frequency of recurrent UTIs in postmenopausal women. 119 An RCT of vaginal estriol cream (0.5 mg) in postmenopausal women with recurrent UTIs led to a significant decrease in number of UTI episodes per year (0.5 compared with 5.9). 120 In another randomized trial, the low-dose estradiol ring was found to prolong the time to next recurrence in postmenopausal women with recurrent UTIs and to decrease the number of recurrences per year (RR, 0.64).",
    "121 Women who use a vaginal pessary for treatment of utero- vaginal prolapse are often advised to use vaginal ET to facilitate pessary use and to limit potential complications such as vaginal discharge and vaginal wall erosions. Prospec- tive data are lacking, but observational studies show lower discontinuation rates and less vaginal discharge when pessary users are treated with vaginal ET. 122 Safety Low-dose vaginal ET has a more favorable risk profile than systemic ET because estrogen doses are significantly lower (Table 2).89-97 Estrogens are systemically absorbed from the vagina in a dose-dependent manner, and in general, serum estrogen levels reported with use of low-dose vaginal ET remain within the postmenopause range. 123 A review of systemic estradiol measurements reported baseline levels in normal, untreated postmenopausal women of 3.1 pg/mL to 4.9 pg/mL using highly sensitive assays such as liquid or gas chromatography/mass spectroscopy and levels that were undetectable to 10.5 pg/mL using the less-sensitive radioim- munoassay.85 Serum estradiol levels with use of the low-dose vaginal ring (releasing approximately 7.5 mg/d) ranged from 5 pg/mL to 10 pg/mL. 107,124,125 Serum estradiol levels with use of the 10- mg vaginal tablet ranged from 3 pg/mL TABLE 2.",
    "107,124,125 Serum estradiol levels with use of the 10- mg vaginal tablet ranged from 3 pg/mL TABLE 2. Government-approved therapies for genitourinary syndrome of menopause in the United States and Canada Type Composition Product name Commonly used starting dose Commonly used maintenance dose Typical serum estra- diol level (pg/mL) Vaginal creams 17B-estradiol 0.01% (0.1 mg active ingredient/g) Estrace vaginal cream a 0.5-1 g/d for 2 wk 0.5-1 g 1-3 times/wk Variable Conjugated estrogens (0.625 mg active ingredient/g) Premarin vaginal cream 0.5-1 g/d for 2 wk 0.5-1 g 1-3 times/wk Variable Estrone 0.1% (1 mg active ingredient/g) Estragyn vaginal cream b 0.5-4 g/d, intended for short-term use; progestogen recommended Variable Vaginal inserts 17B estradiol inserts Imvexxy a 4o r1 0 mg/d for 2 wk 1 insert twice/wk 3.6 (4 mg) 4.6 (10 mg) Estradiol hemihydrate tablets Vagifem Yuvafem 10 mg/d for 2 wk 1 tablet twice/wk 5.5 Prasterone (DHEA) inserts Intrarosa 6.5 mg/d 1 insert/d 5 Vaginal ring 17 b estradiol Estring 2 mg ring releases approx 7.5 mg/d Replace ring every 90 days 8 Oral tablet Ospemifene Osphena a 60 mg/d 1 tablet by mouth/d N/A DHEA, dehydroepiandrosterone. Products not marked are available in both the United States and Canada. aAvailable in the United States but not Canada. bAvailable in Canada but not the United States. Estrace89; Premarin90; Estragyn91; Imvexxy92; Vagifem93; Yuvafem94; Intrarosa95; Estring96; Osphena.97 NAMS POSITION STATEMENT 982 Menopause, Vol.",
    "bAvailable in Canada but not the United States. Estrace89; Premarin90; Estragyn91; Imvexxy92; Vagifem93; Yuvafem94; Intrarosa95; Estring96; Osphena.97 NAMS POSITION STATEMENT 982 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. to 11 pg/mL.126-128 Serum estradiol levels after daily use of the 4-mg and 10-mg vaginal insert for 14 days were 3.6 pg/mL and 4.6 pg/mL, respectively, which was not statistically different from placebo (4.3 pg/mL). After twice weekly use for 84 days, there was no difference in serum estradiol levels compared with baseline or placebo. Serum estradiol levels associated with use of vaginal estradiol cream are derived from older data using higher doses and less-sensitive assays that lack accuracy for lower estrogen levels.",
    "Serum estradiol levels associated with use of vaginal estradiol cream are derived from older data using higher doses and less-sensitive assays that lack accuracy for lower estrogen levels. 129 Use of estradiol cream 0.5 mg (500 mg) daily for 3 weeks resulted in no change in serum estradiol levels.130 In contrast, another study showed that daily use of estradiol cream 0.2 mg (200 mg) daily resulted in serum estradiol levels that rose from a baseline of 16.6 pg/mL to 37.2 pg/mL after 3 weeks of use.131 Use of 0.3 mg conjugated estrogens (CE) cream 3 times weekly for 6 months produced no change in serum estradiol or estrone levels.132 Of note, CE contains a significant number of compounds, some estrogenic and some antiestrogenic, so serum estradiol and estrone levels after use of CE may not reflect actual estrogenic activity. Vaginal bleeding, breast pain, and nausea have been reported in some trials of vaginal estrogen cream. These symptoms are dose related and suggest that the dose was large enough to result in significant systemic absorption. Adverse events associated with use of vaginal ET include vaginal discharge, vulvovaginal candidiasis, vaginal bleed- ing, and breast pain. Differing AE profiles may reflect variations in product formulation and dose. 133,134 The risks typically associated with systemic ET, including breast and endometrial cancer and cardiovascular disease (CVD), have been evaluated in several trials of vaginal ET.",
    "133,134 The risks typically associated with systemic ET, including breast and endometrial cancer and cardiovascular disease (CVD), have been evaluated in several trials of vaginal ET. Clinical trial data beyond 1 year are lacking, however, because the longest duration of any RCT was 52 weeks. 135 Endometrial safety was assessed in two systematic reviews that included RCTs and large observational studies. 136,137 In 20 RCTs, 2,983 women were exposed to vaginal ET for up to 1 year. There was one case of endometrial cancer (0.03%) and 12 cases of endometrial hyperplasia (0.4%). The cases were sporadic and their incidence similar to the baseline rate in the general population. A 2016 Cochrane review of RCTs reported no significant differences among vaginal estrogen formulations in terms of endometrial thickness or hyperplasia or the proportion of women with AEs.112 Large observational studies evaluating longer exposures to vaginal ET identified no increase in endometrial cancer. In the Women’s Health Initiative-Observational Study, the rate of endometrial cancer was not statistically different in users of vaginal ET compared with nonusers (1.3 vs 1 case per 1,000 woman-years, respec- tively). Thus, occurrence of endometrial cancer and hyper- plasia with low-dose vaginal ET use is rare and consistent with rates in the general population.",
    "Thus, occurrence of endometrial cancer and hyper- plasia with low-dose vaginal ET use is rare and consistent with rates in the general population. The risk of venous thromboembolism (VTE) was not increased with vaginal ET use in a 2016 Cochrane review, a 2020 systematic review of RCTs, and three large observa- tional studies. 112,135,137-139 Of note, systematic, prospective data for women at high risk of VTE are lacking. A prospective cohort study of approximately 45,000 women in the Women’s Health Initiative Observational Study examined risks associated with vaginal ET use. Outcomes assessed included coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, and death. The findings were very reassuring, with no increased risk of CVD or cancer in postmenopausal women using vaginal estrogens. 135 Another prospective cohort study of approximately 54,000 postmenopausal women in the Nurses’ Health Study also was very reassuring regarding the safety of vaginal ET. There was no increase in health outcomes assessed with vaginal ET use, including CVD (total myocardial infarction, stroke, pulmo- nary embolism/VTE), hip fracture, and cancer (total invasive, breast, endometrial, ovarian, and colorectal).",
    "138 In a 2019 meta-analysis, investigators used individual participant data from 58 observational studies reported between 1992 and 2018 to assess associations between hormone therapy and breast cancer.140 Use of vaginal estrogen was not found to be associated with risk of breast cancer. Potential contraindications to vaginal estrogen therapy Although most women with GSM are candidates for low- dose vaginal ET, use is contraindicated in women with undiagnosed vaginal/uterine bleeding and should be used with caution in women with estrogen-dependent neoplasia. Management of GSM in women with nonhormone-dependent cancers is similar to that for women without a cancer history. Low-dose vaginal ET has not been studied in women at increased risk of thrombosis, but may be used with caution given minimal systemic absorption, the absence of a hepatic first-pass effect, and minimal, if any, effect on prothrombotic factors. Of note, in large observational studies, neither vaginal estrogen nor systemic transdermal formulations of ET have been associated with an increased risk of VTE. 139 Although circulating estrogen concentrations generally remain within the menopause range with low-dose vaginal ET, the package insert for these products includes the same boxed warning regarding risk of endometrial cancer, breast cancer, cardiovascular disorders, and probable dementia that accompanies systemic HT products.",
    "Women must be edu- cated about the differences between low-dose vaginal and systemic ET and be prepared for the boxed warning, or else they may not initiate prescribed treatment. Vaginal estrogen products Several low-dose vaginal estrogen products have been gov- ernment approved for use in the United States and Canada, including cream (estradiol, estrone, and conjugated estrogens), a slow-release estradiol intravaginal ring, and an estradiol vaginal tablet and insert (Table 2). 89-97 Vaginal estrogen creams are generally used two to three times weekly, estradiol tablets and inserts used twice weekly, and the estradiol ring changed every 3 months. Estrogen creams, tablets and inserts are used daily for 2 weeks at the initiation of treatment for more rapid improvement in symptoms (Table 2).89-97 One vaginal ET NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 983 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. product (Femring) delivers a systemic dose of estradiol and is approved for the treatment of VMS in addition to GSM. 141 Femring should not be confused with Estring, which delivers a low dose of estradiol and is indicated only for GSM. There are no data to suggest an advantage for initial use of combined systemic and vaginal estrogen in cases of severe GSM. Therapy with low-dose vaginal estrogen can be individu- alized to identify the lowest dose and frequency of use that provides the desired effect.",
    "Therapy with low-dose vaginal estrogen can be individu- alized to identify the lowest dose and frequency of use that provides the desired effect. Although efficacy is similar among the available products, estrogen creams dispensed with an applicator may offer mo re immediate soothing relief of symptoms, possibly because of the emollient nature of the carrier. Another potential advantage of the creams is that they can be digitally applied directly to the vulvar and vestibular tissues. However, some wome n consider the creams messy, and some report sensitivity to the vehicle used in the creams. With estrogen cream delivery, the user has the responsibility of preparing the dose because the amount of cream inserted is not in a prepackaged dosing unit —potentially leading to use of higher-than-recommended doses. The clinical implica- tions of potential male partner estrogen absorption remain unknown. Low-dose estradiol tablets and inserts are convenient, fixed-dose vaginal estrogen formulations. Although two doses of the vaginal tablet (25 mg and 10 mg) were shown to be effective, only the lower dose (10 mg) is available in the United States and Canada. 101,102,107-109,111,142 There are two approved doses of the vaginal insert (4 mg and 10 mg), with the 4-mg dose providing the lowest available formulation of vaginal ET. 143-145 The sustained-release, low-dose estradiol vaginal ring pro- vides 90 days of continuous estradiol.",
    "143-145 The sustained-release, low-dose estradiol vaginal ring pro- vides 90 days of continuous estradiol. Effective relief of genitourinary symptoms, including dyspareunia, dysuria, and urge incontinence, has been consistently documented in RCTs with this estrogen delivery system. 99,100,103-107 The estradiol ring may change position or dislodge with bowel movements, Valsalva maneuvers, douching, or vaginal sexual penetration, particularly in women with uterovaginal prolapse or hysterectomy. Vaginal ring users are encouraged to remove and replace their own vaginal rings unless discom- fort or limited dexterity makes such self-care difficult. The ring can remain in the vagina during sexual activity. There are no data to suggest an allergic reaction to the silicone product. If there is significant stenosis of the vagina, regular use of graduated vaginal dilators after initiation of estrogen cream, tablet, or insert may be necessary before an estrogen ring can be inserted. Given similar efficacy among vaginal estrogen formula- tions, women should be provided with information on all options, with personal preference guiding choice. Although some women prefer estrogen creams to allow for vulvar and vestibular as well as vaginal application, others find creams messy and dislike cleaning the applicator after use.",
    "Although some women prefer estrogen creams to allow for vulvar and vestibular as well as vaginal application, others find creams messy and dislike cleaning the applicator after use. Because creams do not provide a specific, fixed dose of estrogen, other options may be preferred if careful dosing and predictable results of serum estrogen levels are desired. Vaginal estradiol tablets and inserts are convenient, requiring only twice weekly application after 2 weeks of daily use. The tablet is placed in the vagina with a plastic applicator, whereas the insert is placed with a finger. Preference for insertion method may determine product choice. For women who are comfort- able using a vaginal ring, this formulation is convenient, requiring placing a new ring only four times yearly. Vaginal estrogen formulations are often costly, and variation in price, depending on a woman’s particular insurance coverage, also may be a factor in product choice. Vaginal dehydroepiandrosterone Dehydroepiandrosterone (also known as prasterone) is a steroid hormone that is an intermediate in the biosynthesis of androgens and estrogens. A low-dose DHEA vaginal insert used daily with an applicator is approved in the United States and Canada for the treatment of moderate to severe dyspar- eunia in menopausal women (Table 2).",
    "A low-dose DHEA vaginal insert used daily with an applicator is approved in the United States and Canada for the treatment of moderate to severe dyspar- eunia in menopausal women (Table 2). 89-97 Dehydroepian- drosterone is transformed by vaginal mucosal cells to estrogens, including estradiol, and to androgens, including testosterone.146 Twelve-week RCTs have demonstrated the efficacy of DHEA 6.5 mg daily in improving the VMI, vaginal pH, dyspareunia, and vaginal dryness in menopausal women with GSM. Vaginal discharge was the most common AE, reported by 6% of study participants. In 422 women receiving DHEA for 52 weeks, endometrial sampling demonstrated inactive or atrophic endometrium in all participants. 147 Ospemifene Ospemifene is an estrogen agonist/antagonist and the only orally available product approved for treatment of vaginal dryness and moderate to severe dyspareunia. It is available in the United States, but not in Canada.97,148 Twelve-week RCTs have demonstrated the efficacy of ospemifene 60 mg daily in improving VMI, vaginal pH, dyspareunia, vaginal dryness, and genital exam findings. 149-151 A 52-week efficacy and safety extension study in 180 women showed sustained improvements on visual examination of the vagina, with no cases of VTE, endometrial hyperplasia, or cancer. 152 Vaso- motor symptoms were the most common AE, with rates of 2% in the placebo group and 7.2% in the group taking 60 mg of ospemifene.",
    "152 Vaso- motor symptoms were the most common AE, with rates of 2% in the placebo group and 7.2% in the group taking 60 mg of ospemifene. Ospemifene was shown to reduce recurrent UTIs in a 6-month retrospective observational study. 153 The prescribing information for ospemifene contains pre- cautions similar to those for estrogens and other estrogen agonist/antagonists, including an increased risk of endome- trial cancer and CVD.97 With regard to breast cancer, labeling states that ospemifene should not be used in women with known or suspected breast cancer because the drug has not been adequately studied in this group. Ospemifene has, however, demonstrated antiestrogenic activity in preclinical models of breast cancer. 154 In ex vivo human breast tissue, ospemifene inhibited proliferation and opposed stimulation caused by estradiol similar to but not as potently as the estrogen agonist/antagonists tamoxifen and raloxifene. 155 Ospemifene 60 mg has been associated with decreased risk NAMS POSITION STATEMENT 984 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. for breast cancer and breast cancer recurrence in preliminary studies.156 Duration of therapy and monitoring Improvement in GSM symptoms typically occurs within a few weeks of starting therapy 157; however, treatment for 12 weeks may be needed for maximum benefit.",
    "In the absence of contraindications, therapy should be continued as long as needed for symptom management as symptoms will recur upon discontinuation. Clinical trial safety data are limited to 1 year, but observational studies demonstrate safety with long-term use. Based on available limited safety data, use of a progesto- gen 112,126 and routine endometrial surveillance 112,158,159 are not recommended in low-risk women using low-dose vaginal ET. Women at increased risk of endometrial cancer because of obesity or diabetes may warrant endometrial surveillance. Because uterine bleeding is generally a sign of endometrial proliferation, any spotting or bleeding requires a thorough evaluation that may include transvaginal ultrasound (TVU) and/or endometrial biopsy. Testosterone Topical testosterone cream has been used for the treatment of vulvovaginal conditions, including lichen sclerosus and vestibulodynia, despite limited efficacy data. 160,161 Although not government approved for this indication, there are limited data supporting the use of vaginal testosterone cream for the treatment for GSM. A 4-week pilot trial of 20 postmenopausal women with breast cancer found that vaginal testosterone (150 mg and 300 mg) improved dyspareunia, vaginal dryness, and VMI without increasing estradiol; median testosterone level increased from 15.5 ng/dL to 21.5 ng/dL (P ¼ .02).",
    "162 A 12-week RCT in 76 menopausal women taking AIs after treatment for early stage breast cancer who reported vaginal dryness, dyspareunia, or reduced libido compared the low- dose estradiol vaginal ring with compounded vaginal testos- terone cream. Symptoms of GSM and sexual desire improved in both treatment arms. The observation that levels of serum estradiol were increased in trial participants at baseline com- plicates interpretation of these findings. 163 Existing clinical trial data are insufficient to recommend the use of vaginal testosterone for GSM. 164 Longer and larger studies are needed to assess safety and efficacy. Energy-based therapies Vulvovaginal energy-based devices including lasers (fractional CO 2, Erbium:YAG) and radio-frequency devices are under investigation as treatments for GSM, but none have FDA approval for this indication. In a 2018 Safety Communication, FDA issued a public warning about the use of these devices for vagina l cosmetic purposes, stating that the effectiveness and safety of the devices have not yet been established. 165 Vulvovaginal energy-based devices are thought to improve vaginal health by causing microtrauma, which induces collagen formation, angiogenesis, and epithelial thickening.",
    "165 Vulvovaginal energy-based devices are thought to improve vaginal health by causing microtrauma, which induces collagen formation, angiogenesis, and epithelial thickening. The frac- tional CO2 laser has demonstrated safety and efficacy in tissues of the skin, face, and neck.166-169 Using a probe adapted to the vagina, fractional CO 2 vaginal laser therapy induces similar morphologic changes in the vagina, and data from small studies support improvement in GSM symptoms of vaginal dryness and dyspareunia. 170-178 Several RCTs have compared laser therapy to vaginal ET. Overall, no treatment was superior to another, and the studies were not designed to assess noninfer- iority. 179-182 Radiofrequency devices are nonablative and emit focused electromagnetic waves that heat the superficial layers of the tissue. Several RCTs evaluating the efficacy of energy- based devices in the treatment of GSM are in progress. Safety Adverse events associated with energy-based therapies include discomfort during treatments, vaginal scarring, vagi- nal lacerations on resumption of intercourse, and persistent and/or worsening dyspareunia. 183 These treatments are costly and generally not covered by insurers. Consensus statements regarding the use of energy-based therapies for GSM treatment have been published by several professional societies summarizing the small but growing body of evidence as well as concerns about safety.",
    "184-187 Additional randomized, prospective, sham-controlled trials of adequate size and scope are necessary before these therapies can be routinely recommended for treatment of GSM. Treatment considerations in women with breast cancer Treatment of GSM in women with breast cancer can be complicated by 1) adjuvant treatment (AIs or tamoxifen), which lower estrogen concentrations or antagonize estrogen effects; 2) product labeling; 3) limited clinical trial data in patients with breast cancer or survivors; and 4) absence of agreement between the oncology community and other prac- titioners involved in genitourinary and sexual healthcare. Many women with breast cancer and GSM will benefit from the regular use of vaginal moisturizers, lubricants for sexual activity, and PFPT. For persistent symptoms, other therapies may be beneficial, including topical lidocaine, low-dose vaginal ET, vaginal DHEA, ospemifene, and vaginal energy-based therapies. 188-191 For women with breast cancer, low-dose vaginal ET is contraindicated according to FDA class labeling. However, off-label use of several products may be acceptable because of their very low systemic absorption. 192 Low-dose vaginal ET formulations, including the estradiol tablet, insert, and ring, result in serum estradiol within the postmenopausal range and similar to placebo.",
    "192 Low-dose vaginal ET formulations, including the estradiol tablet, insert, and ring, result in serum estradiol within the postmenopausal range and similar to placebo. 145,146 Several organizations, including the American College of Obstetricians and Gynecologists, have endorsed the use of low-dose vaginal estrogens in women with breast cancer, including ER-positive disease. A system- atic review and meta-analysis also suggests safety, based on the use of low-dose vaginal ET in survivors of breast cancer using concomitant AIs. 193 Many oncologists allow the use of low-dose vaginal ET or vaginal DHEA in their patients with NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 985 breast cancer when GSM symptoms persist after trials of nonhormone interventions and QOL is adversely affected. Use of vaginal DHEA for GSM in women with breast cancer is not contraindicated, but US labeling advises caution because estrogen is a metabolite of DHEA. 95 Although vagi- nal DHEA has not been studied in women with a history of breast cancer, levels of estradiol and testosterone remain within the postmenopause range. 194 Ospemifene is not recommended for treatment of GSM in women with known or suspected breast cancer because the drug has not been adequately studied in this group. Prelimi- nary data on ospemifene suggest both a decreased risk of incident breast cancer and a reduced risk of breast cancer recurrence with this therapy.",
    "Prelimi- nary data on ospemifene suggest both a decreased risk of incident breast cancer and a reduced risk of breast cancer recurrence with this therapy. 156 Clinical trials of laser therapy for GSM in survivors of breast cancer provide limited evidence for safety and efficacy in this patient population. 195-197 These studies generally do not have either a positive or sham control, a shortcoming of many of the studies on these devices. Education Healthcare providers should educate women about GSM and the urogenital changes that often occur with menopause. Many women are unaware that v aginal dryness, recurrent UTIs, discomfort with sexual activity, and other GSM symptoms are a consequence of estrogen deficiency. Unlike VMS that typically improve with time, GSM symptoms o f t e nw o r s e ni nt h ea b s e n c eo ft r e a t m e n t .W o m e na l s om a y not know that effective and safe OTC and prescription therapies are available. Women who are sexually active are more likely to notice GSM symptoms and seek care, but sexually inactive women als o will benefit from education about GSM. Women who are concerned about future uro- genital function may consider preventive use of lubricants, moisturizers, vaginal dilators , or prescription therapies, but there is no evidence to support this approach. It is unknown whether treatment to preserve sexual function or prevent the future occurrence of GSM is indicated in the absence of urogenital symptoms.",
    "It is unknown whether treatment to preserve sexual function or prevent the future occurrence of GSM is indicated in the absence of urogenital symptoms. CONCLUSIONS AND RECOMMENDATIONS /C15 Education about and screening for GSM is recommended for perimenopausal and postmenopausal women. [Level C] /C15 First-line therapies for women with GSM include non- hormone lubricants with sexual activity and regular use of long-acting vaginal moisturizers. [Level A] /C15 For women with moderate to severe GSM and those who do not respond to lubricants and moisturizers, several safe and effective options are available: – Low-dose vaginal ET [Level A] – Vaginal DHEA [Level A] – Ospemifene [Level A] – Systemic ET (when VMS are also present) [Level A] /C15 For women with a history of breast or endometrial cancer, management depends on a woman’s preferences, symptom severity, and understanding of potential risks after consul- tation with her oncologist. [Level C] /C15 Although product labeling for low-dose vaginal ET notes risks associated with systemic HT (including CHD, stroke, VTE, breast and endometrial cancer), these risks are highly unlikely given minimal systemic absorption and reassuring findings from clinical trials and observational studies. [Level B] /C15 Use of a progestogen is not recommended with low-dose vaginal ET, although women at increased risk of endome- trial cancer may warrant endometrial surveillance.",
    "[Level B] /C15 Use of a progestogen is not recommended with low-dose vaginal ET, although women at increased risk of endome- trial cancer may warrant endometrial surveillance. Endo- metrial safety clinical trial data are not available for use longer than 1 year, although observational studies are reassuring regarding longer-term use. [Level B] /C15 Routine endometrial surveillance is not recommended for asymptomatic women using low dose vaginal ET. Trans- vaginal ultrasound or intermittent progestogen therapy may be considered for women at increased risk of endometrial cancer. [Level C] /C15 Spotting or bleeding in a postmenopausal woman requires a thorough evaluation that may include TVU and/or endo- metrial biopsy. [Level A] /C15 Energy-based therapies, including vaginal laser and radio- frequency devices, require long-term, sham-controlled safety and efficacy studies before their routine use can be recommended. [Level C] /C15 Therapy for GSM should be continued, with appropriate clinical follow up, for as long as bothersome symptoms are present. [Level C] Strength of Recommendation /C15 Level A Supported by sufficient, consistent scientific evidence /C15 Level B Supported by limited or inconsistent evidence /C15 Level C Based primarily on expert opinion ACKNOWLEDGMENTS AND DISCLOSURES NAMS appreciates the contributions of the NAMS 2020 GSM Position Statement Editorial Panel and the work of the NAMS Board of Trustees on this position statement.",
    "The authors, planners, reviewers, and staff who were in a position to control and influence the content of this activity were required to disclosure any relevant financial relationship (s) of the individuals or their spouse/partner that had occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. After reviewing disclosures from all involved in the content of this activity, NAMS has implemented mechanisms to identify and resolve any conflicts for all involved, including review of content by those who had no conflicts of interest. Acknowledgments: The NAMS 2020 GSM Position State- ment Editorial Panel: Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, Lead; Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for Women’s Health; Medical Director, The North American Menopause Society, Pepper Pike, Ohio. Sheryl A. Kingsberg, PhD, Lead; NAMS POSITION STATEMENT 986 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. Chief, Division of Behavioral Medicine, University Hospitals Cleveland Medical Center; MacDonald Women’s Hospital; Professor, Departments of Reproductive Biology and Psychi- atry, Case Western Reserve University School of Medicine, Cleveland, Ohio.",
    "Amanda L. Clark, MD, MCR, NCMP; Affiliate Investigator and Urogynecology Physician, Female Pelvic Medicine and Reconstructive Surgery, Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. Andrew M. Kaunitz, MD, FACOG, NCMP; Univer- sity of Florida Term Professor and Associate Chairman, Department of Obstetrics and Gynecology; University of Florida College of Medicine—Jacksonville; Medical Director and Director of Menopause and Gynecologic Ultrasound Services, University of Florida Women’s Health Special- ists—Emerson, Jacksonville, Florida. Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC; Director of Female Sexual Medicine, Center for Pelvic Medicine, Drexel University College of Medicine; Widener University College of Human Service Professions; Academic Urology Center for Pelvic Medicine, Philadelphia, Pennsylvania. Lisa C. Larkin, MD, FACP, NCMP, IF; Lisa Larkin and Associates, Internal Medicine and Women’s Health, Cincinnati, Ohio. Caroline M. Mitchell, MD, MPH; Associate Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School; Director, Vulvovaginal Disorders Program, Massa- chusetts General Hospital, Boston, Massachusetts. Jan L. Shifren, MD, NCMP; Director, Midlife Women’s Health Center, Massachusetts General Hospital; Vincent Trustees Professor of Obstetrics, Gynecology, and Reproductive Biol- ogy, Harvard Medical School, Boston, Massachusetts.",
    "James A. Simon, MD, CCD, NCMP, IF, FACOG; Clinical Professor, George Washington University; Medical Director, Women’s Health and Research Consultants, Washington, DC. NAMS recognizes the contributions of Ms. Carolyn Develen, NAMS Chief Operating Officer, and Ms. Kathy Method, MA, NAMS Communications Manager. This position statement was reviewed and approved by the 2019-2020 NAMS Board of Trustees: Rebecca C. Thurston, PhD, President; Director, Women’s Biobehavioral Health Laboratory; Professor of Psychiatry, Psychology, Epidemiol- ogy, and Clinical and Translational Science; University of Pittsburgh, Pittsburgh, Pennsylvania. Hadine Joffe, MD, MSc, President-Elect; Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology; Paula A. Johnson Associate Professor of Psychiatry in the Field of Women’s Health; Harvard Medical School; Vice Chair for Psychiatry Research, Department of Psychiatry; Brigham and Women’s Hospital, Dana Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts. James H. Liu, MD, NCMP, Immediate Past President; Arthur H. Bill Professor and Chair; Department of Obstetrics and Gynecology; Uni- versity Hospitals Cleveland Medical Center; MacDonald Women’s Hospital; Department of Reproductive Biology; Case Western Reserve University School of Medicine, Cleveland, Ohio. Lisa C. Larkin, MD, FACP, NCMP, IF, Treasurer; Lisa Larkin and Associates, Internal Medicine and Women’s Health, Cincinnati, Ohio.",
    "Lisa C. Larkin, MD, FACP, NCMP, IF, Treasurer; Lisa Larkin and Associates, Internal Medicine and Women’s Health, Cincinnati, Ohio. Carolyn J. Crandall, MD, MS, FACP, NCMP, FASBMR, Secretary; Professor of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California. Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, Professor and Chair, Depart- ment of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for Women’s Health; Medical Director, The North American Menopause Society, Pepper Pike, Ohio. Lisa Astalos Chism, DNP, APRN, NCMP, FAANP; Clinical Director, Women’s Wellness Clinic; Sexual Health Counselor and Educator; Karmanos Cancer Institute; Adjunct Assistant Professor, Department of Surgery; Wayne State University School of Medicine, Detroit, Michigan. Samar R. El Khoudary, PhD, MPH, BPharm, FAHA; Associate Professor, Department of Epidemiology, Epidemiology Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania. Michael R. McClung, MD, FACP, FASBMR, FACE; Founding Director, Oregon Osteoporosis Center, Portland, Oregon, Professorial Fellow, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.",
    "Susan D. Reed, MD, MPH; Research Director, Women’s Reproductive Health Research Program; Professor and Vice Chair, Department of Obstetrics and Gynecology; Adjunct Professor, Epidemiology, Univer- sity of Washington School of Medicine, Seattle, Washington. Nanette F. Santoro, MD; Professor and E. Stewart Taylor Chair of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado. Chrisandra L. Shufelt, MD, MS, FACP, NCMP; Associate Director, Barbra Strei- sand Women’s Heart Center and Preventive and Rehabilita- tive Cardiac Center; Director, Women’s Hormone and Menopause Program; Associate Professor of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Claudio N. Soares, MD, PhD, FRCPC, MBA; Professor and Head, Department of Psychiatry, Queen’s University School of Medicine; Executive Director, Research and Inno- vation, Providence Care Hospital; Executive Lead, Strategy and New Partnerships, Canadian Biomarker Integration Net- work in Depression (CAN-BIND), St. Michael’s Hospital, Kingston, Ontario, Canada. Isaac Schiff, CM, MD, Editor-in- Chief, Menopause; Joe Vincent Meigs Distinguished Professor of Gynecology, Harvard Medical School; Chief, Department of Obstetrics and Gynecology, Emeritus; The Women’s Care Division, Massachusetts General Hospital, Boston, Massachusetts.",
    "Financial disclosures/conflicts of interest : For the GSM Position Statement Editorial Panel: Dr. Faubion and Dr. Shifren report no relevant financial relationships. Dr. Kingsberg reports Consultant/Advisory Board for Amag, Astellas, Dare, Duchesney, Endoceutics, Lupin, Materna, Mitsubishi Tanaba, Ovaco, Palatin Technologies, Pfizer, Sprout, Strategic Science Technologies, TherapeuticsMD, and Viveve; Speaker for Amag and Therapeutics MD. Dr. Clark reports Consulting Fees for Butler Snow LLC; Grant Funding (paid to institution) from Pfizer. Dr. Kaunitz reports NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 987 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. Consultant for Amag, Mithra, Pfizer; Clinical Trial Support (paid to institution) from Endoceutics, Mithra. Dr. Kellogg Spadt reports Speaker for Amag, Bonafide, TherapeuticsMD. Dr. Larkin reports Consultant/Advisory Board for Amag, Lupin, Procter & Gamble, TherapeuticsMD; Speakers’ Bureau for Amag, Amgen, TherapeuticsMD. Dr. Mitchell reports Spouse Employee at Sanofi Genzyme; Consulting for Scynexis. Research Funding from Merck.",
    "Dr. Mitchell reports Spouse Employee at Sanofi Genzyme; Consulting for Scynexis. Research Funding from Merck. Dr. Simon reports Research/Grant Support from AbbVie, Bayer Healthcare, Endoceutics, GTx, Inc, Ipsen, Myovant Sciences; Consultant for AbbVie, Amag, Bayer HealthCare, CEEK Enterprises, Covance, Dare Bioscience, Duchesnay, Hologic, KaNDy/ NeRRe Therapeutics, Mitsubishi Tanabe Pharma Develop- ment America, Shionogi, Sprout2, TherapeuticsMD; Speaker for AbbVie, Amag, Duchesnay, TherapeuticsMD. For addi- tional contributors, Ms. Develen and Ms. Method report no relevant financial relationships. For the NAMS Board of Trustees members who were not members of the Editorial Panel: Dr. Crandall, Dr. El Khoudary, Dr. Shufelt, and Dr. Schiff report no relevant financial relation- ships. Dr. Thurston reports Consultant/Advisory Board for Astellas, Pfizer, Procter & Gamble, Virtue Health. Dr. Joffe reports Consultant/Advisory Board for Esai, Jazz, Merck, NeRRe/KaNDy, Sojournix; Grant/Research Support from Brigham and Women’s Hospital Funds, Merck, NIH, NIA, NIMH, NCI, NeRRe/KaNDy, Pfizer, QUE Oncology, V Foun- dation; spouse employee for Merck, Arsenal Biosciences and Tango, consulting and equity. Dr. Liu reports Consultant/ Advisory Board for Allergan, Amag, Astellas, Bayer, Dare ´, Ferring, Lupin, Mitsubishi, TherapeuticsMD; Research Grants from AbbVie, Allergan, Amag, Astellas, Femasys. All funds paid to the institution.",
    "All funds paid to the institution. Dr. Chism reports Consultant/Advisory Board for Hologic; Speakers’ Bureau for Amag, Astellas, JDS Therapeutics; Royalties/Patents for Jones and Bartlett Publish- ing. Dr. McClung reports Consultant/Advisory Board for Amgen, Myovant; Speakers’ Bureau for Amgen, Radius. Dr. Reed reports Grant/Research Support from Bayer, NIH; Roy- alties/Patents from UpToDate. Dr. Santoro reports Consultant/ Advisory Board for Ansh Labs, Menogenix, Ogeda/Astellas; Stock/Ownership for Menogenix. Dr. Soares reports Consul- tant/Advisory Board for Lundbeck, Otsuka; Grant/Research Support from Ontario Research Fund, Ontario Brain Institute, AHSC AFP Innovation Fund. REFERENCES 1. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas 2004;49:292-303. 2. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661-666. 3. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142. 4. Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas 2016;83:40-44. 5. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE.",
    "Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas 2016;83:40-44. 5. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause 2013;20:1043-1048. 6. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women’s EMPOWER Survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment.J Sex Med2017;14: 413-424. 7. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women’s Views of Treatment Options for Menopausal Vaginal Changes) survey. J Sex Med 2013;10:1790-1799. 8. Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med 2017;14:425-433. 9. Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause 2019;26:485-491. 10. Shifren JL, Zincavage R, Cho EL, etal. Women’s experience of vulvova- ginal symptoms associated with menopause.Menopause2018;26:341-349. 11. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI.",
    "11. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15: 267-274. 12. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new termi- nology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause 2014;21:1063-1068. 13. Shifren JL. Genitourinary syndrome of menopause.Clin Obstet Gynecol 2018;61:508-516. 14. Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013;19:155-162. 15. Chen GD, Oliver RH, Leung BS, Lin LY, Yeh J. Estrogen receptor alpha and beta expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women. Fertil Steri 1999;71:1099- 1102. 16. Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol 2001;185:1325-1330. 17. Hodgins MB, Spike RC, Mack ie RM, MacLean AB. An immuno- histochemical study of androgen , oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol 1998; 105:216-222. 18. Griebling TL, Liao Z, Smith PG. Systemic and topical hormone thera- pies reduce vaginal innervation density in postmenopausal women. Menopause 2012;19:630-635. 19. Gorodeski GI.",
    "18. Griebling TL, Liao Z, Smith PG. Systemic and topical hormone thera- pies reduce vaginal innervation density in postmenopausal women. Menopause 2012;19:630-635. 19. Gorodeski GI. Estrogen modulation of epithelial permeability in cervi- cal-vaginal cells of premenopausal and postmenopausal women. Meno- pause 2007;14:1012-1019. 20. Bachmann GA, Cheng RJ, Rovner E. Vulvovaginal complaints. In: Lobo RA, editor. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 3rd ed. Burlington, MA: Academic Press; 2007:263-270. 21. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005;73: 1253-1263. 22. Meditz AL, Moreau KL, MaWhinney S, et al. CCR5 expression is elevated on endocervical CD4 þ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr 2012;59:221-228. 23. White HD, Yeaman GR, Givan AL, Wira CR. Mucosal immunity in the human female reproductive tract: cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. Am J Repro Immunol 1997;37:30-38. 24. Sivro A, Lajoie J, Kimani J, et al. Age and menopause affect the expression of specific cytokines/chemokines in plasma and cervical lavage samples from female sex workers in Nairobi, Kenya. Immun Ageing 2013;10:42. 25. Thoma ME, Gray RH, Kiwanuka N, et al.",
    "Immun Ageing 2013;10:42. 25. Thoma ME, Gray RH, Kiwanuka N, et al. Longitudinal changes in vaginal microbiota composition assessed by gram stain among never sexually active pre- and postmenarcheal adolescents in Rakai, Uganda. J Pediatr Adolesc Gynecol 2011;24:42-47. 26. Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atro- phy. Menopause 2014;21:450-458. 27. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011;108:4680-4687. NAMS POSITION STATEMENT 988 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. 28. Lamont RF, Sobel JD, Akins RA. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011;118:533-549. 29. Lai SK, Hida K, Shukair S, et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009;83:11196-11200. 30. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003;36:663-668. 31. Cherpes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis.",
    "Clin Infect Dis 2003;36:663-668. 31. Cherpes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003;37:319-325. 32. Pybus V, Onderdonk AB. Microbial interactions in the vaginal ecosys- tem, with emphasis on the pathogenesis of bacterial vaginosis.Microbes Infect 1999;1:285-292. 33. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human im munodeficiency virus type 1 and sexually transmitted disease acquisition.J Infect Dis 1999;180:1863-1868. 34. Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis 1998;178:446-450. 35. Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 2017;46:29-37. 36. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle- stimulating hormone for menopause diagnosis. Am J Obstet Gynecol 2004;190:1272-1277. 37. Hillier SL, Lau RJ. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. Clin Infect Dis 1997;25:S123-S126. 38. Hummelen R, Macklaim JM, Bisanz JE, et al.",
    "Hillier SL, Lau RJ. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. Clin Infect Dis 1997;25:S123-S126. 38. Hummelen R, Macklaim JM, Bisanz JE, et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One 2011;6:e26602. 39. Shen J, Song N, Williams CJ, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep 2016;6:24380. 40. Mitchell CM, Srinivasan S, Zhan X, et al. Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. Meno- pause 2017;24:1160-1166. 41. Brotman RM, Ravel J, Cone RA, Zenilman JM. Rapid fluctuation of the vaginal microbiota measured by Gram stain analysis. Sex Transm Infect 2010;86:297-302. 42. Cauci S, Driussi S, De Santo. et al. Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J Clin Microbiol 2002;40:2147-2152. 43. Gliniewicz K, Schneider GM, Ridenhour BJ, et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Front Microbiol 2019;10:193. 44. Galhardo CL, Soares JM, Simoes RS, Haidar MA, Rodrigues de Lima G, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin Exp Obstet Gynecol 2006;33:85-89. 45.",
    "Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin Exp Obstet Gynecol 2006;33:85-89. 45. Heineman C, Reid G. Vaginal microbial diversity among postmeno- pausal women with and without hormone replacement therapy. Can J Microbiol 2005;51:777-781. 46. Nappi RE, Martini E, Cucinella L, et al. Addressing vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) for healthy aging women. Front Endocrinol (Lausanne) 2019;10:561. 47. Kagan R, Kellogg-Spadt S, Parish SJ. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs Aging 2019;36:897-908. 48. Pacello PC, Yela DA, Rabelo S, Giraldo PC, Benetti-Pinto CL. Dyspar- eunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric 2014;17:342-347. 49. de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011;18:262-266. 50. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294: 91-96. 51. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007;92:3040-3043. 52. Taylor CE, Meisel JL. Management of breast cancer therapy-related sexual dysfunction. Oncology 2017;31:726-729. 53. Conde DM, Pinto-Neto AM, Cabello C, Sa´ DS, Costa-Paiva L, Martinez EZ.",
    "52. Taylor CE, Meisel JL. Management of breast cancer therapy-related sexual dysfunction. Oncology 2017;31:726-729. 53. Conde DM, Pinto-Neto AM, Cabello C, Sa´ DS, Costa-Paiva L, Martinez EZ. Menopause symptoms and quality of life in women aged 45 to 65 years with and without breast cancer. Menopause 2005;12:436-443. 54. Greendale GA, Petersen L, Zibecchi L, Ganz PA. Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 2001;8:111-119. 55. Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 2006;11:96-110. 56. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006;24:2815-2821. 57. Arora NK, Gustafson DH, Hawkins RP, et al. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study. Cancer 2001;92:1288-1298. 58. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054-1064. 59. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013;20:162-168. 60. Bradford A. Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause 2013;20:128-129. 61.",
    "Menopause 2013;20:162-168. 60. Bradford A. Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause 2013;20:128-129. 61. Kaunitz AM. Sexual dysfunction with aromatase inhibitor therapy: an underestimated problem? NEJM Journal Watch: Women’s Health 2013; 5-6. 62. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialsta9 Group. Quality of life of postmenopausal women in the ATAC (‘‘Arimidex,’’ tamoxifen alone or in combination) trial after completion of 5 years’ adjuvant treatment for early stage breast cancer. Breast Cancer Res Treat 2006;100:273-284. 63. Whelan TJ, Pritchard KI. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 2006;12:1056s-1060s. 64. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.J Clin Oncol 2005;23:6931-6940. 65. Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy.Maturitas 2010;67:233- 238. 66. Kirchheiner K, Fidarova E, Nout RA, et al. Radiation-induced morpho- logical changes in the vagina. Strahlenther Onkol 2012;188:1010-1017. 67. Fisher BK. Normal anatomy of the vulva. In: Fisher BK, Margesson LJ, editors. Genital Skin Disorders: Diagnosis and Treatment . St Louis, MO: Mosby; 1998. pp. 99-107. 68.",
    "67. Fisher BK. Normal anatomy of the vulva. In: Fisher BK, Margesson LJ, editors. Genital Skin Disorders: Diagnosis and Treatment . St Louis, MO: Mosby; 1998. pp. 99-107. 68. Sobel JD, Reichman O, Misra D, Yoo W. Prognosis and treatment of desquamative inflammatory vaginitis.Obstet Gynecol2011;117:850-855. 69. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet 2012;285:397-403. 70. Mercier J, Morin M, Zaki D, et al. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: a single-arm feasibility study. Maturitas 2019;125:57-62. 71. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117:922-927. 72. Mitchell CM0, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial.JAMA Intern Med 2018;178:681- 690. 73. Jozkowski KN, Herbenick D, Schick V, Reece M, Sanders SA, For- tenberry JD. Women’s perceptions about lubricant use and vaginal wetness during sexual activities. J Sex Med 2013;10:484-492. 74.",
    "73. Jozkowski KN, Herbenick D, Schick V, Reece M, Sanders SA, For- tenberry JD. Women’s perceptions about lubricant use and vaginal wetness during sexual activities. J Sex Med 2013;10:484-492. 74. Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas M, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2018;229:45-56. 75. Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.Breast Cancer Res Treat 2016; 158:79-90. 76. Dezzutti CS, Brown ER, Moncla B, et al. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activ- ity. PLos One 2012;7:e48328. NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 989 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. 77. Wilkinson EM, Łaniewski P, Herbst-Kralovetz MM, Brotman RM. Personal and clinical vaginal lubricants: impact on local vaginal micro- environment and implications for epithelial cell host response and barrier function. J Infect Dis 2019;220:2009-2018. 78. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and mois- turizer composition?",
    "J Infect Dis 2019;220:2009-2018. 78. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and mois- turizer composition? Climacteric 2016;19:151-161. 79. Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezareh M. Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States.Obstet Gynecol 2013;121:773-780. 80. Chen J, Geng L, Song X, Li H, Giordan Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel- group, clinical trial. J Sex Med 2013;10:1575-1584. 81. Grimaldi EP, Restaino S, Inglese S, et al. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort. Minerv Ginecol 2012;64:321-329. 82. Ekin M, Yasar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.Arch Gynecol Obstet 2011;283: 539-543. 83. LeDonne M, Caruso C, Mancuso A, et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet 2011;283:1319- 1323. 84.",
    "The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet 2011;283:1319- 1323. 84. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Erlich K. Vaginal, endometrial, and reproductive hormone findings: randomized placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15:51-58. 85. Santen RJ, Pinkerton JV, Liu JH, et al. Workshop on normal reference ranges for estradiol in postmenopausla women, September 2019, Chi- cago, Illinois. Menopause 2020;27:614-624. 86. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728-753. 87. Mitchell CM, Srinivasan S, Plantinga A, et al. Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem. Menopause 2018;25:500-507. 88. Lindau ST, Dude A, Gavrilova N, Hoffmann JN, Schumm LP, McClintock MK. Prevalence and correlates of vaginal estrogenization in postmeno- pausal women in the United States. Menopause 2017;24:536-545. 89. Estrace [package insert]. Madison, NJ: Allergan; 2018. 90. Premarin [package insert]. Philadelphia, PA: Pfizer; 2015. 91. Estragyn [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma; 2016. 92. Imvexxy [package insert].",
    "90. Premarin [package insert]. Philadelphia, PA: Pfizer; 2015. 91. Estragyn [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma; 2016. 92. Imvexxy [package insert]. Boca Raton, FL: TherapeuticsMD; 2019. 93. Vagifem [package insert]. Plainsboro, NJ: Novo Nordisk; 2019. 94. Yuvafem [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals; 2016. 95. Intrarosa [package insert]. W altham, MA: Amag Pharmaceuticals; 2018. 96. Estring [product insert]. New York: Pfizer; 2015. 97. Osphena [package insert]. Florham Park, NJ: Shionogi; 2019. 98. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-263. 99. Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351-358. 100. Nachtigall L. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995;22:S43-S47. 101. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chit- tacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 2001;27:255-260. 102. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS.",
    "J Obstet Gynaecol Res 2001;27:255-260. 102. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta- estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-161. 103. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;7:73-80. 104. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:171-176. 105. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessa- ries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171:624-632. 106. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 2000;107:1029-1034. 107. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92. 108.",
    "BJOG 2000;107:1029-1034. 107. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92. 108. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 1992;44:137-144. 109. Dugal R, Hesla K, Sørdal T, Aase KH, Lilleeidet O, Wickstrøm E. Comparison of usefulness of estradiol vaginal tablets and estriol vagi- tories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-297. 110. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107. 111. Garcia LE. Efficiency of vaginal ovules of estriol for treatment of symptoms of menopause.Investigacion Medica Internacional1993;19: 159-165. 112. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016;CD001500. 113. Rahn DD, Carberry C, Sanses TV, et al; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review.Obstet Gynecol 2014;124: 1147-1156. 114. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD001405. 115.",
    "114. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD001405. 115. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T; HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001;97:116-120. 116. Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR Jr. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011;18:962-966. 117. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary inconti- nence in women: a review. JAMA 2017;318:1592-1604. 118. Suskind AM, Saigal CS, Hanley JM, Lai J, Setodji CM, Clemens JQ; Urologic Diseases of America Project. Incidence and management of uncomplicated recurrent urinary tract infections in a national sample of women in the United States. Urology 2016;90:50-55. 119. Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial.Female Pelvic Med Reconstr Surg 2019; [published online ahead of print June 19, 2019]. 120. Raz R, Stamm WE. A controlled trial of intravaginal estriol in post- menopausal women with recurrent urinary tract infections.N Engl J Med 1993;329:753-757. 121. Eriksen B.",
    "120. Raz R, Stamm WE. A controlled trial of intravaginal estriol in post- menopausal women with recurrent urinary tract infections.N Engl J Med 1993;329:753-757. 121. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infection in postmenopausal women. Am J Obstet Gynecol 1999;180:1072-1079. 122. Dessie SG, Armstrong K, Modest AM, Hacker MR, Hota LS. Effect of vaginal estrogen on pessary use. Int Urogynecol J 2016;27:1423-1429. 123. Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006;91:3791-3797. 124. SchmidtG,AnderssonSB,NordleO,JohanssonCJ,G unnarsson PO. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: phar- macokinetic evaluation.Gynecol Obstet Invest1994;38:253-260. 125. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. Am J Obstet Gynecol 2002;186:944-947. 126. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002; 9:179-187. NAMS POSITION STATEMENT 990 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. 127.",
    "27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. 127. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002; 99:556-562. 128. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric 2010;13:219-227. 129. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007;16:1713-1719. 130. Luisi M, Franchi F, Kicovic PM. A group-comparative study of effects of Ovestin cream versus premarin cream in post-menopausal women with vaginal atrophy. Maturitas 1980;2:311-319. 131. Martin PL, Yen SS, Burnier AM, Hermann H. Systemic absorption and sustained effects of vaginal estrogen creams. JAMA 1979;242:2699- 2700. 132. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84: 215-218. 133. Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis 2011;15:263-267. 134. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol 2001;41:326-328. 135.",
    "J Low Genit Tract Dis 2011;15:263-267. 134. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol 2001;41:326-328. 135. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Meno- pause 2018;25:11-20. 136. Constantine GD, Graham S, Lapane K, et al. Endometrial safety of low- dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause 2019;26:800-807. 137. Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause 2020;27:339-360. 138. Bhupathiraju N, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 2018;26:603-610. 139. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replace- ment therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364: k4810. Erratum in: BMJ 2019;364:l162. 140. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individ- ual participant meta-analysis of the worldwide epidemiological evi- dence. Lancet 2019;394:1159-1168. 141. Femring [package insert]. Rockaway, NJ: Warner Chilcott; 2009. 142.",
    "Lancet 2019;394:1159-1168. 141. Femring [package insert]. Rockaway, NJ: Warner Chilcott; 2009. 142. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-1060. 143. Pickar JH, Amadio JM, Bernick BA, Mirkin S. Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule. Climacteric 2016;19:181-187. 144. Simon JA, Archer DF, Constantine GD, et al. A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: efficacy and pharmacokinetic data review. Maturitas 2017;99:51-58. 145. Constantine GD, Simon JA, Pickar JH, et al. Estradiol vaginal inserts (4 mg and 10 mg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Curr Med Res Opin 2018;34:2131-2136. 146. Labrie F, Archer DF, Koltun W, et al; VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243-256. 147. Portman DJ, Labrie F, Archer DF, et al; other participants of VVA Prasterone Group. Lack of effect of intravaginal dehydroepiandroster- one (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause 2015;22:1289-1295. 148.",
    "Lack of effect of intravaginal dehydroepiandroster- one (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause 2015;22:1289-1295. 148. Pinkerton JV, Thomas S. Use of SERMs for treatment in postmeno- pausal women. J Steroid Biochem Mol Biol 2014;142:142-154. 149. Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atro- phy. Menopause 2013;20:623-630. 150. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effec- tively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-486. 151. Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, mul- ticenter trial. Menopause 2019;26:611-621. 152. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418-427. 153. Schiavi MC, Di Pinto A, Sciuga V, et al. Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene. Gynecol Endocrinol 2018;34:140-143. 154. Wurz GT, Soe LH, Degregorio MW.",
    "Gynecol Endocrinol 2018;34:140-143. 154. Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 2013;74:220-225. 155. Eigeliene N, Kangas L, Hellmer C, Kauko T, Erkkola R, Ha ¨rko¨nen P. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause 2016;23:719-730. 156. Cai B, Simon J, Villa P, et al. Lower incidence and recurrence of breast cancer in ospemifene treated patients with vulvovaginal atrophy (VVA). Maturitas. In press. 157. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876-883. 158. Johnston SL, Farrell SA, Bouchard C, et al; SOGC Joint Committee- Clinical Practice Gynaecology and Urogynaecology. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004;26: 503-515. 159. American CollegeofObstetricians and Gynecologists Women’s Health Care Physicians. Genitourinary tract changes.Obstet Gynecol2004;104:56S-61S. 160. Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus.Cochrane Database Syst Rev 2011;7:CD008240. 161. Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med 2013;1:30-33. 162. Witherby S, Johnson J, Demers L, et al.",
    "161. Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med 2013;1:30-33. 162. Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424-431. 163. Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2017;3:313-319. 164. Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): Interna- tional Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause 2018;25:837-847. 165. US Food and Drug Administration. FDA warns against use of energy- based devices to perform vaginal ‘‘rejuvenation’’ or vaginal cosmetic procedures: FDA Safety Communication. July 30, 2018. 166. Ong MW, Bashir SJ. Fractional laser resurfacing for acne scars: a review. Br J Dermatol 2012;166:1160-1169. 167. Tierney EP, Hanke CW. Fractionated carbon dioxide laser treatment of photoaging: prospective study in 45 patients and review of the literature. Dermatol Surg 2011;37:1279-1290. 168. Tierney EP, Hanke CW. Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol 2009;8:723-731.",
    "Dermatol Surg 2011;37:1279-1290. 168. Tierney EP, Hanke CW. Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol 2009;8:723-731. 169. Peterson JD, Goldman MP. Rejuvenation of the aging chest: a review and our experience. Dermatol Surg 2011;37:555-571. 170. Athanasiou S, Pitsouni E, Grigoriadis T, et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results. Menopause 2019;26:248-255. 171. Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO 2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers Med Sci 2018;33:1047-1054. 172. Biglia N, Bounous VE, Sgro LG, D’Alonzo M, Pecchio S, Nappi RE. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer 2015;15:413-420. 173. Filippini M, Luvero D, Salvatore S, et al. Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study. Menopause 2020;27:43-49. NAMS POSITION STATEMENT Menopause, Vol. 27, No. 9, 2020 991 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. 174. Pagano T, De Rosa P, Vallone R, et al.",
    "27, No. 9, 2020 991 Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. 174. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause 2018;25:657-662. 175. Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Matur- itas 2015;80:296-301. 176. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survi- vors. Arch Gynecol Obstet 2016;294:841-846. 177. Sokol ER, Karram MM. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause 2017;24:810-814. 178. Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after frac- tional carbon dioxide laser treatment. Lasers Med Sci 2015;30:429-436. 179. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 2018;25:21-28. 180. Paraiso MFR, Ferrando CA, Sokol ER, et al.",
    "Menopause 2018;25:21-28. 180. Paraiso MFR, Ferrando CA, Sokol ER, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET Trial. Meno- pause 2020;27:50-56. 181. Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause 2019; 26:833-840. 182. Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of geni- tourinary syndrome of menopause. Lasers Surg Med 2017;49:160-168. 183. Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause 2019;26:423-427. 184. The American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and US Food and Drug Adminis- tration Clearance: position statement. May 2016. Reaffirmed July 2018. 185. Alshiek J, Garcia B, Minasssian V, et al. Vaginal energy-based devices [published online ahead of print April 22, 2020]. Female Pelvic Med Reconstr Surg. 186. Shobeiri SA, Kerkhof M, Minassian VA, Bazi T; IUGA Research and Development Committe.",
    "Female Pelvic Med Reconstr Surg. 186. Shobeiri SA, Kerkhof M, Minassian VA, Bazi T; IUGA Research and Development Committe. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity.I n tU o g y n e c o lJ2019;30:371-376. 187. Preti M, Vieira-Baptista P, Digesu GA, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. Neurourol Urodyn 2019;38:1009-1023. 188. Moreno AC, Sikka SK, Thacker HL. Genitourinary syndrome of menopause in breast cancer survivor s: treatments are available. Cleve Clin J Med 2018;85:760-766Erratum in: Cleve Clin J Med 2018; 85:860. 189. Phua C, Baber R. The management of menopausal symptoms in women following breast cancer: an overview. Drugs Aging 2018;35: 699-705. 190. Streicher L, Simon JA. Sexual function post-breast cancer.Cancer Treat Res 2018;173:167-189. 191. Goetsch M, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled clinical trial. J Clin Oncol 2015;33:3394-3400. 192. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause 2020;27:361-370. 193. Pavlovic´ RT, Jankovic´ SM, Milovanovic´ JR, et al.",
    "192. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause 2020;27:361-370. 193. Pavlovic´ RT, Jankovic´ SM, Milovanovic´ JR, et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. Clin Breast Cancer 2019;19:e731-e740. 194. Martel C, Labrie F, Archer DF, et al; other participating members of the Prasterone Clinical Research Group. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks.J Steroid Biochem Mol Biol 2016;159:142-153. 195. Quick AM, Zvinovski F, Hudson C, et al. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Support Care Cancer 2020;28:3669-3677. 196. Areˆas F, Valadares ALR, Conde DM, Costa-Paiva L. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitouri- nary syndrome of menopause: a prospective study. Menopause 2019;26:1052-1058. 197. Flint R, Cardozo L, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S. Rationale and design for fractional microablative CO 2 laser versus photothermal non-ablative erbium:YAG laser for the management of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial.",
    "Climacteric 2019;22:307-311. q The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society has been designated a CME activity for all NAMS members. NAMS members should log-in to the NAMS website www.menopause.org and then select Online CME in the Member Center. CME credit will be available from September 1, 2020, to September 1, 2021. NAMS POSITION STATEMENT 992 Menopause, Vol. 27, No. 9, 2020 /C2232020 The North American Menopause Society Copyright @ 2020 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.",
    "NAMS POSITION STA TEMENT The 2022 hormone therapy position statement of The North American Menopause Society Abstract “The 2022 Hormone Therapy Position Statement of The North American Menopause Society ” (NAMS) updates “The 2017 Hormone Therapy Position Statement of The North American Menopause Society” and identifies future re- search needs. An Advisory Panel of clinicians and researchers expert in the field of women’s health and menopause was recruited by NAMS to review the 2017 Position Statement, evaluate new literature, assess the evidence, and reach con- sensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Advisory Panel’s recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syn- drome of menopause and has been shown to prevent bone loss and fracture. The risks of hormone therapy differ depend- ing on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treat- ment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing therapy .",
    "Treat- ment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing therapy . For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindica- tions, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss. For women who initiate hormone therapy more than 10 years from menopause onset or who are aged older than 60 years, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS, with shared decision-making and periodic reevaluation. For bothersome genitourinary syndrome of menopause symptoms not relieved with over-the-counter therapies in women without indications for use of systemic hormone ther- apy, low-dose vaginal estrogen therapy or other therapies (eg, vaginal dehydroepiandrosterone or oral ospemifene) are recommended. Key W ords: Breast cancer – Cardiovascular disease – Cognition – Genitourinary syndrome of menopause – Hormone therapy – Menopause – Vasomotor symptoms. T his Position Statement uses gender-specific language as reflected in the referenced publications.",
    "T his Position Statement uses gender-specific language as reflected in the referenced publications. However, The North American Menopause Society recognizes that some persons experiencing menopause may identify differently than with the gender and pronouns used in the statement. This NAMS Position Statement has been endorsed by the American Association of Clinical Endocrinologists; the American Association of Nurse Practitioners; the American Medical Women’s Association; the American Society for Reproductive Medicine; the Asociacion Argentina para el Estudio del Climacterio; the Asociacion Mexicana para el Estudio del Climaterio; the Australasian Menopause Society; the Canadian Menopause Society; the Chilean Climacteric Society; the Chinese Meno- pause Society; the Colombian Association of Menopause; the Czech Menopause and Andropause Society; the Dutch Meno- pause Society; the European Menopause and Andropause Soci- ety; the German Menopause Society; HealthyW omen; the Indian Menopause Society; the International Osteoporosis Foundation; the International Society for the Study of Women’s Sexual Health; the Japan Society of Menopause and Women’s Health; the Korean Society of Menopause; the Mexican College of Specialists in Gyne- cology and Obstetrics; the National Association of Nurse Received May 2, 2022; revised and accepted May 2, 2022.",
    "This position statement was developed by The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement Advisory Panel consisting of representatives of the NAMS Board of Trustees and other experts in women’s health: Stephanie S. Faubion, MD, MBA, F ACP , NCMP ,Lead; Carolyn J. Crandall, MD, MS, MACP , NCMP , F ASBMR; Lori Davis, DNP , FNP-C, NCMP; Samar R. El Khoudary, PhD, MPH, F AHA; Howard N. Hodis, MD; Roger A. Lobo, MD; Pauline M. Maki, PhD; JoAnn E. Manson, MD, DrPH, MACP , NCMP; JoAnn V . Pinkerton, MD, F ACOG, NCMP; Nanette F . Santoro, MD; Jan L. Shifren, MD, NCMP; Chrisandra L. Shufelt, MD, MS, F ACP , NCMP; Rebecca C. Thurston, PhD, F ABMR, F APS; W endy W olfman, MD, FRCSC, F ACOG. The NAMS Board of Trustees conducted an independent review and revision and approved the position statement. This Position Statement was made possible by donations to the NAMS Education & Research Fund. There was no commercial support. Address correspondence to The North American Menopause Society; 30050 Chagrin Blvd, Suite 120 W; Pepper Pike, OH 44124. E-mail: [EMAIL] W ebsite: www .menopause.org Menopause, V ol. 29, No. 7, 2022 767 Menopause: The Journal of The North American Menopause Society V ol. 29, No. 7, pp.",
    "E-mail: [EMAIL] W ebsite: www .menopause.org Menopause, V ol. 29, No. 7, 2022 767 Menopause: The Journal of The North American Menopause Society V ol. 29, No. 7, pp. 767-794 DOI: 10.1097/GME.0000000000002028 © 2022 by The North American Menopause Society Practitioners in Women’s Health; the Philippine Society of Climac- teric Medicine; the Society of Obstetricians and Gynaecologists of Canada; the Spanish Menopause Society; the Taiwanese Meno- pause Society; and the Thai Menopause Society. METHODS An Advisory Panel of clinicians and research experts in the field of women’s health and menopause were enlisted to review “The 2017 Hormone Therapy Position Statement of The North American Menopause Society ,” evaluate the literature published subsequently , and conduct an evidence-based analysis, with the goal of reaching consensus recommendations. NAMS acknowledges that no single trial ’s findings can be extrapolated to all women. The Women’s Health Initiative (WHI) is the largest, randomized, controlled trial (RCT) of hormone ther- apy in women aged 50 to 79 years, and its findings were therefore given prominent consideration.",
    "However, it is important to note that the WHI employed just one route of administration (oral), one formulation of estrogen (conjugated equine estrogens [CEE] 0.625 mg), and only one progestogen (medroxyprogesterone ace- tate [MP A] 2.5 mg), with limited enrollment of women with both- ersome vasomotor symptoms (VMS; hot flashes, night sweats) who were aged younger than 60 years or who were fewer than 10 years from menopause onset—the group of women for whom hormone therapy is currently primarily indicated. In addition, the WHI trials did not include women with early or premature meno- pause. In achieving consensus, the panel took into consideration the level of evidence (RCTs>longitudinal studies>cross-sectional studies), sample sizes, risk of bias, data from meta-analyses and systematic reviews, and expert opinion from guidelines from other major medical societies, when appropriate. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” was written after this ex- tensive review of the pertinent literature and includes key points identified during the review process. The resulting manuscript was submitted to and reviewed and approved by the NAMS Board of Trustees. When recommendations are provided, they are graded ac- cording to these categories:  Level I: Based on good and consistent scientific evidence. Level II: Based on limited or inconsistent scientific evidence. Level III: Based primarily on consensus and expert opinion.",
    "Level II: Based on limited or inconsistent scientific evidence. Level III: Based primarily on consensus and expert opinion. EXPLAINING HORMONE THERAPY RISK Healthcare professionals caring for menopausal women should understand the basic concepts of relative risk and absolute risk to communicate the potential benefits and risks of hormone therapy and other therapies. Relative risk (risk ratio) is the ratio of event rates in two groups, whereas absolute risk (risk differ- ence) is the absolute difference in the event rates between two groups. 1 Absolute risks are more useful to convey risks and ben- efits in the clinical setting. Findings on hormone therapy from RCTs are generally con- sidered to provide stronger evidence, and those from observa- tional studies should be interpreted with greater caution, given the potential for confounding. V ery small effect sizes may have more limited clinical or public health importance, especially if outcomes are rare (Table 1). 2 Key points  Findings from RCTs of hormone therapy can be interpreted with greater confidence than observational studies. (Level I)  Smaller effect sizes may be less clinically relevant, particu- larly for rare outcomes. (Level I) FORMULA TION, DOSING, ROUTES OF ADMINISTRA TION, AND SAFETY Formulation Estrogens A vailable estrogen preparations include CEE, synthetic con- jugated estrogens (CE), micronized 17 β-estradiol, and ethinyl estradiol.",
    "Conjugated equine estrogens, used in the WHI trials, contain a mixture of CE purified from the urine of pregnant mares, including estrone sulfate. In postmenopausal women, es- trone sulfate is a naturally occurring estrogen that serves as a precursor and intermediate for the formation of estrone (a weak estrogen) and estradiol (a more potent estrogen and the predom- inant estrogen in premenopausal and perimenopausal women). Synthetic CE is a blend of synthetic estrogen substances includ- ing estrone sulfate, equilin sulfate, and estradiol sulfate. Pre- scription formulations of micronized 17β-estradiol are identical to the structure of estradiol that is produced by the ovaries. Es- tradiol is reversibly converted to estrone. Ethinyl estradiol is a synthetic estrogen primarily used in combination with a proges- tin in hormone contraceptives. Progestogens administered with estrogen Progestogens (general category that includes synthetic progestins and progesterone) commonly coadministered with estrogen in women with a uterus include MP A, norethindrone acetate (NETA), and micronized progesterone (MP). Medroxyprogesterone ace- tate, levonorgestrel, and NETA are synthetic progestins, whereas MP is structurally identical to the progesterone produced by the corpus luteum. Progestogen indication: need for endometrial protection Chronic unopposed endometrial exposure to estrogen in- creases the risk for endometrial hyperplasia or cancer.",
    "Progestogen indication: need for endometrial protection Chronic unopposed endometrial exposure to estrogen in- creases the risk for endometrial hyperplasia or cancer. 3,4 The menopause-related indication for progestogen use is to prevent endometrial overgrowth and the increased risk of endometrial cancer during estrogen therapy (ET) use. W omen with an intact uterus using systemic ET should receive adequate progestogen, unless they are taking CEE combined with bazedoxifene (BZA). 5-7 TA BLE 1. Frequency of adverse drug reactions V ery common ≥1/10 Common (frequent) ≥1/100 and < 1/10 Uncommon (infrequent) ≥1/1,000 and < 1/100 Rare ≥1/10,000 and < 1/1,000 (≤10/10,000/y) V ery rare <1/10,000 Council for International Organizations of Medical Sciences (CIOMS).2 NAMS POSITION STATEMENT 768 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society Progestogen dose and duration of use are important to ensur- ing endometrial protection. When adequate progestogen is com- bined with systemic estrogen, the risk of endometrial neoplasia is not higher than in untreated women.",
    "When adequate progestogen is com- bined with systemic estrogen, the risk of endometrial neoplasia is not higher than in untreated women. In the WHI, use of con- tinuous oral CEE plus MP A daily was associated with a risk of endometrial cancer similar to placebo (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.48-1.36), 8 with significant re- duction of risk after a median 13 years ’ cumulative follow-up (HR, 0.67; 95% CI, 0.49-0.91).9 As y s t e m a t i cr e v i e ws u g g e s t e d an increased risk of endometrial hyperplasia with MP containing estrogen plus progestogen therapy (EPT). 4 A meta-analysis sug- gested increased risk of endometrial cancer (relative risk [RR], 1.2) with noncontinuous combined EPT (type of progestogen not specified) but not with continuous EPT . 10 Oral MP should be adequately dosed for prevention of endometrial hyperplasia (eg, 200 mg/d for 12-14 d/mo).11,12 Off-label use of a levonorgestrel- containing intrauterine device to prevent endometrial hyperpla- sia may avoid adverse systemic effects of progestogens and can protect against unwanted pregnancy in women initiating hor- mone therapy for symptom management before their final men- strual period. There are limited clinical trial data to support this use. 13 In women using EPT , unscheduled bleeding occurring more than 6 months after initiation should be investigated.",
    "There are limited clinical trial data to support this use. 13 In women using EPT , unscheduled bleeding occurring more than 6 months after initiation should be investigated. Tissue-selective estrogen complex Bazedoxifene, a selective estrogen-receptor modulator (SERM; estrogen agonist or antagonist), has been combined with CEE to form a tissue-selective estrogen complex (TSEC). Studies of up to 2 years in duration suggest that the combination of BZA plus CEE provides endometrial protection without the need for a progestogen. 7,14-16 In women using BZA plus CEE, unsched- uled bleeding occurring more than 6 months after initiation should be investigated. Dosing Estrogen therapy The therapeutic goal should be to use the most appropriate, often lowest, effective dose of systemic ET consistent with treat- ment goals. The appropriate dose of progestogen is added to provide endometrial protection if a woman has a uterus, unless CEE is combined with BZA. Progestogen therapy Progestogen dosing-regimen options that provide for endo- metrial safety are dependent on the potency of the progestogen and vary with the estrogen dose. Different types and doses of progestogens, routes of administration, and types of regimen (sequential or continuous-combined) may have different associ- ations with health outcomes, and patient preference can and should be considered because many women will opt for regi- mens that avoid periodic menstrual bleeding.",
    "17 Routes of administration For treating VMS, systemic estrogens can be prescribed as oral drugs; transdermal patches, sprays, and gels; or as vaginal rings. Meta-analysis of estrogen preparations found no evidence of a significant difference between transdermal EPT and oral EPT for alleviating VMS. 18 Transdermal estradiol and oral CEE are similarly effective in alleviating VMS19; however, clinical trials directly comparing risk of myocardial infarction (MI), stroke, breast cancer, and venous thromboembolism (VTE) associated with various estrogen routes and doses are lacking. Progestogens are available as oral drugs or combination patches with estrogen. Nonoral routes of administration (eg, transdermal, vaginal) may offer potential advantages because nonoral routes bypass the first-pass hepatic effect; however, it is unknown whether nonoral routes of ET or EPT are associated with lower risk (vs oral routes) of VTE, breast cancer, and cardiovascular (CV) events because clinical trials have not been designed to examine those outcomes. Safety During the active treatment phase of the WHI, a higher inci- dence of breast cancer (risk is considered rare; Table 1) was seen in women assigned to CEE plus MP A compared with placebo but a reduced incidence in women assigned to CEE alone com- pared with placebo.",
    "20 After a median of 20 years’ follow-up (in- cluding intervention and postintervention follow-up), the lower incidence of breast cancer in women assigned to CEE alone ver- sus placebo and the higher incidence of breast cancer in women assigned to CEE plus MP A persisted. 21 In contrast to findings of the WHI, observational data have shown that breast cancer risk was increased in women using either systemic ET or EPT and was duration-dependent. 22 Meta-analysis of studies in which most participants (70%) were aged older than 60 years and had some degree of comorbidity shows that EPT is associated with small increases in the risk of a coronary event (after 1 y), VTE (after 1 y), stroke (after 3 y), breast cancer (after 5 y), and gallbladder disease (after 5 y); ET (included oral, transdermal, subcutaneous, and intranasal prepa- rations without disaggregation of data by route of administration) increases the risk of VTE (after 1-2 y), stroke (after 7 y), and gall- bladder disease (after 7 y). One trial examined outcomes in women aged 50 to 59 years who were relatively healthy and found that the only significantly increased risk was of VTE in women on EPT. 23 Although comparative RCT data are lacking, there may be less VTE risk associated with lower doses of oral ET than with higher doses.",
    "23 Although comparative RCT data are lacking, there may be less VTE risk associated with lower doses of oral ET than with higher doses. 24,25 Observational studies have not demonstrated an increased risk of VTE with trans- dermal ET, and limited observational data suggest less risk with transdermal versus oral ET, but comparative RCT data again are lacking. 26-28 The choice of progestogen may also af- fect risk for VTE, with MP potentially being less thrombogenic than other progestins. 26,28 The WHI provided information on the rare risks of CEE com- bined with MP A. It is unknown whether oral MP-containing EPT similarly increases the risk of breast cancer, stroke, gallbladder disease, MI, or VTE because clinical trials have not yet been de- signed to examine these outcomes. Clinical trials are needed to establish the effect of different types of progestogens and different estrogen doses and administration routes on VTE risk. 29 Overall, ET and EPT are each associated with rare increased risk of gall- bladder disease, stroke, VTE, and urinary incontinence; EPT also is associated with increased risk of breast cancer. 22,30 Studies NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 769 were not designed to determine whether the combination of BZA plus CEE further increases the risk of VTE beyond the in- creased risk conferred by CEE alone.",
    "29, No. 7, 2022 769 were not designed to determine whether the combination of BZA plus CEE further increases the risk of VTE beyond the in- creased risk conferred by CEE alone. In women in the WHI aged 50 to 59 years, CEE plus MP A (average, 5.6 y of use) or CEE alone (average, 7.2 y of use in women with previous hysterectomy) did not increase cancer mortality or CV mortality after a median of 18 years’ follow-up compared with placebo. In women aged 50 to 59 years at ran- domization, all-cause mortality was significantly reduced in the pooled trials versus placebo (HR, 0.69; 95% CI, 0.51-0.94). With age groups combined, breast cancer mortality was reduced in women using CEE alone (HR 0.55; 95% CI, 0.33-0.92), and Alzheimer disease or dementia mortality was reduced in women using CEE alone (HR, 0.74; 95% CI, 0.59-0.94) and in the pooled trials (HR, 0.85; 95% CI, 0.74-0.98) after a median of 18 years’ follow-up. 31 After a median of 20 years ’ follow-up (including intervention and postintervention follow-up), the lower breast cancer mortality in women assigned to CEE alone versus placebo persisted, whereas breast cancer mortality was not significantly different in women assigned to CEE plus MP A versus placebo.",
    "21 Contraindications for oral and transdermal hormone therapy include unexplained vaginal bleeding; liver disease; prior estrogen- sensitive cancer (including breast cancer); prior coronary heart dis- ease (CHD), stroke, MI, or VTE; or personal history or inherited high risk of thromboembolic disease. Potential risks of hormone therapy for women aged younger than 60 years include the rare risk of breast cancer with EPT; en- dometrial hyperplasia and endometrial cancer with inadequately opposed estrogen; VTE; and gallbladder disease (Figure 1). 9 More common adverse events (AEs) include nausea, bloating, weight gain, fluid retention, mood swings (progestogen related), breakthrough bleeding, headaches, and breast tenderness. Key points  The appropriate, often lowest, effective dose of systemic ET consistent with treatment goals that provides benefits and minimizes risks for the individual woman should be the ther- apeutic goal. (Level III)  The various formulations, doses, and routes of prescription hormone therapy preparations have comparable high efficacy for relieving VMS. (Level I)  Formulation, dose, and route of administration for hormone therapy should be determined individually and reassessed pe- riodically. (Level III)  Different hormone therapy doses, formulations, and routes of administration may have different effects on target organs, potentially allowing options to minimize risk.",
    "(Level III)  Different hormone therapy doses, formulations, and routes of administration may have different effects on target organs, potentially allowing options to minimize risk. (Level II)  The appropriate formulation, dose, and route of administra- tion of progestogen is needed to counter the proliferative ef- fects of systemic estrogen on the endometrium. (Level I)  Overall, the increased absolute risks associated with EPT and ET are rare (<10/10,000/y) and include increased risk for VTE and gallbladder disease. In addition, EPT carries a rare increased risk for stroke and breast cancer, and if estrogen is inadequately opposed, an increased risk of endometrial hy- perplasia and endometrial cancer. (Level I)  The absolute risks are reduced for all-cause mortality, fracture, diabetes mellitus (EPT and ET), and breast cancer (ET) in women aged younger than 60 years (Figure 1). 9 (Level I) FDA-APPROVED INDICA TIONS Va s o m o t o r s y m p t o m s Hormone therapy has been shown in double-blind RCTs to relieve VMS32 and is FDA approved as first-line therapy for re- lief of moderate to severe VMS because of menopause. FIG. 1. Benefits and risks of the two hormone therapy formulations, conjugated equine estrogens (CEE) alone or in combination with medroxyprogesterone acetate (MP A), evaluated in the W omen’s Health Initiative for women aged 50 to 59 years.",
    "Risks and benefits are expressed as the difference in number of events (number in the hormone therapy group minus the number in the placebo group) per 10,000 women per year, with <10 per 10,000 per year representing a rare event (dashed red line). Adapted from Manson JE, et al. 9 NAMS POSITION STATEMENT 770 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society Prevention of bone loss Hormone therapy has been shown in double-blind RCTs to prevent bone loss, and in the WHI, to reduce fractures in post- menopausal women without osteoporosis. 33,34 The FDA indica- tion includes prevention, but not treatment, of postmenopausal osteoporosis. Nonestrogen medications are preferred for treat- ment of existing osteoporosis. Premature hypoestrogenism Hormone therapy is FDA approved for women with hypoestrogenism resulting from hypogonadism, bilateral oopho- rectomy (BO), or primary ovarian insufficiency (POI). Health benefits have been shown, with greater evidence for women with BO, for menopause symptoms and for prevention of bone loss and in observational studies, heart disease and cognitive decline or dementia.",
    "35-44 Genitourinary symptoms Hormone therapy has been shown in RCTs to effectively treat symptoms of vulvovaginal atrophy (VV A).45,46 Hormone ther- apy is FDA approved to treat moderate to severe symptoms of VV A and dyspareunia because of menopause but with the pref- erence for low-dose vaginal therapy if solely prescribed for vul- var or vaginal symptoms. T wo vaginal therapies, vaginal ET and vaginal dehydroepian- drosterone (DHEA), have been FDA approved for treatment of moderate to severe dyspareunia, a symptom of VV A resulting from menopause. One oral therapy (a SERM) has FDA approval as well. Key point  Hormone therapy is FDA approved for four indications: mod- erate to severe VMS; prevention of osteoporosis in postmen- opausal women; treatment of hypoestrogenism caused by hypogonadism, BO, or POI; and treatment of moderate to se- vere vulvovaginal symptoms. FDA guidance for treatment of genitourinary symptoms related to menopause in the absence of indications for systemic ET suggests the use of low-dose topical vaginal ET . (Level I) COMPOUNDED BIOIDENTICAL HORMONES The termbioidentical hormone therapy(similar to endogenous) can be misleading because there are both government-approved and compounded bioidentical hormone therapies. Government- approved (in the United States, FDA-approved) bioidentical hormones include estradiol, estrone, and MP , which are regu- lated and monitored for purity and efficacy.",
    "Government- approved (in the United States, FDA-approved) bioidentical hormones include estradiol, estrone, and MP , which are regu- lated and monitored for purity and efficacy. These are dispensed with package inserts containing extensive product information (based on RCTs) and may include black-box warnings for AEs. In contrast, compounded bioidentical hormone therapies are pre- pared by a compounding pharmacist using a provider’sp r e s c r i p - tion. These therapies may combine multiple hormones (estradiol, estrone, estriol, DHEA, testosterone, progesterone) and use un- tested, unapproved combinations or formulations or are admin- istered in nonstandard or untested routes such as subdermal im- plants, pellets, or troches. 47-50 Compounded bioidentical hormone therapy has been prescribed or dosed on the basis of serum, salivary, or urine hormone test- ing; however, the use of such testing to guide hormone therapy dosing is considered unreliable because of differences in hor- mone pharmacokinetics and absorption, diurnal variation, and interindividual and intraindividual variability . 51-54 There is a dearth of safety and efficacy data with little or no high-quality pharmacokinetic data to provide evidence of safety and efficacy of compounded bioidentical hormone therapy and insufficient evidence to support overall clinical use of compounded bioidentical hormone therapy for treatment of menopause symp- toms.",
    "Compounded bioidentical hormone therapy presents safety concerns, such as minimal government regulation and monitor- ing, overdosing and underdosing,presence of impurities and lack of sterility, lack of scientific efficacy and safety data, and lack of a label outlining risks. 55 Patient preference for compounded bioidentical hormone therapy should be discussed.56 Prescribers should only consider compounded hormone therapy if women cannot tolerate a government-approved therapy for reasons such as allergies to ingredients in a government-approved hormone therapy formu- lation or for a dose or formulation not currently available in government-approved therapies. Patient preference alone should not be used to justify use of compounded bioidentical hormone therapy. Prescribers of compounded bioidentical hormone ther- apy should document the medical indication for a compounded bioidentical hormone over government-approved therapies. 55 In addition to including financial disclosures of prescribers, pharmacists, and pharmacies, compounding pharmacists should provide standardized content information, include warnings for potential AEs, note that the preparation is not government ap- proved, and provide guidance on reporting AEs.",
    "Key points  Compounded bioidentical hormone therapy presents safety concerns, such as minimal government regulation and moni- toring, overdosing and underdosing, presence of impurities and lack of sterility , lack of scientific efficacy and safety data, and lack of a label outlining risks. (Level I)  Salivary and urine hormone testing to determine dosing are unreliable and not recommended. Serum hormone testing is rarely needed. (Level II/III)  Shared decision-making is important, but patient preference alone should not be used to justify the use of compounded bioidentical hormone preparations, particularly when government- regulated bioidentical hormone preparations are available. (Level III)  Situations in which compounded bioidentical hormones could be considered include allergies to ingredients in a government- approved formulation or dosages not available in government- approved products. (Level III) MENOP AUSE SYMPTOMS V asomotor symptoms V asomotor symptoms are associated with diminished sleep quality , irritability , difficulty concentrating, reduced quality of NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 771 life,57 and poorer health status.",
    "29, No. 7, 2022 771 life,57 and poorer health status. 58 Frequent VMS persisted on average 7.4 years in the Study of W omen ’s Health Across the Nation59 and appear to be linked to CV , bone, and cognitive risks.60-65 Compared with placebo, ET alone or EPT was found to reduce weekly symptom frequency by 75% (95% CI, 64.3-82.3) and significantly reduce symptom severity (odds ratio [OR], 0.13; 95% CI, 0.07-0.23), 34 with no other pharmacologic or alterna- tive therapy found to provide more relief. Considering the dose, there are no appreciable differences in the efficacy of oral versus nonoral formulations, but EPT appears slightly more effective than ET alone. Lower doses of hormone therapy (oral CEE 0.3 mg; oral 17β- estradiol ≤0.5 mg; or estradiol patch 0.025 mg) may take 6 to 8 weeks to provide adequate symptom relief. Although the low- est dose-approved estradiol weekly patch (0.014 mg/d) appears effective in treating VMS, 66 it is FDA approved only for preven- tion of osteoporosis. Progestogen-only formulations have been found to be effective in treating VMS, 67,68 including MP A 10 mg,69 oral megestrol acetate 20 mg,70 and MP 300 mg. 68 No long-term studies have addressed the safety of progestogen-only treatment of meno- pause symptoms. V asomotor symptoms return in approximately 50% of women when hormone therapy is discontinued. 71,72 There is no consensus about whether stopping abruptly or gradually tapering the dose is preferable.",
    "71,72 There is no consensus about whether stopping abruptly or gradually tapering the dose is preferable. Sleep disturbances Sleep disturbances are common after menopause and begin in perimenopause. Sleep disruptions are strongly associated with VMS and a decreased quality of life. Poorer sleep quality has been associated with mood fluctuations, memory problems, metabolic syndrome, obesity, and other CV risk factors. Short (or very long) sleep duration, poor sleep quality, and insomnia have been asso- ciated with greater cardiovascular disease (CVD) risk. 73-76 Hormone therapy in the form of low-dose estrogen or proges- togen may improve chronic insomnia in menopausal women, with 14 of 23 studies reviewed showing positive results. 77 There is some evidence that transdermal ET may benefit sleep in peri- menopausal women, independent of VMS. 78 Oral MP has mildly sedating effects, reducing wakefulness without affecting daytime cognitive functions, possibly through a GABA-agonistic effect, 79 and should therefore be adminis- tered at night. A systematic review and meta-analysis concluded that MP improved sleep-onset latency but not sleep duration or sleep efficiency in RCTs in postmenopausal women.",
    "A systematic review and meta-analysis concluded that MP improved sleep-onset latency but not sleep duration or sleep efficiency in RCTs in postmenopausal women. 80 Genitourinary symptoms The genitourinary syndrome of menopause (GSM) includes the signs and symptoms associated with menopause-related es- trogen deficiency involving changes to the labia, vagina, urethra, and bladder and includes VV A.81 Symptoms may include genital dryness, burning, and irritation;sexual symptoms of diminished lubrication and pain with sexual activity; and urinary symptoms of urgency, dysuria, and recurrent urinary tract infections (UTI). Estrogen therapy, specifically vaginal ET , is an effective treatment for GSM, with no evidence to suggest a difference in safety or ef- ficacy between the various vaginal ET preparations. 45,82,83 Low-dose vaginal ET preparations include creams, tablets, rings, and a softgel vaginal insert. The different preparations all contain estradiol, and one cream preparation contains CEE. One ring is available for long-term (3 mo) delivery of low-dose estradiol to the vagina, but another is aimed at providing systemic levels of estradiol. The low-dose vaginal estradiol products avail- able result in minimal systemic absorption. 84-86 It is preferred to insert vaginal products (except for the vaginal ring) in the prox- imal, lower third of the vagina rather than in the upper third. This improves efficacy for genitourinary symptoms and attenu- ates estradiol absorption.",
    "This improves efficacy for genitourinary symptoms and attenu- ates estradiol absorption. 86 Because of the potential risk of small increases in circulating estrogens,87 the decision to use low-dose vaginal ET in women with breast cancer should be made in conjunction with their on- cologists.88,89 This is particularly important for women on aroma- tase inhibitors (AIs) with suppressed plasma levels of estradiol,90 although no increased risk was seen in an observational trial of survivors of breast cancer on tamoxifen or aromatase therapy with low-dose vaginal ET during 3.5 years’ mean follow-up. 91 A progestogen is generally not indicated when ET is adminis- tered vaginally for GSM at the recommended low doses, although clinical trial data supporting endometrial safety beyond 1 year are lacking.85 V aginal bleeding in a postmenopausal woman requires thorough evaluation. Long-termfollow up of women in the WHI observational study and in the Nurses ’ Health Study who used vaginal ET indicated no increased risk of adverse CV or cancer outcomes.",
    "Long-termfollow up of women in the WHI observational study and in the Nurses ’ Health Study who used vaginal ET indicated no increased risk of adverse CV or cancer outcomes. 92,93 Nonestrogen therapies that improve genitourinary symptoms and are approved for relief of dyspareunia in postmenopausal women include ospemifene94 and intravaginal DHEA.95 Urinary tract symptoms (including pelvic floor disorders) V aginal ET increases the number of vessels around the periurethral and bladder neck region 96 and has been shown to reduce the frequency and amplitude of detrusor contractions to promote detrusor musc le relaxation. 97,98 Estrogen therapy, along with pelvic floor training, pessaries, or surgery, may improve synthe- sis of collagen and improve vaginal epithelium, but evidence for effectiveness for pelvic organ prolapse is lacking. 99 T wo large trials found that users of systemic hormone therapy (CEE 0.625 mg plus MP A 2.5 mg) had an increased incidence of stress incontinence. 100,101 Increased incontinence was found in women using oral ET alone (relative risk [RR], 1.32; 95% CI, 1.17-1.48) and in those using EPT (RR, 1.11; 95% CI, 1.04- 1.18). 102 V aginal estrogen use showed a decreased incidence of incontinence (RR, 0.74; 95% CI, 0.64-0.86) and overactive bladder, with one to two fewer voids in 24 hours and reduced frequency and urgency. A reduced risk of recurrent UTIs with vaginal but not oral estrogen has been shown in RCTs.",
    "A reduced risk of recurrent UTIs with vaginal but not oral estrogen has been shown in RCTs. 103,104 Sexual function Systemic hormone therapy and low-dose vaginal ET provide effective treatment of GSM, improving sexual problems by in- creasing lubrication, blood flow, and sensation in vaginal tis- sues. 105 Studies have not found a significant effect of ET on NAMS POSITION STATEMENT 772 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society sexual interest, arousal, and orgasmic response independent from its role in treating menopause symptoms.106-108 If systemic hormone therapy is indicated in women with low libido, transdermal ET formulations may be preferred to oral, given increased sex hormone-binding globulin and reduced bio- availability of testosterone with oral ET . 105,109,110 Conjugated equine estrogens combined with BZA relieves dyspareunia and improves some aspects of sexual function in postmenopausal women.111-114 Key points V asomotor symptoms  V asomotor symptoms may begin during perimenopause, and frequent VMS may persist on average 7.4 years or longer. They affect quality of life and may be associated with CV , bone, and brain health. (Level I/II)  Hormone therapy remains the gold standard for relief of VMS. – Estrogen-alone therapy can be used for symptomatic women without a uterus. (Level I) – For symptomatic women with a uterus, EPT or a TSEC protects against endometrial neoplasia.",
    "– Estrogen-alone therapy can be used for symptomatic women without a uterus. (Level I) – For symptomatic women with a uterus, EPT or a TSEC protects against endometrial neoplasia. (Level I)  Shared decision-making should be used when considering formulation, route of administration, and dose of hormone therapy for menopause symptom management, with adjust- ment tailored to symptom relief, AEs, and patient prefer- ences. (Level III)  Periodic assessment of the need for ongoing use of hormone therapy should be individualized on the basis of a woman ’s menopause symptoms, general health and underlying medi- cal conditions, risks, treatment goals, and personal prefer- ences. (Level III)  Micronized progesterone 300 mg nightly significantly de- creases VMS (hot flashes and night sweats) compared with placebo and improves sleep. Synthetic progestins have also shown benefit for VMS in some studies. No long-term study results are available, and use of progestogens without estro- gen for either indication is off-label. (Level II) Sleep disturbances  During the menopause transition, women with VMS are more likely to report disrupted sleep. (Level I)  Hormone therapy improves sleep in women with bothersome nighttime VMS by reducing nighttime awakenings. Estrogen may have some effect on sleep, independent of VMS.",
    "(Level I)  Hormone therapy improves sleep in women with bothersome nighttime VMS by reducing nighttime awakenings. Estrogen may have some effect on sleep, independent of VMS. (Level II) Genitourinary symptoms  Low-dose vaginal ET preparations are effective and generally safe for the treatment of GSM, with minimal systemic absorp- tion, and are preferred over systemic therapies when ET is used only for genitourinary symptoms. (Level I)  For women with breast cancer, low-dose vaginal ET should be prescribed in consultation withtheir oncologists. (Level III)  Progestogen therapy is not required with low-dose vaginal es- trogen, but RCT data are lacking beyond 1 year. (Level II)  Nonestrogen prescription FDA-approved therapies that im- prove VV A in postmenopausal women include ospemifene and intravaginal DHEA. (Level I)  V aginal bleeding in a postmenopausal woman requires thor- ough evaluation. (Level I) Urinary tract symptoms (including pelvic floor disorders)  Systemic hormone therapy does not improve urinary inconti- nence and may increase the incidence of stress urinary incon- tinence. (Level I)  Low-dose vaginal ET may provide benefit for urinary symp- toms, including prevention of recurrent UTIs, overactive blad- der, and urge incontinence. (Level II)  Hormone therapy does not have FDA approval for any uri- nary health indication.",
    "(Level II)  Hormone therapy does not have FDA approval for any uri- nary health indication. (Level I) Sexual function  Both systemic hormone therapy and low-dose vaginal ET in- crease lubrication, blood flow, and sensation of vaginal tis- sues. (Level I)  Systemic hormone therapy generally does not improve sex- ual function, sexual interest, arousal, or orgasmic response independent of its effect on GSM. (Level I)  If sexual function or libido are concerns in women with men- opause symptoms, transdermal ET may be preferable over oral ET because of minimal effect on sex hormone-binding globulin and free testosterone levels. (Level II)  L o w - d o s ev a g i n a lE Ti m p r o v e ss e x u a lf u n c t i o ni np o s t m e n o - pausal women with GSM. (Level I)  Nonestrogen alternatives FDA approved for dyspareunia in- clude ospemifene and intravaginal DHEA. (Level I) PRIMARY OV ARIAN INSUFFICIENCY W omen with loss of ovarian function at a young age experi- ence an extended period without ovarian hormones compared with women experiencing menopause at the typical age. Prema- ture menopause is defined as menopause before age 40 years, and early menopause is defined as menopause that occurs be- tween the ages of 40 and 45 years. Whereas menopause implies the permanent cessation of menses, POI describes the loss of ovarian function before age 40 years but with the potential for intermittent, transient return of hormone production and men- strual cycles.",
    "W omen with early or premature loss of ovarian function at any age are at increased risk for AEs related to ovar- ian hormone deficiency . Causes of early or premature loss of ovarian function may be genetic, autoimmune, toxic, metabolic, and iatrogenic, including chemotherapy, radiation, and surgery. Health risks of POI and premature menopause are well docu- mented. 40,41 The strongest evidence from meta-analyses and systematic reviews links early loss of ovarian function to de- creased quality of life and increased risk of fracture, CVD, heart failure, diabetes mellitus (DM), and overall mortality. 115-121 Other significant issues may include persistent VMS, loss of fertility , bone loss, genitourinary symptoms, sexual dysfunction, cogni- tive and mood changes, and increased risk of dementia, ophthal- mic conditions, and depression. 40,41,122-124 Although these risks are generally because of estrogen deficiency, some of these risks may be reflective of premature aging, as evidenced in some studies by shortened telomere length. 125 NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 773 In addition to an increased risk of incident CVD, POI and pre- mature menopause are associated with an increased risk of aortic stenosis, VTE, ischemic stroke, coronary artery disease, atrial fibrillation, and hypertension. 123,126 Early menopause is also as- sociated with a decreased risk of breast cancer.",
    "123,126 Early menopause is also as- sociated with a decreased risk of breast cancer. 127 The surgical removal of both ovaries leads to a much more abrupt loss of the ovarian steroids estrogen and progesterone than does natural menopause and includes a significant decrease in testosterone that does not occur with natural menopause. 128 V asomotor symptoms as well as a variety of estrogen deficiency- related symptoms and diseases are more frequent and more se- vere after oophorectomy and can have a major effect on quality of life. 129,130 In meta-analyses, oophorectomy is associated with an increased risk of CVD,131 cognitive dysfunction and dementia,132 metabolic syndrome,133 low bone mineral density (BMD), 134 and sleep disturbance,135 with some evidence for elevated frac- ture risk.136 Bilateral oophorectomy before age 40 is associated with elevated rates of incident CVD as well as mitral regurgita- tion, VTE, heart failure, coronary artery disease, and hyperten- sion. 123 Other risks may include depression, anxiety, sexual dys- function, bone loss, parkinsonism, DM, ophthalmologic conditions, and stroke, some of which have been shown in observational studies to be reduced by ET . 35 Effective management of POI and premature or early meno- pause may include appropriate doses of hormone therapy, cal- cium with vitamin D, exercise, and screening to detect medical issues, as well as fertility counseling and mental health ser- vices.",
    "40 Hormone therapy is recommended at least until the av- erage age of menopause, approximately 52 years. 35,40,41 Oral contraceptives may be an alternative form of hormone therapy with contraceptive benefits, because spontaneous pregnancy may occur in about 5% of women with POI. 137 Higher doses of hormone therapy may provide better bone protection than oral contraceptives, but this is uncertain. 36,37,138 Unless contraindications are present, ET is indicated for women who have had BO before the average age of menopause to treat VMS, improve BMD, and reduce the risk for osteoporo- sis. 139 Y ounger women may require higher doses to relieve symptoms and protect against bone loss. 41,140 Observational data reveal potential benefits of ET in reducing risk of cognitive impairment or dementia and CV mortality in women with early oophorectomy. 35,141 Estrogen therapy may improve aspects of sexual function and GSM, particularly in women with VMS who have had BO. 107 V aginal estrogens are effective in treating symptoms of GSM. 45,46,142 Ovarian conservation is recom- mended, if possible, when hysterectomy for benign indications is performed in premenopausal women at average risk for ovar- ian cancer.",
    "45,46,142 Ovarian conservation is recom- mended, if possible, when hysterectomy for benign indications is performed in premenopausal women at average risk for ovar- ian cancer. 143 Key points  W omen with POI and premature or early menopause may be at increased risk for fracture, CVD, heart failure, DM, overall mortality , persistent VMS, loss of fertility , bone loss, genito- urinary symptoms, sexual dysfunction, cognitive and mood changes, increased risk of dementia, open-angle glaucoma, depression, and poor quality of life. (Level II)  In the absence of contraindications, hormone therapy is rec- ommended at least until the average age of menopause (ap- proximately age 52 y), with an option for use of oral contra- ceptives in healthy younger women. (Level II)  Results of the WHI trials in older women do not apply to women with POI or premature or early menopause. (Level II)  In women with BO before the average age of menopause, early initiation of ET, with endometrial protection if the uterus is preserved, reduces VMS, genitourinary symptoms, risk for osteoporosis and related fractures, and likely CVD and overall mortality, with benefit seen in observational studies for CV mortality and cognitive impairment or dementia. (Level II)  Fertility preservation and counseling should be explored for young women at risk for POI.",
    "(Level II)  Fertility preservation and counseling should be explored for young women at risk for POI. (Level III)  Ovarian conservation is recommended when hysterectomy is performed for benign indications in premenopausal women at average risk for ovarian cancer. (Level II) SKIN, HAIR, AND SPECIAL SENSES Estrogen therapy may benefit wound healing through modi- fying inflammation, stimulating granulation tissue formation, and accelerating re-epithelialization. Estrogen therapy increased epidermal and dermal thickness, increased collagen and elastin content, and improved skin moisture, with fewer wrinkles. 144 Although menopause is associated with a decrease in hair den- sity and female pattern hair loss, research on the role of hormone therapy in mitigating these changes is lacking. 145 In the WHI, ET reduced intraocular pressure in postmeno- pausal women and mitigated the risk for open-angle glaucoma in Black women.146,147 Similar effects were not seen for EPT.148 Further, hormone therapy decreased the risk of neovascular and soft drusen age-related macular degeneration but not early or late-stage macular degeneration. 149 Evidence on the effect of hor- mone therapy on cataract, dry eye disease, and optic nerve disorders is mixed, and good-quality RCTs are lacking. 150-152Observational data linking hormone therapy to hearing loss is mixed.",
    "150-152Observational data linking hormone therapy to hearing loss is mixed. 153,154 Little is known about olfactory changes and hormone ther- apy.155 In small trials, hormone therapy appears to decrease diz- ziness or vertigo and improve postural balance.156,157 Key points  Estrogen therapy appears to have beneficial effects on skin thickness and elasticity and collagen when given at meno- pause. (Level II)  Changes in hair density and female pattern hair loss worsen after menopause, but research is lacking regarding a role for hormone therapy in mitigating these changes. (Level II)  Hormone therapy appears to decrease the risk of neovascular and soft drusen age-related macular degeneration but not early or late-stage macular degeneration. (Level II)  Estrogen therapy appears to reduce intraocular pressure and mitigate the risk for open-angle glaucoma in Black women. (Level II)  Evidence of hormone therapy effects on cataracts, optic nerve disease, dry-eye disease, and hearing loss is mixed. (Level II) NAMS POSITION STATEMENT 774 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society  Little is known about hormone therapy effects on olfactory changes. (Level II)  In small trials, hormone therapy appears to decrease dizzi- ness or vertigo and improve postural balance. (Level II) HORMONE THERAPY AND QU ALITY OF LIFE Quality of life is defined as an overall assessment of one’sl i f e in relation to one’s goals and expectations.",
    "(Level II) HORMONE THERAPY AND QU ALITY OF LIFE Quality of life is defined as an overall assessment of one’sl i f e in relation to one’s goals and expectations. Quality of life can be applied to one ’s mental and physical health, which is termed health-related quality of life, or specifically to menopause, or menopause-specific quality of life, which emphasizes the bother and interference of menopause symptoms. Clinical trials indi- cate that in women with menopause symptoms, such as VMS, systemic hormone therapy (ET , EPT , TSECs) can improve menopause-specific quality of life. 158-160 These effects appear to be explained largely by the effect of hormone therapy on the frequency of these symptoms. Key points  Menopause symptoms are associated with poorer health-related and menopause-specific quality of life. (Level II)  Systemic hormone therapy can improve menopause-specific quality of life in women experiencing menopause symptoms. (Level II) OSTEOPOROSIS Menopause is associated with increased bone resorption, and ET decreases bone resorption. 161 For osteoporosis treatment, hormone therapy has not been demonstrated in RCTs to reduce fractures in postmenopausal women with established osteoporo- sis; therefore, hormone therapy does not carry an FDA indica- tion for treatment of osteoporosis. 162,163 In women who have osteoporosis, hormone therapy has not been demonstrated in RCTs to decrease fracture risk.",
    "162,163 In women who have osteoporosis, hormone therapy has not been demonstrated in RCTs to decrease fracture risk. In the WHI, for women aged 50 to 79 years (N = 16,608), enrolled without regard to bone density or fracture risk, EPT (0.625 mg CEE plus 2.5 mg MP A) significantly increased lumbar spine and total hip BMD by 4.5% and 3.7%, respectively , relative to placebo and reduced fracture risk. 34 The BMD benefits of pre- venting bone loss persist as long as therapy is continued but abate rapidly when treatment is discontinued. Within a few months, markers of bone turnover returned to pretreatment values, whereas BMD fell to pretreatment levels within 1 to 2 years of stopping therapy. 164 W omen with POI experience long-term AEs on bone density, in addition to other health risks. 35,140 Higher-than-standard doses of hormone therapy may be needed to provide protection against bone-density loss in younger women, particularly those aged younger than 40 years and thus lower future osteoporotic fracture risk. 140,165 In the setting of prevention, RCTs show that hormone therapy decreases fracture risk.162,163 V arious oral and transdermal es- trogen preparations, alone or in combination with progestogens or BZA, have government approval for prevention of osteoporosis. A meta-analysis and a systematic review, based primarily on the WHI, demonstrated that 5 to 7 years of hormone therapy signifi- cantly reduced risk of spine, hip, and nonvertebral fractures.",
    "A meta-analysis and a systematic review, based primarily on the WHI, demonstrated that 5 to 7 years of hormone therapy signifi- cantly reduced risk of spine, hip, and nonvertebral fractures. 166,167 During the WHI intervention phase in women of all ages, the CEE plus MP A group had six fewer hip fractures per 10,000 women and six fewer vertebral fractures per 10,000 women compared with the placebo group. 9 The CEE-alone group had six fewer hip fractures per 10,000 women and six fewer vertebral fractures per 10,000 women compared with the placebo group. However, in the subset of women aged 50 to 59 years at the time of treatment initiation, neither CEE plus MP A nor CEE alone was associated with decreased risk of hip fracture. The reason that hormone therapy was not shown to reduce hip fracture in the subset of women aged 50 to 59 years in the WHI may be partly because of the lower baseline absolute risk of frac- ture in women aged between 50 and 59 years who did not have established osteoporosis. 9,168 In the WHI hormone therapy trials, after hormone therapy discontinuation, there was a return of fracture risk to levels seen in women who had received placebo, with no excess fracture risk observed after discontinuation of hormone therapy . 169,170 There are no prospective fracture studies directly comparing the efficacy of hormone therapy in preventing fractures with other approved pharmacologic therapies.",
    "169,170 There are no prospective fracture studies directly comparing the efficacy of hormone therapy in preventing fractures with other approved pharmacologic therapies. Key points  Hormone therapy prevents bone loss in healthy postmenopausal women, with dose-related effects on bone density. (Level I)  Hormone therapy reduces fracture risk in healthy postmeno- pausal women. (Level I)  Discontinuing hormone therapy results in rapid bone loss; however, no excess in fractures was seen in the WHI after dis- continuation. (Level I)  Hormone therapy is FDA approved for prevention of bone loss, but not for treatment of osteoporosis. (Level I)  In the absence of contraindications, in women aged younger than 60 years or within 10 years of menopause onset, sys- temic hormone therapy is an appropriate therapy to protect against bone loss. (Level I)  Unless contraindicated, women with premature menopause without prior fragility fracture or osteoporosis are best served with hormone therapy or oral contraceptives to prevent bone density loss and reduce fracture risk, rather than other bone-specific treatments, until the average age of menopause, when treatment may be reassessed. (Level II)  Decisions regarding initiation and discontinuation of hormone therapy should be made primarily on the basis of extraskeletal benefits (ie, reduction of VMS) and risks.",
    "(Level II)  Decisions regarding initiation and discontinuation of hormone therapy should be made primarily on the basis of extraskeletal benefits (ie, reduction of VMS) and risks. (Level III) JOINT P AIN Direct binding of estrogen to estrogen receptors acts on joint tissues, protecting their biomechanical structure and function and maintaining overall joint health, but the exact effect of estro- gen on osteoarthritis remains controversial. 171-173 There is no clearly observed association between hormone therapy use and osteoarthritis. 171 Meta-analyses of clinical trials of ET have reported inconsistent results. Thus, there is insufficient evidence to form strong con- clusions regarding the effects of estrogen on osteoarthritis. 173 NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 775 In the WHI, women on CEE plus MP A had less joint pain or stiffness compared with those on placebo (47.1% vs 38.4%; OR, 1.43; 95% CI, 1.24-1.64) and more joint discomfort after stopping. 174 In the CEE-alone arm, women randomized to CEE had a statistically significant reduction in joint pain frequency af- ter 1 year compared with the placebo group (76.3% vs 79.2%; P = .001). 175 In the WHI, using arthroplasty as a clinical indicator of se- verely symptomatic osteoarthritis, the association of CEE alone with any arthroplasty was borderline significant (HR, 0.84; 95% CI, 0.70-1.00; P = .05), but CEE alone did not significantly re- duce the risk of hip or knee arthroplasty .",
    "The EPT trial showed no relationship between hormone use and arthroplasty risk. 176 Key points  W omen in the WHI and other studies have less joint pain or stiff- ness with hormone therapy compared with placebo. (Level I)  There is a need for further understanding of estrogen’sp o t e n - tial effect on joint health. (Level III) SARCOPENIA Frailty is associated with AEs such as falls, hospitalization, disability , and death.177 Skeletal muscle has been shown to have estrogen receptors,178 but there is a paucity of studies evaluating the interplay between estrogen and muscle. The regulation of energy intake and expenditure by estrogens in women has not been well studied, with limited basic and preclinical evidence supporting the concept that the loss of estrogen with menopause or oophorectomy disrupts energy balance through decreases in resting energy expenditure and physical activity . 179 Reviews of preclinical studies and limited clinical studies of hormone therapy in postmenopausal women suggest a benefit on maintaining or increasing muscle mass and related connective tissue and improving strength and posttraumatic or postatrophy muscle recovery when combined with exercise.",
    "180-182 In the WHI hormone therapy trials, women assigned to ET or EPT (vs placebo) had early preservation of lean body mass after 3 years, but hormone therapy did not ameliorate long-term loss in lean body mass associated with aging.183 Similarly, low-dose oral estradiol 0.25 mg per day plus cyclical MP did not signifi- cantly change skeletal muscle mass or lean body mass. 184 Systematic reviews find that hormone therapy had neither a beneficial nor harmful association with muscle mass 185,186; therefore, it is likely that interventions other than hormone ther- apy will have to be developed to aid in the retention of muscle in aging women. Key points  Development of frailty with aging is a health risk. (Level I)  Sarcopenia and osteoporosis are related to aging, estrogen depletion, and the menopause transition. (Level II)  Intervention to improve bioenergetics and prevent loss of mus- cle mass, strength, and performance is needed. (Level III)  Preclinical studies suggest a possible benefit of ET when combined with exercise to prevent the loss of muscle mass, strength, and performance, but this has not been shown in clinical trials. (Level II) GALLBLADDER AND LIVER Estrogens increase biliary cholesterol secretion and satura- tion, promote precipitation of cholesterol in the bile, and reduce gallbladder motility, with increased bile crystallization.",
    "187,188 Postmenopause use of estrogen is associated with an increased risk of cholelithiasis, cholec ystitis, and cholecystectomy. 23 However, no associated risk of biliary cancer has been demon- strated.189 The transdermal route of administration, which bypasses first-pass metabolism of the liver, has been associated with less risk of gallbladder disease in observational studies. 190 The at- tributable risk for gallbladder disease as self-reported in the WHI was an additional 47 cases per 10,000 women per year for CEE plus MP A and 58 cases per 10,000 women per year for CEE, both statistically significant ( P <. 0 0 1 ) . 9 Nonalcoholic fatty liver disease is more common after the menopause transition when the prevalence surpasses men. 191 Older women also have higher rates of severe hepatic fibrosis and greater mortality compared with men. Animal models have demonstrated a causal relationship between the loss of estrogen and increase in fatty liver and steatohepatitis, whereas observa- tional studies show dietary factors also may exacerbate liver dis- ease. Preclinical and observational studies suggest possible ben- efits of hormone therapy on liver fibrosis and fatty liver, 192 but more research is needed before definitive recommendations can be made. Key points  Risk of gallstones, cholecystitis, and cholecystectomy is in- creased with ET and EPT .",
    "Key points  Risk of gallstones, cholecystitis, and cholecystectomy is in- creased with ET and EPT . (Level I)  Observational studies report lower risk of gallstones with transdermal hormone therapy than with oral, and with oral estradiol compared with CEE, but neither observation is con- firmed in RCTs. (Level II)  In women with hepatitis C and with fatty liver, a slower fibro- sis progression has been observed with use of hormone ther- apy, but RCTs are needed to establish the potential benefits and risks with liver disease. (Level II) DIABETES MELLITUS, METABOLIC SYNDROME, A N DB O D YC O M P O S I T I O N Metabolic syndrome and diabetes In the WHI, women receiving continuous-combined CEE plus MP A had a statistically significant 19% reduction (HR, 0.81; 95% CI, 0.70-0.94; P = .005) in the incidence of type 2 DM, translating to 16 fewer cases per 10,000 person-years of therapy. 9 In the CEE-alone cohort, there was a reduction of 14% in new di- agnoses of type 2 DM (HR, 0.86; 95% CI, 0.76-0.98), translat- ing to 21 fewer cases per 10,000 person-years. A meta-analysis of published studies found that EPT reduced multiple components of the metabolic syndrome; incidence of type 2 DM was de- creased by 30%. 193 A second, smaller meta-analysis confirmed these findings and reported that women with type 2 DM using ET or EPT had better glycemic control. 194 The benefit reverses when hormone therapy is discontinued.",
    "194 The benefit reverses when hormone therapy is discontinued. For these reasons, hor- mone therapy can be considered for symptomatic menopausal w o m e nw i t ht y p e2D M . NAMS POSITION STATEMENT 776 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society W eight and body composition The menopause transition is associated with an increase in body fat and a decrease in lean body mass, which results in an increase in the fat-to-lean ratio and decreased basal metabolic rate. After controlling for body size and ethnicity , the average weight gain during midlife and the menopause transition is 1.5 lb per year. 195,196 Central fat distribution (gynoid-to-android pattern) also occurs after menopause after adjustment for aging, total body fat, and physical activity level.196 By about 2 years af- ter the final menstrual period, weight changes flatten.197 Wo me n who used hormone therapy did not have observable differences in the trajectory of weight or body fat gain compared with those who did not take hormones, although numbers are relatively small. Estrogen-progestogen therapy either has no effect on weight or is associated with less weight gain in women who are using it than in women who are not.",
    "Estrogen-progestogen therapy either has no effect on weight or is associated with less weight gain in women who are using it than in women who are not. 198-202 In the WHI, women ran- domized to hormone therapy with CEE with or without MP A had no statistically significant difference in slowing of weight gain and a lesser increase in waist circumference over the first 3 years of use compared with those randomized to placebo. In- creasing physical activity was independently associated with less weight gain over time. 195 Key points  Hormone therapy significantly reduces the diagnosis of new-onset type 2 DM, but it is not government approved for this indication. (Level I)  Hormone therapy is not contraindicated in otherwise healthy women with preexisting type 2 DM and may be beneficial in terms of glycemic control when used for menopause symp- tom management. (Level II)  Although hormone therapy may help attenuate abdominal adipose accumulation and weight gain associated with the menopause transition, the effect is small. (Level II) COGNITION Small clinical trials support the use of ET for cognitive bene- fits when initiated immediately after hysterectomy with bilateral oophorectomy. 203,204 Three large RCTs demonstrated neutral effects of hormone therapy on cognitive function when used early in the postmenopause period.",
    "203,204 Three large RCTs demonstrated neutral effects of hormone therapy on cognitive function when used early in the postmenopause period. 205-207 T wo hypotheses—the critical window or timing hypothesis and the healthy-cell bias hypothesis—provide a framework for understanding the scientific literature on hormone therapy and cognition, but neither has been definitively supported in RCTs of postmenopausal women. The critical window or timing hy- pothesis 208,209 holds that estrogen can confer cognitive benefits if given early in the menopause transition but that later use is neutral or detrimental. The healthy-cell bias hypothesis 210 holds that estrogen confers cognitive benefits when the neural substrate is “healthy” but not diseased, for example in a woman with DM. Later initiation of hormone therapy Several large clinical trials indicate that hormone therapy does not improve memory or other cognitive abilities and that CEE plus MP A may be harmful for memory when initiated in women aged older than 65 years. 211-213 Alzheimer disease Four observational studies provide support for the opinion that the timing of hormone therapy initiation is a significant de- terminant of Alzheimer disease risk, with early initiation lower- ing risk and later initiation associated with increased risk. 214-217 However, long-term effects may differ from short-term effects.",
    "214-217 However, long-term effects may differ from short-term effects. Eighteen-year follow-up data from the WHI showed a reduction in Alzheimer disease mortality in women randomized to hor- mone therapy; this effect was significant for CEE alone but not for CEE plus MP A and was driven by women aged in their 70s at the time of enrollment. 31 T wo nested case-control studies investigated the risk of dementia associated with hormone ther- apy use and showed no increased risk overall but did suggest an increased risk of Alzheimer disease, specifically, with the use of EPT for more than 5 years. 218 All-cause dementia In the WHI Memory Study , CEE plus MP A doubled the risk of all-cause dementia (23 cases/10,000 women) when initiated in women aged older than 65 years, 213 whereas CEE alone did not significantly increase the risk of dementia. 219 The effect of hormone therapy may be modified by baseline cognitive func- tion, with more favorable effects in women with normal cogni- tive function before hormone therapy initiation. 220,221 Key points  In the absence of more definitive findings, hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function or dementia. (Level I)  Initiating hormone therapy in women aged older than 65 years increased the risk for dementia, with an additional 23 cases per 10,000 person-years seen in women randomized to CEE plus MP A in the WHI Memory Study.",
    "(Level I)  The effect of hormone therapy may be modified by baseline cognitive function, with more favorable effects in women with normal cognitive function before hormone therapy initi- ation. (Level II)  Estrogen therapy may have cognitive benefits when initiated immediately after hysterectomy with bilateral oophorectomy, but hormone therapy in the early natural postmenopause pe- riod has neutral effects on cognitive function. (Level II) DEPRESSION Depressive symptoms worsen as women transition through menopause, although evidence is mixed as to whether depres- sive disorders are more common during the menopause transi- tion relative to premenopause. Most women who present with depressive disorders during the menopause transition are women with a history of depression before the menopause transition, and women with a history of depression are at high risk for recurrence during the menopause transition. 222 For that reason, clinical guidelines recommend that clinicians screen for depression in women with a history of depression and use antidepressants or proven psychotherapies (eg, cognitive-behavior therapy, interpersonal therapy, mindfulness-based cognitive therapy) as the primary treatment for recurrent major depressive episodes. 223 Use of hormone therapy to treat menopause symptoms such as NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 777 V M Si nm i d l i f ew o m e nw i t hd e p r e s s i o ns h o u l db ec o n s i d e r e d .",
    "29, No. 7, 2022 777 V M Si nm i d l i f ew o m e nw i t hd e p r e s s i o ns h o u l db ec o n s i d e r e d . V asomotor symptoms increase the risk for elevated depressive symptoms, in part because of nocturnal VMS and sleep inter- ruption, 224 and on a day-to-day basis, VMS co-occur with neg- ative mood and predict negative mood the next day .225 Va s o mo - tor symptoms appear to be more strongly associated with the onset of depressive symptoms than depressive disorders. 226 Estrogen therapy shows some efficacy in the management of depression in midlife women, but its effect varies by menopause stage. For perimenopausal women with depression, there is evi- dence that ET improves depressive symptoms to a degree simi- lar to antidepressant medications. 227 This antidepressant effect of ET applies to perimenopau sal women with and without VMS. In women with major depression treated with ET , depres- sive symptoms improve in relation to improvements in sleep but not VMS. 228 Estrogen therapy does not appear to be effective in treating depressive disorders in postmenopausal women, sug- gesting a window of opportunity in the perimenopause. 229 Little is known about the effects of EPT in treating depressive disor- ders at any menopause stage. There is some evidence that ET enhances mood and improves well-being in nondepressed postmenopausal women.",
    "There is some evidence that ET enhances mood and improves well-being in nondepressed postmenopausal women. 205 Initial evidence suggests that hormone therapy (specifically transder- mal estradiol with intermittent MP) may prevent the onset of de- pressive symptoms in euthymic perimenopausal women.230 Estrogen therapy may augment clinical response to antidepres- sants in midlife and older women, preferably when also indicated for other concurrent menopause-related symptoms such as VMS. 231 Key points  There is some evidence that ET has antidepressant effects of similar magnitude to that observed with antidepressant agents when administered to depressed perimenopausal women with or without concomitant VMS. (Level II)  Estrogen therapy is ineffective as a treatment for depressive disorders in postmenopausal women. Such evidence suggests a possible window of opportunity for the effective use of ET for the management of depressive disorders during the peri- menopause. (Level II)  There is some evidence that ET enhances mood and improves well-being in nondepressed perimenopausal women. (Level II)  Transdermal estradiol with intermittent MP may prevent the onset of depressive symptoms in euthymic perimenopausal women, but the evidence is not sufficient to recommend estrogen-based therapies for preventing depression in asymp- tomatic perimenopausal or postmenopausal women, and the risks and benefits must be weighed.",
    "(Level II)  Estrogen-based therapies may augment clinical response to antidepressants in midlife and older women, preferably when also indicated for other menopause symptoms such as VMS. (Level III)  Most studies on hormone therapy for the treatment of depression examined the effects of unopposed estrogen. Data on EPT or for different progestogens are sparse and inconclusive. (Level II)  Estrogen is not government approved to treat mood distur- bance. (Level I) CARDIOV ASCULAR DISEASE AND ALL-CAUSE MORTALITY Observational data and reanalysis of older studies by age or time since menopause, including the WHI, suggest that for healthy women who are within 10 years of the menopause transition and who have bothersome menopause symptoms, the benefits of hor- mone therapy (ET or EPT) outweigh its risks, with fewer CVD events in younger versus older women. 9,31,219,232-242 Initiation of hormone therapy fewer than 10 years after menopause onset Surrogate markers of coronary heart disease Surrogate markers of CHD are intermediate measures that have been associated with the development of CVD and events such as coronary artery calcification (CAC) and subclinical ath- erosclerosis. Some studies have suggested that initiating hormone therapy in symptomatic women within 10 years of menopause may have benefit in reduction of atherosclerosis progression as measured by CAC, 243-245 whereas RCTs in younger, re- cently postmenopausal women have not.",
    "246,247 In the Early V ersus Late Intervention Trial With Estradiol, hormone therapy (oral 17β-estradiol 1 mg/d plus progesterone vaginal gel 45 mg administered sequentially for women with a uterus) reduced subclinical atherosclerosis progression measured by carotid ar- tery intima-media thickness after a median of 5 years when ini- tiated within 6 years (median, 3.5 y) of menopause onset but not when initiated 10 or more years (median, 14.3 y) afterward. 246 The Kronos Early Estrogen Prevention Study in healthy post- menopausal women aged 42 to 58 years who received hormone therapy (oral CEE 0.45 mg/d; transdermal estradiol patch 50μg/wk; each with sequential oral MP 200 mg for 12 d/mo) showed no effect on subclinical atherosclerosis progression. 247 Meta-analyses of clinical outcomes A2 0 1 5Cochrane review of RCT data found that hormone therapy initiated fewer than 10 years after menopause onset lowered CHD in postmenopausal women (RR, 0.52; 95% CI, 0.29-0.96). 236 It also found a reduction in all-cause mortality (RR, 0.70; 95%, 0.52-0.95) and no increased risk of stroke but an increased risk of VTE (RR, 1.74; 95% CI, 1.11-2.73). A 2020 systematic review and meta-analysis of RCTs pub- lished from 2000 to 2019 showed null effects of hormone therapy initiated fewer than 10 years after menopause or at an age youn- ger than 60 years on all-cause mortality, stroke, and VTE.",
    "248 A 2019 systematic review and meta-regression analysis of RCTs that examined the timing hypothesis of hormone therapy compared with controls or nonusers of hormone therapy found that younger hormone therapy initiation (participants aged <60 y) was associated with lower odds of CHD (OR, 0.61; 95% CI, 0.37-1.00), all-cause mortality (OR, 0.72; 95% CI, 0.57-0.91), and cardiac mortality (OR, 0.61; 95% CI, 0.37-1.00) but with higher odds of a composite measure of incidence stroke, transient ischemic attack, and systemic embolism (OR, 1.40; 95% CI, 1.10-1.78). 249 However, the results for CHD, cardiac mortality , and all-cause mortality were all attenuated after excluding open-label trials in which the knowledge of active treatment may affect treatment options and outcomes. Direct comparisons NAMS POSITION STATEMENT 778 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society across these meta-analyses may not be applicable, given differ- ences in inclusion/exclusion criteria and analytical methods that w e r ea p p l i e di ne a c ha n a l y s i s . Cardiovascular outcomes in the W omen’s Health Initiative Intervention phase For CEE alone, CHD, MI, and coronary artery bypass grafting or percutaneous coronary interventionshowed a lowered HR in women aged younger than 60 years and fewer than 10 years since menopause onset, including in intention-to-treat analyses.",
    "9 In the 50- to 59-year-old age group, the HR for CHD was elevated but not statistically significant at 1.34 (95% CI, 0.82-2.19) for CEE plus MP A. When data from the two WHI trials were combined and analyzed, a reduction in all-cause mortality was shown in younger but not in older women; HRs in women aged 50 to 59 years, 60 to 69 years, and 70 to 79 years were 0.69 (95% CI, 0.51-0.94), 1.04 (95% CI, 0.87-1.25), and 1.13 (95% CI, 0.94-1.36), respectively ( P for trend =. 0 1 ) .31 Cumulative follow-up For CEE alone, in the 13-year cumulative intervention and post- intervention follow-up, significant age-treatment interaction was shown for MI such that only in the 50- to 59-year-old age group a reduction in MI risk was significant (HR, 0.60; 95% CI, 0.39- 0.91). 9 Although a similar interaction was not significant for CHD and all-cause mortality, there was a significant reduction in CHD risk (HR, 0.65; 95% CI, 0.44-0.96) in this age group. In the 18-year intervention and postintervention cumulative follow- up, the reduction in all-cause mortality was shown to be statistically significant for the 50- to 59-year-old age group (HR, 0.79; 95% CI, 0.64-0.96), 31 although interaction between age and treatment was not significant.",
    "Additional analysis focusing on oophorectomy sta- tus in the CEE-alone trial revealed a significant age-treatment inter- action for all-cause mortality; younger women with BO assigned to CEE alone showed a significant reduction in all-cause mortality compared with placebo (HR, 0.68; 95% CI, 0.48-0.96). 242 Initiation of hormone therapy more than 10 years from menopause onset or in women aged older than 60 years For women who initiated hormone therapy more than 10 years from menopause onset or aged older than 60 years, a 2015 Cochrane meta-analysis found no evidence that hormone ther- apy had an effect on CHD (RR, 1.07; 95% CI, 0.96-1.20) or all-cause mortality (RR, 1.06; 95% CI, 0.95-1.18), with an aver- age follow-up of 3.8 years. 236 There was an increased risk of stroke (RR, 1.21; 95% CI, 1.06-1.38) and VTE (RR, 1.96; 95% CI, 1.37-2.80). A 2020 systematic review and meta-analysis of RCTs showed similar results as the 2015 Cochrane analysis for older women who initiated hormone therapy . 248 Compared with placebo or nonusers of hormone therapy, initiating hormone therapy in women aged 60 years or older or after 10 years since menopause had a null effect on CHD (summary estimate, 1.00; 95% CI, 0.87-1.14) and all-cause mort ality (summary estimate, 1.00; 9 5 %C I0 . 9 6 - 1 . 0 5 )b u tw a sa s s o c i a t e dw i t hh i g h e rr i s ko fs t r o k e (summary estimate, 1.17; 95% CI, 1.01-1.37) and VTE (sum- mary estimate, 1.79; 95% CI, 1.39-2.29).",
    "9 6 - 1 . 0 5 )b u tw a sa s s o c i a t e dw i t hh i g h e rr i s ko fs t r o k e (summary estimate, 1.17; 95% CI, 1.01-1.37) and VTE (sum- mary estimate, 1.79; 95% CI, 1.39-2.29). Similarly , in a 2019 systematic review and meta-regression analysis of RCTs testing the timing hypothesis, women who ini- tiated hormone therapy relative to placebo or nonusers of hor- mone therapy aged 60 years or older showed a null effect on CHD and all-cause mortality but was associated with higher risk of a composite measure of incidence stroke, transient ischemic attack, and systemic embolism (OR, 1.52; 95% CI, 1.39-1.71). 249 Attributable risk of stroke in women aged younger than 60 years or within 10 years of menopause onset The 2015 Cochrane meta-analysis found no increased risk of stroke in women who initiated hormone therapy aged younger than 60 years or fewer than 10 years from menopause onset. 236 In subgroup analysis, the attributable risk of stroke in the WHI for women who initiated hormone therapy aged younger than 60 years or within 10 years of menopause onset was rare (<10/10,000 person-years) and statistically nonsignificant for CEE plus MP A, with an absolute risk of 5 per 10,000 person- years, 9,240 similar to other studies.232 Findings were inconsistent for CEE-alone in the WHI.",
    "For women aged 50 to 59 years at randomization, a decrease of 1 per 10,000 person-years was seen for stroke; whereas for women fewer than 10 years from menopause onset, an increase in 13 strokes per 10,000 person-years was seen. 9 On the basis of only observational studies, lower doses of either oral250 or transdermal251 estrogen may confer less risk of stroke; no clear association with age has been found. No head-to-head data comparing oral to transdermal hormone therapy are available. V enous thromboembolism W omen who began hormone therapy fewer than 10 years af- ter menopause onset or who were aged younger than 60 years have higher risk of VTE compared with placebo (RR, 1.74; 95% CI, 1.11-2.73), according to the 2015 Cochrane meta- analysis. 236 In a 2020 systematic review and meta-analysis of RCTs published between 2000 and 2019, risk of VTE was ele- vated in women who initiated hormone therapy aged older than 60 years or after 10 years since menopause (summary estimate, 1.79; 95% CI, 1.39-2.29) and a null effect in women who initiated hormone therapy aged younger than 60 years or within 10 years of menopause (summary estimate, 0.69; 95% CI 0.25-1.93). 248 Lower doses of oral ET may confer less risk of VTE than higher doses, 24,25 but comparative RCT data are lacking.",
    "248 Lower doses of oral ET may confer less risk of VTE than higher doses, 24,25 but comparative RCT data are lacking. Micronized progesterone may be less thrombogenic than other progestins.26 Transdermal hormone therapy has not been associated with VTE risk in observational studies, limited observational data and a sys- tematic review suggest less risk with transdermal hormone therapy than oral 26,27,29; however, comparative RCT data are lacking. Areas of scientific uncertainty and need for randomized, controlled trial data Although observational studies, meta-analyses of RCTs, and smaller RCTs with surrogate CVD risk markers suggest that hormone therapy may reduce CVD risk when initiated in women aged younger than 60 years and/or who are within 10 years of menopause onset, significant research gaps remain regarding dose, formulation, route of delivery, and duration of use. Furthermore, NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 779 because most RCTs are performed on North American and European women, future studies should also evaluate the role of ethnicity with respect to hormone therapy and CVD. Data are insufficient for risk related to long-term hormone therapy use in perimenopausal women and in postmenopausal women aged younger than 50 years. 23,252 Hormone therapy is not govern- ment approved for prevention of CVD.",
    "23,252 Hormone therapy is not govern- ment approved for prevention of CVD. Key points  For healthy symptomatic women aged younger than 60 years or within 10 years of menopause onset, the favorable effects of hormone therapy on CHD and all-cause mortality should be considered against potential rare increases in risks of breast cancer, VTE, and stroke. (Level I)  Hormone therapy is not government approved for primary or secondary cardioprotection. (Level I)  Personal and familial risk of CVD, stroke, VTE, and breast cancer should be considered when initiating hormone therapy. (Level III)  The effects of hormone therapy on CHD may vary depending on when hormone therapy is initiated in relation to a woman’s age or time since menopause onset. (Level I)  Initiation of hormone therapy in recently postmenopausal women reduced or had no effect on subclinical atherosclero- sis progression and coronary artery calcification in random- ized, controlled trials. (Level I)  Observational data and meta-analyses show reduced risk of CHD in women who initiate hormone therapy when aged younger than 60 years or within 10 years of menopause on- set. Meta-analyses show a null effect of hormone therapy on CHD after excluding open-label trials. (Level II)  W omen who initiate hormone therapy aged older than 60 years or more than 10 or 20 years from menopause onset are at higher absolute risks of CHD, VTE, and stroke than women initiating hormone therapy in early menopause.",
    "(Level I) BREAST CANCER Breast cancer affects approximately one in eight US women, so an understanding of the potential effect of hormone therapy on breast cancer risk is of considerable importance. Potential differences of the effects of ET , EPT , and CEE plus BZA on breast tissue may exist. Different types of estrogen or progesto- gen, as well as different formulations, timing of initiation, dura- tion of therapy, and patient characteristics, may play a role in the effects of hormone therapy on the breast. Estrogen-progestogen therapy In the WHI, daily continuous-combined CEE plus MP A re- sulted in an increased risk of breast cancer, with nine additional breast cancer cases per 10,000 person-years of therapy. 9 The HR remained elevated at a median of 20 years’ cumulative follow-up in the unblended, postintervention phase (HR, 1.28; 95% CI, 1.13-1.45). 21 Estrogen-alone therapy Compared with women who received placebo, women who received CEE alone in the WHI showed a nonsignificant reduction in breast cancer risk after an average of 7.2 years of ran- domization, with seven fewer cases of invasive breast cancer per 10,000 person-years of CEE (HR, 0.79; 95% CI, 0.61-1.02). 9 As i g - nificant reduction in breast cancer became evident in the postinter- vention phase, with a median 20 years’ cumulative follow-up (HR, 0.78; 95% CI, 0.65-0.93). 21 Longer duration of hormone therapy use No large RCTs have assessed the effect of long duration of hormone therapy use.",
    "21 Longer duration of hormone therapy use No large RCTs have assessed the effect of long duration of hormone therapy use. Both the ET and the EPT components of the WHI reported data for finite intervals because both were terminated early because of predefined safety considerations, with a median of 7.2 years for ET and 5.6 for EPT . Notably, al- though long-term follow-up at 13 and 20 years provided infor- mation about use for 5 to 7 years, no data were available regard- ing longer-term use. The recent pooled analysis of observational data in the Collaborative Group Study included information on duration of hormone therapy use in women starting hormone therapy when aged 45 to 54 years. 22 In each age category, the risk of breast cancer increased with duration of use. Specifically, for ET, the HRs increased from 1.23 (95% CI, 1.11-1.35) for 1 to 4 years of use, to 1.29 (95% CI, 1.21-1.37) for 5 to 9 years, to 1.44 (95% CI, 1.35-1.53) for 10 to 14 years, and to 1.61 (95% CI, 1.49-1.74) for 15 or more years. For EPT , increases for similar periods were 1.66 (95% CI, 1.55-1.78) for 1 to 4 years of use, 1.96 (95% CI, 1.87-2.05) for 5 to 9 years, 2.31 (95% CI, 2.18- 2.44) for 10 to 14 years, and 2.68 (95% CI, 2.44-2.95) for 15 or more years.",
    "Attributable risk of breast cancer The attributable risk of breast cancer in women (mean age, 63 y) randomized to CEE plus MP A in the WHI is less than one addi- tional case of breast cancer diagnosed per 1,000 users annually , 9 a risk slightly greater than that observed with one daily glass of wine, less than with two daily glasses, and similar to the risk re- ported with obesity and low physical activity. 253,254 Compared with placebo or nonusers of hormone therapy, there appears to be no additive effect of hormone therapy with age or elevated personal breast cancer risk factors on breast cancer incidence. 21,22,255-259Al- though the relative risk of breast cancer associated with hor- mone therapy use is similar in women at average or high risk, the actual number of cases or attributable risk will be greater in women with an increased underlying risk. 86 Use of hormone therapy in women with genetic risk factors for breast cancer Observational evidence suggests that hormone therapy use does not further increase the relative risk of breast cancer in women with a family history of breast cancer, in women after oophorectomy for BRCA 1 or 2 genetic variants, or in women having undergone a benign breast biopsy .",
    "255-258,260-266 Ap r o - spective longitudinal cohort study of BRCA 1 genetic variant carriers without prior history of breast cancer who underwent BO (mean age, 43.4 y) showed no increased risk of developing breast cancer associated with any use of hormone therapy after a mean follow-up of 7.6 years; however, there was a difference be- tween ET and EPT , with a nonsignificant increase in breast NAMS POSITION STATEMENT 780 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society cancer risk associated with the latter.266 Similarly , the T wo Sister Study of 1,419 sister-matched cases of breast cancer in women aged younger than 50 years and 1,665 controls showed no in- creased risk of young-onset breast cancer with use of EPT (OR, 0.80; 95% CI, 0.41-1.59), and unopposed estrogen use was associated with a reduced diagnosis of young-onset breast cancer (OR, 0.58; 95% CI, 0.34-0.99). 267 The absolute risk of breast cancer is low in women with genetic variants who un- dergo risk-reducing BO at a young age, and use of hormone therapy is considered acceptable. Role of type of hormone use, dose, and route of administration Some but not all observational data suggest that MP and dydrogesterone may have a lesser association with breast can- cer, whereas other synthetic progestogens such as MP A may have a more adverse effect. 268 Randomized trials are needed to confirm these findings.",
    "268 Randomized trials are needed to confirm these findings. Prec linical data suggest that CEE may have lesser effects on occult breast cancer growth than estradiol, 269 but clinical data from observational studies, such as the Collaborative Group study, do not report a difference. 22 Regarding route, both oral and transdermal estrogens appear to have similar effects on number of breast cancers diagnosed, whereas vaginal estrogens have no effect. Insufficient clinical data on newer therapies such as TSECs, including CEE plus BZA, are available to assess their breast cancer risk, 270 al- though preclinic al data suggest greater safety. 271 Mammographic breast density and hormone therapy Different hormone therapy regimens may be associated with increased breast density, which may obscure mammographic in- terpretation. 272 More mammograms and breast biopsies were performed in women receiving CEE plus MP A than placebo in the WHI. 273 In trials up to 2-years ’ duration, breast cancer, breast density , and breast tenderness showed no difference be- tween oral CEE plus BZA and placebo. 274-276 Hormone therapy after breast cancer T wo RCTs reported conflicting outcomes of breast cancer re- currence with hormone therapy.",
    "274-276 Hormone therapy after breast cancer T wo RCTs reported conflicting outcomes of breast cancer re- currence with hormone therapy. One study (“Hormonal Replace- ment Therapy After Breast Cancer—Is It Safe?”)s h o w e da ne l e - vated risk of breast cancer recurrence in hormone therapy users relative to nonusers after a median follow-up of 2.1 years (HR, 3.5; 95% CI, 1.5-8.1) 277 and 4 years, (HR, 2.4; 95% CI, 1.3- 4.2),278 whereas another trial (Stockholm Breast Cancer Study) showed no effect on breast cancer recurrence in hormone ther- apy users relative to nonusers after median follow-up of 4.1 years (HR, 0.82; 95% CI, 0.35-1.9) 279 and 10.8 years (HR, 1.3; 95% CI, 0.9-1.9) but did show an increased risk of breast cancer in the contralateral breast (HR, 3.6; 95% CI, 1.2-10.9). 280 Although systemic use of hormone therapy in survivors of breast cancer is generally not advised, if symptoms of estrogen deficiency are severe and unresponsive to nonhormone options, women, in consultation with their oncologists, may choose hor- mone therapy after being fully informed about the risks and ben- efits. Several observational studies in women with a history of breast cancer have shown a decreased risk of recurrent breast cancer or neutral effects compared with nonusers. 281-286 In addition, mortality was reported to be reduced in breast cancer survivors who used hormone therapy relative to those who did not.",
    "281-286 In addition, mortality was reported to be reduced in breast cancer survivors who used hormone therapy relative to those who did not. 282,284 Four meta-analyses reported similar findings.281,284-286 A confounding factor in all of these observational studies is that women at low risk of breast cancer recurrence are more likely to elect hormone therapy use than women at high risk. Low-dose vaginal ET remains an effective treatment option for GSM in survivors of breast cancer, with minimal systemic absorption. Treatment with low-dose vaginal ET or DHEA may be considered if symptoms persist after an initial trial of nonhormone therapies and in consultation with an oncologist, with more concern for women on AIs. 88,90 Breast cancer mortality and hormone therapy Only one randomized trial, the WHI, examined breast cancer- specific mortality. After 20 years of median cumulative follow-up, CEE alone was associated with significantly lower breast cancer in- cidence (HR, 0.78; 95% CI, 0.65-0.93) and breast cancer mortality (HR, 0.60; 95% CI, 0.37-0.97) compared with placebo. In con- trast, CEE plus MP A was associated with significantly higher breast cancer incidence (HR, 1.28; 95% CI, 1.13-1.45) but no significant difference in breast cancer mortality (HR, 1.35; 95% CI, 0.94-1.95) compared with placebo. 21 The mortality risk of breast cancer in hormone therapy users has been reported to be reduced in many but not all observational studies.",
    "21 The mortality risk of breast cancer in hormone therapy users has been reported to be reduced in many but not all observational studies. 287-295 The breast cancers in hormone therapy users (ET and EPT) appear in most (but not all) studies to have more benign histologic features (localized, smaller, better differentiated, lower mean tumor proliferation rate) than in hormone therapy nonusers. The most recent study, using a large data registry in Finland and comparing populations rates, reported a reduction in breast can- cer mortality in users of both ET and EPT. 296 A confounding fac- tor in all these studies is that hormone therapy users undergo more frequent mammograms and diagnostic examinations, espe- cially with occurrence of signs or symptoms. 297-301 This is likely to result in earlier diagnosis and therefore more benign histologic features and lower mortality. Key points  The risk of breast cancer related to hormone therapy use is low, with estimates indicating a rare occurrence (less than one additional case per 1,000 women per year of hormone therapy use or three additional cases per 1,000 women when used for 5 years with CEE plus MP A). (Level I)  W omen should be counseled about the risk of breast cancer with hormone therapy, putting the data into perspective, with risk similar to that of modifiable risk factors such as two daily alcoholic beverages, obesity , and low physical activity .",
    "(Level III)  The effect of hormone therapy on breast cancer risk may de- pend on the type of hormone therapy, duration of use, regi- men, prior exposure, and individual characteristics. (Level II)  Different hormone therapy regimens may be associated with increased breast density , which may obscure mammographic interpretation, leading to more mammograms or more breast biopsies and a potential delay in breast cancer diagnosis. (Level II) NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 781  A preponderance of data does not show an additive effect of underlying breast cancer risk (age, family history of breast cancer, genetic risk of breast cancer, benign breast disease, personal breast cancer risk factors) and hormone therapy use on breast cancer incidence. (Level II)  Insufficient data are available to assess the risk of breast can- cer with newer therapies such as TSECs, including BZA plus CEE. (Level II)  Observational evidence suggests that hormone therapy use does not further increase risk of breast cancer in women at high risk because of a family history of breast cancer or after bilateral salpingo-oophorectomy (BSO) forBRCA 1 or 2 ge- netic variants. (Level II)  Systemic hormone therapy is generally not advised for survi- vors of breast cancer, although hormone therapy use may be considered in women with severe VMS unresponsive to nonhormone options, with shared decision-making in con- junction with their oncologists.",
    "(Level III)  For survivors of breast cancer with GSM, low-dose vaginal ET or DHEA may be considered in consultation with their oncologists if bothersome symptoms persist after a trial of nonhormone therapy. There is increased concern with low-dose v a g i n a lE Tf o rw o m e no nA I s . ( L e v e lI I I )  Regular breast cancer surve illance is advised for all post- menopausal women per current breast cancer screening guidelines, including those who use hormone therapy. (Level I) ENDOMETRIAL CANCER Endometrial cancer is the most common gynecologic malig- nancy in the United States. Unopposed systemic ET in a post- menopausal woman with an intact uterus increases the risk of endometrial cancer, which is dose- and duration-related. Greater risk is seen with higher estrogen doses used for longer duration, and risk persists after discontinuation. Progestogen used contin- uously or cyclically for 10 to 14 days monthly significantly reduces this risk. With long-duration hormone therapy use, observa- tional studies suggest a potentially increased risk of endometrial cancer with cyclic progestogen regimens compared with contin- uous progestogen use and with the use of MP compared with other progestogens. 3,4,302 In the WHI, women with a uterus re- ceiving EPT had a lower risk of endometrial cancer than women randomized to placebo after 13 years of cumulative follow-up because of the baseline risk of endometrial cancer in postmeno- pausal women from endogenous estrogen production.",
    "9 Ade- quate concomitant progestogen is recommended for a woman with an intact uterus when using systemic ET . Low-dose vaginal ET does not appear to increase endometrial cancer risk, 92,93 although trials with endometrial biopsy end points are limited to 1 year in duration. Progestogen is not ad- vised in women using low-dose vaginal ET for the treatment of GSM, although intermittent use may be considered in women at increased risk of endometrial cancer. Postmenopausal bleed- ing must be evaluated thoroughly in any woman, whether she is using hormone therapy or not, because this may be a sign of endometrial hyperplasia or cancer. Hormone therapy after endometrial cancer Although hormone therapy is generally contraindicated in women with estrogen-responsive cancers, hormone therapy may be used to treat bothersome menopause symptoms in women with low-grade, Stage I endometrial cancer after hysterectomy. Meta-analyses of retrospective studies, with one RCT , do not identify an AE on the risk of recurrence or survival in these cases. 303-306 Aw o m a n’s oncologist should be included in shared decision-making. Systemic hormone therapy is not advised with high-grade, advanced-stage endometrial cancers or with endome- trial stromal sarcomas or leiomyosarcomas, because there are in- sufficient studies assessing safety.",
    "307,308 Key points  Unopposed systemic ET in a postmenopausal woman with an intact uterus increases the risk of endometrial cancer, so ade- quate progestogen is recommended. (Level I)  Low-dose vaginal ET does not appear to increase endome- trial cancer risk, although trials with endometrial biopsy end points are limited to 1 year in duration. (Level II)  Use of hormone therapy is an option for the treatment of bothersome menopause symptoms in women with surgically treated, early stage, low-grade endometrial cancer in consul- tation with a woman ’s oncologist if nonhormone therapies are ineffective. (Level II)  Systemic hormone therapy is not advised with high-grade, advanced-stage endometrial cancers or with endometrial stro- m a ls a r c o m a so rl e i o m y o s a r c o m a s . ( L e v e lI I ) OV ARIAN CANCER Ovarian cancer causes more deaths than any other gyneco- logic malignancy. Use of oral contraceptives is associated with a significant reduction in ovarian cancer risk. Risk declines with longer duration of use, with risk reduction seen after 1 to 4 years of use, which persists for up to 30 years after oral contraceptive discontinuation. 309 Current and recent use of hormone therapy is associated with statistically significant but small increased risk of ovarian cancer in observational studies, principally for serous type, with an estimate of one additional ovarian cancer death in 1,700 to 3,300 hormone therapy users.",
    "310,311 This risk is seen with combined EPT and ET alone and dissipates within 5 years of discontinuing hormone therapy . In the WHI, there was no significant increase in ovarian cancer risk with EPT . 9 Hormone therapy after ovarian cancer The use of hormone therapy after a diagnosis of epithelial ovarian cancer does not appear to affect recurrence risk or sur- vival. 312,313 Although most studies are observational, this finding also is supported by two RCTs. Several studies identify improved survival in women with ovarian cancer who use hormone therapy, but this likely represents selection bias. 307 Use of hormone ther- apy is not advised in women with hormone-dependent ovarian cancers, including granulosa-cell tumors and serous carcino- mas. 306,314 Tumors of low malignant potential (borderline) often affect younger women, with excellent survival rates. Limited data are available, but hormone therapy may be considered in women with completely resected disease, especially given the benefits of NAMS POSITION STATEMENT 782 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society hormone therapy in the setting of early menopause.315 Short-term hormone therapy use appears safe in women with BRCA1 and BRCA2 genetic variants who undergo risk-reducing BSO before t h ea v e r a g ea g eo fm e n o p a u s e .308 Key points  Use of oral contraceptives is associated with a significant re- duction in ovarian cancer risk.",
    "(Level I)  Current and recent use of hormone therapy is associated with a small but statistically significant risk of ovarian cancer in observational studies, principally for serous type, although there was no increase in ovarian cancer risk in women ran- domized to EPT in the WHI. (Level II)  In women with a history of ovarian cancer, benefits of hor- mone therapy use generally outweighs risks, especially with bothersome VMS or early menopause; use of hormone ther- apy is not advised in women with hormone-dependent ovar- ian cancers, including granulosa-cell tumors and low-grade serous carcinoma. (Level II)  Short-term hormone therapy use appears safe in women with BRCA1and BRCA2genetic variants who undergo risk-reducing BSO before the average age of menopause. (Level II) COLORECT AL CANCER Colorectal cancer is the third most common cancer and the third leading cause of cancer death in US women. 309 Risk fac- tors include physical inactivity , obesity , smoking, and decreased use of screening strategies, which may be more likely in hor- mone therapy nonusers. Observational studies generally support a reduced risk of colorectal cancer in current hormone therapy users compared with never users (HR, 0.6-0.8), with no benefit associated with past hormone therapy use.",
    "310-312 In observa- tional studies, both EPT and ET alone are associated with re- duced colorectal cancer risk 313,314 and mortality .315 Although confounding may contribute to the reduced risk of colorectal can- cer seen in hormone therapy users, there is also biologic plausibil- ity, because estrogen receptors are present in colonic epithelium, 316 and estrogen reduces colon cancer cell growth in vitro. 317 In the WHI trials, use of CEE plus MP A, but not CEE alone, was associated with a reduced risk of colorectal cancer com- pared with placebo (HR, 0.62; 95% CI, 0.43-0.89). 9 Although EPT reduced the risk of colorectal cancer, the cancers that were detected in EPT users were more likely to be diagnosed at an ad- vanced stage, with positive lymph nodes. 318 The reduced risk of colorectal cancer in EPT users was no longer seen during the postintervention phase of the WHI at 13 years, and there was no difference in colorectal cancer mortality with either EPT or ET alone. 31 The reason for disparate findings between observa- tional studies and the WHI with regard to colorectal cancer risk and mortality is unclear. Key points  Observational studies suggest a reduced incidence of colo- rectal cancer in current hormone therapy users, with reduced mortality . (Level II)  In the WHI, EPT , but not ET alone, reduced colorectal cancer risk, although cancers diagnosed in EPT users were diagnosed at a more advanced stage.",
    "(Level II)  In the WHI, EPT , but not ET alone, reduced colorectal cancer risk, although cancers diagnosed in EPT users were diagnosed at a more advanced stage. There was no difference in colorec- tal cancer mortality with either EPT or ET . (Level I) LUNG CANCER Lung cancer is the second most common cancer and the lead- ing cause of cancer death in US women. 309 Smoking is the prin- cipal risk factor. An interaction between hormone therapy and lung cancer is biologically plausible because estrogen receptors (α and β) and aromatase are identified in both healthy lung tis- sue and lung cancers. 319,320 Non-small cell lung cancer, includ- ing adenocarcinoma and squamous cell carcinoma, is the most common type and the type affected by hormone therapy in ob- servational studies and RCTs. Observational studies, including several large meta-analyses, are conflicting and in aggregate identify no consistent association between hormone therapy use and lung cancer risk. 321-327 Smoking may influence the as- sociation between hormone therapy use and lung cancer risk.326 For women with lung cancer, the effect of hormone therapy use on survival is unclear, with studies showing improved, wors- ened, or no difference in risk of death. In the WHI, in the intervention phase or after a median of 13 years’ cumulative follow-up, the incidence of lung cancer did not differ significantly between placebo and treatment with CEE plus MP A or CEE alone.",
    "9 In a post hoc analysis of the intervention phase of the WHI, women treated with CEE plus MP A had more deaths from lung cancer compared with placebo (HR, 1.71; 95% CI, 1.16-2.52). 328 Cancers were more likely to be poorly differentiated, with distant metastasis. This increase in lung can- cer deaths was not seen with treatment with CEE alone 329 and dissipated over time after stopping hormone therapy.330 Key points  There appears to be an overall neutral effect of hormone ther- apy on lung cancer incidence and survival. (Level II)  Smoking cessation should be encouraged, with increased lung cancer surveillance for older smokers, including current or past users of hormone therapy. (Level I) DURA TION OF USE, INITIA TION AFTER AGE 60 YEARS, AND DISCONTINU A TION OF HORMONE THERAPY Benefits of hormone therapy use generally outweigh risks for healthy women with bothersome menopause symptoms who are aged younger than 60 years or within 10 years of menopause on- set. Because increasing risk is observed with advancing age and extended duration of use, 9,22 women are advised to use the ap- propriate dose for the time needed to manage their symptoms. Because many women will experience bothersome VMS for many years, long-duration hormone therapy use may be needed, and an arbitrary age-based stopping rule is not clinically appro- priate. Frequent VMS persist on average 7.4 years and for many more than 10 years.",
    "Frequent VMS persist on average 7.4 years and for many more than 10 years. 59,331 In a study of Swedish women aged older than 85 years, 16% reported hot flashes at least several times per week, 332 and up to 8% of women continue to have hot flashes for 20 years or longer after menopause. 333 There are important questions related to long-duration hor- mone therapy use and discontinuation that are unanswered by NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 783 available data, because the WHI, the longest adequately pow- ered blinded RCT , was limited to 5 to 7 years of therapy. In the WHI, initiating hormone therapy in women aged older than 60 years or more than 10 years beyond the onset of menopause was associated with greater risk, and initiating hormones in women aged older than 70 years was associated with the highest risk. 9 It is not known whether women who initiate hormone therapy at the time of menopause and continue use at older ages will incur the same risks as women initiating hormones later in life. The WHI studied only one formulation of oral hormones (CEE with or without MP A). Observational data suggest lower CVD risk, including VTE and stroke, with other hormone formu- lations and routes of administration, including transdermal estra- diol, lower-dose estrogens, and different progestogens.",
    "25,251,334-336 Mitigation of risk through the appropriate choice of dosing, formu- lation, and route of administration becomes increasingly important as women age and with longer duration of therapy . Factors that should be considered include severity of symptoms, effective- ness of alternative nonhormone and lifestyle interventions, and underlying risk for osteoporosis, CHD, cerebrovascular ac- cident, VTE, and breast cancer. The decision regarding duration of treatment and when to stop hormone therapy must be consid- ered in the context of the individualized risk-benefit profile, as well as the woman’s personal preferences. 337,338 Initiation after age 60 years Initiation of hormone therapy in women aged older than 60 years or more than 10 years from menopause onset has com- plex risks and requires careful consideration, recognizing that there may be well-counseled women aged older than 60 years who choose to initiate or restart hormone therapy. For women requesting to initiate hormone therapy because of VMS appear- ing many years after menopause onset, further evaluation is needed. Although new-onset VMS in an older woman could be caused by estrogen-deficiency, hot flashes or night sweats may be related to an underlying medical problem (eg, obstruc- tive sleep apnea, hyperthyroidism, carcinoid, lymphoma, Lyme disease, tuberculosis, HIV) or medication or substance use (eg, antidepressants, hypoglycemic agents, or withdrawal from alcohol or opioids).",
    "Extended use after age 65 years There is no general rule for stopping systemic hormone therapy in a woman aged 65 years. The Beers criteria from the American Geriatrics Society 339 has warnings against the use of hormone therapy in women aged older than 65 years. However, the recom- mendation to routinely discontinue systemic hormone therapy in w o m e na g e d6 5y e a r sa n do l d e ri sn e i t h e rc i t e do rs u p p o r t e db y evidence nor is it recommended by the American College of Obstetricians and Gynecologists or The North American Meno- pause Society . 340,341 Of note, the continued use of hormone therapy in healthy women aged older than 65 years at low risk for breast cancer and CVD is limited by insufficient evidence re- garding safety , risks, and benefits. For otherwise healthy women with persistent VMS, continu- ing hormone therapy beyond age 65 years is a reasonable option with appropriate counseling, regular assessment of risks and benefits, and shared decision-making. Hormone therapy also may be considered for prevention of fracture in healthy older women at elevated fracture risk when bothersome VMS persist or when hormone therapy remains the best choice because of lack of efficacy or intolerance of other fracture-prevention ther- apies.",
    "23,340 Long-duration hormone therapy use and use in older women is not appropriate for reduction in the risk of CHD or dementia.23,236,342 When providing hormone therapy to older women, clinicians must remain vigilant about risk stratifica- tion and potential mitigation strategies, such as switching from oral to transdermal hormone therapy, choice of progestogen, and lowering of dose. 337,338 Discontinuation of hormone therapy Controversy exists regarding how long hormone therapy may safely be used and when it should be discontinued. Based on findings from the WHI, breast cancer risk becomes detectable after 3 to 5 years in women using EPT . For women without a uterus using ET alone, breast cancer risk did not increase after 7 years, so a longer duration of hormone therapy use may be ac- ceptable. There are few studies to guide the optimal way for women to stop hormone therapy, and VMS will recur in approx- imately 50% of women after discontinuation. 71 Data directly comparing the effects of abrupt discontinuation with those of slowly tapering are lacking, 343 although clinical experts gener- ally advise gradually decreasing hormone therapy doses over time.",
    "338,343 If hormone therapy is being used for prevention of osteoporosis, it is important to remember that protection against bone density loss and fracture prevention is lost rapidly with dis- continuation.164 Although VMS generally improve with time, GSM worsens with prolonged estrogen deficiency , so women should be provided with treatment options on discontinuation of systemic hormone therapy. Observational studies confirm the long-term safety of low-dose vaginal ET , 92,93 ah i g h l ye f f e c - tive treatment for GSM. In the absence of contraindications, a woman should determine her preferred hormone therapy formu- lation, dose, and duration of use, with ongoing assessment and shared decision-making with her healthcare professional. 337,338 Key points  The safety profile of hormone therapy is most favorable when initiated in healthy women aged younger than 60 years or within 10 years of menopause onset, so initiation of hor- mone therapy by menopausal women aged older than 60 years requires careful consideration of individual benefits and risks. (Level I)  Long-term use of hormone therapy, including for women aged older than 60 years, may be considered in healthy women at low risk of CVD and breast cancer with persistent VMS or at elevated risk of fracture for whom other therapies are not ap- propriate.",
    "(Level III)  Factors that should be considered include severity of symp- toms, effectiveness of alternative nonhormone interventions, and underlying risk for osteoporosis, CHD, cerebrovascular accident, VTE, and breast cancer. (Level III)  Hormone therapy does not need to be routinely discontinued in women aged older than 60 or 65 years. (Level III) NAMS POSITION STATEMENT 784 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society  Mitigation of risk through use of the lowest effective dose and potentially with a nonoral route of administration be- comes increasingly important as women age and with longer duration of therapy. (Level III)  Longer durations or extended use beyond age 65 should in- clude periodic reevaluation of comorbidities with consider- ation of periodic trials of lowering or discontinuing hormone therapy. (Level III)  For women with GSM, low-dose vaginal ET may be consid- ered for use at any age and for extended duration, if needed. (Level III)  In the absence of contraindications, a woman should determine her preferred hormone therapy formulation, dose, and duration of use, with ongoing assessment and shared decision-making with her healthcare professional. (Level III) SUMMARY Hormone therapy formulation, dose, regimen, route of admin- istration, and the timing of initiation of therapy likely produce dif- ferent effects, although these have yet to be evaluated in head-to- head RCTs.",
    "There is a significant difference in the benefits and risks of ET alone compared with EPT. Decision-making sur- rounding the use of hormone therapy should be individualized, with recommendations for the use of the appropriate dose, dura- tion, regimen, and route of administration required to manage a woman’s symptoms and to meet treatment goals. Given the more favorable safety profile of ET alone, longer durations may be more appropriate. Risk stratification by age and time since men- opause is recommended. Transdermal routes of administration and lower doses of hormone therapy may decrease risk of VTE and stroke; however, comparative RCT data are lacking. Personalization with shared decision-making remains key, with periodic reevaluation to determine an individual woman’s benefit-risk profile. Benefits may include relief of bothersome VMS, prevention of bone loss and reduction of fracture, treat- ment of GSM, and improved sleep, well-being, and quality of life. Absolute attributable risks for w o m e ni nt h e5 0 -t o5 9 - y e a r - o l d age group or within 10 years of menopause onset are low, whereas the risks of initiation of hormone therapy for women aged 60 years and older or who are further than 10 years from menopause onset appear greater, particularly for those aged 70 years and older or more than 20 years from menopause onset, with more research needed on potential risks of longer durations of use.",
    "W omen with POI and premature or early menopause have higher risks of bone loss, heart disease, and cognitive or affec- tive disorders associated with estrogen deficiency . In observa- tional studies, these risks appear to be mitigated if ET is given until the average age of menopause, at which time treatment de- cisions should be reevaluated. In limited observational studies, women who areBRCA-positive and have undergone risk-reducing BO appear to receive similar benefits from receiving hormone therapy, with minimal to no increased risk of breast cancer. There is a paucity of RCT data about the risks of extended duration of hormone therapy in women aged older than 60 or 65 years, al- though observational studies suggest a potential rare risk of breast cancer with increased duration of hormone therapy. It remains an individual decision in select, well-counseled women aged older than 60 or 65 years to continue therapy. There are no data to sup- port routine discontinuation in women aged 65 years. For select survivors of breast and endometrial cancer, obser- vational data show that use of low-dose vaginal ET for those who fail nonhormone therapy for treatment of GSM appears safe and greatly improves quality of life for many. The use of systemic hormone therapy needs careful consideration for survi- vors of estrogen-sensitive cancers and should only be used for compelling reasons in collaboration with a woman’so n c o l o g i s t after failure of nonhormone therapies.",
    "Additional research is needed on the thrombotic risk (VTE, pulmonary embolism, and stroke) of oral versus transdermal therapies (including different formulations, doses, and durations of therapy). More clinical trial data are needed to confirm or re- fute the potential beneficial effects of hormone therapy on CHD and all-cause mortality when initiated in perimenopause or early postmenopause. Additional areas for research include the breast effects of different estrogen preparations, including the role for SERM and TSEC therapies; optimal progestogen or SERM reg- imens to prevent endometrial hyperplasia; the relationship be- tween VMS and the risk for heart disease and cognitive changes; and the risks of POI. Studies are needed on the effects of longer use of low-dose vaginal ET after breast or endometrial cancer; extended use of hormone therapy in women who are early initi- ators; improved tools to personalize or individualize benefits and risks of hormone therapy; the role of aging and genetics; and the long-term benefits and risks on women ’sh e a l t ho fl i f e - style modification or complementary or nonhormone therapies if chosen in addition to or over hormone therapy for VMS, bone health, and CVD risk reduction. CONCLUSIONS  Hormone therapy is the most effective treatment for VMS and GSM and has been shown to prevent bone loss and fracture.",
    "CONCLUSIONS  Hormone therapy is the most effective treatment for VMS and GSM and has been shown to prevent bone loss and fracture. Risks of hormone therapy differ for women, depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is needed. Treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation. For women aged younger than 60 years or within 10 years of menopause onset and without contraindications, the benefit-risk ratio appears favorable for treatment of bothersome VMS and for the prevention of bone loss and reduction of fracture. Based on the WHI RCTs, longer duration may be more favorable for ET than for EPT. For women who initiate hormone therapy more than 10 or 20 years from menopause onset or when aged 60 years or older, the benefit-risk ratio appears less favorable than for younger women because of greater absolute risks of CHD, stroke, VTE, and dementia. For GSM symptoms not relieved with nonhormone therapies, low-dose vaginal ET or other government-approved therapies (eg, vaginal DHEA or oral ospemifene) are recommended. NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 785 ACKNOWLEDGMENTS AND DISCLOSURES NAMS appreciates the contributions of the Advisory Panel and the work of the NAMS Board of Trustees on this position statement.",
    "29, No. 7, 2022 785 ACKNOWLEDGMENTS AND DISCLOSURES NAMS appreciates the contributions of the Advisory Panel and the work of the NAMS Board of Trustees on this position statement. The authors, planners, reviewers,and staff who were in a position to control and influence the content of this activity were required to dis- close all financial relationships with any ineligible company within the last 24 months. Any financial relationships that were determined by NAMS to be relevant to the activity have been mitigated. Acknowledgments: “The 2022 Hormone Therapy Position Statement of The North American Menopause Society ” Advi- sory Panel: Lead, Stephanie S. Faubion, MD, MBA, F ACP , NCMP , IF , Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic W omen’s Health; Medical Director, The North American Menopause Society . Carolyn J. Crandall, MD, MS, MACP , NCMP , F ASBMR, Professor of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California. Lori Davis, DNP , FNP-C, NCMP , private practice, Ithaca, New Y ork. Samar R. El Khoudary, PhD, MPH, BPharm, F AHA, Associate Professor, Department of Epidemiology , Epi- demiology Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania.",
    "Samar R. El Khoudary, PhD, MPH, BPharm, F AHA, Associate Professor, Department of Epidemiology , Epi- demiology Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania. Howard N. Hodis, MD, Harry J. Bauer and Dorothy Bauer Rawlins Professorship in Cardiology; Professor of Medicine and Population and Public Health Sciences; Director, Atherosclerosis Research Unit, Department of Medicine, Keck School of Medicine at University of Southern California, Los Angeles, California. Rogerio A. Lobo, MD, Professor of Obstet- rics and Gynecology and Fellowship Director, Division of Repro- ductive Endocrinology, Columbia University, New Y ork, New Y ork. Pauline M. Maki, PhD, Professor of Psychiatry, Psychol- ogy, and Obstetrics and Gynecology; Director of W omen’sM e n - tal Health Research; Associate Director of the Center for Re- search on W omen and Gender, University of Illinois at Chicago, Chicago, Illinois. JoAnn E. Manson, MD, DrPH, MACP , NCMP , Chief, Division of Preventive Medicine, Brigham and Women’s Hospital; Professor of Medicine and the Michael and Lee Bell Professor of W omen’s Health, Harvard Medical School, Profes- sor, Harvard TH Chan School of Public Health, Boston, Massachusetts. JoAnn V . Pinkerton, MD, F ACOG, NCMP , Pro- fessor of Obstetrics and Gynecology and Division Director of Midlife Health, The University of Virginia Health System, Charlottesville, Virginia. Nanette F .",
    "Pinkerton, MD, F ACOG, NCMP , Pro- fessor of Obstetrics and Gynecology and Division Director of Midlife Health, The University of Virginia Health System, Charlottesville, Virginia. Nanette F . Santoro, MD, Professor and E. Stewart Taylor Chair of Obstetrics and Gynecology , Uni- versity of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado. Jan L. Shifren, MD, NCMP , Direc- tor, Midlife W omen’s Health Center, Massachusetts General Hospital; Vincent Trustees Professor of Obstetrics, Gynecology , and Reproductive Biology , Harvard Medical School, Boston, Massachusetts. Chrisandra L. Shufelt, MD, MS, F ACP , NCMP , Anita Dann Friedman Endowed Chair in W omen’s Cardiovas- cular Medicine and Research; Associate Director, Barbra Streisand W omen’s Heart Center and Preventive and Rehabilita- tive Cardiac Center; Director, W omen’s Hormone and Meno- pause Program; Professor of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Rebecca C. Thurston, PhD, F ABMR, F APS, Pittsburgh Foundation Chair in Women ’s Health and Dementia; Professor of Psychiatry, Psychology, Epidemiology and Clinical and Translational Science; Director, Wo me n’s Biobehavioral Health Research Program; Director, Cardiovascular Behavioral Medicine Research Training Program, University of Pittsburgh, Pittsburgh, Pennsylvania.",
    "W endy L. Wolfman, MD, FRCSC, F ACOG, NCMP , Professor, Department of Obstetrics and Gynaecology; Carol Mitchell Chair in Mature Women’s Health, University of Toronto, Toronto, Ontario, Canada. NAMS recognizes the contributions of Ms. Carolyn Develen, NAMS Chief Operating Officer, and Ms. Kathy Method, MA, NAMS Communications Manager. This position statement was reviewed and approved by the 2021-2022 NAMS Board of Trustees: President, Chrisandra L. Shufelt, MD, MS, F ACP , NCMP , Anita Dann Friedman Endowed Chair in W omen’s Cardiovascular Medicine and Re- search; Associate Director, Barbra Streisand W omen ’s Heart Center and Preventive and Rehabilitative Cardiac Center; Direc- tor, Women’s Hormone and Menopause Program; Professor of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.President-Elect,Susan D. Reed, MD, MPH, MS, Re- search Director, W omen’s Reproductive Health Research Pro- gram; Professor and Vice Chair, Department of Obstetrics and Gynecology; Adjunct Professor of Epidemiology , Univer- sity of Washington School of Medicine, Seattle, Washington. Secretary, Claudio N. Soares, MD, PhD, FRCPC, MBA, Profes- sor and Head, Department of Psychiatry, Queen ’sU n i v e r s i t y School of Medicine; Chair, Psychedelic Science Advisory Committee, Queen ’s University; Executive Lead, Canadian Biomarker Integration Network in Depression (CAN-BIND); President and Chief Executive Officer, CAN-BIND Solutions, Ontario, Canada.",
    "Treasurer ,Lisa C. Larkin, MD, F ACP , NCMP , IF , Founder and Chief Executive Officer, Ms.Medicine, Cincin- nati, Ohio. Medical Director, Stephanie S. Faubion, MD, MBA, F ACP , NCMP , IF , Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Di- rector, Mayo Clinic Center for W omen ’sH e a l t h .Immediate Past-President, Hadine Joffe, MD, MSc, Executive Director, Mary Horrigan Connors Center for W omen’s Health and Gen- der Biology; Paula A. Johnson Professor of Psychiatry in the Field of W omen’s Health, Harvard Medical School; Executive Vice Chair for Academic and Faculty Affairs, Department of Psychiatry , Brigham and W omen’s Hospital, Dana Farber Can- cer Institute, Harvard Medical School, Boston, Massachusetts. Janet S. Carpenter, PhD, RN, F AAN, Distinguished Professor, Audrey Geisel Endowed Chair in Innovation, Indiana University School of Nursing, Indianapolis, Indiana. Monica M. Christmas, MD, F ACOG, NCMP , Associate Professor and Director of the Menopause Program and Center for W omen’s Integrated Health, Section of Minimally Invasive Gynecologic Surgery, UChicago Medicine and Biological Sciences, Chicago, Illinois. Samar R. El Khoudary, PhD, MPH, BPharm, F AHA, Associate Professor, Department of Epidemiology, Epidemiology Data Center, Uni- versity of Pittsburgh, Pittsburgh, Pennsylvania. Laurie S Jeffers, DNP , FNP-BC, NCMP , Clinical Assistant Professor, Rory Meyers NAMS POSITION STATEMENT 786 Menopause, V ol.",
    "Laurie S Jeffers, DNP , FNP-BC, NCMP , Clinical Assistant Professor, Rory Meyers NAMS POSITION STATEMENT 786 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society College of Nursing at New Y ork University, New Y ork, New Y ork. Michael R. McClung, MD, F ACP , F ASBMR, F ACE, Founding Di- rector, Oregon Osteoporosis Center, Portland, Oregon; Profes- sorial Fellow, Mary MacKillop Institute for Health Research, Australian Catholic University , Melbourne, Australia. Editor- in-Chief,Menopause, Isaac Schiff, CM, MD, Joe Vincent Meigs Distinguished Professor of Gynecology, Harvard Medical School; Chief, Department of Obstetrics and Gynecology, Emeritus, The Wo me n’s Care Division, Massachusetts General Hospital, Boston, Massachusetts. Wen Shen, MD, MPH, Associate Professor of Gyne- cologic Specialties; Associate Professor of Oncology Center; Associ- ate Professor, Johns Hopkins School of Nursing Joint Appointment; Co-director of Johns Hopkins Women's Wellness and Healthy Aging Program, Johns Hopkins University School of Medicine, Baltimore, Maryland.",
    "Rebecca C. Thurston, PhD, F ABMR, F APS, Chair, 2022 Scientific Program Committee, Pittsburgh Foundation Chair in Wo m e n’s Health and Dementia; Professor of Psychiatry, Psychol- ogy , Epidemiology and Clinical and Translational Science; Di- rector, W omen’s Biobehavioral Health Research Program; Di- rector, Cardiovascular Behavioral Medicine Research Training Program, University of Pittsburgh, Pittsburgh, Pennsylvania. Financial disclosures/Conflicts of interest:All financial relation- ships with ineligible companies have been mitigated. For the Advisory Panel, Dr. Faubion, Dr. Crandall, Dr. El Khoudary, Dr. Hodis, Dr. Lobo, Dr. Manson, Dr. Pinkerton, Dr. Shifren, and Dr. Shufelt each reports no financial relationships with ineligible companies. Dr. Davis reports Advisory Board for Amag Pharmaceutical, Scynexis, and Mayne Pharma. Dr. Maki reports Advisory Board for Astellas, Bayer, and Johnson & Johnson; Consultant for Abbvie, Balchem, and Pfizer. Dr. Santoro reports Advisory Board for Astellas Pharma, Ember, Menogenix, and Que Oncology; Consultant for Ansh Labs. Dr. Thurston reports Consultant for Astellas Pharma, Happify Health, Pfizer, Vira Health, and Virtue Health. Dr. Wolfman reports Advisory Board for Astellas, BioSyent, Lupin, and Pfizer; Speaker for Bayer. For additional contributors, Ms. Develen and Ms. Method re- port no financial relationships with ineligible companies.",
    "For additional contributors, Ms. Develen and Ms. Method re- port no financial relationships with ineligible companies. For the NAMS Board of Trustees members who were not members of the Advisory Panel:Dr. Jeffers and Dr. Schiff report no financial relationships with ineligible companies. Dr. Carpenter re- ports Consultant/Advisory Board: University of Wisconsin Milwaukee; Royalties/Patents: Mapi Trust; Owner: JSCarpenter LLC. Dr. Christmas reports Consultant/Advisory Board: FDA Bone, Reproductive, and Urologic Products Committee, Speakers’ Bureau: Alliance Chicago. Board Member: Hyde Park School of Dance. Dr. Joffe reports Consultant/Advisory Board: Bayer, Eisai, Jazz; Grant/Research Sup- port: Merck, Pfizer. Dr. Larkin reports: Consultant/Advisory Board: Astellas, Myovant/Pfizer, Pharmavite, Procter & Gamble, Solv Wellness, TherapeuticsMD; Speakers’ Bureau: Abbvie; Board Member: HealthyW omen. Dr. McClung reports Consultant/ Advisory Board: Amgen, Myovant; Speakers’ Bureau: Alexion; Board Member: International Osteoporosis Foundation. Dr. Reed reports: Grant/Research Support: Bayer, NIH; Royalties/Patents: UpToDate. Dr. Shen reports Stock/Ownership: Astra Zeneca, Akzo Nobel, Bristol Myers Squibb, Hologic, Johnson & Johnson, Merck. Dr. Soares reports Grant/Research Support: Eisai; Consultant/Advisory Board: Bayer, Eisai, Otsuka, Pfizer; Execu- tive Committee Member: Canadian Biomarker Integration Net- work in Depression, CAN-BIND Solutions. REFERENCES 1.",
    "REFERENCES 1. Barratt A, Wyer PC, Hatala R, et al; Evidence-Based Medicine T eaching Tips Working Group. Tips for teachers of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-358. 2. Council for International Organizations of Medical Science (CIOMS). Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals.R e p o r t of CIOMS W orking Group IV . Geneva, Switzerland: CIOMS; 1998. 3. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012;CD000402. 4. Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review.Maturitas2016;91:25-35. 5. Pinkerton JV , Abraham L, Bushmakin AG, et al. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.J W omens Health (Larchmt)2014;23:18-28. 6. Mirkin S, Ryan KA, Chandran AB, Komma BS. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas 2014;77:24-31. 7. Pinkerton JV , Harvey JA, Lindsay R, et al. SMART -5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189-E198.",
    "SMART -5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189-E198. 8. Anderson GL, Judd HL, Kaunitz AM, et al. W omen ’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the W omen ’s Health Initiative randomized trial. JAMA 2003;290:1739-1748. 9. Manson JE, Chlebowski RT , Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the W omen’s Health Initiative randomized trials. JAMA 2013; 310:1353-1368. 10. Hutt S, Mihaies D, Karteris E, et al. Statistical meta-analysis of risk factors for endometrial cancer and development of a risk prediction model using an artificial neural network algorithm.Cancers (Basel) 2021;13:3689. 11. Stute P , Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review .Climacteric 2016;19:316-328. 12. Eden J. The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: a short review . Aust N Z J Obstet Gynaecol 2017;57:12-15. 13. Santoro N, T eal S, Gavito C, Cano S, Chosich J, Sheeder J. Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study.Menopause 2015;22:1301-1307. 14.",
    "Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study.Menopause 2015;22:1301-1307. 14. Pickar JH, Y eh IT , Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.Fertil Steril 2009;92:1018-1024. 15. Pinkerton JV , Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-1124. 16. Mirkin S, Pinkerton JV , Kagan R, et al. Gynecologic safety of conjugated estrogens plus bazedoxifene: pooled analysis of five phase 3 trials. J W omens Health (Larchmt) 2016;25:431-442. 17. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy.Obstet Gynecol 2009;114:1197-1204. 18. Sarri G, Pedder H, Dias S, Guo Y , Lumsden MA. V asomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effectsfrom the National Institute for Health and Care Excellence guideline on menopause.BJOG 2017;124:1514-1523. 19. Santoro N, Allshouse A, Neal-Perry G, et al.",
    "19. Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: The Kronos Early Estrogen Prevention Study.Menopause 2017;24:238-246. NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 787 20. Manson JE, Kaunitz AM. Menopause management —getting clinical care back on track. N Engl J Med 2016;374:803-806. 21. Chlebowski RT , Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the W omen's Health Initiative randomized clinical trials. JAMA 2020;324:369-380. 22. Collaborative Group on Hormonal Factors in Breast Cancer. T ype and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159-1168. 23. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women.Cochrane Database Syst Rev2017;1:CD004143. 24. Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric 2010;13:429-432. 25. Vinogradova Y , Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.BMJ 2019;364:k4810. Erratum in: BMJ 2019;364:l162. 26.",
    "Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.BMJ 2019;364:k4810. Erratum in: BMJ 2019;364:l162. 26. Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V , Scarabin PY . Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.Menopause 2010;17:1122-1127. 27. Canonico M, Oger E, Plu-Bureau G, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845. 28. Shufelt CL, Manson JE. Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery.J Clin Endocrinol Metab2021;106:1245-1254. 29. Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res 2018;168:83-95. 30. Gartlehner G, Patel SV , Feltner C, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2017;318:2234-2249. 31. Manson JE, Aragaki AK, Rossouw JE, et al. WHI Investigators.",
    "JAMA 2017;318:2234-2249. 31. Manson JE, Aragaki AK, Rossouw JE, et al. WHI Investigators. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Wom en’s Health Initiative randomized trials.JAMA 2017;318:927-938. 32. Maclennan AH, Broadbent JL, Lester S, Moore V . Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev2004:CD002978. 33. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.JAMA 2001; 285:2891-2897. 34. Cauley JA, Robbins J, Chen Z, et al. W omen’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the W omen’s Health Initiative randomized trial. JAMA 2003; 290:1729-1738. 35. Faubion SS, Kuhle CL, Shuster LT , Rocca W A. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015;18:483-491. 36. Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density .JC l i nE n d o c r i n o lM e t a b2016;101:3497-3505. 37. Popat VB, Calis KA, Kalantaridou SN, et al.",
    "37. Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement.J Clin Endocrinol Metab 2014;99:3418-3426. 38. Cintron D, Rodriguez-Gutierrez R, Serrano V , et al. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis. Endocrine 2016;55:366-375. 39. Rocca W A, Grosshardt BR, Shuster L T . Oophorectomy, estrogen, and dementia: a 2014 update. M o lC e l lE n d o c r i n o l2014;389:7-12. 40. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; W ebber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency.Hum Reprod2016;31:926-937. 41. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society white paper.Climacteric2020;23:426-446. 42. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril 2016;106:1588-1599. 43. Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency.Fertil Steril2016; 106:1580-1587. 44. Burgos N, Cintron D, Latortue-Albino P , et al.",
    "Hormone replacement therapy in young women with surgical primary ovarian insufficiency.Fertil Steril2016; 106:1580-1587. 44. Burgos N, Cintron D, Latortue-Albino P , et al. Estrogen-based hormone therapy in women with primary insufficiency: a systematic review.Endocrine 2017;58:413-425. 45. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane Database Syst Rev2016;CD001500. 46. Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause 2019;26:431-453. 47. Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J W omens Health (Larchmt) 2007;16:600-631. 48. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy .Mayo Clin Proc 2011;86:673-680. 49. Sites CK. Bioidentical hormones for menopausal therapy .W omens Health (Lond Engl) 2008;4:163-171. 50. Bhavnani BR, Stanczyk FZ. Misconception and concerns about bioidentical hormones used for custom-compounded hormone therapy.J Clin Endocrinol Metab2012;97:756-759. 51. Stanczyk FZ, Matharu H, Winer SA. Bioidentical hormones. Climacteric 2021;24:38-45. 52. Committee on Gynecologic Practice andthe American Society for Reproductive Medicine Practice Committee. Committee opinion No. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol 2012; 120:411-415. 53.",
    "Committee opinion No. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol 2012; 120:411-415. 53. McBane SE, Borgelt LM, Barnes KN, W estberg SM, Lodise NM, Stassinos M. Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the W omen's Health Practice and Research Network of the American College of Clinical Pharmacy.Pharmacotherapy2014;34:410-423. 54. Fierce Biotech. FDA T akes Action Against Compounded Menopause Hormone Therapy Drugs. January 10, 2008. fda.gov/consumer/updates/ bioidenticals010908.html. Accessed February 22, 2022. 55. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy, Jackson LM, Parker RM, Mattison DR (eds). In: The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use . Washington, DC: National Academies Press; 2020. 56. Thompson JJ, Ritenbaugh C, Nichter M. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.BMC W omens Health2017;17:97. 57. Nelson HD. Menopause. Lancet 2008;371:760-770. 58. Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, Dibonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity.Menopause 2013;20:518-524. 59.",
    "Impact of the severity of vasomotor symptoms on health status, resource use, and productivity.Menopause 2013;20:518-524. 59. A vis NE, Crawford SL, Greendale G, et al. Study of W omen ’sH e a l t h Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531-539. 60. Thurston RC, Sutton-T yrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women’s Health Across the Nation Heart Study. Circulation 2008; 118:1234-1240. 61. Thurston RC, Kuller LH, Edmundowicz D, Matthews KA. History of hot flashes and aortic calcification among postmenopausal women.Menopause 2010;17:256-261. 62. Thurston RC, Sutton-T yrrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA. Hot flashes and carotid intima media thickness among midlife women. Menopause 2011;18:352-358. 63. Crandall CJ, Aragaki A, Cauley JA, et al. Associations of menopausal vasomotor symptoms with fracture incidence. JC l i nE n d o c r i n o lM e t a b 2015;100:524-534. 64. Maki PM. V erbal memory and menopause. Maturitas 2015;82:288-290. 65. Thurston RC, Aslanidou Vlachos HE, Derby CA, et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SW AN.J Am Heart Assoc 2021;10:e017416. 66. Bachmann GA, Schaefers M, Uddin A, Utian WH.",
    "Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SW AN.J Am Heart Assoc 2021;10:e017416. 66. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.Obstet Gynecol2007;110:771-779. NAMS POSITION STATEMENT 788 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society 67. Schiff I, T ulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms.JAMA 1980;244:1443-1445. 68. Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal women.Menopause2012;19:886-893. 69. Prior JC, Nielsen JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.Clin Sci (Lond) 2007;112:517-525. 70. Goodwin JW , Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.J Clin Oncol2008;26:1650-1656. 71. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin.JAMA 2005;294:183-193. 72. Brunner RL, Aragaki A, Barnabei V , et al.",
    "71. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin.JAMA 2005;294:183-193. 72. Brunner RL, Aragaki A, Barnabei V , et al. Menopausal symptom experience before and after stopping estrogen therapy in the W omen’s Health Initiative randomized, placebo-controlled trial.Menopause2010;17:946-954. 73. Makarem N, St-Onge MP , Liao M, et al. Association of sleep characteristics with cardiovascular health among women with differences in race/ethnicity and menopausal status: findings from the American Heart Association Go Red for W omen Strategically Focused Network. Sleep Health 2019; 5:501-508. 74. Yin J, Jin X, Shan Z, et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: a systematic review and dose-response meta-analysis of prospective cohort studies. J Am Heart Assoc 2017; 6:e005947. 75. Sands-Lincoln M, Loucks EB, Lu B, et al. Sleep duration, insomnia, and coronary heart disease among postmenopausal women in the W omen's Health Initiative.JW o m e n’s Health (Larchmt) 2013;22:477-486. 76. Lao XQ, Liu X, Deng HB, et al. Sleep quality, sleep duration, and the risk of coronary heart disease: a prospective cohort study with 60,586 adults. JC l i nS l e e pM e d2018;14:109-117. 77. Attarian H, Hachul H, Guttuso T , Phillips B. Treatment of chronic insomnia disorder in menopause: evaluation of literature. Menopause 2015;22:674-684. 78.",
    "JC l i nS l e e pM e d2018;14:109-117. 77. Attarian H, Hachul H, Guttuso T , Phillips B. Treatment of chronic insomnia disorder in menopause: evaluation of literature. Menopause 2015;22:674-684. 78. Geiger PJ, Eisenlohr-Moul T , Gordon JL, Rubinow DR, Girdler SS. Effect of perimenopausal transdermal estradiol on self-reported sleep, independent of its effects on vasomotor symptom bother and depressive symptoms. Menopause2019;26:1318-1323. 79. Schüssler P , Kluge M, Y assouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology2008;33:1124-1131. 80. Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis of randomized controlled trial data. J Clin Endocrinol Metab 2021;106:942-951. 81. Portman DJ, Gass ML. Vulvovaginal Atrophy T erminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of W omen’s Sexual Health and the North American Menopause Society . Menopause 2014;21:1063-1068. 82. Rahn DD, Carberry C, Sanses TV , et al. Society of Gynecologic Surgeons Systematic Review Group. V aginal estrogen for genitourinary syndrome of menopause: a systematic review .Obstet Gynecol 2014;124:1147-1156. 83. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI.",
    "83. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012; 15:267-274. 84. Santen RJ. V aginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015;18:121-134. 85. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society .Menopause 2020;27:976-992. 86. Santen RJ, Mirken S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens.Menopause 2020;27:361-370. 87. Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review.Menopause 2020;27:339-360. 88. Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of W omen ’sS e x u a lH e a l t h . Menopause 2018;25:596-608. 89. American College of Obstetricians and Gynecologists ’ Committee on Gynecologic PracticeFarrell R. ACOG Committee Opinion No. 659 summary: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016;127:618-619. 90. Dixon JM, Renshaw L, Y oung O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.J Clin Oncol 2008;26:1671-1676. 91.",
    "Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.J Clin Oncol 2008;26:1671-1676. 91. Le Ray I, Dell ’Aniello S, Bonnetain F , Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.Breast Cancer Res Treat2012;135:603-609. 92. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study.Menopause2018;25:11-20. 93. Bhupathiraju SN, Grodstein F , Stampfer MJ, et al. V aginal estrogen use and chronic disease risk in the Nurses’ Health Study.Menopause2018;26:603-610. 94. Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015;18:226-232. 95. Labrie F , Archer DF , Koltun W , et al, VV A Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy , and of the genitourinary syndrome of menopause. Menopause 2016;23:243-256. 96. Long CY , Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM.",
    "Menopause 2016;23:243-256. 96. Long CY , Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006;85:155-160. 97. Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourol Urodyn2014;33:1086-1091. 98. Matsubara S, Okada H, Shirakawa T , Gotoh A, Kuno T , Kamidono S. Estrogen levels influence beta-3-adrenoceptor-mediated relaxation of the female rat detrusor muscle. Urology 2002;59:621-625. 99. Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev 2010;CD007063. 100. Grady D, Brown JS, Vittinghoff E, Applegate W , V arner E, Snyder T , HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97:116-120. 101. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence.JAMA 2005;293:935-948. 102. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD001405. 103. Dueñas-Garcia OF , Sullivan G, Hall CD, Flynn MK, OʼDell K. Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women.",
    "103. Dueñas-Garcia OF , Sullivan G, Hall CD, Flynn MK, OʼDell K. Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women. A systematic review.Female Pelvic Med Reconstr Surg2016;22:63-69. 104. Ferrante KL, Asanda EJ, Jung CE, Adams-Piper ER, Lukacz ES. V aginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. Female Pelvic Med Reconstr Surg 2021;27:112-117. 105. Long CY , Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737-743. 106. Shifren JL, Monz BU , Russo P A, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970-978. 107. Santoro N, W orsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med 2016;13:305-316. 108. Wierman ME, Nappi RE, A vis N, et al. Endocrine aspects of women ’s sexual function. J Sex Med 2010;7:561-585. 109. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985-994.",
    "Menopause 2007;14:985-994. 110. Taylor HS, Tal A, Pal L, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med 2017;177:1471-1479. 111. Komm BS, Mirkin S, Jenkins SN. Development of conjugated estrogens/ bazedoxifene, the first tissue selective estr ogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Steroids 2014;90:71-81. NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 789 112. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.Menopause2010;17:281-289. 113. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.Climacteric 2010;13:132-140. 114. Abraham L, Pinkerton JV , Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas 2014;78:212-218. Erratum in: Maturitas 2014;79:488. 115. Anagnostis P , Siolos P , Gkekas NK, et al. Association between age at menopause and fracture risk: a systematic review and meta-analysis. Endocrine 2019;63:213-224. 116. Appiah D, Schreiner PJ, Demerath EW , Loehr LR, Chang PP , Folsom AR.",
    "Association between age at menopause and fracture risk: a systematic review and meta-analysis. Endocrine 2019;63:213-224. 116. Appiah D, Schreiner PJ, Demerath EW , Loehr LR, Chang PP , Folsom AR. Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. J Am Heart Assoc 2016;5:e003769. 117. Li XT , Li PY , Liu Y , et al. Health-related quality-of-life among patients with premature ovarian insufficiency: a systematic review and meta-analysis. Qual Life Res 2020;29:19-36. 118. Muka T , Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits,and all-cause mortality: a systematic review and meta-analysis.JAMA Cardiol2016;1:767-776. 119. Roeters van Lennep JE, Heida KY , Bots ML, Hoek A, Collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management After Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis.Eur J Prev Cardiol 2016;23:178-186. 120. Zhu D, Chung HF , Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019;4:e553-e564. 121. Anagnostis P , Christou K, Artzouchaltzi AM, et al.",
    "Lancet Public Health 2019;4:e553-e564. 121. Anagnostis P , Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis.Eur J Endocrinol 2019;180:41-50. 122. Schmidt PJ, Luff JA, Haq NA, et al. Depression in women with spontaneous 46, XX primary ovarian insufficiency. J Clin Endocrinol Metab 2011;96:E278-E287. 123. Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA 2019;322:2411-2421. 124. Hulsman CA, W estendorp IC, Ramrattan RS, et al. Is open-angle glaucoma associated with early menopause? The Rotterdam Study. Am J Epidemiol 2001;154:138-144. 125. Fattet AJ, Toupance S, Thornton SN, et al. T elomere length in granulosa cells and leukocytes: a potential marker of female fertility? A systematic review of the literature. J Ovarian Res 2020;13:96. 126. Anagnostis P , Theocharis P , Lallas K, et al. Early menopause is associated with increased risk of arterial hypertension: a systematic review and meta- analysis. Maturitas 2020;135:74-79. 127. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13:1141-1151. 128.",
    "Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13:1141-1151. 128. Castelo-Branco C, Martínez de Osaba MJ, V anrezc JA, Fortuny A, González-Merlo J. Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function.Maturitas 1993;17:101-111. 129. Gallicchio L, Whiteman MK, Tomic D, Miller KP , Langenberg P , Flaws JA. T ype of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 2006;85:1432-1440. 130. Blümel JE, Chedraui P , Baron G, et al, Collaborative Group for Research of the Climacteric in Latin America (REDLINC). A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18:778-785. 131. Atsma F , Bartelink MLEL, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279. 132. Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET . Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology2019;106:9-19. 133. Pu D, Tan R, Y u Q, Wu J. Metabolic syndrome in menopause and associated factors: a meta-analysis.Climacteric 2017;20:583-591. 134. Fakkert I, T eixeira N, Abma EM, Slart R, Mourits M, de Bock GH.",
    "Pu D, Tan R, Y u Q, Wu J. Metabolic syndrome in menopause and associated factors: a meta-analysis.Climacteric 2017;20:583-591. 134. Fakkert I, T eixeira N, Abma EM, Slart R, Mourits M, de Bock GH. Bone mineral density and fractures after surgical menopause: systematic review and meta-analysis.BJOG 2017;124:1525-1535. 135. Xu Q, Lang CP . Examining the relationship between subjective sleep disturbance and menopause: a systematic review and meta-analysis. Menopause 2014;21:1301-1318. 136. T uppurainen M, Kröger H, Honkanen R, et al. Risks of perimenopausal fractures—a prospective population-based study. Acta Obstet Gynecol Scand 1995;74:624-628. 137. Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. JC l i n Endocrinol Metab 2011;96:3864-3872. 138. Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf ) 2010;73:707-714. 139. Jackson RD, Wactawski-W ende J, LaCroix AZ, et al, W omen ’sH e a l t h Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the W omen's Health Initiative randomized trial. J Bone Miner Res 2006;21:817-828. 140.",
    "J Bone Miner Res 2006;21:817-828. 140. Kaunitz AM, Kapoor E, Faubion S. Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause.JAMA 2021; 326:1429-1430. 141. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy.Menopause 2009;16:15-23. 142. Archer DF , Kimble TD, Lin FDY , Battucci S, Sniukiene V , Liu JH. A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. J W omens Health (Larchmt) 2018;27:231-237. 143. Mytton J, Evison F , Chilton PJ, Lilford RJ. Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. BMJ 2017;356:j372. 144. Thornton MJ. Estrogens and aging skin. Dermatoendocrinol 2013; 5:264-270. 145. Desai K, Almeida B, Miteva M. Understanding hormonal therapies: overview for the dermatologist focused on hair.Dermatology2021;237:786-791. 146. V ajaranant TS, Maki PM, Pasquale LR, Lee A, Kim H, Haan MN. Effects of hormone therapy on intraocular pressure: the W omen's Health Initiative-Sight Exam Study .Am J Ophthalmol 2016;165:115-124. 147. V ajaranant TS, Ray RM, Pasquale LR, et al. Racial differences in the effects of hormone therapy on incident open-angle glaucoma in a randomized trial.",
    "147. V ajaranant TS, Ray RM, Pasquale LR, et al. Racial differences in the effects of hormone therapy on incident open-angle glaucoma in a randomized trial. Am J Ophthalmol 2018;195:110-120. 148. Newman-Casey P A, Talwar N, Nan B, Musch DC, Pasquale LR, Stein JD. The potential association between postmenopausal hormone use and primary open-angle glaucoma.JAMA Ophthalmol2014;132:298-303. 149. Haan MN, Klein R, Klein BE, et al. Hormone therapy and age-related macular degeneration: the W omen’s Health Initiative Sight Exam Study. Arch Ophthalmol 2006;124:988-992. 150. Lai K, Cui J, Ni S, Zhang Y , He J, Y ao K. The effects of postmenopausal hormone use on cataract: a meta-analysis. PLoS One 2013;8:e78647. 151. Nuzzi R, Scalabrin S, Becco A, Panzica G. Sex hormones and optic nerve disorders: a review .Front Neurosci2019;13:57. 152. Dang A, Nayeni M, Mather R, Malvankar-Mehta MS. Hormone replacement therapy for dry eye disease patients: sy stematic review and meta-analysis. Can J Opthamol 2020;55:3-11. 153. Curhan SG, Eliassen AH, Eavey RD, Wang M, Lin BM, Curhan GC. Menopause and postmenopausal hormone therapy and risk of hearing loss. Menopause 2017;24:1049-1056. 154. Suh MJ, Oh SK, Lee SB, Kim SH. Effects of endogenous and exogenous oestrogen exposure on hearing level in postmenopausal women: a cross- sectional study. Clin Otolaryngol 2021;46:508-514. 155. Doty RL, Tourbier I, Ng V , et al.",
    "Effects of endogenous and exogenous oestrogen exposure on hearing level in postmenopausal women: a cross- sectional study. Clin Otolaryngol 2021;46:508-514. 155. Doty RL, Tourbier I, Ng V , et al. Influences of hormone replacement therapy on olfactory and cognitive function in postmenopausal women. Neurobiol Aging 2015;36:2053-2059. 156. Coksuer H, Koplay M, Oghan F , Coksuer C, Keskin N, Ozveren O. Effects of estradiol-drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women.Arch Gynecol Obstet 2011;283:1045-1051. 157. Naessen T , Lindmark B, Lagerström C, Larsen HC, Persson I. Early postmenopausal hormone therapy improves postural balance.Menopause 2007;14:14-19. NAMS POSITION STATEMENT 790 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society 158. Utian WH, W oods NF . Impact of hormone therapy on quality of life after menopause. Menopause 2013;20:1098-1105. 159. W oods NF , Utian W . Quality of life, menopause, and hormone therapy: an update and recommendations for future research. Menopause 2018; 25:713-720. 160. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women.Am J Med 2009;122:1016.e1-1022.e1. 161. Khosla S, Monroe DG. Regulation of bone metabolism by sex steroids. Cold Spring Harb Perspect Med 2018;8:a031211. 162.",
    "161. Khosla S, Monroe DG. Regulation of bone metabolism by sex steroids. Cold Spring Harb Perspect Med 2018;8:a031211. 162. Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017;166:818-839. Erratum in:Ann Intern Med2017;167:448. 163. Crandall CJ, Newberry SJ, Diamant A, et al. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report [Internet]. AHRQ Comparative Effectiveness Reviews2012; Report No. 12-EHC023-EF . 164. Papadakis G, Hans D, Gonzalez-Rodriguez E, et al. The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal.JC l i nE n d o c r i n o lM e t a b2016;101:5004-5011. 165. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676. 166. Barrionuevo P , Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis.J Clin Endocrinol Metab 2019;104:1623-1630. 167. Fink HA, MacDonald R, Forte ML, et al.",
    "167. Fink HA, MacDonald R, Forte ML, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review.Ann Intern Med 2019;171:37-50. 168. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. JC l i n Endocrinol Metab 2015;100:3975-4011. 169. Heiss G, Wallace R, Anderson GL, et al. WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045. 170. Watts NB, Cauley JA, Jackson RD, et al. W omen ’s Health Initiative Investigators. No increase in fractures after stopping hormone therapy: results from the women’s health initiative. J Clin Endocrinol Metab 2017; 102:302-308. 171. Xiao YP , Tian FM, Dai MW , Wang WY , Shao LT , Zhang L. Are estrogen-related drugs new alternatives for the management of osteoarthritis? Arthritis Res Ther 2016;18:151. 172. de Klerk BM, Schiphof D, Groeneveld FP , et al. Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review.Rheumatology (Oxford)2009;48:104-112. 173. Watt FE. Hand osteoarthritis, menopause and menopausal hormone therapy.Maturitas 2016;83:13-18. 174. Barnabei VM, Cochrane BB, Aragaki AK, et al. W omen’s Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the W omen’s Health Initiative.",
    "Barnabei VM, Cochrane BB, Aragaki AK, et al. W omen’s Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the W omen’s Health Initiative. Obstet Gynecol 2005;105:1063-1073. 175. Chlebowski RT , Cirillo DJ, Eaton CB, et al. Estrogen alone and joint symptoms in the Women’s Health Initiative randomized trial. Menopause 2013;20:600-608. 176. Cirillo DJ, Wallace RB, Wu L, Y ood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the W omen ’s Health Initiative. Arthritis Rheum 2006;54:3194-3204. 177. Ahmed N, Mandel R, Fain MJ. Frailty: an emerging geriatric syndrome. Am J Med 2007;120:748-753. 178. Ikeda K, Horie-Inoue K, Inoue S. Functions of estrogen and estrogen receptor signaling on skeletal muscle. J Steroid Biochem Mol Biol 2019; 191:105375. 179. V an Pelt RE, Gavin KM, Kohrt WM. Regulation of body composition and bioenergetics by estrogens. Endocrinol Metab Clin North Am 2015; 44:663-676. 180. Nedergaard A, Henriksen K, Karsdal MA, Christiansen C. Menopause, estrogens and frailty.Gynecol Endocrinol 2013;29:418-423. 181. Lightfoot AP , Cooper RG. The role of myokines in muscle health and disease. Curr Opin Rheumatol 2016;28:661-666. 182. Tiidus PM, Lowe DA, Brown M. Estrogen replacement and skeletal muscle: mechanisms and population health. JA p p lP h y s i o l( 1 9 8 5 )2013; 115:569-578. 183. Bea JW , Zhao Q, Cauley JA, et al.",
    "Tiidus PM, Lowe DA, Brown M. Estrogen replacement and skeletal muscle: mechanisms and population health. JA p p lP h y s i o l( 1 9 8 5 )2013; 115:569-578. 183. Bea JW , Zhao Q, Cauley JA, et al. Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the W omen’s Health Initiative hormone trials. Menopause 2011;18:44-52. 184. Kenny AM, Kleppinger A, Wang Y , Prestwood KM. Effects of ultra-low- dose estrogen therapy on muscle and physical function in older women. J Am Geriatr Soc 2005;53:1973-1977. 185. Javed AA, Mayhew AJ, Shea AK, Raina P . Association between hormone therapy and muscle mass in postmenopausal women: a systematic review and meta-analysis.JAMA Netw Open 2019;2:e1910154. 186. De Spiegeleer A, Beckwée D, Bautmans I, Petrovic M, Sarcopenia Guidelines Development Group of the Belgian Society of Gerontology and Geriatrics (BSGG). Pharmacological interventions to improve muscle mass, muscle strength and physical performance in older people: an umbrella review of systematic reviews and meta-analyses.Drugs Aging 2018;35:719-734. 187. Everson GT , McKinley C, Kern F Jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. JC l i nI n v e s t1991;87:237-246. 188. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease.JAMA 2005;293:330-339. 189.",
    "JC l i nI n v e s t1991;87:237-246. 188. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease.JAMA 2005;293:330-339. 189. Kilander C, Lagergren J, Konings P , Sadr-Azodi O, Brusselaers N. Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden.Acta Oncol 2019;58:290-295. 190. Liu B, Beral V , Balkwill A, Green J, Sweetland S, Reeves G. Million W omen Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study .BMJ 2008;337:a386. 191. DiStefano JK. NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment.Endocrinology2020;161:bqaa134. 192. Brady CW . Liver disease in menopause.World J Gastroenterol2015;21:7613-7620. 193. Salpeter SR, Walsh JM, Ormiston TM, Greybar E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.Diabetes Obes Metab2006; 8:538-554. 194. Xu Y , Lin J, Wang S, Xiong J, Zhu Q. Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus. Kaohsiung J Med Soc 2014;30:350-361. 195. Sternfeld B, Wang H, Quesenberry CP Jr., et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of W omen’s Health Across the Nation. Am J Epidemiol 2004;160:912-922. 196.",
    "Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of W omen’s Health Across the Nation. Am J Epidemiol 2004;160:912-922. 196. Karvonen-Gutierrez C, Kim C. Association of mid-life changes in body size, body composition and obesity status with the menopausal transition. Healthcare (Basel)2016;4:42. 197. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition.JCI Insight 2019;4:e124865. 198. Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev 2000:CD001018. 199. Jensen LB, V estergaard P , Hermann AP , et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study.J Bone Miner Res2003;18:333-342. 200. Guthrie JR, Dennerstein L, Dudley EC. W eight gain and the menopause: a 5-year prospective study .Climacteric 1999;2:205-211. 201. Chen Z, Bassford T , Green SB, et al. Postmenopausal hormone therapy and body composition—a substudy of the estrogen plus progestin trial of the W omen’s Health Initiative. Am J Clin Nutr 2005;82:651-656. 202. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths.",
    "Am J Clin Nutr 2005;82:651-656. 202. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997;82:1549-1556. 203. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women.Psychoneuroendocrinology1992;17:485-495. 204. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women.Psychoneuroendocrinology 1988;13:345-357. 205. Gleason CE, Dowling NM, Wharton W , et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study .PLoS Med 2015;12:e1001833. 206. Espeland MA, Shumaker SA, Leng I, et al, WHIMSY Study Group. Long- term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013; 173:1429-1436. NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 791 207. Henderson VW , St John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology 2016;87:699-708. 208. Marder K, Sano M. Estrogen to treat Alzheimer ’s disease: too little, too late? So what's a woman to do? Neurology 2000;54:2035-2037. 209. Resnick SM, Henderson VW .",
    "Neurology 2016;87:699-708. 208. Marder K, Sano M. Estrogen to treat Alzheimer ’s disease: too little, too late? So what's a woman to do? Neurology 2000;54:2035-2037. 209. Resnick SM, Henderson VW . Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 2002;288:2170-2172. 210. Brinton LA, Richesson D, Leitzmann MF , et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev2008;17:3150-3160. 211. Grady D, Y affe K, Kristof M, Lin F , Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study.Am J Med 2002;113:543-548. 212. Resnick SM, Maki PM, Rapp SR, et al. W omen’s Health Initiative Study of Cognitive Aging Investigators. Effects of combination estrogen plus progestin hormone treatment on cognition and affect.J Clin Endocrinol Metab2006; 91:1802-1810. 213. Shumaker SA, Legault C, Rapp SR, et al, WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the W omen’s Health Initiative Memory Study: a randomized controlled trial.JAMA 2003;289:2651-2662. 214. Whitmer RA, Quesenberry CP , Zhou J, Y affe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011;69:163-169. 215. Shao H, Breitner JC, Whitmer RA, et al, Cache County Investigators.",
    "Ann Neurol 2011;69:163-169. 215. Shao H, Breitner JC, Whitmer RA, et al, Cache County Investigators. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012;79:1846-1852. 216. Henderson VW , Benke KS, Green RC, Cupples LA, Farrer LA, MIRAGE Study Group. Postmenopausal hormone therapy and Alzheimer’s disease risk: interaction with age.J Neurol Neurosurg Psychiatry2005;76:103-105. 217. Imtiaz B, T uppurainen M, Rikkonen T , et al. Postmenopausal hormone therapy and Alzheimer disease: a prospective cohort study. Neurology 2017;88:1062-1068. 218. Vinogradova Y , Dening T , Hippisley-Cox J, Taylor L, Moore M, Coupland C. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.BMJ 2021;374:n2182. 219. Shufelt CL, Johnson BD, Berga SL, et al, W omen ’s Ischemia Syndrome Evaluation Study Group. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored W omen ’s Ischemia Syndrome Evaluation. Menopause 2011;18:943-950. 220. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study . Neurology 2009;72:135-142. 221. Coker LH, Espeland MA, Hogan PE, et al, WHIMS-MRI Study Group. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies.Neurology2014;82:427-434. 222.",
    "221. Coker LH, Espeland MA, Hogan PE, et al, WHIMS-MRI Study Group. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies.Neurology2014;82:427-434. 222. Bromberger JT , Schott L, Kravitz HM, Joffe H. Risk factors for major depression during midlife among a community sample of women with and without prior major depression: are they the same or different? Psychol Med 2015;45:1653-1664. 223. Maki PM, Kornstein SG, Joffe H, et al, Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause 2018;25:1069-1085. 224. Joffe H, Crawford SL, Freeman MP , et al. Independent contributions of nocturnal hot flashes and sleep disturbance to depression in estrogen-deprived women.J Clin Endocrinol Metab2016;101:3847-3855. 225. Gibson CJ, Thurston RC, Bromberger JT , Kamarck T , Matthews KA. Negative affect and vasomotor symptoms in the Study of W omen’sH e a l t h Across the Nation Daily Hormone Study.Menopause 2011;18:1270-1277. 226. W orsley R, Bell R, Kulkarni J, Davis SR. The association between vasomotor symptoms and depression during perimenopause: a systematic review.Maturitas 2014;77:111-117. 227. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report.Am J Obstet Gynecol 2000;183:414-420.",
    "227. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report.Am J Obstet Gynecol 2000;183:414-420. 228. Joffe H, Petrillo LF , Koukopoulos A, et al. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition.JC l i nE n d o c r i n o lM e t a b2011;96:E1044-E1054. 229. Morrison MF , Kallan MJ, T en Have T , Katz I, T weedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial.Biol Psychiatry 2004;55:406-412. 230. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial.JAMA Psychiatry 2018;75:149-157. 231. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF . Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry 2005;66:774-780. 232. Mikkola TS, Tuomikoski P , Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality.Menopause 2015;22:976-983. 233. Savolainen-Peltonen H, Tuomikoski P , Korhonen P , et al. Cardiac death risk in relation to the age at initiation or the progestin component of hormone therapies. JC l i nE n d o c r i n o lM e t a b2016;101:2794-2801. 234. T uomikoski P , Lyytinen H, Korhonen P , et al.",
    "JC l i nE n d o c r i n o lM e t a b2016;101:2794-2801. 234. T uomikoski P , Lyytinen H, Korhonen P , et al. The risk of fatal stroke in Finnish postmenopausal hormone therapy users before and after the Wome n’s Health Initiative: a cohort study. Maturitas 2015;81:384-388. 235. Carrasquilla GD, Berglund A, Gigante B, et al. Does menopausal hormone therapy reduce myocardial infarction risk if initiated early after menopause? A population-based case-control study.Menopause2015;223:598-606. 236. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women.Cochrane Database Syst Rev 2015;CD002229. 237. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women.Am J Med 2009;122:42-52.e2. 238. Salpeter SR, Walsh JM, Greybar E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis.J Gen Intern Med 2004;19:791-804. 239. Salpeter SR, Walsh JM, Greybar E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis.J Gen Intern Med 2006;21:363-366. 240. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297:1465-1477. Erratum in:JAMA2008;299:1426. 241. Schierbeck LL, Rejnmark L, Tofteng CL, et al.",
    "JAMA2007;297:1465-1477. Erratum in:JAMA2008;299:1426. 241. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409. 242. Manson JE, Aragaki AK, Bassuk SS, et al, WHI Investigators. Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. A n nI n t e r nM e d 2019;171:406-414. 243. Akhrass F , Evans A T , Wang Y , et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. JC l i nE n d o c r i n o lM e t a b2003;88:5611-5614. 244. Barrett-Connor E, Laughlin GA. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study.Menopause 2005;12:40-48. 245. Manson JE, Allison MA, Rossouw JE, et al, WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. NE n g l JM e d2007;356:2591-2602. 246. Hodis HN, Mack WJ, Henderson VW , et al, ELITE Research Group. Effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221-1231. 247. Harman SM, Black DM, Naftolin F , et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249-260. 248. Kim JE, Chang JH, Jeong MJ, et al.",
    "Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249-260. 248. Kim JE, Chang JH, Jeong MJ, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Sci Rep 2020;10:20631. 249. Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the“timing hypothesis” of hormone replacement therapy on mortality, coronary heart disease, and stroke.I n tJC a r d i o lH e a r tV a s c2019;22:123-131. 250. Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke 2016;47:1734-1741. 251. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.BMJ 2010;340:c2519. 252. El Khoudary SR, Aggarwal B, Beckie TM, et al, American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: implication for timing of early prevention: a scientific statement from the American Heart Association. Circulation 2020;142:e506-e532. NAMS POSITION STATEMENT 792 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society 253. Li CI, Daling JR, Tang MTC, Haugen KL, Porter PL, Malone KE.",
    "NAMS POSITION STATEMENT 792 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society 253. Li CI, Daling JR, Tang MTC, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013;173:1629-1637. 254. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237:474-482. 255. Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F , Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014; 145:535-543. Erratum in: Breast Cancer Res Treat2014;147:225. 256. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72. 257. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-1480. 258. Lécuru F , Laforest H, Darles C, Taurelle R. Does hormone replacement therapy increase the risk of breast cancer? Eur J Obstet Gynecol Reprod Biol 1995;62:159-166. 259. Chlebowski RT , Hendrix SL, Langer RD, et al, WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the W omen’s Health Initiative randomized trial. JAMA 2003;289:3243-3253. 260. Rebbeck TR, Friebel T , Wagner T , et al, PROSE Study Group.",
    "JAMA 2003;289:3243-3253. 260. Rebbeck TR, Friebel T , Wagner T , et al, PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. JC l i nO n c o l2005;23:7804-7810. 261. Eisen A, Lubinski J, Gronwald J, et al. Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-1367. 262. Domchek SM, Mitchell G, Lindeman GJ, et al. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/ 2-associated breast cancer.J Clin Oncol 2011;29:4224-4226. 263. Chai X, Domchek S, Kauff N, Rebbeck T , Chen J. Re: breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107:djv217. 264. Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.Fam Cancer2009;8:23-28. 265. Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, et al, Hereditary Breast and Ovarian Cancer Research Group Netherlands.",
    "265. Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, et al, Hereditary Breast and Ovarian Cancer Research Group Netherlands. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.J Natl Cancer Inst2015;107:djv033. 266. Kotsopoulos J, Gronwald J, Karlan BY , et al. Hormone replacement therapy after oophorectomy and breast cancer risk amongBRCA1 mutation carriers. JAMA Oncol2018;4:1059. 267. O ’Brien KM, Fei C, Sandler DP , Nichols HB, DeRoo LA, W einberg CR. Hormone therapy and young-onset breast cancer. Am J Epidemiol 2015; 181:799-807. 268. Fournier A, Berrino F , Clavel-Chapelon F . Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111. Erratum in: Breast Cancer Res Treat2008;107:307-308. 269. Y ue W , Wang J, Atkins KA, et al. Effect of tissue selective estrogen complex on breast cancer: role of unique properties of conjugated equine estrogen. Int J Cancer 2018;143:1259-1268. 270. Fabian CJ, Nye L, Powers KR, et al. Effect of bazedoxifene and conjugated estrogen (Duavee) on breast cancer risk biomarkers in high-risk women: a pilot study .Cancer Prev Res (Phila) 2019;12:711-720. 271. Santen RJ, Song Y , Wang JP , Y ue W . Preclinical breast effects of a tissue selective estrogen complex (TSEC) including conjugated estrogen with bazedoxifene.J Steroid Biochem Mol Biol 2017;170:61-64.",
    "Preclinical breast effects of a tissue selective estrogen complex (TSEC) including conjugated estrogen with bazedoxifene.J Steroid Biochem Mol Biol 2017;170:61-64. 272. Pettersson A, Graff RE, Ursin G, et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis.J Natl Cancer Inst2014;106:dju078. 273. Chlebowski RT , Anderson G, Pettinger M, et al. W omen ’s Health Initiative Investigators. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.Arch Intern Med 2008;168:370-377. 274. Harvey JA, Pinkerton JV , Baracat EC, Shi H, Chines AA, Mirkin S. Breast density changes in a randomized controlled trial evaluating bazedoxifene/ conjugated estrogens.Menopause. 2013;20:138-145. 275. Pinkerton JV , Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial.Obstet Gynecol2013;121:959-968. 276. Pinkerton JV , Pickar JH, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric2012;15:411-418. 277. Holmberg L, Anderson H, HABITS Steering Committee and Data Monitoring Committee. HABITS (Hormonal Replacement Therapy After Breast Cancer —Is It Safe? ), a randomised comparison: trial stopped. Lancet 2004;363:453-455. 278. Holmberg L, Iversen OE, Rudenstam CM, et al. HABITS Study Group.",
    "), a randomised comparison: trial stopped. Lancet 2004;363:453-455. 278. Holmberg L, Iversen OE, Rudenstam CM, et al. HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.J Natl Cancer Inst 2008;100:475-482. Erratum in:JN a t l Cancer Inst2008;100:685. 279. von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.J Natl Cancer Inst2005;97:533-535. 280. Fahlén M, Fornander T , Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013;49:52-59. 281. Col NF , Kim JA, Chlebowski RT . Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.Breast Cancer Res 2005;7:R535-R540. 282. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review.Obstet Gynecol 2001;98:498-508. 283. Gambrell RD Jr. Hormone replacement therapy and breast cancer risk. Arch Fam Med 1996;5:341-348. 284. Meurer LN, Lená S. Cancer recurrence and mortality in women using hormone replacement therapy after breast cancer: meta-analysis. JF a m Pract 2002;51:1056-1062. 285. Wang Y , Lewin N, Qaoud Y , Rajaee NA, Scheer AS. The oncologic impact of hormone replacement therapy in premenopausal breast cancer survivors: a systematic review .Breast 2018;40:123-130. 286.",
    "285. Wang Y , Lewin N, Qaoud Y , Rajaee NA, Scheer AS. The oncologic impact of hormone replacement therapy in premenopausal breast cancer survivors: a systematic review .Breast 2018;40:123-130. 286. Col NF , Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.J Clin Oncol2001;19:2357-2363. 287. Reding KW , Doody DR, McTiernan A, et al. Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat2011;126:749-761. 288. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. NE n g lJM e d 1995;332:1589-1593. 289. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: as systematic review.Am J Obstet Gynecol2002; 186:325-334. 290. Chen W , Petitti DB, Geiger AM. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study.Br J Cancer 2005;93:392-398. 291. Pocobelli G, Newcomb P A, Li CI, Cook LS, Barlow WE, W eiss NS. Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy . Breast Cancer Res Treat 2014;145:439-447. Erratum in: Breast Cancer Res Treat2014;145:449. 292. Newcomb P A, Egan KM, Trentham-Dietz A, et al.",
    "Breast Cancer Res Treat 2014;145:439-447. Erratum in: Breast Cancer Res Treat2014;145:449. 292. Newcomb P A, Egan KM, Trentham-Dietz A, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:864-871. Erratum in: Cancer Epidemiol Biomarkers Prev 2009;18:1943. 293. Chlebowski RT , Anderson GL, Gass M, et al, WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-1692. 294. Norman SA, W eber AL, Localio AR, et al. Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf2010;19:440-447. 295. Benkhadra K, Mohammed K, Al Nofal A, et al. Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:4021-4028. 296. Mikkola TS, Savolainen-Peltonen H, T uomikoski P , et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study.Menopause2016;23:1199-1203. 297. Gapstur SM, Morrow M, Sellers T A. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa W omen’s Health Study .JAMA 1999;281:2091-2097. 298. Daling JR, Malone KE, Doody DR, et al. Association of regimens of hormone therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.Cancer Epidemiol Biomarkers Prev2003;12:1175-1181. 299.",
    "Association of regimens of hormone therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.Cancer Epidemiol Biomarkers Prev2003;12:1175-1181. 299. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP , Janzon L. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 2001;92:919-922. 300. Holi K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.J Clin Oncol1998;16:3115-3120. NAMS POSITION STATEMENT Menopause, V ol. 29, No. 7, 2022 793 301. Delgado RC, Lubian Lopez DM. Prognosis of breast cancers detected in women receiving hormone replacement therapy.Maturitas2001;38:147-156. 302. Trabert B, W entzensen N, Y ang HP , et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2013;132:417-426. 303. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS, Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in Stage I or II endometrial cancer: a Gynecologic Oncology Group Study.JC l i nO n c o l2006;24:587-592. 304. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014;50:1628-1637. 305.",
    "304. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014;50:1628-1637. 305. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev 2018;5:CD008830. 306. Harris BS, Bishop KC, Kuller JA, et al. Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause2020;27:243-248. 307. Del Carmen MG, Rice L W . Management of menopausal symptoms in women with gynecologic cancers.Gynecol Oncol 2017;146:427-435. 308. Rees M, Angioli R, Coleman RL, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.Int J Gynecol Cancer2020; 30:428-433. 309. American Cancer Society.Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021. 310. Mørch LS, Lidegaard Ø, Keiding N, Løkkegaard E, Kjær SK. The influence of hormone therapies on colon and rectal cancer.Eur J Epidemiol 2016;31:481-489. 311. Botteri E, Støer NC, Sakshaug S, et al. Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway . BMJ Open 2017;7:e017639. 312.",
    "311. Botteri E, Støer NC, Sakshaug S, et al. Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway . BMJ Open 2017;7:e017639. 312. Jang YC, Huang HL, Leung C. Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis.BMC Cancer 2019;19:1199. 313. Lin KJ, Cheung WY , Lai JYC, Giovannucci EL. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer.Int JC a n c e r2012;130:419-430. 314. Bhupathiraju SN, Grodstein F , Rosner BA, et al. Hormone therapy use and risk of chronic disease in the Nurses' Health Study: a comparative analysis with the W omen’s Health Initiative. Am J Epidemiol 2017;15:696-708. 315. Symer MM, W ong NZ, Abelson JS, Milsom JW , Y eo HL. Hormone replacement therapy and colorectal cancer incidence and mortality in the prostate, lung, colorectal, and ovarian cancer screening trial.Clin Colorectal Cancer2018;17:e281-e288. 316. Nikolaou S, Qiu S, Fiorentino F , Rasheed S, T ekkis P , Kontovounisios C. The prognostic and therapeutic role of hormones in colorectal cancer: a review.Mol Biol Rep 2019;46:1477-1486. 317. Lointier P , Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992;12:1327-1330. 318. Chlebowski RT , Wactawski-W ende J, Ritenbaugh C, et al, W omen’sH e a l t h Initiative Investigators.",
    "Anticancer Res 1992;12:1327-1330. 318. Chlebowski RT , Wactawski-W ende J, Ritenbaugh C, et al, W omen’sH e a l t h Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women.N Engl J Med 2004;350:991-1004. 319. Hsu LH, Chu NM, Kao SH. Estrogen, estrogen receptor and lung cancer. Int J Mol Sci. 2017;18:1713. 320. Abe K, Miki Y , Ono K, et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.Hum Pathol2010; 41:190-198. 321. Oh SW , Myung SK, Park JY , Lym YL, Ju W . Hormone therapy and risk of lung cancer: a meta-analysis.J W omens Health (Larchmt)2010;19:279-288. 322. Pesatori AC, Carugno M, Consonni D, et al. Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO). Br J Cancer 2013;109:1954-1964. 323. Y ao Y , Gu X, Zhu J, Y uan D, Song Y . Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. PLoS One2013;8:e71236. 324. Bae JM, Kim EH. Hormonal replacement therapy and the risk of lung cancer in women: an adaptive meta-analysis of cohort studies. JP r e v Med Public Health 2015;48:280-286. 325. Jin C, Lang B. Hormone replacement therapy and lung cancer risk in women: a meta-analysis of cohort studies: hormone replacement therapy and lung cancer risk. Medicine (Baltimore)2019;98:e17532. 326. Titan AL, He H, Lui N, et al.",
    "Medicine (Baltimore)2019;98:e17532. 326. Titan AL, He H, Lui N, et al. The influence of hormone replacement therapy on lung cancer incidence and mortality . JT h o r a cC a r d i o v a s c Surg 2020;159:1546.e4-1556.e4. 327. Abdel-Rahman O. Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis. Int J Clin Oncol 2020;25:885-891. 328. Chlebowski RT , Schwartz AG, Wakelee H, et al, W omen’s Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women ’s Health Initiative trial): a post-hoc analysis of a randomized trial. Lancet 2009;374:1243-1251. 329. Chlebowski RT , Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the W omen ’s Health Initiative randomized trial.J Natl Cancer Inst 2010;102:1413-1421. 330. Chlebowski RT , Wakelee H, Pettinger M, et al. Estrogen plus progestin and lung cancer: follow-up of the W omen’s Health Initiative randomized trial. Clin Lung Cancer 2016;17:10-17. 331. Gartoulla P , W orsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause 2015;22:694-701. 332. Vikström J, Spetz Holm AC, Sydsjö G, Marcusson J, Wressle E, Hammar M. Hot flashes still occur in a population of 85-year-old Swedish women. Climacteric 2013;16:453-459. 333. Zeleke BM, Davis SR, Fradkin P , Bell RJ.",
    "Climacteric 2013;16:453-459. 333. Zeleke BM, Davis SR, Fradkin P , Bell RJ. V asomotor symptoms and urogenital atrophy in older women: a systematic review.Climacteric2015; 18:112-120. 334. Stanczyk FZ, Hapgood JP , Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013; 34:171-208. 335. Kaunitz AM. Extended duration use of menopausal hormone therapy. Menopause 2014;21:679-681. 336. Løkkegaard E, Nielsen LH, Keiding N. Risk of stroke with various types of menopausal hormone therapies: a national cohort study . Stroke 2017; 48:2266-2269. Erratum in: Stroke 2018;49:e142. 337. Shifren JL, Crandall CJ, Manson JE. Menopausal hormone therapy .JAMA 2019;321:2458-2459. 338. Pinkerton JV . Hormone therapy for postmenopausal women.N Engl J Med 2020;382:446-455. 339. The 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults.J Am Geriatr Soc2019;674-694. 340. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202-216. 341. North American Menopause Society. The North American Menopause Society statement on continuing use of systemic hormone therapy after age 65. Menopause 2015;22:693. 342. US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, et al.",
    "Menopause 2015;22:693. 342. US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement.JAMA2017;318:2224-2233. 343. Grady D, Sawaya GF . Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118:163-165. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society ” h a sb e e nd e s i g n a t e daC M Ea c - tivity for all NAMS members. NAMS members should log in to the NAMS website, www.menopause.org, and then select Online CME in the Member Center. CME credit will be available from July 1, 2022, to July 1, 2023. NAMS POSITION STATEMENT 794 Menopause, V ol. 29, No. 7, 2022 © 2022 The North American Menopause Society"
  ],
  "metadatas": [
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 0,
      "total_chunks": 120,
      "char_count": 1257,
      "estimated_tokens": 314
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 1,
      "total_chunks": 120,
      "char_count": 1313,
      "estimated_tokens": 328
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 2,
      "total_chunks": 120,
      "char_count": 1331,
      "estimated_tokens": 332
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 3,
      "total_chunks": 120,
      "char_count": 1370,
      "estimated_tokens": 342
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 4,
      "total_chunks": 120,
      "char_count": 1410,
      "estimated_tokens": 352
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 5,
      "total_chunks": 120,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 6,
      "total_chunks": 120,
      "char_count": 1356,
      "estimated_tokens": 339
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 7,
      "total_chunks": 120,
      "char_count": 1442,
      "estimated_tokens": 360
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 8,
      "total_chunks": 120,
      "char_count": 1345,
      "estimated_tokens": 336
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 9,
      "total_chunks": 120,
      "char_count": 1374,
      "estimated_tokens": 343
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 10,
      "total_chunks": 120,
      "char_count": 1436,
      "estimated_tokens": 359
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 11,
      "total_chunks": 120,
      "char_count": 1313,
      "estimated_tokens": 328
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 12,
      "total_chunks": 120,
      "char_count": 1413,
      "estimated_tokens": 353
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 13,
      "total_chunks": 120,
      "char_count": 1352,
      "estimated_tokens": 338
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 14,
      "total_chunks": 120,
      "char_count": 1183,
      "estimated_tokens": 295
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 15,
      "total_chunks": 120,
      "char_count": 1357,
      "estimated_tokens": 339
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 16,
      "total_chunks": 120,
      "char_count": 1351,
      "estimated_tokens": 337
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 17,
      "total_chunks": 120,
      "char_count": 1407,
      "estimated_tokens": 351
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 18,
      "total_chunks": 120,
      "char_count": 1386,
      "estimated_tokens": 346
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 19,
      "total_chunks": 120,
      "char_count": 1392,
      "estimated_tokens": 348
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 20,
      "total_chunks": 120,
      "char_count": 844,
      "estimated_tokens": 211
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 21,
      "total_chunks": 120,
      "char_count": 1518,
      "estimated_tokens": 379
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 22,
      "total_chunks": 120,
      "char_count": 1459,
      "estimated_tokens": 364
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 23,
      "total_chunks": 120,
      "char_count": 1405,
      "estimated_tokens": 351
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 24,
      "total_chunks": 120,
      "char_count": 1287,
      "estimated_tokens": 321
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 25,
      "total_chunks": 120,
      "char_count": 1447,
      "estimated_tokens": 361
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 26,
      "total_chunks": 120,
      "char_count": 1322,
      "estimated_tokens": 330
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 27,
      "total_chunks": 120,
      "char_count": 1431,
      "estimated_tokens": 357
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 28,
      "total_chunks": 120,
      "char_count": 1134,
      "estimated_tokens": 283
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 29,
      "total_chunks": 120,
      "char_count": 1388,
      "estimated_tokens": 347
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 30,
      "total_chunks": 120,
      "char_count": 1440,
      "estimated_tokens": 360
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 31,
      "total_chunks": 120,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 32,
      "total_chunks": 120,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 33,
      "total_chunks": 120,
      "char_count": 1416,
      "estimated_tokens": 354
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 34,
      "total_chunks": 120,
      "char_count": 1327,
      "estimated_tokens": 331
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 35,
      "total_chunks": 120,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 36,
      "total_chunks": 120,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 37,
      "total_chunks": 120,
      "char_count": 1454,
      "estimated_tokens": 363
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 38,
      "total_chunks": 120,
      "char_count": 1494,
      "estimated_tokens": 373
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 39,
      "total_chunks": 120,
      "char_count": 1429,
      "estimated_tokens": 357
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 40,
      "total_chunks": 120,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 41,
      "total_chunks": 120,
      "char_count": 1294,
      "estimated_tokens": 323
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 42,
      "total_chunks": 120,
      "char_count": 1344,
      "estimated_tokens": 336
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 43,
      "total_chunks": 120,
      "char_count": 1424,
      "estimated_tokens": 356
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 44,
      "total_chunks": 120,
      "char_count": 1417,
      "estimated_tokens": 354
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 45,
      "total_chunks": 120,
      "char_count": 1229,
      "estimated_tokens": 307
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 46,
      "total_chunks": 120,
      "char_count": 499,
      "estimated_tokens": 124
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 47,
      "total_chunks": 120,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 48,
      "total_chunks": 120,
      "char_count": 1328,
      "estimated_tokens": 332
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 49,
      "total_chunks": 120,
      "char_count": 1362,
      "estimated_tokens": 340
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 50,
      "total_chunks": 120,
      "char_count": 1346,
      "estimated_tokens": 336
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 51,
      "total_chunks": 120,
      "char_count": 1480,
      "estimated_tokens": 370
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 52,
      "total_chunks": 120,
      "char_count": 1382,
      "estimated_tokens": 345
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 53,
      "total_chunks": 120,
      "char_count": 1452,
      "estimated_tokens": 363
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 54,
      "total_chunks": 120,
      "char_count": 1359,
      "estimated_tokens": 339
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 55,
      "total_chunks": 120,
      "char_count": 476,
      "estimated_tokens": 119
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 56,
      "total_chunks": 120,
      "char_count": 1300,
      "estimated_tokens": 325
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 57,
      "total_chunks": 120,
      "char_count": 1315,
      "estimated_tokens": 328
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 58,
      "total_chunks": 120,
      "char_count": 1442,
      "estimated_tokens": 360
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 59,
      "total_chunks": 120,
      "char_count": 1441,
      "estimated_tokens": 360
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 60,
      "total_chunks": 120,
      "char_count": 1445,
      "estimated_tokens": 361
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 61,
      "total_chunks": 120,
      "char_count": 1478,
      "estimated_tokens": 369
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 62,
      "total_chunks": 120,
      "char_count": 1429,
      "estimated_tokens": 357
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 63,
      "total_chunks": 120,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 64,
      "total_chunks": 120,
      "char_count": 1487,
      "estimated_tokens": 371
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 65,
      "total_chunks": 120,
      "char_count": 1479,
      "estimated_tokens": 369
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 66,
      "total_chunks": 120,
      "char_count": 1382,
      "estimated_tokens": 345
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 67,
      "total_chunks": 120,
      "char_count": 1488,
      "estimated_tokens": 372
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 68,
      "total_chunks": 120,
      "char_count": 1408,
      "estimated_tokens": 352
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 69,
      "total_chunks": 120,
      "char_count": 1458,
      "estimated_tokens": 364
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 70,
      "total_chunks": 120,
      "char_count": 1424,
      "estimated_tokens": 356
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 71,
      "total_chunks": 120,
      "char_count": 1285,
      "estimated_tokens": 321
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 72,
      "total_chunks": 120,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 73,
      "total_chunks": 120,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 74,
      "total_chunks": 120,
      "char_count": 1407,
      "estimated_tokens": 351
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 75,
      "total_chunks": 120,
      "char_count": 1435,
      "estimated_tokens": 358
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 76,
      "total_chunks": 120,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 77,
      "total_chunks": 120,
      "char_count": 1307,
      "estimated_tokens": 326
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 78,
      "total_chunks": 120,
      "char_count": 1261,
      "estimated_tokens": 315
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 79,
      "total_chunks": 120,
      "char_count": 390,
      "estimated_tokens": 97
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 80,
      "total_chunks": 120,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 81,
      "total_chunks": 120,
      "char_count": 1498,
      "estimated_tokens": 374
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 82,
      "total_chunks": 120,
      "char_count": 821,
      "estimated_tokens": 205
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 83,
      "total_chunks": 120,
      "char_count": 1383,
      "estimated_tokens": 345
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 84,
      "total_chunks": 120,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 85,
      "total_chunks": 120,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 86,
      "total_chunks": 120,
      "char_count": 1491,
      "estimated_tokens": 372
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 87,
      "total_chunks": 120,
      "char_count": 1481,
      "estimated_tokens": 370
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 88,
      "total_chunks": 120,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 89,
      "total_chunks": 120,
      "char_count": 1483,
      "estimated_tokens": 370
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 90,
      "total_chunks": 120,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 91,
      "total_chunks": 120,
      "char_count": 1476,
      "estimated_tokens": 369
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 92,
      "total_chunks": 120,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 93,
      "total_chunks": 120,
      "char_count": 1324,
      "estimated_tokens": 331
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 94,
      "total_chunks": 120,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 95,
      "total_chunks": 120,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 96,
      "total_chunks": 120,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 97,
      "total_chunks": 120,
      "char_count": 1326,
      "estimated_tokens": 331
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 98,
      "total_chunks": 120,
      "char_count": 1438,
      "estimated_tokens": 359
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 99,
      "total_chunks": 120,
      "char_count": 1467,
      "estimated_tokens": 366
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 100,
      "total_chunks": 120,
      "char_count": 1432,
      "estimated_tokens": 358
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 101,
      "total_chunks": 120,
      "char_count": 1493,
      "estimated_tokens": 373
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 102,
      "total_chunks": 120,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 103,
      "total_chunks": 120,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 104,
      "total_chunks": 120,
      "char_count": 1354,
      "estimated_tokens": 338
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 105,
      "total_chunks": 120,
      "char_count": 1456,
      "estimated_tokens": 364
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 106,
      "total_chunks": 120,
      "char_count": 1373,
      "estimated_tokens": 343
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 107,
      "total_chunks": 120,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 108,
      "total_chunks": 120,
      "char_count": 1448,
      "estimated_tokens": 362
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 109,
      "total_chunks": 120,
      "char_count": 1424,
      "estimated_tokens": 356
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 110,
      "total_chunks": 120,
      "char_count": 1460,
      "estimated_tokens": 365
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 111,
      "total_chunks": 120,
      "char_count": 1426,
      "estimated_tokens": 356
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 112,
      "total_chunks": 120,
      "char_count": 1485,
      "estimated_tokens": 371
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 113,
      "total_chunks": 120,
      "char_count": 1475,
      "estimated_tokens": 368
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 114,
      "total_chunks": 120,
      "char_count": 1377,
      "estimated_tokens": 344
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 115,
      "total_chunks": 120,
      "char_count": 1336,
      "estimated_tokens": 334
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 116,
      "total_chunks": 120,
      "char_count": 1345,
      "estimated_tokens": 336
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 117,
      "total_chunks": 120,
      "char_count": 1479,
      "estimated_tokens": 369
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 118,
      "total_chunks": 120,
      "char_count": 1426,
      "estimated_tokens": 356
    },
    {
      "source": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "source_type": "pdf",
      "file_hash": "72dac8e22d304c10",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:58.353179",
      "filename": "2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf",
      "page_count": 25,
      "title": "GMEv28n9--issue-proof.pdf",
      "author": "Carolyn",
      "chunk_index": 119,
      "total_chunks": 120,
      "char_count": 1241,
      "estimated_tokens": 310
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 0,
      "total_chunks": 96,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 1,
      "total_chunks": 96,
      "char_count": 1359,
      "estimated_tokens": 339
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 2,
      "total_chunks": 96,
      "char_count": 1253,
      "estimated_tokens": 313
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 3,
      "total_chunks": 96,
      "char_count": 1397,
      "estimated_tokens": 349
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 4,
      "total_chunks": 96,
      "char_count": 1342,
      "estimated_tokens": 335
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 5,
      "total_chunks": 96,
      "char_count": 1471,
      "estimated_tokens": 367
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 6,
      "total_chunks": 96,
      "char_count": 1474,
      "estimated_tokens": 368
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 7,
      "total_chunks": 96,
      "char_count": 1343,
      "estimated_tokens": 335
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 8,
      "total_chunks": 96,
      "char_count": 1425,
      "estimated_tokens": 356
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 9,
      "total_chunks": 96,
      "char_count": 1328,
      "estimated_tokens": 332
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 10,
      "total_chunks": 96,
      "char_count": 1355,
      "estimated_tokens": 338
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 11,
      "total_chunks": 96,
      "char_count": 1433,
      "estimated_tokens": 358
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 12,
      "total_chunks": 96,
      "char_count": 1386,
      "estimated_tokens": 346
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 13,
      "total_chunks": 96,
      "char_count": 1457,
      "estimated_tokens": 364
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 14,
      "total_chunks": 96,
      "char_count": 1374,
      "estimated_tokens": 343
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 15,
      "total_chunks": 96,
      "char_count": 1289,
      "estimated_tokens": 322
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 16,
      "total_chunks": 96,
      "char_count": 1490,
      "estimated_tokens": 372
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 17,
      "total_chunks": 96,
      "char_count": 1480,
      "estimated_tokens": 370
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 18,
      "total_chunks": 96,
      "char_count": 1475,
      "estimated_tokens": 368
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 19,
      "total_chunks": 96,
      "char_count": 1303,
      "estimated_tokens": 325
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 20,
      "total_chunks": 96,
      "char_count": 1289,
      "estimated_tokens": 322
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 21,
      "total_chunks": 96,
      "char_count": 1368,
      "estimated_tokens": 342
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 22,
      "total_chunks": 96,
      "char_count": 1367,
      "estimated_tokens": 341
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 23,
      "total_chunks": 96,
      "char_count": 1475,
      "estimated_tokens": 368
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 24,
      "total_chunks": 96,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 25,
      "total_chunks": 96,
      "char_count": 1453,
      "estimated_tokens": 363
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 26,
      "total_chunks": 96,
      "char_count": 833,
      "estimated_tokens": 208
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 27,
      "total_chunks": 96,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 28,
      "total_chunks": 96,
      "char_count": 1412,
      "estimated_tokens": 353
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 29,
      "total_chunks": 96,
      "char_count": 1400,
      "estimated_tokens": 350
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 30,
      "total_chunks": 96,
      "char_count": 1031,
      "estimated_tokens": 257
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 31,
      "total_chunks": 96,
      "char_count": 1360,
      "estimated_tokens": 340
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 32,
      "total_chunks": 96,
      "char_count": 1090,
      "estimated_tokens": 272
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 33,
      "total_chunks": 96,
      "char_count": 1327,
      "estimated_tokens": 331
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 34,
      "total_chunks": 96,
      "char_count": 1351,
      "estimated_tokens": 337
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 35,
      "total_chunks": 96,
      "char_count": 1453,
      "estimated_tokens": 363
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 36,
      "total_chunks": 96,
      "char_count": 1168,
      "estimated_tokens": 292
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 37,
      "total_chunks": 96,
      "char_count": 1339,
      "estimated_tokens": 334
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 38,
      "total_chunks": 96,
      "char_count": 1393,
      "estimated_tokens": 348
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 39,
      "total_chunks": 96,
      "char_count": 1399,
      "estimated_tokens": 349
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 40,
      "total_chunks": 96,
      "char_count": 1451,
      "estimated_tokens": 362
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 41,
      "total_chunks": 96,
      "char_count": 1328,
      "estimated_tokens": 332
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 42,
      "total_chunks": 96,
      "char_count": 1284,
      "estimated_tokens": 321
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 43,
      "total_chunks": 96,
      "char_count": 1434,
      "estimated_tokens": 358
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 44,
      "total_chunks": 96,
      "char_count": 1458,
      "estimated_tokens": 364
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 45,
      "total_chunks": 96,
      "char_count": 1277,
      "estimated_tokens": 319
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 46,
      "total_chunks": 96,
      "char_count": 1275,
      "estimated_tokens": 318
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 47,
      "total_chunks": 96,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 48,
      "total_chunks": 96,
      "char_count": 1340,
      "estimated_tokens": 335
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 49,
      "total_chunks": 96,
      "char_count": 1371,
      "estimated_tokens": 342
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 50,
      "total_chunks": 96,
      "char_count": 1427,
      "estimated_tokens": 356
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 51,
      "total_chunks": 96,
      "char_count": 1460,
      "estimated_tokens": 365
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 52,
      "total_chunks": 96,
      "char_count": 1310,
      "estimated_tokens": 327
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 53,
      "total_chunks": 96,
      "char_count": 1346,
      "estimated_tokens": 336
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 54,
      "total_chunks": 96,
      "char_count": 488,
      "estimated_tokens": 122
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 55,
      "total_chunks": 96,
      "char_count": 1191,
      "estimated_tokens": 297
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 56,
      "total_chunks": 96,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 57,
      "total_chunks": 96,
      "char_count": 494,
      "estimated_tokens": 123
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 58,
      "total_chunks": 96,
      "char_count": 1313,
      "estimated_tokens": 328
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 59,
      "total_chunks": 96,
      "char_count": 1321,
      "estimated_tokens": 330
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 60,
      "total_chunks": 96,
      "char_count": 1433,
      "estimated_tokens": 358
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 61,
      "total_chunks": 96,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 62,
      "total_chunks": 96,
      "char_count": 1483,
      "estimated_tokens": 370
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 63,
      "total_chunks": 96,
      "char_count": 1431,
      "estimated_tokens": 357
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 64,
      "total_chunks": 96,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 65,
      "total_chunks": 96,
      "char_count": 1446,
      "estimated_tokens": 361
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 66,
      "total_chunks": 96,
      "char_count": 1443,
      "estimated_tokens": 360
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 67,
      "total_chunks": 96,
      "char_count": 1454,
      "estimated_tokens": 363
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 68,
      "total_chunks": 96,
      "char_count": 1417,
      "estimated_tokens": 354
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 69,
      "total_chunks": 96,
      "char_count": 1478,
      "estimated_tokens": 369
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 70,
      "total_chunks": 96,
      "char_count": 1485,
      "estimated_tokens": 371
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 71,
      "total_chunks": 96,
      "char_count": 1471,
      "estimated_tokens": 367
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 72,
      "total_chunks": 96,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 73,
      "total_chunks": 96,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 74,
      "total_chunks": 96,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 75,
      "total_chunks": 96,
      "char_count": 1430,
      "estimated_tokens": 357
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 76,
      "total_chunks": 96,
      "char_count": 1398,
      "estimated_tokens": 349
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 77,
      "total_chunks": 96,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 78,
      "total_chunks": 96,
      "char_count": 1369,
      "estimated_tokens": 342
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 79,
      "total_chunks": 96,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 80,
      "total_chunks": 96,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 81,
      "total_chunks": 96,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 82,
      "total_chunks": 96,
      "char_count": 1479,
      "estimated_tokens": 369
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 83,
      "total_chunks": 96,
      "char_count": 1201,
      "estimated_tokens": 300
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 84,
      "total_chunks": 96,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 85,
      "total_chunks": 96,
      "char_count": 1320,
      "estimated_tokens": 330
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 86,
      "total_chunks": 96,
      "char_count": 1476,
      "estimated_tokens": 369
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 87,
      "total_chunks": 96,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 88,
      "total_chunks": 96,
      "char_count": 1436,
      "estimated_tokens": 359
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 89,
      "total_chunks": 96,
      "char_count": 1414,
      "estimated_tokens": 353
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 90,
      "total_chunks": 96,
      "char_count": 1437,
      "estimated_tokens": 359
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 91,
      "total_chunks": 96,
      "char_count": 1449,
      "estimated_tokens": 362
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 92,
      "total_chunks": 96,
      "char_count": 1430,
      "estimated_tokens": 357
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 93,
      "total_chunks": 96,
      "char_count": 1354,
      "estimated_tokens": 338
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 94,
      "total_chunks": 96,
      "char_count": 1460,
      "estimated_tokens": 365
    },
    {
      "source": "2023-nonhormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "94cf041592dc7c98",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.092684",
      "filename": "2023-nonhormone-therapy-position-statement.pdf",
      "page_count": 18,
      "title": "MENO_230215 573..590",
      "chunk_index": 95,
      "total_chunks": 96,
      "char_count": 1176,
      "estimated_tokens": 294
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 0,
      "total_chunks": 132,
      "char_count": 1262,
      "estimated_tokens": 315
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 1,
      "total_chunks": 132,
      "char_count": 979,
      "estimated_tokens": 244
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 2,
      "total_chunks": 132,
      "char_count": 1601,
      "estimated_tokens": 400
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 3,
      "total_chunks": 132,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 4,
      "total_chunks": 132,
      "char_count": 1204,
      "estimated_tokens": 301
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 5,
      "total_chunks": 132,
      "char_count": 1316,
      "estimated_tokens": 329
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 6,
      "total_chunks": 132,
      "char_count": 1418,
      "estimated_tokens": 354
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 7,
      "total_chunks": 132,
      "char_count": 1481,
      "estimated_tokens": 370
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 8,
      "total_chunks": 132,
      "char_count": 1471,
      "estimated_tokens": 367
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 9,
      "total_chunks": 132,
      "char_count": 1443,
      "estimated_tokens": 360
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 10,
      "total_chunks": 132,
      "char_count": 1493,
      "estimated_tokens": 373
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 11,
      "total_chunks": 132,
      "char_count": 1328,
      "estimated_tokens": 332
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 12,
      "total_chunks": 132,
      "char_count": 1390,
      "estimated_tokens": 347
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 13,
      "total_chunks": 132,
      "char_count": 1451,
      "estimated_tokens": 362
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 14,
      "total_chunks": 132,
      "char_count": 1419,
      "estimated_tokens": 354
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 15,
      "total_chunks": 132,
      "char_count": 1450,
      "estimated_tokens": 362
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 16,
      "total_chunks": 132,
      "char_count": 1350,
      "estimated_tokens": 337
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 17,
      "total_chunks": 132,
      "char_count": 1255,
      "estimated_tokens": 313
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 18,
      "total_chunks": 132,
      "char_count": 903,
      "estimated_tokens": 225
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 19,
      "total_chunks": 132,
      "char_count": 1383,
      "estimated_tokens": 345
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 20,
      "total_chunks": 132,
      "char_count": 1299,
      "estimated_tokens": 324
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 21,
      "total_chunks": 132,
      "char_count": 1399,
      "estimated_tokens": 349
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 22,
      "total_chunks": 132,
      "char_count": 1298,
      "estimated_tokens": 324
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 23,
      "total_chunks": 132,
      "char_count": 1393,
      "estimated_tokens": 348
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 24,
      "total_chunks": 132,
      "char_count": 1487,
      "estimated_tokens": 371
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 25,
      "total_chunks": 132,
      "char_count": 1249,
      "estimated_tokens": 312
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 26,
      "total_chunks": 132,
      "char_count": 1461,
      "estimated_tokens": 365
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 27,
      "total_chunks": 132,
      "char_count": 1423,
      "estimated_tokens": 355
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 28,
      "total_chunks": 132,
      "char_count": 1330,
      "estimated_tokens": 332
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 29,
      "total_chunks": 132,
      "char_count": 1496,
      "estimated_tokens": 374
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 30,
      "total_chunks": 132,
      "char_count": 1375,
      "estimated_tokens": 343
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 31,
      "total_chunks": 132,
      "char_count": 1403,
      "estimated_tokens": 350
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 32,
      "total_chunks": 132,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 33,
      "total_chunks": 132,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 34,
      "total_chunks": 132,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 35,
      "total_chunks": 132,
      "char_count": 1188,
      "estimated_tokens": 297
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 36,
      "total_chunks": 132,
      "char_count": 1479,
      "estimated_tokens": 369
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 37,
      "total_chunks": 132,
      "char_count": 1396,
      "estimated_tokens": 349
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 38,
      "total_chunks": 132,
      "char_count": 1486,
      "estimated_tokens": 371
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 39,
      "total_chunks": 132,
      "char_count": 1467,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 40,
      "total_chunks": 132,
      "char_count": 1461,
      "estimated_tokens": 365
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 41,
      "total_chunks": 132,
      "char_count": 1450,
      "estimated_tokens": 362
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 42,
      "total_chunks": 132,
      "char_count": 1387,
      "estimated_tokens": 346
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 43,
      "total_chunks": 132,
      "char_count": 1370,
      "estimated_tokens": 342
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 44,
      "total_chunks": 132,
      "char_count": 1496,
      "estimated_tokens": 374
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 45,
      "total_chunks": 132,
      "char_count": 1285,
      "estimated_tokens": 321
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 46,
      "total_chunks": 132,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 47,
      "total_chunks": 132,
      "char_count": 1488,
      "estimated_tokens": 372
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 48,
      "total_chunks": 132,
      "char_count": 1410,
      "estimated_tokens": 352
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 49,
      "total_chunks": 132,
      "char_count": 1130,
      "estimated_tokens": 282
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 50,
      "total_chunks": 132,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 51,
      "total_chunks": 132,
      "char_count": 1344,
      "estimated_tokens": 336
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 52,
      "total_chunks": 132,
      "char_count": 1410,
      "estimated_tokens": 352
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 53,
      "total_chunks": 132,
      "char_count": 1448,
      "estimated_tokens": 362
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 54,
      "total_chunks": 132,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 55,
      "total_chunks": 132,
      "char_count": 952,
      "estimated_tokens": 238
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 56,
      "total_chunks": 132,
      "char_count": 1460,
      "estimated_tokens": 365
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 57,
      "total_chunks": 132,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 58,
      "total_chunks": 132,
      "char_count": 1438,
      "estimated_tokens": 359
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 59,
      "total_chunks": 132,
      "char_count": 1451,
      "estimated_tokens": 362
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 60,
      "total_chunks": 132,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 61,
      "total_chunks": 132,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 62,
      "total_chunks": 132,
      "char_count": 1447,
      "estimated_tokens": 361
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 63,
      "total_chunks": 132,
      "char_count": 1267,
      "estimated_tokens": 316
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 64,
      "total_chunks": 132,
      "char_count": 1304,
      "estimated_tokens": 326
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 65,
      "total_chunks": 132,
      "char_count": 1463,
      "estimated_tokens": 365
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 66,
      "total_chunks": 132,
      "char_count": 1471,
      "estimated_tokens": 367
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 67,
      "total_chunks": 132,
      "char_count": 1329,
      "estimated_tokens": 332
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 68,
      "total_chunks": 132,
      "char_count": 1483,
      "estimated_tokens": 370
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 69,
      "total_chunks": 132,
      "char_count": 1398,
      "estimated_tokens": 349
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 70,
      "total_chunks": 132,
      "char_count": 1358,
      "estimated_tokens": 339
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 71,
      "total_chunks": 132,
      "char_count": 1303,
      "estimated_tokens": 325
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 72,
      "total_chunks": 132,
      "char_count": 1269,
      "estimated_tokens": 317
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 73,
      "total_chunks": 132,
      "char_count": 1439,
      "estimated_tokens": 359
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 74,
      "total_chunks": 132,
      "char_count": 1369,
      "estimated_tokens": 342
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 75,
      "total_chunks": 132,
      "char_count": 1296,
      "estimated_tokens": 324
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 76,
      "total_chunks": 132,
      "char_count": 1230,
      "estimated_tokens": 307
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 77,
      "total_chunks": 132,
      "char_count": 1411,
      "estimated_tokens": 352
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 78,
      "total_chunks": 132,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 79,
      "total_chunks": 132,
      "char_count": 1481,
      "estimated_tokens": 370
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 80,
      "total_chunks": 132,
      "char_count": 1290,
      "estimated_tokens": 322
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 81,
      "total_chunks": 132,
      "char_count": 1476,
      "estimated_tokens": 369
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 82,
      "total_chunks": 132,
      "char_count": 1498,
      "estimated_tokens": 374
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 83,
      "total_chunks": 132,
      "char_count": 1446,
      "estimated_tokens": 361
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 84,
      "total_chunks": 132,
      "char_count": 1334,
      "estimated_tokens": 333
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 85,
      "total_chunks": 132,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 86,
      "total_chunks": 132,
      "char_count": 1301,
      "estimated_tokens": 325
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 87,
      "total_chunks": 132,
      "char_count": 1341,
      "estimated_tokens": 335
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 88,
      "total_chunks": 132,
      "char_count": 1296,
      "estimated_tokens": 324
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 89,
      "total_chunks": 132,
      "char_count": 1440,
      "estimated_tokens": 360
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 90,
      "total_chunks": 132,
      "char_count": 1377,
      "estimated_tokens": 344
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 91,
      "total_chunks": 132,
      "char_count": 1386,
      "estimated_tokens": 346
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 92,
      "total_chunks": 132,
      "char_count": 1253,
      "estimated_tokens": 313
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 93,
      "total_chunks": 132,
      "char_count": 1382,
      "estimated_tokens": 345
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 94,
      "total_chunks": 132,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 95,
      "total_chunks": 132,
      "char_count": 1446,
      "estimated_tokens": 361
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 96,
      "total_chunks": 132,
      "char_count": 1411,
      "estimated_tokens": 352
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 97,
      "total_chunks": 132,
      "char_count": 1329,
      "estimated_tokens": 332
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 98,
      "total_chunks": 132,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 99,
      "total_chunks": 132,
      "char_count": 1359,
      "estimated_tokens": 339
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 100,
      "total_chunks": 132,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 101,
      "total_chunks": 132,
      "char_count": 1422,
      "estimated_tokens": 355
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 102,
      "total_chunks": 132,
      "char_count": 1400,
      "estimated_tokens": 350
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 103,
      "total_chunks": 132,
      "char_count": 1409,
      "estimated_tokens": 352
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 104,
      "total_chunks": 132,
      "char_count": 1232,
      "estimated_tokens": 308
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 105,
      "total_chunks": 132,
      "char_count": 1468,
      "estimated_tokens": 367
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 106,
      "total_chunks": 132,
      "char_count": 1438,
      "estimated_tokens": 359
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 107,
      "total_chunks": 132,
      "char_count": 1387,
      "estimated_tokens": 346
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 108,
      "total_chunks": 132,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 109,
      "total_chunks": 132,
      "char_count": 1474,
      "estimated_tokens": 368
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 110,
      "total_chunks": 132,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 111,
      "total_chunks": 132,
      "char_count": 1367,
      "estimated_tokens": 341
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 112,
      "total_chunks": 132,
      "char_count": 1318,
      "estimated_tokens": 329
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 113,
      "total_chunks": 132,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 114,
      "total_chunks": 132,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 115,
      "total_chunks": 132,
      "char_count": 1319,
      "estimated_tokens": 329
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 116,
      "total_chunks": 132,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 117,
      "total_chunks": 132,
      "char_count": 1336,
      "estimated_tokens": 334
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 118,
      "total_chunks": 132,
      "char_count": 1436,
      "estimated_tokens": 359
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 119,
      "total_chunks": 132,
      "char_count": 1382,
      "estimated_tokens": 345
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 120,
      "total_chunks": 132,
      "char_count": 1451,
      "estimated_tokens": 362
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 121,
      "total_chunks": 132,
      "char_count": 1394,
      "estimated_tokens": 348
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 122,
      "total_chunks": 132,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 123,
      "total_chunks": 132,
      "char_count": 1404,
      "estimated_tokens": 351
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 124,
      "total_chunks": 132,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 125,
      "total_chunks": 132,
      "char_count": 1298,
      "estimated_tokens": 324
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 126,
      "total_chunks": 132,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 127,
      "total_chunks": 132,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 128,
      "total_chunks": 132,
      "char_count": 1275,
      "estimated_tokens": 318
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 129,
      "total_chunks": 132,
      "char_count": 1427,
      "estimated_tokens": 356
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 130,
      "total_chunks": 132,
      "char_count": 1473,
      "estimated_tokens": 368
    },
    {
      "source": "NICE_doctor.pdf",
      "source_type": "pdf",
      "file_hash": "cea37916f0dda945",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.763221",
      "filename": "NICE_doctor.pdf",
      "page_count": 106,
      "title": "Menopause: identification and management",
      "author": "National Institute for Health and Care Excellence (NICE)",
      "chunk_index": 131,
      "total_chunks": 132,
      "char_count": 729,
      "estimated_tokens": 182
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 0,
      "total_chunks": 52,
      "char_count": 1390,
      "estimated_tokens": 347
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 1,
      "total_chunks": 52,
      "char_count": 1357,
      "estimated_tokens": 339
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 2,
      "total_chunks": 52,
      "char_count": 1171,
      "estimated_tokens": 292
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 3,
      "total_chunks": 52,
      "char_count": 1209,
      "estimated_tokens": 302
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 4,
      "total_chunks": 52,
      "char_count": 2049,
      "estimated_tokens": 512
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 5,
      "total_chunks": 52,
      "char_count": 1407,
      "estimated_tokens": 351
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 6,
      "total_chunks": 52,
      "char_count": 1424,
      "estimated_tokens": 356
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 7,
      "total_chunks": 52,
      "char_count": 1500,
      "estimated_tokens": 375
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 8,
      "total_chunks": 52,
      "char_count": 1435,
      "estimated_tokens": 358
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 9,
      "total_chunks": 52,
      "char_count": 1374,
      "estimated_tokens": 343
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 10,
      "total_chunks": 52,
      "char_count": 1494,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 11,
      "total_chunks": 52,
      "char_count": 1321,
      "estimated_tokens": 330
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 12,
      "total_chunks": 52,
      "char_count": 1357,
      "estimated_tokens": 339
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 13,
      "total_chunks": 52,
      "char_count": 1343,
      "estimated_tokens": 335
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 14,
      "total_chunks": 52,
      "char_count": 1493,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 15,
      "total_chunks": 52,
      "char_count": 1364,
      "estimated_tokens": 341
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 16,
      "total_chunks": 52,
      "char_count": 1352,
      "estimated_tokens": 338
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 17,
      "total_chunks": 52,
      "char_count": 1421,
      "estimated_tokens": 355
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 18,
      "total_chunks": 52,
      "char_count": 1494,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 19,
      "total_chunks": 52,
      "char_count": 1359,
      "estimated_tokens": 339
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 20,
      "total_chunks": 52,
      "char_count": 1377,
      "estimated_tokens": 344
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 21,
      "total_chunks": 52,
      "char_count": 1491,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 22,
      "total_chunks": 52,
      "char_count": 1458,
      "estimated_tokens": 364
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 23,
      "total_chunks": 52,
      "char_count": 1348,
      "estimated_tokens": 337
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 24,
      "total_chunks": 52,
      "char_count": 1350,
      "estimated_tokens": 337
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 25,
      "total_chunks": 52,
      "char_count": 1411,
      "estimated_tokens": 352
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 26,
      "total_chunks": 52,
      "char_count": 1412,
      "estimated_tokens": 353
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 27,
      "total_chunks": 52,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 28,
      "total_chunks": 52,
      "char_count": 1412,
      "estimated_tokens": 353
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 29,
      "total_chunks": 52,
      "char_count": 1367,
      "estimated_tokens": 341
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 30,
      "total_chunks": 52,
      "char_count": 1450,
      "estimated_tokens": 362
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 31,
      "total_chunks": 52,
      "char_count": 1372,
      "estimated_tokens": 343
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 32,
      "total_chunks": 52,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 33,
      "total_chunks": 52,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 34,
      "total_chunks": 52,
      "char_count": 794,
      "estimated_tokens": 198
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 35,
      "total_chunks": 52,
      "char_count": 1231,
      "estimated_tokens": 307
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 36,
      "total_chunks": 52,
      "char_count": 1406,
      "estimated_tokens": 351
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 37,
      "total_chunks": 52,
      "char_count": 1487,
      "estimated_tokens": 371
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 38,
      "total_chunks": 52,
      "char_count": 1392,
      "estimated_tokens": 348
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 39,
      "total_chunks": 52,
      "char_count": 1478,
      "estimated_tokens": 369
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 40,
      "total_chunks": 52,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 41,
      "total_chunks": 52,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 42,
      "total_chunks": 52,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 43,
      "total_chunks": 52,
      "char_count": 1493,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 44,
      "total_chunks": 52,
      "char_count": 1454,
      "estimated_tokens": 363
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 45,
      "total_chunks": 52,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 46,
      "total_chunks": 52,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 47,
      "total_chunks": 52,
      "char_count": 1360,
      "estimated_tokens": 340
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 48,
      "total_chunks": 52,
      "char_count": 1485,
      "estimated_tokens": 371
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 49,
      "total_chunks": 52,
      "char_count": 1481,
      "estimated_tokens": 370
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 50,
      "total_chunks": 52,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS014067362302799X.pdf",
      "source_type": "pdf",
      "file_hash": "979530a2a09b907f",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:15:59.990042",
      "filename": "PIIS014067362302799X.pdf",
      "page_count": 11,
      "title": "An empowerment model for managing menopause",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 51,
      "total_chunks": 52,
      "char_count": 740,
      "estimated_tokens": 185
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 0,
      "total_chunks": 53,
      "char_count": 1319,
      "estimated_tokens": 329
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 1,
      "total_chunks": 53,
      "char_count": 1326,
      "estimated_tokens": 331
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 2,
      "total_chunks": 53,
      "char_count": 1405,
      "estimated_tokens": 351
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 3,
      "total_chunks": 53,
      "char_count": 1035,
      "estimated_tokens": 258
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 4,
      "total_chunks": 53,
      "char_count": 1409,
      "estimated_tokens": 352
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 5,
      "total_chunks": 53,
      "char_count": 1326,
      "estimated_tokens": 331
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 6,
      "total_chunks": 53,
      "char_count": 1410,
      "estimated_tokens": 352
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 7,
      "total_chunks": 53,
      "char_count": 1479,
      "estimated_tokens": 369
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 8,
      "total_chunks": 53,
      "char_count": 1397,
      "estimated_tokens": 349
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 9,
      "total_chunks": 53,
      "char_count": 1338,
      "estimated_tokens": 334
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 10,
      "total_chunks": 53,
      "char_count": 1296,
      "estimated_tokens": 324
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 11,
      "total_chunks": 53,
      "char_count": 1381,
      "estimated_tokens": 345
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 12,
      "total_chunks": 53,
      "char_count": 1330,
      "estimated_tokens": 332
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 13,
      "total_chunks": 53,
      "char_count": 1341,
      "estimated_tokens": 335
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 14,
      "total_chunks": 53,
      "char_count": 1262,
      "estimated_tokens": 315
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 15,
      "total_chunks": 53,
      "char_count": 1407,
      "estimated_tokens": 351
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 16,
      "total_chunks": 53,
      "char_count": 1310,
      "estimated_tokens": 327
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 17,
      "total_chunks": 53,
      "char_count": 1402,
      "estimated_tokens": 350
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 18,
      "total_chunks": 53,
      "char_count": 1449,
      "estimated_tokens": 362
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 19,
      "total_chunks": 53,
      "char_count": 1302,
      "estimated_tokens": 325
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 20,
      "total_chunks": 53,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 21,
      "total_chunks": 53,
      "char_count": 1343,
      "estimated_tokens": 335
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 22,
      "total_chunks": 53,
      "char_count": 1192,
      "estimated_tokens": 298
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 23,
      "total_chunks": 53,
      "char_count": 1396,
      "estimated_tokens": 349
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 24,
      "total_chunks": 53,
      "char_count": 1331,
      "estimated_tokens": 332
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 25,
      "total_chunks": 53,
      "char_count": 1411,
      "estimated_tokens": 352
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 26,
      "total_chunks": 53,
      "char_count": 1475,
      "estimated_tokens": 368
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 27,
      "total_chunks": 53,
      "char_count": 1351,
      "estimated_tokens": 337
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 28,
      "total_chunks": 53,
      "char_count": 1490,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 29,
      "total_chunks": 53,
      "char_count": 354,
      "estimated_tokens": 88
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 30,
      "total_chunks": 53,
      "char_count": 1500,
      "estimated_tokens": 375
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 31,
      "total_chunks": 53,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 32,
      "total_chunks": 53,
      "char_count": 641,
      "estimated_tokens": 160
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 33,
      "total_chunks": 53,
      "char_count": 1383,
      "estimated_tokens": 345
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 34,
      "total_chunks": 53,
      "char_count": 1346,
      "estimated_tokens": 336
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 35,
      "total_chunks": 53,
      "char_count": 1434,
      "estimated_tokens": 358
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 36,
      "total_chunks": 53,
      "char_count": 913,
      "estimated_tokens": 228
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 37,
      "total_chunks": 53,
      "char_count": 1825,
      "estimated_tokens": 456
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 38,
      "total_chunks": 53,
      "char_count": 1439,
      "estimated_tokens": 359
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 39,
      "total_chunks": 53,
      "char_count": 1467,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 40,
      "total_chunks": 53,
      "char_count": 1401,
      "estimated_tokens": 350
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 41,
      "total_chunks": 53,
      "char_count": 1491,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 42,
      "total_chunks": 53,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 43,
      "total_chunks": 53,
      "char_count": 1417,
      "estimated_tokens": 354
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 44,
      "total_chunks": 53,
      "char_count": 1406,
      "estimated_tokens": 351
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 45,
      "total_chunks": 53,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 46,
      "total_chunks": 53,
      "char_count": 1483,
      "estimated_tokens": 370
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 47,
      "total_chunks": 53,
      "char_count": 1480,
      "estimated_tokens": 370
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 48,
      "total_chunks": 53,
      "char_count": 1476,
      "estimated_tokens": 369
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 49,
      "total_chunks": 53,
      "char_count": 1443,
      "estimated_tokens": 360
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 50,
      "total_chunks": 53,
      "char_count": 1401,
      "estimated_tokens": 350
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 51,
      "total_chunks": 53,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS0140673623028003.pdf",
      "source_type": "pdf",
      "file_hash": "6a35680300af17ac",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.189298",
      "filename": "PIIS0140673623028003.pdf",
      "page_count": 11,
      "title": "Optimising health after early menopause",
      "author": "Prof Gita D Mishra PhD",
      "chunk_index": 52,
      "total_chunks": 53,
      "char_count": 1249,
      "estimated_tokens": 312
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 0,
      "total_chunks": 66,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 1,
      "total_chunks": 66,
      "char_count": 1342,
      "estimated_tokens": 335
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 2,
      "total_chunks": 66,
      "char_count": 1293,
      "estimated_tokens": 323
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 3,
      "total_chunks": 66,
      "char_count": 572,
      "estimated_tokens": 143
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 4,
      "total_chunks": 66,
      "char_count": 1403,
      "estimated_tokens": 350
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 5,
      "total_chunks": 66,
      "char_count": 1321,
      "estimated_tokens": 330
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 6,
      "total_chunks": 66,
      "char_count": 1290,
      "estimated_tokens": 322
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 7,
      "total_chunks": 66,
      "char_count": 1306,
      "estimated_tokens": 326
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 8,
      "total_chunks": 66,
      "char_count": 989,
      "estimated_tokens": 247
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 9,
      "total_chunks": 66,
      "char_count": 1942,
      "estimated_tokens": 485
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 10,
      "total_chunks": 66,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 11,
      "total_chunks": 66,
      "char_count": 1491,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 12,
      "total_chunks": 66,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 13,
      "total_chunks": 66,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 14,
      "total_chunks": 66,
      "char_count": 1493,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 15,
      "total_chunks": 66,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 16,
      "total_chunks": 66,
      "char_count": 818,
      "estimated_tokens": 204
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 17,
      "total_chunks": 66,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 18,
      "total_chunks": 66,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 19,
      "total_chunks": 66,
      "char_count": 1611,
      "estimated_tokens": 402
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 20,
      "total_chunks": 66,
      "char_count": 1221,
      "estimated_tokens": 305
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 21,
      "total_chunks": 66,
      "char_count": 1486,
      "estimated_tokens": 371
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 22,
      "total_chunks": 66,
      "char_count": 1376,
      "estimated_tokens": 344
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 23,
      "total_chunks": 66,
      "char_count": 1363,
      "estimated_tokens": 340
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 24,
      "total_chunks": 66,
      "char_count": 1422,
      "estimated_tokens": 355
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 25,
      "total_chunks": 66,
      "char_count": 1242,
      "estimated_tokens": 310
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 26,
      "total_chunks": 66,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 27,
      "total_chunks": 66,
      "char_count": 1421,
      "estimated_tokens": 355
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 28,
      "total_chunks": 66,
      "char_count": 1430,
      "estimated_tokens": 357
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 29,
      "total_chunks": 66,
      "char_count": 1416,
      "estimated_tokens": 354
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 30,
      "total_chunks": 66,
      "char_count": 1409,
      "estimated_tokens": 352
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 31,
      "total_chunks": 66,
      "char_count": 1236,
      "estimated_tokens": 309
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 32,
      "total_chunks": 66,
      "char_count": 1304,
      "estimated_tokens": 326
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 33,
      "total_chunks": 66,
      "char_count": 1467,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 34,
      "total_chunks": 66,
      "char_count": 1325,
      "estimated_tokens": 331
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 35,
      "total_chunks": 66,
      "char_count": 1158,
      "estimated_tokens": 289
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 36,
      "total_chunks": 66,
      "char_count": 1444,
      "estimated_tokens": 361
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 37,
      "total_chunks": 66,
      "char_count": 1450,
      "estimated_tokens": 362
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 38,
      "total_chunks": 66,
      "char_count": 1334,
      "estimated_tokens": 333
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 39,
      "total_chunks": 66,
      "char_count": 1104,
      "estimated_tokens": 276
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 40,
      "total_chunks": 66,
      "char_count": 1496,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 41,
      "total_chunks": 66,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 42,
      "total_chunks": 66,
      "char_count": 757,
      "estimated_tokens": 189
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 43,
      "total_chunks": 66,
      "char_count": 1425,
      "estimated_tokens": 356
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 44,
      "total_chunks": 66,
      "char_count": 1356,
      "estimated_tokens": 339
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 45,
      "total_chunks": 66,
      "char_count": 615,
      "estimated_tokens": 153
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 46,
      "total_chunks": 66,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 47,
      "total_chunks": 66,
      "char_count": 1379,
      "estimated_tokens": 344
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 48,
      "total_chunks": 66,
      "char_count": 1314,
      "estimated_tokens": 328
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 49,
      "total_chunks": 66,
      "char_count": 1415,
      "estimated_tokens": 353
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 50,
      "total_chunks": 66,
      "char_count": 1463,
      "estimated_tokens": 365
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 51,
      "total_chunks": 66,
      "char_count": 1432,
      "estimated_tokens": 358
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 52,
      "total_chunks": 66,
      "char_count": 1476,
      "estimated_tokens": 369
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 53,
      "total_chunks": 66,
      "char_count": 1488,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 54,
      "total_chunks": 66,
      "char_count": 1389,
      "estimated_tokens": 347
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 55,
      "total_chunks": 66,
      "char_count": 1383,
      "estimated_tokens": 345
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 56,
      "total_chunks": 66,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 57,
      "total_chunks": 66,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 58,
      "total_chunks": 66,
      "char_count": 1352,
      "estimated_tokens": 338
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 59,
      "total_chunks": 66,
      "char_count": 1459,
      "estimated_tokens": 364
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 60,
      "total_chunks": 66,
      "char_count": 1439,
      "estimated_tokens": 359
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 61,
      "total_chunks": 66,
      "char_count": 1493,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 62,
      "total_chunks": 66,
      "char_count": 1494,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 63,
      "total_chunks": 66,
      "char_count": 1496,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 64,
      "total_chunks": 66,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "PIIS0140673623028015.pdf",
      "source_type": "pdf",
      "file_hash": "9f4d1afee7ea46b7",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.458806",
      "filename": "PIIS0140673623028015.pdf",
      "page_count": 15,
      "title": "Promoting good mental health over the menopause transition",
      "author": "Lydia Brown PhD MPsych",
      "chunk_index": 65,
      "total_chunks": 66,
      "char_count": 934,
      "estimated_tokens": 233
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 0,
      "total_chunks": 65,
      "char_count": 1405,
      "estimated_tokens": 351
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 1,
      "total_chunks": 65,
      "char_count": 1327,
      "estimated_tokens": 331
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 2,
      "total_chunks": 65,
      "char_count": 1467,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 3,
      "total_chunks": 65,
      "char_count": 1397,
      "estimated_tokens": 349
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 4,
      "total_chunks": 65,
      "char_count": 308,
      "estimated_tokens": 77
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 5,
      "total_chunks": 65,
      "char_count": 1488,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 6,
      "total_chunks": 65,
      "char_count": 1432,
      "estimated_tokens": 358
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 7,
      "total_chunks": 65,
      "char_count": 1488,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 8,
      "total_chunks": 65,
      "char_count": 1468,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 9,
      "total_chunks": 65,
      "char_count": 1751,
      "estimated_tokens": 437
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 10,
      "total_chunks": 65,
      "char_count": 1429,
      "estimated_tokens": 357
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 11,
      "total_chunks": 65,
      "char_count": 1444,
      "estimated_tokens": 361
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 12,
      "total_chunks": 65,
      "char_count": 1295,
      "estimated_tokens": 323
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 13,
      "total_chunks": 65,
      "char_count": 1476,
      "estimated_tokens": 369
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 14,
      "total_chunks": 65,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 15,
      "total_chunks": 65,
      "char_count": 1408,
      "estimated_tokens": 352
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 16,
      "total_chunks": 65,
      "char_count": 1287,
      "estimated_tokens": 321
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 17,
      "total_chunks": 65,
      "char_count": 518,
      "estimated_tokens": 129
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 18,
      "total_chunks": 65,
      "char_count": 1534,
      "estimated_tokens": 383
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 19,
      "total_chunks": 65,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 20,
      "total_chunks": 65,
      "char_count": 1244,
      "estimated_tokens": 311
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 21,
      "total_chunks": 65,
      "char_count": 1196,
      "estimated_tokens": 299
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 22,
      "total_chunks": 65,
      "char_count": 1498,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 23,
      "total_chunks": 65,
      "char_count": 1053,
      "estimated_tokens": 263
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 24,
      "total_chunks": 65,
      "char_count": 1308,
      "estimated_tokens": 327
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 25,
      "total_chunks": 65,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 26,
      "total_chunks": 65,
      "char_count": 1354,
      "estimated_tokens": 338
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 27,
      "total_chunks": 65,
      "char_count": 723,
      "estimated_tokens": 180
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 28,
      "total_chunks": 65,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 29,
      "total_chunks": 65,
      "char_count": 1253,
      "estimated_tokens": 313
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 30,
      "total_chunks": 65,
      "char_count": 1359,
      "estimated_tokens": 339
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 31,
      "total_chunks": 65,
      "char_count": 1041,
      "estimated_tokens": 260
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 32,
      "total_chunks": 65,
      "char_count": 1558,
      "estimated_tokens": 389
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 33,
      "total_chunks": 65,
      "char_count": 1421,
      "estimated_tokens": 355
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 34,
      "total_chunks": 65,
      "char_count": 1437,
      "estimated_tokens": 359
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 35,
      "total_chunks": 65,
      "char_count": 1426,
      "estimated_tokens": 356
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 36,
      "total_chunks": 65,
      "char_count": 1474,
      "estimated_tokens": 368
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 37,
      "total_chunks": 65,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 38,
      "total_chunks": 65,
      "char_count": 1351,
      "estimated_tokens": 337
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 39,
      "total_chunks": 65,
      "char_count": 1375,
      "estimated_tokens": 343
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 40,
      "total_chunks": 65,
      "char_count": 1376,
      "estimated_tokens": 344
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 41,
      "total_chunks": 65,
      "char_count": 1416,
      "estimated_tokens": 354
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 42,
      "total_chunks": 65,
      "char_count": 1408,
      "estimated_tokens": 352
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 43,
      "total_chunks": 65,
      "char_count": 1401,
      "estimated_tokens": 350
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 44,
      "total_chunks": 65,
      "char_count": 1419,
      "estimated_tokens": 354
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 45,
      "total_chunks": 65,
      "char_count": 1486,
      "estimated_tokens": 371
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 46,
      "total_chunks": 65,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 47,
      "total_chunks": 65,
      "char_count": 1478,
      "estimated_tokens": 369
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 48,
      "total_chunks": 65,
      "char_count": 1418,
      "estimated_tokens": 354
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 49,
      "total_chunks": 65,
      "char_count": 1488,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 50,
      "total_chunks": 65,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 51,
      "total_chunks": 65,
      "char_count": 1318,
      "estimated_tokens": 329
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 52,
      "total_chunks": 65,
      "char_count": 1345,
      "estimated_tokens": 336
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 53,
      "total_chunks": 65,
      "char_count": 1460,
      "estimated_tokens": 365
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 54,
      "total_chunks": 65,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 55,
      "total_chunks": 65,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 56,
      "total_chunks": 65,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 57,
      "total_chunks": 65,
      "char_count": 1496,
      "estimated_tokens": 374
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 58,
      "total_chunks": 65,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 59,
      "total_chunks": 65,
      "char_count": 1414,
      "estimated_tokens": 353
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 60,
      "total_chunks": 65,
      "char_count": 1446,
      "estimated_tokens": 361
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 61,
      "total_chunks": 65,
      "char_count": 1471,
      "estimated_tokens": 367
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 62,
      "total_chunks": 65,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 63,
      "total_chunks": 65,
      "char_count": 1422,
      "estimated_tokens": 355
    },
    {
      "source": "PIIS0140673623028027.pdf",
      "source_type": "pdf",
      "file_hash": "cfdc9e0fe68aa1d9",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.704397",
      "filename": "PIIS0140673623028027.pdf",
      "page_count": 13,
      "title": "Managing menopause after cancer",
      "author": "Prof Martha Hickey MBChB MD",
      "chunk_index": 64,
      "total_chunks": 65,
      "char_count": 385,
      "estimated_tokens": 96
    },
    {
      "source": "PIIS0140673624003684.pdf",
      "source_type": "pdf",
      "file_hash": "39b2e57f352cae0c",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.745596",
      "filename": "PIIS0140673624003684.pdf",
      "page_count": 1,
      "title": "Martha Hickey: responding to the complexity of menopause",
      "author": "Udani Samarasekera",
      "chunk_index": 0,
      "total_chunks": 5,
      "char_count": 1310,
      "estimated_tokens": 327
    },
    {
      "source": "PIIS0140673624003684.pdf",
      "source_type": "pdf",
      "file_hash": "39b2e57f352cae0c",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.745596",
      "filename": "PIIS0140673624003684.pdf",
      "page_count": 1,
      "title": "Martha Hickey: responding to the complexity of menopause",
      "author": "Udani Samarasekera",
      "chunk_index": 1,
      "total_chunks": 5,
      "char_count": 1417,
      "estimated_tokens": 354
    },
    {
      "source": "PIIS0140673624003684.pdf",
      "source_type": "pdf",
      "file_hash": "39b2e57f352cae0c",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.745596",
      "filename": "PIIS0140673624003684.pdf",
      "page_count": 1,
      "title": "Martha Hickey: responding to the complexity of menopause",
      "author": "Udani Samarasekera",
      "chunk_index": 2,
      "total_chunks": 5,
      "char_count": 1288,
      "estimated_tokens": 322
    },
    {
      "source": "PIIS0140673624003684.pdf",
      "source_type": "pdf",
      "file_hash": "39b2e57f352cae0c",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.745596",
      "filename": "PIIS0140673624003684.pdf",
      "page_count": 1,
      "title": "Martha Hickey: responding to the complexity of menopause",
      "author": "Udani Samarasekera",
      "chunk_index": 3,
      "total_chunks": 5,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "PIIS0140673624003684.pdf",
      "source_type": "pdf",
      "file_hash": "39b2e57f352cae0c",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.745596",
      "filename": "PIIS0140673624003684.pdf",
      "page_count": 1,
      "title": "Martha Hickey: responding to the complexity of menopause",
      "author": "Udani Samarasekera",
      "chunk_index": 4,
      "total_chunks": 5,
      "char_count": 1263,
      "estimated_tokens": 315
    },
    {
      "source": "PIIS0140673624003696.pdf",
      "source_type": "pdf",
      "file_hash": "dbf09fc79ecab9fc",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.803089",
      "filename": "PIIS0140673624003696.pdf",
      "page_count": 10,
      "title": "500 Strong: celebrating older women's bodies in menopause and beyond",
      "author": "Ponch Hawkes",
      "chunk_index": 0,
      "total_chunks": 5,
      "char_count": 1414,
      "estimated_tokens": 353
    },
    {
      "source": "PIIS0140673624003696.pdf",
      "source_type": "pdf",
      "file_hash": "dbf09fc79ecab9fc",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.803089",
      "filename": "PIIS0140673624003696.pdf",
      "page_count": 10,
      "title": "500 Strong: celebrating older women's bodies in menopause and beyond",
      "author": "Ponch Hawkes",
      "chunk_index": 1,
      "total_chunks": 5,
      "char_count": 1324,
      "estimated_tokens": 331
    },
    {
      "source": "PIIS0140673624003696.pdf",
      "source_type": "pdf",
      "file_hash": "dbf09fc79ecab9fc",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.803089",
      "filename": "PIIS0140673624003696.pdf",
      "page_count": 10,
      "title": "500 Strong: celebrating older women's bodies in menopause and beyond",
      "author": "Ponch Hawkes",
      "chunk_index": 2,
      "total_chunks": 5,
      "char_count": 1440,
      "estimated_tokens": 360
    },
    {
      "source": "PIIS0140673624003696.pdf",
      "source_type": "pdf",
      "file_hash": "dbf09fc79ecab9fc",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.803089",
      "filename": "PIIS0140673624003696.pdf",
      "page_count": 10,
      "title": "500 Strong: celebrating older women's bodies in menopause and beyond",
      "author": "Ponch Hawkes",
      "chunk_index": 3,
      "total_chunks": 5,
      "char_count": 1364,
      "estimated_tokens": 341
    },
    {
      "source": "PIIS0140673624003696.pdf",
      "source_type": "pdf",
      "file_hash": "dbf09fc79ecab9fc",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.803089",
      "filename": "PIIS0140673624003696.pdf",
      "page_count": 10,
      "title": "500 Strong: celebrating older women's bodies in menopause and beyond",
      "author": "Ponch Hawkes",
      "chunk_index": 4,
      "total_chunks": 5,
      "char_count": 1120,
      "estimated_tokens": 280
    },
    {
      "source": "PIIS0140673624004628.pdf",
      "source_type": "pdf",
      "file_hash": "6dbe4d1b07b7e25d",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.827962",
      "filename": "PIIS0140673624004628.pdf",
      "page_count": 1,
      "title": "Time for a balanced conversation about menopause",
      "author": "The Lancet",
      "chunk_index": 0,
      "total_chunks": 5,
      "char_count": 1361,
      "estimated_tokens": 340
    },
    {
      "source": "PIIS0140673624004628.pdf",
      "source_type": "pdf",
      "file_hash": "6dbe4d1b07b7e25d",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.827962",
      "filename": "PIIS0140673624004628.pdf",
      "page_count": 1,
      "title": "Time for a balanced conversation about menopause",
      "author": "The Lancet",
      "chunk_index": 1,
      "total_chunks": 5,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "PIIS0140673624004628.pdf",
      "source_type": "pdf",
      "file_hash": "6dbe4d1b07b7e25d",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.827962",
      "filename": "PIIS0140673624004628.pdf",
      "page_count": 1,
      "title": "Time for a balanced conversation about menopause",
      "author": "The Lancet",
      "chunk_index": 2,
      "total_chunks": 5,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "PIIS0140673624004628.pdf",
      "source_type": "pdf",
      "file_hash": "6dbe4d1b07b7e25d",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.827962",
      "filename": "PIIS0140673624004628.pdf",
      "page_count": 1,
      "title": "Time for a balanced conversation about menopause",
      "author": "The Lancet",
      "chunk_index": 3,
      "total_chunks": 5,
      "char_count": 876,
      "estimated_tokens": 219
    },
    {
      "source": "PIIS0140673624004628.pdf",
      "source_type": "pdf",
      "file_hash": "6dbe4d1b07b7e25d",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:00.827962",
      "filename": "PIIS0140673624004628.pdf",
      "page_count": 1,
      "title": "Time for a balanced conversation about menopause",
      "author": "The Lancet",
      "chunk_index": 4,
      "total_chunks": 5,
      "char_count": 697,
      "estimated_tokens": 174
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 0,
      "total_chunks": 88,
      "char_count": 1355,
      "estimated_tokens": 338
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 1,
      "total_chunks": 88,
      "char_count": 1396,
      "estimated_tokens": 349
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 2,
      "total_chunks": 88,
      "char_count": 1077,
      "estimated_tokens": 269
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 3,
      "total_chunks": 88,
      "char_count": 1442,
      "estimated_tokens": 360
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 4,
      "total_chunks": 88,
      "char_count": 1374,
      "estimated_tokens": 343
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 5,
      "total_chunks": 88,
      "char_count": 1436,
      "estimated_tokens": 359
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 6,
      "total_chunks": 88,
      "char_count": 1386,
      "estimated_tokens": 346
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 7,
      "total_chunks": 88,
      "char_count": 1323,
      "estimated_tokens": 330
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 8,
      "total_chunks": 88,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 9,
      "total_chunks": 88,
      "char_count": 1377,
      "estimated_tokens": 344
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 10,
      "total_chunks": 88,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 11,
      "total_chunks": 88,
      "char_count": 1365,
      "estimated_tokens": 341
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 12,
      "total_chunks": 88,
      "char_count": 1162,
      "estimated_tokens": 290
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 13,
      "total_chunks": 88,
      "char_count": 1473,
      "estimated_tokens": 368
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 14,
      "total_chunks": 88,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 15,
      "total_chunks": 88,
      "char_count": 1430,
      "estimated_tokens": 357
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 16,
      "total_chunks": 88,
      "char_count": 1490,
      "estimated_tokens": 372
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 17,
      "total_chunks": 88,
      "char_count": 1416,
      "estimated_tokens": 354
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 18,
      "total_chunks": 88,
      "char_count": 1356,
      "estimated_tokens": 339
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 19,
      "total_chunks": 88,
      "char_count": 1427,
      "estimated_tokens": 356
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 20,
      "total_chunks": 88,
      "char_count": 1444,
      "estimated_tokens": 361
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 21,
      "total_chunks": 88,
      "char_count": 1020,
      "estimated_tokens": 255
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 22,
      "total_chunks": 88,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 23,
      "total_chunks": 88,
      "char_count": 1416,
      "estimated_tokens": 354
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 24,
      "total_chunks": 88,
      "char_count": 1330,
      "estimated_tokens": 332
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 25,
      "total_chunks": 88,
      "char_count": 1456,
      "estimated_tokens": 364
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 26,
      "total_chunks": 88,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 27,
      "total_chunks": 88,
      "char_count": 1256,
      "estimated_tokens": 314
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 28,
      "total_chunks": 88,
      "char_count": 1334,
      "estimated_tokens": 333
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 29,
      "total_chunks": 88,
      "char_count": 1289,
      "estimated_tokens": 322
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 30,
      "total_chunks": 88,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 31,
      "total_chunks": 88,
      "char_count": 895,
      "estimated_tokens": 223
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 32,
      "total_chunks": 88,
      "char_count": 1459,
      "estimated_tokens": 364
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 33,
      "total_chunks": 88,
      "char_count": 1354,
      "estimated_tokens": 338
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 34,
      "total_chunks": 88,
      "char_count": 1288,
      "estimated_tokens": 322
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 35,
      "total_chunks": 88,
      "char_count": 1416,
      "estimated_tokens": 354
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 36,
      "total_chunks": 88,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 37,
      "total_chunks": 88,
      "char_count": 1443,
      "estimated_tokens": 360
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 38,
      "total_chunks": 88,
      "char_count": 1328,
      "estimated_tokens": 332
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 39,
      "total_chunks": 88,
      "char_count": 1317,
      "estimated_tokens": 329
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 40,
      "total_chunks": 88,
      "char_count": 1446,
      "estimated_tokens": 361
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 41,
      "total_chunks": 88,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 42,
      "total_chunks": 88,
      "char_count": 1382,
      "estimated_tokens": 345
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 43,
      "total_chunks": 88,
      "char_count": 1250,
      "estimated_tokens": 312
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 44,
      "total_chunks": 88,
      "char_count": 1428,
      "estimated_tokens": 357
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 45,
      "total_chunks": 88,
      "char_count": 1341,
      "estimated_tokens": 335
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 46,
      "total_chunks": 88,
      "char_count": 1444,
      "estimated_tokens": 361
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 47,
      "total_chunks": 88,
      "char_count": 1466,
      "estimated_tokens": 366
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 48,
      "total_chunks": 88,
      "char_count": 1428,
      "estimated_tokens": 357
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 49,
      "total_chunks": 88,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 50,
      "total_chunks": 88,
      "char_count": 1457,
      "estimated_tokens": 364
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 51,
      "total_chunks": 88,
      "char_count": 1423,
      "estimated_tokens": 355
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 52,
      "total_chunks": 88,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 53,
      "total_chunks": 88,
      "char_count": 1249,
      "estimated_tokens": 312
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 54,
      "total_chunks": 88,
      "char_count": 1335,
      "estimated_tokens": 333
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 55,
      "total_chunks": 88,
      "char_count": 1171,
      "estimated_tokens": 292
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 56,
      "total_chunks": 88,
      "char_count": 1442,
      "estimated_tokens": 360
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 57,
      "total_chunks": 88,
      "char_count": 1420,
      "estimated_tokens": 355
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 58,
      "total_chunks": 88,
      "char_count": 1474,
      "estimated_tokens": 368
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 59,
      "total_chunks": 88,
      "char_count": 1482,
      "estimated_tokens": 370
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 60,
      "total_chunks": 88,
      "char_count": 1431,
      "estimated_tokens": 357
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 61,
      "total_chunks": 88,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 62,
      "total_chunks": 88,
      "char_count": 1418,
      "estimated_tokens": 354
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 63,
      "total_chunks": 88,
      "char_count": 1388,
      "estimated_tokens": 347
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 64,
      "total_chunks": 88,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 65,
      "total_chunks": 88,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 66,
      "total_chunks": 88,
      "char_count": 1449,
      "estimated_tokens": 362
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 67,
      "total_chunks": 88,
      "char_count": 1342,
      "estimated_tokens": 335
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 68,
      "total_chunks": 88,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 69,
      "total_chunks": 88,
      "char_count": 1300,
      "estimated_tokens": 325
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 70,
      "total_chunks": 88,
      "char_count": 1475,
      "estimated_tokens": 368
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 71,
      "total_chunks": 88,
      "char_count": 1437,
      "estimated_tokens": 359
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 72,
      "total_chunks": 88,
      "char_count": 1375,
      "estimated_tokens": 343
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 73,
      "total_chunks": 88,
      "char_count": 1483,
      "estimated_tokens": 370
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 74,
      "total_chunks": 88,
      "char_count": 1430,
      "estimated_tokens": 357
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 75,
      "total_chunks": 88,
      "char_count": 1473,
      "estimated_tokens": 368
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 76,
      "total_chunks": 88,
      "char_count": 1465,
      "estimated_tokens": 366
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 77,
      "total_chunks": 88,
      "char_count": 1397,
      "estimated_tokens": 349
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 78,
      "total_chunks": 88,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 79,
      "total_chunks": 88,
      "char_count": 1481,
      "estimated_tokens": 370
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 80,
      "total_chunks": 88,
      "char_count": 1385,
      "estimated_tokens": 346
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 81,
      "total_chunks": 88,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 82,
      "total_chunks": 88,
      "char_count": 1342,
      "estimated_tokens": 335
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 83,
      "total_chunks": 88,
      "char_count": 1434,
      "estimated_tokens": 358
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 84,
      "total_chunks": 88,
      "char_count": 1331,
      "estimated_tokens": 332
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 85,
      "total_chunks": 88,
      "char_count": 1354,
      "estimated_tokens": 338
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 86,
      "total_chunks": 88,
      "char_count": 1494,
      "estimated_tokens": 373
    },
    {
      "source": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "source_type": "pdf",
      "file_hash": "d41b9a1bf248aa4a",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:01.237742",
      "filename": "The_2020_genitourinary_syndrome_of_menopause.5.pdf",
      "page_count": 17,
      "chunk_index": 87,
      "total_chunks": 88,
      "char_count": 599,
      "estimated_tokens": 149
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 0,
      "total_chunks": 150,
      "char_count": 1327,
      "estimated_tokens": 331
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 1,
      "total_chunks": 150,
      "char_count": 1370,
      "estimated_tokens": 342
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 2,
      "total_chunks": 150,
      "char_count": 1360,
      "estimated_tokens": 340
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 3,
      "total_chunks": 150,
      "char_count": 1245,
      "estimated_tokens": 311
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 4,
      "total_chunks": 150,
      "char_count": 1140,
      "estimated_tokens": 285
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 5,
      "total_chunks": 150,
      "char_count": 1481,
      "estimated_tokens": 370
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 6,
      "total_chunks": 150,
      "char_count": 1427,
      "estimated_tokens": 356
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 7,
      "total_chunks": 150,
      "char_count": 1452,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 8,
      "total_chunks": 150,
      "char_count": 1098,
      "estimated_tokens": 274
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 9,
      "total_chunks": 150,
      "char_count": 1379,
      "estimated_tokens": 344
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 10,
      "total_chunks": 150,
      "char_count": 1451,
      "estimated_tokens": 362
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 11,
      "total_chunks": 150,
      "char_count": 1321,
      "estimated_tokens": 330
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 12,
      "total_chunks": 150,
      "char_count": 1307,
      "estimated_tokens": 326
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 13,
      "total_chunks": 150,
      "char_count": 1364,
      "estimated_tokens": 341
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 14,
      "total_chunks": 150,
      "char_count": 1228,
      "estimated_tokens": 307
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 15,
      "total_chunks": 150,
      "char_count": 1414,
      "estimated_tokens": 353
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 16,
      "total_chunks": 150,
      "char_count": 1376,
      "estimated_tokens": 344
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 17,
      "total_chunks": 150,
      "char_count": 1143,
      "estimated_tokens": 285
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 18,
      "total_chunks": 150,
      "char_count": 1438,
      "estimated_tokens": 359
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 19,
      "total_chunks": 150,
      "char_count": 1434,
      "estimated_tokens": 358
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 20,
      "total_chunks": 150,
      "char_count": 1239,
      "estimated_tokens": 309
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 21,
      "total_chunks": 150,
      "char_count": 1180,
      "estimated_tokens": 295
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 22,
      "total_chunks": 150,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 23,
      "total_chunks": 150,
      "char_count": 1214,
      "estimated_tokens": 303
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 24,
      "total_chunks": 150,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 25,
      "total_chunks": 150,
      "char_count": 1055,
      "estimated_tokens": 263
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 26,
      "total_chunks": 150,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 27,
      "total_chunks": 150,
      "char_count": 1445,
      "estimated_tokens": 361
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 28,
      "total_chunks": 150,
      "char_count": 1322,
      "estimated_tokens": 330
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 29,
      "total_chunks": 150,
      "char_count": 1356,
      "estimated_tokens": 339
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 30,
      "total_chunks": 150,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 31,
      "total_chunks": 150,
      "char_count": 1418,
      "estimated_tokens": 354
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 32,
      "total_chunks": 150,
      "char_count": 1454,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 33,
      "total_chunks": 150,
      "char_count": 1212,
      "estimated_tokens": 303
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 34,
      "total_chunks": 150,
      "char_count": 1343,
      "estimated_tokens": 335
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 35,
      "total_chunks": 150,
      "char_count": 1361,
      "estimated_tokens": 340
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 36,
      "total_chunks": 150,
      "char_count": 1470,
      "estimated_tokens": 367
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 37,
      "total_chunks": 150,
      "char_count": 1429,
      "estimated_tokens": 357
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 38,
      "total_chunks": 150,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 39,
      "total_chunks": 150,
      "char_count": 1428,
      "estimated_tokens": 357
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 40,
      "total_chunks": 150,
      "char_count": 1363,
      "estimated_tokens": 340
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 41,
      "total_chunks": 150,
      "char_count": 1484,
      "estimated_tokens": 371
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 42,
      "total_chunks": 150,
      "char_count": 1195,
      "estimated_tokens": 298
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 43,
      "total_chunks": 150,
      "char_count": 1370,
      "estimated_tokens": 342
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 44,
      "total_chunks": 150,
      "char_count": 1374,
      "estimated_tokens": 343
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 45,
      "total_chunks": 150,
      "char_count": 1430,
      "estimated_tokens": 357
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 46,
      "total_chunks": 150,
      "char_count": 1233,
      "estimated_tokens": 308
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 47,
      "total_chunks": 150,
      "char_count": 1339,
      "estimated_tokens": 334
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 48,
      "total_chunks": 150,
      "char_count": 1378,
      "estimated_tokens": 344
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 49,
      "total_chunks": 150,
      "char_count": 1438,
      "estimated_tokens": 359
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 50,
      "total_chunks": 150,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 51,
      "total_chunks": 150,
      "char_count": 1366,
      "estimated_tokens": 341
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 52,
      "total_chunks": 150,
      "char_count": 1431,
      "estimated_tokens": 357
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 53,
      "total_chunks": 150,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 54,
      "total_chunks": 150,
      "char_count": 1394,
      "estimated_tokens": 348
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 55,
      "total_chunks": 150,
      "char_count": 1402,
      "estimated_tokens": 350
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 56,
      "total_chunks": 150,
      "char_count": 1242,
      "estimated_tokens": 310
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 57,
      "total_chunks": 150,
      "char_count": 1469,
      "estimated_tokens": 367
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 58,
      "total_chunks": 150,
      "char_count": 1301,
      "estimated_tokens": 325
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 59,
      "total_chunks": 150,
      "char_count": 1293,
      "estimated_tokens": 323
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 60,
      "total_chunks": 150,
      "char_count": 1356,
      "estimated_tokens": 339
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 61,
      "total_chunks": 150,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 62,
      "total_chunks": 150,
      "char_count": 1485,
      "estimated_tokens": 371
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 63,
      "total_chunks": 150,
      "char_count": 1255,
      "estimated_tokens": 313
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 64,
      "total_chunks": 150,
      "char_count": 1228,
      "estimated_tokens": 307
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 65,
      "total_chunks": 150,
      "char_count": 1417,
      "estimated_tokens": 354
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 66,
      "total_chunks": 150,
      "char_count": 1232,
      "estimated_tokens": 308
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 67,
      "total_chunks": 150,
      "char_count": 1427,
      "estimated_tokens": 356
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 68,
      "total_chunks": 150,
      "char_count": 1460,
      "estimated_tokens": 365
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 69,
      "total_chunks": 150,
      "char_count": 1423,
      "estimated_tokens": 355
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 70,
      "total_chunks": 150,
      "char_count": 1456,
      "estimated_tokens": 364
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 71,
      "total_chunks": 150,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 72,
      "total_chunks": 150,
      "char_count": 1334,
      "estimated_tokens": 333
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 73,
      "total_chunks": 150,
      "char_count": 1450,
      "estimated_tokens": 362
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 74,
      "total_chunks": 150,
      "char_count": 1454,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 75,
      "total_chunks": 150,
      "char_count": 1284,
      "estimated_tokens": 321
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 76,
      "total_chunks": 150,
      "char_count": 1435,
      "estimated_tokens": 358
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 77,
      "total_chunks": 150,
      "char_count": 1451,
      "estimated_tokens": 362
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 78,
      "total_chunks": 150,
      "char_count": 1425,
      "estimated_tokens": 356
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 79,
      "total_chunks": 150,
      "char_count": 1335,
      "estimated_tokens": 333
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 80,
      "total_chunks": 150,
      "char_count": 1475,
      "estimated_tokens": 368
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 81,
      "total_chunks": 150,
      "char_count": 1279,
      "estimated_tokens": 319
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 82,
      "total_chunks": 150,
      "char_count": 1175,
      "estimated_tokens": 293
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 83,
      "total_chunks": 150,
      "char_count": 1330,
      "estimated_tokens": 332
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 84,
      "total_chunks": 150,
      "char_count": 1447,
      "estimated_tokens": 361
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 85,
      "total_chunks": 150,
      "char_count": 1431,
      "estimated_tokens": 357
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 86,
      "total_chunks": 150,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 87,
      "total_chunks": 150,
      "char_count": 1369,
      "estimated_tokens": 342
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 88,
      "total_chunks": 150,
      "char_count": 1408,
      "estimated_tokens": 352
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 89,
      "total_chunks": 150,
      "char_count": 1308,
      "estimated_tokens": 327
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 90,
      "total_chunks": 150,
      "char_count": 1417,
      "estimated_tokens": 354
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 91,
      "total_chunks": 150,
      "char_count": 1341,
      "estimated_tokens": 335
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 92,
      "total_chunks": 150,
      "char_count": 1464,
      "estimated_tokens": 366
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 93,
      "total_chunks": 150,
      "char_count": 1500,
      "estimated_tokens": 375
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 94,
      "total_chunks": 150,
      "char_count": 1085,
      "estimated_tokens": 271
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 95,
      "total_chunks": 150,
      "char_count": 1406,
      "estimated_tokens": 351
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 96,
      "total_chunks": 150,
      "char_count": 1478,
      "estimated_tokens": 369
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 97,
      "total_chunks": 150,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 98,
      "total_chunks": 150,
      "char_count": 1425,
      "estimated_tokens": 356
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 99,
      "total_chunks": 150,
      "char_count": 1305,
      "estimated_tokens": 326
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 100,
      "total_chunks": 150,
      "char_count": 1498,
      "estimated_tokens": 374
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 101,
      "total_chunks": 150,
      "char_count": 1406,
      "estimated_tokens": 351
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 102,
      "total_chunks": 150,
      "char_count": 1341,
      "estimated_tokens": 335
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 103,
      "total_chunks": 150,
      "char_count": 1421,
      "estimated_tokens": 355
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 104,
      "total_chunks": 150,
      "char_count": 1417,
      "estimated_tokens": 354
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 105,
      "total_chunks": 150,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 106,
      "total_chunks": 150,
      "char_count": 1364,
      "estimated_tokens": 341
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 107,
      "total_chunks": 150,
      "char_count": 1462,
      "estimated_tokens": 365
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 108,
      "total_chunks": 150,
      "char_count": 1446,
      "estimated_tokens": 361
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 109,
      "total_chunks": 150,
      "char_count": 1486,
      "estimated_tokens": 371
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 110,
      "total_chunks": 150,
      "char_count": 1485,
      "estimated_tokens": 371
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 111,
      "total_chunks": 150,
      "char_count": 1377,
      "estimated_tokens": 344
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 112,
      "total_chunks": 150,
      "char_count": 1459,
      "estimated_tokens": 364
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 113,
      "total_chunks": 150,
      "char_count": 1498,
      "estimated_tokens": 374
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 114,
      "total_chunks": 150,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 115,
      "total_chunks": 150,
      "char_count": 1396,
      "estimated_tokens": 349
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 116,
      "total_chunks": 150,
      "char_count": 1422,
      "estimated_tokens": 355
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 117,
      "total_chunks": 150,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 118,
      "total_chunks": 150,
      "char_count": 1380,
      "estimated_tokens": 345
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 119,
      "total_chunks": 150,
      "char_count": 1472,
      "estimated_tokens": 368
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 120,
      "total_chunks": 150,
      "char_count": 1411,
      "estimated_tokens": 352
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 121,
      "total_chunks": 150,
      "char_count": 1422,
      "estimated_tokens": 355
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 122,
      "total_chunks": 150,
      "char_count": 1405,
      "estimated_tokens": 351
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 123,
      "total_chunks": 150,
      "char_count": 1489,
      "estimated_tokens": 372
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 124,
      "total_chunks": 150,
      "char_count": 1436,
      "estimated_tokens": 359
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 125,
      "total_chunks": 150,
      "char_count": 1427,
      "estimated_tokens": 356
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 126,
      "total_chunks": 150,
      "char_count": 1481,
      "estimated_tokens": 370
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 127,
      "total_chunks": 150,
      "char_count": 1499,
      "estimated_tokens": 374
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 128,
      "total_chunks": 150,
      "char_count": 1443,
      "estimated_tokens": 360
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 129,
      "total_chunks": 150,
      "char_count": 1447,
      "estimated_tokens": 361
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 130,
      "total_chunks": 150,
      "char_count": 1455,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 131,
      "total_chunks": 150,
      "char_count": 1497,
      "estimated_tokens": 374
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 132,
      "total_chunks": 150,
      "char_count": 1492,
      "estimated_tokens": 373
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 133,
      "total_chunks": 150,
      "char_count": 1478,
      "estimated_tokens": 369
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 134,
      "total_chunks": 150,
      "char_count": 1409,
      "estimated_tokens": 352
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 135,
      "total_chunks": 150,
      "char_count": 1494,
      "estimated_tokens": 373
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 136,
      "total_chunks": 150,
      "char_count": 1428,
      "estimated_tokens": 357
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 137,
      "total_chunks": 150,
      "char_count": 1341,
      "estimated_tokens": 335
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 138,
      "total_chunks": 150,
      "char_count": 1495,
      "estimated_tokens": 373
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 139,
      "total_chunks": 150,
      "char_count": 1373,
      "estimated_tokens": 343
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 140,
      "total_chunks": 150,
      "char_count": 1454,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 141,
      "total_chunks": 150,
      "char_count": 1442,
      "estimated_tokens": 360
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 142,
      "total_chunks": 150,
      "char_count": 1441,
      "estimated_tokens": 360
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 143,
      "total_chunks": 150,
      "char_count": 1398,
      "estimated_tokens": 349
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 144,
      "total_chunks": 150,
      "char_count": 1364,
      "estimated_tokens": 341
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 145,
      "total_chunks": 150,
      "char_count": 1454,
      "estimated_tokens": 363
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 146,
      "total_chunks": 150,
      "char_count": 1423,
      "estimated_tokens": 355
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 147,
      "total_chunks": 150,
      "char_count": 1487,
      "estimated_tokens": 371
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 148,
      "total_chunks": 150,
      "char_count": 1477,
      "estimated_tokens": 369
    },
    {
      "source": "nams-2022-hormone-therapy-position-statement.pdf",
      "source_type": "pdf",
      "file_hash": "22a05f37b2f52af0",
      "collection": "knowledge_base",
      "ingested_at": "2026-01-31T18:16:02.503339",
      "filename": "nams-2022-hormone-therapy-position-statement.pdf",
      "page_count": 28,
      "chunk_index": 149,
      "total_chunks": 150,
      "char_count": 824,
      "estimated_tokens": 206
    }
  ]
}